

FINAL PROGRAM

San Diego

IDWeek²⁰¹⁷TM




October 4-8, 2017
www.IDWeek.org

A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS



IDSA



SHEA
The Society for Healthcare
Epidemiology of America

hivma
hiv medicine association



**PEDIATRIC INFECTIOUS
DISEASES SOCIETY**



Isentress[®]HD

raltegravir

NOW APPROVED

Visit isentress.com
for more information.



Copyright © 2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
All rights reserved. INFC-1211546-0000 03/17

October 4-8 • San Diego, CA • www.idweek.org



IDWeek²⁰¹⁷_{TM}

Advancing Science, Improving Care

FINAL PROGRAM

A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS



Copyright 2017 IDWeekTM

All Rights Reserved

Printed in the United States of America



IDWeek™ TOWN HALL 2.0

JOIN THE CONVERSATION

#IDWeekTownHall
idweektownhall@idweek.org

What matters most to you about the field of ID?
Do you have ideas you want to share?
Questions you want to ask?

Join your peers for a lively discussion with Society leaders on **Friday, October 6, 6:00-7:30 pm in room 06DE**. Share your thoughts/ask your question during the event, or submit them ahead of time via twitter or email.

Welcome Letter

Dear Colleagues,

On behalf of the **IDWeek** Program Committee, we welcome you to San Diego for the sixth annual **IDWeek**. With the theme—*Advancing Science, Improving Care*—**IDWeek™** 2017 will feature the latest science and bench-to-bedside approaches to the epidemiology, diagnosis, treatment, and prevention of infectious diseases, across all ages and locations.

IDWeek leverages the broad expertise and diverse memberships of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and the Pediatric Infectious Diseases Society, providing an unparalleled opportunity for healthcare professionals of multidisciplinary backgrounds to learn from each other's knowledge, experience, and expertise to improve patient care and public health.

As we welcome colleagues from around the globe we share the passion of the specialty through cutting-edge science, collegial interactions, exceptional speakers, and educational tracks geared to meet your individual practice needs. **IDWeek™** 2017 provides a unique educational opportunity for professionals to hear real case studies from experts managing current infectious diseases outbreaks; learn about the newest diagnostic and treatment modalities; as well as the latest epidemiology and prevention strategies; and apply state-of-the-art science to clinical care. Most importantly it provides a forum for attendees to network with colleagues from around the world and build relationships that outlast the conference.

Enjoy **IDWeek™** 2017! While you are here, if you have suggestions for topics you would like to see covered during **IDWeek™** 2018, which will be held in San Francisco, October 3-7, 2018 please tell a staff member. Your input is critical to the long-term success of future **IDWeek** meetings.

We trust you will have a rewarding and productive time while you are in San Diego!

With best regards,



David R. Andes, MD, FIDSA, IDWeek Chair, IDSA



Hilary M. Babcock, MD, IDWeek Chair, SHEA



Rajesh T. Gandhi, MD, FIDSA, IDWeek Chair, HIVMA



Archana Chatterjee, MD, PhD, FIDSA, FPIDS, IDWeek Chair, PIDS

Acknowledgements

The IDWeek partners wish to extend a special **Thank You** to the following organizations who developed sessions in collaboration with the IDWeek Program Committee (see Allied Partners on page xiii for specific session details):

- American Academy of Pediatrics (AAP)
- American Association of Blood Banks (AABB)
- American Society for Addiction Medicine (ASAM)
- American Society of Transplantation (AST)
- Brazilian Society of Infectious Diseases
- Centers for Disease Control and Prevention (CDC)
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
- IDSA Clinical Affairs Committee
- IDSA Education Committee and the Medical Education Work Group
- IDSA ID Training Program Directors' Committee
- National Foundation for Infectious Diseases (NFID)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Pan-American Society of Infectious Diseases
- Society of Infectious Diseases Pharmacists (SIDP)

The IDWeek Program Committee would like to extend a special **Thank You** to the following individuals who generously donated their time and expertise to review abstracts for IDWeek 2017:

Paul Ambrose, PharmD, FIDSA, Institute for Clinical Pharmacodynamics, Inc., Schenectady, NY
Senu Apewokin, MD, University of Cincinnati, Cincinnati, OH
David Aronoff, MD, FIDSA, Vanderbilt University School of Medicine, Division of Infectious Diseases, Nashville, TN
Muhammad Salman Ashraf, MBBS, East Carolina University, Greenville, NC
Ritu Banerjee, MD, PhD, Vanderbilt University, Nashville, TN
Robert Bednarczyk, PhD, Emory University, Atlanta, GA
Elie F. Berbari, MD, FIDSA, Mayo Clinic, Rochester, MN
Anne J. Blaschke, MD, PhD, FIDSA, FPIDS, University of Utah School of Medicine, Salt Lake City, UT
Beau Bruce, MD, MS, Centers for Disease Control and Prevention, Atlanta, GA
Whitney Buckel, PharmD, Intermountain Healthcare, Murray, UT
Michelle Cespedes, MD, MS, Icahn School of Medicine at Mount Sinai, New York, NY
Ann Chahroudi, MD, PhD, Emory University, Atlanta, GA
Natasha Chida, MD, Johns Hopkins University School of Medicine, Laurel, MD
Pearlie Chong, MD, University of North Carolina School of Medicine, Chapel Hill, NC
Andrea Ciaranello, MD, MPH, Massachusetts General Hospital, Boston, MA
Nina Clark, MD, Loyola University Medical Center, Maywood, IL
Jonathan Colasanti, MD, MSPH, Emory University, Atlanta, GA
Benjamin Colton, PharmD, National Institutes of Health, Bethesda, MD
Christopher Crnich, MD, PhD, University of Wisconsin School of Medicine and Public Health, Madison, WI
Richard Danila, PhD, MPH, Minnesota Department of Health, St. Paul, MN
Carlos del Rio, MD, FIDSA, Emory University Rollins School of Public Health, Atlanta, GA
Louise Dembry, MD, MS, MBA, FSHEA, Yale University School of Medicine/YNHH, New Haven, CT
Shireesha Dhanireddy, MD, University of Washington, Seattle, WA
Sarah B. Doernberg, MD, Yale University, New Haven, CT
Shira Doron, MD, MS, FIDSA, Tufts Medical Center, Boston, MA
Jennifer Duchon, MDCM, MPH, Columbia Presbyterian Medical Center, New York, NY
Michael J. Durkin, MD MPH, Washington University School of Medicine, Saint Louis, MO
Judith Feinberg, MD, West Virginia University School of Medicine, Morgantown, WV
Michelle Floris-Moore, MD, MS, University of North Carolina School of Medicine, Chapel Hill, NC
Bettina Fries, MD, FIDSA, Montefiore Medical Center, Bronx, NY
E. Yoko Furuya, MD, MS, Columbia University Medical Center, New York, NY
James Gaensbauer, MD, MScPH, University of Colorado School of Public Health, Aurora, CO
Bruce Gellin, MD, MPH, FIDSA, Sabin Vaccine Institute, Washington, DC
Kathleen Gensheimer, MD, MPH, FIDSA, US Food & Drug Administration, College Park, MD
Lori Gordon, PharmD, Xavier University of Louisiana, New Orleans, LA
Susan Graham, MD; MPH; PhD, University of Washington, Seattle, WA
Jeannette Guarner, MD, Emory University, Atlanta, GA
Natasha Halasa, MD, MPH, FPIDS, Vanderbilt University Medical Center, Nashville, TN
Hunter Handsfield, FIDSA, University of Washington Center for AIDS and STD, Seattle, WA
W. David Hardy, MD, Whitman Walker Health, Washington DC
Joshua Hartzell, MD, FIDSA, Walter Reed National Military Medical Center, Bethesda, MD
Rodrigo Hasbun, MD, MPH, University of Texas Health Science Center at Houston, Houston, TX
Tobias M. Hohl, MD, PhD, FIDSA, Memorial Sloan Kettering Cancer Center, New York, NY
Mark Holodniy, MD, FIDSA, FSHEA, Department of Veterans Affairs, Stanford, CA
Emily Hyle, MD, MSc, Massachusetts General Hospital, Boston, MA
David Hyun, MD, Pew Charitable Trusts, Washington, DC
Will Irving, MBBCh, FRCPath, PhD, Nottingham University, Nottingham, UK
Mamta Jain, MD, University of Texas Southwestern, Dallas, TX
Seema Jain, MD, Centers for Disease Control and Prevention, Atlanta, GA
Ravi Jhaveri, MD, FIDSA, FPIDS, University of North Carolina School of Medicine, Chapel Hill, NC
Melissa Johnson, PharmD, MHS, Duke University School of Medicine, Durham, NC
Anne Kasmar, MD MSc, Harvard Medical School, Boston, MA
Susana Keeshin, MD, University of Utah, Salt Lake City, UT
Colleen Kelley, MD, MPH, Emory University, Infectious Diseases, Decatur, GA
Nina Kim, MD MS, University of Washington, Seattle, WA
Thomas Kirn, MD, PhD, Rutgers University, New Brunswick, NJ
Jennie Kwon, DO, Washington University School of Medicine, St. Louis, MO
W. Matthew Linam, MD, MS, Arkansas Children's Hospital/ University of Arkansas for Medical Sciences, Little Rock, AR
Anurag Malani, MD, FIDSA, St. Joseph Mercy Health System, Ypsilanti, MI
Trini Matthew, MD, MPH, Conemaugh Health System, Johnstown, PA
Andre G. Melendez, MD, Emory University School of Medicine, Atlanta, GA
Michael T. Melia, MD, Johns Hopkins University School of Medicine, Baltimore, MD
Kevin Messacar, MD, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO
Ian C. Michelow, MD, DTM&H, Rhode Island Hospital and Brown University, Providence, RI
Maria Mileno, MD, Brown University, Providence, RI
Andy Miller, MD, Hospital for Special Surgery, New York, NY
Kathleen Mullane, DO, FIDSA, University of Chicago Medicine, Chicago, IL
Yoshiko Nakamachi, RN, BScN, BA, PMP ASP, University Health Network, Toronto, ON
Ank E Nijhawan, MD, MPH, MSCS, University of Texas Southwestern Medical Center, Dallas, TX
Marina Núñez, MD, PhD, Wake Forest University, Winston-Salem, NC
Ann-Christine Nyquist, MD, MSPH, FPIDS, University of Colorado School of Medicine/ Children's Hospital Colorado, Aurora, CO
Christopher Ohl, MD, FIDSA, Wake Forest School of Medicine, Winston-Salem, NC
Luis Ostrosky-Zeichner, MD, FIDSA, FSHEA, UTHealth, Houston, TX
Turner Overton, MD, Washington University School of Medicine, St Louis, MO
Julie Parsonnet, MD, FIDSA, Stanford University School of Medicine, Stanford, CA
Megan Patch, MS, PharmD, BCPS, Lee Memorial Health System, Fort Myers, FL
Federico Perez, MD, Louis Stokes Cleveland VA Medical Center, Cleveland, OH
Paula Peyrani, MD, University of Louisville, Louisville, KY
Varun Phadke, MD, Emory University, Atlanta, GA
Jason M. Pogue, PharmD, Detroit Medical Center, Detroit, MI
Christina S. Polyak, MD, MPH, Walter Reed Army Institute of Research, Silver Spring, MD
Kyle J. Popovich, MD MS FIDSA, Rush University Medical Center, Chicago, IL
Aadia Rana, MD, The Miriam Hospital, Providence, RI
Rabeeya Sabzwari, MD, Department of Veterans Affairs, Hines, IL
Rafik Samuel, MD, FIDSA, Temple University School of Medicine, Philadelphia, PA
John Sanders, MD, MPH, Wake Forest Baptist Medical Center, Winston-Salem, NC
Brian Schwartz, MD, University of California, San Francisco, San Francisco, CA
Michael U. Shiloh, MD, PhD, University of Texas Southwestern Medical Center, Dallas, TX
Michael Smit, MD, MSPH, Hasbro Children's Hospital, Providence, RI
Becky Smith, MD, Duke University Medical Center, Durham, NC
Geeta Sood, MD, Johns Hopkins University School of Medicine, Baltimore, MD
Shafer Spires, MD, Vanderbilt University Medical Center, Nashville, TN
Victoria Statler, MD, MSc, University of Louisville School of Medicine, Louisville, KY
Usha Stiefel, MD, Case Western Reserve University School of Medicine, Cleveland, OH
Scott Stienecker, MD, Parkview Health, Fort Wayne, IN
Rochelle Walensky, MD, MPH, FIDSA, Massachusetts General Hospital, Boston, MA
David J. Weber, MD, MPH, FIDSA, FSHEA, University of North Carolina, School of Public Health, Chapel Hill, NC
Nathan P. Wiederhold, PharmD, University of Texas Health San Antonio, San Antonio, TX
Zachary Willis, MD, University of North Carolina School of Medicine, Chapel Hill, NC
Karen Wong, BS, Columbia Univ. Coll. of Physicians and Surgeons, New York, NY

Table of Contents

Welcome Letter	iii	Honors, Awards, and Grants.....	xv
Acknowledgements	iv	Opening Plenary Session.....	xv
General Information	vii	Closing Plenary Session	xvii
Headquarters Office	vii	Named Lectures.....	xix
Childcare, Child Safety, and Nursing Mothers	vii	Awards Presentation Schedule:.....	xxv
IDWeek Booth/ Society Memberships	vii	IDSA Society Awards	xxvi
Newsroom	vii	IDSA Education and Research Foundation Awards	xxxvi
Smoking Policy	vii	Robert C. Moellering Trainee Travel Awards	xxxvi
IDWeek Mobile App.....	vii	SHEA Society Awards	xxxvii
IDWeek Digital Session Library.....	vii	HIVMA Awards	xli
IDWeek 2017 Program Committee.....	viii	HIVMA Clinical Fellowships.....	xlili
Program Information	ix	PIDS Society Awards	xliv
IDWeek Description.....	ix	IDWeek Awards	xliv
IDWeek Objectives	ix	CME/CPE/MOC Credit Tracker	lii
Accreditation Statement for Physicians	ix	Schedule-at-a-Glance.....	lvi
Accreditation Statement for Pharmacists	ix	IDWeek Program Tracks	lx
ACCME Guidelines for Moderators	ix	IDWeek 2017 Program Committee Financial Disclosures.....	143
Credit Designation Statement	ix		
ABIM MOC Statement.....	ix		
ABP MOC Statement	ix		
Claim CME/CPE/MOC Credit.....	x		
Continuing Education Credit for Pharmacists.....	x		
Faculty Disclosures	x		
Commercial Support Statement.....	x		
Scientific Sessions and Room Capacity.....	x		
Opening Reception and “Posters in the Park”	x		
IDWeek Town Hall 2.0 – Join the Conversation.....	x		
SHEA Business Meeting	x		
PIDS Business Meeting	x		
IDSA/HIVMA/PIDS Advocacy Luncheon.....	x		
Abstracts	x		
Poster Discussion Rounds	xi		
Poster Presentation Schedule	xi		
Speaker Ready Room.....	xii		
IDWeek Supporters.....	xii		
Allied Partners.....	xiii		

access IDWeek 2017 abstracts via OFID

All conference abstracts have been published as a supplement to *Open Forum Infectious Diseases* (OFID), the online only, fully open access journal from IDSA and HIVMA. Oral, poster, and late-breaking abstracts are being permanently archived as part of the journal and are accessible to all journal readers, not only meeting attendees or society members.



To access the IDWeek abstracts published via *OFID*, download the IDSA Journals app from the iTunes app store or go to academic.oup.com/ofid.



General Information

Headquarters Office

The IDWeek Headquarters Office will be located in Room 4 on the upper level of the San Diego Convention Center.

Certificate of Attendance

Attendees may obtain certificates of attendance at the designated IDWeek registration desk in the Exhibit Hall A or after the meeting at www.idweek.org/post-meeting-tools/.

Childcare, Child Safety, and Nursing Mothers

For childcare services at the meeting, please contact your hotel concierge.

A nursing mothers' lounge will be available during the meeting hours near registration in a dedicated area in Exhibit Hall A at the San Diego Convention Center. Only nursing mothers and their infants are permitted in this room. Water and temporary refrigeration for storage will be available for your convenience.

IDWeek Booth/ Society Booths

All attendees are invited to stop by the IDWeek booth and individual societies' booths in the registration area to learn more about the meeting and membership in IDWeek's partnering societies. At the society booths, learn more about what each society is doing to work on your behalf. Please visit the individual booths to get the latest advocacy news, and sign up to become an advocate for each society to support federal policies for ID and HIV physicians, scientists, and patients. You can also join and become a member on site or renew your membership for 2018. Stop by and say hello!

Newsroom

The Newsroom will be located in Room 19 on the upper level of the San Diego Convention Center. Press conferences will be held on selected abstracts in Room 18. Interviews with authors can also be arranged for the media.

Smoking Policy

No smoking is allowed at IDWeek.

IDWeek Mobile App

- Browse for IDWeek 2017 in the Apple App Store or Google Play market to download.
- Registered attendees may download the IDWeek mobile application for their iPhone, iPad, or Android devices for free.
- Participate in the Interactive Sessions with the mobile app, which will be used as the audience response system.
- The mobile app helps you navigate event details, manage your personal meeting agenda, connect with other attendee colleagues on Facebook and Twitter, view full abstracts and posters, and search the list of exhibiting companies.
- Authenticate the app using the email address you used to register for IDWeek.

View the App for the following information:

- Attendees with Disabilities
- Badge Policies
- Baggage and Coat Check
- Lost and Found
- Registration Information

IDWeek Digital Session Library

- View sessions from your Mac, PC, smartphone, or tablet.
- The recordings feature high-quality digital audio and visuals.
- All sessions will include synchronized speaker slides, animations, videos, and pointer movements displayed at the event.
- Access the digital library through the IDWeek app or online at www.IDWeek.org.
- Access will be free for all paid scientific attendees.

IDWeek 2017 Program Committee

Chairs:

David R. Andes, MD, FIDSA, IDWeek Chair, IDSA, University of Wisconsin Hospital, Madison, WI

Hilary M. Babcock, MD, IDWeek Chair, SHEA, Washington University School of Medicine, St. Louis, MO

Rajesh T. Gandhi, MD, FIDSA, IDWeek Chair, HIVMA, Massachusetts General Hospital, Boston, MA

Archana Chatterjee, MD, PhD, FIDSA, FPIDS, IDWeek Chair, PIDS, University of South Dakota Sanford School of Medicine, Sioux Falls, SD

Vice-Chairs:

Andrew T. Pavia, MD, FIDSA, IDWeek Vice-Chair, IDSA, University of Utah, Salt Lake City, UT

Ebbing Lautenbach, MD, FIDSA, FSHEA, Vice-Chair, SHEA, University of Pennsylvania School of Medicine, Philadelphia, PA

Jeanne M. Marrazzo, MD, MPH, FIDSA, Vice-Chair, HIVMA, University of Alabama at Birmingham School of Medicine, Birmingham, AL

Marsha S. Anderson, MD, FIDSA, IDWeek Vice-Chair, PIDS, University of Colorado School of Medicine, Aurora, CO

Members:

Cesar Arias, MD, PhD, FIDSA, University of Texas Medical School at Houston, Houston, TX

Adarsh Bhimraj, MD, Cleveland Clinic Foundation, Cleveland, OH

Robert A. Bonomo, MD, Case Western Reserve University, Cleveland, OH

Kristina A. Bryant, MD, FPIDS, University of Louisville, Louisville, KY

Christina M. Coyle, MD, Albert Einstein College of Medicine, Larchmont, NY

Inger K. Damon, MD, PhD, FIDSA, Centers for Diseases Control and Prevention, Atlanta, GA

Eric S. Daar, MD, Harbor-UCLE Medical Center, Torrance, CA

Roberta DeBiasi, MD, FPIDS, The George Washington University School of Medicine, Washington, DC

Jeffrey S. Duchin, MD, FIDSA, Public Health - Seattle and King County, Seattle, WA

Hana El Sahly, MD, FIDSA, Baylor College of Medicine, Houston, TX

Debra Goff, PharmD, The Ohio State University Medical Center, Westerville, OH

David E. Greenberg, MD, University of Texas Southwestern, Dallas, TX

Patricia Griffin, MD, FIDSA, Centers for Disease Control and Prevention, Atlanta, GA

Paul D. Griffiths, MD, University College London, London, United Kingdom

Randall T. Hayden, MD, St. Jude Children's Research Hospital, Memphis, TN

Michail Lionakis, MD, National Institutes of Health, Washington, DC

John B. Lynch, III, MD, University of Washington, Seattle, WA

Rachel A. Miller, MD, FIDSA, Duke University, Durham, NC

Joshua D. Nosanchuk, MD, FIDSA, Albert Einstein College of Medicine, Bronx, NY

Tara N. Palmore, MD, National Institutes of Health, Bethesda, MD

Jean A. Patel, PhD, Centers for Disease Control and Prevention, Atlanta, GA

Raymund R. Razonable, MD, FIDSA, Mayo Clinic, Rochester, MN

Samuel A. Shelburne, MD, PhD, FIDSA, MD Anderson Cancer Center, Houston, TX

Arjun Srinivasan, MD, FSHEA, Centers for Disease Control and Prevention, Atlanta, GA

H. Keipp Talbot, MD, MPH, FIDSA, Vanderbilt University Medical Center, Nashville, TN

Kavita Trivedi, MD, Trivedi Consultants, Albany, CA

David Van Duin, MD, University of North Carolina School of Medicine, Chapel Hill, NC

Wesley Van Voorhis, MD, PhD, FIDSA, University of Washington, Seattle, WA

Vincent B. Young, MD, PhD, FIDSA, University of Michigan, Ann Arbor, MI

Ex-officio:

William G. Powderly, MD, FIDSA, IDSA President, Washington University School of Medicine, St. Louis, MO

Paul G. Auwaerter, MD, FIDSA, IDSA President-Elect, Johns Hopkins University School of Medicine, Baltimore, MD

Chris Busky, CAE, Chief Executive Officer IDSA, Arlington, VA

Sandra Vura Harwood, CMP, Meeting Secretariat, IDWeek, Arlington, VA

Eve Humphreys, MBA, CAE, Executive Director, SHEA, Arlington, VA

Andrea Weddle, MSW, Executive Director, HIVMA, Arlington, VA

Terri Christene Phillips, MSA, Executive Director, PIDS, Arlington, VA

Infectious Diseases Society
of America
www.idsociety.org

The Society for Healthcare
Epidemiology of America
www.shea-online.org

HIV Medicine Association
www.hivma.org

Pediatric Infectious
Diseases Society
www.pids.org

IDWeek 2017
1300 Wilson Blvd., Suite 300, Arlington, VA 22209, 703-740-4961
info@idweek.org • www.idweek.org

Program Information

IDWeek Description

IDWeek 2017 is a joint meeting of IDSA, SHEA, HIVMA, and PIDS, focusing on the theme—Advancing Science, Improving Care—and featuring the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek is geared toward healthcare professionals in infectious diseases and healthcare epidemiology and prevention, including researchers, clinicians, quality and patient safety practitioners, epidemiologists, and public health officials, including those who see HIV and pediatric patients. There are no prerequisites for attendance. The four and a half day meeting will provide state-of-the-art science and clinical care updates on key topics and issues.

IDWeek Objectives

- Update infectious diseases clinicians and investigators with state of-the-art developments in the field, including timely reviews of recent advances in clinical care and research, and original reports of clinical, translational, and basic research.
- Bridge the widening gaps among the fields of infectious diseases clinical practice, clinical research, epidemiological and health services research, translational research, and basic research.
- Promote multi-disciplinary dialogue and collaboration among clinicians and investigators, thus facilitating advances in the prevention, diagnosis, and treatment of infectious diseases.

Accreditation Statement for Physicians

The Infectious Diseases Society of America (IDSA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Accreditation Statement for Pharmacists



The continuing education activities for pharmacists have been developed through a joint providership of ProCE, Inc. and the Infectious Diseases Society of America (IDSA). ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Numbers 0221-9999-17-216-L01-P through 0221-9999-17-326-L01-P, 0221-9999-17-341-L01-P through 0221-9999-17-342-L04-P, and 0221-9999-17-380-L01-P through 0221-9999-17-384-L01-P have been assigned to these live knowledge-based and application based sessions (Initial release date October 3-8, 2017). This conference is acceptable for up to 38.0 contact hours (3.8 CEUs) in states that recognize ACPE providers. The registration fee covers the cost of CE credits. CE statement will be issued by the Infectious Diseases Society of America (IDSA) at the conclusion of the conference. Participants must complete an evaluation for each session they attended to receive pharmacy CE credit. **The deadline for completing the evaluations is Monday, November 27, 2017.**

Society for Infectious Diseases Pharmacists (SIDP) has identified and contributed to content relevant for ID Pharmacists and ACPE credit at IDWeek 2017.

ACCME Guidelines for Moderators

In accordance with ACCME guidelines, and to ensure balanced presentations, at least one IDWeek Program Committee member will serve as a moderator of each session.

Credit Designation Statement

IDSA designates this live activity for a maximum of 41.75 *AMA PRA Category 1 Credits™*. The core IDWeek sessions are designated for 29.75 credit hours and premeeting workshops are an additional 12. Physicians should only claim credit commensurate with the extent of their participation in the activity.

MOC: New this year

American Board of Internal Medicine MOC

- All CME accredited sessions are also available for attendees to earn American Board of ABIM MOC points.

American Board of Pediatrics MOC

- All 13 interactive sessions are available for attendees to earn ABP MOC points. Attendees may earn a total of 8 MOC points and must attend 4 of the 13 sessions.

ABIM MOC Statement

Successful completion of this CME activity enables the participant to earn up to 29.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

More MOC points can be earned through pre-meeting workshops for an additional fee.

IDWeek 2017 physician participation information will be shared with ABIM through ACCME PARS.

ABP MOC Statement

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 8 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

IDWeek 2017 physician participation information will be shared with ABP through ACCME PARS.

Claim CME/CPE/MOC Credit

Statements of credit must be claimed either at the CME Pavilion or online after the meeting. Attendees will be required to complete a short evaluation for every session for which credit is claimed. **The deadline to claim credit is Monday November 27, 2017.** Attendees must attend each selected session in its entirety to receive CME/CPE/MOC credit. Partial credit is not available.

Continuing Education Credit for Pharmacists

Pharmacy credit will be available for select sessions at IDWeek™ 2017. Please refer to the CME/CPE/MOC Credit Tracker on pages iii - iv for a detailed list and ACPE number assigned to each applicable session. Pharmacists must attend each select session in its entirety to receive CPE credit.

Faculty Disclosures

In accordance with the ACCME Standards for Commercial Support, IDWeek must provide balance, objectivity, and scientific rigor in all sponsored educational activities accredited for CME. The intent of the disclosures is to provide the audience with information on which they can make their own independent judgments pertaining to program content. IDWeek requires all faculty to disclose relevant financial relationships that they or a spouse/partner have, or have had, within the past 12 months with companies or commercial supporters of any products/services that are related to the research being presented at IDWeek (for example, employee, grants, research support, speaker, sponsors, stockholder, etc.). In addition to verbal and written disclosures, faculty are required to provide on the first slide of PowerPoint presentations any significant financial interest(s)/relationship(s) or note that there is “nothing to disclose.”

Commercial Support Statement

IDWeek and ProCE, Inc. follow and support the ACCME/ACPE guidelines for commercial support.

Scientific Sessions and Room Capacity

Scientific sessions will be held at the San Diego Convention Center. For floor plans and maps please check the meeting app. IDWeek has made every effort to assign sessions to the appropriate room. Attendance is on a first-come, first-served basis and we ask that attendees use all available seating before standing. We apologize in advance if attendance exceeds available seating.

Opening Reception and “Posters in the Park”

The IDWeek Opening Reception and the “Posters in the Park” event will be held together on Wednesday, October 4 from 6 - 7:30 p.m. in the Poster Hall of the San Diego Convention Center, immediately following the Opening Plenary Session. Mingle with colleagues and talk to poster presenters whose research has been specially selected by each of the partner societies. While you are there, make sure to stop by the IDSA/HIVMA/PIDS/SHEA Opening Reception Advocacy Pop-Up Booth. If you are curious about how to become involved in our national advocacy efforts, stop by the booth during the opening

reception to learn how to make your voices heard on federal ID/HIV policy. This event is open to all registered attendees.

IDWeek Town Hall 2.0 – Join the Conversation

Join a lively discussion with colleagues and participate in this Town Hall discussion. This session is your chance to share the critical issues and future plans with each other. Leadership from all the societies, IDSA, SHEA, HIVMA, and PIDS will be there to hear how you want to change the world and showcase how the societies are working on issues critical to the specialty. This is your chance to add your voice and join the conversation! Please make plans to attend the Town Hall 2.0 on Friday, October 6, 6 p.m., in room 6DE in the San Diego Convention Center.

SHEA Business Meeting

Join SHEA Leadership for SHEA's Annual Business Meeting on Thursday, October 5, 2017 at 5:45 pm in the San Diego Convention Center, Room 5. SHEA's newly elected leadership will be announced along with a wrap up of SHEA's activities for the past year. Plus, SHEA will present one SHEA Society Award. Please join us for cocktails as we discuss SHEA's successful year!

PIDS Business Meeting

Join PIDS Leadership for PIDS' Annual Business Meeting at 6 p.m. on Saturday, October 7 in the Marina Ballroom D at the San Diego Marriott Marquis. Several PIDS Society Awards will be presented along with a wrap up from the year and a look forward at the year to come.

IDSA/HIVMA/PIDS Advocacy Luncheon

The annual Advocacy Luncheon highlights the work of IDSA, HIVMA, and PIDS to improve federal policy for ID and HIV physicians and other healthcare professionals, scientists, and patients. IDSA, HIVMA, and PIDS policy staff will share the latest policy news from Washington, DC, including developments on our top ID and HIV policy priorities. The luncheon will also provide an overview of the past year's advocacy achievements. Finally, the event will feature testimonials from IDSA, HIVMA, and PIDS members about their experience participating in advocacy activities, and information about current opportunities for members to get involved. This luncheon is scheduled for noon on Thursday, October 5 in the Marina Ballroom Salon D at the Marriott Marquis. All attendees are welcome to attend.

Abstracts

Abstracts are available online through the Interactive Program Planner at www.IDWeek.org. An app is available for mobile devices to access abstracts. See IDWeek Mobile App for details.

IDWeek 2017 abstracts will be published as an online supplement to *Open Forum Infectious Diseases (OFID)*, the open access journal from IDSA. They will be permanently archived as part of the journal and will be accessible to all journal readers, not only meeting attendees or society members.

Poster Discussion Rounds

These sessions emphasize poster presentations of highlighted abstracts chosen through peer review. For each session, an expert in the field will summarize the research findings in context and participants will have the opportunity to ask questions of the authors. The group leader will determine the objectives and scope of discussion.

Preregistration is not required. Participants are asked to meet in the Poster Discussion area 10 minutes prior to the beginning of the session. These sessions are scheduled as follows in the Poster Hall of the San Diego Convention Center.

Thursday, October 5, 12:30 - 2 p.m.

- 79. Managing Emerging Resistance in Gram Negatives
- 80. Big Beasts
- 81. Global Health
- 82. HIV Metabolic Diseases
- 83. Stewardship

Friday, October 6, 12:30 - 2 p.m.

- 174a. Antiretroviral Therapy
- 174b. PrEP
- 175. Big Beasts – Clinical
- 176. *Clostridium difficile*
- 177. Education
- 178. Stewardship II

Saturday, October 7, 12:30 - 2 p.m.

- 260. Advances in Diagnostics and Impact on Stewardship
- 261. Gram Positives in Healthcare Epidemiology
- 262. New Antibiotics
- 263. Pediatric Bacterial Infections
- 264. Pediatric Viral Infections
- 265. HIV and Hepatitis
- 266. Transplants

Poster Presentation Sessions

A select group of high-caliber abstract have been chosen for poster presentations. Poster presenters are encouraged to prepare handouts. Posters will be on display in the Poster Hall of the San Diego Convention Center from Thursday, October 5 to Saturday, October 7. Presenters will be available for discussion at their respective poster board on the following days and times:

Thursday, 12:30 p.m. - 2:00 p.m.

- 43. *Candida auris*: Coming Soon to a Patient Near You
- 44. Clinical Mycology
- 45. Clinical: Bone and Joint Infection
- 46. Clinical: Sexually Transmitted Infections
- 47. Clinical: Skin and Soft Tissue
- 48. Fungus Among Us: Basic Science
- 49. Global Health Potpourri

- 50. Global Infections
- 51. Emerging Resistance - Epidemiology and Mechanisms
- 52. HAI: MDRO-GNR/Emerging Resistant Bacterial Pathogens
- 53. HAI Non-Acute Care
- 54. HAI: Epidemiologic Methods
- 55. HAI: Occupational Health
- 56. HAI: Outbreaks
- 57. HAI: Surveillance + Reporting
- 58. HAI: The Environment
- 59. Hepatitis B and C in Varied Settings
- 60. HIV and Central Nervous System
- 61. HIV and Fungal Infection
- 62. HIV and Mycobacterial Infections
- 63. HIV Clinical Care and Outcomes
- 64. HIV: Cancer and Dysplasia
- 65. HIV: Cardiovascular Disease, Lipids, Diabetes
- 66. HIV: General Opportunistic Infections
- 67. HIV: Kidney, Bone + Liver Effects
- 68. HIV: Pathogenesis and Inflammation
- 69. Immunology: Host Response
- 70. Legionella
- 71. Microbial Pathogenesis
- 72. Microbiome
- 73. Outbreaks and Public Health Across the Globe
- 74. Stewardship: Data and Program Planning
- 75. Stewardship: Program Implementation
- 76. Treatment of Resistant Infections - Clinical Analyses
- 77. Use of PK/PD to optimize existing antibiotics and antifungals
- 78. Zika Virus

Friday, October 6, 12:30 p.m. - 2:00 p.m.

- 137. Adult CNS Infection
- 138. Adult Immunization: Miscellaneous
- 139. Adult Viral Infection
- 140. Assorted Pediatric Vaccines
- 141. Clinical Practice Issues
- 142. Clinical: Soup to Nuts
- 143. Clinical: UTI
- 144. Diagnostics: Biomarkers
- 145. Diagnostics: Viral
- 146. Enteric Infections and Diagnostics
- 147. Expanded Spectrum: New Antimicrobial Susceptibility Testing
- 148. *C. difficile*: From the Bench to Bedside
- 149. HAI: *C. difficile* Epidemiology, Impact, and Testing
- 150. HAI: *C. difficile* Risk Assessment and Prevention
- 151. HAI: Hand Hygiene
- 152. Herpes Zoster Vaccine
- 153. HIV Care Continuum
- 154. HIV Drug Resistance
- 155. HIV Testing
- 156. HIV: Antiretroviral Therapy
- 157. HIV: Healthcare Utilization and Costs
- 158. HIV: Pre-Exposure Prophylaxis

continues

- 159. HIV: Rapid ART Initiation
- 160. ID Medical Education
- 161. Influenza and Influenza Vaccines
- 162. Maternal/Infant Immunization
- 163. Pediatric Viral Infections
- 164. Pneumococcal Immunization and Epidemiology-Global
- 165. Pneumococcal Immunization and Epidemiology-North America
- 166. Pneumococcal Immunization in Adults
- 167. Preclinical Study with New Antibiotics and Antifungals
- 168. Stewardship: Improving Outcomes
- 169. Stewardship: Pediatric Antimicrobial Stewardship
- 170. Stewardship: Targets for Intervention
- 171. Vaccine Hesitancy
- 172. Vaccine Strategy and Policy
- 173. Viral Treatment and Prevention

Saturday, October 7, 12:30 p.m. - 2:00 p.m.

- 231. Clinical Study with New Antibiotics and Antifungals
- 232. Clinical: Bacteremia and Endocarditis
- 233. Clinical: Respiratory Track
- 234. Diagnostics: Bacterial Identification & Resistance
- 235. Diagnostics: Diarrheal Disease
- 236. Diagnostics: Mycology
- 237. Diagnostics: Novel Diagnostics
- 238. Diagnostics: Pharyngitis
- 239. Diagnostics: Mycobacteriology
- 240. Stewardship: Impact of Diagnostics
- 241. HAI: Device Related Infections
- 242. HAI: MRSA, MSSA, and Other Gram Positives
- 243. HAI: Surgical Site Infections
- 244. HIV and HBV
- 245. HIV and HCV
- 246. HIV and Women
- 247. HIV: Pediatrics
- 248. HIV: Sexually Transmitted Infections
- 249. Non-Tuberculous Mycobacteria: Epidemiology and Management
- 250. Pediatric Bacterial Infections: From A to Z
- 251. Pediatric Potpourri
- 252. Pediatric Virology
- 253. Transplant Infections: Epidemiology
- 254. Transplantation: Bacterial Infections
- 255. Transplantation: Pretransplantation Screening + Evaluation
- 256. Transplantation: Prophylaxis and Prediction
- 257. Transplantation: Fungal Infections
- 258. Tuberculosis: Epidemiology and Management
- 259. Viral Infections in Transplantation

Speaker Ready Room

Check-in is required for all speakers. All speakers must use PowerPoint presentations. Speakers should check-in at the onsite Speaker Ready Room at least 24 hours prior to presentation time. Please bring an electronic copy of your presentation. The Speaker Ready Room will be located in the Ballroom 6 Lobby of the San Diego Convention Center. In the Speaker Ready Room, you can review your presentation and approve the file to be uploaded to the central server. Professional audiovisual consultants and IDWeek staff will be available for assistance. Computers in the Speaker Ready Room will be configured with hardware and software exactly like the ones in the meeting rooms and will allow you to preview your presentation, identify problems, and make corrections as necessary before your presentation. All speakers are requested to leave a version of the PowerPoint presentation in the Speaker Ready Room for posting in the IDWeek digital library after the meeting.

Speaker Ready Room Hours of Operation:

Monday, October 2..... 2 – 6 p.m.
 Tuesday, October 3 7 a.m.– 6 p.m.
 Wednesday, October 4 6:30 a.m.– 6 p.m.
 Thursday, October 5 6:30 a.m.– 6 p.m.
 Friday, October 6 6:30 a.m.– 6 p.m.
 Saturday, October 7 6:30 a.m.– 6 p.m.
 Sunday, October 8 7 – 9 a.m.

IDWeek Supporters

IDWeek gratefully acknowledges the support of the following companies as of August 22, 2018:

Diamond Patron

Gilead Sciences, Inc.
 The Medicines Company

Platinum Patron

Pfizer
 ViiV Healthcare

Gold Patron

Astellas

Silver Patron

Merck Sharp & Dohme Corp.
 Sanofi Pasteur, Inc.

Bronze Patron

Allergan
 Healix Infusion Therapy, Inc.
 Medical Device Business Services, Inc.
 Oxford Immunotec, Inc.
 Takeda Pharmaceuticals International AG

Supported by an independent educational grant from AbbVie.
 Supported by a grant from Pfizer Inc.

Allied Partners

The following partners assisted in the development of IDWeek sessions:

- **Co-organized with the American Society for Addiction Medicine**
SYMPOSIUM

- Managing Infections in Opioid Users**

- Wednesday, October 4, 1:30 - 2:30 p.m.

- **American Association of Blood Banks**
SYMPOSIUM

- Donations with Unintended Consequences: A Multidisciplinary Approach to Reduce Blood, Cell, Tissue, and Organ Donor-Transmitted Infections**

- Saturday, October 7, 2 - 3:30 p.m.

- **American Society of Transplantation**
INTERACTIVE SESSION

- Challenging Transplant Cases: When Transplant ID Specialists say, What?!**

- Saturday, October 7, 8:30 - 10 a.m.

- **Brazilian Society of Infectious Diseases and the Pan-American Society of Infectious Diseases**
SYMPOSIUM

- Zika Without Borders**

- Saturday, October 7, 10:30 a.m. - noon

- **Centers for Disease Control and Prevention**
PREMEETING WORKSHOP

- Best Practices for Antimicrobial Stewardship Programs (\$)**

- Tuesday, October 3, 8 a.m. - 5:15 p.m.

- SYMPOSIUM**

- What's new with Zika**

- Thursday, October 5, 8:30 - 10 a.m.

- **European Society of Clinical Microbiology and Infectious Diseases**

- INTERACTIVE SESSION**

- Challenging Cases in Infectious Diseases**

- Friday, October 6, 10:30 a.m. - noon

- **Co-organized with the IDSA Clinical Affairs Committee**
MEET-THE-PROFESSOR SESSION

- Wound Care 101**

- Thursday, October 5, 7 - 8:15 a.m.

- SYMPOSIUM**

- ID Physicians Adapting to Healthcare Reform**

- Thursday, October 5, 8:30 - 10 a.m.

- MEET-THE-PROFESSOR SESSION**

- Outpatient Parenteral Antimicrobial Therapy**

- Saturday, October 7, 7 - 8:15 a.m.

- SYMPOSIUM**

- Infectious Disease Telehealth**

- Saturday, October 7, 8:30 - 10 a.m.

- **IDSA Education Committee and the Medical Education Work Group**

- MEET-THE-PROFESSOR SESSION**

- Essentials for the Everyday Leader**

- Thursday, October 5, 7 - 8:15 a.m.

- MEET-THE-PROFESSOR SESSION**

- Make Learning Last in the Large Group Setting**

- Friday, October 6, 7 - 8:15 a.m.

- SYMPOSIUM**

- Hot Topics in Medical Education**

- Friday, October 6, 8:30 - 10 a.m.

- **IDSA ID Training Program Directors' Committee**
Fellows' Day

- Wednesday, October 4, 8 a.m. - noon

- **National Institute of Allergy and Infectious Diseases**
SYMPOSIUM

- Global Fungal Infections**

- Thursday, October 5, 2 - 3:30 p.m.

- **Society of Infectious Diseases Pharmacists**
INTERACTIVE SESSION

- Controversies in Antimicrobial Stewardship Programs: Pro/Con Debates**

- Thursday, October 5, 8:30 - 10 a.m.

- SYMPOSIUM**

- Stewardship Accreditation Standards in Action**

- Friday, October 6, 2 - 3:30 p.m.

- MEET-THE-PROFESSOR SESSION**

- Don't Make These Mistakes: Frequent Barriers in Antimicrobial Stewardship Programs**

- Saturday, October 7, 7 - 8:15 a.m.

- **Society of Infectious Diseases Pharmacists and the Pediatric Infectious Diseases Society**

- MINI-SYMPOSIUM**

- Maternal-Child Infections: Antimicrobial Pharmacokinetics and Pharmacodynamics**

- Sunday, October 8, 8 - 9 a.m.

DOWNLOAD THE OFFICIAL **IDWeek 2017™** mobile application

Search the Apple App Store and Google Play for “**IDWeek**” or access the mobile app online at **app.idweek.org**.

- Search for sessions
- Create your schedule
- Read abstracts and view posters
- Browse the exhibitors
- Find helpful meeting information
- Connect with other attendees
- Participate in audience response

**Use your registration email address to gain access.*



Honors, Awards, and Grants

Special Opening Plenary Session: Evolution and Revolution: Infectious Disease Promise and Challenges in the 21st Century

Wednesday, October 4, 2017: 3:45 - 5:45 p.m.
San Diego Convention Center: Room 20ABCD



The Challenge of Pandemic Preparedness

ANTHONY FAUCI, MD, FIDSA, is director of the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health, where he oversees an extensive research portfolio devoted to preventing, diagnosing, and treating infectious and immune-mediated diseases. Dr. Fauci has been a key advisor to five Presidents and their administrations on global AIDS issues, and on initiatives to bolster medical and public health preparedness against emerging infectious disease threats such as pandemic influenza. As an HIV/AIDS researcher he has been involved in the scientific effort since AIDS was recognized in 1981, conducting pivotal studies that underpin the current understanding of the disease and efforts to develop therapies and tools of prevention. Dr. Fauci was one of the principal architects of the President's Emergency Plan for AIDS Relief (PEPFAR), which has helped save millions of lives throughout the developing world.

ANTHONY FAUCI, MD, FIDSA

Dr. Fauci is the long-time chief of the NIAID Laboratory of Immunoregulation. He has made many contributions to basic and clinical research on the pathogenesis and treatment of immune-mediated and infectious diseases. He helped pioneer the field of human immunoregulation by making important basic scientific observations that underpin the current understanding of the regulation of the human immune response. In addition, Dr. Fauci is widely recognized for delineating the precise mechanisms whereby immunosuppressive agents modulate the human immune response. He developed effective therapies for formerly fatal inflammatory and immune-mediated diseases such as polyarteritis nodosa, granulomatosis with polyangiitis (formerly Wegener's granulomatosis), and lymphomatoid granulomatosis.

Dr. Fauci is a member of the US National Academy of Sciences and the US National Academy of Medicine, and is the recipient of numerous prestigious awards for his scientific and global health accomplishments. He has been awarded 43 honorary doctoral degrees and is the author, coauthor, or editor of more than 1,300 scientific publications, including several major textbooks.

Dr. Fauci's talk, titled, "The Challenge of Pandemic Preparedness," will focus what can be learned from past pandemic responses, how to improve responses going forward, and strategies to accelerate vaccine development during future outbreaks.



**MARGARET (PEGGY) A.
HAMBURG, MD**

A New Strategy to Stop Future Epidemics: Role of CEPI in New Vaccine Development

MARGARET (PEGGY) A. HAMBURG, MD, is an internationally recognized leader in public health and medicine. Dr. Hamburg is the former commissioner of the US Food and Drug Administration (FDA), having served for almost six years. As FDA commissioner she was known for advancing regulatory science, streamlining and modernizing FDA's regulatory pathways, and globalization of the agency. Before joining FDA, Dr. Hamburg was founding vice president and senior scientist at the Nuclear Threat Initiative, a foundation dedicated to reducing nuclear, chemical and biological threats. Previous government positions include assistant secretary for planning and evaluation, US Department of Health and Human Services, health commissioner for New York City, and assistant director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

As foreign secretary of the National Academy of Medicine, the health arm of the National Academy of Sciences, Engineering and Medicine, Dr. Hamburg serves as senior advisor on international matters and is the liaison with other Academies of Medicine around the world. She is president-elect of the American Association for the

Advancement of Science, as well as an elected member of the Council on Foreign Relations and the National Academy of Medicine. Dr. Hamburg currently sits on the boards of the Commonwealth Fund, the Simons Foundation, the Urban Institute, the Global Alliance for Vaccines and Immunization, the Parker Institute for Cancer Immunotherapy and the American Museum of Natural History. She is chair of the Joint Coordinating Group for the Coalition for Epidemic Preparedness and Innovation (CEPI), and a member of the Harvard University Global Advisory Council, the Global Health Scientific Advisory Committee for the Gates Foundation, the Harvard Medical School Board of Fellows, and the World Dementia Council.

Dr. Hamburg earned her BA from Harvard College, her MD from Harvard Medical School and completed her medical residency at Weill Cornell Medical Center.

Dr. Hamburg's talk, titled "A New Strategy to Stop Future Epidemics: Role of CEPI in New Vaccine Development," will address the critical challenges in vaccine development and outline the role and activities of the newly formed Coalition for Epidemic Preparedness Innovations, which can help meeting those challenges.

Closing Plenary Session:

21st Century Curse and Infectious Disease

Sunday, October 8, 2017: 9:15 - 10:45 a.m.
San Diego Convention Center: Room 6AB



**JAMES E. CROWE Jr., MD,
FIDSA**

Monoclonal Antibodies for Infectious Diseases: Why We Are on the Threshold of a Major Therapeutic Revolution

JAMES E. CROWE Jr., MD, FIDSA, is director of the Vanderbilt Vaccine Center and the Ann Scott Carell Professor of Pediatrics, Pathology, Microbiology and Immunology at Vanderbilt University Medical Center. Dr. Crowe's laboratory studies the human immune response to infection or vaccination. His team has studied immunity to a wide variety of major human pathogens, including avian influenza, chikungunya virus, Ebola and Marburg viruses, dengue and Zika viruses and others. His team has developed new methods for rapid and efficient isolation of broad and potent neutralizing human monoclonal antibodies from human survivors of viral diseases. Antibodies to four viral targets from this program are now in clinical development. His group also is working to develop novel methods in computational immunology for rational structure-based design of vaccines and antibodies. Dr. Crowe is also the director of the Human Immunome Program in the Human Vaccines Project, an ambitious effort to identify the sequence of all transcripts for adaptive immune receptors on the planet.

Dr. Crowe's presentation, titled, "Monoclonal Antibodies for Infectious Diseases: Why We are on the Threshold of a Major Therapeutic Revolution," will explore the potential protective or therapeutic role of antibodies in infectious diseases, the mechanisms antibodies use to inhibit major viral pathogens, and the concept of structure-based vaccine design using information on antibody epitopes.



**CHRISTOPHER KARP, MD,
FIDSA**

Pathogen Eradication: The View Ahead

CHRISTOPHER KARP, MD, FIDSA, leads the team that targets fundamental scientific and technological advances in global health to create and improve preventive and therapeutic interventions for infectious diseases, as well as conditions that affect mothers, infants and children in the area of family health. An immunologist, infectious diseases specialist and internist, Dr. Karp joined the Bill & Melinda Gates Foundation in 2012 as deputy director, Vaccines & Host-Pathogen Biology on the Global Health Discovery and Translational Sciences team. Prior to the foundation, he was on the faculty of the Departments of Medicine and Molecular Microbiology and Immunology at Johns Hopkins University School of Medicine, and founded the Division of Molecular Immunology at Cincinnati Children's Hospital Research Foundation, where he was Esiason/Bell Professor of Pediatrics. Dr. Karp received an undergraduate degree from Brandeis University and an MD from the University of North Carolina School of Medicine, where he was a Morehead Fellow. He trained in Medicine at Brown University and Georgetown University, and then was an NRSA fellow in the Laboratory of Parasitic Diseases at NIAID, and an infectious diseases fellow at Johns Hopkins.

Dr. Karp's presentation, titled, "Pathogen Eradication," will focus on the important role and progress of global pathogen eradication efforts.



**DAVID THOMAS, MD, MPH,
FIDSA**

The Pivotal Role of Treatment in the Elimination of HCV

DAVID THOMAS, MD, MPH, FIDSA, is chief of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine at the Johns Hopkins School of Medicine. Dr. Thomas's research is focused on hepatitis C virus (HCV). His team discovered that there were racial differences in the outcome of HCV infection and have uncovered about half of the host genetic basis. The interactions between HIV and HCV have been a special research and clinical emphasis. Dr. Thomas has served the National Institutes of Health, Centers for Disease Control and Prevention, American Association of Liver Disease, Infectious Diseases Society of America, the Conference on Retroviruses and Associated Infections, and the associated biomedical journals in multiple leadership/editorial capacities. He is a member of ASCI (2001), AAP (2011), and received the Society Citation Award from IDSA (2014). He currently co-leads the panel writing guidelines for HCV infection. Dr. Thomas is deeply committed to fostering the physician-scientist career pathway.


Dr. Thomas' talk, titled, "The Pivotal Role of Treatment in the Elimination of HCV," will focus on how treatment contributes to the elimination of hepatitis C infection, compare and contrast the roles of antiviral medication in prevention and treatment to eliminate hepatitis C infection, and look at the obstacles to eliminating hepatitis C infection in the US.

Named Lectures

2016 Edward H. Kass Lecture

Thursday, October 5, 2017: 3:45 - 4:30 p.m.

San Diego Convention Center, 20ABCD



Edward H. Kass, MD
1917-1990

EDWARD H. KASS, MD, was one of the founding leaders of IDSA. He served as the Society's seventh president in 1970 as well as the Society's secretary from 1964 to 1967. He helped to create not only IDSA, but also the Channing Memorial Laboratory and the International Congress on Infectious Diseases. Dr. Kass was instrumental in securing IDSA's role in publishing *The Journal of Infectious Diseases*, and he developed the concept for *Reviews of Infectious Diseases* – now *Clinical Infectious Diseases*. Not only was he a pioneer in the study of infection, he was an advocate for social justice and passionate about addressing poverty, racism and discrimination. Dr. Kass held the positions of William Ellery Channing Professor of Medicine at Harvard Medical School and director of the Channing Laboratory at Harvard Medical School and Brigham and Women's Hospital. In his memory, IDSA maintains the annual Edward H. Kass Lectureship in the History of Medicine and the Kass Awards, which assist medical students and residents with travel expenses to IDWeek. The first Kass Lectureship was given in 1991 by Theodore E. Woodward, MD.



JAMES M. HUGHES, MD, FIDSA

He is a member of the National Academy of Medicine (NAM), vice chair of the NAM Forum on Microbial Threats, a past president of the Infectious Diseases Society of America, a member of the Board of Governors of the American Academy of Microbiology, and co-chair of the ASM Antimicrobial Resistance Coalition.

Dr. Hughes' presentation, titled, "Reflections on Emerging Microbial Threats: Relevance of the One Health Concept," will explore the One Health concept and its value as well as the importance of a One Health approach to emerging microbial threats.

2017 Featured Lecturer

Reflections on Emerging Microbial Threats: Relevance of the One Health Concept

JAMES M. HUGHES, MD, FIDSA, is professor of medicine (Infectious Diseases) and Public Health (Global Health) at Emory University and co-director of the Emory Antibiotic Resistance Center. Prior to joining Emory, he worked for the Centers for Disease Control and Prevention (CDC), serving as director of the National Center for Infectious Diseases from 1992 to 2005 and as an assistant surgeon general in the US Public Health Service. Dr. Hughes received his MD from Stanford University and trained in internal medicine at the University of Washington, infectious diseases at the University of Virginia, and preventive medicine at CDC.


Past Lecturers

2016	JOHN PERFECT	2007	DAVID RELMAN	1998	MARTIN J. BLASER
2015	KAREN C. CARROLL	2006	WAFAA EL-SADR	1997	JUDITH WASSERHEIT
2014	JANET GILSDORF	2005	CONSTANCE BENSON	1996	CHARLES S. BRYAN
2013	PETER HOTEZ	2004	LUCY TOMPKINS	1995	ALFRED EVANS
2012	ELAINE LARSON	2003	SEYMOUR J. KLEBANOFF	1994	JAY SANFORD
2011	LARRY PICKERING	2002	STANLEY A. PLOTKIN	1993	FLOYD DENNY
2010	RICHARD WENZEL	2001	JOHN G. BARTLETT	1992	ALLAN BRANDT
2009	PAUL A. VOLBERDING	2000	WALTER E. STAMM	1991	THEODORE E. WOODWARD
2008	ARTURO CASADEVALL	1999	SHARON L. HILLIER		

continues

2017 John F. Enders Lecture

Thursday, October 5, 2017: 5 - 5:45 p.m.
San Diego Convention Center, 20ABCD



John F. Enders, PhD
1897-1985

JOHN F. ENDERS, PhD, served as the second president of IDSA. Dr. Enders and two of his colleagues received the 1954 Nobel Laureate in Medicine for their discovery of the ability of poliomyelitis viruses to grow in cultures of various types of tissue. This discovery led to the development of vaccines against polio, measles, rubella, and mumps, as well as other advances. For almost 15 years, he worked in Dr. Hans Zinnser's department at Harvard where his early use of tissue cultures for the growth of viruses in vitro began in collaboration with Dr. Zinnser. Dr. Enders received numerous awards in addition to the Nobel Prize, including the Albert Lasker Award of the American Public Health Association, Germany's Koch Medal, and the Cameron Prize of the University of Edinburgh. He received the Presidential Medal of Freedom and honorary degrees from many universities. Dr. Enders has been described as "one of the most modest, magnificent men in the history of sciences." His contributions also include major advances in the field of genetics, links between viruses and cancer, and insights into the pattern and process of tumor growth, and are noted among the most important of the 20th century. The John F. Enders Distinguished Lecture in Medical Virology, which bears his name, was first given in 1988 by Thomas Weller, MD.



CONNIE CELUM, MD, MPH, FIDSA

2017 Featured Lecturer

HIV Prevention: It's All About People, Products, and Choices

CONNIE CELUM, MD, MPH, FIDSA, is professor of global health and medicine, adjunct professor of epidemiology and co-director of the International Clinical Research Center in the Department of Global Health at University of Washington. Dr. Celum is an infectious disease epidemiologist with a focus on HIV prevention. She has led multi-center HIV prevention efficacy trials, including genital herpes suppression for prevention of HIV acquisition (HPTN 039) and prevention of HIV transmission and disease progression in HIV serodiscordant couples (Partners in Prevention HSV/HIV Transmission Study). Dr. Celum co-led the Partners PrEP Study of tenofovir-based pre-exposure antiretroviral prophylaxis among HIV serodiscordant couples and a demonstration project of ARV-based prevention in serodiscordant couples in Kenya and Uganda (the Partners Demo project). Dr. Celum is leading implementation science research about PrEP implementation for young women in Kenya, South Africa, and Zimbabwe (HPTN 082/HERS, 3Ps, POWER and MTN 034/REACH studies).

Dr. Celum's talk, titled, "HIV Prevention: It's All About People, Products, and Choices," will focus on the progress and lessons learned regarding effective HIV prevention interventions and the remaining gaps and challenges of prevention options.

Past Lecturers

2016	JUDITH CURRIER	2006	FREDERICK G. HAYDEN	1996	ANNE GERSHON
2015	LYNNE MOFENSON	2005	STEPHEN E. STRAUS	1995	CIRO DE QUADROS
2014	ROGER GLASS	2004	MARTIN S. HIRSCH	1994	CLARENCE PETERS
2013	NANCY J. COX	2003	CATHERINE M. WILFERT	1993	CAROLINE BREESE HALL
2012	DAVID THOMAS	2002	ANN M. ARVIN	1992	BARRY BLOOM
2011	ANGELA M. CALIENDO	2001	LAWRENCE COREY	1991	ROBERT SCHOOLEY
2010	DON GANEM	2000	RICHARD J. WHITLEY	1990	GERTRUDE ELION
2009	STANLEY M. LEMON	1999	SAMUEL L. KATZ	1989	GEORGE MILLER
2008	BRUCE WALKER	1998	RICHARD JOHNSON	1988	THOMAS WELLER
2007	THOMAS C. QUINN	1997	DIANE GRIFFIN		

Caroline B. Hall Lectureship

Friday, October 6, 2017: 11:00 a.m. - noon

San Diego Convention Center, 15AB



Caroline B. Hall, MD

The lectureship is dedicated to and honors Dr. Caroline B. Hall, a world renowned pediatrician, teacher, researcher, and a founding member of PIDS. Dr. Hall held the position of professor of pediatrics and medicine at the University of Rochester School of Medicine for over 40 years. She was a legend in pediatric infectious diseases for her groundbreaking and prolific research on respiratory syncytial virus, human herpesvirus 6, and other respiratory viral pathogens and authored over 500 peer-reviewed publications. Her contributions significantly enhanced our understanding of diverse respiratory viral infections and resulted in the development of diagnostic and management guidelines for infections that continue to be important clinical references. Dr. Hall served as the fifth president of PIDS and was the society's historian. She was a member of the Institute of Medicine and the Royal College of Physicians and received numerous honors, including the Distinguished Physician and Distinguished Service awards from PIDS, the IDSA John F. Enders Lectureship, the Pan American Society for Virology Award, and the Robert M. Chanock Lifetime Achievement Award.



**JANET A. ENGLUND, MD,
FIDSA, FPIDS**

2017 Featured Lecturer

Respiratory Viral Infections in the High Risk Patient

The research interests of **JANET A. ENGLUND, MD, FIDSA, FPIDS**, include the study of the diagnosis, prevention and treatment of viral respiratory diseases in children, pregnant women, and immunocompromised hosts. As a clinical associate at Fred Hutchinson Cancer Research Center, she is actively involved in transplant-related protocols. Dr. Englund's research group at Seattle Children's Hospital is part of the New Vaccine Surveillance Network of the Centers for Disease Control (CDC) (2010 through 2021), participating in respiratory and gastrointestinal viral surveillance.

Dr. Englund is active in national and international organizations

including American Academy of Pediatrics, the CDC-sponsored Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee (VRPBAC), and the maternal immunization safety group at the World Health Organization (WHO). She is past president of PIDS, a past member of the influenza working groups of both WHO and IDSA, and a current member of the IDSA Board of Directors. She believes a challenging aspect of the field of Infectious Diseases today is to continue the important work we have already done by training and working with students, fellows, and young faculty in our field.

Dr. Englund's presentation, titled, "Respiratory Viral Infections in the High Risk Patient," will look at the impact of respiratory viral infections on high-risk patients, particularly the types of patients at risk, the clinical presentation in immunocompromised hosts, and current and potential future therapy to prevent or treat respiratory viral infections in the high-risk patient.

Past Lecturers

2016	OCTAVIO RAMILO
2015	JOHN V. WILLIAMS

continues

2017 SHEA Lectureship
Friday, October 6, 2017: 3:45 - 4:15 p.m.
San Diego Convention Center, 20ABCD



NEIL O. FISHMAN, MD, MA,
FSHEA, FIDSA

2017 Featured Lecturer

NEIL O. FISHMAN, MD, MA, FSHEA, FIDSA, is associate chief medical officer for the University of Pennsylvania Health System. He is also an associate professor of Medicine at the University of Pennsylvania School of Medicine. His research focuses on outcome assessment and quality management issues in infectious diseases. Specific interests include models to improve the use of antibiotics, risk factors for the emergence of resistance, and the relationship between antimicrobial use and the emergence of resistance. He received the 1996 Abbott Achievement Award from the Infectious Diseases Society of America in recognition of his ongoing efforts to improve antibiotic utilization throughout the University of Pennsylvania Health System and for a proposal to study the effects of a comprehensive antimicrobial management program on the quality and cost of patient care in community hospitals. Additional ongoing studies include an investigation of risk factors for the emergence of drug resistant pneumococci and a randomized controlled trial of antimicrobial management strategies. Dr. Fishman trained in infectious diseases at the University of Pennsylvania and received his medical degree at Temple University. He served as president of the Society for Healthcare Epidemiology of America in 2010 and during his tenure founded the SHEA Education & Research Foundation. He currently chairs SHEA’s Antimicrobial Stewardship Committee.

Dr. Fishman’s presentation, titled, “My Worlds Collide: Infectious Diseases and High Reliability in Healthcare,” will describe the principles of high reliability organizations. It will also discuss how infectious diseases physicians, healthcare epidemiologists, and antimicrobial stewardship leaders can promote interventions to achieve high reliability in healthcare and influence behavior change in the context of a high reliability model.

The SHEA Lectureship award is given annually to recognize the career contributions of a senior investigator in healthcare epidemiology and infection prevention and control. Awardees have shown leadership through notable contributions to the science of healthcare epidemiology, demonstration of ongoing dedication to advancing the field, demonstration of mentorship, and dedication to SHEA and its mission to prevent healthcare-associated infections.

Past Lecturers

2016	DANIEL SEXTON	2005	ROBERT WEINSTEIN
2015	RICHARD PLATT	2004	LINDSAY NICOLE
2014	LISA SAIMAN	2003	WILLIAM JARVIS
2013	DENISE CARDO	2001	WILLIAM SCHECKLER
2012	WILLIAM RUTALA	2000	WALTER HIERHOLZER
2011	VICTORIA FRASER	1999	DENNIS MAKI
2010	DAVID HENDERSON	1998	JOHN E. MCGOWAN
2009	ELAINE LARSON	1997	RICHARD WENZEL
2008	DIDIER PITTET	1996	WILLIAM SCHAFFNER
2007	DALE GERDING	1995	PHILIP S. BRACHMAN
2006	C . GLEN MAYHALL	1993	JOHN V. BENETT

2017 Joseph E. Smael Lecture

Saturday, October 7, 2017: 3:45 - 4:30 p.m.

San Diego Convention Center, 6AB



Joseph E. Smael, MD, MA, DSci
1907-1963

JOSEPH E. SMADEL, MD, MA, DSci, was a physician and investigator who created a bridge between basic laboratory science and the clinician, making significant contributions to the knowledge of psittacosis, vaccinia, variola, myxomatosis, and viral encephalitis. During World War II, Dr. Smael led a study of control measures of typhus fever in Egypt and southern Italy. Dr. Smael served at the Department of Virus and Rickettsial Diseases of the Army Medical School, Walter Reed Army Institute of Research and National Institutes of Health (NIH). He held the position of chief of virology and rickettsiology in the Division of Biologic Standards at NIH until his death. The Joseph E. Smael Lecture is intended to honor someone who has made a significant impact in public health.



RUTH LYNFIELD, MD, FIDSA

the co-principal investigator of the Minnesota Emerging Infections Program. Dr. Lynfield has conducted numerous infectious disease investigation and responses to outbreaks; she has also developed surveillance systems, and conducted public health research, evaluation and planning. Her research focuses on emerging infections, antimicrobial resistance and prevention of infectious diseases. Dr. Lynfield has also worked on antimicrobial stewardship tools and guidance across the continuum of care. Dr. Lynfield is a member of the National Vaccine Advisory Committee, the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee, and the Centers for Disease Control and Prevention (CDC) Board of Scientific Counselors, Office of Infectious Diseases. She is also a member of the American Academy of Pediatrics' Committee on Infectious Disease. She has co-chaired the CDC Emerging Infections Program Steering Committee since 2008. Dr. Lynfield has chaired the IDSA Public Health Committee and has served on multiple other public health workgroups and committees. She is an adjunct professor of medicine at the University of Minnesota.

Dr. Lynfield's talk, titled, "Human Activity and Infectious Disease Outbreaks: Can Insight Impact the Trajectory?" will explore the ecological factors that impact the emergence of infectious diseases, how social factors can influence the transmission of infectious diseases, and the many ways to detect, prevent, and control emerging infectious diseases.

2017 Featured Lecturer

Human Activity and Infectious Disease Outbreaks: Can Insight Impact the Trajectory?

RUTH LYNFIELD, MD, FIDSA, received her medical degree from Cornell University Medical College and did postgraduate training in pediatrics and in pediatric infectious diseases at Massachusetts General Hospital (MGH). She attended in pediatric infectious disease at MGH from 1992 to 1997, and was assistant director of the New England Regional Newborn Screening Program at the Massachusetts State Laboratory from 1992 to 1997. Dr. Lynfield then joined the Minnesota Department of Health as a medical epidemiologist, and was appointed state epidemiologist in 2007 and medical director of the Department in 2010. She is

Past Lecturers


2016	PATRICIA GRIFFIN	2003	DIDIER RAOULT	1989	THOMAS GRAYSTON
2015	BRUNO MOONEN*	2002	DONALD A. HENDERSON	1988	P. FREDERICK SPARLING
	(IN HONOR OF ALAN MAGILL)	2001	KARL M. JOHNSON	1987	JACK M. GWALTNEY
2014	ROBERT WEINSTEIN	2000	ANNE SCHUCHAT	1986	RICHARD T. JOHNSON
2013	MYRON S. COHEN	1999	LOU H. MILLER	1985	FRANKLIN A. NEVA
2012	DIANE HAVLIR	1998	THOMAS WELLEMS	1984	MAURICE R. HILLEMANN
2011	WILLIAM SCHAFFNER	1997	BRETT FINLAY	1983	GARRISON RAPMUND
2010	KATHLEEN NEUZIL	1996	SCOTT B. HALSTEAD	1982	RICHARD B. HORNICK
2009	MYRON LEVINE	1995	DAVID T. DENNIS	1981	BARUJ BENACERRAF
2008	JANE E. KOEHLER	1994	ROY ANDERSON	1980	ROBERT M. CHANOCK
2007	KATHRYN M. EDWARDS	1993	RICHARD GUERRANT	1979	PHILIP K. RUSSELL
2006	ALLAN R. RONALD	1992	ALFRED SOMMER	1978	PHILIP Y. PATERSON
2005	LYLE PETERSON	1991	CHARLES CARPENTER	1977	D. CARLETON GAJDUSEK
2004	ERIC OTTESON	1990	ZENVIL COHEN		

continues

2017 Maxwell Finland Lecture

Saturday, October 7, 2017: 5 - 5:45 p.m.

San Diego Convention Center, 6AB



Maxwell Finland, MD, DSci
1902-1987

MAXWELL FINLAND, MD, DSci, served as the first president of IDSA. His prestigious medical career spanned more than 50 years at Harvard University and Boston City Hospital. He was internationally recognized for his study of the incidence and character of infectious diseases and their specific treatments. Dr. Finland's unbiased judgment on the role of antimicrobial agents in medical treatment was universally respected. He is credited with influencing pioneering studies of antibiotic therapy and the treatment for pneumonia and respiratory injuries linked to exposure to noxious gases. He was noted as establishing early identification of new infectious hazards and the emergence of dangerous new infections in hospitalized patients. The Maxwell Finland Lecture, which bears his name, was first given in 1972 by Theodore E. Woodward, MD.



STEVEN HOLLAND, MD, FIDSA

Dr. Holland's presentation, titled, "Understanding Nontuberculous Mycobacteria in the Human Context," will focus on the critical differences between pulmonary and disseminated nontuberculous mycobacterial disease, the most common immune defects associated with disseminated nontuberculous mycobacterial disease, and the different genetic lesions leading to either pulmonary or disseminated nontuberculous mycobacterial disease.

2017 Featured Lecturer

Understanding Nontuberculous Mycobacteria in the Human Context

STEVEN HOLLAND, MD, FIDSA, serves as director of the Division of Intramural Research (DIR) at National Institute of Allergy and Infectious Diseases (NIAID). Dr. Holland provides overall executive direction and scientific leadership for the division's basic and clinical research activities, which cover a wide range of biomedical disciplines related to infectious diseases, immunology, and allergy. Dr. Holland also serves as the chief of the Immunopathogenesis Section within the Laboratory of Clinical Infectious Diseases (LCID). Dr. Holland received his BA from St. John's College in Annapolis, Maryland, and his MD from the Johns Hopkins University School of Medicine. He remained at Johns Hopkins for his internal medicine residency, chief residency, and fellowship in infectious diseases. Dr. Holland started at NIAID in 1989 as a National Research Council fellow. In 1991, he joined the Laboratory of Host Defenses (LHD). He was tenured in 2000 and became chief of the Immunopathogenesis Section. In 2004, Dr. Holland became chief of the newly created Laboratory of Clinical Infectious Diseases, a position he held until becoming director. Dr. Holland is the author of more than 500 publications and has been named an NIH Distinguished Investigator.

Past Lecturers

2016	ROBERT C. READ	2001	MARGARET K. HOSTETTER	1986	ALEXANDER D. LANGMUIR
2015	HENRY "CHIP" CHAMBERS	2000	P. FREDERICK SPARLING	1985	HARRY F. DOWLING
2014	LIISE-ANNE PIROFSKI	1999	FREDERICK S. SOUTHWICK	1984	ALBERT B. SABIN
2013	VICTORIA J. FRASER	1998	ELAINE TOUMANEN	1983	PAUL G. QUIE
2012	GEORGE MCCracken	1997	GERALD KEUSCH	1982	JACK S. REMINGTON
2011	JULIE PARSONNET	1996	BARBARA MURRAY	1981	ABRAHAM I. BRAUDE
2010	GERALD FRIEDLAND	1995	THEODORE EICKHOFF	1980	MACLYN MCCARTY
2009	CYNTHIA L. SEARS	1994	CAROL J. BAKER	1979	HARRY A. FELDMAN
2008	ANTHONY FAUCI	1993	STANLEY FALKOW	1978	DOROTHY M. HORSTMANN
2007	LOUIS B. RICE	1992	JOHN E. BENNETT	1977	GEORGE G. JACKSON
2006	W. MICHAEL SCHELD	1991	MICHAEL BLAESE	1976	EDWARD H. KASS
2005	WILLIAM DISMUKES	1990	ROBERT GALLO	1975	GEORGE MEIKLEJOHN
2004	KING HOLMES	1989	JOHN ROBBINS	1974	ROBERT AUSTRIAN
2003	ROBERT C. MOELLERING, JR.	1988	THOMAS MERIGAN	1973	LOUIS WEINSTEIN
2002	JEROME KLEIN	1987	R. PALMER BEASLEY	1972	THEODORE E. WOODWARD

Awards Presentation Schedule:

■ IDSA Society Awards

IDSA Alexander Fleming Award for Lifetime Achievement - Barbara E. Murray, MD, FIDSA

Wednesday, October 4, at 3:45 p.m. in 20ABCD, San Diego Convention Center

IDSA Society Citation Award - Wendy Armstrong, MD, FIDSA; Patrick Joseph, MD, FIDSA, FSHEA; Dean L. Winslow, MD, FIDSA

Thursday, October 5, at 4:30 p.m. in 20ABCD, San Diego Convention Center

IDSA Watanakunakorn Clinician Award - Douglas R. Osmon, MD, MPH, FIDSA

Thursday, October 5, at 4:30 p.m. in 20ABCD, San Diego Convention Center

IDSA Clinical Teacher Award - Michael J. Barza, MD, FIDSA

Saturday, October 7, at 4:30 p.m. in 6AB, San Diego Convention Center

IDSA Oswald Avery Award for Early Achievement - William J. Steinbach, MD, FIDSA, FPIDS

Saturday, October 7, at 4:30 p.m. in 6AB, San Diego Convention Center

IDSA Walter E. Stamm Mentor Award - Stephen B. Calderwood, MD, FIDSA

Saturday, October 7, at 4:30 p.m. in 6AB, San Diego Convention Center

IDSA Clinical Practice Innovation Award - Kavita P. Bhavan, MD, FIDSA

Saturday, October 7, at 4:30 p.m. in 6AB, San Diego Convention Center

IDSA D.A. Henderson Award for Outstanding Contributions to Public Health - F. Marc LaForce, MD, FIDSA

Saturday, October 7, at 4:30 p.m. in 6AB, San Diego Convention Center

■ SHEA Society Awards

SHEA Senior Scholarship Award - William Schaffner, MD, FSHEA, FIDSA

Wednesday, October 4, at 3:45 p.m. in 20ABCD, San Diego Convention Center

SHEA Advanced Practice Infection Preventionist Award - Kathleen Gase, MPH, CIC, FAPIC

Thursday, October 5, at 5:45 p.m. in 5, San Diego Convention Center, SHEA Business Meeting

SHEA Antibiotic Stewardship Scholarship Award - Sara Cosgrove, MD, MS, FSHEA, FIDSA

Friday, October 6, at 4:30 p.m. in 20ABCD, San Diego Convention Center

SHEA Mentor Scholar Award - Kent Sepkowitz, MD, FSHEA, FIDSA

Friday, October 6, at 4:30 p.m. in 20ABCD, San Diego Convention Center

SHEA Mid-Career Scholarship Award - Nasia Safdar, MD, FSHEA

Friday, October 6, at 4:30 p.m. in 20ABCD, San Diego Convention Center

SHEA Pediatric Scholarship Award - Pranita Tamma, MD, MHS

Friday, October 6, at 4:30 p.m. in 20ABCD, San Diego Convention Center

SHEA William Jarvis Award - Jacqui S. Reilly, PhD

Friday, October 6, at 4:30 p.m. in 20ABCD, San Diego Convention Center

SHEA Barry Farr Award - David K. Warren, MD, MPH

Friday, October 6, at 4:30 p.m. in 20ABCD, San Diego Convention Center

■ HIVMA Leadership Awards

HIVMA Clinical Educator Award - Monica Gandhi, MD, MPH

Wednesday, October 4, at 3:45 p.m. in 20ABCD, San Diego Convention Center

HIVMA Research Award - Raphael J. Landovitz, MD, MSc

Thursday, October 5, at 4:30 p.m. in 20ABCD, San Diego Convention Center

■ PIDS Society Awards


PIDS Distinguished Service Award - Kathryn M. Edwards, MD, FIDSA, FPIDS

Wednesday, October 4, at 3:45 p.m. in 20ABCD, San Diego Convention Center

IDSA Society Awards

IDSA Alexander Fleming Award for Lifetime Achievement

*Presented on Wednesday, October 4, at 3:45 p.m. in 20ABCD,
San Diego Convention Center*



**BARBARA E. MURRAY, MD,
FIDSA**

BARBARA E. MURRAY, MD, FIDSA, a leading authority on the role of enterococci in infectious diseases, from the bench to the bedside, is the recipient of IDSA's 2017 Alexander Fleming Award for Lifetime Achievement. This award recognizes a career that reflects major contributions to the acquisition and dissemination of knowledge about infectious diseases.

Starting with her first publications in the late 1970s and continuing to the present, Dr. Murray's investigations

have outlined the basic science that forms much of the foundation for our current understanding of the genetic basis and mechanisms of enterococcal drug resistance and pathogenesis. She is recognized globally for her extensive research in enterococcal resistance, genotyping, genomics, and virulence factors. Her contributions have established many of the modern therapeutic paradigms for these important pathogens. Dr. Murray also has expanded our knowledge of antimicrobial resistance in many other key bacterial pathogens. Her impact extends to new antibiotic development as well, through efforts to help characterize new and promising compounds using a substantial collection of susceptible and resistant organisms that she maintains and through guidance to pharmaceutical companies.

The recipient of a National Institutes of Health (NIH) MERIT Award, Dr. Murray's research has had NIH funding for over 25 years. Her published articles, which number over 300, have been cited more than 23,000 times, and she writes the enterococcal chapters for infectious diseases and internal medicine text and on-line books. An active leader in the field at the local, national, and international levels, she has served on the Food and Drug Administration's Anti-

Infective Drugs Advisory Committee, the NIH Recombinant DNA Advisory Committee—for which she also served as chair—and NIH's Bacteriology and Mycology Study Section. She has been a member of several additional NIH committees and data safety and monitoring boards for clinical trials around the world.

An IDSA Maxwell Finland Lecturer in 1996, Dr. Murray was president of IDSA from 2013 to 2014 and served on the IDSA Board of Directors in multiple roles, including as treasurer for six years and as secretary for three years. Since 2015, she has been chair of the Society's Antimicrobial Resistance Committee. Her numerous honors have included visiting professorships and named lectures at academic medical centers across the country. She has been elected to the American Society for Clinical Investigation, serving as the organization's vice president, and to the Association of American Physicians, and served three years as the scientific program chair for Interscience Conference on Antimicrobial Agents and Chemotherapy. A current associate editor for *Clinical Infectious Diseases*, she also served as an editor for Antimicrobial Agents and Chemotherapy for 10 years and is on the editorial boards of several other prominent journals in the field.

Dr. Murray is the J. Ralph Meadows Professor in Internal Medicine and director of the Division of Infectious Diseases at the McGovern Medical School at the University of Texas Health Science Center at Houston. After earning her medical degree from the University of Texas Southwestern Medical School in Dallas, she completed an internship and residency in internal medicine at Massachusetts General Hospital in Boston, followed by clinical and research fellowships in infectious diseases at Massachusetts General and Harvard Medical School. Since 1980, Dr. Murray has been on the faculty of the University of Texas Medical School in Houston. She has directly sponsored or mentored more than 50 trainees in the field, adding to her enduring legacy.

Widely recognized for her significant contributions spanning microbial physiology, virulence, antimicrobial resistance, and drug development throughout her career, Dr. Murray's achievements have had an enormous impact on the field. IDSA is proud to honor her with the 2017 Alexander Fleming Award for Lifetime Achievement.

IDSA Society Citation

Presented on Thursday, October 5, at 4:30 p.m. in 20ABCD, San Diego Convention Center



WENDY ARMSTRONG, MD, FIDSA

WENDY S. ARMSTRONG, MD, FIDSA, a leading physician, researcher, and educator who has worked tirelessly on behalf of patients, trainees, and the profession, is the recipient of a 2017 IDSA Society Citation. First awarded in 1977, this is a discretionary award given in recognition of exemplary contribution to IDSA, an outstanding discovery in the field of infectious diseases, or a lifetime of outstanding achievement.

An ID physician whose research and practice have focused on HIV and health disparities, Dr. Armstrong is currently a professor of medicine in the Division of Infectious Diseases and vice chair of education and integration at Emory University School of Medicine in Atlanta, where she has led one of the nation's premier ID fellowship training programs as director since 2008. She is also medical director of the Ponce de Leon Center, one of the largest urban HIV/AIDS clinics in the country. In addition to these many responsibilities, she has committed countless hours to help move the ID specialty's educational programs forward and mobilize the IDSA community to attract trainees to the field.

As chair of IDSA's ID Training Program Directors Committee from 2013 to 2016, and chair of the Society's Task Force on ID Fellowship Recruitment since 2015, Dr. Armstrong has spearheaded multiple initiatives focused on improving fellowship education, assessing and enhancing the current workforce, and growing the specialty. These efforts included a national, cross-sectional study she co-authored identifying important factors influencing residents' choice of specialty.

Published in *Clinical Infectious Diseases*, the research provided critical insights and laid the foundation for future work by the Society. Through thoughtful collaboration with training program directors across the country, she also successfully led the transition to an "all in" match for the 2016 cycle. The percentage of ID fellowship program slots that were filled increased, as did the number of total programs filled, providing grounds for cautious optimism looking forward.

Dr. Armstrong continues to lead efforts to engage students and trainees in ID-related activities to further generate interest in the field. Under her leadership, IDSA's recruitment task force has worked to improve the visibility of ID among medical students, including through the development of ID Interest Groups at numerous medical schools throughout the US. She helped develop the IDWeek Mentorship Program, which offers opportunities for mentorship and networking through one-on-one interactions between leaders in the field and fellows, residents, and medical students during IDWeek. She also helped create the IDSA Fellows Subcommittee, which fosters fellow, resident, and medical student participation and membership in the Society.

After receiving a medical degree from Harvard Medical School, Dr. Armstrong completed an internship, residency, and chief residency at the University of Michigan Medical Center, where she also completed a fellowship in infectious diseases. A member of IDSA's Gender Disparities Task Force and the Antimicrobial Stewardship Curriculum Committee, she is the current chair of the HIVMA Board of Directors, of which she has been a member since 2011, and has been a leading advocate on many HIV-related issues. The recipient of several teaching awards and other honors, and a fellow of the American College of Physicians, she is an active and sought-after mentor.

For her thoughtful approach to moving the ID specialty forward, and her deep commitment to patient care, medical education, and the future of the ID workforce, the Society is proud to recognize Dr. Armstrong with a 2017 Society Citation.

IDSA Society Citation

Presented on Thursday, October 5, at 4:30 p.m. in 20ABCD, San Diego Convention Center



PATRICK JOSEPH, MD, FIDSA, FSHEA

PATRICK JOSEPH, MD, FIDSA, FSHEA, a highly respected clinician and diagnostic laboratory expert, is the recipient of a 2017 IDSA Society Citation. First awarded in 1977, this is a discretionary award given in recognition of exemplary contribution to IDSA, an outstanding discovery in the field of infectious diseases, or a lifetime of outstanding achievement.

An active contributor to IDSA for the past 30 years, Dr. Joseph is an associate clinical professor

of medicine at the University of California, San Francisco (UCSF), manages a busy private practice in San Ramon, California, and is the medical director of four molecular diagnostic laboratories in Northern California. With a long and distinguished career as a dedicated clinician, always willing to counsel the next generation of ID physicians, he is considered a role model by his peers. An expert in diagnostic laboratory medicine, his activities and leadership in this important area have significantly improved the standards in many diagnostic laboratories in the western United States.

Dr. Joseph is a frequent and highly regarded speaker at local, regional, national, and international infectious disease meetings, and he has regularly moderated the popular “clinical controversies” session at IDSA’s annual meetings. Able to relate to department chiefs, research

scientists, and junior fellows with equal skill and ease, his lectures at the IDSA Clinical Fellows Meeting are among the highest rated. A fellow of IDSA and SHEA, Dr. Joseph’s contributions and insights have benefited several IDSA committees, including the Clinical Affairs Committee and the Education Program Committee. He has also served as a member of IDSA’s Diagnostics Task Force, which published a 2013 policy paper reviewing the current diagnostic landscape and outlining specific recommendations to spur research and development.

Named one of America’s Top Physicians and a Best Physician in America multiple times, and the recipient of several teaching awards, Dr. Joseph continues to mentor ID fellows and residents at UCSF. He does this while volunteering as a faculty member, maintaining an active private practice, and conducting other extensive work in the field, as demonstrated by his numerous publications and presentations in clinical and laboratory medicine. He is also a lead inspector for laboratory accreditation by the College of American Pathologists.

Dr. Joseph earned his medical degree from the West Virginia University School of Medicine, followed by an internship, residency, and chief residency at Highland General Hospital in Oakland, California, and an infectious diseases fellowship at UCSF, where he joined the faculty in 1979. A member of multiple professional societies and organizations, he is a past president of the National Foundation for Infectious Diseases and also served as the organization’s liaison to the Board of Scientific Counselors of the Office of Infectious Diseases at the Centers for Disease Control and Prevention.

In recognition of his long, successful career and many valued contributions to the Society and to the field of infectious diseases, IDSA is pleased to honor Dr. Joseph with a 2017 Society Citation.

IDSA Society Citation

Presented on Thursday, October 5, at 4:30 p.m. in 20ABCD, San Diego Convention Center



DEAN L. WINSLOW, MD, FIDSA

DEAN L. WINSLOW, MD, FIDSA, a compassionate, committed clinician, teacher, and military veteran who has been a champion for patients with HIV and victims of war and disaster, is the recipient of a 2017 IDSA Society Citation. First awarded in 1977, this is a discretionary award given in recognition of exemplary contribution to IDSA, an outstanding discovery in the field of infectious diseases, or a lifetime of outstanding achievement.

Dr. Winslow is vice chair of the Department of Medicine and a professor of medicine in the Division of Hospital Medicine and the Division of Infectious Diseases and Geographic Medicine at Stanford University, where he has been on the faculty since 1998. He is also academic physician-in-chief at Stanford/ValleyCare, a community teaching hospital. His professional career began in private practice in Delaware, where he started the state's first multidisciplinary clinic for HIV-infected patients in 1985. During his later time in industry, he worked on studies of HIV drug resistance as a bench scientist and designed the clinical trials leading to the Food and Drug Administration's approval of efavirenz. He also helped direct the clinical studies of nelfinavir and led the group responsible for regulatory approval of the first pharmacogenomics diagnostic device for HIV-1 drug resistance.

Before returning to Stanford fulltime in 2013, Dr. Winslow was chief of the Division of AIDS Medicine and chair of the Department of Medicine at Santa Clara Valley Medical Center, the institution's largest academic and clinical unit. In addition to caring for adults, Dr. Winslow

regularly attended on the pediatric infectious diseases consult service at the county hospital. From 2003 to 2011, he deployed to Iraq and Afghanistan six times as a flight surgeon in the Air National Guard in support of combat operations there, including serving as the commander of an Air Force combat hospital unit in Baghdad in 2008. Closer to home, Dr. Winslow coordinated military public health and force protection in Louisiana after Hurricane Katrina. He has been awarded numerous military decorations for his service.

In addition to his care for wounded service personnel in the Middle East, Dr. Winslow also treated many local civilians. A passionate supporter of human rights and health, he has, since 2006, arranged for medical care, transportation, and housing in the US for more than 20 Iraqi children and adults with complicated medical conditions for which surgical care was not available in Iraq. He has been recognized by the Iraqi Army for his humanitarian service to the Iraqi people and was named a Paul Harris Fellow by Rotary International.

After earning his medical degree from Jefferson Medical College in Philadelphia, Dr. Winslow completed his internship and residency in internal medicine at the Medical Center of Delaware, followed by a fellowship in infectious diseases at the Ochsner Clinic in New Orleans. A highly regarded attending physician on the ID consultation services at Stanford and the Palo Alto Veterans Administration Medical Center, Dr. Winslow has received multiple teaching awards. His wide-ranging knowledge and experience, combined with his passion for teaching and patient care, are legendary among ID fellows and residents. The author of more than 60 peer-reviewed publications and more than 90 presentations at national and international meetings, he is the current chair of IDSA's Standards and Practice Guidelines Committee.

Dr. Winslow's extensive knowledge, deep compassion, and wide-ranging experience over more than four decades have greatly impacted patients around the world, his colleagues, and the next generation of ID physicians. The Society is delighted to add a 2017 Society Citation to his long list of accomplishments.

IDSA Watanakunakorn Clinician Award

Presented on Thursday, October 5, at 4:30 p.m. in 20ABCD, San Diego Convention Center



**DOUGLAS R. OSMON, MD, MPH,
FIDSA**

DOUGLAS R. OSMON, MD, MPH, FIDSA, whose passion for clinical care has greatly advanced the treatment of musculoskeletal infections, is the recipient of IDSA's 2017 Watanakunakorn Clinician Award. Named to honor the memory of Chatrchai Watanakunakorn, this award is presented by the IDSA Education and Research Foundation to recognize an IDSA member or fellow for outstanding achievement in the clinical practice of infectious diseases.

On staff at the Mayo Clinic since 1992 and a professor of medicine at the Mayo Clinic College of Medicine and Science in Rochester, Minnesota, Dr. Osmon has been instrumental in improving the care of patients with musculoskeletal infections throughout his career, spanning nearly three decades. A superb, meticulous, compassionate clinician who spends more than 50 percent of his time in the clinical practice of ID, his strong patient advocacy has earned the admiration of patients, colleagues, and peers at other institutions. The Orthopedic Infectious Diseases Practice he developed and leads at Mayo as chair, which recognizes the necessary link between ID and surgical specialists in caring for patients with orthopedic infections, has set the bar for many other institutions.

Dr. Osmon has been integral in advancing patient care through clinical research. His more than 130 peer-reviewed publications include

investigations of the diagnosis of chronic periprosthetic infection, prospective and retrospective studies of optimal management strategies for prosthetic joint infection, and research clarifying the role of dental prophylaxis for patients with arthroplasties. Internationally recognized in this field, he was the lead author of IDSA's clinical practice guidelines for prosthetic joint infection and also helped author the Society's vertebral osteomyelitis guidelines, further extending his impact on the care of patients with these infections.


An active member and past president of the Musculoskeletal Infection Society, Dr. Osmon has received numerous clinical research awards from the organization and in 2016 was inducted into its Hall of Fame. A fellow of the American College of Physicians and a sought-after speaker at national and international meetings, he received his medical degree from the Mayo Clinic College of Medicine at Mayo Medical School, followed by an internship, residency, and infectious diseases fellowship at the Mayo Graduate School of Medicine. He also earned a master of public health degree from the University of Minnesota School of Public Health.

In 1992, Dr. Osmon joined the Mayo faculty, where, as a mentor, he has attracted many medical students, residents, fellows, and visiting faculty to train in the management and treatment of orthopedic infections. He has participated in and led several Mayo committees, teams, and task forces, including the Computer-Based Antimicrobial Monitoring Program, for which he served as director.

Modest and quick to credit others for his achievements, Dr. Osmon is a consummate clinician, clinical researcher, advocate, colleague, and mentor who has greatly advanced the care of patients with musculoskeletal infections at his institution and around the world. The Society is proud to recognize him with the 2017 Watanakunakorn Award.

IDSA Clinical Teacher Award

Presented on Saturday, October 7, at 4:30 p.m. in 6AB, San Diego Convention Center



MICHAEL J. BARZA, MD, FIDSA

MICHAEL J. BARZA, MD, FIDSA, an outstanding clinician and educator, is the recipient of IDSA's 2017 Clinical Teacher Award. This award honors a career dedicated to teaching clinical infectious diseases to fellows, residents, and medical students and recognizes excellence as a clinician and motivation to teach the next generation of physicians.

Currently vice chair for clinical affairs at Tufts Medical Center and

the Sara Murray Jordan Professor of Medicine at Tufts University School of Medicine in Boston, Dr. Barza's legendary teaching has been a major influence on scores of medical students, residents, and infectious disease fellows over the past 45 years. Equally adept at the podium and the bedside, his ability to synthesize difficult concepts and present them in an exceedingly clear manner is considered unparalleled. A superb clinician, he is well known for the breadth of his differential diagnosis, his clear thinking and assessment of a problem, the logic with which he comes to conclusions, and his ability to impart these traits to others.

Dr. Barza's many teaching honors and accomplishments speak to his substantial impact as an educator. Designated as an outstanding Tufts University School of Medicine lecturer from 2009 to 2014, he is the recipient of a Distinguished Faculty Award and the Zucker Clinical Teaching Prize for Outstanding Accomplishment. He has received citations for teaching excellence from Tufts University School of Medicine more than 20 times since 1974. Medical residents at New England Medical Center, where he served as associate chief of the Division of Geographic Medicine and Infectious Disease and as

hospital epidemiologist, and at Carney Hospital in Boston, where he was chief of medicine, have also recognized him with best teacher awards on multiple occasions.

In one telling example of Dr. Barza's impact, after he became director of the internal medicine training program at Carney Hospital, the percentage of initial test takers passing their American Board of Internal Medicine examination rose from 70 percent to 100 percent over a four-year period. Among the more than 150 fellows who have benefited from his teaching over the years are many current division chiefs, deans, professors, and other accomplished leaders in the field, many of whom cite Dr. Barza's example as a role model in their own careers.

Dr. Barza received a medical degree from McGill University and completed an internship and residency at Royal Victoria Hospital, both in Montreal, Canada. He was then posted in Sarawak, Malaysia, for a year working under the auspices of Canadian philanthropic organization at a public hospital. Following a chief residency at Queen Elizabeth Hospital in Montreal, Dr. Barza completed a fellowship in infectious diseases at New England Medical Center. The author or co-author of 225 original published articles, he is a recognized authority on pharmacokinetics, antimicrobial use, and infections of the eye. He has been named among America's Best Doctors yearly since the mid-1990s.

Dr. Barza has had a longstanding role in medical publication. He was the editor of *Antimicrobial Agents and Chemotherapy* and associate editor of the *Yearbook of Infectious Diseases*, both for a decade. He served as the deputy editor of *Clinical Infectious Diseases* from 2000 to 2016, a period during which the journal's reputation and influence grew impressively.

Over more than four decades, Dr. Barza has significantly contributed to the training of countless medical students, residents, and ID fellows through his effective and engaging teaching and his renowned skills as a clinician. IDSA is pleased to add the 2017 Clinical Teacher Award to his impressive record of achievements.

IDSA Oswald Avery Award for Early Achievement

Presented on Saturday, October 7, at 4:30 p.m. in 6AB, San Diego Convention Center



WILLIAM J. STEINBACH, MD, FIDSA, FPIDS

WILLIAM J. STEINBACH, MD, FIDSA, FPIDS, whose study of invasive fungal infections has significantly expanded our understanding of these conditions, is the recipient of IDSA's 2017 Oswald Avery Award for Early Achievement. This honor recognizes members or fellows of IDSA age 45 or younger who have demonstrated outstanding achievements in an area of infectious diseases.

Dr. Steinbach has quickly become an international leader as an

investigator studying the molecular basis and clinical manifestations of invasive fungal infections. Currently professor of pediatrics, professor in molecular genetics and microbiology, and chief of the Division of Pediatric Infectious Diseases at Duke University School of Medicine in Durham, NC, his interest in these infections began during his pediatric residency. The immense morbidity and mortality associated with these conditions, and the limited therapies available, set his research efforts into motion, starting with 26 papers—original laboratory research articles, methodology papers, multi-center clinical investigations, and others—published during his residency and pediatric ID fellowship.

The principal investigator for three current National Institutes of Health (NIH) R01 grants as well as several other grants, Dr. Steinbach's translational work over the past 10 years has focused on defining the molecular controls of *Aspergillus* hyphal growth and characterizing a variety of *Aspergillus* cell signaling pathways, including calcineurin, Ras, and heat shock protein 90 (Hsp90). Recognizing a specific gap in the pediatric ID field, in 2006 he founded and still directs the International Pediatric Fungal Network. This 55-site, global research

consortium is currently supported by more than \$7 million in NIH funding to lead novel treatment and diagnostic clinical studies in pediatric invasive fungal disease. In 2004, he also co-founded, and continues to co-chair, the biennial Advances Against Aspergillosis international conference, dedicated to *Aspergillus* clinical care and research.


The author of more than 130 peer-reviewed publications, Dr. Steinbach is a co-editor of the largest textbook in the field, *Aspergillus fumigatus and Aspergillosis*, and has co-edited several other pediatric ID textbooks, including two editions of *Feigin & Cherry's Textbook of Pediatric Infectious Diseases* and yearly editions of *Nelson's Pediatric Antimicrobial Therapy* textbook. He has been the lead guest editor for multiple journal supplements focused on invasive aspergillosis. A fellow of the American Academy of Pediatrics and the American Academy of Microbiology, he served as the sole pediatric representative on the expert panel for the 2008 and 2016 updates of IDSA's aspergillosis practice guidelines.

Dr. Steinbach received his medical degree from the University of North Carolina School of Medicine, followed by a pediatric residency at Stanford University and a fellowship in pediatric infectious diseases at Duke. He joined the Duke faculty in 2004, where he became a full professor in 2015, and also serves as director of the pediatric ID fellowship program and co-directs the nation's only T32 focused on molecular mycology, the Tri-Institutional Molecular Mycology and Pathogenesis Training Program. He is a member of the PIDS Board of Directors, has served on several PIDS committees, and is a member of the editorial board of the *Journal of the Pediatric Infectious Diseases Society*, in addition to serving on the editorial boards of several other clinical and basic science journals. The recipient of numerous young investigator awards and other honors, he was elected to the American Society for Clinical Investigation in 2015.

For his immense clinical and scientific contributions, which have significantly impacted the field of pediatric mycology, IDSA is proud to honor Dr. Steinbach with the 2017 Oswald Avery Award for Early Achievement.

IDSA Walter E. Stamm Mentor Award

Presented on Saturday, October 7, at 4:30 p.m. in 6AB, San Diego Convention Center



STEPHEN B. CALDERWOOD, MD, FIDSA

STEPHEN B. CALDERWOOD, MD, FIDSA, an exceptional clinician, teacher, and researcher, is the recipient of IDSA's 2017 Walter E. Stamm Mentor Award. Named to honor the memory of a former IDSA president who was renowned for nurturing the careers of others, this award recognizes individuals who have served as exemplary mentors and who have been exceptional in guiding the professional growth of infectious disease professionals.

Chief of the Infectious Diseases Division at Massachusetts General Hospital in Boston for the past 27 years, Dr. Calderwood is also the Morton N. Swartz, MD, Academy Professor of Medicine and director of undergraduate medical education at Massachusetts General Hospital. Despite his multiple positions and numerous leadership roles locally, nationally, and internationally, Dr. Calderwood's commitment to the professional development of others over the course of their careers has been unrelenting and far reaching. He has impacted the lives and careers of numerous students, residents, fellows, and faculty, from the junior to the senior level, through his ongoing dedication to mentorship over many years.

Within his clinical division, Dr. Calderwood has created a culture that encourages mentorship and serves as a model for other institutions. He has made the career development of others a central goal of his collaborative research activities, encouraging his mentees to develop into independent physician-scientists and mentors themselves. A committed advocate for the appointment and advancement of women faculty, he is considered a role model for how to be an effective

and inclusive leader. Many former trainees cite his influence in their own mentoring activities, extending his impact even further. He has received multiple awards in recognition of his mentoring, including the William Silen Lifetime Achievement in Mentoring Award from Harvard Medical School, the John T. Potts Jr., MD, Faculty Mentoring Award from Massachusetts General Hospital, the Partners Medical Education Outstanding Mentoring Award from Partners Healthcare, and the Joseph B. Martin Dean's Leadership Award for the Advancement of Women from Harvard Medical School.

Dr. Calderwood's research interests, demonstrated through his more than 200 peer-reviewed publications, focus on immune responses to enteric infections, microbial pathogenesis, microbial-host interactions, regulation of gene expression in the human host, and vaccine development for cholera. His laboratory has ongoing collaborations with the International Centre for Diarrhoeal Disease Research in Dhaka, Bangladesh, focused on cholera and typhoid fever. President of IDSA from 2014 to 2015 and a former member of the Society's Board of Directors, his service to IDSA has included multiple committees, among them the ID Training Program Directors Committee, the Education Committee, the Research Committee, and the **IDWeek** Program Committee.

A fellow of the American College of Physicians, the American Society of Tropical Medicine and Hygiene, the American Academy of Microbiology, and the American Association for the Advancement of Science, and a member of the Association of American Physicians, Dr. Calderwood received his medical degree from Harvard Medical School. He completed internship, residency, chief residency, and clinical and research fellowships in infectious diseases at Massachusetts General and Harvard Medical School, where he joined the faculty in 1981.

Recognized for his exceptional dedication to the professional development of others, in addition to his skills as a clinician and a researcher, Dr. Calderwood is considered a mentor without parallel by those he has guided and counseled. IDSA is delighted to recognize him with the 2017 Walter E. Stamm Mentor Award.

IDSA Clinical Practice Innovation Award

Presented on Saturday, October 7, at 4:30 p.m. in 6AB, San Diego Convention Center



KAVITA P. BHAVAN, MD, MHS, FIDSA

KAVITA P. BHAVAN, MD, MHS, FIDSA, an expert in outpatient parenteral antimicrobial therapy (OPAT), whose innovative approach brought this vital treatment to uninsured patients, is the recipient of IDSA's 2017 Clinical Practice Innovation Award. This new award recognizes members who devote the majority of their time to patient care and have, within the last five years, significantly advanced the clinical practice of infectious diseases by making innovations in clinical practice design or management,

or by fostering change to better recognize the value of infectious diseases practice.

Despite the benefits of OPAT for patients on long-term antibiotics, this therapy is typically not available to the uninsured who cannot afford it, leading to long, unnecessary hospitalizations solely for antibiotic infusions at safety-net hospitals. The medical director of the Outpatient Parenteral Antimicrobial Clinic at Parkland Hospital, a large safety-net hospital in Dallas, Texas, Dr. Bhavan developed a successful program in which even the most underserved patients can receive outpatient antibiotic therapy. Engaging and empowering patients, the multidisciplinary program, which began in 2009, offers uninsured patients the option to be taught to self-administer intravenous antibiotics, using a standardized protocol to ensure patient mastery, with weekly in-clinic follow up.

In the program's first four years, clinical outcomes for self-administered antimicrobial therapy were similar to or better than those for provider-administered methods, with a 47 percent lower hospital readmission

rate among self-administered patients compared to those discharged with traditional forms of OPAT. Mortality was also equivalent in the two groups. The program vastly improved resource utilization, saving more than 27,000 hospital bed days at an estimated cost savings of approximately \$40 million in the first four years, with high patient satisfaction rates. Recognized nationally as an innovation in delivering improved patient care in the safety-net setting, the program's approach is now being replicated in underserved areas across the country.


A nationally recognized OPAT expert, and a member of the Institute for Healthcare Improvement, Dr. Bhavan serves on the committee currently updating IDSA's OPAT guidelines. In 2016, in recognition of the impact of the self-administered OPAT program she developed, Dr. Bhavan and Parkland Hospital received a Gage Award for Innovation and Excellence from America's Essential Hospitals, an association dedicated to high-quality care. Parkland Hospital, where she previously served as director of Antimicrobial Stewardship and now serves as medical director of the Parkland Center for High Impact Clinical Outcomes Studies, in addition to the Infectious Diseases/OPAT clinic, named her physician of the year in 2012 in recognition of the outpatient program's success.

Dr. Bhavan received a medical degree from Penn State University and completed her internship at Rochester General Hospital and the University of Rochester in New York, followed by residency at the Ochsner Clinic Foundation in New Orleans and an ID fellowship at Washington University in St. Louis. She also earned a master of health science degree from Johns Hopkins University School of Public Health. In 2009, Dr. Bhavan joined the faculty of the University of Texas Southwestern Medical Center, where she is an associate professor of internal medicine.

Dedicated and passionate about improving patient care, Dr. Bhavan has clearly demonstrated how infectious disease clinicians can champion innovation at their own institutions and the healthcare system at large. The Society is delighted to recognize her with the 2017 Clinical Practice Innovation Award.

IDSA D.A. Henderson Award for Outstanding Contributions to Public Health

Presented on Saturday, October 7, at 4:30 p.m. in 6AB, San Diego Convention Center



F. MARC LaFORCE, MD, FIDSA, who spearheaded the development of a vaccine that has greatly reduced group A meningococcal disease, is the recipient of IDSA's inaugural D.A. Henderson Award for Outstanding Contributions to Public Health. Named to honor the memory of Dr. Henderson, who led the successful eradication of smallpox, this new award recognizes a lifetime of achievement in public health.

F. MARC LaFORCE, MD, FIDSA

Meningitis epidemics caused by group A *Neisseria meningitidis* have long been a serious public health threat in sub-Saharan Africa. Following a major outbreak in the region in the mid-1990s, in which about 250,000 people were sickened and 25,000 died, Dr. LaForce became director of the newly formed Meningitis Vaccine Project, a unique partnership between PATH and the World Health Organization (WHO), supported by the Bill & Melinda Gates Foundation, with the goal of developing an affordable vaccine. With little interest from large pharmaceutical companies, Dr. LaForce devised a novel strategy that brought together a vaccine manufacturer in India and other partners across four continents to develop and deliver a vaccine at less than one-tenth of the cost usually required to bring a new vaccine to market.

Under his leadership from 2001 to 2012, the project successfully developed, tested, licensed, and introduced a safe and effective conjugate meningococcal vaccine, MenAfriVac, available at less than 50 cents (US) per dose. The vaccine was first introduced in 2010 in

Burkina Faso, Mali, and Niger. By the end of 2016, more than 320 million young Africans in the 26 countries that make up the continent's "meningitis belt" were expected to have received the vaccine—preventing an estimated 1.3 million cases of disease, 250,000 cases of disability, and 130,000 deaths.

Dr. LaForce's contributions to public health began in the 1960s, when he was an Epidemic Intelligence Service Officer with the Centers for Disease Control and Prevention. Over the next several decades, he continued to work as a consultant, participating in the smallpox eradication program, WHO's Expanded Program on Vaccination, and projects to combat childhood communicable diseases in Africa and Asia. During this time, he also held research and academic positions at the University of Colorado School of Medicine and the University of Rochester School of Medicine and Dentistry in New York. In addition, he served in several clinical leadership roles at the Veterans Administration Medical Center in Denver.

Since 2012, Dr. LaForce has been the director of technical services for the Serum Institute of India, Ltd., the manufacturer of MenAfriVac, based in the US. He is also a clinical professor of medicine at New York University School of Medicine. After earning a medical degree from Seton Hall College of Medicine and Dentistry in New Jersey, he completed his internal medicine and infectious disease training on the Harvard Service at Boston City Hospital. A fellow of the American College of Physicians, he has received numerous honors, including the Jimmy and Rosalynn Carter Humanitarian Award from the National Foundation for Infectious Diseases and the Albert B. Sabin Gold Medal Award from the Sabin Vaccine Institute.

A visionary leader who was the driving force behind a groundbreaking, low-cost vaccine that today protects hundreds of millions of people from death and disability, Dr. LaForce has had a tremendous impact on the world's health. IDSA is pleased to recognize his outstanding contributions to public health with the 2017 D.A. Henderson Award.

IDSA Education and Research Foundation Awards

Robert C. Moellering Trainee Travel Awards

The Robert C. Moellering Trainee Travel Award supports attendance at IDWeek for fellows-in-training who submit excellent research in the field of antibiotic resistance. Applicants must be IDSA members-in-training for 2017 and have an accepted abstract to IDWeek. Member donations to the IDSA Education and Research Foundation directly support these awards.

ALINA IOVLEVA, MD, University of Pittsburgh School of Medicine,
Pittsburgh, PA

DEREK MACFADDEN, MD, University of Toronto, Toronto, ON, Canada

SHEA Society Awards

SHEA Senior Scholarship Award

*Presented on Wednesday, October 4, at 3:45 p.m. in 20ABCD,
San Diego Convention Center*



**WILLIAM SCHAFFNER, MD,
FSHEA, FIDSA**

WILLIAM SCHAFFNER, MD, FSHEA, FIDSA, is the recipient of the 2017 SHEA Senior Scholar Award recognizes his work as a senior investigator in infection prevention and healthcare epidemiology over the course of his career. Dr. Schaffner is a professor of preventive medicine in the Department of Health Policy as well as professor of medicine in the Division of Infectious Diseases at the Vanderbilt University School of Medicine, Nashville, Tennessee. Dr. Schaffner's major interest has been

the prevention of infectious diseases; he has worked extensively in healthcare-associated infections and vaccines.

Dr. Schaffner was the chief epidemiologist for the Vanderbilt University Medical Center for 35 years and continues to serve as an associate epidemiologist. Having established a comprehensive infection control program in his own institution, Dr. Schaffner and his team trained infection control personnel throughout the region and he was instrumental in helping train the first cadre of infection preventionists in the US through his long participation on the faculty of the famed foundational CDC course "1200 G". His teaching extended to healthcare students, house officers and infectious disease Fellows as well as CDC's Epidemic Intelligence Service Officers through his affiliation with the Tennessee Department of Health.

Dr. Schaffner has led many investigations of healthcare-associated infections including the first look-back investigation of a surgeon with AIDS and one identifying defective bronchoscopes that led to a worldwide recall. He also has worked extensively on the effective use of vaccines in both pediatric and adult populations and has been a member of numerous expert advisory committees that establish national vaccine policy.

After his undergraduate studies at Yale, Dr. Schaffner attended the University of Freiburg, Germany as a Fulbright Scholar. He received his medical education at the Weill Cornell Medical College and completed residency training and a Fellowship in infectious diseases at Vanderbilt. He then was commissioned in the US Public Health Service as an Epidemic Intelligence Service Officer with the Centers for Disease Control and Prevention. While with the CDC, Dr. Schaffner became intimately familiar with public health and investigated outbreaks of communicable diseases both in the United States and abroad. These experiences were a formative stimulus for his subsequent career.

Dr. Schaffner has served as president of SHEA, as secretary and member of the Executive Board of IDSA, and as a past president and as current medical director of the National Foundation for Infectious

Diseases. He has received numerous national and local recognitions of his contributions to preventive medicine, including the James D. Bruce Award of the American College of Physicians, the Sedgwick Medal of the American Public Health Association and the Walter Stamm Mentor Award of the IDSA.

SHEA is pleased to present Dr. Schaffner the 2017 SHEA Senior Scholarship Award for his ongoing career contributions to healthcare epidemiology and infection prevention.

SHEA Advanced Practice Infection Preventionist Award

Presented on Thursday, October 5, at 5:45 p.m. in 5, San Diego Convention Center, SHEA Business Meeting



**KATHLEEN GASE, MPH, CIC,
FAPIC**

KATHLEEN GASE, MPH, CIC, FAPIC, is the recipient of the 2017 SHEA Advanced Practice Infection Preventionist Award based on her career achievements in infection prevention. Ms. Gase graduated from Washington University in St. Louis with a bachelor's degree in psychology and a minor in biology, and then began her career at Memorial Sloan-Kettering Cancer Center in New York City as a research assistant in 2003. In this role, she worked closely with the Infection Prevention team and

quickly realized that IP was a challenging and exciting career that she wanted to pursue. In 2005, Ms. Gase earned her CIC certification and became the first non-nurse to be an Infection Control Professional at MSKCC.

Ms. Gase completed her MPH at City University New York – Hunter College in 2007 and began working for the New York State Department of Health as the regional representative in New York City for the Hospital Acquired Infection Reporting Program. During her tenure with New York State, Ms. Gase collaborated with key stakeholders and played an integral role in determining the state's strategy for mandatory public reporting.

In 2012, she joined the team at BJC HealthCare as the manager of Infection Prevention and Quality Patient Care. In that role she leads a team to determine strategy for reducing HAIs, evaluating program mission, goals, and future opportunities for intervention development and implementation. Recently, she was promoted to be the group manager for Clinical Epidemiology coordinating the operational work of three teams to increase patient safety, reduce preventable harms, and improve patient outcomes. These teams include Infection Prevention, Evidence-Based Care, and Surgical Quality Improvement. Ms. Gase was designated as a Fellow of APIC in 2016. It is for her overall contributions and commitment to excellence in infection prevention that SHEA is pleased to present Kathleen Gase the 2017 Advanced Practice Infection Preventionist Award.

continues

SHEA Antibiotic Stewardship Scholarship Award

Presented on Friday, October 6, at 4:30 p.m. in 20ABCD, San Diego Convention Center



SARA COSGROVE, MD, MS, FSHEA, FIDSA

SARA COSGROVE, MD, MS, FSHEA, FIDSA, was selected as the inaugural awardee of the SHEA Antibiotic Stewardship Scholarship Award, created to recognize the contributions of an investigator or practitioner in antibiotic stewardship programs and research. Sara E. Cosgrove, MD, MS, is a professor of medicine in the Division of Infectious Disease at Johns Hopkins University School of Medicine and has a joint appointment in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public

Health. She serves as director of the Department of Antimicrobial Stewardship and Associate Hospital Epidemiologist at The Johns Hopkins Hospital. Dr. Cosgrove's research interests the epidemiology and outcomes of antimicrobial resistance, the development of tools and programs to promote the rational use of antimicrobials, the prevention of hospital-acquired infections and the epidemiology and management of *S. aureus* bacteremia. She is currently developing a large implementation program to assist hospitals, nursing homes, and ambulatory practices across the United States in developing and expanding antimicrobial stewardship capacity that is funded by the Agency for Healthcare Research and Quality. Dr. Cosgrove currently serves as president of the Society for Healthcare Epidemiology of America's Board of Directors. She was member of the President's Council of Advisors on Science and Technology Working Group on Antimicrobial Resistance and is a voting member on the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. Dr. Cosgrove received her undergraduate degree from Columbia College in New York, New York, her medical degree from Baylor College of Medicine in Houston, Texas, and her master of science degree in epidemiology from Harvard School of Public Health in Boston, Massachusetts. She completed her postgraduate training in internal medicine at The Johns Hopkins Hospital and underwent subsequent training in infectious disease at Beth Israel Deaconess Medical Center in Boston. SHEA is pleased to recognize the career contributions of Dr. Cosgrove in antibiotic stewardship for the 2017 SHEA Antibiotic Stewardship Scholarship Award.

SHEA Mentor Scholar Award

Presented on Friday, October 6, at 4:30 p.m. in 20ABCD, San Diego Convention Center



KENT SEPKOWITZ, MD, FSHEA, FIDSA

KENT SEPKOWITZ, MD, FSHEA, FIDSA, is being recognized as the 2017 SHEA Mentor Scholar Awardee for his distinguished record in mentoring fellows and junior faculty over the course of his career, many of whom have gone on to be key contributors in infection prevention. Dr. Sepkowitz led the infection control program at Memorial Sloan Kettering for many years before becoming the deputy physician in chief for quality & safety at Memorial Sloan Kettering. During his time as director of

infection control, he focused on the particular risks to patients and staff of infections in persons with cancer. During the 1990s he wrote extensively about the risk to healthcare workers of acquiring various infections, such as HIV and tuberculosis, from occupational exposure. He has received federal grants, has published hundreds of articles in the medical and lay literature, and is a professor of medicine at Weill Cornell Medical College, but is most proud of the various people he has helped train in medicine and infectious disease.

SHEA is pleased to recognize Dr. Sepkowitz and his commitment to mentoring leaders in infection prevention and healthcare epidemiology through the presentation of the 2017 SHEA Mentor Scholar Award.

SHEA Mid-Career Scholarship Award

Presented on Friday, October 6, at 4:30 p.m. in 20ABCD, San Diego Convention Center



NASIA SAFDAR, MD, FSHEA

NASIA SAFDAR, MD, FSHEA, is the recipient of the 2017 SHEA Mid-Career Scholarship Award recognizing her contributions as a mid-career investigator in infection prevention and healthcare epidemiology. Dr. Safdar is vice chair for research and an associate professor in the Department of Medicine at the University of Wisconsin-Madison (UW), where she has been a faculty member in the Division of Infectious Disease since 2008. She is also the

associate chief of staff for research and a staff physician at the William S. Middleton Memorial Veterans Hospital in Madison, WI.

Dr. Safdar earned her medical degree at Aga Khan University Medical College in Pakistan, where she graduated as class valedictorian. She completed her residency training at UW Hospital and Clinics, followed by fellowships in Infectious Disease and Women's Health. Additionally, she earned an MS degree in Population Health Sciences and a PhD in Clinical Research at UW-Madison.

Dr. Safdar's research focuses on treatment and prevention of healthcare-associated infections. She is interested in examining the efficacy of novel interventions and quality improvement initiatives to reduce healthcare-associated infections. Notably, she is the principle investigator on ongoing trials investigating the use of probiotics for reducing colonization by methicillin-resistant *Staphylococcus aureus* and the use of fecal microbiota transplantation for *Clostridium difficile* infection. Dr. Safdar's well-funded research program has been supported by agencies such as the Department of Veterans Affairs, the Agency for Healthcare Research and Quality (AHRQ), NIH, and PCORI. In recognition of her research contributions, she recently received a Presidential Early Career Award for Scientists and Engineers (PECASE) award.

Dr. Safdar has been an active SHEA Member since 2003. She was a member of the publications committee from 2006 to 2009, and was part of the research committee from 2009 to 2014, most recently serving as Chair in 2014 and 2015. SHEA is pleased to present her the 2017 SHEA Mid-Career Scholarship Award for her ongoing contributions to healthcare epidemiology and infection prevention.

SHEA Pediatric Scholarship Award

Presented on Friday, October 6, at 4:30 p.m. in 20ABCD, San Diego Convention Center



PRANITA TAMMA, MD, MHS

PRANITA D. TAMMA, MD, MHS, was selected as the 2017 SHEA Pediatric Scholarship Award Recipient recognizing her contributions to the fields of antimicrobial resistance and antimicrobial stewardship. Dr. Tamma is an assistant professor of pediatrics at the Johns Hopkins University School of Medicine. She completed a Pediatric Residency in 2007 followed by a Pediatric Infectious Diseases Fellowship in 2011, both at Johns Hopkins

Hospital. During her fellowship, she obtained a Master's degree in Epidemiology at The Johns Hopkins Bloomberg School of Public Health. Dr. Tamma was recruited as an Instructor of Pediatrics in 2012 and was promoted to an assistant professor in 2013. She has been the recipient of numerous teaching awards as a resident, fellow, and faculty member by both medical students and housestaff.

Dr. Tamma's research focuses on the diagnosis and treatment of multidrug-resistant gram-negative infections in both children and adults. She is currently funded by an NIH K23 award entitled "The Use of MALDI TOF for the Rapid Detection of Carbapenemases from Clinical Isolates." In addition, she is the Co-PI on a large contract from the AHRQ to enhance antibiotic stewardship activities in acute care, long-term care, and ambulatory care facilities across the US. She is also the PI of an FDA contract "Development of an Automated and Sustainable Electronic Approach for Data Mining to Evaluate Clinical Outcomes of Patients with Gram-Negative Infections." Dr. Tamma has authored over 85 publications related to gram-negative resistance and/or antimicrobial stewardship- many of which have been published in high-impact, peer reviewed journals.

Dr. Tamma has been the director of The Pediatric Antimicrobial Stewardship Program at The Johns Hopkins Hospital since 2012. In this capacity she assists clinicians with optimizing the administration of antibiotics, developing guidelines to guide the appropriate and judicious use of antibiotics, and monitoring patient outcomes after implementation of these practices. Dr. Tamma is considered a national leader in pediatric antibiotic stewardship. For the past several years she chaired the ID Week Pre-Meeting Antibiotic Stewardship Workshop. She is a committee member of both the SHEA and PIDS Antimicrobial Stewardship Committees. In addition, Dr. Tamma is an advisor to The Clinical Laboratory Standards Institute Antimicrobial Susceptibility Testing Committee and in this capacity is involved in informing antibiotic breakpoint changes. Dr. Tamma is also an advisor to the CDC efforts to improve inpatient antibiotic prescribing. Finally, she is an editor of the SHEA-sponsored textbook "Practical Implementation of Antibiotic Stewardship Programs." For her ongoing contributions towards furthering our understanding of the diagnosis and treatment of antibiotic resistance and improving approaches to effective antibiotic stewardship, SHEA is pleased to present Dr. Tamma with the 2017 SHEA Pediatric Scholarship Award.

SHEA William Jarvis Award

Presented on Friday, October 6, at 4:30 p.m. in 20ABCD, San Diego Convention Center



JACQUI S. REILLY, PhD

The editors of Infection Control and Hospital Epidemiology (ICHE) selected the following manuscript to receive the William Jarvis Award for most outstanding international clinical study published in ICHE in 2017: "A Pragmatic Randomized Controlled Trial of 6-Step vs 3-Step Hand Hygiene Technique in Acute Hospital Care in the United Kingdom," ICHE (2016) 37(6): 661-666.

The study set out to evaluate the microbiologic effectiveness of the

World Health Organization's 6-step and the Centers for Disease Control and Prevention's 3-step hand hygiene techniques using alcohol-based handrub using a parallel group randomized controlled trial. Results found that the 6-step technique was microbiologically more effective at reducing the median log₁₀ bacterial count. The 6-step technique reduced the count from 3.28 CFU/mL (95% CI, 3.11–3.38 CFU/mL) to 2.58 CFU/mL (2.08–2.93 CFU/mL), whereas the 3-step reduced it from 3.08 CFU/mL (2.977–3.27 CFU/mL) to 2.88 CFU/mL (–2.58 to 3.15 CFU/mL) ($P=.02$). However, the 6-step technique did not increase the total hand coverage area (98.8% vs 99.0%, $P=.15$) and required 15% (95% CI, 6%–24%) more time (42.50 seconds vs 35.0 seconds, $P=.002$). Total hand coverage and extended time was not related to the reduction in bacterial count.

Lead author Jacqui S. Reilly, PhD has a joint appointment between the National Health Service (NHS) and Glasgow Caledonian University (GCU) in the United Kingdom. Prof. Reilly leads a team of researchers in GCU working on healthcare associated infection (HAI). In the NHS she works for Health Protection Scotland where she is lead consultant for HAI, Antimicrobial resistance (AMR) and infection prevention and control. Additional authors include were Lesley Price, Sue Lang, Chris Robertson, Francine Cheater, Kirsty Skinner and Angela Chow.

SHEA Barry Farr Award

Presented on Friday, October 6, at 4:30 p.m. in 20ABCD, San Diego Convention Center



DAVID K. WARREN, MD, MPH

The editors of Infection Control and Hospital Epidemiology (ICHE) selected the following manuscript to receive the Barry Farr Award for most outstanding domestic clinical study published in ICHE in 2016: "Prevalence of *qacA/B* Genes and Mupirocin Resistance Among Methicillin-Resistant *Staphylococcus aureus* (MRSA) Isolates in the Setting of Chlorhexidine Bathing Without Mupirocin," ICHE (2016) 37(5):590-597.

The study aimed to determine the frequency of *qacA/B* chlorhexidine tolerance genes and high-level mupirocin resistance among MRSA isolates before and after the introduction of a chlorhexidine (CHG) daily bathing intervention in a surgical intensive care unit (SICU). The research was a retrospective cohort study using data from 2005–2012 at a large tertiary-care center. The study analyzed a random sample of banked MRSA anterior nares isolates recovered during (2005) and after (2006–2012) implementation of a daily CHG bathing protocol was examined for *qacA/B* genes and high-level mupirocin resistance. Staphylococcal cassette chromosome *mec* (SCC*mec*) typing was also performed. Of the 504 randomly selected isolates (63 per year), 36 (7.1%) were *qacA/B* positive (+) and 35 (6.9%) were mupirocin resistant. Of these, 184 (36.5%) isolates were SCC*mec* type IV. There was a significant trend for increasing *qacA/B* ($P=.02$; highest prevalence, 16.9% in 2009 and 2010) and SCC*mec* type IV ($P<.001$; highest prevalence, 52.4% in 2012) during the study period. *qacA/B*(+) MRSA isolates were more likely to be mupirocin resistant (9 of 36 [25%] *qacA/B*(+) vs 26 of 468 [5.6%] *qacA/B*(–); $P=.003$).

A long-term, daily CHG bathing protocol was associated with a change in the frequency of *qacA/B* genes in MRSA isolates recovered from the anterior nares over an 8-year period. This change in the frequency of *qacA/B* genes is most likely due to patients in those years being exposed in prior admissions.

Lead Author David K. Warren, MD, MPH, is professor of medicine at Washington University in St. Louis, Hospital Epidemiologist for Barnes-Jewish Hospital, and program director of the Masters of Science in Clinical Investigation at Washington University in St. Louis. Dr. Warren's research interests center around the epidemiology and prevention of healthcare-associated infections. Other authors on the study were Martin Prager, Satish Munigala, Meghan A. Wallace and Carey-Ann Burnham.

HIVMA Awards

HIVMA Clinical Educator Award

*Presented on Wednesday, October 4, at 3:45 p.m. in 20ABCD,
San Diego Convention Center*



MONICA GANDHI, MD, MPH

MONICA GANDHI, MD, MPH, an internationally recognized clinician and educator who has woven teaching and mentoring into all aspects of her work, is the recipient of the 2017 HIVMA Clinical Educator Award. This award recognizes HIVMA members who have demonstrated significant achievement in the area of clinical care and provider education.

Dr. Gandhi is currently a professor of clinical medicine in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco (UCSF) and San Francisco General Hospital. She is also medical director of the Ward 86 HIV Clinic, where she oversees care for more than 2,800 patients. In this safety-net clinic and hospital setting, she has devoted herself to caring for an HIV-infected and at-risk patient population that includes the urban poor, homeless, women, racial and ethnic minorities, and immigrants—people often hard to engage and retain but who greatly need high-quality medical care.

Dr. Gandhi's teaching is tightly linked to these settings and these populations, and encompasses not only the scientific aspects of medical knowledge and practice, but also the real-world practicality gained from working with challenging populations in challenging settings. Truly excited to see students and trainees learn, whether during a "chalk talk" or a bedside discussion, Dr. Gandhi consistently receives outstanding teaching reviews, and many students and residents return for HIV electives or clinical rotations based on their previous work with her. She is the recipient of many awards, including the UCSF Meg Newman Teaching Award, the Sarlo Award for Teaching Excellence from UCSF's AIDS Research Institute, and the Defender of Humanity Award and Clinical Teaching Award from ID fellows in recognition of her compassionate clinical work.

During her six years as division education director, Dr. Gandhi solidified and expanded the division's educational mission and continues to be closely involved in these activities, including in her current roles as associate division chief and assistant director of UCSF's ID fellowship program. She has led the longitudinal outpatient clinic training of ID and HIV fellows in the Ward 86 clinic and expanded this training from one to two years, in addition to leading the development of a robust formal curriculum for the two-year fellows training program. She has done hundreds of didactic talks, small group sessions, and presentations for numerous groups at her institutions, in the community, and nationally educating a variety of audiences about HIV care and prevention.

Dr. Gandhi's commitment to teaching and mentoring extends well beyond UCSF. Supported by a National Institutes of Health grant, she developed a mentoring program for early career investigators of diversity and a "Mentoring the Mentors" national workshop series for midcareer and senior HIV investigators (to learn specialized techniques and tools of effective mentoring) and has led trainings in the US and in Peru, Kenya, India, and South Africa supported by funding from the Fogarty International Center. After earning her medical degree from Harvard Medical School, Dr. Gandhi completed her residency, infectious diseases fellowship, and a postdoctoral research fellowship at UCSF, where she has been on the faculty since 2003. She also received a master of public health degree from the University of California, Berkeley.

For her dedication to caring for patients and to teaching clinicians, from the novice to the experienced, to practice HIV medicine at the highest standards, HIVMA is honored to recognize Dr. Gandhi with the 2017 HIVMA Clinical Educator Award.

HIVMA Research Award

Presented on Thursday, October 5, at 4:30 p.m. in 20ABCD,
San Diego Convention Center



RAPHAEL J. LANDOVITZ, MD, MSc

RAPHAEL J. LANDOVITZ, MD, MSc, a skilled HIV clinician and researcher who has been a leader in advancing biomedical HIV prevention, is the recipient of the 2017 HIVMA Research Award. This award recognizes members who have made outstanding contributions to HIV medicine in clinical or basic research early in their careers.

An associate professor of medicine in the Division of Infectious Diseases at the David Geffen

School of Medicine at the University of California, Los Angeles (UCLA), and associate director of the UCLA Center for Clinical AIDS Research & Education, Dr. Landovitz also serves as co-director of the UCLA Center for HIV Identification, Prevention, and Treatment Services. His research has focused on HIV behavioral science, pre-exposure prophylaxis (PrEP), and post-exposure prophylaxis (PEP), including novel research findings related to motivators and barriers for these approaches, the efficacy of contingency management to facilitate their use in substance users, and HIV risk trajectories that warrant PrEP.

Considered a leading PrEP expert, Dr. Landovitz has conducted some of his work in collaboration with Los Angeles County, through establishing PEP and PrEP demonstration projects in collaboration with the Department of Health, including the use of real-time drug levels to trigger staged-level adherence interventions. Since 2009, when he obtained his National Institutes of Health career development award, he has published more than 40 primary research studies, reviews, and editorials, including commentaries in publications including *The New England Journal of Medicine*, *Lancet Infectious Diseases*, and *The Journal of Infectious Diseases*.

A sought after lecturer, Dr. Landovitz has spoken at IDWeek multiple times about the evolving field of PrEP. Currently, he is the protocol chair of HPTN 077, a phase II study of long-acting PrEP, and HPTN 083, a large phase III efficacy trial of long-acting injectable PrEP planning to enroll 4,500 subjects, which launched in 2016. Active in the AIDS Clinical Trials Group (ACTG), which in 2010 recognized him with its John Carey Young Investigator Award, he is also chair of ACTG's Antiretroviral Strategies subcommittee.

Dr. Landovitz received his medical degree from Harvard Medical School. After an internship and residency at Brigham and Women's Hospital in Boston, where he also served as chief resident, he completed an infectious diseases fellowship at Brigham and Women's and Massachusetts General Hospital while serving as an HIV clinical fellow. He joined the faculty at Brigham and Women's before relocating in 2006 to UCLA, where he also received an MSc degree, to pursue research and continue his clinical career. An avid clinician on the inpatient consult service at UCLA, he has been named a Best Doctor in America several times.

For his important and ongoing contributions to our understanding of biomedical prevention strategies for HIV infection, HIVMA is delighted to honor Dr. Landovitz with the 2017 HIVMA Research Award.

HIVMA Clinical Fellowship

HIVMA Clinical Fellows



YURY PARRA, MD

YURY PARRA, MD, received her medical degree from the University of Illinois, College of Medicine at Chicago in 2013 and completed her residency in Family and Community Medicine at Thomas Jefferson University Hospital in Philadelphia, in 2017. With her clinical training fueled by caring for and working with vulnerable patient populations, Dr. Parra is eager to further her training in HIV medicine and to join the community of individuals advancing the work of addressing

the social determinants of health that affect the current HIV epidemic. Dr. Parra's primary clinical training site will be Thomas Jefferson University Hospital, and HIVMA member Kathleen Squires, MD will serve as her mentor.

Drawing on her own experiences as an immigrant, growing up in a working class family, and in an area with major social, health, and economic disparities, Dr. Parra seeks to continue her training as a physician who is an advocate for patients beyond the clinic. During her residency, she has worked in a community with a high prevalence of HIV infection, where many individuals struggle with access to care, including recent immigrants and refugees learning to navigate the healthcare system and patients affected by mental conditions and/or addiction. These experiences have motivated her to learn more about HIV medicine, including expanding her understanding of the context in which HIV is acquired and the factors that lead to disease progression and transmission, despite major advances in treatment.

"Through the HIVMA Clinical Fellowship and my future career, I plan to practice medicine at community sites involved in medical training, as I envision the opportunity to mentor and transmit my passion in caring for vulnerable populations living with HIV," Dr. Parra said. "Additionally, I desire a career that combines clinical care and advocacy work, which would allow for the development of partnerships with local communities and agencies to improve outreach and access."

A volunteer physician and resident liaison with Puentes de Salud, an organization serving Philadelphia's Latino immigrant population, Dr. Parra has served as a curriculum developer and resident liaison for the underserved care track at Thomas Jefferson University Hospital, a specialized concentration where family medicine residents gain additional training in caring for underserved communities. She is also the founder of a forum series that allows residents and faculty to discuss topics related to health and social justice.



VANESSA ROJAS, MD

VANESSA ROJAS, MD, earned a medical degree in 2013 from Ross University School of Medicine in Dominica and in June 2017 she completed her residency at Jamaica Hospital Medical Center in Jamaica, New York. Motivated to pursue further training in HIV medicine following her experiences with HIV-infected patients dealing with stigma, Dr. Rojas seeks to provide HIV care and primary care in an integrated, continuous way to underserved patients at Jamaica

Hospital Medical Center and at Montefiore Medical Center. HIVMA members Peter Selwyn, MD, MPH, and Farshad Bagheri, MD, will serve as her mentors.

Passionate about working with patients living with HIV and about primary care, Dr. Rojas observed firsthand how complex and challenging the care of underserved patients infected with HIV can be during HIV rotations at Montefiore Medical Center and Bronx-Lebanon Medical Center in Bronx, NY, and as a resident at Jamaica Hospital Medical Center. This included navigating not only complex medical problems but often also psychosocial and socioeconomic issues. She hopes to build on these experiences and what she has already learned in providing care to patients in these settings as she continues her training through the HIVMA Clinical Fellowship. In particular, she looks forward to the opportunity to provide continuity of care to HIV-infected patients over the long term.

"I envision facilitating a space in which my patients can receive both primary care and HIV care all in one place," Dr. Rojas said. "Ultimately, I believe that my work could also encourage other primary care physicians to provide this type of care, changing perceptions about the difficulty in doing so in the field."

Previously a community outreach worker with the AmeriCorps VISTA program at the Edward R. Leahy Jr. Center Clinic for the Uninsured in Scranton, Pennsylvania, which provides non-emergency healthcare to uninsured local residents, Dr. Rojas also has experience as a medical scribe before her beginning her residency training. She served as educational liaison at Jamaica Hospital Medical Center, where she was also named resident of the month in February 2015 and May 2017.

PIDS Society Awards

PIDS Distinguished Service Award

Presented on Wednesday, October 4, at 3:45 p.m. in 20ABCD, San Diego Convention Center



KATHRYN M. EDWARDS, MD, FIDSA, FPIDS

KATHRYN M. EDWARDS, MD, FIDSA, FPIDS, professor of pediatrics and the Sarah H. Sell and Cornelius Vanderbilt Endowed Chair in Pediatrics at Vanderbilt University School of Medicine, has been selected as the thirteenth recipient of the PIDS Distinguished Service Award. This award recognizes a Society member who has made an outstanding contribution to the specialty of pediatric infectious diseases.

Dr. Edwards received her medical degree from the University of Iowa College of Medicine, and completed her pediatric residency and pediatric infectious diseases fellowship training at Children's Memorial Hospital and Northwestern University School of Medicine in Chicago. Following a postdoctoral fellowship in immunology at Presbyterian St. Luke's Hospital, she joined the faculty at Vanderbilt University in 1980. Dr. Edwards rose through the ranks at Vanderbilt and has remained there throughout her illustrious career.

Dr. Edwards has made many outstanding contributions to the field of pediatric infectious diseases. She is the author of more than 480 peer-reviewed publications. Her work touches many aspects of pediatric ID, with a major focus on vaccine evaluation and vaccine safety. She has conducted large efficacy trials of influenza vaccines and has led numerous multicenter trials of pediatric vaccines including those for *Haemophilus influenzae*, pertussis, *Streptococcus pneumoniae*, and combination vaccines from several manufacturers. She led the Vanderbilt Vaccine Research Program for many years and has been a major contributor within the Vaccine and Treatment Evaluation Unit network of the National Institutes of Health. Dr. Edwards has served as a member of national and international committees examining vaccine policies and priorities, including the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, the Vaccines and Related Biological Products Advisory Committee of the Food and Drug Administration, and several World Health Organization advisory boards.

Known for her outstanding mentoring and advocacy for young investigators, Dr. Edwards has received mentoring awards both locally and nationally. She frequently serves as a visible and enthusiastic representative for careers in pediatric ID, serving as a source of inspiration to those she directly works with as well as those who have a chance to meet her or hear her speak at national meetings. As a leader in pediatric infectious diseases, she has encouraged many outstanding young people to join our field and follow in her footsteps in making a major impact on the health of children.

For her exemplary contributions to the field of pediatric infectious diseases and her outstanding mentoring of current and future leaders in our discipline, PIDS is pleased to honor Dr. Edwards with the 2017 Distinguished Service Award.

PIDS Poster Awards

This event will be held on Wednesday, October 4 from 6 to 7:30 in the Poster Hall of the San Diego Convention Center.

The PIDS Poster Presentation Program is an educational program that recognizes PIDS fellows, medical students, and pediatric residents who have performed outstanding research in pediatric infectious diseases, providing a forum for the top ranked abstracts by these groups to be presented as research posters to PIDS members.

IDWeek Program Committee Choice Awards

This \$2,500 award recognizes up to four of the best abstracts overall. IDWeek's Program Committee selected the following recipients based on outstanding scientific research:

CATHARINE C. BULIK, PHARM D, ICPD, Schenectady, NY - Presentation: 956 "Getting it Right the First Time: Relating Pharmacokinetic-Pharmacodynamic Target Attainment and Patient Outcomes" Session 123: Stewardship Tools, Friday, October 6, 2017 8:30 - 10 a.m.

SUSAN S. HUANG, MD, MPH, FIDSA, FSHEA, University of California Irvine School of Medicine, Irvine, CA - Presentation: 1712 "The CDC SHIELD Orange County Project – Baseline Multi Drug-Resistant Organism (MDRO) Prevalence in a Southern California Region" Session 194: SHEA Featured Oral Abstract, Friday, October 6, 2017 4:15 - 4:30 p.m.

CONCETTA MARSICO, MD, University of Bologna, Bologna, Italy - Presentation: 947 "Blood Viral Load (VL) Not Clinically Meaningful in Symptomatic Congenital Cytomegalovirus (cCMV) Infection" Session 121: Emerging Paradigms: Pediatric Viral Infections, Friday, October 6, 2017 8:30 - 10 a.m.

PAUL SALCUNI, MPH, New York City Department of Health and Mental Hygiene, Long Island City, NY - Presentation: 898 "Trends and Associations with PrEP Prescription among 602 New York City (NYC) Ambulatory Care Practices, 2014-16" Session 99: Featured Oral Abstract, Thursday, October 5, 2017 4:30 - 4:45 p.m.

IDWeek Diagnostic Awards

The IDWeek Award for top abstracts submitted in Diagnostics is intended to recognize the best abstracts in the Category of Diagnostics. The IDWeek Program Committee selected the recipients based on outstanding scientific research in the field of diagnostics.

ROBY BHATTACHARYYA, MD PhD, Massachusetts General Hospital, Boston, MA - Presentation: 993 "Rapid phenotypic antibiotic susceptibility testing through RNA detection" Session 133: Diagnostics and Why They Matter, Friday, October 6, 2017, 10:30 a.m. - noon

HENRY CHENG, MS, Stanford University, Stanford, CA - Presentation: 2505 "Integration of Next-Generation Sequencing, Viral Sequencing, and Host-Response Profiling for the Diagnosis of Acute Infections" Session 281: Featured Oral Abstract, Saturday, October 7, 2017, 4:30 - 4:45 p.m.

MORGAN IVY, BS, Mayo Clinic, Rochester, MN - Presentation: 989 "Direct Detection and Identification of Prosthetic Joint Pathogens in Synovial Fluid (SF) by Metagenomic Shotgun Sequencing" Session 133: Diagnostics and Why They Matter, Friday, October 6, 2017, 10:30 a.m. - noon

LISA WANDA, BS, BA, Duke University Medical Center, Durham, NC - Presentation: 2083 "Direct Detection and Quantification of Bacterial Cell-free DNA in Patients with Bloodstream Infection (BSI) Using the Karius Plasma Next Generation Sequencing (NGS) Test" Session 237: Diagnostics - Novel Diagnostics, Saturday, October 7, 2017, 12:30 - 2 p.m.

IDWeek Investigator Awards

The Investigator Awards are intended to recognize the work of investigators in practice for less than 15 years, whose submitted abstracts are accepted for presentation at IDWeek. The award consists of \$1,250, and selection was based on the quality of the scientific merit of the nominee's accepted abstract. Each IDWeek sponsoring society has chosen one outstanding abstract from a member in their specialty to highlight. Following are the awardees for IDWeek 2017:

IDSA Awardee: DANIEL LEUNG, MD, University of Utah, Salt Lake City, UT - Presentation: 2063 "Fecal Host Transcriptomics for Non-invasive Mucosal Immune Profiling in Human *Clostridium difficile* Infection" Session 235: Diagnostics - Diarrheal Disease, Saturday, October 7, 2017 12:30 - 2 p.m.

SHEA Awardee: SHELLEY S. MAGILL, MD, PhD, Centers for Disease Control and Prevention, Atlanta, GA - Presentation: 215 "Reduction in

the prevalence of healthcare-associated infections in US acute care hospitals, 2015 versus 2011" Session 45: National Trends in HAIs, Saturday, October 7, 2017 8:30 - 10 a.m.

PIDS Awardee: SARAH MULKEY, MD, PhD, Children's National Health System, Washington, DC - Presentation: 945 "Fetal and Postnatal Brain Imaging for the Detection of ZIKV Encephalopathy in the Fetus/Newborn" Session 121: Emerging Paradigms: Pediatric Viral Infections, Friday, October 6, 2017 8:30 - 10 a.m.

HIVMA Awardee: NAVA YEGANEH, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA - Presentation: 883 "HIV antiretroviral resistance and transmission in mother-infant pairs enrolled in a large perinatal study" Session 93: Preventing and Identifying New HIV Infections, Thursday, October 5, 2017 2 - 3:30 p.m.

IDWeek International Investigator Awards

The IDWeek International Investigator Awards are intended to recognize and support the work of individuals outside the United States and Canada who are either currently in training or who have been in practice for five years or less, and have an abstract accepted for presentation at IDWeek. The grant selection was based on scientific merit of the submitted abstract, and presenting authors receive \$1,500. Following are the awardees for 2017 IDWeek:

LUCIA CHAMBAL, MSc, MD, Maputo Central Hospital, Maputo, Mozambique - Presentation: 2223 "HBV infection in untreated HIV-infected adults in Maputo, Mozambique" Session 244: HIV and HBV, Saturday, October 7, 2017 12:30 - 2 p.m.

LENE FOGT LUNDBO, MD PhD, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark - Presentation: 125 "Increased risk of invasive meningococcal disease associated with primary and secondary immunodeficiency" Session 40: Adult Central Nervous System Infection, Thursday, October 5, 2017 10:30 a.m. - noon

TAKASHI MATONO, MD, National Institute of Infectious Diseases, Tokyo, Japan - Presentation: 2490 "Phylogenetic Analysis of an Unusual Increase in Salmonella enterica serovar Paratyphi A Infection among Travelers Returning from Myanmar" Session 277: Global Infections, Saturday, October 7, 2017 2 - 3:30 p.m.

DEBDEEP MITRA, MD DERMATOLOGY, Army Hospital New Delhi, New Delhi, India - Presentation: 2278 "A Randomized Controlled Trial of Anti-TNF α Bio-similar Adalimumab versus Prednisolone in the Management of Leprosy Patients with New Type 1 Leprosy Reaction" Session 249: Non-Tuberculous Mycobacteria: Epidemiology and Management, Saturday, October 7, 2017 12:30 - 2 p.m.

ROSNI DA MOHD NOH, MMED, Universiti Teknologi MARA, Sungai Buloh, Malaysia - Presentation: 459 "An Outbreak of *Pseudomonas aeruginosa* Infection in Coronary Artery Bypass Graft Patients Related to Endoscopic Vein Harvesting Equipment." Session 56: HAI: Outbreaks, Thursday, October 5, 2017 12:30 - 2 p.m.

DAISUKE YAMASAKI, PhD, Mie University Hospital, Mie, Japan - Presentation: 1617 "Age-specific Distribution of Antimicrobial Use Surveillance using National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB Japan) 2011-2013" Session 170: Stewardship: Targets for Intervention, Friday, October 6, 2017 12:30 - 2 p.m.

Each sponsoring society has chosen one outstanding abstract from a member in their specialty. These abstracts are recognized as the top submissions from international investigators, and the presenting authors have received an award in the amount of \$1,750. Following are the awardees for 2017 IDWeek:

SHEA Awardee: DARUNEE CHOTIPRASITSAKUL, MD, MPH, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand - Presentation: 961 "The Role of Negative Methicillin-Resistant *Staphylococcus aureus* Nasal Surveillance Swabs in Predicting the Need for Empiric Vancomycin Therapy" Session 123: Stewardship Tools, Friday, October 6, 2017 8:30 - 10 a.m.

PIDS Awardee: KAZUHIRO HORIBA, MD, Nagoya University Graduate School of Medicine, Nagoya, Japan - Presentation: 85 "Comprehensive detection of pathogens in immunocompromised children with bloodstream infections by next-generation sequencing" Session 29: Identification, Treatment, and Prevention of Pediatric Bacterial Pathogens, Thursday, October 5, 2017 8:30 - 10 a.m.

IDS Awardee: JENS ULRIK STÆHR JENSEN, MD, PhD, Rigshospitalet - University of Copenhagen, Copenhagen East, Denmark - Presentation: 984 "Induced Hypothermia in Patients with Septic Shock and Ventilator-demanding Respiratory Failure" Session 132: Advances in Management of Bacteremia and Sepsis, Friday, October 6, 2017 10:30 a.m. - noon

HIVMA Awardee: MARK KRISTOFFER PASAYAN, MD, Research Institute for Tropical Medicine, Muntinlupa, Philippines - Presentation: 1816 "Effect of Macrolide Prophylactic Therapy on AIDS-Defining Conditions and HIV-Related Mortality" Session 227: HIV: Modern ART, Friday, October 6, 2017 2 - 3:30 p.m.

Guerrant International Travel Grants

The Guerrant International Travel Grants are awarded to fund travel to IDWeek from low- and lower-middle income countries (based on the World Bank's definition). A limited number of grants up to \$1,600 are available to participants whose abstracts are accepted. The following are the recipients who have received this award for 2017:

PADMAPRIYADARSINI CHANDRASEKARAN, MD, MS, National Institute for Research in Tuberculosis, Chennai, India - Presentation: 2426 "A Novel Tool to Detect Treatment Failures Early in the course of Antituberculosis treatment: Old Wine in New Bottle?" Session 66517: Tuberculosis: Epidemiology and Management, Saturday, October 7, 2017 12:30 – noon.

MARIO MELGAR, MD, Universidad del Valle de Guatemala, Guatemala City, Guatemala - Presentation: 1181 "Enteropathogen Identification by Multiplex PCR in Guatemalan Children with Acute, Non-bloody Diarrhea" Session 146: Enteric Infections and Diagnostics, Friday, October 6, 2017 12:30 - 2 p.m.

PRINCE JONATHAN PAPPOE-ASHONG, MPhil MEDICAL MICROBIOLOGY, University of Ghana, Accra, Ghana - Presentation: 1175 "Optimization of a Polymerase Chain Reaction System for Whole Genome

Amplification of Human Immunodeficiency Virus Type 2 (HIV-2)" Session 145: Diagnostics: Viral, Friday, October 6, 2017 12:30 - 2 p.m.

HAYAM EL AGGAN, PROFESSOR OF MEDICINE, Department of Medicine (Nephrology Unit), Faculty of Medicine, University of Alexandria, Alexandria, Egypt - Presentation: 308 "Endothelial Injury and Oxidative Stress in Patients with Schistosomal Hepatic Fibrosis: Relation to Renal Dysfunction and Hemodynamics." Session 50: Global Infections, Thursday, October 5, 2017 12:30 - 2 p.m.

RAJALAKSHMI ANANTHANARAYANAN, MBBS, DNB, Kerala Institute of Medical Sciences, Trivandrum, India - Presentation: 2114 "Prevalence of Tuberculous Spondylodiscitis and Diagnostic Utility of Xpert MTB RIF" Session 239: Diagnostics Mycobacteriology, Saturday, October 7, 2017 12:30 - 2 p.m.

DOMINICUS HUSADA, MD, School of Medicine, Airlangga University / Dr. Soetomo Hospital, Surabaya, Indonesia - Presentation: 1162 "Measles Oral Swab as Field Based Screening Test in Children" Session 145: Diagnostics: Viral, Friday, October 6, 2017 12:30 - 2 p.m.

Kass Awards

The Kass Awards were established to honor the achievements of Edward H. Kass, a past IDSA president and leader in infectious diseases research. Grants in the amount of \$750 are awarded to medical students, residents, or house officers who have demonstrated excellence in research in infectious diseases and allied fields. Following are the recipients of this award for 2017:

DAVID BAKAL, BS, University of California, Los Angeles, Los Angeles, CA - Presentation: 1684 "Obesity Following Antiretroviral Therapy (ART) Initiation is Common and Influenced by Both Traditional and HIV-/ART-Specific Risk Factors" Session 188: HIV: Modern ART, Friday, October 6, 2017 2 - 3:30 p.m.

STEPHEN CLARK, MD, University of Virginia, Charlottesville, VA - Presentation: 991 "Clinical Yield of Routine Use of Molecular Testing for Adult Outpatients with Diarrhea" Session 133: Diagnostics and Why They Matter, Friday, October 6, 2017 10:30 a.m. - noon

ADRIANA CLINE, MD, University of North Carolina Healthcare, Chapel Hill, NC - Presentation: 2082 "Rapid Detection of Pediatric Bacteriuria Using Narrow Angle Forward Laser Scattering Technology (NAFLST) with Bacterioscan" Session 237: Diagnostics - Novel Diagnostics, Saturday, October 7, 2017 12:30 - 2 p.m.

NAIOMI GUNARATNE, BS, University of Miami Miller School of Medicine, Miami, FL - Presentation: 1782 "Outcomes of women with laboratory evidence of Zika infection in pregnancy" Session 217: Zika - A to Z, Saturday, October 7, 2017 8:30 - 10 a.m.

NEHA GUPTA, BS, Wayne State University, Detroit, MI - Presentation: 271 "Development of a clinically relevant murine model of fungal

(Aspergillus) endophthalmitis" Session 48: Fungus Among Us: Basic Science, Thursday, October 5, 2017 12:30 - 2 p.m.

BRANDON IMP, MD, Kaiser Permanente Northern California, San Francisco, CA - Presentation: 879 "Medical Students Have Limited Awareness, Knowledge, Beliefs, and Experiences of Pre-exposure Prophylaxis (PrEP) for HIV Prevention" Session 93: Preventing and Identifying New HIV Infections, Thursday, October 5, 2017 2 - 3:30 p.m.

KELSEY B. LOELIGER, MPhil, BS, Yale University, New Haven, CT - Presentation: 1685 "Predictors of Linkage to and Retention in HIV Care Following Release from Connecticut Jails and Prisons" Session 188: HIV: Modern ART, Friday, October 6, 2017 2 - 3:30 p.m.

LAUREN PLATT, BA, David Geffen School of Medicine at UCLA, Los Angeles, CA - Presentation: 2496 "A population-based study of recurrent symptomatic Bordetella pertussis infections in children in California, 2010-2015" Session 278: Pneumococcal and Pertussis Vaccines, Saturday, October 7, 2017 2 - 3:30 p.m.

ZACHARY TABB, BS, The Alpert Medical School of Brown University, Providence, RI - Presentation: 2243 "Association of Self-Reported Adherence and Antiretroviral Drug Concentrations in Hair Among Youth with Virologic Failure in Tanzania" Session 247: HIV: Pediatrics, Saturday, October 7, 2017 12:30 - 2 p.m.

ANDREW WALLACE, MD, Cone Health, Greensboro, NC - Presentation: 621 "Lessons Learned from Pseudo-Outbreak of *Legionella pneumophila* Serogroup 1 Infections" Session 70: Legionella, Thursday, October 5, 2017 12:30 - 2 p.m.

IDWeek Trainee Awards

Each IDWeek partnering society has chosen one outstanding abstract from a member in their specialty. These abstracts are recognized as the top submissions from trainees, and the presenting author has received an award in the amount of \$1,250. Following are the awardees for IDWeek 2017:

HIVMA Trainee: **MARY EVANS, MD, MPH**, Centers for Disease Control and Prevention, Atlanta, GA

SHEA Trainee: **AMRITA JOHN, MBBS**, University Hospitals Case Medical Center, Cleveland, OH

ISDA Trainee: **CARLOS MEJIA, MD**, Washington University, Saint Louis, MO

PIDS Trainee: **CRISTINA TOMATIS SOUVERBIELE, MD**, Nationwide Children's Hospital, Columbus, OH

In addition to the above awards to trainees, IDWeek Trainee Awards are awarded to trainees who submitted excellent research. The 2017 IDWeek recipients are listed below:

JUSTIN G. AARON, MD, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY

ALEXANDRA ABRAMS-DOWNEY, MD, Icahn School of Medicine at Mount Sinai, New York, NY

JESSICA I. ABRANTES-FIGUEIREDO, MD, University of Connecticut Health Center, Farmington, CT

ANTENEH ADDISU, MD, PhD, University of South Florida, Tampa, FL

SONALI ADVANI, MD, MPH, University of Alabama at Birmingham, Birmingham, AL

ELFRIEDE AGYEMANG, MD, MPH, Centers for Disease Control and Prevention, Atlanta, GA

SAIRA AJMAL, MD, Mayo Clinic, Rochester, MN

HANA AKSELROD, MD, MPH, George Washington University Medical Center, Washington, DC

MOHANAD AL OBAIDI, MD, The University of Texas Health Science Center at Houston, Houston, TX

MUAYAD ALALI, MD, University of Chicago/ Comer Children Hospital, Chicago, IL

LAILA ALAWDAH, MBBS, Boston Children's Hospital, Boston, MA

ZAID ALHINAI, MD, Hasbro Children's Hospital, Brown University, Providence, RI

MOROUGE ALRAMADHAN, MD, University of Texas McGovern Medical School, Houston, TX

GADIEL ALVARADO, DO, San Antonio Military Medical Center, Fort Sam Houston, TX

TESSA ANDERMANN, MD, MPH, Stanford University, Stanford, CA

SHANNON ANDREWS, MD, University of Minnesota, Minneapolis, MN

GABRIELA M. ANDUJAR-VAZQUEZ, MD, Tufts Medical Center, Boston, MA

SHWETA ANJAN, MD, Jackson Memorial Hospital-University of Miami Miller School of Medicine, Miami, FL

TANNAZ ASADI, MD, Cleveland Clinic Foundation, Cleveland, OH

HAYLEY ASHBAUGH, DVM, MPH, University of California, Los Angeles, Los Angeles, CA

REDA AWALI, MD, MPH, Wayne State University School of Medicine, Detroit, MI

FOLUSAKIN AYOADE, MD, Louisiana State University Health Science Center, Shreveport, LA

ADAM BAGHBAN, MD, Yale School of Medicine, New Haven, CT

VALIDA BAJROVIC, MD, Beaumont Health System, Royal Oak, MI

NATALIE BANNIETTIS, MD, State University of New York Downstate Medical Center, Brooklyn, NY

TINZAR BASEIN, MD, Tufts Medical Center, Boston, MA

HOLLY BEAN, DO, Allegheny Health Network, Pittsburgh, PA

FATMA BEN ABID, MD, Hamad Medical Corporation, Doha, Qatar

ESTHER BENAMU, MD, Stanford University School of Medicine, Stanford, CA

CARLA BENJAMIN, MD, SUNY Downstate Medical Center, Brooklyn, NY

JULIA BINI VIOTTI, MD, University of Miami-Jackson Memorial Hospital, Miami, FL

BENJAMIN BLUEN, MD, Drexel University College of Medicine, Philadelphia, PA

JEFFERSON BOHAN, PHARM D, BCPS, Bosie Veteran's Affairs Medical Center, Boise, ID

JIM BOONYARATANAKORNKIT, MD, PhD, University of Washington, Seattle, WA

JARRED BOWDEN, PHARM D, UF Health Shands Hospital, Gainesville, FL

ALFONZA BROWN, MPH, Army Public Health Center, Aberdeen Proving Ground, MD

CHLOE BRYSON-CAHN, MD, University of Washington, Seattle, WA

ANDREA BUCHWALD, BA, University of Maryland School of Medicine, Baltimore, MD

JASON BURNHAM, MD, Washington University in Saint Louis, Saint Louis, MO

LAURA CARAGOL, MD, University of Colorado - Anschutz Medical Campus, Aurora, CO

ROBERT CASTRO, MD, University of South Florida College of Medicine, Tampa, FL

SUJITTRA CHAISAVANEYAKORN, MD, PhD, University of Texas Southwestern Medical Center, Dallas, TX

RISHI CHANDERRAJ, MD, University of Michigan Health System, Ann Arbor, MI

YEH-CHUNG CHANG, MD, Children's Hospital of Philadelphia, Philadelphia, PA

CHLOE CHAUDHURY, BS, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD

LAKSHMI CHAUHAN, MD, University of Colorado, Aurora, CO

LAURA CHENEY, MD, PhD, Montefiore Medical Center, Bronx, NY

EMILY CICCONE, MD, MHS, University of North Carolina, Chapel Hill, NC

MEREDITH CLEMENT, MD, Duke Clinical Research Institute, Durham, NC

A ASA CLEMENZI-ALLEN, MD, University of California San Francisco, San Francisco, CA

KC COFFEY, MD, MPH, Massachusetts General Hospital, Boston, MA

JENNIFER COLLINS, MD, Emory University, Decatur, GA

GERMAN CONTRERAS, MD MSc, University of Texas McGovern Medical School, Houston, TX

NICOLAS CORTES-PENFIELD, MD, Baylor College of Medicine, Houston, TX

CAYTLIN DEERING, DO, Drexel University College of Medicine, Philadelphia, PA

ALPA DESAI, MD, MPH, Wright State University, Dayton, OH

MICHAËL DESJARDINS, MD, Université de Montréal, Montreal, QC

YAJUN DING, PhD, Baylor College of Medicine, Houston, TX

CHRISTA EICKHOFF, MD, Walter Reed National Military Medical Center, Bethesda, MD

LYNN EL HADDAD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX

VANESSA EL KAMARI, MD, Case Western Reserve University, Cleveland, OH

MALAK ELSHEIKH, MD, University of Illinois at Chicago, Chicago, IL

RACHEL EPSTEIN, MD, MA, Boston Medical Center, Boston, MA

ZERELDA ESQUER GARRIGOS, MD, Mayo Clinic, Rochester, MN

REBECCA FALLIS, MD, Temple University Hospital, Philadelphia, PA

GARY FONG, PHARM D, University of Houston College of Pharmacy, Houston, TX

CATHERINE FOSTER, MD, Baylor College of Medicine and Texas Children's Hospital, Houston, TX

RACHEL FOSTER, PHARM D, MBA, South Carolina College of Pharmacy, Columbia, SC

ALEXANDRA FRANCO GARCIA, MD, Memorial Sloan Kettering Cancer Center, New York, NY

MONICA FUNG, MD, MPH, University of California, San Francisco, San Francisco, CA

MEGAN GALLAGHER, MD, Dartmouth-Hitchcock Medical Center, Lebanon, NH

CINTHIA GALLEGOS, MD, University of Texas Medical School at Houston, Houston, TX

JAIME GALLEGOS SALAZAR, MD, Boston Medical Center, Boston, MA

BRADLEY GARDINER, MBBS, Tufts Medical Center, Boston, MA

BENJAMIN GERN, MD, Seattle Children's Hospital, Seattle, WA

RAQUEL GIACOMELLI CAO, MD PhD, Nationwide Children's Hospital, Columbus, OH

HARMEET GILL, MD, University of South Carolina, Columbia, SC

BASHIRAT GIWA, MBBS, MSPH, Howard University Hospital, Washington, DC

DHEERAJ GOYAL, MD, MPH, University of Utah, Salt Lake City, UT

ERIC GREGORY, PHARM D, University of Kentucky HealthCare, Lexington, KY

ELIZABETH GULLEEN, MD, University of Virginia, Charlottesville, VA

LAWRENCE HA, MD, Northwell Health, Hofstra Northwell School of Medicine, Manhasset, NY

GHADY HAIDAR, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

ANDREW HALE, MD, Beth Israel Deaconess Medical Center, Boston, MA

TONI HALL, DO, Jackson Health/University of Miami/Miami Veterans Affairs Healthcare, Miami, FL

MUSTAFA HASAN, MD, Newark Beth Israel Medical Center, Newark, NJ

HABIBA HASSOUNA, MD, Cleveland Clinic Foundation, Cleveland, OH

JUSTIN F. HAYES, MD, University of Alabama at Birmingham, Birmingham, AL

BREANNE HEAD, MSc, PhD CANDIDATE, University of Manitoba, Winnipeg, MB, Canada

ELIE HELOU, MD, Yale University School of Medicine, New Haven, CT

MARION HEMMERSBACH MILLER, MD PhD, Duke University Medical Center, Durham, NC

ERICA HERC, MD, University of Michigan, Ann Arbor, MI

FRANCISCO HERNANDEZ MUNOZ, MD, UMMS-Baystate Medical Center, Springfield, MA

MATTHEW HITCHCOCK, MD, MPH, Stanford University School of Medicine, Stanford, CA

MATIFADZA HLATSHWAYO, MD, MPH, Washington University School of Medicine, St. Louis, MO

LEILA HOJAT, MD, MetroHealth Medical Center, Cleveland, OH

M. SIOBHAN HOLLAND, MD, University of Calgary, Calgary, AB, Canada

LUCY E. HORTON, MD, MPH, UC San Diego, San Diego, CA

JEFF HOSRY, MD, University of Texas Health Science, Houston, TX

CHRISTOPHER HOSTLER, MD, MPH, Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC

HERMIONE HURLEY, MBChB, Colorado University, Aurora, CO

HOANG A. HUYNH, PHARM D, MBA, University of Arkansas for Medical Sciences, Little Rock, AR

CELESTINE ISHIEKWENE, MBBS, MBA, Maimonides Medical Center, Brooklyn, NY

KELSEY S. IVEY, MD, Vanderbilt University Medical Center, Nashville, TN

ANIL JAGTIANI, MD, Mayo Clinic, Rochester, MN

DEEKSHA JANDHYALA, MD, University of Texas Health Science Center at Houston, Houston, TX

BLESSY JOHN, MD, Yale University School of Medicine, New Haven, CT

CANDACE JOHNSON, MD, Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, NY

JOYCE J. JOHNSRUD, MD, University of Arkansas for Medical Sciences, Little Rock, AR

MILISSA JONES, MD, Walter Reed National Military Medical Center, Bethesda, MD

SU JIN JOO, MD, Emory University, School of Medicine, Division of Pediatric Infectious Diseases, Atlanta, GA

HAJIME KANAMORI, MD, PhD, MPH, University of North Carolina Health Care, Chapel Hill, NC

ANUBHAV KANWAR, MD, Case Western Reserve University School of Medicine/UH Cleveland Medical Center, Cleveland, OH

CAROL KAO, MD, Albert Einstein College of Medicine, Bronx, NY

YUICHI KATANAMI, MD, National Center for Global Health and Medicine, Tokyo, Japan

ISHMINDER KAUR, MD, St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, PA

RAZIEH KEBRIAIEI, PhD, Wayne State University, Detroit, MI

DEVIN KELLY, DO, San Antonio Military Medical Center, Joint Base San Antonio-Fort Sam Houston, TX

continues

SALMAN KHAN, MD, Icahn School of Medicine at Mount Sinai, New York, NY

TERESA KHOO, MD, Stony Brook University Hospital, Stony Brook, NY

NORIKO KINOSHITA, MD, National Center for Child Health and Development, Tokyo, Japan

LING YUAN KONG, MD, McGill University Health Centre, Montreal, QC, Canada

BRANDON KULENGOWSKI, PHARM D, MS, University of Kentucky, College of Pharmacy, Lexington, KY

JOHN LAM, MD, University of Calgary, Calgary, AB, Canada

MARIANA LANATA PIAZZON, MD, Nationwide Children's Hospital, Columbus, OH

DAVID LANZA, PHARM D, Kennedy Health, Stratford, NJ

ROTEM LAPIDOT, MD, Boston Medical Center, Boston, MA

DEREK LARSON, DO, Naval Medical Center San Diego, San Diego, CA

ALLISON LASTINGER, MD, West Virginia University, Morgantown, WV

DORA LEBRON, MD, Brody School of Medicine at East Carolina University, Greenville, NC

SUI KWONG LI, MD, Oregon Health & Science University, Portland, OR

PATRICK LINDSAY, MD, University of Toronto, Toronto, ON

TARA LINES, PHARM D, Vanderbilt University Medical Center, Nashville, TN

BAOMING LIU, PhD, University of Tennessee Health Science Center, Memphis, TN

MEGAN LUTHER, PHARM D, Providence Veterans Affairs Medical Center, Providence, RI

MAMUKA MACHAIDZE, MD, NYU School of Medicine, New York, NY

MARYAM MAHMOOD, MD, Mayo Clinic, Rochester, MN

ANEELA MAJEED, MD, University of Arizona College of Medicine - Tucson, Tucson, AZ

SIDDHI MANKAME, MD, Hofstra Northwell School of Medicine, Manhasset, NY

KETZELA J. MARSH, MD, University of Minnesota, Minneapolis, MN

ISABELLA MARTIN, MD, Dartmouth-Hitchcock Medical Center, Lebanon, NH

JONATHAN MARTIN, DO, Rush University Medical Center, Chicago, IL

RAPEEPHAN MAUDE, MD, MSc, DTM&H, Tufts Medical Center, Boston, MA

JOSEPH MCBRIDE, MD, University of Wisconsin, Madison, WI

DARRELL MCBRIDE, DO, Washington University in St. Louis, St. Louis, MO

MOIRA C. McNULTY, MD, University of Chicago Medicine, Chicago, IL

RICHARD MEDFORD, MD, FRCP(C), Stanford University School of Medicine, Palo Alto, CA

KAYUR MEHTA, MD, The Hospital for Sick Children, Toronto, ON, Canada

JOANNA MERCKX, MD, MSc(c), McGill University, Montreal, QC, Canada

JULIA MESSINA, MD, Duke University Medical Center, Durham, NC

MAYANK MODI, MD, Sir Sayajirao General Hospital, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India

MUHANAD MOHAMED, MD, University of Minnesota, Minneapolis, MN

ESTHER MOLNAR, MD, Temple University Hospital, Philadelphia, PA

MARGUERITE MONOGUE, PHARM D, Hartford Hospital, Hartford, CT

LOUIS-PHILIPPE MONTPETIT, MD, Université de Sherbrooke, Sherbrooke, QC, Canada

MALLIKARJUNA MUKKA, MD, Southern Illinois University School of Medicine, Springfield, IL

MARY MUSGROVE, PHARM D, Henry Ford Hospital, Detroit, MI

SAMIA NACCACHE, PhD, Children's Hospital Los Angeles, Los Angeles, CA

DEEPA NANAYAKKARA, MD, MS, University of Southern California, Los Angeles, CA

MUKIL NATARAJAN, MD, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD

YOICHIRO NATORI, MD, University Health Network, Toronto, ON, Canada

KARYNA NEYRA, MD, Cleveland Clinic, Cleveland, OH

CIMA NOWBAKHT, DO, McGovern Medical School, Houston, TX

RITA NWANYANWU, MD, Jackson Health System, Miami, FL

JANE O'HALLORAN, MD, PhD, Washington University in St Louis, Saint Louis, MO

STELLA OKOYE, MD, University of South Carolina School of Medicine, Columbia, SC

SCOTT OLESEN, PhD, Harvard Chan School of Public Health, Boston, MA

LUKE ONUORAH, MBBS, MPH, Wright State University, Dayton, OH

AMRUTA PADHYE, MD, Washington University School of Medicine, St Louis, MO

ROMA PATEL, MD, University of California-Los Angeles, Los Angeles, CA

SACHIN PATEL, MD, Case Western Reserve University, Cleveland, OH

OTAVIO PEREIRA RODRIGUES, MD, Beaumont Health System, Royal Oak, MI

SIMI PHILIP, MD, Maimonides Medical Center, Brooklyn, NY

JONATHAN POLAK, MD, Brody School of Medicine at East Carolina University, Greenville, NC

HUSAIN POONAWALA, MBBS, Yale School of Medicine, New Haven, CT

HALEY PRITCHARD, MD, Baylor College of Medicine, Houston, TX

AMOL PURANDARE, MD, Children's National Medical Center, Washington, DC

SHRUTI PURI, MD, University of Pittsburgh Medical Center, Cranberry Twp, PA

SYEDA QUADRI, DO, University of Texas Southwestern Medical Center, Dallas, TX

ALISON B. RAPOPORT, MD, Beth Israel Deaconess Medical Center, Boston, MA

KRUNAL RAVAL, MD, Barnes Jewish Hospital - Washington University of St. Louis, St. Louis, MO

AMBREEN RAZA, MD, Cooper University, Camden, NJ

PATRICK REICH, MD, Washington University School of Medicine, Saint Louis, MO

ANDREA REYES VEGA, MD, University of Louisville, Louisville, KY
W. CLIFF RUTTER, PHARM D, MS, University of Kentucky, Lexington, KY
ARICK SABIN, DO, MPH, University of Minnesota, Minneapolis, MN
ENA SAINI, MD, Penn State Milton S Hershey Medical Center, Hershey, PA
TANZILA SALIM, MBBS, Northwell Health, Manhasset, NY
ILAN S. SCHWARTZ, MD, FRCPC, UT Health San Antonio, San Antonio, TX
ANNA SCOTT, MS, Johns Hopkins University, Baltimore, MD
MORGAN SCULLY, MD, UAB, Birmingham, AL
JUSTIN SEARNS, MD, Children's Hospital Colorado, Aurora, CO
JESSICA SEIDELMAN, MD, Duke University, Durham, NC
SUBHASHINI SELLERS, MD, University of North Carolina Medical School, Chapel Hill, NC
RUTH SERRANO, MD, University of Texas Health Science Center at San Antonio, San Antonio, TX
PRATIBHA SESHADRI, MD, Beth Israel Deaconess Medical Center, Boston, MA
MICHELLE SEWNARINE, MD, Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, NY
MARY ELIZABETH SEXTON, MD, Emory University School of Medicine, Atlanta, GA
MAROUN SFEIR, MD, MPH, Weill Cornell Medicine/ New York Presbyterian Medical Center, New York, NY
POOJA SHAH, MD, East Carolina University, Greenville, NC
SHIVANG SHAH, MD, DPHIL, Columbia University Medical Center, New York, NY
ARPAN SHAH, M.D., Allegheny General Hospital/Allegheny Health Network, Pittsburgh, PA
JACQUELINE SHERBUK, MD, Yale University School of Medicine, New Haven, CT
NATHAN R. SHIVELY, MD, University of Pittsburgh Medical Center, Pittsburgh, PA
JAMES SHURKO, PHARM D, The University of Texas Health Science Center San Antonio, San Antonio, TX
KEDESHA SIBLISS, MD, Drexel University College of Medicine, Philadelphia, PA
ANDREW SIMMS, MD, Rush University Medical Center, Chicago, IL
SARA SIRAJUDDIN, MD, University of California Irvine Health, Orange, CA
JENNIFER L. SMALL-SAUNDERS, MD, PhD, Columbia University Medical Center, New York, NY
TIMOTHY SMITH, DO, University of Utah, Salt Lake City, UT
JESSICA SMITH, PHARM D, Wake Forest Baptist Health, Winston-Salem, NC
ELIZABETH SODA, MD, Centers for Disease Control and Prevention, Atlanta, GA
CONOR M. STACK, MD, Beth Israel Deaconess Medical Center, Boston, MA
KIMBERLY STAWARZ, MD, Rutgers New Jersey Medical School, Newark, NJ
JULIE STEINBRINK, MD, University of Michigan Healthcare System, Ann Arbor, MI
ERICA STOHS, MD, MPH, University of Washington, Seattle, WA
WILLIAM STOKES, MD, University of Calgary, Calgary, AB, Canada
SUHAIREIRENE SUADY BARAKE, MD, Texas Tech University Health Sciences Center, Lubbock, TX
SUSANNA K. TAN, MD, Stanford University, Stanford, CA
WINDY TANNER, PhD, University of Utah School of Medicine, Salt Lake City, UT
FARAH TANVEER, MD, Saint John Hospital and Medical Center, Grosse Pointe Woods, MI
ANDREA THET, MD, Harlem Hospital, New York, NY
YAGYA TIWARI, MD, Northwell Health, North Shore University Hospital, Manhasset, NY
TRANG D. TRINH, PHARM D, Wayne State University, Detroit, MI
LUIS TULLOCH, MD, University of California, Los Angeles, Los Angeles, CA
NICHOLAS TURNER, MD, Duke University Medical Center, Durham, NC
ORLANDO D TURNER, MD, University of Alabama at Birmingham, Birmingham, AL
KAZUHIRO UDA, MD, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan
ALON VAISMAN, MD, California Department of Public Health, Richmond, CA
TAM VAN, PhD, Children's Hospital Los Angeles, Los Angeles, CA
TILLY A. VARUGHESE, MD, Memorial Sloan Kettering Cancer Center, New York, NY
BETTY VU, PHARM D, Rush University Medical Center, Chicago, IL
JOEL WADDELL, DO, Children's Mercy Hospitals & Clinics, Kansas City, MO
NAN WANG, PHARM D, Cleveland Clinic, Cleveland, OH
LUKASZ WEINER, MD, University Hospitals Rainbow Babies and Children's Hospital, Cleveland, OH
ERIC WENZLER, PHARM D, University of Illinois at Chicago, Chicago, IL
JONATHAN WILLIAMS, MD, Henry Ford Healthcare System, Detroit, MI
RITA WILSON DIB, MD, UT MD Anderson Cancer Center, Houston, TX
SHANNON WOOD, MD, MPH, Walter Reed National Military Medical Center, Bethesda, MD
MEKLIT WORKNEH, MD, MPH, Infectious Diseases Institute, Makerere University, Kampala, Uganda
SHELTON WRIGHT, MD, MS, University of Washington, Seattle, WA
HARIKA YALAMANCHILI, DO, The University of Texas Health Science Center at Houston - MD Anderson Cancer Center, Houston, TX
MASAKI YAMADA, MD, Children's Hospital of Pittsburgh, Pittsburgh, PA
GOKUL YARATHA, MD, Albert Einstein Medical Center, Philadelphia, PA
NICHOLAS YARED, MD, University of Minnesota, Minneapolis, MN
EDUARDO YEPEZ GUEVARA, MD, University of Texas Health Science Center at Houston - MD Anderson Cancer Center, Houston, TX
EVAN J. ZASOWSKI, PHARM D, Wayne State University, Detroit, MI
YUAN ZHOU, MD, University of Washington, Seattle, WA
MATTHEW ZIEGLER, MD, University of Pennsylvania, Philadelphia, PA

CME/CPE/MOC Credit Tracker

Use the CME/CPE/MOC Tracker below as a guide to track the sessions you've attended, then go to www.idweek.org to enter your sessions, complete a short evaluation for each session, and claim CME/CPE/MOC credit. In accordance with ACCME guidelines, and to ensure balanced presentations, at least one IDWeek Program Committee member will serve as a moderator of each session. IDSA, in conjunction with ProCE, Inc. will offer pharmacists continuing pharmacy education (CPE) credit for select sessions. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Attended ✓	Session #	Session Title	CME/MOC Credits	Universal Activity Number (for CPE credit)
	PW1	The Vincent T. Andriole ID Board Review Course (\$)	Maximum of 7.5 hours of AMA PRA Category 1 Credit™	No CPE Credit
	PW2	Best Practices for Antimicrobial Stewardship Programs (\$) *no MOC	Maximum of 7.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-216-L01-P
	PW8	TB Workshop (\$) *no MOC	Maximum of 4 hours of AMA PRA Category 1 Credit™	0221-9999-17-341-L01-P
	PW5	Hepatitis C Workshop (\$) *no MOC	Maximum of 4 hours of AMA PRA Category 1 Credit™	0221-9999-17-217-L01-P
	PW7	Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA MOC Modules: HIV Medicine in Clinical Practice and Infections in the Non-HIV Immunocompromised Host (\$)	Maximum of 4.5 hours of AMA PRA Category 1 Credit™	No CPE Credit
	PW6	Improving ID Learner Assessment via a Multiple-Choice Question Writing Workshop (\$) *no MOC	Maximum of 4 hours of AMA PRA Category 1 Credit™	0221-9999-17-218-L04-P
	1	Challenging Cases in Pediatric Infectious Diseases 	Maximum of 2 hours of AMA PRA Category 1 Credit™	0221-9999-17-219-L01-P
	2	Controversies in Infection Prevention: Pro/Con 	Maximum of 2 hours of AMA PRA Category 1 Credit™	0221-9999-17-220-L01-P
	3	Controversies in Travel/Tropical Medicine	Maximum of 2 hours of AMA PRA Category 1 Credit™	0221-9999-17-221-L01-P
	4	Late Breaker I	Maximum of 2 hours of AMA PRA Category 1 Credit™	0221-9999-17-380-L01-P
	5	Managing Infections in Opioid Users	Maximum of 1 hours of AMA PRA Category 1 Credit™	0221-9999-17-222-L01-P
	6	Sexually Transmitted Infections: Current Epidemiologic Trends and Management Approaches	Maximum of 2 hours of AMA PRA Category 1 Credit™	0221-9999-17-223-L01-P
	7	What's Hot in ID + HIV	Maximum of 2 hours of AMA PRA Category 1 Credit™	0221-9999-17-224-L02-P
	8	Opening Plenary	Maximum of 2 hours of AMA PRA Category 1 Credit™	0221-9999-17-381-L01-P
	9	Changes in Hospital Laboratory Practice and Their Impact on Clinical Care	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-225-L01-P
	10	Essentials for the Everyday Leader	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-226-L04-P
	11	Media Training for ID Specialists	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-227-L04-P
	12	Our Most Difficult Antiretroviral Management Case	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-228-L02-P
	13	Rapid Responses to Common IP Crises	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	No CPE Credit
	14	Tele-Antimicrobial Stewardship	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-229-L01-P
	15	Travelers Health: Special Patients	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	No CPE Credit
	16	Updates from the Antibacterial Resistance Leadership Group: Methodology and Results in AMR Research	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-342-L04-P
	17	When to Suspect Immunodeficiency in the Adult?	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	No CPE Credit
	18	Wound Care 101	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-230-L01-P
	19	Controversies in Antimicrobial Stewardship Programs: Pro/Con Debates 	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-231-L01-P
	20	Fungal Resistance: Focus on <i>Candida auris</i>	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-232-L01-P
	21	HIV State of the Art	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-233-L02-P
	22	ID Physicians Adapting to Healthcare Reform	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-234-L04-P
	23	Impact of Sepsis Measures	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-235-L01-P
	24	Neurological Manifestations of Infectious Diseases	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	No CPE Credit



Only sessions with this symbol are available for ABP MOC points.

Attended ✓	Session #	Session Title	CME/MOC Credits	Universal Activity Number (for CPE credit)
	25	New Antimicrobial Resistance Surveillance Programs	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-236-L01-P
	26	TB 2017: Pregnancy, IRIS, and MDR/XDR	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-237-L01-P
	27	What's new with Zika	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-238-L01-P
	31	Ambulatory Infection Prevention	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-239-L05-P
	32	Antimicrobial Stewardship Programs In Non-Acute Settings	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-240-L01-P
	33	Big Beasts in Global Health	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-241-L01-P
	34	Big Beasts in ID I	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-242-L01-P
	35	Current Issues, Conundrums, and Challenges with Respiratory Viruses	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-243-L01-P
	36	Have a Yogurt and Call Me in the Morning: Update on Probiotics	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-244-L01-P
	37	HIV on the Horizon	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-245-L02-P
	38	Mano-a-Mano II: Controversies in Pediatric ID	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-246-L01-P
	39	Preventing Vaccine-Preventable Diseases in Healthcare: Policy & Politics	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-247-L01-P
	84	Diagnostic Clinical Cases 	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-249-L01-P
	85	A Case Based Approach to Guidelines: Meningitis, Encephalitis, and Nervous System Lyme Disease	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-248-L01-P
	86	Global Fungal Infections	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-250-L01-P
	87	Hot Topics in Pediatric Infectious Diseases	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-251-L01-P
	89	New Discoveries in an Old Field: Bacterial Toxins	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-252-L01-P
	90	Playing the Long Game: Infection Prevention in Long Term Care	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-253-L01-P
	91	Preventing and Managing Endoscope-Associated Outbreaks and Infection Control Breaches	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	No CPE Credit
	92	When Transplantation Goes Viral: Mitigating CMV, Herpes, and HIV in Transplantation	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-254-L01-P
	96	Bone of Contention: Challenging Cases in Vertebral Osteomyelitis	Maximum of 2 hours of AMA PRA Category 1 Credit™	No CPE Credit
	97	Edward H. Kass Lecture	Maximum of 0.75 hours of AMA PRA Category 1 Credit™	0221-9999-17-255-L01-P
	100	John F. Enders Lecture	Maximum of 0.75 hours of AMA PRA Category 1 Credit™	0221-9999-17-256-L01-P
	101	Advancing Federal ID and HIV Priorities: Making the Case to Federal Policymakers	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	No CPE Credit
	102	Big Data in Infectious Diseases	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-257-L01-P
	103	Controversies in Empiric and Definitive Treatment of ESBL Infections	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-258-L01-P
	104	Make Learning Last in the Large Group Setting	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-259-L04-P
	105	Malaria: What's New?	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-260-L01-P
	106	Mid-Career Challenges and Opportunities	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	No CPE Credit
	108	Rapid Fire: Questions for the Transplant ID Expert	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-261-L01-P
	109	Second Generation B-Lactamase Inhibitor Combinations: Promise and Peril	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-262-L01-P
	110	Setting up an Antimicrobial Stewardship Program for a Long-Term Care Facility: Practical Pointers from the Front Line	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-263-L01-P
	111	The ID Physician New to Infection Prevention and/or Antimicrobial Stewardship	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-264-L01-P
	112	Challenging HIV Cases 	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-265-L02-P
	113	Big Beasts of Healthcare Epidemiology	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	No CPE Credit



Only sessions with this symbol are available for ABP MOC points.

continues

Attended ✓	Session #	Session Title	CME/MOC Credits	Universal Activity Number (for CPE credit)
	114	CMV: Pathogenicity Not Limited to Congenital and Transplant Infections	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-266-L01-P
	115	Hot Topics in Medical Education	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-267-L04-P
	116	Non-Traditional Approaches for Bad Bugs	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-268-L01-P
	117	Prevention and Management of Legionnaire's Disease: What's New?	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-269-L01-P
	118	Questions in Bacteremia	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-270-L01-P
	119	The Pediatric Microbiome	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-271-L01-P
	120	Viral Hepatitis	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-272-L01-P
	124	Challenging Cases in Infectious Diseases 	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-275-L01-P
	125	Antimicrobial Stewardship Programs in Challenging Populations	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-273-L01-P
	126	Dosing Antibiotics in Critically Ill Patients	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-276-L01-P
	127	Foodborne Infections: Disease Burden and Advances	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-277-L01-P
	128	Late Breaker II	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-382-L01-P
	129	Managing Comorbidities and Co-Infections in Patients with HIV	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-278-L02-P
	130	Methods in Epidemiology Research: Asking the Right Questions, Recognizing Valid Answers	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-279-L01-P
	131	Remembrance of Things Past	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-280-L01-P
	136	Caroline B. Hall Lectureship	Maximum of 1 hours of AMA PRA Category 1 Credit™	0221-9999-17-274-L01-P
	179	Case-Based Problems in Vaccines: Beyond the Guidelines 	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-281-L01-P
	180	Nightmare Bugs: A Case-Based Symposium 	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-284-L01-P
	181	Sexually Transmitted Infections in the HIV Care Setting: An Interactive Case-Based Approach 	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-286-L02-P
	182	Diagnostic Updates: Syndrome-Based Diagnostics	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	No CPE Credit
	183	Evolution Informing Infectious Diseases, Infectious Diseases Informing Evolution	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-282-L01-P
	184	Expect the Unexpected: Evolving Infection Risks in Transplantation	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-283-L01-P
	185	Infection Prevention Down the Drain: Water Fixtures in Healthcare Settings	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	No CPE Credit
	186	Nontuberculous Mycobacterial Infections in Children	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-285-L01-P
	187	Stewardship Accreditation Standards in Action	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-287-L01-P
	191	Debate: Clinical Controversies 	Maximum of 2 hours of AMA PRA Category 1 Credit™	0221-9999-17-288-L01-P
	192	Tropical Medicine Cases: Conundrums and Case Management 	Maximum of 2 hours of AMA PRA Category 1 Credit™	No CPE Credit
	193	SHEA Lectureship	Maximum of 1 hours of AMA PRA Category 1 Credit™	0221-9999-17-383-L04-P
	196	Influential Publications in Healthcare Epidemiology and Infection Control in the Past Year	Maximum of 1 hours of AMA PRA Category 1 Credit™	No CPE Credit
	197	Active Surveillance Testing for MDROs: Where and When?	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-289-L01-P
	198	Combination Antifungal Treatment for Mold Infections: Pros and Cons	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-290-L01-P
	199	Don't Make These Mistakes: Frequent Barriers in Antimicrobial Stewardship Programs	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-291-L01-P
	200	National Healthcare Safety Network Updates	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-292-L05-P
	201	Our Toughest Coinfection Cases	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-293-L01-P
	202	Outpatient Parenteral Antimicrobial Therapy	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-294-L01-P



Only sessions with this symbol are available for ABP MOC points.

Attended ✓	Session #	Session Title	CME/MOC Credits	Universal Activity Number (for CPE credit)
	203	Tuberculosis Management	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-295-L01-P
	204	Women in Infectious Diseases	Maximum of 1.25 hours of AMA PRA Category 1 Credit™	0221-9999-17-296-L04-P
	205	Challenging Transplant Cases: When Transplant ID Specialists say, What?!	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-299-L01-P
	206	Advancing Pediatric Infection Prevention: Moving the Needle	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-297-L01-P
	207	Bad Bugs: Emerging High Consequence Viruses	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-298-L01-P
	208	<i>Clostridium difficile</i> Diagnostics	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-300-L01-P
	209	Combination Therapies for Super-Bugs	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-301-L01-P
	210	Infectious Disease Telehealth	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-302-L04-P
	211	Promising Interventions in Antimicrobial Stewardship Programs	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-303-L01-P
	212	Shots Across the Bow: Debates in Vaccinology	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-304-L01-P
	213	Update on the HIV Prevention and Care Cascade	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-305-L02-P
	218	State of the Art: Clinical Management of Hepatitis C	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-311-L01-P
	219	B Cell Biology: What the ID Physician Needs to Know	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	No CPE Credit
	220	Beating and Breathing: Updates in the Management of Transplant Candidates and Recipients	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-306-L01-P
	221	Big Beasts in ID II	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-307-L01-P
	222	Cryptococcus in 2017: Bench to Bedside	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-308-L01-P
	223	HIV Prevention 2017	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-309-L01-P
	224	Kawasaki Disease: What's New?	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-310-L01-P
	225	Using Whole Genome Sequencing to Advance Infection Prevention	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-312-L01-P
	226	Zika Without Borders	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-313-L01-P
	267	ID BugBowl	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	No CPE Credit
	268	Antimicrobial Stewardship Programs in Pediatrics	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-314-L01-P
	269	Challenges in the Management of Complicated Urinary Tract Infections	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-315-L01-P
	270	Critical Medical Devices: Friend and Foe	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-316-L01-P
	271	Donations with Unintended Consequences: A Multidisciplinary Approach to Reduce Blood, Cell, Tissue, and Organ Donor-Transmitted Infections	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	No CPE Credit
	272	Holistic Management of Patients with HIV	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-317-L02-P
	273	Hot, Hot, Hot, Topics in Public Health	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-318-L01-P
	274	New Anti-Infective Clinical Trials that Will Change Your Practice	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-319-L01-P
	275	The Cutting Edge of Science in Pediatric Transplantation	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-320-L01-P
	276	The Microbiome and Antibiotic Resistance	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-321-L01-P
	280	Joseph E. Smadel Lecture	Maximum of 0.75 hours of AMA PRA Category 1 Credit™	0221-9999-17-322-L01-P
	283	Maxwell Finland Lecture	Maximum of 0.75 hours of AMA PRA Category 1 Credit™	0221-9999-17-323-L01-P
	284	Controversies in Prosthetic Joint Infections	Maximum of 1 hours of AMA PRA Category 1 Credit™	0221-9999-17-324-L01-P
	285	Global Eradication of Hepatitis C	Maximum of 1 hours of AMA PRA Category 1 Credit™	0221-9999-17-325-L01-P
	286	Maternal-Child Infections: Antimicrobial Pharmacokinetics and Pharmacodynamics	Maximum of 1 hours of AMA PRA Category 1 Credit™	0221-9999-17-326-L01-P
	287	Closing Plenary	Maximum of 1.5 hours of AMA PRA Category 1 Credit™	0221-9999-17-384-L01-P



Only sessions with this symbol are available for ABP MOC points.

Schedule-at-a-Glance

Tuesday, October 3, 2017

8 a.m. - 5 p.m.	PREMEETING WORKSHOP ■ The Vincent T. Andriole ID Board Review Course (\$) - 1AB
8 a.m. - 5:15 p.m.	■ Best Practices for Antimicrobial Stewardship Programs (\$) - 5AB
2 - 7 p.m.	REGISTRATION

Wednesday, October 4, 2017

7 a.m. - 7 p.m.	REGISTRATION
7:45 a.m. - noon	■ Pediatric Fellows' Day Workshop (\$) - 8
8 a.m. - noon	■ Fellows' Day Premeeting Workshop (\$) - 17AB ■ TB Workshop (\$) - 15AB ■ Hepatitis C Workshop (\$) - 16AB ■ Improving ID Learner Assessment via a Multiple-Choice Question Writing Workshop (\$) - 2
8 a.m. - 12:30 p.m.	■ Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA MOC Modules: HIV Medicine in Clinical Practice and Infections in the Non-HIV Immunocompromised Host (\$) - 11AB
1:30 - 2:30 p.m.	SYMPOSIUM ■ Managing Infections in Opioid Users - 17AB
1:30 - 3:30 p.m.	INTERACTIVE SESSION ■ Challenging Cases in Pediatric Infectious Diseases - 6CF ■ Controversies in Infection Prevention: Pro/Con - 6DE SYMPOSIUM ■ Controversies in Travel/Tropical Medicine - 16AB ■ Late Breaker I - 6AB ■ Sexually Transmitted Infections: Current Epidemiologic Trends and Management Approaches - 15AB ■ What's Hot in ID + HIV - 20ABCD
3:45 - 5:45 p.m.	PLENARY SESSION ■ Opening Plenary - 20ABCD
6 - 7:30 p.m.	RECEPTION ■ Opening Reception and "Posters in the Park" - Poster Hall CD

Thursday, October 5, 2017

6:30 a.m. - 4 p.m.	REGISTRATION
7 - 8:15 a.m.	MEET-THE-PROFESSOR SESSION ■ Changes in Hospital Laboratory Practice and Their Impact on Clinical Care - 2 ■ Essentials for the Everyday Leader - 15AB ■ Media Training for ID Specialists - 7AB ■ Our Most Difficult Antiretroviral Management Case - 16AB ■ Rapid Responses to Common IP Crises - 5AB ■ Tele-Antimicrobial Stewardship - 1AB ■ Travelers Health: Special Patients - 11AB ■ Updates from the Antibacterial Resistance Leadership Group: Methodology and Results in AMR Research - 14AB ■ When to Suspect Immunodeficiency in the Adult? - 8 ■ Wound Care 101 - 17AB
8:30 - 10 a.m.	INTERACTIVE SESSION ■ Controversies in Antimicrobial Stewardship Programs: Pro/Con Debates - 6DE SYMPOSIUM ■ Fungal Resistance: Focus on <i>Candida auris</i> - 15AB ■ HIV State of the Art - 6CF ■ ID Physicians Adapting to Healthcare Reform - 6AB ■ Impact of Sepsis Measures - 11AB

- Neurological Manifestations of Infectious Diseases - 20ABCD
- New Antimicrobial Resistance Surveillance Programs - 17AB
- TB 2017: Pregnancy, IRIS, and MDR/XDR - 16AB
- What's new with Zika - 14AB

ORAL ABSTRACT SESSION

- CDI Prevention - 7AB
- Identification, Treatment, and Prevention of Pediatric Bacterial Pathogens - 5AB
- It's not just Bones: Skin and Bones - 1AB

SYMPOSIUM

- Ambulatory Infection Prevention - 16AB
- Antimicrobial Stewardship Programs In Non-Acute Settings - 17AB
- Big Beasts in Global Health - 15AB
- Big Beasts in ID I - 6AB
- Current Issues, Conundrums, and Challenges with Respiratory Viruses - 14AB
- Have a Yogurt and Call Me in the Morning: Update on Probiotics - 6CF
- HIV on the Horizon - 11AB
- Mano-a-Mano II: Controversies in Pediatric ID - 20ABCD
- Preventing Vaccine-Preventable Diseases in Healthcare: Policy & Politics - 6DE

ORAL ABSTRACT SESSION

- Adult Central Nervous System Infection - 7AB
- Infections in Transplantation - 5AB
- The Cutting Edge in Antimicrobial Resistance Emergence Therapy - 1AB

POSTER ABSTRACT SESSION

- *Candida auris*: Coming Soon to a Patient Near You - Poster Hall CD
- Clinical Mycology - Poster Hall CD
- Clinical: Bone and Joint Infection - Poster Hall CD
- Clinical: Sexually Transmitted Infections - Poster Hall CD
- Clinical: Skin and Soft Tissue - Poster Hall CD
- Fungus Among Us: Basic Science - Poster Hall CD
- Global Health Potpourri - Poster Hall CD
- Global Infections - Poster Hall CD
- Emerging Resistance - Epidemiology and Mechanisms - Poster Hall CD
- HAI: MDRO-GNR/Emerging Resistant Bacterial Pathogens - Poster Hall CD
- HAI Non-Acute Care - Poster Hall CD
- HAI: Epidemiologic Methods - Poster Hall CD
- HAI: Occupational Health - Poster Hall CD
- HAI: Outbreaks - Poster Hall CD
- HAI: Surveillance + Reporting - Poster Hall CD
- HAI: The Environment - Poster Hall CD
- Hepatitis B and C in Varied Settings - Poster Hall CD
- HIV and Central Nervous System - Poster Hall CD
- HIV and Fungal Infection - Poster Hall CD
- HIV and Mycobacterial Infections - Poster Hall CD
- HIV Clinical Care and Outcomes - Poster Hall CD

	<ul style="list-style-type: none"> ■ HIV: Cancer and Dysplasia - Poster Hall CD ■ HIV: Cardiovascular Disease, Lipids, Diabetes - Poster Hall CD ■ HIV: General Opportunistic Infections - Poster Hall CD ■ HIV: Kidney, Bone + Liver Effects - Poster Hall CD ■ HIV: Pathogenesis and Inflammation - Poster Hall CD ■ Immunology - Host Response - Poster Hall CD ■ Legionella - Poster Hall CD ■ Microbial Pathogenesis - Poster Hall CD ■ Microbiome - Poster Hall CD ■ Outbreaks and Public Health Across the Globe - Poster Hall CD ■ Stewardship: Data and Program Planning - Poster Hall CD ■ Stewardship: Program Implementation - Poster Hall CD ■ Treatment of Resistant Infections - Clinical Analyses - Poster Hall CD ■ Use of PK/PD to Optimize Existing Antibiotics and Antifungals - Poster Hall CD ■ Zika Virus - Poster Hall CD <p>POSTER DISCUSSION ROUND</p> <ul style="list-style-type: none"> ■ Managing Emerging Resistance in Gram Negatives - Poster Hall CD ■ Big Beasts - Poster Hall CD ■ Global Health - Poster Hall CD ■ HIV Metabolic Diseases - Poster Hall CD ■ Stewardship - Poster Hall CD <p>INTERACTIVE SESSION</p> <ul style="list-style-type: none"> ■ Diagnostic Clinical Cases - 6CF <p>SYMPOSIUM</p> <ul style="list-style-type: none"> ■ A Case Based Approach to Guidelines: Meningitis, Encephalitis, and Nervous System Lyme Disease - 6AB ■ Global Fungal Infections - 15AB ■ Hot Topics in Pediatric Infectious Diseases - 11AB ■ New Antibiotics: What's in the Pipeline - 20ABCD ■ New Discoveries in an Old Field: Bacterial Toxins - 17AB ■ Playing the Long Game: Infection Prevention in Long Term Care - 16AB ■ Preventing and Managing Endoscope-Associated Outbreaks and Infection Control Breaches - 14AB ■ When Transplantation Goes Viral: Mitigating CMV, Herpes, and HIV in Transplantation - 6DE <p>ORAL ABSTRACT SESSION</p> <ul style="list-style-type: none"> ■ Preventing and Identifying New HIV Infections - 7AB ■ Respiratory Infection Diagnosis - 1AB ■ Use 'em and Lose 'em: Preventing Antibiotic Overuse - 5AB 	
2 - 3:30 p.m.		
3:45 - 4:30 p.m.	<p>NAMED LECTURE</p> <ul style="list-style-type: none"> ■ Edward H. Kass Lecture - 20ABCD 	
3:45 - 5:45 p.m.	<p>SYMPOSIUM</p> <ul style="list-style-type: none"> ■ Bone of Contention: Challenging Cases in Vertebral Osteomyelitis - 6AB 	
4:30 - 4:45 p.m.	<p>AWARDS SESSION</p> <ul style="list-style-type: none"> ■ Awards Session - 20ABCD 	
4:45 - 5 p.m.	<p>ORAL ABSTRACT SESSION</p> <ul style="list-style-type: none"> ■ Featured Oral Abstract - 20ABCD 	
5 - 5:45 p.m.	<p>NAMED LECTURE</p> <ul style="list-style-type: none"> ■ John F. Enders Lecture - 20ABCD 	
		<p>Friday, October 6, 2017</p> <p>6:30 a.m. - 4 p.m.</p> <p>7 - 8:15 a.m.</p> <p>8:30 - 10 a.m.</p> <p>10:30 - 11 a.m.</p> <p>10:30 a.m. - noon</p>
		<p>REGISTRATION</p> <p>MEET-THE-PROFESSOR SESSION</p> <ul style="list-style-type: none"> ■ Advancing Federal ID and HIV Priorities: Making the Case to Federal Policymakers - Marriott Marquis, Santa Rosa ■ Big Data in Infectious Diseases - 2 ■ Controversies in Empiric and Definitive Treatment of ESBL Infections - 16AB ■ Make Learning Last in the Large Group Setting - 8 ■ Malaria: What's New? - 5AB ■ Mid-Career Challenges and Opportunities - 11AB ■ Pipeline 2.0 - 6DE ■ Rapid Fire: Questions for the Transplant ID Expert - 17AB ■ Second Generation B-Lactamase Inhibitor Combinations: Promise and Peril - 15AB ■ Setting up an Antimicrobial Stewardship Program for a Long-Term Care Facility: Practical Pointers from the Front Line - 1AB ■ The ID Physician New to Infection Prevention and/or Antimicrobial Stewardship - 14AB <p>INTERACTIVE SESSION</p> <ul style="list-style-type: none"> ■ Challenging HIV Cases - 20ABCD <p>SYMPOSIUM</p> <ul style="list-style-type: none"> ■ Big Beasts of Healthcare Epidemiology - 6DE ■ CMV: Pathogenicity Not Limited to Congenital and Transplant Infections - 17AB ■ Hot Topics in Medical Education - 11AB ■ Non-Traditional Approaches for Bad Bugs - 14AB ■ Prevention and Management of Legionnaire's Disease: What's New? - 15AB ■ Questions in Bacteremia - 6CF ■ The Pediatric Microbiome - 16AB ■ Viral Hepatitis - 6AB <p>ORAL ABSTRACT SESSION</p> <ul style="list-style-type: none"> ■ Emerging Paradigms: Pediatric Viral Infections - 1AB ■ Public Health Potpourri - 7AB ■ Stewardship Tools - 5AB ■ PIDS Featured Abstracts - 15AB <p>INTERACTIVE SESSION</p> <ul style="list-style-type: none"> ■ Challenging Cases in Infectious Diseases - 20ABCD <p>SYMPOSIUM</p> <ul style="list-style-type: none"> ■ Antimicrobial Stewardship Programs in Challenging Populations - 6DE ■ Dosing Antibiotics in Critically Ill Patients - 6AB ■ Foodborne Infections: Disease Burden and Advances - 11AB ■ Late Breaker II - 6CF ■ Managing Comorbidities and Co-Infections in Patients with HIV - 14AB ■ Methods in Epidemiology Research: Asking the Right Questions, Recognizing Valid Answers - 16AB ■ Remembrance of Things Past - 17AB <p>ORAL ABSTRACT SESSION</p> <ul style="list-style-type: none"> ■ Advances in Management of Bacteremia and Sepsis - 7AB ■ Diagnostics and Why They Matter - 5AB ■ Where Did That Come From? Transmission Risks in Healthcare - 1AB

continues

Schedule at-a-Glance *continued*

11 a.m. - noon	NAMED LECTURE ■ Caroline B. Hall Lectureship - 15AB	2 - 3:30 p.m.	INTERACTIVE SESSION ■ Case-Based Problems in Vaccines: Beyond the Guidelines - 11AB ■ Nightmare Bugs: A Case-Based Symposium - 20ABCD ■ Sexually Transmitted Infections in the HIV Care Setting: An Interactive Case-Based Approach - 6AB SYMPOSIUM ■ Diagnostic Updates: Syndrome-Based Diagnostics - 16AB ■ Evolution Informing Infectious Diseases, Infectious Diseases Informing Evolution - 14AB ■ Expect the Unexpected: Evolving Infection Risks in Transplantation - 6DE ■ Infection Prevention Down the Drain: Water Fixtures in Healthcare Settings - 17AB ■ Nontuberculous Mycobacterial Infections in Children - 6CF ■ Stewardship Accreditation Standards in Action - 15AB ORAL ABSTRACT SESSION ■ HIV: Modern ART - 7AB ■ Hepatitis B and C Across the Lifespan - 5AB ■ Resist! MDROs in Healthcare - 1AB
12:30 - 2 p.m.	POSTER ABSTRACT SESSION ■ Adult CNS Infection - Poster Hall CD ■ Adult Immunization: Miscellaneous - Poster Hall CD ■ Adult Viral Infection - Poster Hall CD ■ Assorted Pediatric Vaccines - Poster Hall CD ■ Clinical Practice Issues - Poster Hall CD ■ Clinical: Soup to Nuts - Poster Hall CD ■ Clinical: UTI - Poster Hall CD ■ Diagnostics: Biomarkers - Poster Hall CD ■ Diagnostics: Viral - Poster Hall CD ■ Enteric Infections and Diagnostics - Poster Hall CD ■ Expanded Spectrum: New Antimicrobial Susceptibility Testing - Poster Hall CD ■ <i>C. difficile</i> : From the Bench to Bedside - Poster Hall CD ■ HAI: <i>C. difficile</i> Epidemiology, Impact, and Testing - Poster Hall CD ■ HAI: <i>C. difficile</i> Risk Assessment and Prevention - Poster Hall CD ■ HAI: Hand Hygiene - Poster Hall CD ■ Herpes Zoster Vaccine - Poster Hall CD ■ HIV Care Continuum - Poster Hall CD ■ HIV Drug Resistance - Poster Hall CD ■ HIV Testing - Poster Hall CD ■ HIV: Antiretroviral Therapy - Poster Hall CD ■ HIV: Healthcare Utilization and Costs - Poster Hall CD ■ HIV: Pre-Exposure Prophylaxis - Poster Hall CD ■ HIV: Rapid ART Initiation - Poster Hall CD ■ ID Medical Education - Poster Hall CD ■ Influenza and Influenza Vaccines - Poster Hall CD ■ Maternal/Infant Immunization - Poster Hall CD ■ Pediatric Viral Infections - Poster Hall CD ■ Pneumococcal Immunization and Epidemiology-Global - Poster Hall CD ■ Pneumococcal Immunization and Epidemiology-North America - Poster Hall CD ■ Pneumococcal Immunization in Adults - Poster Hall CD ■ Preclinical Study with New Antibiotics and Antifungals - Poster Hall CD ■ Stewardship: Improving Outcomes - Poster Hall CD ■ Stewardship: Pediatric Antimicrobial Stewardship - Poster Hall CD ■ Stewardship: Targets for Intervention - Poster Hall CD ■ Vaccine Hesitancy - Poster Hall CD ■ Vaccine Strategy and Policy - Poster Hall CD ■ Viral Treatment and Prevention - Poster Hall CD POSTER DISCUSSION ROUND ■ Antiretroviral Therapy - Poster Hall CD ■ PrEP - Poster Hall CD ■ Big Beasts - Clinical - Poster Hall CD ■ <i>Clostridium difficile</i> - Poster Hall CD ■ Education - Poster Hall CD ■ Stewardship II - Poster Hall CD	3:45 - 4:15 p.m. 3:45 - 5:45 p.m. 4:15 - 4:30 p.m. 4:30 - 4:45 p.m. 4:45 - 5:45 p.m. 6 - 7:30 p.m.	NAMED LECTURE ■ SHEA Lectureship - 20ABCD INTERACTIVE SESSION ■ Debate: Clinical Controversies - 6AB ■ Tropical Medicine Cases: Conundrums and Case Management - 6CF ORAL ABSTRACT SESSION ■ SHEA Featured Oral Abstract - 20ABCD AWARDS SESSION ■ Awards Session - 20ABCD SYMPOSIUM ■ Influential Publications in Healthcare Epidemiology and Infection Control in the Past Year - 20ABCD IDWEEK 2017 TOWN HALL ■ IDWeek Town Hall 2.0 – Join the Conversation - 6DE
Saturday, October 7, 2017			
		6:30 a.m. - 4 p.m.	REGISTRATION MEET-THE-PROFESSOR SESSION ■ Active Surveillance Testing for MDROs: Where and When? - 1AB ■ Combination Antifungal Treatment for Mold Infections: Pros and Cons - 11AB ■ Don't Make These Mistakes: Frequent Barriers in Antimicrobial Stewardship Programs - 7AB ■ National Healthcare Safety Network Updates - 17AB ■ Our Toughest Coinfection Cases - 16AB ■ Outpatient Parenteral Antimicrobial Therapy - 5AB ■ Tuberculosis Management - 14AB ■ Women in Infectious Diseases - Marriott Marquis Grand Ballroom 1+2
		7 - 8:15 a.m.	
		8:30 - 10 a.m.	INTERACTIVE SESSION ■ Challenging Transplant Cases: When Transplant ID Specialists say, What?! - 6CF SYMPOSIUM ■ Advancing Pediatric Infection Prevention: Moving the Needle - 15AB ■ Bad Bugs: Emerging High Consequence Viruses - 14AB ■ <i>Clostridium difficile</i> Diagnostics - 11AB ■ Combination Therapies for Super-Bugs - 6AB

10:30 a.m. - noon	<ul style="list-style-type: none">■ Infectious Disease Telehealth - 17AB■ Promising Interventions in Antimicrobial Stewardship Programs - 5AB■ Shots Across the Bow: Debates in Vaccinology - 6DE■ Update on the HIV Prevention and Care Cascade - 16AB ORAL ABSTRACT SESSION <ul style="list-style-type: none">■ Host-Pathogen Integration - 7AB■ National Trends in HAIs - 8■ The Fungus Among-us - Clinical Advances - 1AB■ Zika - A to Z - 2 INTERACTIVE SESSION <ul style="list-style-type: none">■ State of the Art: Clinical Management of Hepatitis C - 6CF SYMPOSIUM <ul style="list-style-type: none">■ B Cell Biology: What the ID Physician Needs to Know - 17AB■ Beating and Breathing: Updates in the Management of Transplant Candidates and Recipients - 16AB■ Big Beasts in ID II - 6AB■ Cryptococcus in 2017: Bench to Bedside - 15AB■ HIV Prevention 2017 - 14AB■ Kawasaki Disease: What's New? - 11AB■ Using Whole Genome Sequencing to Advance Infection Prevention - 5AB■ Zika Without Borders - 6DE ORAL ABSTRACT SESSION <ul style="list-style-type: none">■ HIV: Co-morbidities and Co-infections - 8■ Late Breaker Oral Abstracts - 2■ Pediatric Vaccines - 7AB■ Thinking Beyond Your Hospital: Stewardship on a Broader Scale - 1AB	2 - 3:30 p.m.	<ul style="list-style-type: none">■ Pediatric Virology - Poster Hall CD■ Transplant Infections: Epidemiology - Poster Hall CD■ Transplantation: Bacterial Infections - Poster Hall CD■ Transplantation: Pretransplantation Screening + Evaluation - Poster Hall CD■ Transplantation: Prophylaxis and Prediction - Poster Hall CD■ Transplantation Fungal Infections - Poster Hall CD■ Tuberculosis: Epidemiology and Management - Poster Hall CD■ Viral Infections in Transplantation - Poster Hall CD POSTER DISCUSSION ROUND <ul style="list-style-type: none">■ Advances in Diagnostics and Impact on Stewardship - Poster Hall CD■ MRSA - Poster Hall CD■ New Antibiotics - Poster Hall CD■ Pediatric Bacterial Infections - Poster Hall CD■ Pediatric Viral Infections - Poster Hall CD■ HIV - Poster Hall CD■ Transplants - Poster Hall CD INTERACTIVE SESSION <ul style="list-style-type: none">■ ID BugBowl - 6AB SYMPOSIUM <ul style="list-style-type: none">■ Antimicrobial Stewardship Programs in Pediatrics - 17AB■ Challenges in the Management of Complicated Urinary Tract Infections - 6DE■ Critical Medical Devices: Friend and Foe - 14AB■ Donations with Unintended Consequences: A Multidisciplinary Approach to Reduce Blood, Cell, Tissue, and Organ Donor-Transmitted Infections - 20D■ Holistic Management of Patients with HIV - 16AB■ Hot, Hot, Hot, Topics in Public Health - 5AB■ New Anti-Infective Clinical Trials that Will Change Your Practice - 11AB■ The Cutting Edge of Science in Pediatric Transplantation - 15AB■ The Microbiome and Antibiotic Resistance - 6CF ORAL ABSTRACT SESSION <ul style="list-style-type: none">■ Global Infections - 1AB■ Pneumococcal and Pertussis Vaccines - 8■ STIs - Diagnostics and Therapy - 7AB NAMED LECTURE <ul style="list-style-type: none">■ Joseph E. Smadel Lecture - 6AB AWARDS SESSION <ul style="list-style-type: none">■ Awards Session - 6AB ORAL ABSTRACT SESSION <ul style="list-style-type: none">■ Featured Oral Abstract - 6AB NAMED LECTURE <ul style="list-style-type: none">■ Maxwell Finland Lecture - 6AB	
	12:30 - 2 p.m.		POSTER ABSTRACT SESSION <ul style="list-style-type: none">■ Clinical Study with New Antibiotics and Antifungals - Poster Hall CD■ Clinical: Bacteremia and Endocarditis - Poster Hall CD■ Clinical: Respiratory Track - Poster Hall CD■ Diagnostics: Bacterial Identification & Resistance - Poster Hall CD■ Diagnostics: Diarrheal Disease - Poster Hall CD■ Diagnostics: Mycology - Poster Hall CD■ Diagnostics: Novel Diagnostics - Poster Hall CD■ Diagnostics: Pharyngitis - Poster Hall CD■ Diagnostics Mycobacteriology - Poster Hall CD■ Stewardship: Impact of Diagnostics - Poster Hall CD■ HAI: Device Related Infections - Poster Hall CD■ HAI: MRSA, MSSA, and Other Gram Positives - Poster Hall CD■ HAI: Surgical Site Infections - Poster Hall CD■ HIV and HBV - Poster Hall CD■ HIV and HCV - Poster Hall CD■ HIV and Women - Poster Hall CD■ HIV: Pediatrics - Poster Hall CD■ HIV: Sexually Transmitted Infections - Poster Hall CD■ Non-Tuberculous Mycobacteria: Epidemiology and Management - Poster Hall CD■ Pediatric Bacterial Infections: From A to Z - Poster Hall CD■ Pediatric Potpourri - Poster Hall CD	<ul style="list-style-type: none">3:45 - 4:30 p.m.4:30 - 4:45 p.m.4:45 - 5 p.m.5 - 5:45 p.m.
	Sunday, October 8, 2017			
	7:30 - 11 a.m.	REGISTRATION		
	8 - 9 a.m.	MINI-SYMPOSIUM <ul style="list-style-type: none">■ Controversies in Prosthetic Joint Infections - 11AB■ Global Eradication of Hepatitis C - 1AB■ Maternal-Child Infections: Antimicrobial Pharmacokinetics and Pharmacodynamics - 5AB PLENARY SESSION <ul style="list-style-type: none">■ Closing Plenary - 6AB		
	9:15 - 10:45 a.m.			

2017 IDWeek Program Tracks

Tuesday, October 3

8 a.m. - 5 p.m.

Premeeting Workshop

- ▶ PW1. The Vincent T. Andriole ID Board Review Course (\$) -1AB

Wednesday, October 4

8 a.m. - noon

Premeeting Workshops

- ▶ PW6. Improving ID Learner Assessment via a Multiple-Choice Question Writing Workshop (\$) -2
- ▶ PW8. TB Workshop (\$) -15AB

1:30 - 3:30 p.m.

Symposia

- ▶ 3. Controversies in Travel/Tropical Medicine -16AB
- ▶ 7. What's Hot in ID + HIV -20ABCD

3:45 - 5:45 p.m.

Plenary Session

- ▶ 8. Opening Plenary -20ABCD

6 - 7:30 p.m.

Reception

- ▶ Opening Reception and "Posters in the Park" -Poster Hall CD

Thursday, October 5

7 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 10. Essentials for the Everyday Leader -15AB
- ▶ 11. Media Training for ID Specialists -7AB
- ▶ 15. Travelers Health: Special Patients -11AB

8:30 - 10 a.m.

Symposia

- ▶ 20. Fungal Resistance: Focus on *Candida auris* -15AB
- ▶ 26. TB 2017: Pregnancy, IRIS, and MDR/XDR -16AB
- ▶ 27. What's new with Zika -14AB

10:30 a.m. - noon

Symposia

- ▶ 33. Big Beasts in Global Health -15AB
- ▶ 35. Current Issues, Conundrums, and Challenges with Respiratory Viruses -14AB

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 49. Global Health Potpourri -Poster Hall CD
- ▶ 50. Global Infections -Poster Hall CD
- ▶ 51. Emerging Resistance - Epidemiology and Mechanisms -Poster Hall CD
- ▶ 53. HAI Non-Acute Care -Poster Hall CD
- ▶ 59. Hepatitis B and C in Varied Settings -Poster Hall CD
- ▶ 64. HIV: Cancer and Dysplasia -Poster Hall CD
- ▶ 66. HIV: General Opportunistic Infections -Poster Hall CD
- ▶ 67. HIV: Kidney, Bone + Liver Effects -Poster Hall CD
- ▶ 73. Outbreaks and Public Health Across the Globe -Poster Hall CD

Poster Discussion Round

- ▶ 81. Global Health -Poster Hall CD

2 - 3:30 p.m.

Interactive Session

- ▶ 84. Diagnostic Clinical Cases -6CF

Symposia

- ▶ 85. A Case Based Approach to Guidelines: Meningitis, Encephalitis, and Nervous System Lyme Disease -6AB
- ▶ 86. Global Fungal Infections -15AB
- ▶ 87. Hot Topics in Pediatric Infectious Diseases -11AB

Oral Abstract Session

- ▶ 93. Preventing and Identifying New HIV Infections -7AB

3:45 - 4:30 p.m.

Named Lecture

- ▶ 97. Edward H. Kass Lecture -20ABCD

3:45 - 5:45 p.m.

Symposium

- ▶ 96. Bone of Contention: Challenging Cases in Vertebral Osteomyelitis -6AB

4:30 - 4:45 p.m.

Awards Session

- ▶ 98. Awards Session -20ABCD

5 - 5:45 p.m.

Named Lecture

- ▶ 100. John F. Enders Lecture -20ABCD

Friday, October 6

7 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 101. Advancing Federal ID and HIV Priorities: Making the Case to Federal Policymakers -Marriott Marquis, Santa Rosa
- ▶ 102. Big Data in Infectious Diseases -2
- ▶ 105. Malaria: What's New? -5AB
- ▶ 106. Mid-Career Challenges and Opportunities -11AB

8:30 - 10 a.m.

Symposium

- ▶ 119. The Pediatric Microbiome -16AB
- Oral Abstract Sessions
- ▶ 121. Emerging Paradigms: Pediatric Viral Infections -1AB
- ▶ 122. Public Health Potpourri -7AB

10:30 a.m. - noon

Symposium

- ▶ 128. Late Breaker II -6CF

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 151. HAI: Hand Hygiene -Poster Hall CD
- ▶ 155. HIV Testing -Poster Hall CD
- ▶ 156. HIV: Antiretroviral Therapy -Poster Hall CD
- ▶ 157. HIV: Healthcare Utilization and Costs -Poster Hall CD
- ▶ 158. HIV: Pre-Exposure Prophylaxis -Poster Hall CD
- ▶ 160. ID Medical Education -Poster Hall CD
- ▶ 168. Stewardship: Improving Outcomes -Poster Hall CD
- ▶ 169. Stewardship: Pediatric Antimicrobial Stewardship -Poster Hall CD
- ▶ 170. Stewardship: Targets for Intervention -Poster Hall CD

2 - 3:30 p.m.

Symposium

- ▶ 183. Evolution Informing Infectious Diseases, Infectious Diseases Informing Evolution -14AB

Oral Abstract Session

- ▶ 189. Hepatitis B and C Across the Lifespan -5AB

3:45 - 4:15 p.m.

Named Lecture

- ▶ 193. SHEA Lectureship -20ABCD

3:45 - 5:45 p.m.

Interactive Session

- ▶ 192. Tropical Medicine Cases: Conundrums and Case Management -6CF

4:30 - 4:45 p.m.

Awards Session

- ▶ 195. Awards Session -20ABCD

6 - 7:30 p.m.

IDWeek 2017 Town Hall

- ▶ IDWeek Town Hall 2.0 -6DE

Saturday, October 7**7 - 8:15 a.m.**

Meet-the-Professor Sessions

- ▶ 198. Combination Antifungal Treatment for Mold Infections: Pros and Cons -11AB
- ▶ 199. Don't Make These Mistakes: Frequent Barriers in Antimicrobial Stewardship Programs -7AB
- ▶ 203. Tuberculosis Management -14AB

8:30 - 10 a.m.

Symposium

- ▶ 207. Bad Bugs: Emerging High Consequence Viruses -14AB

Oral Abstract Session

- ▶ 217. Zika - A to Z -2

10:30 a.m. - noon

Symposia

- ▶ 221. Big Beasts in ID II -6AB
- ▶ 222. Cryptococcus in 2017: Bench to Bedside -15AB
- ▶ 226. Zika Without Borders -6DE

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 243. HAI: Surgical Site Infections -Poster Hall CD
- ▶ 248. HIV: Sexually Transmitted Infections -Poster Hall CD
- ▶ 250. Pediatric Bacterial Infections: From A to Z -Poster Hall CD
- ▶ 252. Pediatric Virology -Poster Hall CD

2 - 3:30 p.m.

Symposia

- ▶ 271. Donations with Unintended Consequences: A Multidisciplinary Approach to Reduce Blood, Cell, Tissue, and Organ Donor-Transmitted Infections -20D
- ▶ 273. Hot, Hot, Hot, Topics in Public Health -5AB

Oral Abstract Session

- ▶ 277. Global Infections -1AB

3:45 - 4:30 p.m.

Named Lecture

- ▶ 280. Joseph E. Smadel Lecture -6AB

4:30 - 4:45 p.m.

Awards Session

- ▶ 281. Awards Session -6AB

5 - 5:45 p.m.

Named Lecture

- ▶ 283. Maxwell Finland Lecture -6AB

Sunday, October 8**8 - 9 a.m.**

Mini-Symposia

- ▶ 285. Global Eradication of Hepatitis C -1AB
- ▶ 286. Maternal-Child Infections: Antimicrobial Pharmacokinetics and Pharmacodynamics -5AB

9:15 - 10:45 a.m.

Plenary Session

- ▶ 287. Closing Plenary -6AB

2017 IDWeek Program Tracks *continued*

Tuesday, October 3

8 a.m. - 5 p.m.

Premeeting Workshop

- ▶ PW1. The Vincent T. Andriole ID Board Review Course (\$) -1AB

8 a.m. - 5:15 p.m.

Premeeting Workshop

- ▶ PW2. Best Practices for Antimicrobial Stewardship Programs (\$) -5AB

Wednesday, October 4

8 a.m. - noon

Premeeting Workshops

- ▶ PW3. Fellows' Day Premeeting Workshop (\$) -17AB
- ▶ PW5. Hepatitis C Workshop (\$) -16AB
- ▶ PW6. Improving ID Learner Assessment via a Multiple-Choice Question Writing Workshop (\$) -2
- ▶ PW8. TB Workshop (\$) -15AB

8 a.m. - 12:30 p.m.

Premeeting Workshop

- ▶ PW7. Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA MOC Modules: HIV Medicine in Clinical Practice and Non-HIV Immunocompromised Host (\$) -11AB

1:30 - 2:30 p.m.

Symposium

- ▶ 5. Managing Infections in Opioid Users -17AB

1:30 - 3:30 p.m.

Interactive Session

- ▶ 2. Controversies in Infection Prevention: Pro/Con -6DE

Symposia

- ▶ 3. Controversies in Travel/Tropical Medicine -16AB
- ▶ 4. Late Breaker I -6AB
- ▶ 6. Sexually Transmitted Infections: Current Epidemiologic Trends and Management Approaches -15AB
- ▶ 7. What's Hot in ID + HIV -20ABCD

3:45 - 5:45 p.m.

Plenary Session

- ▶ 8. Opening Plenary -20ABCD

6 - 7:30 p.m.

Reception

- ▶ Opening Reception and "Posters in the Park" -Poster Hall CD

Thursday, October 5

7 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 10. Essentials for the Everyday Leader -15AB
- ▶ 11. Media Training for ID Specialists -7AB
- ▶ 12. Our Most Difficult Antiretroviral Management Case -16AB
- ▶ 13. Rapid Responses to Common IP Crises -5AB
- ▶ 15. Travelers Health: Special Patients -11AB
- ▶ 16. Updates from the Antibacterial Resistance Leadership Group: Methodology and Results in AMR Research -14AB
- ▶ 17. When to Suspect Immunodeficiency in the Adult? -8
- ▶ 18. Wound Care 101 -17AB
- ▶ 9. Changes in Hospital Laboratory Practice and Their Impact on Clinical Care -2

8:30 - 10 a.m.

Interactive Session

- ▶ 19. Controversies in Antimicrobial Stewardship Programs: Pro/Con Debates -6DE

Symposia

- ▶ 20. Fungal Resistance: Focus on *Candida auris* -15AB
- ▶ 21. HIV State of the Art -6CF
- ▶ 22. ID Physicians Adapting to Healthcare Reform -6AB
- ▶ 23. Impact of Sepsis Measures -11AB
- ▶ 24. Neurological Manifestations of Infectious Diseases -20ABCD
- ▶ 25. New Antimicrobial Resistance Surveillance Programs -17AB
- ▶ 26. TB 2017: Pregnancy, IRIS, and MDR/XDR -16AB
- ▶ 27. What's new with Zika -14AB

Oral Abstract Sessions

- ▶ 28. CDI Prevention -7AB
- ▶ 29. Identification, Treatment, and Prevention of Pediatric Bacterial Pathogens -5AB
- ▶ 30. It's not just Bones: Skin and Bones -1AB

10:30 a.m. - noon

Symposia

- ▶ 31. Ambulatory Infection Prevention -16AB
- ▶ 32. Antimicrobial Stewardship Programs In Non-Acute Settings -17AB
- ▶ 33. Big Beasts in Global Health -15AB
- ▶ 34. Big Beasts in ID I -6AB
- ▶ 35. Current Issues, Conundrums, and Challenges with Respiratory Viruses -14AB
- ▶ 36. Have a Yogurt and Call Me in the Morning: Update on Probiotics -6CF
- ▶ 37. HIV on the Horizon -11AB
- ▶ 39. Preventing Vaccine-Preventable Diseases in Healthcare: Policy & Politics -6DE

Oral Abstract Sessions

- ▶ 40. Adult Central Nervous System Infection -7AB
- ▶ 41. Infections in Transplantation -5AB
- ▶ 42. The Cutting Edge in Antimicrobial Resistance Emergence Therapy -1AB

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 49. Global Health Potpourri -Poster Hall CD
- ▶ 50. Global Infections -Poster Hall CD
- ▶ 51. Emerging Resistance - Epidemiology and Mechanisms -Poster Hall CD
- ▶ 52. HAI: MDRO-GNR/Emerging Resistant Bacterial Pathogens -Poster Hall CD
- ▶ 53. HAI Non-Acute Care -Poster Hall CD
- ▶ 54. HAI: Epidemiologic Methods -Poster Hall CD
- ▶ 55. HAI: Occupational Health -Poster Hall CD

Friday, October 6

7 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 101. Advancing Federal ID and HIV Priorities: Making the Case to Federal Policymakers -Marriott Marquis, Santa Rosa
- ▶ 102. Big Data in Infectious Diseases -2
- ▶ 103. Controversies in Empiric and Definitive Treatment of ESBL Infections -16AB
- ▶ 104. Make Learning Last in the Large Group Setting -8
- ▶ 105. Malaria: What's New? -5AB
- ▶ 106. Mid-Career Challenges and Opportunities -11AB
- ▶ 107. Pipeline 2.0 -6DE
- ▶ 108. Rapid Fire: Questions for the Transplant ID Expert -17AB
- ▶ 109. Second Generation B-Lactamase Inhibitor Combinations: Promise and Peril -15AB
- ▶ 110. Setting up an Antimicrobial Stewardship Program for a Long-Term Care Facility: Practical Pointers from the Front Line -1AB
- ▶ 111. The ID Physician New to Infection Prevention and/or Antimicrobial Stewardship -14AB

8:30 - 10 a.m.

Interactive Session

- ▶ 112. Challenging HIV Cases -20ABCD

Symposia

- ▶ 113. Big Beasts of Healthcare Epidemiology -6DE
 - ▶ 114. CMV: Pathogenicity Not Limited to Congenital and Transplant Infections -17AB
 - ▶ 115. Hot Topics in Medical Education -11AB
 - ▶ 116. Non-Traditional Approaches for Bad Bugs -14AB
 - ▶ 117. Prevention and Management of Legionnaire's Disease: What's New? -15AB
 - ▶ 118. Questions in Bacteremia -6CF
 - ▶ 119. The Pediatric Microbiome -16AB
 - ▶ 120. Viral Hepatitis -6AB
- Oral Abstract Sessions
- ▶ 121. Emerging Paradigms: Pediatric Viral Infections -1AB
 - ▶ 122. Public Health Potpourri -7AB

10:30 a.m. - noon

Interactive Session

- ▶ 124. Challenging Cases in Infectious Diseases -20ABCD

Symposia

- ▶ 125. Antimicrobial Stewardship Programs in Challenging Populations -6DE
 - ▶ 126. Dosing Antibiotics in Critically Ill Patients -6AB
 - ▶ 127. Foodborne Infections: Disease Burden and Advances -11AB
 - ▶ 128. Late Breaker II -6CF
 - ▶ 129. Managing Comorbidities and Co-Infections in Patients with HIV -14AB
 - ▶ 130. Methods in Epidemiology Research: Asking the Right Questions, Recognizing Valid Answers -16AB
 - ▶ 131. Remembrance of Things Past -17AB
- Oral Abstract Sessions
- ▶ 132. Advances in Management of Bacteremia and Sepsis -7AB
 - ▶ 133. Diagnostics and Why They Matter -5AB
 - ▶ 134. Where Did That Come From? Transmission Risks in Healthcare -1AB

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 137. Adult CNS Infection -Poster Hall CD
- ▶ 139. Adult Viral Infection -Poster Hall CD
- ▶ 141. Clinical Practice Issues -Poster Hall CD
- ▶ 142. Clinical: Soup to Nuts -Poster Hall CD
- ▶ 144. Diagnostics: Biomarkers -Poster Hall CD
- ▶ 145. Diagnostics: Viral -Poster Hall CD
- ▶ 147. Expanded Spectrum: New Antimicrobial Susceptibility Testing -Poster Hall CD

- ▶ 57. HAI: Surveillance + Reporting -Poster Hall CD
 - ▶ 58. HAI: The Environment -Poster Hall CD
 - ▶ 59. Hepatitis B and C in Varied Settings -Poster Hall CD
 - ▶ 60. HIV and Central Nervous System -Poster Hall CD
 - ▶ 61. HIV and Fungal Infection -Poster Hall CD
 - ▶ 62. HIV and Mycobacterial Infections -Poster Hall CD
 - ▶ 63. HIV Clinical Care and Outcomes -Poster Hall CD
 - ▶ 64. HIV: Cancer and Dysplasia -Poster Hall CD
 - ▶ 65. HIV: Cardiovascular Disease, Lipids, Diabetes -Poster Hall CD
 - ▶ 66. HIV: General Opportunistic Infections -Poster Hall CD
 - ▶ 67. HIV: Kidney, Bone + Liver Effects -Poster Hall CD
 - ▶ 68. HIV: Pathogenesis and Inflammation -Poster Hall CD
 - ▶ 70. Legionella -Poster Hall CD
 - ▶ 73. Outbreaks and Public Health Across the Globe -Poster Hall CD
 - ▶ 74. Stewardship: Data and Program Planning -Poster Hall CD
 - ▶ 75. Stewardship: Program Implementation -Poster Hall CD
- Poster Discussion Rounds

- ▶ 79. Managing Emerging Resistance in Gram Negatives -Poster Hall CD
- ▶ 80. Big Beasts -Poster Hall CD
- ▶ 81. Global Health -Poster Hall CD
- ▶ 82. HIV Metabolic Diseases -Poster Hall CD
- ▶ 83. Stewardship -Poster Hall CD

2 - 3:30 p.m.

Interactive Session

- ▶ 84. Diagnostic Clinical Cases -6CF

Symposia

- ▶ 85. A Case Based Approach to Guidelines: Meningitis, Encephalitis, and Nervous System Lyme Disease -6AB
- ▶ 86. Global Fungal Infections -15AB
- ▶ 88. New Antibiotics: What's in the Pipeline -20ABCD
- ▶ 89. New Discoveries in an Old Field: Bacterial Toxins -17AB
- ▶ 90. Playing the Long Game: Infection Prevention in Long Term Care -16AB
- ▶ 91. Preventing and Managing Endoscope-Associated Outbreaks and Infection Control Breaches -14AB
- ▶ 92. When Transplantation Goes Viral: Mitigating CMV, Herpes, and HIV in Transplantation -6DE

Oral Abstract Sessions

- ▶ 93. Preventing and Identifying New HIV Infections -7AB
- ▶ 94. Respiratory Infection Diagnosis -1AB
- ▶ 95. Use 'em and Lose 'em: Preventing Antibiotic Overuse -5AB

3:45 - 4:30 p.m.

Named Lecture

- ▶ 97. Edward H. Kass Lecture -20ABCD

3:45 - 5:45 p.m.

Symposium

- ▶ 96. Bone of Contention: Challenging Cases in Vertebral Osteomyelitis -6AB

4:30 - 4:45 p.m.

Awards Session

- ▶ 98. Awards Session -20ABCD

4:45 - 5 p.m.

Oral Abstract Session

- ▶ 99. Featured Oral Abstract -20ABCD

5 - 5:45 p.m.

Named Lecture

- ▶ 100. John F. Enders Lecture -20ABCD

2017 IDWeek Program Tracks continued

- ▶ 149. HAI: *C. difficile* Epidemiology, Impact, and Testing -Poster Hall CD
- ▶ 150. HAI: *C. difficile* Risk Assessment and Prevention -Poster Hall CD
- ▶ 151. HAI: Hand Hygiene -Poster Hall CD
- ▶ 153. HIV Care Continuum -Poster Hall CD
- ▶ 154. HIV Drug Resistance -Poster Hall CD
- ▶ 155. HIV Testing -Poster Hall CD
- ▶ 156. HIV: Antiretroviral Therapy -Poster Hall CD
- ▶ 157. HIV: Healthcare Utilization and Costs -Poster Hall CD
- ▶ 158. HIV: Pre-Exposure Prophylaxis -Poster Hall CD
- ▶ 159. HIV: Rapid ART Initiation -Poster Hall CD
- ▶ 160. ID Medical Education -Poster Hall CD
- ▶ 167. Preclinical Study with New Antibiotics and Antifungals -Poster Hall CD
- ▶ 168. Stewardship: Improving Outcomes -Poster Hall CD
- ▶ 170. Stewardship: Targets for Intervention -Poster Hall CD
- ▶ 172. Vaccine Strategy and Policy -Poster Hall CD
- Poster Discussion Rounds
- ▶ 175. Big Beasts - Clinical -Poster Hall CD
- ▶ 176. *Clostridium difficile* -Poster Hall CD
- ▶ 177. Education -Poster Hall CD
- ▶ 178. Stewardship II -Poster Hall CD

2 - 3:30 p.m.

Interactive Sessions

- ▶ 179. Case-Based Problems in Vaccines: Beyond the Guidelines -11AB
- ▶ 180. Nightmare Bugs: A Case-Based Symposium -20ABCD
- ▶ 181. Sexually Transmitted Infections in the HIV Care Setting: An Interactive Case-Based Approach -6AB

Symposia

- ▶ 182. Diagnostic Updates: Syndrome-Based Diagnostics -16AB
- ▶ 183. Evolution Informing Infectious Diseases, Infectious Diseases Informing Evolution -14AB
- ▶ 184. Expect the Unexpected: Evolving Infection Risks in Transplantation -6DE
- ▶ 185. Infection Prevention Down the Drain: Water Fixtures in Healthcare Settings -17AB
- ▶ 186. Nontuberculous Mycobacterial Infections in Children -6CF
- ▶ 187. Stewardship Accreditation Standards in Action -15AB
- Oral Abstract Sessions
- ▶ 188. HIV: Modern ART -7AB
- ▶ 189. Hepatitis B and C Across the Lifespan -5AB
- ▶ 190. Resist! MDROs in Healthcare -1AB

3:45 - 4:15 p.m.

Named Lecture

- ▶ 193. SHEA Lectureship -20ABCD

3:45 - 5:45 p.m.

Interactive Sessions

- ▶ 191. Debate: Clinical Controversies -6AB
- ▶ 192. Tropical Medicine Cases: Conundrums and Case Management -6CF

4:15 - 4:30 p.m.

Oral Abstract Session

- ▶ 194. SHEA Featured Oral Abstract -20ABCD

4:30 - 4:45 p.m.

Awards Session

- ▶ 195. Awards Session -20ABCD

4:45 - 5:45 p.m.

Symposium

- ▶ 196. Influential Publications in Healthcare Epidemiology and Infection Control in the Past Year -20ABCD

6 - 7:30 p.m.

IDWeek 2017 Town Hall

- ▶ IDWeek Town Hall 2.0 -6DE

Saturday, October 7

7 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 197. Active Surveillance Testing for MDROs: Where and When? -1AB
- ▶ 198. Combination Antifungal Treatment for Mold Infections: Pros and Cons -11AB
- ▶ 199. Don't Make These Mistakes: Frequent Barriers in Antimicrobial Stewardship Programs -7AB
- ▶ 200. National Healthcare Safety Network Updates -17AB
- ▶ 201. Our Toughest Coinfection Cases -16AB
- ▶ 202. Outpatient Parenteral Antimicrobial Therapy -5AB
- ▶ 203. Tuberculosis Management -14AB
- ▶ 204. Women in Infectious Diseases -Grand Ballroom 1+2

8:30 - 10 a.m.

Interactive Session

- ▶ 205. Challenging Transplant Cases: When Transplant ID Specialists say, What?! -6CF

Symposia

- ▶ 207. Bad Bugs: Emerging High Consequence Viruses -14AB
- ▶ 208. *Clostridium difficile* Diagnostics -11AB
- ▶ 209. Combination Therapies for Super-Bugs -6AB
- ▶ 210. Infectious Disease Telehealth -17AB
- ▶ 211. Promising Interventions in Antimicrobial Stewardship Programs -5AB
- ▶ 212. Shots Across the Bow: Debates in Vaccinology -6DE
- ▶ 213. Update on the HIV Prevention and Care Cascade -16AB

Oral Abstract Sessions

- ▶ 214. Host-Pathogen Integration -7AB
- ▶ 216. The Fungus Among-us - Clinical Advances -1AB
- ▶ 217. Zika - A to Z -2

10:30 a.m. - noon

Interactive Session

- ▶ 218. State of the Art: Clinical Management of Hepatitis C -6CF

Symposia

- ▶ 219. B Cell Biology: What the ID Physician Needs to Know -17AB
- ▶ 220. Beating and Breathing: Updates in the Management of Transplant Candidates and Recipients -16AB
- ▶ 221. Big Beasts in ID II -6AB
- ▶ 222. Cryptococcus in 2017: Bench to Bedside -15AB
- ▶ 223. HIV Prevention 2017 -14AB
- ▶ 225. Using Whole Genome Sequencing to Advance Infection Prevention -5AB
- ▶ 226. Zika Without Borders -6DE

Oral Abstract Session

- ▶ 230. Thinking Beyond Your Hospital: Stewardship on a Broader Scale -1AB

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 240. Stewardship: Impact of Diagnostics -Poster Hall CD
- ▶ 241. HAI: Device Related Infections -Poster Hall CD
- ▶ 242. HAI: MRSA, MSSA, and Other Gram Positives -Poster Hall CD
- ▶ 243. HAI: Surgical Site Infections -Poster Hall CD
- ▶ 244. HIV and HBV -Poster Hall CD
- ▶ 245. HIV and HCV -Poster Hall CD
- ▶ 246. HIV and Women -Poster Hall CD
- ▶ 248. HIV: Sexually Transmitted Infections -Poster Hall CD
- ▶ 250. Pediatric Bacterial Infections: From A to Z -Poster Hall CD
- ▶ 252. Pediatric Virology -Poster Hall CD
- Poster Discussion Rounds
- ▶ 260. Advances in Diagnostics and Impact on Stewardship -Poster Hall CD
- ▶ 261. Gram Positives in Healthcare Epidemiology -Poster Hall CD
- ▶ 262. New Antibiotics -Poster Hall CD
- ▶ 266. Transplants -Poster Hall CD

2 - 3:30 p.m.

Symposia

- ▶ 269. Challenges in the Management of Complicated Urinary Tract Infections -6DE
- ▶ 270. Critical Medical Devices: Friend and Foe -14AB
- ▶ 271. Donations with Unintended Consequences: A Multidisciplinary Approach to Reduce Blood, Cell, Tissue, and Organ Donor-Transmitted Infections -20D
- ▶ 272. Holistic Management of Patients with HIV -16AB
- ▶ 273. Hot, Hot, Hot, Topics in Public Health -5AB
- ▶ 274. New Anti-Infective Clinical Trials that Will Change Your Practice -11AB
- ▶ 275. The Cutting Edge of Science in Pediatric Transplantation -15AB
- ▶ 276. The Microbiome and Antibiotic Resistance -6CF

3:45 - 4:30 p.m.

Named Lecture

- ▶ 280. Joseph E. Smadel Lecture -6AB

4:30 - 4:45 p.m.

Awards Session

- ▶ 281. Awards Session -6AB

4:45 - 5 p.m.

Oral Abstract Session

- ▶ 282. Featured Oral Abstract -6AB

5 - 5:45 p.m.

Named Lecture

- ▶ 283. Maxwell Finland Lecture -6AB

Sunday, October 8**8 - 9 a.m.**

Mini-Symposia

- ▶ 284. Controversies in Prosthetic Joint Infections -11AB
- ▶ 285. Global Eradication of Hepatitis C -1AB
- ▶ 286. Maternal-Child Infections: Antimicrobial Pharmacokinetics and Pharmacodynamics -5AB

9:15 - 10:45 a.m.

Plenary Session

- ▶ 287. Closing Plenary -6AB

2017 IDWeek Program Tracks *continued*

Tuesday, October 3

8 a.m. - 5 p.m.

Premeeting Workshop

- ▶ PW1. The Vincent T. Andriole ID Board Review Course (\$) -1AB

8 a.m. - 5:15 p.m.

Premeeting Workshop

- ▶ PW2. Best Practices for Antimicrobial Stewardship Programs (\$) -5AB

Wednesday, October 4

8 a.m. - noon

Premeeting Workshops

- ▶ PW6. Improving ID Learner Assessment via a Multiple-Choice Question Writing Workshop (\$) -2
- ▶ PW8. TB Workshop (\$) -15AB

1:30 - 3:30 p.m.

Interactive Session

- ▶ 2. Controversies in Infection Prevention: Pro/Con -6DE

Symposia

- ▶ 4. Late Breaker I -6AB
- ▶ 7. What's Hot in ID + HIV -20ABCD

3:45 - 5:45 p.m.

Plenary Session

- ▶ 8. Opening Plenary -20ABCD

6 - 7:30 p.m.

Reception

- ▶ Opening Reception and "Posters in the Park" -Poster Hall CD

Thursday, October 5

7 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 10. Essentials for the Everyday Leader -15AB
- ▶ 13. Rapid Responses to Common IP Crises -5AB
- ▶ 14. Tele-Antimicrobial Stewardship -1AB
- ▶ 9. Changes in Hospital Laboratory Practice and Their Impact on Clinical Care -2

8:30 - 10 a.m.

Interactive Session

- ▶ 19. Controversies in Antimicrobial Stewardship Programs: Pro/Con Debates -6DE

Symposia

- ▶ 20. Fungal Resistance: Focus on *Candida auris* -15AB
- ▶ 23. Impact of Sepsis Measures -11AB
- ▶ 25. New Antimicrobial Resistance Surveillance Programs -17AB
- ▶ 27. What's new with Zika -14AB

Oral Abstract Session

- ▶ 28. CDI Prevention -7AB

10:30 a.m. - noon

Symposia

- ▶ 31. Ambulatory Infection Prevention -16AB
- ▶ 32. Antimicrobial Stewardship Programs In Non-Acute Settings -17AB
- ▶ 33. Big Beasts in Global Health -15AB
- ▶ 34. Big Beasts in ID I -6AB
- ▶ 35. Current Issues, Conundrums, and Challenges with Respiratory Viruses -14AB
- ▶ 38. Mano-a-Mano II: Controversies in Pediatric ID -20ABCD
- ▶ 39. Preventing Vaccine-Preventable Diseases in Healthcare: Policy & Politics -6DE

Oral Abstract Session

- ▶ 42. The Cutting Edge in Antimicrobial Resistance Emergence Therapy -1AB

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 51. Emerging Resistance - Epidemiology and Mechanisms -Poster Hall CD
 - ▶ 52. HAI: MDRO-GNR/Emerging Resistant Bacterial Pathogens -Poster Hall CD
 - ▶ 53. HAI Non-Acute Care -Poster Hall CD
 - ▶ 54. HAI: Epidemiologic Methods -Poster Hall CD
 - ▶ 55. HAI: Occupational Health -Poster Hall CD
 - ▶ 57. HAI: Surveillance + Reporting -Poster Hall CD
 - ▶ 58. HAI: The Environment -Poster Hall CD
 - ▶ 59. Hepatitis B and C in Varied Settings -Poster Hall CD
 - ▶ 70. Legionella -Poster Hall CD
 - ▶ 73. Outbreaks and Public Health Across the Globe -Poster Hall CD
 - ▶ 74. Stewardship: Data and Program Planning -Poster Hall CD
 - ▶ 75. Stewardship: Program Implementation -Poster Hall CD
- Poster Discussion Rounds
- ▶ 79. Managing Emerging Resistance in Gram Negatives -Poster Hall CD
 - ▶ 80. Big Beasts -Poster Hall CD
 - ▶ 83. Stewardship -Poster Hall CD

2 - 3:30 p.m.

Interactive Session

- ▶ 84. Diagnostic Clinical Cases -6CF

Symposia

- ▶ 87. Hot Topics in Pediatric Infectious Diseases -11AB
- ▶ 88. New Antibiotics: What's in the Pipeline -20ABCD
- ▶ 90. Playing the Long Game: Infection Prevention in Long Term Care -16AB
- ▶ 91. Preventing and Managing Endoscope-Associated Outbreaks and Infection Control Breaches -14AB

3:45 - 4:30 p.m.

Named Lecture

- ▶ 97. Edward H. Kass Lecture -20ABCD

4:30 - 4:45 p.m.

Awards Session

- ▶ 98. Awards Session -20ABCD

5 - 5:45 p.m.

Named Lecture

- ▶ 100. John F. Enders Lecture -20ABCD

Friday, October 6

7 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 101. Advancing Federal ID and HIV Priorities: Making the Case to Federal Policymakers -Marriott Marquis, Santa Rosa
- ▶ 102. Big Data in Infectious Diseases -2
- ▶ 105. Malaria: What's New? -5AB
- ▶ 106. Mid-Career Challenges and Opportunities -11AB
- ▶ 107. Pipeline 2.0 -6DE
- ▶ 109. Second Generation B-Lactamase Inhibitor Combinations: Promise and Peril -15AB
- ▶ 110. Setting up an Antimicrobial Stewardship Program for a Long-Term Care Facility: Practical Pointers from the Front Line -1AB
- ▶ 111. The ID Physician New to Infection Prevention and/or Antimicrobial Stewardship -14AB

8:30 - 10 a.m.

Symposia

- ▶ 113. Big Beasts of Healthcare Epidemiology -6DE
- ▶ 116. Non-Traditional Approaches for Bad Bugs -14AB
- ▶ 117. Prevention and Management of Legionnaire's Disease: What's New? -15AB

Oral Abstract Session

- ▶ 122. Public Health Potpourri -7AB

10:30 a.m. - noon

Symposia

- ▶ 125. Antimicrobial Stewardship Programs in Challenging Populations -6DE
- ▶ 126. Dosing Antibiotics in Critically Ill Patients -6AB
- ▶ 127. Foodborne Infections: Disease Burden and Advances -11AB
- ▶ 130. Methods in Epidemiology Research: Asking the Right Questions, Recognizing Valid Answers -16AB

Oral Abstract Sessions

- ▶ 133. Diagnostics and Why They Matter -5AB
- ▶ 134. Where Did That Come From? Transmission Risks in Healthcare -1AB

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 139. Adult Viral Infection -Poster Hall CD
- ▶ 141. Clinical Practice Issues -Poster Hall CD
- ▶ 147. Expanded Spectrum: New Antimicrobial Susceptibility Testing -Poster Hall CD
- ▶ 149. HAI: *C. difficile* Epidemiology, Impact, and Testing -Poster Hall CD
- ▶ 150. HAI: *C. difficile* Risk Assessment and Prevention -Poster Hall CD
- ▶ 151. HAI: Hand Hygiene -Poster Hall CD
- ▶ 160. ID Medical Education -Poster Hall CD
- ▶ 167. Preclinical Study with New Antibiotics and Antifungals -Poster Hall CD
- ▶ 168. Stewardship: Improving Outcomes -Poster Hall CD
- ▶ 169. Stewardship: Pediatric Antimicrobial Stewardship -Poster Hall CD
- ▶ 170. Stewardship: Targets for Intervention -Poster Hall CD

Poster Discussion Rounds

- ▶ 176. *Clostridium difficile* -Poster Hall CD
- ▶ 178. Stewardship II -Poster Hall CD

2 - 3:30 p.m.

Interactive Sessions

- ▶ 179. Case-Based Problems in Vaccines: Beyond the Guidelines -11AB
- ▶ 180. Nightmare Bugs: A Case-Based Symposium -20ABCD

Symposia

- ▶ 182. Diagnostic Updates: Syndrome-Based Diagnostics -16AB
- ▶ 183. Evolution Informing Infectious Diseases, Infectious Diseases Informing Evolution -14AB
- ▶ 185. Infection Prevention Down the Drain: Water Fixtures in Healthcare Settings -17AB
- ▶ 186. Nontuberculous Mycobacterial Infections in Children -6CF
- ▶ 187. Stewardship Accreditation Standards in Action -15AB

Oral Abstract Sessions

- ▶ 189. Hepatitis B and C Across the Lifespan -5AB
- ▶ 190. Resist! MDROs in Healthcare -1AB

3:45 - 4:15 p.m.

Named Lecture

- ▶ 193. SHEA Lectureship -20ABCD

4:15 - 4:30 p.m.

Oral Abstract Session

- ▶ 194. SHEA Featured Oral Abstract -20ABCD

4:30 - 4:45 p.m.

Awards Session

- ▶ 195. Awards Session -20ABCD

4:45 - 5:45 p.m.

Symposium

- ▶ 196. Influential Publications in Healthcare Epidemiology and Infection Control in the Past Year -20ABCD

6 - 7:30 p.m.

IDWeek 2017 Town Hall

- ▶ IDWeek Town Hall 2.0 -6DE

Saturday, October 7**7 - 8:15 a.m.**

Meet-the-Professor Sessions

- ▶ 197. Active Surveillance Testing for MDROs: Where and When? -1AB
- ▶ 199. Don't Make These Mistakes: Frequent Barriers in Antimicrobial Stewardship Programs -7AB
- ▶ 200. National Healthcare Safety Network Updates -17AB
- ▶ 203. Tuberculosis Management -14AB

8:30 - 10 a.m.

Symposia

- ▶ 206. Advancing Pediatric Infection Prevention: Moving the Needle -15AB
- ▶ 208. *Clostridium difficile* Diagnostics -11AB
- ▶ 209. Combination Therapies for Super-Bugs -6AB
- ▶ 211. Promising Interventions in Antimicrobial Stewardship Programs -5AB

10:30 a.m. - noon

Symposia

- ▶ 221. Big Beasts in ID II -6AB
 - ▶ 226. Zika Without Borders -6DE
- Oral Abstract Sessions
- ▶ 229. Pediatric Vaccines: Miscellaneous Advances in Vaccinology -7AB
 - ▶ 230. Thinking Beyond Your Hospital: Stewardship on a Broader Scale -1AB

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 240. Stewardship: Impact of Diagnostics -Poster Hall CD
- ▶ 241. HAI: Device Related Infections -Poster Hall CD
- ▶ 242. HAI: MRSA, MSSA, and Other Gram Positives -Poster Hall CD
- ▶ 243. HAI: Surgical Site Infections -Poster Hall CD
- ▶ 250. Pediatric Bacterial Infections: From A to Z -Poster Hall CD
- ▶ 252. Pediatric Virology -Poster Hall CD

Poster Discussion Rounds

- ▶ 260. Advances in Diagnostics and Impact on Stewardship -Poster Hall CD
- ▶ 261. Gram Positives in Healthcare Epidemiology -Poster Hall CD

2 - 3:30 p.m.

Symposia

- ▶ 268. Antimicrobial Stewardship Programs in Pediatrics -17AB
- ▶ 269. Challenges in the Management of Complicated Urinary Tract Infections -6DE
- ▶ 270. Critical Medical Devices: Friend and Foe -14AB
- ▶ 273. Hot, Hot, Hot, Topics in Public Health -5AB
- ▶ 275. The Cutting Edge of Science in Pediatric Transplantation -15AB
- ▶ 276. The Microbiome and Antibiotic Resistance -6CF

3:45 - 4:30 p.m.

Named Lecture

- ▶ 280. Joseph E. Smadel Lecture -6AB

4:30 - 4:45 p.m.

Awards Session

- ▶ 281. Awards Session -6AB

5 - 5:45 p.m.

Named Lecture

- ▶ 283. Maxwell Finland Lecture -6AB

Sunday, October 8**9:15 - 10:45 a.m.**

Plenary Session

- ▶ 287. Closing Plenary -6AB

2017 IDWeek Program Tracks *continued*

Tuesday, October 3

8 a.m. - 5 p.m.

Premeeting Workshop

- ▶ PW1. The Vincent T. Andriole ID Board Review Course (\$) -1AB

Wednesday, October 4

8 a.m. - noon

Premeeting Workshops

- ▶ PW5. Hepatitis C Workshop (\$) -16AB
- ▶ PW6. Improving ID Learner Assessment via a Multiple-Choice Question Writing Workshop (\$) -2
- ▶ PW8. TB Workshop (\$) -15AB

8 a.m. - 12:30 p.m.

Premeeting Workshop

- ▶ PW7. Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA MOC Modules: HIV Medicine in Clinical Practice and Non-HIV Immunocompromised Host (\$) -11AB

1:30 - 2:30 p.m.

Symposium

- ▶ 5. Managing Infections in Opioid Users -17AB

1:30 - 3:30 p.m.

Symposia

- ▶ 3. Controversies in Travel/Tropical Medicine -16AB
- ▶ 6. Sexually Transmitted Infections: Current Epidemiologic Trends and Management Approaches -15AB
- ▶ 7. What's Hot in ID + HIV -20ABCD

3:45 - 5:45 p.m.

Plenary Session

- ▶ 8. Opening Plenary -20ABCD

6 - 7:30 p.m.

Reception

- ▶ Opening Reception and "Posters in the Park" -Poster Hall CD

Thursday, October 5

7 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 10. Essentials for the Everyday Leader -15AB
- ▶ 12. Our Most Difficult Antiretroviral Management Case -16AB

8:30 - 10 a.m.

Symposia

- ▶ 21. HIV State of the Art -6CF
- ▶ 26. TB 2017: Pregnancy, IRIS, and MDR/XDR -16AB

10:30 a.m. - noon

Symposia

- ▶ 33. Big Beasts in Global Health -15AB
- ▶ 37. HIV on the Horizon -11AB

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 60. HIV and Central Nervous System -Poster Hall CD
 - ▶ 61. HIV and Fungal Infection -Poster Hall CD
 - ▶ 62. HIV and Mycobacterial Infections -Poster Hall CD
 - ▶ 63. HIV Clinical Care and Outcomes -Poster Hall CD
 - ▶ 64. HIV: Cancer and Dysplasia -Poster Hall CD
 - ▶ 65. HIV: Cardiovascular Disease, Lipids, Diabetes -Poster Hall CD
 - ▶ 66. HIV: General Opportunistic Infections -Poster Hall CD
 - ▶ 67. HIV: Kidney, Bone + Liver Effects -Poster Hall CD
 - ▶ 68. HIV: Pathogenesis and Inflammation -Poster Hall CD
- Poster Discussion Round
- ▶ 82. HIV Metabolic Diseases -Poster Hall CD

2 - 3:30 p.m.

Interactive Session

- ▶ 84. Diagnostic Clinical Cases -6CF

Symposia

- ▶ 87. Hot Topics in Pediatric Infectious Diseases -11AB
- ▶ 92. When Transplantation Goes Viral: Mitigating CMV, Herpes, and HIV in Transplantation -6DE

Oral Abstract Session

- ▶ 93. Preventing and Identifying New HIV Infections -7AB

3:45 - 4:30 p.m.

Named Lecture

- ▶ 97. Edward H. Kass Lecture -20ABCD

4:30 - 4:45 p.m.

Awards Session

- ▶ 98. Awards Session -20ABCD

4:45 - 5 p.m.

Oral Abstract Session

- ▶ 99. Featured Oral Abstract -20ABCD

5 - 5:45 p.m.

Named Lecture

- ▶ 100. John F. Enders Lecture -20ABCD

Friday, October 6

7 - 8:15 a.m.

Meet-the-Professor Session

- ▶ 101. Advancing Federal ID and HIV Priorities: Making the Case to Federal Policymakers -Marriott Marquis, Santa Rosa
- ▶ 106. Mid-Career Challenges and Opportunities -11AB

8:30 - 10 a.m.

Interactive Session

- ▶ 112. Challenging HIV Cases -20ABCD

Symposium

- ▶ 120. Viral Hepatitis -6AB

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 153. HIV Care Continuum -Poster Hall CD
 - ▶ 154. HIV Drug Resistance -Poster Hall CD
 - ▶ 155. HIV Testing -Poster Hall CD
 - ▶ 156. HIV: Antiretroviral Therapy -Poster Hall CD
 - ▶ 157. HIV: Healthcare Utilization and Costs -Poster Hall CD
 - ▶ 158. HIV: Pre-Exposure Prophylaxis -Poster Hall CD
 - ▶ 159. HIV: Rapid ART Initiation -Poster Hall CD
 - ▶ 160. ID Medical Education -Poster Hall CD
- Poster Discussion Round
- ▶ 174a. Antiretroviral Therapy -Poster Hall CD
 - ▶ 174b. PrEP -Poster Hall CD

2 - 3:30 p.m.

Interactive Sessions

- ▶ 179. Case-Based Problems in Vaccines: Beyond the Guidelines -11AB
- ▶ 181. Sexually Transmitted Infections in the HIV Care Setting: An Interactive Case-Based Approach -6AB

Symposium

- ▶ 186. Nontuberculous Mycobacterial Infections in Children -6CF

Oral Abstract Session

- ▶ 188. HIV: Modern ART -7AB

3:45 - 4:15 p.m.

Named Lecture

- ▶ 193. SHEA Lectureship -20ABCD

3:45 - 5:45 p.m.

Interactive Session

- ▶ 192. Tropical Medicine Cases: Conundrums and Case Management -6CF

4:30 - 4:45 p.m.

Awards Session

- ▶ 195. Awards Session -20ABCD

6 - 7:30 p.m.

IDWeek 2017 Town Hall

- ▶ IDWeek Town Hall 2.0 -6DE

Saturday, October 7**7 - 8:15 a.m.**

Meet-the-Professor Sessions

- ▶ 201. Our Toughest Coinfection Cases -16AB
- ▶ 203. Tuberculosis Management -14AB

8:30 - 10 a.m.

Symposia

- ▶ 207. Bad Bugs: Emerging High Consequence Viruses -14AB
- ▶ 213. Update on the HIV Prevention and Care Cascade -16AB

10:30 a.m. - noon

Interactive Session

- ▶ 218. State of the Art: Clinical Management of Hepatitis C -6CF

Symposia

- ▶ 219. B Cell Biology: What the ID Physician Needs to Know -17AB
- ▶ 222. Cryptococcus in 2017: Bench to Bedside -15AB
- ▶ 223. HIV Prevention 2017 -14AB

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 244. HIV and HBV -Poster Hall CD
 - ▶ 245. HIV and HCV -Poster Hall CD
 - ▶ 246. HIV and Women -Poster Hall CD
 - ▶ 248. HIV: Sexually Transmitted Infections -Poster Hall CD
 - ▶ 252. Pediatric Virology -Poster Hall CD
- Poster Discussion Round
- ▶ 265. HIV and Hepatitis -Poster Hall CD

2 - 3:30 p.m.

Symposium

- ▶ 272. Holistic Management of Patients with HIV -16AB

3:45 - 4:30 p.m.

Named Lecture

- ▶ 280. Joseph E. Smadel Lecture -6AB

4:30 - 4:45 p.m.

Awards Session

- ▶ 281. Awards Session -6AB

5 - 5:45 p.m.

Named Lecture

- ▶ 283. Maxwell Finland Lecture -6AB

Sunday, October 8**8 - 9 a.m.**

Mini-Symposium

- ▶ 285. Global Eradication of Hepatitis C -1AB

9:15 - 10:45 a.m.

Plenary Session

- ▶ 287. Closing Plenary -6AB

2017 IDWeek Program Tracks *continued*

Tuesday, October 3

8 a.m. - 5 p.m.

Premeeting Workshop

- ▶ PW1. The Vincent T. Andriole ID Board Review Course (\$) -1AB

Wednesday, October 4

8 a.m. - noon

Premeeting Workshop

- ▶ PW6. Improving ID Learner Assessment via a Multiple-Choice Question Writing Workshop (\$) -2

1:30 - 3:30 p.m.

Symposia

- ▶ 4. Late Breaker I -6AB
- ▶ 7. What's Hot in ID + HIV -20ABCD

3:45 - 5:45 p.m.

Plenary Session

- ▶ 8. Opening Plenary -20ABCD

6 - 7:30 p.m.

Reception

- ▶ Opening Reception and "Posters in the Park" -Poster Hall CD

Thursday, October 5

7 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 10. Essentials for the Everyday Leader -15AB
- ▶ 16. Updates from the Antibacterial Resistance Leadership Group: Methodology and Results in AMR Research -14AB

8:30 - 10 a.m.

Symposia

- ▶ 20. Fungal Resistance: Focus on *Candida auris* -15AB
- ▶ 27. What's new with Zika -14AB

Oral Abstract Sessions

- ▶ 28. CDI Prevention -7AB
- ▶ 29. Identification, Treatment, and Prevention of Pediatric Bacterial Pathogens -5AB

10:30 a.m. - noon

Symposium

- ▶ 33. Big Beasts in Global Health -15AB

Oral Abstract Sessions

- ▶ 41. Infections in Transplantation -5AB
- ▶ 42. The Cutting Edge in Antimicrobial Resistance Emergence Therapy -1AB

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 51. Emerging Resistance - Epidemiology and Mechanisms -Poster Hall CD
- ▶ 52. HAI: MDRO-GNR/Emerging Resistant Bacterial Pathogens -Poster Hall CD
- ▶ 53. HAI Non-Acute Care -Poster Hall CD
- ▶ 54. HAI: Epidemiologic Methods -Poster Hall CD
- ▶ 57. HAI: Surveillance + Reporting -Poster Hall CD
- ▶ 60. HIV and Central Nervous System -Poster Hall CD
- ▶ 61. HIV and Fungal Infection -Poster Hall CD
- ▶ 62. HIV and Mycobacterial Infections -Poster Hall CD
- ▶ 63. HIV Clinical Care and Outcomes -Poster Hall CD
- ▶ 65. HIV: Cardiovascular Disease, Lipids, Diabetes -Poster Hall CD
- ▶ 68. HIV: Pathogenesis and Inflammation -Poster Hall CD
- ▶ 70. Legionella -Poster Hall CD
- ▶ 74. Stewardship: Data and Program Planning -Poster Hall CD
- ▶ 75. Stewardship: Program Implementation -Poster Hall CD

2 - 3:30 p.m.

Symposia

- ▶ 86. Global Fungal Infections -15AB
- ▶ 88. New Antibiotics: What's in the Pipeline -20ABCD
- ▶ 89. New Discoveries in an Old Field: Bacterial Toxins -17AB
- ▶ 91. Preventing and Managing Endoscope-Associated Outbreaks and Infection Control Breaches -14AB

Oral Abstract Session

- ▶ 95. Use 'em and Lose 'em: Preventing Antibiotic Overuse -5AB

3:45 - 4:30 p.m.

Named Lecture

- ▶ 97. Edward H. Kass Lecture -20ABCD

4:30 - 4:45 p.m.

Awards Session

- ▶ 98. Awards Session -20ABCD

5 - 5:45 p.m.

Named Lecture

- ▶ 100. John F. Enders Lecture -20ABCD

Friday, October 6

7 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 101. Advancing Federal ID and HIV Priorities: Making the Case to Federal Policymakers -Marriott Marquis, Santa Rosa
- ▶ 102. Big Data in Infectious Diseases -2
- ▶ 105. Malaria: What's New? -5AB
- ▶ 106. Mid-Career Challenges and Opportunities -11AB
- ▶ 107. Pipeline 2.0 -6DE
- ▶ 109. Second Generation B-Lactamase Inhibitor Combinations: Promise and Peril -15AB

8:30 - 10 a.m.

Symposia

- ▶ 116. Non-Traditional Approaches for Bad Bugs -14AB
- ▶ 117. Prevention and Management of Legionnaire's Disease: What's New? -15AB

Oral Abstract Session

- ▶ 121. Emerging Paradigms: Pediatric Viral Infections -1AB

10:30 a.m. - noon

Symposia

- ▶ 130. Methods in Epidemiology Research: Asking the Right Questions, Recognizing Valid Answers -16AB
- ▶ 131. Remembrance of Things Past -17AB

Oral Abstract Sessions

- ▶ 132. Advances in Management of Bacteremia and Sepsis -7AB
- ▶ 133. Diagnostics and Why They Matter -5AB
- ▶ 134. Where Did That Come From? Transmission Risks in Healthcare -1AB

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 137. Adult CNS Infection -Poster Hall CD
- ▶ 139. Adult Viral Infection -Poster Hall CD
- ▶ 142. Clinical: Soup to Nuts -Poster Hall CD
- ▶ 144. Diagnostics: Biomarkers -Poster Hall CD
- ▶ 145. Diagnostics: Viral -Poster Hall CD
- ▶ 147. Expanded Spectrum: New Antimicrobial Susceptibility Testing -Poster Hall CD
- ▶ 149. HAI: *C. difficile* Epidemiology, Impact, and Testing -Poster Hall CD
- ▶ 150. HAI: *C. difficile* Risk Assessment and Prevention -Poster Hall CD
- ▶ 151. HAI: Hand Hygiene -Poster Hall CD
- ▶ 153. HIV Care Continuum -Poster Hall CD
- ▶ 155. HIV Testing -Poster Hall CD
- ▶ 158. HIV: Pre-Exposure Prophylaxis -Poster Hall CD
- ▶ 159. HIV: Rapid ART Initiation -Poster Hall CD
- ▶ 160. ID Medical Education -Poster Hall CD
- ▶ 167. Preclinical Study with New Antibiotics and Antifungals -Poster Hall CD
- ▶ 168. Stewardship: Improving Outcomes -Poster Hall CD
- ▶ 170. Stewardship: Targets for Intervention -Poster Hall CD

2 - 3:30 p.m.

Interactive Session

- ▶ 180. Nightmare Bugs: A Case-Based Symposium -20ABCD

Symposium

- ▶ 183. Evolution Informing Infectious Diseases, Infectious Diseases Informing Evolution -14AB

3:45 - 4:15 p.m.

Named Lecture

- ▶ 193. SHEA Lectureship -20ABCD

4:15 - 4:30 p.m.

Oral Abstract Session

- ▶ 194. SHEA Featured Oral Abstract -20ABCD

4:30 - 4:45 p.m.

Awards Session

- ▶ 195. Awards Session -20ABCD

4:45 - 5:45 p.m.

Symposium

- ▶ 196. Influential Publications in Healthcare Epidemiology and Infection Control in the Past Year -20ABCD

6 - 7:30 p.m.

IDWeek 2017 Town Hall

- ▶ IDWeek Town Hall 2.0 -6DE

Saturday, October 7**7 - 8:15 a.m.**

Meet-the-Professor Session

- ▶ 203. Tuberculosis Management -14AB

8:30 - 10 a.m.

Symposia

- ▶ 207. Bad Bugs: Emerging High Consequence Viruses -14AB
- ▶ 209. Combination Therapies for Super-Bugs -6AB

Oral Abstract Session

- ▶ 214. Host-Pathogen Integration -7AB

10:30 a.m. - noon

Symposia

- ▶ 219. B Cell Biology: What the ID Physician Needs to Know -17AB
- ▶ 222. Cryptococcus in 2017: Bench to Bedside -15AB
- ▶ 225. Using Whole Genome Sequencing to Advance Infection Prevention -5AB
- ▶ 226. Zika Without Borders -6DE

Oral Abstract Session

- ▶ 230. Thinking Beyond Your Hospital: Stewardship on a Broader Scale -1AB

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 240. Stewardship: Impact of Diagnostics -Poster Hall CD
- ▶ 241. HAI: Device Related Infections -Poster Hall CD
- ▶ 242. HAI: MRSA, MSSA, and Other Gram Positives -Poster Hall CD
- ▶ 243. HAI: Surgical Site Infections -Poster Hall CD
- ▶ 244. HIV and HBV -Poster Hall CD
- ▶ 245. HIV and HCV -Poster Hall CD
- ▶ 246. HIV and Women -Poster Hall CD
- ▶ 252. Pediatric Virology -Poster Hall CD

Poster Discussion Rounds

- ▶ 260. Advances in Diagnostics and Impact on Stewardship -Poster Hall CD
- ▶ 262. New Antibiotics -Poster Hall CD

2 - 3:30 p.m.

Symposia

- ▶ 271. Donations with Unintended Consequences: A Multidisciplinary Approach to Reduce Blood, Cell, Tissue, and Organ Donor-Transmitted Infections -20D
- ▶ 273. Hot, Hot, Hot, Topics in Public Health -5AB
- ▶ 274. New Anti-Infective Clinical Trials that Will Change Your Practice -11AB
- ▶ 275. The Cutting Edge of Science in Pediatric Transplantation -15AB
- ▶ 276. The Microbiome and Antibiotic Resistance -6CF

3:45 - 4:30 p.m.

Named Lecture

- ▶ 280. Joseph E. Smadel Lecture -6AB

4:30 - 4:45 p.m.

Awards Session

- ▶ 281. Awards Session -6AB

5 - 5:45 p.m.

Named Lecture

- ▶ 283. Maxwell Finland Lecture -6AB

Sunday, October 8**9:15 - 10:45 a.m.**

Plenary Session

- ▶ 287. Closing Plenary -6AB

2017 IDWeek Program Tracks *continued*

Tuesday, October 3

8 a.m. - 5:15 p.m.

Premeeting Workshop

- ▶ PW2. Best Practices for Antimicrobial Stewardship Programs (\$) -5AB

Wednesday, October 4

7:45 a.m. - noon

Premeeting Workshop

- ▶ PW4. Pediatric Fellows' Day Workshop (\$) -8

8 a.m. - noon

Premeeting Workshops

- ▶ PW5. Hepatitis C Workshop (\$) -16AB
- ▶ PW6. Improving ID Learner Assessment via a Multiple-Choice Question Writing Workshop (\$) -2
- ▶ PW8. TB Workshop (\$) -15AB

8 a.m. - 12:30 p.m.

Premeeting Workshop

- ▶ PW7. Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA MOC Modules: HIV Medicine in Clinical Practice and Non-HIV Immunocompromised Host (\$) -11AB

1:30 - 3:30 p.m.

Interactive Session

- ▶ 1. Challenging Cases in Pediatric Infectious Diseases -6CF
- Symposia
- ▶ 3. Controversies in Travel/Tropical Medicine -16AB
 - ▶ 7. What's Hot in ID + HIV -20ABCD

3:45 - 5:45 p.m.

Plenary Session

- ▶ 8. Opening Plenary -20ABCD

6 - 7:30 p.m.

Reception

- ▶ Opening Reception and "Posters in the Park" -Poster Hall CD

Thursday, October 5

7 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 10. Essentials for the Everyday Leader -15AB
- ▶ 11. Media Training for ID Specialists -7AB
- ▶ 13. Rapid Responses to Common IP Crises -5AB
- ▶ 14. Tele-Antimicrobial Stewardship -1AB
- ▶ 15. Travelers Health: Special Patients -11AB
- ▶ 17. When to Suspect Immunodeficiency in the Adult? -8
- ▶ 18. Wound Care 101 -17AB
- ▶ 9. Changes in Hospital Laboratory Practice and Their Impact on Clinical Care -2

8:30 - 10 a.m.

Interactive Session

- ▶ 19. Controversies in Antimicrobial Stewardship Programs: Pro/Con Debates -6DE

Symposia

- ▶ 20. Fungal Resistance: Focus on *Candida auris* -15AB
- ▶ 21. HIV State of the Art -6CF
- ▶ 22. ID Physicians Adapting to Healthcare Reform -6AB
- ▶ 24. Neurological Manifestations of Infectious Diseases -20ABCD
- ▶ 25. New Antimicrobial Resistance Surveillance Programs -17AB
- ▶ 26. TB 2017: Pregnancy, IRIS, and MDR/XDR -16AB
- ▶ 27. What's new with Zika -14AB

Oral Abstract Sessions

- ▶ 28. CDI Prevention -7AB
- ▶ 29. Identification, Treatment, and Prevention of Pediatric Bacterial Pathogens -5AB
- ▶ 30. It's not just Bones: Skin and Bones -1AB

10:30 a.m. - noon

Symposia

- ▶ 31. Ambulatory Infection Prevention -16AB
 - ▶ 32. Antimicrobial Stewardship Programs In Non-Acute Settings -17AB
 - ▶ 33. Big Beasts in Global Health -15AB
 - ▶ 35. Current Issues, Conundrums, and Challenges with Respiratory Viruses -14AB
 - ▶ 36. Have a Yogurt and Call Me in the Morning: Update on Probiotics -6CF
 - ▶ 37. HIV on the Horizon -11AB
 - ▶ 38. Mano-a-Mano II: Controversies in Pediatric ID -20ABCD
 - ▶ 39. Preventing Vaccine-Preventable Diseases in Healthcare: Policy & Politics -6DE
- Oral Abstract Sessions
- ▶ 41. Infections in Transplantation -5AB
 - ▶ 42. The Cutting Edge in Antimicrobial Resistance Emergence Therapy -1AB

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 49. Global Health Potpourri -Poster Hall CD
 - ▶ 50. Global Infections -Poster Hall CD
 - ▶ 51. Emerging Resistance - Epidemiology and Mechanisms -Poster Hall CD
 - ▶ 52. HAI: MDRO-GNR/Emerging Resistant Bacterial Pathogens -Poster Hall CD
 - ▶ 53. HAI Non-Acute Care -Poster Hall CD
 - ▶ 54. HAI: Epidemiologic Methods -Poster Hall CD
 - ▶ 58. HAI: The Environment -Poster Hall CD
 - ▶ 59. Hepatitis B and C in Varied Settings -Poster Hall CD
 - ▶ 70. Legionella -Poster Hall CD
 - ▶ 73. Outbreaks and Public Health Across the Globe -Poster Hall CD
 - ▶ 74. Stewardship: Data and Program Planning -Poster Hall CD
 - ▶ 75. Stewardship: Program Implementation -Poster Hall CD
- Poster Discussion Rounds
- ▶ 80. Big Beasts -Poster Hall CD
 - ▶ 81. Global Health -Poster Hall CD
 - ▶ 82. HIV Metabolic Diseases -Poster Hall CD
 - ▶ 83. Stewardship -Poster Hall CD

2 - 3:30 p.m.

Interactive Session

- ▶ 84. Diagnostic Clinical Cases -6CF

Symposia

- ▶ 86. Global Fungal Infections -15AB
- ▶ 87. Hot Topics in Pediatric Infectious Diseases -11AB
- ▶ 88. New Antibiotics: What's in the Pipeline -20ABCD
- ▶ 89. New Discoveries in an Old Field: Bacterial Toxins -17AB
- ▶ 91. Preventing and Managing Endoscope-Associated Outbreaks and Infection Control Breaches -14AB
- ▶ 92. When Transplantation Goes Viral: Mitigating CMV, Herpes, and HIV in Transplantation -6DE

Oral Abstract Sessions

- ▶ 93. Preventing and Identifying New HIV Infections -7AB
- ▶ 94. Respiratory Infection Diagnosis -1AB
- ▶ 95. Use 'em and Lose 'em: Preventing Antibiotic Overuse -5AB

3:45 - 4:30 p.m.

Named Lecture

- ▶ 97. Edward H. Kass Lecture -20ABCD

3:45 - 5:45 p.m.

Symposium

- ▶ 96. Bone of Contention: Challenging Cases in Vertebral Osteomyelitis -6AB

4:30 - 4:45 p.m.

Awards Session

- ▶ 98. Awards Session -20ABCD

5 - 5:45 p.m.

Named Lecture

- ▶ 100. John F. Enders Lecture -20ABCD

Friday, October 6
7 - 8:15 a.m.
Meet-the-Professor Sessions

- ▶ 101. Advancing Federal ID and HIV Priorities: Making the Case to Federal Policymakers -Marriott Marquis, Santa Rosa
- ▶ 102. Big Data in Infectious Diseases -2
- ▶ 103. Controversies in Empiric and Definitive Treatment of ESBL Infections -16AB
- ▶ 104. Make Learning Last in the Large Group Setting -8
- ▶ 105. Malaria: What's New? -5AB
- ▶ 106. Mid-Career Challenges and Opportunities -11AB
- ▶ 107. Pipeline 2.0 -6DE
- ▶ 108. Rapid Fire: Questions for the Transplant ID Expert -17AB
- ▶ 109. Second Generation B-Lactamase Inhibitor Combinations: Promise and Peril -15AB
- ▶ 111. The ID Physician New to Infection Prevention and/or Antimicrobial Stewardship -14AB

8:30 - 10 a.m.
Symposia

- ▶ 113. Big Beasts of Healthcare Epidemiology -6DE
- ▶ 114. CMV: Pathogenicity Not Limited to Congenital and Transplant Infections -17AB
- ▶ 115. Hot Topics in Medical Education -11AB
- ▶ 116. Non-Traditional Approaches for Bad Bugs -14AB
- ▶ 117. Prevention and Management of Legionnaire's Disease: What's New? -15AB

- ▶ 119. The Pediatric Microbiome -16AB

Oral Abstract Sessions

- ▶ 121. Emerging Paradigms: Pediatric Viral Infections -1AB
- ▶ 122. Public Health Potpourri -7AB

10:30 - 11 a.m.
Oral Abstract Session

- ▶ 135. PIDS Featured Abstracts -15AB

10:30 a.m. - noon
Symposia

- ▶ 125. Antimicrobial Stewardship Programs in Challenging Populations -6DE
- ▶ 126. Dosing Antibiotics in Critically Ill Patients -6AB
- ▶ 127. Foodborne Infections: Disease Burden and Advances -11AB
- ▶ 128. Late Breaker II -6CF
- ▶ 129. Managing Comorbidities and Co-Infections in Patients with HIV -14AB
- ▶ 130. Methods in Epidemiology Research: Asking the Right Questions, Recognizing Valid Answers -16AB

Oral Abstract Sessions

- ▶ 132. Advances in Management of Bacteremia and Sepsis -7AB
- ▶ 134. Where Did That Come From? Transmission Risks in Healthcare -1AB

11 a.m. - noon
Named Lecture

- ▶ 136. Caroline B. Hall Lectureship -15AB

12:30 - 2 p.m.
Poster Abstract Sessions

- ▶ 141. Clinical Practice Issues -Poster Hall CD
- ▶ 142. Clinical: Soup to Nuts -Poster Hall CD
- ▶ 144. Diagnostics: Biomarkers -Poster Hall CD
- ▶ 145. Diagnostics: Viral -Poster Hall CD
- ▶ 147. Expanded Spectrum: New Antimicrobial Susceptibility Testing -Poster Hall CD

- ▶ 149. HAI: *C. difficile* Epidemiology, Impact, and Testing -Poster Hall CD
- ▶ 150. HAI: *C. difficile* Risk Assessment and Prevention -Poster Hall CD

- ▶ 151. HAI: Hand Hygiene -Poster Hall CD

- ▶ 160. ID Medical Education -Poster Hall CD

- ▶ 167. Preclinical Study with New Antibiotics and Antifungals -Poster Hall CD

- ▶ 168. Stewardship: Improving Outcomes -Poster Hall CD

- ▶ 169. Stewardship: Pediatric Antimicrobial Stewardship -Poster Hall CD

- ▶ 170. Stewardship: Targets for Intervention -Poster Hall CD

- ▶ 172. Vaccine Strategy and Policy -Poster Hall CD

Poster Discussion Rounds

- ▶ 177. Education -Poster Hall CD

- ▶ 178. Stewardship II -Poster Hall CD

2 - 3:30 p.m.
Interactive Sessions

- ▶ 179. Case-Based Problems in Vaccines: Beyond the Guidelines -11AB

- ▶ 180. Nightmare Bugs: A Case-Based Symposium -20ABCD

- ▶ 181. Sexually Transmitted Infections in the HIV Care Setting: An Interactive Case-Based Approach -6AB

Symposia

- ▶ 182. Diagnostic Updates: Syndrome-Based Diagnostics -16AB

- ▶ 183. Evolution Informing Infectious Diseases, Infectious Diseases Informing Evolution -14AB

- ▶ 184. Expect the Unexpected: Evolving Infection Risks in Transplantation -6DE

- ▶ 185. Infection Prevention Down the Drain: Water Fixtures in Healthcare Settings -17AB

- ▶ 186. Nontuberculous Mycobacterial Infections in Children -6CF

- ▶ 187. Stewardship Accreditation Standards in Action -15AB

Oral Abstract Sessions

- ▶ 189. Hepatitis B and C Across the Lifespan -5AB

- ▶ 190. Resist! MDROs in Healthcare -1AB

3:45 - 4:15 p.m.
Named Lecture

- ▶ 193. SHEA Lectureship -20ABCD

3:45 - 5:45 p.m.
Interactive Session

- ▶ 192. Tropical Medicine Cases: Conundrums and Case Management -6CF

4:15 - 4:30 p.m.
Oral Abstract Session

- ▶ 194. SHEA Featured Oral Abstract -20ABCD

4:30 - 4:45 p.m.
Awards Session

- ▶ 195. Awards Session -20ABCD

6 - 7:30 p.m.
IDWeek 2017 Town Hall

- ▶ IDWeek Town Hall 2.0 -6DE

2017 IDWeek Program Tracks continued

Saturday, October 7

7 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 197. Active Surveillance Testing for MDROs: Where and When? -1AB
- ▶ 198. Combination Antifungal Treatment for Mold Infections: Pros and Cons -11AB
- ▶ 199. Don't Make These Mistakes: Frequent Barriers in Antimicrobial Stewardship Programs -7AB
- ▶ 200. National Healthcare Safety Network Updates -17AB
- ▶ 202. Outpatient Parenteral Antimicrobial Therapy -5AB
- ▶ 203. Tuberculosis Management -14AB
- ▶ 204. Women in Infectious Diseases -Grand Ballroom 1+2

8:30 - 10 a.m.

Interactive Session

- ▶ 205. Challenging Transplant Cases: When Transplant ID Specialists say, What?! -6CF

Symposia

- ▶ 206. Advancing Pediatric Infection Prevention: Moving the Needle -15AB
- ▶ 207. Bad Bugs: Emerging High Consequence Viruses -14AB
- ▶ 208. *Clostridium difficile* Diagnostics -11AB
- ▶ 209. Combination Therapies for Super-Bugs -6AB
- ▶ 210. Infectious Disease Telehealth -17AB
- ▶ 211. Promising Interventions in Antimicrobial Stewardship Programs -5AB
- ▶ 212. Shots Across the Bow: Debates in Vaccinology -6DE

10:30 a.m. - noon

Interactive Session

- ▶ 218. State of the Art: Clinical Management of Hepatitis C -6CF

Symposia

- ▶ 219. B Cell Biology: What the ID Physician Needs to Know -17AB
- ▶ 220. Beating and Breathing: Updates in the Management of Transplant Candidates and Recipients -16AB
- ▶ 221. Big Beasts in ID II -6AB
- ▶ 222. *Cryptococcus* in 2017: Bench to Bedside -15AB
- ▶ 223. HIV Prevention 2017 -14AB
- ▶ 224. Kawasaki Disease: What's New? -11AB
- ▶ 225. Using Whole Genome Sequencing to Advance Infection Prevention -5AB
- ▶ 226. Zika Without Borders -6DE

Oral Abstract Sessions

- ▶ 229. Pediatric Vaccines: Miscellaneous Advances in Vaccinology -7AB
- ▶ 230. Thinking Beyond Your Hospital: Stewardship on a Broader Scale -1AB

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 240. Stewardship: Impact of Diagnostics -Poster Hall CD
- ▶ 241. HAI: Device Related Infections -Poster Hall CD
- ▶ 242. HAI: MRSA, MSSA, and Other Gram Positives -Poster Hall CD
- ▶ 243. HAI: Surgical Site Infections -Poster Hall CD
- ▶ 250. Pediatric Bacterial Infections: From A to Z -Poster Hall CD
- ▶ 251. Pediatric Potpourri -Poster Hall CD
- ▶ 252. Pediatric Virology -Poster Hall CD

Poster Discussion Rounds

- ▶ 260. Advances in Diagnostics and Impact on Stewardship -Poster Hall CD
- ▶ 261. Gram Positives in Healthcare Epidemiology -Poster Hall CD
- ▶ 262. New Antibiotics -Poster Hall CD
- ▶ 263. Pediatric Bacterial Infections -Poster Hall CD
- ▶ 264. Pediatric Viral Infections -Poster Hall CD
- ▶ 266. Transplants -Poster Hall CD

2 - 3:30 p.m.

Symposia

- ▶ 268. Antimicrobial Stewardship Programs in Pediatrics -17AB
 - ▶ 269. Challenges in the Management of Complicated Urinary Tract Infections -6DE
 - ▶ 271. Donations with Unintended Consequences: A Multidisciplinary Approach to Reduce Blood, Cell, Tissue, and Organ Donor-Transmitted Infections -20D
 - ▶ 272. Holistic Management of Patients with HIV -16AB
 - ▶ 273. Hot, Hot, Hot, Topics in Public Health -5AB
 - ▶ 274. New Anti-Infective Clinical Trials that Will Change Your Practice -11AB
 - ▶ 275. The Cutting Edge of Science in Pediatric Transplantation -15AB
 - ▶ 276. The Microbiome and Antibiotic Resistance -6CF
- Oral Abstract Session
- ▶ 278. Pneumococcal and Pertussis Vaccines -8

3:45 - 4:30 p.m.

Named Lecture

- ▶ 280. Joseph E. Smadel Lecture -6AB

4:30 - 4:45 p.m.

Awards Session

- ▶ 281. Awards Session -6AB

5 - 5:45 p.m.

Named Lecture

- ▶ 283. Maxwell Finland Lecture -6AB

Sunday, October 8

8 - 9 a.m.

Mini-Symposia

- ▶ 284. Controversies in Prosthetic Joint Infections -11AB
- ▶ 285. Global Eradication of Hepatitis C -1AB
- ▶ 286. Maternal-Child Infections: Antimicrobial Pharmacokinetics and Pharmacodynamics -5AB

9:15 - 10:45 a.m.

Plenary Session

- ▶ 287. Closing Plenary -6AB

Tuesday, October 3**8 a.m. - 5 p.m.**

Premeeting Workshop

- ▶ PW1. The Vincent T. Andriole ID Board Review Course (\$) -01AB

Wednesday, October 4**7:45 a.m. - noon**

Premeeting Workshop

- ▶ PW4. Pediatric Fellows' Day Workshop (\$) -08

8 a.m. - noon

Premeeting Workshops

- ▶ PW3. Fellows' Day Premeeting Workshop (\$) -17AB
- ▶ PW6. Improving ID Learner Assessment via a Multiple-Choice Question Writing Workshop (\$) -02

1:30 - 3:30 p.m.

Interactive Session

- ▶ 1. Challenging Cases in Pediatric Infectious Diseases -06CF

Symposia

- ▶ 3. Controversies in Travel/Tropical Medicine -16AB
- ▶ 6. Sexually Transmitted Infections: Current Epidemiologic Trends and Management Approaches -15AB
- ▶ 7. What's Hot in ID + HIV -20ABCD

3:45 - 5:45 p.m.

Plenary Session

- ▶ 8. Special Opening Plenary Session: Evolution and Revolution: Infectious Disease Promise and Challenges in the 21st Century -20ABCD

Thursday, October 5**7 - 8:15 a.m.**

Meet-the-Professor Sessions

- ▶ 9. Changes in Hospital Laboratory Practice and Their Impact on Clinical Care -02
- ▶ 10. Essentials for the Everyday Leader -15AB
- ▶ 11. Media Training for ID Specialists -07AB
- ▶ 15. Travelers Health: Special Patients -11AB
- ▶ 18. Wound Care 101 -17AB

8:30 - 10 a.m.

Interactive Session

- ▶ 19. Controversies in Antimicrobial Stewardship Programs: Pro/Con Debates -06DE

Symposia

- ▶ 20. Fungal Resistance: Focus on *Candida auris* -15AB
- ▶ 24. Neurological Manifestations of Infectious Diseases -20ABCD
- ▶ 25. New Antimicrobial Resistance Surveillance Programs -17AB
- ▶ 26. TB 2017: Pregnancy, IRIS, and MDR/XDR -16AB
- ▶ 27. What's new with Zika -14AB

10:30 a.m. - noon

Symposia

- ▶ 33. Big Beasts in Global Health -15AB
 - ▶ 35. Current Issues, Conundrums, and Challenges with Respiratory Viruses -14AB
 - ▶ 38. Mano-a-Mano II: Controversies in Pediatric ID -20ABCD
- Oral Abstract Sessions
- ▶ 41. Infections in Transplantation -05AB
 - ▶ 42. The Cutting Edge in Antimicrobial Resistance Emergence Therapy -01AB

12:30 - 2 p.m.

Poster Discussion Rounds

- ▶ 80. Big Beasts -Poster Hall CD
- ▶ 81. Global Health -Poster Hall CD
- ▶ 82. HIV Metabolic Diseases -Poster Hall CD
- ▶ 83. Stewardship -Poster Hall CD

2 - 3:30 p.m.

Interactive Session

- ▶ 84. Diagnostic Clinical Cases -06CF

Symposia

- ▶ 85. A Case Based Approach to Guidelines: Meningitis, Encephalitis, and Nervous System Lyme Disease -06AB
- ▶ 86. Global Fungal Infections -15AB
- ▶ 87. Hot Topics in Pediatric Infectious Diseases -11AB
- ▶ 88. New Antibiotics: What's in the Pipeline -20ABCD
- ▶ 89. New Discoveries in an Old Field: Bacterial Toxins -17AB
- ▶ 90. Playing the Long Game: Infection Prevention in Long Term Care -16AB
- ▶ 92. When Transplantation Goes Viral: Mitigating CMV, Herpes, and HIV in Transplantation -06DE

3:45 - 4:30 p.m.

Named Lecture

- ▶ 97. Edward H. Kass Lecture -20ABCD

3:45 - 5:45 p.m.

Symposium

- ▶ 96. Bone of Contention: Challenging Cases in Vertebral Osteomyelitis -06AB

4:30 - 4:45 p.m.

Awards Session

- ▶ 98. Awards Session -20ABCD

5 - 5:45 p.m.

Named Lecture

- ▶ 100. John F. Enders Lecture -20ABCD

Friday, October 6**7 - 8:15 a.m.**

Meet-the-Professor Sessions

- ▶ 101. Advancing Federal ID and HIV Priorities: Making the Case to Federal Policymakers -Marriott Marquis Santa Rosa
- ▶ 102. Big Data in Infectious Diseases -02
- ▶ 103. Controversies in Empiric and Definitive Treatment of ESBL Infections -16AB
- ▶ 104. Make Learning Last in the Large Group Setting -08
- ▶ 105. Malaria: What's New? -05AB
- ▶ 108. Rapid Fire: Questions for the Transplant ID Expert -17AB
- ▶ 109. Second Generation B-Lactamase Inhibitor Combinations: Promise and Peril -15AB
- ▶ 111. The ID Physician New to Infection Prevention and/or Antimicrobial Stewardship -14AB

8:30 - 10 a.m.

Symposia

- ▶ 113. Big Beasts of Healthcare Epidemiology -06DE
- ▶ 115. Hot Topics in Medical Education -11AB
- ▶ 116. Non-Traditional Approaches for Bad Bugs -14AB
- ▶ 119. The Pediatric Microbiome -16AB

10:30 a.m. - noon

Symposia

- ▶ 126. Dosing Antibiotics in Critically Ill Patients -06AB
- ▶ 130. Methods in Epidemiology Research: Asking the Right Questions, Recognizing Valid Answers -16AB

Oral Abstract Sessions

- ▶ 133. Diagnostics and Why They Matter -05AB
- ▶ 134. Where Did That Come From? Transmission Risks in Healthcare -01AB

11 a.m. - noon

Named Lecture

- ▶ 136. Caroline B. Hall Lectureship -15AB

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 137. Adult CNS Infection -Poster Hall CD

continues

2017 IDWeek Program Tracks *continued*

- ▶ 139. Adult Viral Infection -Poster Hall CD
- ▶ 142. Clinical: Soup to Nuts -Poster Hall CD
- ▶ 144. Diagnostics: Biomarkers -Poster Hall CD
- ▶ 145. Diagnostics: Viral -Poster Hall CD
- ▶ 147. Expanded Spectrum - New Antimicrobial Susceptibility Testing -Poster Hall CD
- ▶ 169. Stewardship: Pediatric Antimicrobial Stewardship -Poster Hall CD
- Poster Discussion Rounds
- ▶ 175. Big Beasts: Clinical -Poster Hall CD
- ▶ 176. *Clostridium difficile* -Poster Hall CD
- ▶ 177. Education -Poster Hall CD
- ▶ 178. Stewardship II -Poster Hall CD

2 - 3:30 p.m.

Interactive Sessions

- ▶ 179. Case-Based Problems in Vaccines: Beyond the Guidelines -11AB
- ▶ 180. Nightmare Bugs: A Case-Based Symposium -20ABCD
- ▶ 182. Diagnostic Updates: Syndrome-Based Diagnostics -16AB
- ▶ 183. Evolution Informing Infectious Diseases, Infectious Diseases Informing Evolution -14AB
- ▶ 184. Expect the Unexpected: Evolving Infection Risks in Transplantation -06DE
- ▶ 186. Nontuberculous Mycobacterial Infections in Children -06CF
- ▶ 188. HIV: Modern ART -07AB

3:45 - 4:15 p.m.

Named Lecture

- ▶ 193. SHEA Lectureship -20ABCD

3:45 - 5:45 p.m.

Interactive Sessions

- ▶ 191. Debate: Clinical Controversies -06AB
- ▶ 192. Tropical Medicine Cases: Conundrums and Case Management -06CF

4:15 - 4:30 p.m.

Oral Abstract Session

- ▶ 194. SHEA Featured Oral Abstract -20ABCD

4:30 - 4:45 p.m.

Awards Session

- ▶ 195. Awards Session -20ABCD

4:45 - 5:45 p.m.

Symposium

- ▶ 196. Influential Publications in Healthcare Epidemiology and Infection Control in the Past Year -20ABCD

6 - 7:30 p.m.

IDWeek 2017 Town Hall

- ▶ IDWeek Town Hall 2.0 -06DE

Saturday, October 7

7 - 8:15 a.m.

Meet-the-Professor Sessions

- ▶ 197. Active Surveillance Testing for MDROs: Where and When? -01AB
- ▶ 198. Combination Antifungal Treatment for Mold Infections: Pros and Cons -11AB
- ▶ 199. Don't Make These Mistakes: Frequent Barriers in Antimicrobial Stewardship Programs -07AB
- ▶ 203. Tuberculosis Management -14AB
- ▶ 204. Women in Infectious Diseases -Grand Ballroom 1+2

8:30 - 10 a.m.

Interactive Sessions

- ▶ 205. Challenging Transplant Cases: When Transplant ID Specialists say, What?! -06CF
- ▶ 207. Bad Bugs: Emerging High Consequence Viruses -14AB
- ▶ 208. *Clostridium difficile* Diagnostics -11AB
- ▶ 209. Combination Therapies for Super-Bugs -06AB
- ▶ 210. Infectious Disease Telehealth -17AB

Oral Abstract Session

- ▶ 214. Host-Pathogen Integration -07AB

10:30 a.m. - noon

Interactive Sessions

- ▶ 218. State of the Art: Clinical Management of Hepatitis C -06CF
- ▶ 219. B Cell Biology: What the ID Physician Needs to Know -17AB

Symposia

- ▶ 220. Beating and Breathing: Updates in the Management of Transplant Candidates and Recipients -16AB
- ▶ 221. Big Beasts in ID II -06AB
- ▶ 222. Cryptococcus in 2017: Bench to Bedside -15AB
- ▶ 223. HIV Prevention 2017 -14AB
- ▶ 224. Kawasaki Disease: What's New? -11AB
- ▶ 226. Zika Without Borders -06DE

12:30 - 2 p.m.

Poster Abstract Sessions

- ▶ 240. Stewardship: Impact of Diagnostics -Poster Hall CD
- ▶ 242. HAI: MRSA, MSSA, and Other Gram Positives -Poster Hall CD
- ▶ 243. HAI: Surgical Site Infections -Poster Hall CD
- ▶ 244. HIV and HBV -Poster Hall CD
- ▶ 245. HIV and HCV -Poster Hall CD
- ▶ 246. HIV and Women -Poster Hall CD
- ▶ 248. HIV: Sexually Transmitted Infections -Poster Hall CD
- ▶ 252. Pediatric Virology -Poster Hall CD

Poster Discussion Rounds

- ▶ 260. Advances in Diagnostics and Impact on Stewardship -Poster Hall CD
- ▶ 261. Gram Positives in Healthcare Epidemiology -Poster Hall CD
- ▶ 262. New Antibiotics -Poster Hall CD
- ▶ 264. Pediatric Viral Infections -Poster Hall CD
- ▶ 265. HIV and Hepatitis -Poster Hall CD
- ▶ 266. Transplants -Poster Hall CD

2 - 3:30 p.m.

Interactive Session

- ▶ 267. ID BugBowl -06AB

Symposia

- ▶ 268. Antimicrobial Stewardship Programs in Pediatrics -17AB
- ▶ 269. Challenges in the Management of Complicated Urinary Tract Infections -06DE
- ▶ 270. Critical Medical Devices: Friend and Foe -14AB
- ▶ 272. Holistic Management of Patients with HIV -16AB
- ▶ 273. Hot, Hot, Hot, Topics in Public Health -05AB
- ▶ 274. New Anti-Infective Clinical Trials that Will Change Your Practice -11AB
- ▶ 275. The Cutting Edge of Science in Pediatric Transplantation -15AB
- ▶ 276. The Microbiome and Antibiotic Resistance -06CF

3:45 - 4:30 p.m.

Named Lecture

- ▶ 280. Joseph E. Smadel Lecture -06AB

4:30 - 4:45 p.m.

Awards Session

- ▶ 281. Awards Session -06AB

5 - 5:45 p.m.

Named Lecture

- ▶ 283. Maxwell Finland Lecture -06AB

Sunday, October 8

8 - 9 a.m.

Mini-Symposium

- ▶ 286. Maternal-Child Infections: Antimicrobial Pharmacokinetics and Pharmacodynamics -05AB

9:15 - 10:45 a.m.

Plenary Session

- ▶ 287. Closing Plenary -06AB

Premeeting Workshops

^{\$}Additional fees apply

Adult ID/Epidemiology and Infection Control/Global ID/
HIV-STD-TB/Investigative ID/Trainee

PW1. Premeeting Workshop

The Vincent T. Andriole ID Board Review Course (\$)

Tuesday, 8 a.m. – 5 p.m.

01AB

Objectives: At the conclusion of this session, participants will be able to:

- discuss and apply updated information on diagnosis and treatment of sexually transmitted infections, tuberculosis and other mycobacteria, and HIV care
- discuss the diagnosis and treatment of Rickettsial and other tick-borne diseases, and common parasitic disease infections
- recognize and apply in diagnostic and therapeutic ways the epidemiologic, tempo, and sign/symptom features of important bacterial infections
- assess and apply components of effective infection control/prevention programs
- discuss the most common non-infectious causes of elevated temperature
- identify and apply characteristic pharmacologic and clinical features of antimicrobial agents used in treating the spectrum of clinical infections
- discuss and apply updated information on vaccination and the diagnosis and treatment of non-HIV/non-transplant viral syndromes
- assess and apply current trends in the diagnosis and treatment of transplant-associated infections

Intended Audience: infectious diseases physicians, members-in-training.

Moderators:

PATTY WRIGHT, MD, FIDSA; Vanderbilt University School of Medicine, Nashville, TN
GEORGE H. KARAM, MD; Louisiana State University Medical School, Baton Rouge, LA

Speakers:

- W1** 8 a.m. **Introductory Remarks**
- W2** 8:15 a.m. **Sexually Transmitted Infections**
KHALIL G. GHANEM, MD, PHD, FIDSA; Johns Hopkins University School of Medicine, Baltimore, MD
- W3** 8:50 a.m. **TB and Other Mycobacteria**
LISA ARMITIGE, MD, PHD, FIDSA; Heartland National Tuberculosis Center, San Antonio, TX
- W4** 9:25 a.m. **Rickettsial and Other Tick-Borne Illnesses**
CHRISTOPHER OHL, MD, FIDSA; Wake Forest School of Medicine, Winston-Salem, NC
- 10 a.m. **BREAK**
- W5** 10:15 a.m. **Parasitic Diseases**
PHILIP J. BUDGE, MD, PHD; Centers for Disease Control and Prevention, Atlanta, GA

- W6** 10:50 a.m. **Bacterial Syndrome Pearls**
CATHERINE O'NEAL, MD; Louisiana State University Health Sciences Center, Baton Rouge, LA
- W7** 11:25 a.m. **Infection Control/Prevention**
BECKY SMITH, MD; Duke University Medical Center, Durham, NC
- 12 p.m. **Lunch**
- W8** 1 p.m. **Non-Infectious Causes of Elevated Temperature**
BARBARA S. TAYLOR, MD, MS, FIDSA; University of Texas Health Science Center At San Antonio, San Antonio, TX
- W9** 1:35 p.m. **Antibiotics 2017: What's Old, New, Good, and Bad?**
DAVID N. GILBERT, MD, FIDSA; Providence-Portland Medical Center, Portland, OR
- W10** 2:10 p.m. **Vaccines**
H. KEIPP TALBOT, MD, MPH, FIDSA; Vanderbilt University Medical Center, Nashville, TN
- 2:45 p.m. **BREAK**
- W11** 3 p.m. **HIV**
ROY M. GULICK, MD, MPH, FIDSA; Weill Cornell Medicine, New York, NY
- W12** 3:35 p.m. **Non-HIV/Non-Transplant Viral Syndromes**
JOHN W. GNANN JR., MD; Medical University of South Carolina, Charleston, SC
- W13** 4:10 p.m. **Transplant Infections**
ANDREA ZIMMER, MD; University of Nebraska Medical Center, Omaha, NE
- 4:45 p.m. **Closing Questions and Comments**



Maximum of 7.50 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Pediatric ID PW2. Premeeting Workshop

Best Practices for Antimicrobial Stewardship Programs (\$)

Co-organized by The Society for Healthcare Epidemiology of America (SHEA) and Pediatric Infectious Diseases Society (PIDS) in collaboration with the Centers for Disease Prevention and Control (CDC) Sponsored by the Infectious Diseases Society of America

Tuesday, 8 a.m. – 5:15 p.m.

05AB

Objectives: At the conclusion of this session, participants will be able to:

- evaluate components of effective antimicrobial stewardship programs and implement interventions in their healthcare setting
- review and apply the strategies for the implementation process and the outcome measures

- apply antimicrobial stewardship interventions for unique populations and across healthcare settings
- critically assess available data, including pharmacy and microbiology data, needed to support antimicrobial stewardship in their institution

Intended Audience: hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, microbiologists, pharmacists, other: healthcare providers who wish to create, implement, or improve an antimicrobial stewardship program for their healthcare institution.


Moderators:

TAMAR BARLAM, MD, MSC, FIDSA, FSHEA; Boston University School of Medicine, Boston, MA
EMILY SPIVAK, MD, MHS; University of Utah Health, Salt Lake City, UT

Speakers:

- W14** 8 a.m. **The Social Determinants of Antibiotic Prescribing: Implications for the Development and Implementation of Stewardship Interventions**
JULIA E. SZYMCAK, PHD; University of Pennsylvania, Philadelphia, PA
- 8:30 a.m. **Q&A**
- W15** 8:35 a.m. **Tailoring to Your Reality: How do I Know What to Tackle and What to Measure?**
REBEKAH W. MOEHRING, MD, MPH; Duke University Medical Center, Durham, NC
- 9:05 a.m. **Q&A**
- W16** 9:10 a.m. **Pre-Prescription Approval vs. Prospective Audit and Feedback. Which Should I Do?**
JEFFREY S. GERBER, MD, PHD; The Children's Hospital of Philadelphia, Philadelphia, PA
- 9:40 a.m. **Q&A**
- W17** 9:45 a.m. **Clinical Controversies: *Clostridium difficile* Prophylaxis in Patients on Antibiotics**
NASIA SAFDAR, MD, PHD, FSHEA; University of Wisconsin School of Medicine and Public Health, Madison, WI
- 10:10 a.m. **Q&A**
- W18** 10:15 a.m. **Syndrome-Specific Interventions: Combining Interventions to Improve Care**
TREVOR C. VAN SCHOONEVELD, MD; University of Nebraska Medical Center, Omaha, NE
- 10:45 a.m. **Q&A**
- 10:50 a.m. **BREAK**
- W19** 11 a.m. **Clinical Controversies: Duration of Therapy for Bacteremia: How Low Can We Go?**
JESSE SUTTON, PHARMD; George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT
- 11:25 a.m. **Q&A**
- W20** 11:30 a.m. **The Missing Member of the Stewardship Team: Bringing Nurses into the Equation**
ELIZABETH MONSEES, MSN, MBA, RN, CIC; Children's Mercy Hospital, Kansas City, MO
- 11:55 a.m. **Q&A**
- 12 p.m. **Lunch**

- W21** 1:15 p.m. **Outpatient Stewardship and the Role of Patient and Caregiver Education**
JEFFREY LINDER, MD, MPH; Northwestern University School of Medicine, Boston, MA
- 1:40 p.m. **Q&A**
- W22** 1:45 p.m. **The Life of a Private Stewardship Consultant**
KAVITA K. TRIVEDI, MD; Trivedi Consults, LLC, Berkeley, CA
- 2:10 p.m. **Q&A**
- W23** 2:15 p.m. **Stewardship in Immunocompromised Patients: Where Are the Opportunities?**
SARAH B. DOERNBERG, MD, MAS; University of California San Francisco Medical Center, San Francisco, CA
- 2:40 p.m. **Q&A**
- 2:45 p.m. **BREAK**
- W24** 3 p.m. **Interventions That Have Worked in Long-Term Care**
ANURAG MALANI, MD, FIDSA, FSHEA; Saint Joseph Mercy Health System, Ann Arbor, MI
- 3:25 p.m. **Q&A**
- W25** 3:30 p.m. **Recent Publications Stewards Should Know**
PRANITA D. TAMMA, MD, MHS; Johns Hopkins University School of Medicine, Baltimore, MD
- 3:55 p.m. **Q&A**
- W26** 4 p.m. **Clinical Controversies: When Does Asymptomatic Bacteriuria Really Warrant Treatment?**
KALPANA GUPTA, MD, MPH; Boston University School of Medicine, Boston, MA
- 4:25 p.m. **Q&A**
- W27** 4:30 p.m. **Update on National Stewardship Activities**
ARJUN SRINIVASAN, MD, FSHEA; Centers for Disease Control and Prevention, Atlanta, GA
- 5:05 – 5:10 **Q&A**
- 5:10 – 5:15 **Final Thoughts**

 Maximum of 7.50 hours of *AMA PRA Category 1 Credit*[™]



ACPE 7.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-216-L01-P

Adult ID/Trainee

PW3. Premeeting Workshop

Fellows' Day Premeeting Workshop (\$)

Co-organized by the IDSA ID Training Program Directors' Committee.

Wednesday, 8 a.m. – noon

17AB

Objectives: At the conclusion of this session, participants will be able to:

- discuss challenging infectious disease cases and approaches to differential diagnosis
- describe career pathways in at least two different infectious diseases fields
- develop an initial action plan in pursuit of a post-fellowship position

Intended Audience: members-in-training, medical students and residents, infectious diseases physicians, fellows.

Moderators:

RAJESH GANDHI, MD, FIDSA; Massachusetts General Hospital, Boston, MA
MICHAEL T. MELIA, MD; Johns Hopkins University School of Medicine, Baltimore, MD

Speakers:

- 8 a.m. **ID Images Interactive Session (Case Reports and Discussants)**
ID Images Expert Panelists
CARLOS DEL RIO, MD, FIDSA; Emory University Rollins School of Public Health, Atlanta, GA
MICHAEL T. MELIA, MD; Johns Hopkins University School of Medicine, Baltimore, MD
SARAH TURBETT, MD; Massachusetts General Hospital, Boston, MA
- W28** 8 a.m. HELEN STANKIEWICZ KARITA, MD; University of Washington, Seattle, WA
- W29** 8:15 a.m. TALHA RIAZ, MD; Medical University of South Carolina, Charleston, SC
- W30** 8:30 a.m. ZANTHIA WILEY, MD; Emory University, Atlanta, GA
- W31** 8:45 a.m. NIKOLAUS JILG, MD, PHD; Massachusetts General Hospital, Boston, MA
- W32** 9 a.m. JOY CHEN, MD; Mayo Clinic, Rochester, MN
- W33** 9:15 a.m. KEVIN KURIAKOSE, MD; Vanderbilt University Medical Center, Nashville, TN
- W34** 9:30 a.m. LUIS TULLOCH, MD; David Geffen School of Medicine/University of California, Los Angeles, Los Angeles, CA
- 9:45 a.m. **BREAK**
- 10 a.m. **ID Career Paths Breakout Discussions**
- W35** **Antimicrobial Stewardship**
LILIAN M. ABBO, MD, FIDSA; University of Miami-Jackson Memorial Hospital, Miami, FL
- W36** **Antimicrobial Stewardship**
EMILY SPIVAK, MD, MHS; University of Utah Health, Salt Lake City, UT
- W37** **Clinical Practice**
JOEL GALLANT, MD, MPH, FIDSA; Southwest CARE Center, Santa Fe, NM
- W38** **Clinical Practice**
ROBIN TROTMAN, DO, FIDSA; CoxHealth, Springfield, MO
- W39** **Global/International Health**
EDWIN J. ASTURIAS, MD; Children's Hospital Colorado/University of Colorado School of Medicine, Aurora, CO
- W40** **Global/International Health**
CARLOS DEL RIO, MD, FIDSA; Emory University Rollins School of Public Health, Atlanta, GA
- W41** **Hospital Epidemiology and Infection Control**
NEIL O. FISHMAN, MD, FIDSA, FSHEA; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

W42

Hospital Epidemiology and Infection Control
TRISH PERL, MD, MSC, FIDSA, FSHEA; University of Texas, Southwestern, Dallas, TX

W43a

Careers in Industry
ELIZABETH HERMSEN, PHARM.D., BCPS (AQ-ID) MBA; Merck & Co., Inc., Rahway, NJ

W43b

Careers in Industry
DAVID SWERDLOW, MD; Pfizer Vaccines, Collegeville, PA

W44

Medical Education
BRIAN SCHWARTZ, MD; University of California, San Francisco, San Francisco, CA

W45

Medical Education
WENDY STEAD, MD; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

W46

Public Health
LAURI HICKS, DO; Centers for Disease Control and Prevention, Atlanta, GA

W47

Public Health
PENNAN BARRY, MD, MPH; California Department of Public Health, Richmond, CA

W48

Research-Based Careers
AMITA GUPTA, MD, MHS; Johns Hopkins University School of Medicine, Baltimore, MD

W49

Research-Based Careers
ROBERT T. SCHOOLEY, MD, FIDSA; University of California at San Diego, La Jolla, CA

W50

Transplant/Oncology ID
BARBARA D. ALEXANDER, MD, MHS, FIDSA; Duke University Medical Center, Durham, NC

W51

Transplant/Oncology ID
RICARDO LA HOZ, MD, FAST; University of Texas Southwestern Medical Center, Dallas, TX

No CME credit is offered for this session.

No CPE credit is offered for this session.

Pediatric ID/Trainee

PW4. Premeeting Workshop

Pediatric Fellows' Day Workshop (\$)

Wednesday, 7:45 a.m. – noon

08

Objectives: At the conclusion of this session, participants will be able to:

- discuss challenging infectious disease cases and approaches to patient management
- summarize career opportunities and pathways to achieve professional goals
- review issues related to finding a job after fellowship

Intended Audience: members-in-training, medical students and residents, infectious diseases pediatricians, fellows.

Moderators:

ANDI L. SHANE, MD, MPH, MSC, FIDSA, FPIDS; Emory University School of Medicine, Atlanta, GA
ANGELA MYERS, MD, MPH, FPIDS; Children's Mercy Hospital, Kansas City and University of Missouri-Kansas City School of Medicine, Kansas City, MO

Speakers:

- 7:45 a.m. **Challenging Cases Presented by Pediatric ID Fellows**
- W52** 7:45 a.m. PATRICK GAVIGAN, MD; University of Tennessee Health Science Center, Memphis, TN
- W53** 8 a.m. JUSTIN SEARNS, MD; Children's Hospital Colorado, Aurora, CO
- W54** 8:15 a.m. ELIZABETH LLOYD, MD; Michigan Medicine, Ann Arbor, MI
- W55** 8:30 a.m. KATHERINE RICHARDSON, MD; Children's Mercy Hospital, Kansas City, MO
- W56** 8:45 a.m. ALEJANDRO DIAZ, MD; The Research Institute at Nationwide Children's Hospital, Columbus, OH
- W57** 9 a.m. RYAN ROCHAT, MD; Baylor College of Medicine, Houston, TX
- 9:15 a.m. **BREAK**
- W58** 9:30 a.m. **Getting What You Deserve and Knowing What to Ask for: Negotiating During Your Job Search**
RAVI JHAVERI, MD, FIDSA, FPIDS; Duke University Medical Center, Durham, NC
- 10 a.m. **Small Group Discussions**
- W59** **Infection Control and Prevention**
JUDITH GUZMAN-COTTRILL, DO; Oregon Health and Science University, Portland, OR
- W60** **Industry**
KIMBERLY J. CENTER, MD; Pfizer, Collegeville, PA
- W61** **Antimicrobial Stewardship Programs**
SARAH PARKER, MD; Children's Hospital Colorado/University of Colorado School of Medicine, Aurora, CO
- W62** **Transplant**
BRIAN T. FISHER, DO, MSCE, MPH; The Children's Hospital of Philadelphia, Philadelphia, PA
- W63** **Education**
DENISE F. BRATCHER, DO; Children's Mercy Hospital, Kansas City, MO
- W64** **CDC/EIS**
SARA ELIZABETH OLIVER, MD, Centers for Disease Control and Prevention, Atlanta, GA

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Global ID/HIV-STD-TB/Pediatric ID

PW5. Premeeting Workshop

TB Workshop (\$)

Wednesday, 8 a.m. – 12 p.m. 15AB

Objectives: At the conclusion of this session, participants will be able to:

- identify the recent advances in TB diagnostics
- formulate management of complex TB cases, such as TB with meningitis or multi-drug resistant TB

- explain the advances and challenges of latent tuberculosis infection


Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners.


Moderators:

SOUMYA CHATTERJEE, MD; Saint Louis University, St Louis, MO
HANA M. EL SAHLY, MD, FIDSA; Baylor College of Medicine, Houston, TX

Speakers:

- W65** 8 a.m. **Diagnostic Pipeline**
TIMOTHY C. RODWELL, MD PHD MPH; University of California - San Diego, La Jolla, CA
- W66** 9 a.m. **Latent Tuberculosis Infection-Advances and Challenges**
TIMOTHY R. STERLING, MD, FIDSA; Vanderbilt University Medical Center, Nashville, TN
- W67** 10 a.m. **TB Meningitis**
ROBERT WILKINSON, MRCP, PHD, FMEDSCI; Institute of Infectious Diseases and Molecular Medicine, Cape Town, South Africa
- W68** 11 a.m. **MDR-TB**
MAX O'DONNELL, MD, MPH; Columbia University Medical Center, New York City, NY

 Maximum of 4.00 hours of *AMA PRA Category 1 Credit*TM

 ACPE 4.0 knowledge-based contact hours of pharmacy CE; 0221-9999-17-341-L01-P

Adult ID/HIV-STD-TB/Pediatric ID

PW6. Premeeting Workshop

Hepatitis C Workshop (\$)

Wednesday, 8 a.m. – 12 p.m. 16AB

Objectives: At the conclusion of this session, participants will be able to:

- design the treatment options for HCV patients according to their RAVS, treatment experience, HCV genotype, and disease stage
- compare methods for staging liver disease
- distinguish steatosis from steatohepatitis
- diagnose common liver diseases


Intended Audience: clinicians, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, pharmacists.


Moderators:

ELIOT GODOFSKY, MD, FIDSA; Bach and Godofsky, Bradenton, FL
DAVID THOMAS, MD, MPH, FIDSA; Johns Hopkins University School of Medicine, Baltimore, MD

Speakers:

- 8 a.m. **Welcome and Introduction**
- W69** 8:10 a.m. **Starting Right: Liver Staging**
DAVID THOMAS, MD, MPH, FIDSA; Johns Hopkins University School of Medicine, Baltimore, MD
- W70** 8:30 a.m. **Precision Therapy: Optimizing Initial Treatment**
KRISTEN M. MARKS, MD; Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY
- W71** 9 a.m. **Retreatment, RAVS, and Resistance**
DAVID WYLES, MD; Denver Health, Denver, CO
- W72** 9:30 a.m. **Fatty Liver Disease: A Large Problem for the ID Doctor**
ROHIT LOOMBA, MBBS; University of California at San Diego, La Jolla, CA
- W73** 10:10 a.m. **Hepatitis B: Update for Clinicians**
GUI-QIANG WANG, MD; Peking University First Hospital, Beijing, China
- 10:40 a.m. **Questions**
- 10:50 a.m. **BREAK**
- W74** 11 a.m. **Hepatology for the ID Doctor**
CATHERINE FRENETTE, MD, FAST, AGAF; Scripps Clinic, La Jolla, CA
- 11:30 a.m. **Questions and Cases**

 Maximum of 4.00 hours of *AMA PRA Category 1 Credit™*

 ACPE 4.0 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-217-L01-P

Adult ID/HIV-STD-TB/Pediatric ID

PW7. Premeeting Workshop

Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA MOC Modules: HIV Medicine in Clinical Practice and Infections in the Non-HIV Immunocompromised Host (\$)

Wednesday, 8 a.m. – 12:30 p.m.

11AB

Objectives: At the conclusion of this session, attendees will be able to:

- discuss the evidence supporting answer choices in 33 HIV case scenarios and 25 non-HIV immunocompromised host case scenarios
- apply updated information to the management of common infectious diseases in HIV and non-HIV immunocompromised hosts
- summarize new treatment and diagnostic strategies in common infectious diseases for HIV patients and non-HIV immunocompromised hosts

Intended Audience: clinicians, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians.

Moderators:

CHRISTOPHER OHL, MD, FIDSA; Wake Forest School of Medicine, Winston-Salem, NC

Speakers:

- W75** 8 a.m. **HIV Medicine in Clinical Practice**
LUIS F. BARROSO, MD; Wake Forest University Health Sciences, Winston-Salem, NC
- 10 a.m. **BREAK**
- W76** 10:30 a.m. **Infections in the Non-HIV Immunocompromised Host**
CHRISTOPHER OHL, MD, FIDSA; Wake Forest School of Medicine, Winston-Salem, NC



Maximum of 4.50 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Global ID/HIV-STD-TB/Investigative ID/Pediatric ID/Trainee

PW8. Premeeting Workshop

Improving ID Learner Assessment via a Multiple-Choice Question Writing Workshop (\$)

Wednesday, 8 a.m. – 12 p.m.

02

Objectives: At the conclusion of this session, participants will be able to:

- describe and compare three methods for formally assessing medical knowledge
- identify the core characteristics of an effective multiple-choice question (MCQ)
- write a MCQ

Intended Audience: academicians, clinicians, epidemiologists, fellows, HIV clinicians, HIV specialists, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, investigators, members-in-training, microbiologists, pharmacists, researchers, scientists.

Moderators:

BRIAN SCHWARTZ, MD; University of California, San Francisco, San Francisco, CA
JOSHUA NOSANCHUK, MD, FIDSA; Albert Einstein College of Medicine, Bronx, NY

Speakers:

- W77** 8 a.m. **Effective Assessment Methods in Medical Education**
HEATHER YUN, MD, FIDSA; San Antonio Military Medical Center, Joint Base San Antonio-Fort Sam Houston, TX
- W78** 10 a.m. **Best Practices in Crafting Multiple-Choice Questions (MCQ)**
MIGUEL PANIAGUA, MD; NBME, Philadelphia, PA



Maximum of 4.00 hours of *AMA PRA Category 1 Credit™*



ACPE 4.0 application-based contact hours of pharmacy
CE; 0221-9999-17-218-L04-P

Official ID Week Scientific Program

Pediatric ID/Trainee

1. Interactive Session

Challenging Cases in Pediatric Infectious Diseases

Wednesday, 1:30 – 3:30 p.m.

06CF

Objectives: At the conclusion of this session, participants will be able to:

- identify unusual infectious diseases in children
- analyze and formulate differential diagnoses and management plans for challenging cases
- assess and compare knowledge anonymously with peers

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners.

Moderators:

CAROL J. BAKER, MD, FIDSA, FSHEA, FPIDS; Texas Children's Hospital, Baylor College of Medicine, Houston, TX
MORVEN EDWARDS, MD, FIDSA, FPIDS; Baylor College of Medicine, Houston, TX

Panelists:

JESSICA SNOWDEN, MD, FIDSA; University of Nebraska Medical Center, Omaha, NE
ALICE PONG, MD; Rady Children's Hospital San Diego, University of California San Diego, San Diego, CA
JASON NEWLAND, MD, MED, FPIDS; Washington University, St. Louis, St. Louis, MO
SURESH BOPPANA, MD, FIDSA; University of Alabama School of Medicine, Birmingham, AL



Maximum of 2.00 hours of *AMA PRA Category 1 Credit*TM



ACPE 2 application-based contact hours of pharmacy CE; 0221-9999-17-219-L01-P

Adult ID/Epidemiology and Infection Control

2. Interactive Session

Controversies in Infection Prevention: Pro/Con

Wednesday, 1:30 – 3:30 p.m.

06DE

Objectives: At the conclusion of this session, participants will be able to:

- describe the potential role that floors play in disease transmission in healthcare



- describe how to prioritize CLABSI prevention resources
- list pros and cons to adding the VAE measure to public reporting and payment programs

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioner.

Moderators:

TARA PALMORE, MD; National Institutes of Health Clinical Center, Bethesda, MD
ARJUN SRINIVASAN, MD, FSHEA; Centers for Disease Control and Prevention, Atlanta, GA

Speakers:

1:30 p.m. **Floors Are an Important Reservoir for Cross-Transmission in Healthcare**

1 Pro
CURTIS J. DONSKEY, MD; Case Western Reserve University, Cleveland, OH

2 Con
MARK E. RUPP, MD, FIDSA, FSHEA; University of Nebraska Medical Center, Omaha, NE

2:10 p.m. **How Low Can You Go (With CLABSI): Is there an Upper Limit to the Number Needed to Treat/Prevent?**

3 Resource Allocation Should Match Risk
LISA L. MARAGAKIS, MD, MPH, FIDSA, FSHEA; Johns Hopkins University School of Medicine, Baltimore, MD

4 Only Zero is Acceptable
MICHAEL BELL, MD; Centers for Disease Control and Prevention, Atlanta, GA

2:50 p.m. **The VAE Measure is Ready for Prime Time: Add it to CMS!**

5 Pro
MARCI DREES, MD, MS; Christiana Care Health System, Newark, DE

6 Con
MARIN KOLLEF, MD; Washington University School of Medicine, St. Louis, MO



Maximum of 2.00 hours of *AMA PRA Category 1 Credit*TM



ACPE 2 knowledge-based contact hours of pharmacy CE; 0221-9999-17-220-L01-P

3. Symposium

Controversies in Travel/Tropical Medicine

Wednesday, 1:30 – 3:30 p.m.

16AB

Objectives: At the conclusion of this session, participants will be able to:

- explain the approach to diagnosis, clinical presentation and treatment of cutaneous leishmania
- understand the approach to diagnosis and treatment of Chagas disease
- discuss the approach to diagnosis, disease spectrum, and treatment of typhus

Intended Audience: academicians, clinicians, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, pharmacists, public health practitioners.

Moderator:

CHRISTINA COYLE, MD; Albert Einstein College of Medicine, Bronx, NY

Speakers:

- 7 1:30 p.m. **Cutaneous Leishmania: Unraveling Treatment Options**
NAOMI ARONSON, MD, FIDSA; Uniformed Services University of the Health Sciences, Bethesda, MD
- 8 1:55 p.m. **Chagas Disease: An Update**
SUSAN MONTGOMERY, DVM, MPH; Centers for Disease Control and Prevention, Atlanta, GA
- 9 2:20 p.m. **Typhus: Clinical Management**
GEORGE VARGHESE, MD, DNB, DTMH, FIDSA; Christian Medical College, Vellore, India
- 10 2:45 p.m. **Infection Prevention Concerns in the Returning Traveler**
PAUL ANANTH TAMBYAH, MD; National University of Singapore, Singapore
- 3:10 p.m. **Q&A**



Maximum of 2.00 hours of *AMA PRA Category 1 Credit™*



ACPE 2 knowledge-based contact hours of pharmacy CE; 0221-9999-17-221-L01-P

Adult ID/Epidemiology and Infection Control/Investigative ID

4. Symposium

Late Breaker I

Wednesday, 1:30 – 3:30 p.m.

06AB

Objectives: At the conclusion of this session, participants will be able to:

- discuss the latest on the H7N9 outbreak in China and development of a new vaccine
- summarize the current findings and recommendations regarding *Candida auris*
- describe the epidemiology of the *Legionella* outbreak and responses of various healthcare entities

Intended Audience: academicians, clinicians, hospital administrators, hospital epidemiologists, infectious diseases physicians, nurses.

Moderator:

ANDREW PAVIA, MD, FIDSA, FSHEA, FPIDS; University of Utah School of Medicine, Salt Lake City, UT

Speakers:

- 11 1:30 p.m. **H7N9 Update**
TIMOTHY UYEKI, MD, MPH, MPP; Centers for Disease Control and Prevention, Atlanta, GA
- 12 1:55 p.m. ***Candida auris***
TOM CHILLER, MD, MPH; Centers for Disease Control and Prevention, Atlanta, GA
- 13 2:20 p.m. ***Legionella***
LAURA A. COOLEY, MD, MPHTM; Centers for Disease Control and Prevention, Atlanta, GA
- 14 2:45 p.m. **TBD 4**
SPEAKER TBD
- 3:10 p.m. **Q&A**



Maximum of 2.00 hours of *AMA PRA Category 1 Credit™*



ACPE 2 knowledge-based contact hours of pharmacy CE; 0221-9999-17-380-L01-P

Adult ID/HIV-STD-TB

5. Symposium

Managing Infections in Opioid Users

Co-organized with the American Society for Addiction Medicine

Wednesday, 1:30 – 2:30 p.m.

17AB

Objectives: At the conclusion of this session, participants will be able to:

- describe effective approaches to treating opioid addiction in patients with hepatitis C
- identify appropriate treatment options for skin/soft tissue and joint infections in people who inject drugs

Intended Audience: academicians, clinicians, healthcare workers, HIV clinicians, HIV specialists, infectious diseases physicians, investigators, members-in-training, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists.

Moderators:

RAJESH GANDHI, MD, FIDSA; Massachusetts General Hospital, Boston, MA
JUDITH FEINBERG, MD, FIDSA; West Virginia University School of Medicine

Speakers:

- 15 1:30 p.m. **Co-management of Opioid Treatment and Hepatitis C Treatment**
ALAIN LITWIN, MD, MPH, MS; Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
- 16 1:55 p.m. **Treating Skin/Soft Tissue and Joint Infections in IDUs**
LOREN MILLER, MD, MPH, FIDSA; Infectious Disease Clinical Outcomes Research, Los Angeles Biomed at Harbor-University of California - Los Angeles Medical Center, Torrance, CA
- 2:20 p.m. **Q&A**



Maximum of 1.00 hours of *AMA PRA Category 1 Credit™*



ACPE 1 knowledge-based contact hours of pharmacy CE;
0221-9999-17-222-L01-P

Adult ID/HIV-STD-TB/Trainee

6. Symposium

Sexually Transmitted Infections: Current Epidemiologic Trends and Management Approaches

Wednesday, 1:30 – 3:30 p.m.

15AB

Objectives: At the conclusion of this session, participants will be able to:

- explain the recent incidence trends of sexually transmitted infections in the United States
- review the epidemiologic characteristics of current sexually transmitted infections

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, infection preventionists, investigators, medical students and residents, members-in-training, pharmacists, public health practitioners, researchers, scientists.

Moderators:

RICHARD HAMILL, MD, FIDSA; Baylor College of Medicine, Houston, TX

HANA M. EL SAHLY, MD, FIDSA; Baylor College of Medicine, Houston, TX

Speakers:

- 17 1:30 p.m. **The Rise in STI Incidence: Epidemiologic Features**
GAIL BOLAN, MD; Centers for Disease Control and Prevention, Atlanta, GA
- 18 2:05 p.m. **PrEP and the Current STI Epidemic: Adding Fuel to the Fire?**
KENNETH MAYER, MD, FIDSA; The Fenway Institute, Boston, MA
- 19 2:40 p.m. **Advances in Approaches to STI Management**
KHALIL G. GHANEM, MD, PHD, FIDSA; Johns Hopkins University School of Medicine, Baltimore, MD

3:15 p.m. **Q&A**



Maximum of 2.00 hours of *AMA PRA Category 1 Credit™*



ACPE 2 knowledge-based contact hours of pharmacy CE;
0221-9999-17-223-L01-P

Adult ID/Epidemiology and Infection Control/Global ID/HIV-STD-TB/Investigative ID/Pediatric ID/Trainee

7. Symposium

What's Hot in ID + HIV

Wednesday, 1:30 – 3:30 p.m.

20ABCD

Objectives: At the conclusion of this session, participants will be able to:

- describe what is new in the fields of infectious diseases basic and clinical science

- describe what is new in the fields of basic science and pathogenesis of HIV
- describe what is new in HIV clinical care and epidemiology

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiology.

Moderators:

DAVID ANDES, MD, FIDSA; University of Wisconsin School of Medicine and Public Health, Madison, WI

ERIC DAAR, MD; Harbor-UCLA Medical Center, Torrance, CA

Speakers:

- 20 1:30 p.m. **What's Hot in ID Clinical Science**
STAN DERESINSKI, MD, FIDSA; Stanford University, Palo Alto, CA
- 21 2 p.m. **What's Hot in ID Basic Science**
LIISE-ANNE PIROFSKI, MD, FIDSA; Albert Einstein College of Medicine, Bronx, NY
- 22 2:30 p.m. **What's Hot in HIV Clinical Science**
WENDY ARMSTRONG, MD, FIDSA; Emory University, Atlanta, GA
- 23 3 p.m. **What's Hot in HIV Basic Science**
JOEL BLANKSON, MD, PHD; Johns Hopkins Hospital, Baltimore, MD



Maximum of 2.00 hours of *AMA PRA Category 1 Credit™*



ACPE 2 knowledge-based contact hours of pharmacy CE;
0221-9999-17-224-L02-P

Adult ID/Epidemiology and Infection Control/Global ID/HIV-STD-TB/Investigative ID/Pediatric ID/Trainee

8. Plenary Session

Special Opening Plenary Session: Evolution and Revolution: Infectious Disease Promise and Challenges in the 21st Century

Wednesday, 3:45 – 5:45 p.m.

20ABCD

Objectives: At the conclusion of this session, participants will be able to:

- review key lessons learned from past emerging infectious disease responses
- outline possible approaches to improve emerging infectious disease preparedness
- discuss strategies to accelerate vaccine development in future outbreak scenarios
- underscore value of vaccines in both epidemic preparedness and response
- critical challenges in vaccine research and development, including science, regulatory, investment and socio-political context
- outline the background, mission, role and activities of the newly formed Coalition for Epidemic Preparedness Innovations (CEPI)

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases

physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiology.

Speakers:

3:45 p.m. Introductory Remarks

DAVID ANDES, MD, FIDSA; University of Wisconsin School of Medicine and Public Health, Madison, WI

SHEA Senior Scholarship Award

Introductory Remarks: SARA E. COSGROVE, MD, MS, FIDSA, FSHEA; Johns Hopkins Medical Institutions, Baltimore, MD; SHEA President

AWARDEE: WILLIAM SCHAFFNER, MD, FIDSA, FSHEA; Vanderbilt University School of Medicine, Nashville, TN

PIDS Distinguished Service Award

Introductory Remarks: PAUL SPEARMAN, MD, FIDSA, FPIDS; Emory University School of Medicine, Atlanta, GA; PIDS President

AWARDEE: KATHRYN EDWARDS, MD, FIDSA, FPIDS; Vanderbilt University School of Medicine, Nashville, TN

HIVMA Clinical Educator Award

Introductory Remarks: WENDY ARMSTRONG, MD, FIDSA; Emory University School of Medicine, Atlanta, GA; HIVMA Chair

AWARDEE: MONICA GANDHI, MD, MPH; University of California San Francisco, San Francisco, CA

IDSA Alexander Fleming Award for Lifetime Achievement

Introductory Remarks: WILLIAM POWDERLY, MD, FIDSA; Washington University School of Medicine, Saint Louis, MO; IDSA President


AWARDEE: BARBARA MURRAY, MD, FIDSA; University of Texas Health Science Center at Houston, Houston, TX


24 4:20 p.m. The Challenge of Pandemic Preparedness

ANTHONY FAUCI, MD, FIDSA; Director, National Institute of Allergy and Infectious Diseases, Bethesda, MD

25 5:02 p.m. A New Strategy to Stop Future Epidemics: Role of CEPI in New Vaccine Development

MARGARET HAMBURG, MD; National Academy of Science, Engineering, and Medicine, Washington, DC

 Maximum of 2.00 hours of *AMA PRA Category 1 Credit™*

 ACPE 2 knowledge-based contact hours of pharmacy CE; 0221-9999-17-381-L01-P

Adult ID/Epidemiology and Infection Control/Pediatric ID/Trainee

9. Meet-the-Professor Session

Changes in Hospital Laboratory Practice and Their Impact on Clinical Care

Thursday, 7 – 8:15 a.m. 02

Objectives: At the conclusion of this session, participants will be able to:

- describe how near patient diagnostics are changing patient management

- explain the current trends in centralized laboratory testing and the impact on patient care

Intended Audience: academicians, clinicians, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, members-in-training, microbiologists, nurses.

Moderator:

RANDALL HAYDEN, MD; St. Jude Children's Research Hospital, Memphis, TN

Speakers:

26 7 a.m. Near Patient Diagnostics

SUSAN M. NOVAK, PHD; SCPMG Regional Reference Lab, North Hollywood, CA

27 7:30 a.m. Centralization of Clinical Microbiology Services: The Calgary Experience

DEIRDRE CHURCH, MD, PHD; University of Calgary, Calgary, AB, Canada

8 a.m. Q&A



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-17-225-L01-P

Adult ID/Epidemiology and Infection Control/Global ID/HIV-STD-TB/Investigative ID/Pediatric ID/Trainee

10. Meet-the-Professor Session

Essentials for the Everyday Leader

Co-organized with the IDSA Education Committee and the Medical Education Work Group

Thursday, 7 – 8:15 a.m. 15AB

Objectives: At the conclusion of this session, participants will be able to:

- differentiate effective vs. ineffective leadership and management skills
- describe some key leadership practices of effective everyday leaders
- identify ways to apply effective leadership practices to become more effective in your daily work

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiology.

Moderators:

JOSHUA NOSANCHUK, MD, FIDSA; Albert Einstein College of Medicine, Bronx, NY

BRIAN SCHWARTZ, MD; University of California, San Francisco, San Francisco, CA

Speakers:

28 7 a.m. GEOFF HART-COOPER, MD; Stanford Children's Health, San Mateo, CA

29 JYOTHI MARBIN, MD; University of California, San Francisco, San Francisco, CA

8 a.m. Q&A



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-17-226-L04-P

Adult ID/Global ID/Pediatric ID/Trainee

11. Meet-the-Professor Session

Media Training for ID Specialists

Thursday, 7 – 8:15 a.m.

07AB

Objectives: At the conclusion of this session, participants will be able to:

- discuss best practices to prepare for media interviews
- describe common pitfalls and how to avoid them during media interviews

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, pharmacists, public health practitioners, scientists, vaccinologists.

Moderator:

ARCHANA CHATTERJEE, MD, PHD, FIDSA, FPIDS; University of South Dakota Sanford School of Medicine, Sioux Falls, SD

Speakers:

30 7 a.m. MATTHEW ZAHN, MD, FIDSA; Orange County Health Care Agency, Santa Ana, CA

31 7:30 a.m. SAUL HYMES, MD; Stony Brook Children's Hospital, Stony Brook, NY

8 a.m. Q&A



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-17-227-L04-P

Adult ID/HIV-STD-TB

12. Meet-the-Professor Session

Our Most Difficult Antiretroviral Management Cases

Thursday, 7 – 8:15 a.m.

16AB

Objectives: At the conclusion of this session, participants will be able to:

- identify key aspects of managing antiretroviral therapy in HIV-infected patients
- evaluate different strategies and options in selecting an antiretroviral treatment regimen with HIV-infected patients

Intended Audience: academicians, clinicians, HIV clinicians, HIV specialists, investigators, members-in-training, nurses,

pharmacists, public health practitioners, researchers, scientists, vaccinologists.

Moderator:

RAJESH GANDHI, MD, FIDSA; Massachusetts General Hospital, Boston, MA

Speakers:

32 7 a.m. SHIREESHA DHANIREDDY, MD, FIDSA; University of Washington, Seattle, WA

33 7:30 a.m. ROY M. GULICK, MD, MPH, FIDSA; Infectious Diseases, Weill Cornell Medicine, New York, NY

8 a.m. Q&A



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-17-228-L02-P

Adult ID/Epidemiology and Infection Control/Pediatric ID

13. Meet-the-Professor Session

Rapid Responses to Common IP Crises

Thursday, 7 – 8:15 a.m.

05AB

Objectives: At the conclusion of this session, participants will be able to:

- discuss strategies used by experienced hospital epidemiologists for common crises.

Intended Audience: academicians, epidemiologists, fellows, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, public health practitioners.

Speakers:

34 7 a.m. LILIAN M. ABBO, MD, FIDSA; University of Miami-Jackson Memorial Hospital, Miami, FL

35 7:30 a.m. AARON M. MILSTONE, MD, MHS, FIDSA, FSHEA; The Johns Hopkins Medical Institutions, Baltimore, MD

8 a.m. Q&A



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Epidemiology and Infection Control/Pediatric ID

14. Meet-the-Professor Session

Tele-Antimicrobial Stewardship

Thursday, 7 – 8:15 a.m.

01AB

Objectives: At the conclusion of this session, participants will be able to:

- describe approaches to performing antibiotic stewardship remotely

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners.

Moderators:

ARJUN SRINIVASAN, MD, FSHEA; Centers for Disease Control and Prevention, Atlanta, GA

JOHN B. LYNCH, MD, MPH; University of Washington, Seattle, WA

Speakers:

36 7 a.m. **Tele-Antimicrobial Stewardship**
JAVEED SIDDIQUI, MD, MPH; TeleMed2U, Roseville, CA

37 7:30 a.m. **Tele-Antimicrobial Stewardship: Academic Opportunities**
PAUL POTTINGER, MD, FIDSA; University of Washington, Seattle, WA

8 a.m. **Q&A**



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-17-229-L01-P

Adult ID/Global ID/Pediatric ID/Trainee

15. Meet-the-Professor Session

Travelers Health: Special Patients

Thursday, 7 – 8:15 a.m.

11AB

Objectives: At the conclusion of this session, participants will be able to:

- review the approach to the pediatric traveler
- explain the approach to the adventurous traveler

Intended Audience: academicians, clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training.

Moderator:

CHRISTINA COYLE, MD; Albert Einstein College of Medicine, Bronx, NY

Speakers:

38 7 a.m. **Traveling With Children: A Travel Medicine Toolkit**
SUSAN KUHN, MD; University of Calgary, Calgary, AB, Canada

39 7:30 a.m. **Off the Beaten Track: Adventure and Extreme Travelers**
JENNY VISSER, MD; University of Otago, Wellington, New Zealand

8 a.m. **Q&A**



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Adult ID/Investigative ID

16. Meet-the-Professor Session

Updates from the Antibacterial Resistance Leadership Group: Methodology and Results in AMR Research

Thursday, 7 – 8:15 a.m.

14AB

Objectives: At the conclusion of this session, participants will be able to:

- describe novel diagnostic study designs and analyses
- compare and contrast non-inferiority with superiority trial designs
- list the operational barriers to subject enrollment in randomized control trials of infectious diseases

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, investigators, microbiologists, nurses, pharmacists, researchers, scientists.

Moderator:

HENRY CHAMBERS, MD, FIDSA; University of California San Francisco, Clinical and Translational Sciences Institute, San Francisco, CA

Speakers:

40 7 a.m. SCOTT EVANS, PHD, MS; Harvard School of Public Health, Boston, MA

41 7:30 a.m. VANCE FOWLER JR., MD, MHS, FIDSA; Duke University Medical Center, Durham, NC

8 a.m. **Q&A**



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-17-342-L04-P

Adult ID

17. Meet-the-Professor Session

When to Suspect Immunodeficiency in the Adult?

Thursday, 7 – 8:15 a.m.

08

Objectives: At the conclusion of this session, participants will be able to:

- identify common clinical presentations of immunodeficiency in adult patients
- explain diagnostic approaches to evaluating the adult with suspected immunodeficiency

Intended Audience: academicians, clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training.

Moderator:

DAVID GREENBERG, MD, FIDSA; University of Texas Southwestern Medical Center, Dallas, TX

Speakers:

42 7 a.m. ALEXANDRA F. FREEMAN, MD; National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD

43 7:30 a.m. PAUL MAGLIONE, MD, PHD; Mount Sinai, New York, NY

8 a.m. Q&A



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Adult ID/Pediatric ID/Trainee

18. Meet-the-Professor Session

Wound Care 101

Co-organized with the IDSA Clinical Affairs Committee

Thursday, 7 – 8:15 a.m.

17AB

Objectives: At the conclusion of this session, participants will be able to:

- review wound types and interventions
- describe approaches for healing including topical therapies, skin grafts

Intended Audience: academicians, clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians, pharmacists.

Moderators:

JOHN B. LYNCH, MD, MPH; University of Washington, Seattle, WA

PAUL AUWAERTER, MD, MBA, FIDSA; Johns Hopkins University School of Medicine, Baltimore, MD

Speakers:

44 7 a.m. ANJUM OWAISI, MD; Metro Infectious Disease Consultants, LLC, Bolingbrook, IL

45 7:30 a.m. ELIOT GODOFSKY, MD, FIDSA; Bach & Godofsky, Bradenton, FL

8 a.m. Q&A



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-17-230-L01-P

Adult ID/Epidemiology and Infection Control/Pediatric ID/Trainee

19. Interactive Session

Controversies in Antimicrobial

Stewardship Programs: Pro/Con Debates

Co-organized with Society of Infectious Diseases Pharmacists

Thursday, 8:30 – 10 a.m.

06DE

Objectives: At the conclusion of this session, participants will be able to:

- discuss the advantages and disadvantages of mandating hospital data required to develop CDC's Standardized Antimicrobial Administration Ratio.
- compare electronic vs. sociobehavioral interventions when implementing antimicrobial stewardship strategies.
- discuss the benefits and drawbacks of expanding an Antimicrobial Stewardship Program into the Intensive Care Unit.



Intended Audience: academicians, clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, pharmacists, public health practitioners, researchers.

Moderators:

KAVITA TRIVEDI, MD; Trivedi Consults, LLC, Berkeley, CA
JOHN B. LYNCH, MD, MPH; Harborview Medical Center, Seattle, WA

Speakers:

46 8:30 a.m. **Is SAAR Ready for Primetime? PRO**

ELIZABETH DODDS ASHLEY, PHARMD, MHS; University of Rochester Medical Center, Rochester, NY

47 8:45 a.m. **Is SAAR Ready for Primetime? CON**

NEIL O. FISHMAN, MD, FIDSA, FSHEA; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

48 9 a.m. **EMR/IT vs. Sociobehavioral Interventions: Most Bang for your Buck? EMR/IT Interventions**

HIEN HUYNH NGUYEN, MD, MAS; University of California, Davis Medical Center, Sacramento, CA

49 9:15 a.m. **EMR/IT vs. Sociobehavioral Interventions: Most Bang for Your Buck? Sociobehavioral Interventions**

JULIA E. SZYMCAK, PHD; University of Pennsylvania, Philadelphia, PA

50 9:30 a.m. **Should Your ASP Include the ICU? PRO**

ALYSSA R. LETOURNEAU, MD, MPH; Massachusetts General Hospital, Harvard Medical School, Boston, MA

51 9:45 a.m. **Should Your ASP Include the ICU? CON**

RICHARD G. WUNDERINK, MD; Northwestern University Feinberg School of Medicine, Chicago, IL



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.50 application-based contact hours of pharmacy CE; 0221-9999-17-231-L01-P

Adult ID/Epidemiology and Infection Control/Global ID/Investigative ID/Pediatric ID/Trainee

20. Symposium

Fungal Resistance: Focus on *Candida auris*

Thursday, 8:30 – 10 a.m.

15AB

Objectives: At the conclusion of this session, participants will be able to:

- identify opportunities and challenges in antifungal stewardship
- explain the epidemiology of the emerging yeast *Candida auris*
- describe the therapeutic challenges of managing patients with *Candida auris*
- list emerging therapeutics for combating candidiasis

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents,

members-in-training, microbiologists, pharmacists, public health practitioners, researchers, scientists.

Moderators:

JOSHUA NOSANCHUK, MD, FIDSA; Albert Einstein College of Medicine, Bronx, NY
JENIEL NETT, MD, PHD; University of Wisconsin, Madison, Madison, WI

Speakers:

- 52 8:30 a.m. **The Epidemiology of *Candida auris*: Rapid Emergence of an MDR Fungus**
TOM CHILLER, MD, MPH; Centers for Disease Control and Prevention, Atlanta, GA
- 53 8:55 a.m. **Best Practices in Antifungal Stewardship**
EMILY SPIVAK, MD, MHS; University of Utah Health, Salt Lake City, UT
- 54 9:20 a.m. **Emerging Therapeutics for *Candida* Infections**
JENIEL NETT, MD, PHD; University of Wisconsin, Madison, Madison, WI

9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-232-L01-P

Adult ID/HIV-STD-TB/Pediatric ID

21. Symposium

HIV State of the Art

Thursday, 8:30 – 10 a.m.

06CF

Objectives: At the conclusion of this session, participants will be able to:

- identify the most appropriate antiretroviral therapy regimens for initial treatment and subsequent therapies for management of HIV infection in adults
- evaluate drug costs and their potential impact on HIV treatment
- review the approaches to effectively responding to the substance and mental health needs of patients with HIV

Intended Audience: fellows, HIV clinicians, HIV specialists, members-in-training, pharmacists, public health practitioners.

Moderators:

ERIC DAAR, MD; Harbor-UCLA Medical Center, Torrance, CA
MONICA GANDHI, MD, MPH; University of California San Francisco, San Francisco, CA

Speakers:

- 55 8:30 a.m. **What to Start and When to Switch**
JOSEPH ERON, MD; University of North Carolina at Chapel Hill, Chapel Hill, NC
- 56 8:55 a.m. **HIV and Cost Considerations - Entering a New Era**
ROCHELLE WALENSKY, MD, MPH, FIDSA; Massachusetts General Hospital, Boston, MA
- 57 9:20 a.m. **Approaches to Management of HIV Patients with Substance Use and Mental Health Issues**

GREGORY LUCAS, MD; Johns Hopkins University, Baltimore, MD

9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-233-L02-P

Adult ID/Pediatric ID

22. Symposium

ID Physicians Adapting to Healthcare Reform

Co-organized with the IDSA Clinical Affairs Committee

Thursday, 8:30 – 10 a.m.

06AB

Objectives: At the conclusion of this session, participants will be able to:

- describe the major changes underway in the US healthcare system
- discuss the position of the infectious diseases physician in a bundled payment system
- recognize actions that enhance the practice of infectious diseases and patient care

Intended Audience: academicians, clinicians, epidemiologists, hospital administrators, infectious diseases pediatricians, infectious diseases physicians, pharmacists.

Moderators:

ANN T. MACINTYRE, DO, MHS; Mercy Hospital, Miami, FL
DANIEL MCQUILLEN, MD, FIDSA; Lahey Hospital & Medical Center, Burlington, MA

Speakers:

- 58 8:30 a.m. **Defining Value: ID Physicians**
PHILIP ROBINSON, MD; Hoag Hospital/ Providence St. Joseph Health, Newport Beach, CA
- 59 8:50 a.m. **The State of Healthcare**
KEN LEONCZYK, JR, JD; The Advisory Board, Washington, DC
- 60 9:10 a.m. **Risk Mitigation: How to Effectively Explain the Role of ID Physicians in Bundled Payment Systems**
SANDRA NELSON, MD, FIDSA; Massachusetts General Hospital, Boston, MA



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-234-L04-P

Adult ID/Epidemiology and Infection Control

23. Symposium

Impact of Sepsis Measures

Thursday, 8:30 – 10 a.m.

11AB

Objectives: At the conclusion of this session, participants will be able to:

- describe the current epidemiologic and incidence data on sepsis

- list important aspects of the CMS sepsis measure
- describe desirable features of new sepsis measures

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, nurses, pharmacists.

Moderators:

ARJUN SRINIVASAN, MD, FSHEA; Centers for Disease Control and Prevention, Atlanta, GA
EBBING LAUTENBACH, MD, MPH, MSCE, FIDSA, FSHEA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Speakers:

- 61** 8:30 a.m. **Epidemiology and Definitions of Sepsis**
CHANU RHEE, MD, MPH; Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, MA
- 62** 8:55 a.m. **Development of the CMS Sepsis Measure**
TEFERA LEMENEH, MD, MSC; Centers for Medicare & Medicaid Services, Baltimore, MD
- 63** 9:20 a.m. **Next Steps in Sepsis Surveillance**
LAUREN EPSTEIN, MD, MSC; Centers for Disease Control and Prevention, Atlanta, GA

9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-235-L01-P

Adult ID/Pediatric ID/Trainee

24. Symposium

Neurological Manifestations of Infectious Diseases

Thursday, 8:30 – 10 a.m.

20ABCD

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, researchers, scientists.

Moderators:

CAROL GLASER, DVM, MPVM, MD; Kaiser Permanente, Oakland, CA
KAREN BLOCH, MD, MPH, FIDSA; Vanderbilt University Medical Center, Nashville, TN

Speakers:

- 64** 8:30 a.m. **Acute Flaccid Myelitis - EV -D68, WNV and Others**
KEVIN MESSACAR, MD; University of Colorado School of Medicine, Aurora, CO
- 65** 8:55 a.m. **Immune-Mediated Manifestations of CNS Disease: FIRES, ADEM, GBS**

ARIANE SOLDATOS, MD, MPH; National Institute of Neurological Disorders and Stroke/ National Institutes of Health, Bethesda, MD

- 66** 9:20 a.m. **Molecular Sequencing for the Diagnosis of CNS Infections**

CHARLES Y. CHIU, MD, PHD; University of California, San Francisco, San Francisco, CA

9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Pediatric ID/Trainee

25. Symposium

New Antimicrobial Resistance Surveillance Programs

Thursday, 8:30 – 10 a.m.

17AB

Objectives: At the conclusion of this session, participants will be able to:

- list new efforts to survey for antimicrobial resistant infections
- report antimicrobial resistant pathogens that require enhanced tracking mechanisms
- describe how new antimicrobial resistance surveillance efforts will benefit patient care

Intended Audience: clinicians, epidemiologists, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, microbiologists, pharmacists, public health practitioners.

Moderators:

MARION KAINER, MBBS, MPH, FSHEA; Tennessee Department of Health, Nashville, TN
JEAN PATEL, PHD, D(ABMM); Centers of Disease Control and Prevention, Atlanta, GA

Speakers:

- 67** 8:30 a.m. **AR Surveillance by Electronic Reporting of Laboratory Data**
DANIEL POLLOCK, MD; Centers for Disease Control and Prevention, Atlanta, GA
- 68** 8:55 a.m. **The Antibiotic Resistance Laboratory Network**
MARION KAINER, MBBS, MPH, FSHEA; Tennessee Department of Health, Nashville, TN
- 69** 9:20 a.m. **Strategies for Detecting Resistance in an Era of Culture-Independent Diagnostics**
CINDY FRIEDMAN, MD; Centers for Disease Control and Prevention, Atlanta, GA

9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-236-L01-P

26. Symposium

TB 2017: Pregnancy, IRIS, and MDR/XDR

Thursday, 8:30 – 10 a.m.

16AB

Objectives: At the conclusion of this session, participants will be able to:

- review management of TB in the setting of Pregnancy
- describe the complexity of TB and IRIS
- review the transmission, epidemiology and outcomes in MDR/XDR

Intended Audience: clinicians, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, pharmacists, public health practitioners.

Moderators:

WESLEY VAN VOORHIS, MD, PHD, FIDSA; University of Washington, Seattle, WA
CHRISTINA COYLE, MD; Albert Einstein College of Medicine, Bronx, NY

Speakers:

70 8:30 a.m. **Shedding Light on an Inflammatory Topic: HIV-1 Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome**
ROBERT WILKINSON, MRCP, PHD; University of Cape Town, Rondebosch, South Africa

71 8:55 a.m. **MDR and XDR Tuberculosis: Lessons Learned**
NEEL GANDHI, MD; Emory University, Atlanta, GA

72 9:20 a.m. **Tuberculosis in Pregnant Women: Epidemiology and Management**
AMITA GUPTA, MD, MHS; Johns Hopkins University School of Medicine, Baltimore, MD

9:45 a.m. **Q&A**

Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-237-L01-P

Adult ID/Epidemiology and Infection Control/Global ID/Investigative ID/Pediatric ID/Trainee

27. Symposium

What's New with Zika

Co-organized with the Centers for Disease Control and Prevention

Thursday, 8:30 – 10 a.m.

14AB

Objectives: At the conclusion of this session, participants will be able to:

- name two things that animal models tell us about sexual transmission of Zika virus
- describe one complication of Zika in pregnancy and one recommendation for infants born to infected mothers
- describe two features of the epidemiology of Zika virus infection

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital

epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists.

Moderators:

PATRICIA M. GRIFFIN, MD, FIDSA; Centers of Disease Control and Prevention, Atlanta, GA
MICHAEL BUSCH, MD, PHD; Blood Systems Research Institute, San Francisco, CA

Speakers:

73 8:30 a.m. **Epidemiology of Zika Virus Infection**
LYLE PETERSEN, MD, MPH; Centers for Disease Control and Prevention, Fort Collins, CO

74 8:55 a.m. **Zika Virus Infection in Pregnancy**
MARGARET (PEGGY) HONEIN, PHD; Centers for Disease Control and Prevention, Atlanta, GA

75 9:20 a.m. **What Animal Models Tell Us About Sexual Transmission of Zika Virus**
AARON BRAULT, PHD; Centers for Disease Control and Prevention, Fort Collins, CO

9:45 a.m. **Q&A**

Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-238-L01-P

Adult ID/Epidemiology and Infection Control/Investigative ID/Pediatric ID

28. Oral Abstract Session

CDI Prevention

Thursday, 8:30 – 10 a.m.

07AB

Objectives: Oral abstract session objectives coincide with the IDWeek meeting objectives and are available online at www.idweek.org.

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists.

Moderators:

L. CLIFFORD MCDONALD, MD, FSHEA; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA
MARCI DREES, MD, MS; Christiana Care Health System, Newark, DE

Speakers:

76 8:30 a.m. **Association of Hospital-Onset *Clostridium difficile* Infection Rates and Antibiotic Use in U.S. Acute Care Hospitals, 2006–2012: an Ecologic Analysis**
SOPHIA KAZAKOVA, MD, MPH, PHD, Centers for Disease Control and Prevention, Atlanta, GA

- 77 8:45 a.m. ***Clostridium difficile*: investigating transmission patterns between symptomatic and asymptomatic patients using whole genome sequencing**
LING YUAN KONG, MD, McGill University Health Centre, Montreal, QC, Canada
- 78 9 a.m. **Antibiotic Prescribing for Dental Procedures in Community-Associated *Clostridium difficile* cases, Minnesota, 2009–2015**
MARIA BYE, MPH, Minnesota Department of Health, St. Paul, MN
- 79 9:15 a.m. **Testing Stewardship: A ‘Hard Stop’ to Reduce Inappropriate *C. diff* Testing**
MARCI DREES, MD, MS, Christiana Care Health System, Newark, DE
- 80 9:30 a.m. **Impact of an automatic hospital probiotic protocol on *Clostridium difficile* infection rates and antibiotic usage patterns**
DOUGLAS SLAIN, PHARM, BCPS, FCCP, FASHP, West Virginia University, Morgantown, WV
- 81 9:45 a.m. **Etiology of Infectious Diarrhea in Patients Tested for *Clostridium difficile*: If It Isn’t *Clostridium difficile*, What Is It?**
JENNIE H. KWON, DO, MSCI, Washington University School of Medicine, St. Louis, MO

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Investigative ID/Pediatric ID

29. Oral Abstract Session

Identification, Treatment, and Prevention of Pediatric Bacterial Pathogens

Thursday, 8:30 – 10 a.m.

05AB

Moderators:

KATHRYN EDWARDS, MD, FIDSA; Vanderbilt University School of Medicine, Nashville, TN
KATHLEEN MCGANN, MD; Duke University Medical Center, Durham, NC

Speakers:

- 82 8:30 a.m. **The association of molecular characteristics, vancomycin MIC and clinical outcomes in methicillin-susceptible *Staphylococcus aureus* osteoarticular infections in children.**
JONATHON MCNEIL, MD, Baylor College of Medicine, Houston, TX
- 83 8:45 a.m. **Impact of Vancomycin Serum Trough Concentrations and Vancomycin AUC/MIC on Vancomycin Response, In-Hospital Outcomes and Acute Kidney Injury in Pediatric *Staphylococcus aureus* Pneumonia**
JONATHON MCNEIL, MD, Baylor College of Medicine, Houston, TX
- 84 9 a.m. **Comparative Effectiveness of Beta-lactams Versus Azithromycin for Treatment of Outpatient Pediatric Community-Acquired Pneumonia**

- LORI HANDY, MD, MSCE, The Children’s Hospital of Philadelphia, Philadelphia, PA
- 85 9:15 a.m. **Comprehensive detection of pathogens in immunocompromised children with bloodstream infections by next-generation sequencing**
KAZUHIRO HORIBA, MD, Nagoya University Graduate School of Medicine, Nagoya, Japan
- 86 9:30 a.m. **Passive Immunization with Anti-Pertussis Toxin Humanized Monoclonal Antibody Mitigates Clinical Signs of Pertussis Infection in Newborn Baboons**
JENNIFER MAYNARD, PHD, University of Texas at Austin, Austin, TX
- 87 9:45 a.m. **Epidemiology and Trends of Pertussis among Infants — United States, 2000–2015**
CATHERINE BOZIO, PHD, MPH, Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Pediatric ID

30. Oral Abstract Session

It’s Not Just Bones: Skin and Bones

Thursday, 8:30 – 10 a.m.

01AB

Intended Audience: academicians, clinicians, infectious diseases pediatricians, infectious diseases physicians.

Moderators:

ELIE F. BERBARI, MD, FIDSA; Mayo Clinic, Rochester, MN
MARINA NUNEZ, MD, PhD, Wake Forest University, Winston-Salem, NC

Speakers:

- 88 8:30 a.m. **Risk factors for early hip or knee prosthetic joint infection (PJI): Analysis of a nationwide American insurance claims dataset**
AARON TANDE, MD, Mayo Clinic, Rochester, MN
- 89 8:45 a.m. **U.S. Combat-related Invasive Fungal Wound Infection (IFI) Epidemiology and Wound Microbiology: Afghanistan Theater 2009–2014**
ANURADHA GANESAN, MD, MPH, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Rockville, MD
- 90 9 a.m. **Increasing *Kingella* Identification in Bone and Joint Infections in Young Children**
RACHEL QUICK, RN, MSN, CNS, Seton Healthcare Family, Austin, TX
- 91 9:15 a.m. **Microbiology of Vertebral Osteomyelitis and Implications on Empiric Therapy**
ABBYE CLARK, BS, University of South Carolina School of Medicine, Columbia, SC
- 92 9:30 a.m. **Concordance of Results of Blood and Tissue Cultures from Patients with Pyogenic Spondylitis**
JI YUN BAE, MD, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)

- 93 9:45 a.m. **Home environmental contamination is associated with community-associated methicillin-resistant *Staphylococcus aureus* re-colonization in treated patients**
MEGHAN DAVIS, PHD, DVM, MPH, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Pediatric ID 31. Symposium

Ambulatory Infection Prevention

Thursday, 10:30 a.m. – noon

16AB

Objectives: At the conclusion of this session, participants will be able to:

- plan *S. aureus* decolonization of families (children and adults)
- review best practices for infection prevention in ambulatory surgical centers
- describe strategies to prevent healthcare-associated respiratory infections in children and adults in ambulatory settings

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, members-in-training, nurses, pharmacists, public health practitioners.


Moderators:


GONZALO BEARMAN, MD, MPH, MPA, FSHEA; Virginia Commonwealth University Medical Center, Richmond, VA
ALICE PONG, MD; Rady Children's Hospital San Diego, University of California San Diego, San Diego, CA

Speakers:

- 94 10:30 a.m. ***S. aureus* Decolonization of Outpatients**
STEPHANIE FRITZ, MD; Washington University, St. Louis, MO
- 95 10:55 a.m. **Ambulatory Surgical Centers: The New Frontier**
PHILIP BARIE, MD; New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY
- 96 11:20 a.m. **Respiratory Infection Prevention in Ambulatory Setting**
KRISTEN FEEMSTER, MD, MPH, MSHP; The Children's Hospital of Philadelphia, Philadelphia, PA

11:45 a.m. **Q&A**

 Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-239-L05-P

Adult ID/Epidemiology and Infection Control/Pediatric ID

32. Symposium

Antimicrobial Stewardship Programs In Non-Acute Settings

Thursday, 10:30 a.m. – noon

17AB

Objectives: At the conclusion of this session, participants will be able to:

- describe how antibiotic stewardship programs may be designed and maintained in non-acute settings
- describe difficulties in implementing antibiotic stewardship strategies in non-acute settings
- describe how antibiotic stewardship programs differ in these non-acute settings from their counterparts in acute care hospitals

Intended Audience: clinicians, fellows, hospital epidemiologists, infection preventionists, infectious diseases physicians, members-in-training, pharmacists, public health practitioners.

Moderators:

SARAH B. DOERNBERG, MD; University of California San Francisco Medical Center, San Francisco, CA
JENNIFER HAN, MD, MSCE; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Speakers:

- 97 10:30 a.m. **ASP in Long-Term Care**
JOE BOERO, MD; Park Manor Nursing Home, Ltd., Park Falls, WI
- 98 10:55 a.m. **ASP in Outpatient Settings**
JEFFREY LINDER, MD, MPH; Northwestern University School of Medicine, Chicago, IL
- 99 11:20 a.m. **ASP in OPAT**
EMILY SPIVAK, MD, MHS; University of Utah Health, Salt Lake City, UT
- 11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-240-L01-P

Adult ID/Epidemiology and Infection Control/Global ID/
HIV-STD-TB/Investigative ID/Pediatric ID/Trainee

33. Symposium

Big Beasts in Global Health

Thursday, 10:30 a.m. – noon

15AB

Objectives: At the conclusion of this session, participants will be able to:

- review the relative role of the major ID causes of morbidity and mortality in global health
- identify that respiratory diseases is the leading cause of ID mortality in children
- describe how malaria drug resistance is leading to difficulty in malaria control
- identify pathways to an effective malaria vaccine
- explain how drug resistance and immune evasion leads to difficulty in tuberculosis control

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists.

Moderator:

WESLEY VAN VOORHIS, MD, PHD, FIDSA; University of Washington, Seattle, WA

Speakers:

100 10:30 a.m. **Respiratory Diseases: The Leading Killer**
KEITH KLUGMAN, MD, PHD, FIDSA; Bill & Melinda Gates Foundation, Seattle, WA

101 10:55 a.m. **Malaria: Where We Are and Where We are Going**
LAURENCE SLUTSKER, MD, MPH; PATH, Seattle, WA

102 11:20 a.m. **TB: The Master of Adaptation and Evasion**
JOEL ERNST, MD, FIDSA; New York University School of Medicine, New York, NY

11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-241-L01-P

— **Adult ID/Epidemiology and Infection Control** —

34. Symposium

Big Beasts in ID I

Thursday, 10:30 a.m. – noon

06AB

Objectives: At the conclusion of this session, participants will be able to:

- describe current epidemiology, diagnosis and treatment of cellulitis
- discuss current epidemiology, diagnosis and treatment of line-associated bacteremia
- explain current epidemiology, diagnosis and treatment of *Clostridium difficile* infection

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, lab personnel, members-in-training, microbiologists, pharmacists.

Moderators:

DAVID VAN DUIN, MD, PHD; University of North Carolina, Chapel Hill, NC
ADARSH BHIMRAJ, MD, FIDSA; Cleveland Clinic, Cleveland, OH

Speakers:

103 10:30 a.m. **Cellulitis and the Other Red Leg**
DANIELA KROSHINSKY, MD, MPH; Harvard University, Boston, MA

104 10:55 a.m. **Line-Associated Bacteremia: Zeroing in on Zero**
NAOMI O'GRADY, MD, FIDSA; National Institutes of Health, Bethesda, MD

105 11:20 a.m. ***Clostridium difficile* Continues to Live Up to its Name**

CURTIS DONSKEY, MD; Case Western Reserve University, Cleveland, OH

11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-242-L01-P

**Adult ID/Epidemiology and Infection Control/Global ID/
Pediatric ID/Trainee**

35. Symposium

**Current Issues, Conundrums, and Challenges
with Respiratory Viruses**

Thursday, 10:30 a.m. – noon

14AB

Objectives: At the conclusion of this session, participants will be able to:

- describe the epidemiology of respiratory adenovirus infections
- identify adenovirus disease prevention strategies
- describe the management of antibiotics in the setting of acute respiratory illness caused by viruses,
- discuss up to date surveillance regarding MERS-CoV and control strategies for emerging human coronavirus infections

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, pharmacists, public health practitioners.

Moderators:

INGER DAMON, MD, PHD, FIDSA; Centers for Disease Control and Prevention, Atlanta, GA
SUSAN GERBER, MD; Centers for Disease Control and Prevention, Atlanta GA, GA

Speakers:

106 10:30 a.m. **Current Epidemiology and Insights into Prevention and Management of Respiratory Adenovirus Infections**

ADRIANA KAJON, PHD; Lovelace Respiratory Research Institute, Albuquerque, NM

107 10:55 a.m. **It is All in the Timing. (When to Take Patients Who Have Respiratory Viral Infections Off of Antibiotics)**

HELEN CHU, MD, MPH; University of Washington, Seattle, WA

108 11:20 a.m. **SARS Ended, MERS Continues, What is Next for Coronaviruses?**

JOHN WATSON, MD, MSC; Centers for Disease Control and Prevention, Atlanta, GA

11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-243-L01-P

36. Symposium

Have a Yogurt and Call Me in the Morning: Update on Probiotics

Thursday, 10:30 a.m. – noon

06CF

Objectives: At the conclusion of this session, participants will be able to:

- review the current data supporting the use of probiotics for gastrointestinal disease
- review the data to support the use of prebiotics or probiotics in the immunocompromised host
- review the existing data to inform which probiotic to use for various conditions

Intended Audience: academicians, clinicians, fellows, health-care workers, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, pharmacists, public health practitioners, researchers.

Moderators:

DAVID GREENBERG, MD, FIDSA; University of Texas Southwestern Medical Center, Dallas, TX
BONNIE PROKESCH, MD; University of Texas Southwestern, Dallas, TX

Speakers:

- 109** 10:30 a.m. **Probiotics and Gastrointestinal Disease: What is the Current State of Affairs?**
HANIA SZAJEWSKA, MD; Medical University of Warsaw, Warsaw, Poland
- 110** 10:55 a.m. **Prebiotics and Probiotics in the Immunocompromised Host: Do the Risks Outweigh the Benefits?**
AMI BHATT, MD, PHD; Dana-Farber Cancer Institute, Boston, MA
- 111** 11:20 a.m. **Which Probiotic to Choose?**
PATRICIA HIBBERD, MD, PHD; Boston University School of Public Health, Boston, MA
- 11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-244-L01-P

37. Symposium

HIV on the Horizon

Thursday, 10:30 a.m. – noon

11AB

Objectives: At the conclusion of this session, participants will be able to:

- discuss the state of HIV cure research and potential clinical implications
- describe the role of broadly neutralizing antibodies for treatment and prevention of HIV infection
- explain the management of inflammation in patients with HIV

Intended Audience: academicians, clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases physicians,

investigators, members-in-training, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists.

Moderators:

RAJESH GANDHI, MD, FIDSA; Massachusetts General Hospital, Boston, MA
EILEEN SCULLY, MD, PHD; Johns Hopkins School of Medicine, Baltimore, MD

Speakers:

- 112** 10:30 a.m. **HIV Cure Research Update**
DANIEL KURITZKES, MD, FIDSA; Brigham and Women's Hospital/Harvard Medical School, Cambridge, MA
- 113** 10:55 a.m. **Broadly Neutralizing Antibodies for Treatment and Prevention**
KATHARINE BAR, MD; University of Pennsylvania, Philadelphia, PA
- 114** 11:20 a.m. **Reducing Inflammation to Improve Clinical Outcomes**
TURNER OVERTON, MD; University of Alabama at Birmingham, Birmingham, AL
- 11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-245-L02-P

Epidemiology and Infection Control/Pediatric ID/Trainee

38. Symposium

Mano-a-Mano II: Controversies in Pediatric ID

Thursday, 10:30 a.m. – noon

20ABCD

Objectives: At the conclusion of this session, participants will be able to:

- discuss the use of Fluconazole vs. micafungin for neonatal candidiasis
- describe pathogen based vs. symptom-based isolation for pediatric inpatients
- discuss the pros and cons of RSV prophylaxis

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, investigators, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists.

Moderators:

RAVI JHAVERI, MD, FIDSA, FPIDS; University of North Carolina, Chapel Hill, NC
ANDI L. SHANE, MD, MPH, MSC, FIDSA, FPIDS; Emory University School of Medicine, Atlanta, GA

Speakers:

- 115** 10:30 a.m. **Fluconazole vs. Micafungin for Neonatal Candidiasis**
THEOKLIS ZAOUTIS, MD, MSCE; The Children's Hospital of Philadelphia, Philadelphia, PA

- 116** 10:45 a.m. **Fluconazole vs. Micafungin for Neonatal Candidiasis**
ANTONIO ARRIETA, MD, FIDSA; Children's Hospital of Orange County Children's Hospital, Orange, CA
- 117** 11 a.m. **Pathogen-Based Isolation for Pediatric Inpatients**
THOMAS J. SANDORA, MD, MPH, FSHEA; Boston Children's Hospital and Harvard Medical School, Boston, MA
- 118** 11:15 a.m. **Symptom-Based Isolation for Pediatric Inpatients**
ANDI L. SHANE, MD, MPH, MSC, FIDSA, FPIDS; Emory University School of Medicine, Atlanta, GA
- 119** 11:30 a.m. **RSV Prophylaxis**
SHAWN RALSTON, MD; Children's Hospital at Dartmouth, Lebanon, NH
- 120** 11:45 a.m. **RSV Prophylaxis**
ASUNCION MEJIAS, MD, PHD, MSCS; The Research Institute at Nationwide Children's Hospital, Columbus, OH



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-246-L01-P

Adult ID/Epidemiology and Infection Control/Pediatric ID

39. Symposium

Preventing Vaccine-Preventable Diseases In Healthcare: Policy & Politics

Thursday, 10:30 a.m. – noon

06DE

Objectives: At the conclusion of this session, participants will be able to:

- describe the reason for vaccination of healthcare workers
- discuss the reasons vaccines are mandated
- identify ways to increase healthcare worker vaccination rates

Intended Audience: academicians, clinicians, epidemiologists, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, pharmacists, public health practitioners, researchers, scientists, vaccinologists.

Moderators:

ANDREW PAVIA, MD, FIDSA, FSHEA, FPIDS; University of Utah School of Medicine, Salt Lake City, UT
H. KEIPP TALBOT, MD, MPH, FIDSA; Vanderbilt University Medical Center, Nashville, TN

Speakers:

- 121** 10:30 a.m. **Impact of Vaccine Preventable Illness in the Hospital: From Measles to MERS**
EMILY SPIVAK, MD, MHS; University of Utah Health, Salt Lake City, UT
- 122** 10:55 a.m. **Current Landscape of State Healthcare Worker and Patient Vaccination Laws and Challenges to Mandating Vaccines**
ALEXANDRA BHATTI, JD, MPH; Centers for Disease Control and Prevention, Atlanta, GA

Chenega Professional and Technical Services LLC, Atlanta, GA

- 123** 11:20 a.m. **Improving Healthcare Personnel Vaccine Uptake: Moving Beyond Influenza**
THOMAS TALBOT, MD, MPH, FIDSA, FSHEA; Vanderbilt University, Nashville, TN

11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-247-L01-P

Adult ID

40. Oral Abstract Session

Adult Central Nervous System Infection

Thursday, 10:30 a.m. – noon

07AB

Moderators:

DIEDERIK VAN DE BEEK, MD, PHD; Academic Medical Center, Amsterdam, Netherlands
HANA M. EL SAHLY, MD, FIDSA; Baylor College of Medicine, Houston, TX

Speakers:

- 124** 10:30 a.m. **Current Epidemiology of Serogroup W Meningococcal Disease—United States, 2010–2015**
HEIDI SOETERS, PHD, MPH, Centers of Disease Control and Prevention, Atlanta, GA
- 125** 10:45 a.m. **Increased risk of invasive meningococcal disease associated with primary and secondary immunodeficiency**
LENE FOGT LUNDBO, MD, PHD, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark
- 126** 11 a.m. **Use of Adjunctive Steroids and Incidence of Delayed Cerebral Venous Thrombosis in Adults with Bacterial Meningitis**
CINTHIA GALLEGOS, MD, University of Texas Medical School at Houston, Houston, TX
- 127** 11:15 a.m. **Retrospective Evaluation of Infants 1–60 Days Evaluated for Meningitis Using the FilmArray® Meningitis/Encephalitis (ME) Panel**
ANNE J. BLASCHKE, MD, PHD, FIDSA, FPIDS, University of Utah School of Medicine, Salt Lake City, UT
- 128** 11:30 a.m. **A Single-center, Quasi-experimental Study to Evaluate the Impact of a Multiplex Polymerase Chain Reaction System Combined with Antimicrobial Stewardship Intervention on Time to Targeted Therapy in Patients with Suspected Central Nervous System Infection**
KELSEY POWELL, PHARM, Froedtert & the Medical College of Wisconsin, Milwaukee, WI
- 129** 11:45 a.m. **How do advanced molecular tests compare to routine clinical laboratory evaluation of CSF in meningoencephalitis? A Study in 10 Urban Emergency Departments across the United States.**
TOBY L. MERLIN, MD, Centers for Disease Control and Prevention, Atlanta, GA

No CME credit is offered for this session.

No CPE credit is offered for this session.

41. Oral Abstract Session

Infections in Transplantation

Thursday, 10:30 a.m. – noon

05AB

Moderator:

RAYMUND R. RAZONABLE, MD, FIDSA; Mayo Clinic, Rochester, MN

Speakers:

- 130** 10:30 a.m. **Does Detection of Respiratory Viral Infection in Upper Respiratory Tract (URT) Predict Lower Respiratory Tract (LRT) Disease in Hematopoietic Cell Transplant (HCT) Patients?**
MEGHANA VIVEK, MD, Fred Hutchinson Cancer Research Center, Seattle, WA
- 131** 10:45 a.m. **A Multicenter Study on Clinical Outcomes of Infections within 200 days of Liver Transplantation among Recipients age 65 years and older**
MARICAR MALINIS, MD, FACP, Yale University School of Medicine, New Haven, CT
- 132** 11 a.m. **Solid Organ Transplantation (SOT) & Data Mining: Bloodstream Infections (BSI) Have a Significant Impact on One-Year Survival, and qSOFA ≥ 2 Predicts 30-Day Mortality.**
TERRENCE LIU, BS, University of Texas Southwestern Medical Center, Dallas, TX
- 133** 11:15 a.m. ***Strongyloides stercoralis* Infection Incidence, Risk Factors and Outcomes Among Solid Organ Transplant Candidates and Recipients; a Florida Center Experience**
ROBERT CASTRO, MD, University of South Florida College of Medicine, Tampa, FL
- 134** 11:30 a.m. **Investigation of a Contaminated, Nationally-Distributed, Organ Transplant Preservation Solution — United States, 2016–2017**
MATTHEW STUCKEY, PHD, MPH, Centers for Disease Control and Prevention, Atlanta, GA
- 135** 11:45 a.m. **Outcomes of Kidney Transplantation with a CMV Matching Allocation Schema**
LYNNE STRASFELD, MD, Oregon Health & Science University, Portland, OR

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Investigative ID/Pediatric ID/Trainee

42. Oral Abstract Session

The Cutting Edge in Antimicrobial Resistance Emergence Therapy

Thursday, 10:30 a.m. – noon

01AB

Moderators:

WARREN ROSE, PHARMD, MPH; University of Wisconsin School of Pharmacy, Madison, WI
CESAR ARIAS, MD, PHD, FIDSA; University of Texas McGovern Medical School at Houston, Houston, TX

Speakers:

- 136** 10:30 a.m. **SYN-004 (ribaxamase) prevents New Onset *Clostridium difficile* Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study**
JOHN KOKAI-KUN, PHD, Synthetic Biologics, Inc., Rockville, MD
- 137** 10:45 a.m. **Collaborative Use Repurposing Engine (CURE): FDA-NCATS/NIH Effort to Capture the Global Clinical Experience of Drug Repurposing to Facilitate Development of New Treatments for Neglected and Emerging Infectious Diseases**
HEATHER STONE, MPH, US Food and Drug Administration, Silver Spring, MD
- 138** 11 a.m. **Cefazolin plus Clavulanic Acid Overcomes the Inoculum Effect in a Methicillin-Susceptible *Staphylococcus aureus* (MSSA) Rat Endocarditis Model**
WILLIAM MILLER, MD, University of Texas McGovern Medical School at Houston, Houston, TX
- 139** 11:15 a.m. **Epidemiology of Inappropriate Empiric Antibiotic Therapy for Bacteremia Based on Discordant *In vitro* Susceptibilities: Risk factors and Taxon-level Variation in Burden and Outcome in 156 US hospitals, 2000–2014**
SAMEER S. KADRI, MD, MS, National Institutes of Health Clinical Center, Bethesda, MD
- 140** 11:30 a.m. **Evolution of antibiotic tolerance during oxacillin, daptomycin and dalbavancin therapy results in breakthrough *Staphylococcus aureus* bacteremias**
ANDREW BERTI, PHARMD, PHD, Wayne State University, Detroit, MI
- 141** 11:45 a.m. **Carbapenem-resistant Enterobacteriaceae (CRE) or Delayed Appropriate Therapy (DAT)—Does One Affect Outcomes More Than the Other Among Patients With Serious Infections Due to Enterobacteriaceae?**
THOMAS LODISE, PHARMD, PHD, Albany College of Pharmacy and Health Sciences, Albany, NY

No CME credit is offered for this session.

No CPE credit is offered for this session.

Poster Sessions

Poster Hall CD

Thursday 10:00 a.m. – 6:00 p.m.	On display
12:30 – 2 p.m.	Lunch in the Exhibit Hall
12:30 – 2:00 p.m.	Presenters at posters

#	Session Title
43.	<i>Candida auris</i> : Coming Soon to a Patient Near You (142–146)
44.	Clinical Mycology (147–193)
45.	Clinical: Bone and Joint Infection (194–230)
46.	Clinical: Sexually Transmitted Infections (231–249)
47.	Clinical: Skin and Soft Tissue (250–269)
48.	Fungus Among Us: Basic Science (270–279)
49.	Global Health Potpourri (280–292)

50. **Global Infections** (293–315)
51. **Emerging Resistance: Epidemiology and Mechanisms** (316–344)
52. **HAI: MDRO-GNR/Emerging Resistant Bacterial Pathogens** (345–410)
53. **HAI: Non-Acute Care** (411–421)
54. **HAI: Epidemiologic Methods** (422–433)
55. **HAI: Occupational Health** (434–448)
56. **HAI: Outbreaks** (449–464)
57. **HAI: Surveillance + Reporting** (465–479)
58. **HAI: The Environment** (480–512)
59. **Hepatitis B and C in Varied Settings** (513–546)
60. **HIV and Central Nervous System** (547–551)
61. **HIV and Fungal Infection** (552–556)
62. **HIV and Mycobacterial Infections** (557–558)
63. **HIV Clinical Care and Outcomes** (559–568)
64. **HIV: Cancer and Dysplasia** (569–571)
65. **HIV: Cardiovascular Disease, Lipids, Diabetes** (572–581)
66. **HIV: General Opportunistic Infections** (582–586)
67. **HIV: Kidney, Bone + Liver Effects** (587–597)
68. **HIV: Pathogenesis and Inflammation** (598–601)
69. **Immunology – Host Response** (602–618)
70. **Legionella** (619–622)
71. **Microbial Pathogenesis** (623–627)
72. **Microbiome** (628–641)
73. **Outbreaks and Public Health Across the Globe** (642–673)
74. **Stewardship: Data and Program Planning** (674–707)
75. **Stewardship: Program Implementation** (708–775)
76. **Treatment of Resistant Infections – Clinical Analyses** (776–802)
77. **Use of PK/PD to Optimize Existing Antibiotics and Antifungals** (803–838)
78. **Zika Virus** (839–845)

Adult ID/Epidemiology and Infection Control

79. Poster Discussion Round

Managing Emerging Resistance in Gram Negatives

Thursday, 12:30 – 2 p.m. Poster Hall CD

Speakers:

- 846** **Group Leader**
 MARY K. HAYDEN, MD, FIDSA, FSHEA;
 Rush University Medical Center, Chicago, IL

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Pediatric ID/Trainee

80. Poster Discussion Round

Big Beasts

Thursday, 12:30 – 2 p.m. Poster Hall CD

Speakers:

- 847** **Group Leader**
 SANDRA NELSON, MD, FIDSA;
 Massachusetts General Hospital, Boston, MA

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Global ID/Pediatric ID/Trainee

81. Poster Discussion Round

Global Health

Thursday, 12:30 – 2 p.m. Poster Hall CD

Speakers:

- 848** **Group Leader**
 KEITH KLUGMAN, MD, PHD, FIDSA; Bill &
 Melinda Gates Foundation, Seattle, WA

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/HIV-STD-TB/Pediatric ID/Trainee

82. Poster Discussion Round

HIV Metabolic Diseases

Thursday, 12:30 – 2 p.m. Poster Hall CD

Speakers:

- 849** **Group Leader**
 JUDITH CURRIER, MD, MSC, MPH, FIDSA;
 University of California, Los Angeles, Los Angeles, CA

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Pediatric ID/Trainee

83. Poster Discussion Round

Stewardship

Thursday, 12:30 – 2 p.m. Poster Hall CD

Speakers:

- 850** **Group Leader**
 ARJUN SRINIVASAN, MD, FSHEA; Centers
 for Disease Control and Prevention, Atlanta, GA

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Global ID/HIV-STD-TB/Pediatric ID/Trainee

84. Interactive Session

Diagnostic Clinical Cases

Thursday, 2 – 3:30 p.m. 06CF

Objectives: At the conclusion of this session, participants will be able to:

- identify the etiology of challenging infectious disease clinical cases
- describe diagnostic testing strategies for challenging infectious disease clinical cases
- explain the diagnostic test results for the diagnosis of infectious disease clinical cases



Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists.

Moderators:

GARY PROCOP, MD, FIDSA; Cleveland Clinic, Cleveland, OH
THOMAS KIRN, MD, PHD; Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

Panelists:

FERRIC C. FANG, MD; University of Washington, Seattle, WA
KIM HANSON, MD, MHS; University of Utah School of Medicine, Salt Lake City, UT
L. BARTH RELLER, MD, FIDSA; Duke University Medical Center, Durham, NC
VIRGINIA PIERCE, MD; Massachusetts General Hospital, Boston, MA



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-249-L01-P

Adult ID/Global ID/Trainee

85. Symposium

A Case Based Approach to Guidelines: Meningitis, Encephalitis, and Nervous System Lyme Disease

Thursday, 2 – 3:30 p.m.

06AB

Objectives: At the end of the presentation the participant will be able to:

- describe the diagnostic approach, outlined in the guidelines, to patients with meningitis, encephalitis and nervous system Lyme disease.
- describe how to manage patients with meningitis, encephalitis and nervous system Lyme disease.
- list the key features in the guidelines for meningitis, encephalitis and nervous system Lyme disease.

Intended Audience: academicians, clinicians, fellows, infectious diseases physicians, medical students and residents, pharmacists, scientists.

Moderators:

JEAN-PAUL STAHL, MD, PHD; Maladies Infectieuses et Tropicales, Grenoble, France
ADARSH BHIMRAJ, MD, FIDSA; Cleveland Clinic, Cleveland, OH

Speakers:

- 851 2 p.m. **A Case Based Approach to Community Acquired Meningitis Guidelines**
DIEDERIK VAN DE BEEK, MD, PHD; Academic Medical Center, Amsterdam, Netherlands
- 852 2:25 p.m. **A Case Based Approach to Encephalitis Guidelines**

CHRISTINA MARRA, MD; University of Washington, Seattle, WA

- 853 2:50 p.m. **A Case Based Approach to Nervous System Lyme disease**

JOHN HALPERIN, MD, FIDSA; Overlook Medical Center, Summit, NJ

3:15 p.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-248-L01-P

Adult ID/Global ID/Investigative ID/Pediatric ID/Trainee

86. Symposium

Global Fungal Infections

Co-organized with the National Institute of Allergy and Infectious Diseases

Thursday, 2 – 3:30 p.m.

15AB

Objectives: At the conclusion of this session, participants will be able to:

- review the global impact of systemic fungal infections
- describe the challenges in diagnosis and management of invasive fungal infections in resource-limited settings
- recognize the impact of cryptococcal infection on mortality in HIV disease

Intended Audience: academicians, clinicians, epidemiologists, fellows, HIV clinicians, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, pharmacists, public health practitioners, researchers.

Moderators:

WILLIAM POWDERLY, MD, FIDSA; Washington University School of Medicine, Saint Louis, MO
MICHAEL LIONAKIS, MD, SCD, FIDSA; NIH, Bethesda, MD

Speakers:

- 854 2 p.m. **The Global Impact of Mold Infections**
DAVID DENNING, MD, FIDSA; University Hospital of South Manchester, Manchester, United Kingdom
- 855 2:25 p.m. **Endemic Mycoses in Latin America**
BEATRIZ L. GOMEZ, PHD; Universidad del Rosario, Medellín, Colombia
- 856 2:50 p.m. **The Worldwide Burden and Challenge of Cryptococcal Infection**
DAVID BOULWARE, MD, MPH; University of Minnesota, Minneapolis, MN
- 3:15 p.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-250-L01-P

87. Symposium

Hot Topics in Pediatric Infectious Diseases

Thursday, 2 – 3:30 p.m.

11AB

Objectives: At the conclusion of this session learners will be able to:

- discuss the year's important clinical advances and biomedical discoveries that have the potential to impact clinical care
- describe the content of new scientific findings from experts in the field
- discuss strategies to apply new data to further discovery or clinical practices

Intended Audience: academicians, clinicians, fellows, HIV specialists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, medical students and residents, microbiologists, pharmacists, public health practitioners, researchers, scientists.

Moderators:

JAMES CONWAY, MD; University of Wisconsin School of Medicine and Public Health, Madison, WI
TINA TAN, MD, FIDSA; Northwestern Feinberg School of Medicine, Chicago, IL

Panelists:

ANN-CHRISTINE NYQUIST, MD, MSPH, FPIDS; University of Colorado School of Medicine, Aurora, CO
SAUL HYMES, MD; Stony Brook Children's Hospital, Stony Brook, NY
ELIZABETH BARNETT, MD; Boston University School of Medicine, Boston, MA
DOUGLAS SWANSON, MD; Children's Mercy Hospital, Kansas City, MO



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-251-L01-P

Adult ID/Epidemiology and Infection Control/Investigative
ID/Pediatric ID/Trainee

88. Symposium

New Antibiotics: What's in the Pipeline

Thursday, 2 – 3:30 p.m.

20ABCD

Objectives: At the conclusion of this session, participants will be able to:

- familiarize infectious disease clinicians with the clinical, Microbiologyological, and pharmacological data of new antibiotics that are likely to be approved for clinical use
- provide evidence-based data to support development of new antibiotics against multidrug-resistant microorganisms
- explain the mechanism of action and strategies to overcome resistance that will have clinical application if the short term

Intended Audience: academicians, clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious

diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, pharmacists, researchers, scientists.

Moderators:

CESAR ARIAS, MD, PHD, FIDSA; University of Texas Medical School at Houston, Houston, TX
ROBERT A. BONOMO, MD, FIDSA; Case Western Reserve University, Cleveland, OH
DAVID ANDES, MD, FIDSA; University of Wisconsin School of Medicine and Public Health, Madison, WI
JOHN MOHR, PHARM D; Medical Affairs Strategic Solutions, LLC, Acton, MA

Speakers:

- 857 2 p.m. Delafloxacin**
SUE K. CAMMARATA, MD; Melinta Therapeutics, Lincolnshire, IL
- 858 2:09 p.m. Fosfomycin for Injection**
EVELYN J. ELLIS-GROSSE, PhD.; Zavante Therapeutics, Inc., San Diego, CA
- 859 2:18 p.m. Cefiderocol**
ROGER ECHOLS, MD, FIDSA; ID3C, Easton, CT
- 860 2:27 p.m. Plazomicin**
IAN FRIEDLAND, MD; Achaogen, Inc., South San Francisco, CA
- 861 2:36 p.m. Omadacycline**
PAUL MCGOVERN, MD; Paratek Pharmaceuticals, King of Prussia, PA
- 862 2:45 p.m. Lefamulin**
STEVEN P. GELONE, PHARM D; Nabriva Therapeutics AG, King of Prussia, PA
- 863 2:54 p.m. Iclaprim**
DAVID HUANG, MD, PHD, FIDSA; Motif BioSciences, New York, NY
- 864 3:03 p.m. Meropenem-vaborbactam**
MICHAEL DUDLEY, PHARM D, FIDSA; Mpex Pharmaceuticals, San Diego, CA
- 865 3:12 p.m. Imipenem-Relebactam**
AMANDA PASCHKE, MD, MSCE; Merck & Co., Inc., Kenilworth, NJ
- 866 3:21 p.m. Eravacycline**
PATRICK HORN, MD, PHD; Tetrphase Pharmaceuticals, Watertown, MA

No CME credit is offered for this session.

No CPE credit is offered for this session.

— Adult ID/Investigative ID/Pediatric ID/Trainee —

89. Symposium

New Discoveries in an Old Field: Bacterial Toxins

Thursday, 2 – 3:30 p.m.

17AB

Objectives: At the conclusion of this session, participants will be able to:

- discuss the function of toxins produced by *Salmonella typhi*, *Clostridium difficile*, and *Candida albicans* in human infection.

Intended Audience: academicians, clinicians, infectious diseases physicians, investigators, microbiologists, pharmacists, researchers, scientists.

Moderator:

MARCIA GOLDBERG, MD, FIDSA; Massachusetts General Hospital and Harvard Medical School, Cambridge, MA


Speakers:


867 2 p.m. *Salmonella typhi* Toxin and Human Adaptation
JORGE GALAN, PHD; Yale University, New Haven, CT

868 2:25 p.m. *Clostridium difficile* Toxins, Structure, and Function
D. BORDEN LACY, PHD; Vanderbilt University Medical Center, Nashville, TN

869 2:50 p.m. Candidalysin is a Fungal Peptide Toxin Critical for Mucosal Infection and Immune Activation
JULIAN NAGLIK, PHD; King's College London, London, United Kingdom

3:15 p.m. **Q&A**

 Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-252-L01-P

Adult ID/Epidemiology and Infection Control/Trainee

90. Symposium

Playing the Long Game: Infection Prevention in Long Term Care

Thursday, 2 – 3:30 p.m. 16AB

Objectives: At the conclusion of this session, participants will be able to:

- discuss UTI prevention, testing and treatment in the long-term care setting
- describe recent advances in the recognition and prevention of spread of multidrug-resistant organisms (MDROs) in the long-term care setting
- explain the recognition and prevention of spread of *Clostridium difficile* infection in the long-term care setting

Intended Audience: clinicians, fellows, hospital epidemiologists, infection preventionists, infectious diseases physicians, pharmacists, public health practitioners, researchers.

Moderators:

JON P. FURUNO, PHD; Oregon State University, Portland, OR
LONA MODY, MD, MSC; University of Michigan, Ann Arbor, MI


Speakers:


870 2 p.m. UTI Prevention: Focused Testing and Treatment
MANISHA JUTHANI-MEHTA, MD, FIDSA, FSHEA; Yale School of Medicine, New Haven, CT

871 2:25 p.m. MDRO Recognition and Prevention of Spread
MARY-CLAIRE ROGHMANN, MD, MS, FIDSA, FSHEA; University of Maryland School of Medicine, Baltimore, MD

872 2:50 p.m. CDI Recognition and Prevention of Spread
TEENA CHOPRA, MD, MPH, FIDSA; Detroit Medical Center Detroit, MI

3:15 p.m. **Q&A**

 Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*

 ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-253-L01-P

Adult ID/Epidemiology and Infection Control/Investigative ID/Pediatric ID

91. Symposium

Preventing and Managing Endoscope-Associated Outbreaks and Infection Control Breaches

Thursday, 2 – 3:30 p.m. 14AB

Objectives: At the conclusion of this session, participants will be able to:

- review current guidance & strategies to reduce risk of infectious disease transmission from endoscope-related infection control breaches
- understand the key elements of risk assessment and look-back investigations in response to endoscope-related infection control breaches
- describe ethical and practical considerations for patient and public notification in response to infection control breaches

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, nurses, pharmacists, public health practitioners.

Moderators:

JEFF DUCHIN, MD, FIDSA; University of Washington, Seattle, Seattle, WA
JOSEPH PERZ, DRPH; Centers for Disease Control and Prevention, Atlanta, GA


Speakers:

873 2 p.m. HICPAC Update and Prevention of ERCP-Related CRE/MDRO
MICHAEL KOCHMAN, MD; University of Pennsylvania Health System, Philadelphia, PA

874 2:25 p.m. Infection Control Breaches and Outbreaks: How to Assess Risk and Conduct Look-Back Investigations
ISAAC BENOWITZ, MD; Centers for Disease Control and Prevention, Atlanta, GA

875 2:50 p.m. Patient and Public Notification After Infection Control Breaches and Outbreaks: Ethical and Practical Considerations
THOMAS GALLAGHER, MD; University of Washington, Seattle, WA

3:15 p.m. **Q&A**

 Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

92. Symposium

When Transplantation Goes Viral: Mitigating CMV, Herpes, and HIV in Transplantation

Thursday, 2 – 3:30 p.m.

06DE

Objectives: At the conclusion of this session, participants will be able to:

- review the strategies for the diagnosis, prevention and treatment of cytomegalovirus infection after transplantation
- describe the impact of herpes virus infections in transplantation.
- discuss the current state of transplantation in HIV-infected persons.

Intended Audience: academicians, clinicians, fellows, healthcare workers, HIV clinicians, HIV specialists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, researchers, scientists.

Moderators:

RAYMUND R. RAZONABLE, MD, FIDSA; Mayo Clinic, Rochester, MN
RACHEL MILLER, MD, FIDSA; Duke University, Durham, NC

Speakers:

876 2 p.m. Updates in the Management of Cytomegalovirus in Transplantation
FRANCISCO M. MARTY, MD, FIDSA; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA

877 2:25 p.m. When Other Herpesviruses Strike!
DANIELLE ZERR, MD, MPH, FPIDS; University of Washington, Seattle, WA

878 2:50 p.m. Transplantation in HIV-Infected Persons
EMILY BLUMBERG, MD, FIDSA; University of Pennsylvania Health System, Philadelphia, PA

3:15 p.m. Q&A



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-254-L01-P

93. Oral Abstract Session

Preventing and Identifying New HIV Infections

Thursday, 2 – 3:30 p.m.

07AB

Moderators:

JEANNE MARRAZZO, MD, MPH, FIDSA, University of Alabama at Birmingham School of Medicine, Birmingham, AL
CHARLOTTE-PAIGE ROLLE, MD, MPH; Emory University Rollins School of Public Health, Atlanta, GA

Speakers:

879 2 p.m. Medical Students Have Limited Awareness, Knowledge, Beliefs, and Experiences of Pre-exposure Prophylaxis (PrEP) for HIV Prevention

BRANDON IMP, MD, Kaiser Permanente Northern California, San Francisco, CA

880 2:15 p.m. Characterization of New HIV Infections among Adults ≥45 Years — New York City, North Carolina, San Francisco, 2011–2013.

MARY EVANS, MD, MPH, Centers for Disease Control and Prevention, Atlanta, GA

881 2:30 p.m. HIV Transmission Rates and Factors Associated with Recent HIV Infection: Results from the Ndhiwa HIV Impact Assessment, South Nyanza, Kenya, 2012

ELFRIEDE AGYEMANG, MD, MPH, Centers for Disease Control and Prevention, Atlanta, GA

882 2:45 p.m. Recent HIV Risk Behavior and Partnership Type Predict PrEP Adherence in Men who have Sex with Men

JILL BLUMENTHAL, MD, University of California, San Diego, San Diego, CA

883 3 p.m. HIV antiretroviral resistance and transmission in mother-infant pairs enrolled in a large perinatal study

NAVA YEGANEH, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA

884 3:15 p.m. Missed Opportunities to Initiate Pre-exposure Prophylaxis in South Carolina – 2013–2016

STELLA OKOYE, MD, University of South Carolina School of Medicine, Columbia, SC

No CME credit is offered for this session.

No CPE credit is offered for this session.

94. Oral Abstract Session

Respiratory Infection Diagnosis

Thursday, 2 – 3:30 p.m.

01AB

Moderators:

KEVIN MESSACAR, MD; University of Colorado School of Medicine, Aurora, CO

RUTH LYNFIELD, MD, FIDSA; Minnesota Department of Health, St. Paul, MN

Speakers:

885 2 p.m. Comparison of respiratory pathogen detections from routine hospital testing and expanded systematic testing from the Minnesota Severe Acute Respiratory Illness surveillance program, 2015–2016

ANDREA STEFFENS, MPH, Centers for Disease Control and Prevention, Atlanta, GA

886 2:15 p.m. Pneumococcal urinary antigen testing in US hospitals: underutilized and rarely acted upon.

SARAH HAESSLER, MD, Baystate Medical Center, Springfield, MA

- 887** 2:30 p.m. **Impact of Procalcitonin Guidance on the Management of Adults Hospitalized with Pneumonia**
DEREK BREMMER, PHARMD, BCPS, Allegheny Health Network, Pittsburgh, PA
- 888** 2:45 p.m. **Detection of Respiratory Pathogens in Parapneumonic Effusions by Hypothesis-free, Next-Generation Sequencing (NGS)**
KROW AMPOFO, MD, FIDSA, FPIDS., University of Utah School of Medicine, Salt Lake City, UT
- 889** 3 p.m. **Utility and challenges of a multi-pathogen diagnostic platform for characterizing public health threats of severe acute respiratory infections in six countries**
JENNIFER MILUCKY, MPH, Division of Bacterial Diseases, Centers of Disease Control and Prevention, Atlanta, GA
- 890** 3:15 p.m. **Impact of Antivirals in the Prevention of Serious Outcomes Associated with Influenza in Hospitalized Canadian Adults: A Pooled Analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN)**
ZACH SHAFFELBURG, BSC, Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, NS, Canada

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Investigative ID/Pediatric ID

95. Oral Abstract Session

Use 'em and Lose 'em: Preventing Antibiotic Overuse

Thursday, 2 – 3:30 p.m. 05AB

Moderators:

E. YOKO FURUYA, MD, MS; Columbia University Medical Center, New York, NY
USHA STIEFEL, MD; Case Western Reserve University School of Medicine, Cleveland, OH

Speakers:

- 891** 2 p.m. **Antibiotic Consumption and Antibiotic Resistance across Organisms, Drugs, and Consumer Groups**
SCOTT OLESEN, PHD, Harvard Chan School of Public Health, Boston, MA
- 892** 2:15 p.m. **Improvement of Gram Negative Susceptibility to Fluoroquinolones After Implementation of a Pre-Authorization Policy for Fluoroquinolone Use: A Decade-Long Experience**
MORGAN SCULLY, MD, UAB, Birmingham, AL

- 893** 2:30 p.m. **Inpatient plus post-discharge durations of therapy to identify antimicrobial stewardship opportunities at transitions of care**
APRIL DYER, PHARMD, MBA, MSCR, BCPS, Duke Antimicrobial Stewardship Outreach Network (DASON), Durham, NC
- 894** 2:45 p.m. **Prevent Antibiotic overUSE (PAUSE): Impact of a provider driven antibiotic-time out on antibiotic use and prescribing**
KERRI THOM, MD, MS, University of Maryland, Baltimore, Baltimore, MD
- 895** 3 p.m. **Implementing Antimicrobial Stewardship in Two Community Nepali Hospitals**
MICHAEL P VEVE, PHARMD, Henry Ford Global Health Initiative, Detroit, MI
- 896** 3:15 p.m. **The Ontario Program To Improve AntiMicrobial USE (OPTIMISE): A Descriptive Analysis of Dispensed Antibiotics**
KEVIN SCHWARTZ, MD, MSC, Public Health Ontario, Toronto, ON, Canada

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Global ID/Pediatric ID/Trainee

96. Symposium

Bone of Contention: Challenging Cases in Vertebral Osteomyelitis

Thursday, 3:45 – 5:45 p.m. 06AB

Objectives: At the end of the presentation the participant will be able to:

- describe the clinical features of vertebral osteomyelitis
- read and interpret an MRI spine in patients with suspected vertebral osteomyelitis
- describe medical and surgical management of vertebral osteomyelitis and its complications

Intended Audience: academicians, clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians, pharmacists.

Moderators:

ELIE F. BERBARI, MD, FIDSA; Mayo Clinic, Rochester, MN
MAJA BABIC, MD; Cleveland Clinic, Cleveland, OH

Panelists:

CAMELIA MARCULESCU, MD; Medical University of South Carolina, Charleston, SC
SANDRA NELSON, MD, FIDSA; Massachusetts General Hospital, Boston, MA
PAUL HUDDLESTON, MD; Mayo Clinic, Rochester, MN
CLAUS SIMPFENDORFER, MD; Cleveland Clinic, Cleveland, OH



Maximum of 2.00 hours of AMA PRA Category 1 Credit™

No CPE credit is offered for this session.

97. Named Lecture

Edward H. Kass Lecture

Thursday, 3:45 – 4:30 p.m.

20ABCD

Objectives: At the conclusion of this session, participants will be able to:

- define the One Health concept
- discuss the importance of a One Health approach to emerging microbial threats
- describe examples highlighting the value of a One Health approach

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiology.

Moderator:

WILLIAM G. POWDERLY, MD, FIDSA; Washington University in St. Louis, St. Louis, MO

Speakers:

- 897 3:45 p.m. Reflections on Emerging Microbial Threats: Relevance of the One Health Concept**
JAMES M. HUGHES, MD, FIDSA; Emory University, Atlanta, GA



Maximum of 0.75 hours of *AMA PRA Category 1 Credit™*



ACPE 0.75 knowledge-based contact hours of pharmacy CE; 0221-9999-17-255-L01-P

98. Awards Session

Awards Session

Thursday, 4:30 – 4:45 p.m.

20ABCD

Moderators:

WILLIAM POWDERLY, MD, FIDSA; Washington University School of Medicine, Saint Louis, MO
WENDY ARMSTRONG, MD, FIDSA; Emory University School of Medicine, Atlanta, GA

Awardees:

HIVMA Research Award

RAPHAEL J. LANDOVITZ, MD, MSc; David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA

IDSA Society Citation Award

WENDY ARMSTRONG, MD, FIDSA; Emory University School of Medicine, Atlanta, GA

IDSA Society Citation Award

PATRICK JOSEPH, MD, FIDSA; University of California, San Francisco, CA

IDSA Society Citation Award

DEAN L. WINSLOW, MD, FIDSA; Stanford University School of Medicine, Stanford, CA

IDSA Watanakunakorn Clinician Award

DOUGLAS OSMON, MD, FIDSA; Stanford University School of Medicine, Stanford, CA

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/HIV-STD-TB

99. Oral Abstract Session

Featured Oral Abstract

Thursday, 4:45 – 5 p.m.

20ABCD

Moderator:

WENDY ARMSTRONG, MD, FIDSA; Emory University, Atlanta, GA

Speakers:

- 898 4:45 p.m. Trends and Associations with PrEP Prescription among 602 New York City (NYC) Ambulatory Care Practices, 2014–16**
PAUL SALCUNI, MPH, New York City Department of Health and Mental Hygiene, Long Island City, NY

No CME credit is offered for this session.

No CPE credit is offered for this session.

100. Named Lecture

John F. Enders Lecture

Thursday, 5 – 5:45 p.m.

20ABCD

Objectives: At the conclusion of this session, participants will be able to:

- describe progress in effective HIV prevention interventions and lessons learned in implementation
- explain remaining gaps and challenges and the importance of choice of prevention options

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiology.

Moderator:

WENDY ARMSTRONG, MD, FIDSA; Emory University, Atlanta, GA

Speakers:

- 899 5 p.m. HIV Prevention: It's All About People, Products, and Choices**
CONNIE CELUM, MD, MPH, FIDSA; University of Washington, Seattle, WA



Maximum of 0.75 hours of *AMA PRA Category 1 Credit™*



ACPE 0.75 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-256-L01-P

Special Event

SHEA Business Meeting

Thursday, 5:45 – 6:30 p.m.

05

SARA E. COSGROVE, MD, MS, FIDSA, FSHEA; Johns Hopkins Medical Institutions, Baltimore, MD

Awardee:

SHEA Advanced Practice Infection Preventionist

KATHLEEN GASE, MPH, CIC; BJC HealthCare, St. Louis, MO

Adult ID/Epidemiology and Infection Control/Global ID/
HIV-STD-TB/Investigative ID/Pediatric ID/Trainee

101. Meet-the-Professor Session

Advancing Federal ID and HIV Priorities: Making the Case to Federal Policymakers

Marriott Marquis, Santa Rosa

Friday, 7 – 8:15 a.m.

Objectives: At the conclusion of this session, participants will be able to:

- identify opportunities for educating members of Congress and advocating for infectious disease and HIV policy priorities
- describe how to effectively communicate with members of Congress and execute successful Congressional meetings
- describe the guidelines for recipients of federal funding for research and public health programs to educate members of Congress about the importance of these programs

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiology.

Moderators:

AMANDA JEZEK; Infectious Diseases Society of America, Arlington, VA
JENNY COLLIER, JD; HIVMA's Ryan White Medical Providers Coalition, Arlington, VA

Speakers:

- 900 7 a.m. Advocacy Overview**
MELANIE THOMPSON, MD; AIDS Research Consortium of Atlanta, Atlanta, GA
- 901 7:20 a.m. Best Practices for Congressional Meetings**
MATTHEW ZAHN, MD, FIDSA; Orange County Health Care Agency, Santa Ana, CA



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Global ID/
Investigative ID/Pediatric ID/Trainee

102. Meet-the-Professor Session

Big Data in Infectious Diseases

Friday, 7 – 8:15 a.m.

02

Objectives: At the conclusion of this session, participants will be able to:

- explain how data science can help us understand the complexity that governs the development, spread and control of infectious diseases
- describe the insights that data-driven modeling approaches can provide on the interaction between pathogens and the immune system

Intended Audience: academicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, pharmacists, researchers, scientists.

Moderator:

EMILY MIRALDI, PHD; Cincinnati Children's Hospital, Cincinnati, OH

Speakers:

- 902 7 a.m. A Systems Approach to Understanding Immune Responses**
EMILY MIRALDI, PHD; Cincinnati Children's Hospital, Cincinnati, OH
- 903 7:30 a.m. Seeking Patterns in Complexity, Mining the Electronic Medical Record**
JENNA WIENS, PHD; University of Michigan, Ann Arbor, MI
- 8 a.m. Q&A**



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-257-L01-P

Adult ID/Pediatric ID/Trainee

103. Meet-the-Professor Session

Controversies in Empiric and Definitive Treatment of ESBL Infections

Friday, 7 – 8:15 a.m.

16AB

Objectives: At the conclusion of this session, participants will be able to:

- identify controversies in the treatment of ESBL infections.
- describe the evidence for active empiric therapy for ESBL infections.
- describe the evidence for what antibiotics should be used for definitive therapy when an ESBL infection has been identified.

Intended Audience: academicians, clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, pharmacists.

Moderator:

DAVID GREENBERG, MD, FIDSA; University of Texas Southwestern Medical Center, Dallas, TX

Speakers:

- 904** 7 a.m. LATANIA K. LOGAN, MD; Rush University Medical Center, Chicago, IL
- 905** 7:30 a.m. PRANITA D. TAMMA, MD, MHS; Johns Hopkins University School of Medicine, Baltimore, MD
- 8 a.m. **Q&A**



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-17-258-L01-P

Adult ID/Pediatric ID/Trainee

104. Meet-the-Professor Session**Make Learning Last in the Setting**

Co-organized with the IDSA Education Committee and the Medical Education Work Group

Friday, 7 – 8:15 a.m.

08

Objectives: At the conclusion of this session, participants will be able to:

- describe characteristics of effective lectures
- using your own talk, identify areas for improvement using the rubric provided in the session
- commit to using two new techniques to enhance your own educational sessions

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiology.

Note: Attendees should bring a copy of a slide set/presentation to the session for review and discussion.

Moderator:

BRIAN SCHWARTZ, MD; University of California, San Francisco, San Francisco, CA

Speakers:

- 906** 7 a.m. VERA LUTHER, MD, FIDSA; Wake Forest School of Medicine, Winston-Salem, NC
- 907** JENNIFER BABIK, MD, PHD; University of California, San Francisco, San Francisco, CA
- 8 a.m. **Q&A**



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-17-259-L04-P

**Adult ID/Epidemiology and Infection Control/Global ID/
Investigative ID/Pediatric ID/Trainee**
105. Meet-the-Professor Session**Malaria: What's New?**

Friday, 7 – 8:15 a.m.

05AB

Objectives: At the conclusion of this session, participants will be able to:

- review the burden of malaria in pregnancy and infants
- describe maternal and fetal immunology and how that affects outcomes in malaria infection
- identify the difficulties in developing a malaria vaccine
- discuss progress towards a malaria vaccine.

Intended Audience: academicians, epidemiologists, fellows, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists.

Moderator:

WESLEY VAN VOORHIS, MD, PHD, FIDSA; University of Washington, Seattle, WA

Speakers:

- 908** 7 a.m. **Maternal-Fetal Malaria Immunology**
MARGARET FEENEY, MD, MSC; University of California, San Francisco, San Francisco, CA
- 909** 7:30 a.m. **Progress Toward a Malaria Vaccine**
KIRSTEN LYKE, MD; University of Maryland School of Medicine, Baltimore, MD
- 8 a.m. **Q&A**



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-17-260-L01-P

**Adult ID/Epidemiology and Infection Control/Global ID/
HIV-STD-TB/Investigative ID/Pediatric ID**
106. Meet-the-Professor Session**Mid-Career Challenges and Opportunities**

Friday, 7 – 8:15 a.m.

11AB

Objectives: At the conclusion of this session, participants will be able to:

- list at least 3 challenges experienced in Mid-Career.
- list opportunities that Mid-Career physicians could take advantage of.

Intended Audience: academicians, clinicians, epidemiologists, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, researchers, scientists, vaccinologists.

Moderator:

MARSHA ANDERSON, MD, FIDSA; University of Colorado School of Medicine, Aurora, CO

Speakers:

- 910** 7 a.m. VICTORIA FRASER, MD, FIDSA, FSHEA; Washington University School of Medicine, Saint Louis, MO
- 911** 7:30 a.m. GERARD RABALAIS, MD, MHA; University of Louisville, Louisville, KY
- 8 a.m. **Q&A**



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Investigative ID/Pediatric ID

107. Meet-the-Professor Session

Pipeline 2.0

Friday, 7 – 8:15 a.m.

06DE

Intended Audience: academicians, clinicians, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, microbiologists, pharmacists, researchers, scientists, vaccinologists.

Moderators:

CESAR ARIAS, MD, PHD, FIDSA; University of Texas McGovern School of Medicine, Houston, TX
ROBERT A. BONOMO, MD, FIDSA; Case Western Reserve University, Cleveland, OH
DAVID ANDES, MD, FIDSA; University of Wisconsin School of Medicine and Public Health, Madison, WI
JOHN MOHR, PHARMD; Medical Affairs Strategic Solutions, LLC, Acton, MA

Panelists:

SUE CAMMARATA, MD; Melinta Therapeutics, Lincolnshire, IL
EVELYN J. ELLIS-GROSSE, PHD; Zavante Therapeutics, Inc., San Diego, CA
ROGER ECHOLS, MD, FIDSA; ID3C, Easton, CT
IAN FRIEDLAND, MD; Achaogen, Inc., South San Francisco, CA
PAUL MCGOVERN, MD; Paratek Pharmaceuticals, King of Prussia, PA
STEVEN P. GELONE, PHARMD; Nabriva Therapeutics AG, King of Prussia, PA
DAVID HUANG, MD, PHD, FIDSA; Motif BioSciences, New York, NY
MICHAEL DUDLEY, PHARMD, FIDSA; The Medicines Company, San Diego, CA
AMANDA PASCHKE; Merck & Co, Inc.; Kenilworth, NJ
PATRICK HORN, MD, PHD; Tetrphase Pharmaceuticals, Watertown, MA

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Pediatric ID/Trainee

108. Meet-the-Professor Session

Rapid Fire: Questions for the Transplant ID Expert

Friday, 7 – 8:15 a.m.

17AB

Objectives: At the conclusion of this session, participants will be able to:

- explain and answer questions related to infections after transplantation.
- describe insights into the management of infections after transplantation.
- discuss nuances in the practice of transplant infectious diseases.

Intended Audience: academicians, clinicians, fellows, health-care workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, researchers, scientists.

Moderators:

RAYMUND R. RAZONABLE, MD, FIDSA; Mayo Clinic, Rochester, MN
RACHEL MILLER, MD, FIDSA; Duke University, Durham, NC

Speakers:

- 912** 7 a.m. MARIAN MICHAELS, MD, MPH; Children's Hospital of Pittsburgh, Pittsburgh, PA
- 913** 7:30 a.m. AJIT LIMAYE, MD, FIDSA; University of Washington, Seattle, WA
- 8 a.m. **Q&A**



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-17-261-L01-P

Adult ID/Epidemiology and Infection Control/Investigative ID/Pediatric ID/Trainee

109. Meet-the-Professor Session

Second Generation B-Lactamase Inhibitor Combinations: Promise and Peril

Friday, 7 – 8:15 a.m.

15AB

Objectives: At the conclusion of this session, participants will be able to:

- discuss the clinical impact of emergence of resistance against newer B-lactam-B-lactamase inhibitor combination
- discuss the clinical implications of therapy and resistance against newer B-lactam-B-lactamase inhibitor combinations
- review the epidemiology and mechanisms of resistance against newer B-lactam-B-lactamase inhibitor combinations

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, scientists.

Moderators:

CESAR ARIAS, MD, PHD, FIDSA; University of Texas, McGovern School of Medicine, Houston, TX
ROBERT A. BONOMO, MD, FIDSA; Case Western Reserve University, Cleveland, OH
DAVID ANDES, MD, FIDSA; University of Wisconsin School of Medicine and Public Health, Madison, WI

Speakers:

- 914** 7 a.m. **Resistance to Ceftolozane/Tazobactam: Mechanisms, Epidemiology, and Management**
JOSE M. MUNITA, MD; Clinica Alemana Universidad del Desarrollo, Santiago, Chile
- 915** 7:30 a.m. **Resistance to Ceftazidime/Avibactam: Mechanisms, Epidemiology, and Management**
YOHEI DOI, MD, PHD; University of Pittsburgh Medical Center, Pittsburgh, PA
- 8 a.m. **Q&A**



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-17-262-L01-P

Adult ID/Epidemiology and Infection Control

110. Meet-the-Professor Session

Setting up an Antimicrobial Stewardship Program for a Long-Term Care Facility: Practical Pointers from the Front Line

Friday, 7 – 8:15 a.m. 01AB

Objectives: At the conclusion of this session, participants will be able to:

- discuss practical pointers for establishing an antimicrobial stewardship program in a long-term care facility and a long-term acute care hospital.
- discuss barriers to implementation in these settings and ways to overcome them.

Intended Audience: clinicians, fellows, infection preventionists, infectious diseases pediatricians, pharmacists, public health practitioners, researchers.

Moderator:

KAVITA TRIVEDI, MD; Trivedi Consults, LLC, Berkeley, CA

Speakers:

- 916** 7 a.m. **Establishing an Antimicrobial Stewardship Program in a Nursing Home**
JOE BOERO, MD; Park Manor Nursing Home, Ltd., Park Falls, WI
- 917** 7:30 a.m. **Establishing an Antimicrobial Stewardship Program in the Long-Term Acute Care Hospital**
SHIRA DORON, MD, MS, FIDSA; Tufts Medical Center, Boston, MA
- 8 a.m. **Q&A**



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-17-263-L01-P

Adult ID/Epidemiology and Infection Control/Pediatric ID/Trainee

111. Meet-the-Professor Session

The ID Physician New to Infection Prevention and/or Antimicrobial Stewardship

Friday, 7 – 8:15 a.m.

14AB

Objectives: At the conclusion of this session, participants will be able to:

- describe the role of leaders in hospital-based infection prevention and antimicrobial stewardship
- identify strategies to incorporate infection prevention and antimicrobial stewardship into the daily role of an infectious diseases physician
- list resources available to healthcare providers new to infection prevention and/or antimicrobial stewardship.

Intended Audience: clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases physicians, pharmacists, public health practitioners.

Moderator:

KAVITA TRIVEDI, MD; Trivedi Consults, LLC, Berkeley, CA

Speakers:

- 918** 7 a.m. **The ID Physician New to Infection Prevention**
SARAH HAESSLER, MD; Baystate Medical Center, Springfield, MA
- 919** 7:30 a.m. **The ID Physician New to Antimicrobial Stewardship**
FRANCESCA LEE, MD; University of Texas Southwestern Medical Center, Dallas, TX
- 8 a.m. **Q&A**



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-17-264-L01-P

Adult ID/HIV-STD-TB

112. Interactive Session

Challenging HIV Cases

Friday, 8:30 – 10 a.m.

20ABCD

Objectives: At the conclusion of this session, participants will be able to:

- identify complicating factors in HIV-infected patients
- apply strategies to address treatment complications in HIV-infected patients
- choose between different treatment strategies or managing HIV-infected patients

Intended Audience: clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases pediatricians, pharmacists, public health practitioners.

Moderators:

PAUL SAX, MD, FIDSA; Brigham and Women's Hospital, Boston, MA
CHARLENE FLASH, MD, MPH; Baylor College of Medicine, Houston, TX

Panelists:

RICHARD HAMILL, MD, FIDSA; Baylor College of Medicine, Houston, TX
TURNER OVERTON, MD; University of Alabama at Birmingham, Birmingham, AL
CHARLES HICKS, MD; Duke University Medical Center, Chapel Hill, NC
SHIREESHA DHANIREDDY, MD; University of Washington, Seattle, WA



Maximum of 1.50 hours of *AMA PRA Category 1 Credit*[™]



ACPE 1.5 application-based contact hours of pharmacy CE; 0221-9999-17-265-L02-P

Adult ID/Epidemiology and Infection Control/Pediatric ID/Trainee

113. Symposium

Big Beasts of Healthcare Epidemiology

Friday, 8:30 – 10 a.m.

06DE

Objectives: At the conclusion of this session, participants will be able to:

- explain the key elements for a CAUTI prevention program
- describe the key elements for a CLABSI prevention program
- describe key elements for a CDI prevention program

Intended Audience: clinicians, epidemiologists, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, public health practitioners.

Moderators:

KRISTINA BRYANT, MD, FPIDS; University of Louisville School of Medicine, Louisville, KY
BERNARD CAMINS, MD, MSC; University of Alabama at Birmingham, Birmingham, AL

Speakers:

920 8:30 a.m. CLABSI Prevention: Where Do We Go from Here?
DAVID WARREN, MD, MPH, FIDSA; Washington University in St Louis, St Louis, MO

921 8:55 a.m. CAUTI Prevention: Still Can't Get No Respect
JENNIFER MEDDINGS, MD; University of Michigan, Ann Arbor, MI

922 9:20 a.m. CDI: Focus on Prevention
ERIK R. DUBBERKE, MD, MSPH, FIDSA; Washington University, St Louis, MO

9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit*[™]

No CPE credit is offered for this session.

Adult ID/Pediatric ID

114. Symposium

CMV: Pathogenicity Not Limited to Congenital and Transplant Infections

Friday, 8:30 – 10 a.m.

17AB

Objectives: At the conclusion of this session, participants will be able to:

- describe how novel drugs and vaccines in development might be evaluated for their ability to control the excess mortality associated with CMV
- identify future treatment goals for CMV infection in non-immunocompromised patients admitted to intensive care
- describe strategies to identify the contribution of CMV to immunosenescence

Intended Audience: academicians, clinicians, epidemiologists, fellows, infectious diseases physicians, investigators, researchers, scientists, vaccinologists.

Moderators:

PAUL GRIFFITHS, MD, DSC; University College London, London, United Kingdom
MICHAEL BOECKH, MD, FIDSA; Fred Hutchinson Cancer Research Center, Seattle, WA

Speakers:

923 8:30 a.m. CMV in ICU patients

AJIT LIMAYE, MD, FIDSA; University of Washington, Seattle, WA

924 8:55 a.m. CMV and Immunosenescence

GRAHAM PAWELEC, PHD; University of Tübingen Center for Medical Research, Tübingen, Germany

925 9:20 a.m. CMV Affects Mortality in the General Public
AMANDA SIMANEK, PHD, MPH; University of Wisconsin-Milwaukee, Milwaukee, WI

9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit*[™]



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-266-L01-P

Adult ID/Pediatric ID/Trainee

115. Symposium

Hot Topics in Medical Education

Co-organized with the IDSA Education Committee and the Medical Education Work Group

Friday, 8:30 – 10 a.m.

11AB

Objectives: At the conclusion of this session, the participant will be able to:

- compare the characteristics and preferred learning styles of millennial and post-millennial learners from those of Generation X and preceding generations
- discuss ways in which you can incorporate a preferred learning modality of millennials and post-millennials – team-based learning – into your teaching
- identify three strategies for more effective delivery of information to millennial and post-millennial learners

- define unconscious bias and ways that it can harm patients and inhibit an inclusive workplace
- describe three successful strategies to address institutional biases
- list three techniques to improve the learning climate in health professions education

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, hospital administrators, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers.

Moderators:

JOSHUA NOSANCHUK, MD, FIDSA; Albert Einstein College of Medicine, Bronx, NY
BRIAN SCHWARTZ, MD; University of California, San Francisco, San Francisco, CA

Speakers:

- 926** 8:30 a.m. **Effectively Educating the Millennial Learner and Beyond**
RICHARD SCHWARTZSTEIN, MD; Harvard Medical School, Boston, MA
- 927** 8:55 a.m. **Recognizing Unconscious Bias**
DENISE DAVIS, MD; University of California, San Francisco, San Francisco, CA
- 928** 9:20 a.m. **Appreciating the Importance of the Learning Climate**
JOHN DAVIS, PHD, MD, FIDSA; University of California San Francisco School of Medicine, San Francisco, CA

9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-267-L04-P

Adult ID/Epidemiology and Infection Control/Investigative ID/Pediatric ID/Trainee

116. Symposium

Non-Traditional Approaches for Bad Bugs

Friday, 8:30 – 10 a.m.

14AB

Objectives: At the conclusion of this session, participants will be able to:

- review current approaches that involves the role and influence of the gut microbiome in antibiotic therapy in patients undergoing bone marrow transplant
- evaluate novel anti-toxin strategies against infections caused by *Staphylococcus aureus*
- discuss novel concepts in cell wall metabolism and the identification of new targets that could be explored therapeutically.

Intended Audience: academicians, clinicians, fellows, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, pharmacists, researchers, scientists.

Moderators:

ROBERT A. BONOMO, MD, FIDSA; Case Western Reserve University, Cleveland, OH

DAVID ANDES, MD, FIDSA; University of Wisconsin School of Medicine and Public Health, Madison, WI
CESAR ARIAS, MD, PHD, FIDSA; University of Texas McGovern School of Medicine, Houston, TX

Speakers:

- 929** 8:30 a.m. **Microbiome and Antibiotics in Bone Marrow Transplants**
YING TAUR, MD, MPH; Memorial Sloan Kettering Cancer Center, New York, NY
- 930** 8:55 a.m. **Anti-Toxin Therapies Against *S. aureus***
VICTOR TORRES, PHD; New York University School of Medicine, New York, NY
- 931** 9:20 a.m. **New Paradigms in Cell Wall Synthesis**
THOMAS BERNHARDT, PHD; Harvard Medical School, Boston, MA

9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-268-L01-P

Adult ID/Epidemiology and Infection Control/Investigative ID/Pediatric ID

117. Symposium

Prevention and Management of Legionnaire's Disease: What's New?

Friday, 8:30 – 10 a.m.

15AB

Objectives: At the conclusion of this session, participants will be able to:

- review current guidance and strategies for detection, investigation and response to *Legionella* cases and outbreaks
- describe the key elements of an environmental risk assessment and *Legionella* control plan
- describe the special consideration related to *Legionella* infection and outbreak response in immunocompromised patients

Intended Audience: clinicians, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases physicians, microbiologists, pharmacists, public health practitioners, researchers.

Moderators:

JEFF DUCHIN, MD, FIDSA; University of Washington, Seattle, Seattle, WA
CYNTHIA WHITNEY, MD, MPH, FIDSA; Centers for Disease Control and Prevention, Atlanta, GA

Speakers:

- 932** 8:30 a.m. **Update on Strategies for Nosocomial Legionnaire's Disease Prevention and Response: What's New?**
LAURA COOLEY, MD, MPH; Centers for Disease Control and Prevention, Atlanta, GA
- 933** 8:55 a.m. **Investigation and Mitigation of Environmental Sources in Healthcare-Associated *Legionella* Outbreaks**
LINDA DICKEY, RN, MPH, CIC; Epidemiology and Infection Prevention, University of California Irvine Medical Center, Orange, CA

- 934 9:20 a.m. **Legionella Infections in Immunocompromised Patients: Clinical and Outbreak-Related Considerations**
STEVEN PERGAM, MD, MPH, FIDSA;
University of Washington, Seattle, WA
- 9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-269-L01-P

Adult ID

118. Symposium

Questions in Bacteremia

Friday, 8:30 – 10 a.m.

06CF

Objectives: At the conclusion of this session, participants will be able to:

- explain the role of source control in the management of bacteremia
- discuss the impact of antibacterial resistance patterns on patients outcomes after bacteremia
- describe the role of combination therapy in the management of bacteremia

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, microbiologists, nurses, pharmacists, researchers, scientists.

Moderators:

DAVID VAN DUIN, MD, PHD; University of North Carolina, Chapel Hill, NC
FEDERICO PEREZ, MD; Louis Stokes Cleveland VA Medical Center, Cleveland, OH

Speakers:

- 935 8:30 a.m. **Role of Source Control in Bacteremia: What is the Data?**
BELINDA OSTROWSKY, MD, MPH, FIDSA,
FSHEA; Montefiore Medical Center, Bronx, NY
- 936 8:55 a.m. **Antibacterial Resistance Patterns and Outcomes after Bacteremia: Does it Really Matter?**
BRAD SPELLBERG, MD, FIDSA; LAC + USC
Medical Center, Los Angeles, CA
- 937 9:20 a.m. **Combination Therapy in Bacteremia: For Which Bugs and With Which Drugs?**
JESÚS RODRÍGUEZ-BAÑO, MD, PHD;
Hospital Universitario Virgen Macarena,
Sevilla, Spain
- 9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-270-L01-P

Adult ID/Global ID/Pediatric ID/Trainee

119. Symposium

The Pediatric Microbiome

Friday, 8:30 – 10 a.m.

16AB

Objectives: At the conclusion of this session, participants will be able to:

- describe the role of the airway microbiome in cystic fibrosis
- explain how surgery influences infection processes in the human gut
- review what a pathobiome is and how can it influence sepsis progression
- discuss the routes by which the microbiome can influence tumorigenesis
- discuss the role of early life events in the developing microbiome

Intended Audience: academicians, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, pharmacists, researchers, scientists.

Moderators:

ARCHANA CHATTERJEE, MD, PHD, FIDSA, FPIDS;
University of South Dakota Sanford School of Medicine, Sioux Falls, SD
VINCENT B. YOUNG, MD, PHD, FIDSA; The University of Michigan, Ann Arbor, MI

Speakers:

- 938 8:30 a.m. **The Developing Infant Microbiome**
SE JIN SONG, PHD; University of California at San Diego, La Jolla, CA
- 939 8:55 a.m. **Microbiome in Cancer and Surgery: A New Perspective**
JACK GILBERT, PHD; Argonne National Laboratory, Argonne, IL
- 940 9:20 a.m. **The Airway Microbiome in Cystic Fibrosis**
JOHN LIPUMA, MD, PHD, FIDSA; University of Michigan, Ann Arbor, MI
- 9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-271-L01-P

Adult ID/HIV-STD-TB

120. Symposium

Viral Hepatitis

Friday, 8:30 – 10 a.m.

06AB

Objectives: At the conclusion of this session, participants will be able to:

- evaluate new treatment options for HCV and for HBV
- assess appropriate follow up and monitoring for patients treated for HCV
- describe how to manage patients who fail on first line HCV treatment options

Intended Audience: clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, members-in-training, nurses, pharmacists, public health practitioners.

Moderators:

ERIC DAAR, MD; Harbor-UCLA Medical Center, Torrance, CA
DAVID L. WYLES, MD; Denver Health, Denver, CO

Speakers:

- 941** 8:30 a.m. **HCV and HBV Treatment Updates 2017**
SUSANNA NAGGIE, MD, FIDSA; Duke University Medical Center, Durham, NC
- 942** 8:55 a.m. **Post HCV Treatment Follow-Up and Reinfection**
MARK SULKOWSKI, MD, FIDSA; Johns Hopkins University School of Medicine, Baltimore, MD
- 943** 9:20 a.m. **Management of First Line HCV Treatment Failures**
ARTHUR KIM, MD, FIDSA; Massachusetts General Hospital, Boston, MA
- 9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-272-L01-P

— Adult ID/Global ID/Investigative ID/Pediatric ID —

121. Oral Abstract Session

Emerging Paradigms: Pediatric Viral Infections

Friday, 8:30 – 10 a.m. 01AB

Moderators:

DAVID W. KIMBERLIN, MD, FIDSA, FPIDS; University of Alabama at Birmingham, Birmingham, AL
NATASHA B. HALASA, MD, MPH, FPIDS; Vanderbilt University School of Medicine, Nashville, TN

Speakers:

- 944** 8:30 a.m. **Perinatal Case Fatality Rate Related to Congenital Zika Syndrome in Brazil: a Cross-Sectional Study**
NILSON N. MENDES NETO, MS, University of California, Davis, Davis, CA
- 945** 8:45 a.m. **Fetal and Postnatal Brain Imaging for the Detection of ZIKV Encephalopathy in the Fetus/Newborn**
SARAH MULKEY, MD, PHD, Children's National Health System, Washington, DC
- 946** 9 a.m. **Maternal Immunization with a Single-Cycle Herpes Simplex Virus (HSV) Candidate Vaccine, ΔgD-2, Protects Neonatal Mice from Lethal Viral Challenge**
CAROL KAO, MD, Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY

- 947** 9:15 a.m. **Blood Viral Load (VL) Not Clinically Meaningful in Symptomatic Congenital Cytomegalovirus (CMV) Infection**
CONCETTA MARSICO, MD, University of Bologna, Bologna, Italy
- 948** 9:30 a.m. **Incidence of UL97 Resistance Mutations in Infants with Congenital Cytomegalovirus Disease Receiving Six Months of Oral Valganciclovir Therapy**
SCOTT H. JAMES, MD, University of Alabama at Birmingham, Birmingham, AL
- 949** 9:45 a.m. **Programmatic Congenital CMV Universal Screening Program**
MARIA CARRILLO-MARQUEZ, MD, Le Bonheur Children's Hospital, Memphis, TN

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Global ID/
Pediatric ID

122. Oral Abstract Session

Public Health Potpourri

Friday, 8:30 – 10 a.m. 07AB

Moderators:

PATRICIA M. GRIFFIN, MD, FIDSA; Centers of Disease Control and Prevention, Atlanta, GA
TIMOTHY UYEKI, MD, MPH, MPP; Centers for Disease Control and Prevention, Atlanta, GA

Speakers:

- 950** 8:30 a.m. **Evidence for Cross-species Influenza A Virus Transmission within Swine Farms, China**
GREGORY GRAY, MD, MPH, Duke-NUS Medical School, Singapore, Singapore
- 951** 8:45 a.m. **Causes of in-hospital and post discharge mortality among patients hospitalized with laboratory-confirmed influenza, Influenza Hospitalization Surveillance Network, 2014–15**
CRAIG MCGOWAN, MS, Centers for Disease Control and Prevention, Atlanta, GA
- 952** 9 a.m. **Estimating Risk to Humans Exposed to Highly Pathogenic Avian Influenza Outbreaks in the United States, 2014–2017**
SONJA OLSEN, PHD, Centers for Disease Control and Prevention, Atlanta, GA
- 953** 9:15 a.m. **Vaccine waning and mumps re-emergence in the United States**
JOSEPH LEWNARD, PHD, Harvard TH Chan School of Public Health, Boston, MA
- 954** 9:30 a.m. **Interdisciplinary Public Health Intervention in a Multigenerational Tuberculosis (TB) Outbreak in Harris County, Texas: A Case Study with Implications for Disease Control Process Improvement and Transmission Cycle Interruption**
AISHA HAYNIE, MD, MPA, Harris County Public Health, Houston, TX

- 955 9:45 a.m. **Retail meat as a potential transmission source of community-acquired urinary tract infection**
REINA YAMAJI, MD, PHD, MPH, School of Public Health, University of California at Berkeley, Berkeley, CA

No CME credit is offered for this session.

No CPE credit is offered for this session.

123. Oral Abstract Session

Stewardship Tools

Friday, 8:30 – 10 a.m.

05AB

Moderators:

REBEKAH W. MOEHRING, MD, MPH; Duke University Medical Center, Durham, NC

PRANITA D. TAMMA, MD, MHS; Johns Hopkins University School of Medicine, Baltimore, MD

Speakers:

- 956 8:30 a.m. **Getting it Right the First Time: Relating Pharmacokinetic-Pharmacodynamic Target Attainment and Patient Outcomes**
CATHARINE C. BULIK, PHARMD, ICPD, Schenectady, NY

- 957 8:45 a.m. **Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients**
EMILY HEIL, PHARMD, BCPS-AQ ID, University of Maryland School of Pharmacy, Baltimore, MD

- 958 9 a.m. **A Novel Antimicrobial Stewardship Program-Guided Procalcitonin Initiative for Emergency Department Diagnosis of Bacterial Pneumonia in New York City**
GEORGE D. RODRIGUEZ, PHARMD, NewYork-Presbyterian Queens, Flushing, NY

- 959 9:15 a.m. **Communicating Microbiology Results: It's Not Just What You Say, But How You Say It.**
MARY MUSGROVE, PHARMD, Henry Ford Hospital, Detroit, MI

- 960 9:30 a.m. **Can antibiotic de-escalation be measured without chart review? A proposed electronic definition**
REBEKAH W. MOEHRING, MD, MPH, Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC

- 961 9:45 a.m. **The Role of Negative Methicillin-Resistant *Staphylococcus aureus* Nasal Surveillance Swabs in Predicting the Need for Empiric Vancomycin Therapy**
DARUNEE CHOTIPRASITSAKUL, MD, MPH, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID

124. Interactive Session

Challenging Cases in Infectious Diseases

Co-organized with the European Society of Clinical Microbiology and Infectious Diseases

Friday, 10:30 a.m. – noon

20ABCD



Objectives: At the conclusion of this session, participants will be able to:

- discuss the clinical presentation and diagnostics of challenging cases in infectious diseases
- describe atypical presentations of certain Infectious Diseases
- discuss clinical presentations mimicking Infectious Diseases

Intended Audience: academicians, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, microbiologists, pharmacists.

Moderators:

NESLI BASGOZ, MD, FIDSA; Massachusetts General Hospital, Boston, MA

HENRY CHAMBERS, MD, FIDSA; University of California, San Francisco, San Francisco, CA

Panelists:

AMNERIS LUQUE, MD; UT Southwestern Medical Center, Dallas, TX

LISA G. WINSTON, MD; University of California, San Francisco, San Francisco, CA

SARAH HAMMOND, MD, FIDSA; Brigham & Women's Hospital, Boston, MA

STAN DERESINSKI, MD, FIDSA; Stanford University, Palo Alto, CA



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.50 application-based contact hours of pharmacy CE; 0221-9999-17-275-L01-P

Adult ID/Epidemiology and Infection Control/Pediatric ID

125. Symposium

Antimicrobial Stewardship Programs in Challenging Populations

Friday, 10:30 a.m. – noon

06DE

Objectives: At the conclusion of this session, participants will be able to:

- identify key tenets of the core elements for stewardship in surgical patients
- apply available experience in establishing a stewardship program in transplant populations
- describe unique aspects of stewardship in the oncology population

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, pharmacists, researchers, scientists.

Moderators:

KEITH HAMILTON, MD; Hospital of the University of Pennsylvania, Philadelphia, PA
LILIAN M. ABBO, MD, FIDSA; University of Miami-Jackson Memorial Hospital, Miami, FL

Speakers:

962 10:30 a.m. Antimicrobial Stewardship Programs in Oncology

SUSAN SEO, MD, FIDSA; Memorial Sloan Kettering Cancer Center, New York, NY

963 10:55 a.m. Antimicrobial Stewardship Programs in Transplant Populations

CATHERINE LIU, MD, FIDSA; University of Washington, Seattle, WA

964 11:20 a.m. Antimicrobial Stewardship Programs in Surgical Populations

PAMELA LIPSETT, MD; The Johns Hopkins University School of Medicine, Baltimore, MD

11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-273-L01-P

Adult ID/Epidemiology and Infection Control/Pediatric ID/Trainee

126. Symposium

Dosing Antibiotics in Critically Ill Patients

Friday, 10:30 a.m. – noon

06AB

Objectives: At the conclusion of this session, participants will be able to:

- review strategies in the use of B-lactams in children who are critically ill.
- discuss the decision making process and choice of polymyxin in a critically ill patient
- compare different dosing approaches for the use of vancomycin and daptomycin in critically ill patients.

Intended Audience: academicians, clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, researchers, scientists.

Moderators:

CESAR ARIAS, MD, PHD, FIDSA; University of Texas McGovern School of Medicine, Houston, TX
DAVID ANDES, MD, FIDSA; University of Wisconsin School of Medicine and Public Health, Madison, WI
ROBERT A. BONOMO, MD, FIDSA; Case Western Reserve University, Cleveland, OH

Speakers:

965 10:30 a.m. B-lactams and Continuous Infusion, Is That the Way to Go?

PRANITA D. TAMMA, MD, MHS; Johns Hopkins University School of Medicine, Baltimore, MD

966 10:55 a.m. Colistin, Polymyxin or Both?

KEITH S. KAYE, MD, MPH, FIDSA, FSHEA; University of Michigan Medical School, Ann Arbor, MI

967 11:20 a.m. PK/PD Considerations for Vancomycin and Daptomycin

MICHAEL J. RYBAK, PHARMD, MPH, PHD, FIDSA; Wayne State University, Eugene Applebaum College of Pharmacy & Health Sciences, Detroit, MI

11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-276-L01-P

Adult ID/Epidemiology and Infection Control/Pediatric ID 127. Symposium

Foodborne Infections: Disease Burden and Advances

Friday, 10:30 a.m. – noon

11AB

Objectives: At the conclusion of this session, participants will be able to:

- discuss the emerging role of whole genome sequencing in *Listeria monocytogenes* outbreak management
- review the role of farming practices in food-borne illnesses
- explain current epidemiologic trends in food-borne illnesses

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, investigators, medical students and residents, members-in-training, microbiologists, pharmacists.

Moderators:

ROBERT V. TAUXE, MD, MPH, FIDSA; Centers for Disease Control and Prevention, Atlanta, GA
ROBERT ATMAR, MD, FIDSA; Baylor College of Medicine, Houston, TX

Speakers:

968 10:30 a.m. Adoption of Culture-Independent Techniques in Foodborne Disease Surveillance: State Public Health Department Standpoint

AIMEE L. GEISLER, PHD; Centers for Disease Control and Prevention, Atlanta, GA

969 10:55 a.m. Whole Genome Sequencing and Listeria Outbreak Management

IAN WILLIAMS, PHD; Centers of Disease Control and Prevention, Atlanta, GA

970 11:20 a.m. Farm to Table: Not Just Our Food

MICHAEL DOYLE, PHD; University of Georgia, Griffin, GA

11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-277-L01-P

128. Symposium

Late Breaker II

Friday, 10:30 a.m. – noon

06CF

Objectives: At the conclusion of this sessions, participants will be able to:

- describe the impact of the opioid crisis on infectious diseases and various healthcare entities response
- discuss the outbreak of Cholera in Yemen as well as current issues surrounding the vaccine

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiology.

Moderator:

DAVID ANDES, MD, FIDSA; University of Wisconsin School of Medicine and Public Health, Madison, WI

Speakers:

- 971** 10:30 a.m. **Opioid Crisis**
JUDITH FEINBERG, MD, FIDSA; West Virginia University, Morgantown, WV
- 972** 10:55 a.m. **Cholera Update**
LOUISE IVERS, MD, DTMH; Brigham and Women's Hospital, Boston, MA
- 973** 11:20 a.m. **Yellow Fever**
SPEAKER TBD
- 11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-382-L01-P

Adult ID/Pediatric ID

129. Symposium

Managing Co-Morbidities and Co-Infections in Patients with HIV

Friday, 10:30 a.m. – noon

14AB

Objectives: At the conclusion of this session, participants will be able to:

- evaluate new approaches for preventing and treating STIs in HIV patients
- assess the effects of HIV infections on neurologic functioning
- describe strategies for diagnosing and treating HPV in HIV patients

Intended Audience: academicians, clinicians, fellows, healthcare workers, HIV clinicians, HIV specialists, infectious diseases physicians, investigators, members-in-training, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists.

Moderators:

RAJESH GANDHI, MD, FIDSA; Massachusetts General Hospital, Boston, MA
LORI GORDON, PHARM.D.; Xavier University of Louisiana, New Orleans, LA

Speakers:

- 974** 10:30 a.m. **HIV and STIs**
SUSAN PHILLIP, MD, MPH; San Francisco Department of Public Health, San Francisco, CA
- 975** 10:55 a.m. **HIV in the Brain**
SHIBANIMUKERJI, MD, PHD; Massachusetts General Hospital, Boston, MA
- 976** 11:20 a.m. **HIV and HPV**
TIMOTHY WILKIN, MD, MPH, FIDSA; Weill Cornell Medicine, New York, NY
- 11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-278-L02-P

Adult ID/Epidemiology and Infection Control/Investigative ID/Pediatric ID/Trainee

130. Symposium

Methods in Epidemiology Research: Asking the Right Questions, Recognizing Valid Answers

Friday, 10:30 a.m. – noon

16AB

Objectives: At the conclusion of this session, participants will be able to:

- identify the opportunities and challenges in using large data sets including claims data
- describe the unique attributes of quasi-experimental study designs
- discuss the role of mathematical modeling in the study of health-care epidemiology

Intended Audience: academicians, clinicians, epidemiologists, hospital epidemiologists, infection preventionists, infectious diseases physicians, investigators, members-in-training, pharmacists, public health practitioners, researchers, scientists.

Moderators:

AARON M. MILSTONE, MD, MHS, FIDSA, FSHEA; The Johns Hopkins Medical Institutions, Baltimore, MD
MARCI DREES, MD, MS; Christiana Care Health System, Newark, DE

Speakers:

- 977** 10:30 a.m. **Big Data: Promise and Peril**
MARGARET OLSEN, PHD, MPH; Washington University School of Medicine, Saint Louis, MO
- 978** 10:55 a.m. **Advances in Quasi-Experimental Designs**
MARIN SCHWEIZER, PHD; University of Iowa Carver College of Medicine, Iowa City, IA
- 979** 11:20 a.m. **Mathematical Modeling: Research Without Leaving Your Office**
RACHEL SLAYTON, PHD, MPH; Centers for Disease Control and Prevention, Atlanta, GA
- 11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-279-L01-P

131. Symposium

Remembrance of Things Past

Friday, 10:30 a.m. – noon

17AB

Objectives: At the conclusion of this session, participants will be able to:

- explain the effect of waning immunity on vaccines in older adults
- discuss the clinical impact of vaccine preventable diseases in older adults
- list novel strategies for improving immune response to vaccines in older adults

Intended Audience: academicians, clinicians, healthcare workers, infectious diseases physicians, investigators, members-in-training, pharmacists, researchers, scientists, vaccinologists.

Moderators:

H. KEIPP TALBOT, MD, MPH, FIDSA; Vanderbilt University Medical Center, Nashville, TN
 STANLEY A. PLOTKIN, MD, FIDSA, FPIDS; University of Pennsylvania, Doylestown, PA
 ANDREW PAVIA, MD, FIDSA, FSHEA, FPIDS; University of Utah School of Medicine, Salt Lake City, UT

Speakers:

- 980** 10:30 a.m. **Ain't What it Used to Be: Waning Immunity and Vaccines**
 ALBERT SHAW, MD, PHD, FIDSA; Yale University, New Haven, CT
- 981** 10:55 a.m. **Clinical Impact of Vaccine Preventable Disease in Older Adults**
 KENNETH SCHMADER, MD; Duke University Medical Center, Durham, NC
- 982** 11:20 a.m. **Springtime Again? Novel Strategies**
 STANLEY A. PLOTKIN, MD, FIDSA, FPIDS; University of Pennsylvania, Doylestown, PA
- 11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-280-L01-P

132. Oral Abstract Session

Advances in Management of Bacteremia and Sepsis

Friday, 10:30 a.m. – noon

07AB

Moderators:

HELEN W. BOUCHER, MD, FIDSA; Tufts Medical Center, Boston, MA
 THOMAS LODISE, PHARM.D., PHD; Albany College of Pharmacy, Albany, NY

Speakers:

- 983** 10:30 a.m. **Doing the Same with Less: A Randomized, Multinational, Open-Label, Adjudicator-Blinded Trial of an Algorithm vs. Standard**

of Care to Determine Treatment Duration for Staphylococcal Bacteremia

THOMAS L. HOLLAND, MD, Duke University Medical Center, Durham, NC

- 984** 10:45 a.m. **Induced Hypothermia in Patients with Septic Shock and Ventilator-demanding Respiratory Failure**

JENS ULRIK STÆHR JENSEN, MD, PHD, Rigshospitalet – University of Copenhagen, Copenhagen East, Denmark

- 985** 11 a.m. **The Emperor's New Clothes: Prospective Observational Evaluation of the Association between the Day 2 Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE)**

THOMAS P. LODISE JR., PHARM.D., PHD, Albany College of Pharmacy & Health Sciences, Albany, NY

- 986** 11:15 a.m. **Comparing the Outcomes of Adults with Enterobacteriaceae Bacteremia Receiving Short-Course versus Prolonged-Course Antibiotic Therapy**

DARUNEE CHOTIPRASITSAKUL, MD, MPH, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

- 987** 11:30 a.m. **Infectious Disease Consultation Is Associated with Decreased Mortality with Enterococcal Bloodstream Infections**

DANIEL VO, MD, University of Alabama at Birmingham, Birmingham, AL

- 988** 11:45 a.m. **"Big data" and gram-negative resistance: a multiple logistic regression model using EMR data to predict carbapenem resistance in patients with Klebsiella pneumonia bloodstream infection**

TIMOTHY SULLIVAN, MD, Icahn School of Medicine at Mount Sinai, New York, NY

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Investigative ID/Trainee

133. Oral Abstract Session

Diagnostics and Why They Matter

Friday, 10:30 a.m. – noon

05AB

Moderators:

JEAN PATEL, PHD, D(ABMM); Centers for Disease Control and Prevention, Atlanta, GA

JEANNETTE GUARNER, MD; Emory University, Atlanta, GA

Speakers:

- 989** 10:30 a.m. **Direct Detection and Identification of Prosthetic Joint Pathogens in Synovial Fluid (SF) by Metagenomic Shotgun Sequencing**
 MORGAN IVY, BS, Mayo Clinic, Rochester, MN

- 990** 10:45 a.m. **Clinical Impact of Two Different Multiplex Respiratory Panel Assays on Management of Hospitalized Children aged ≤24 months**

RANGARAJ SELVARANGAN, PHD,
Children's Mercy Hospital and Clinics, Kansas
City, MO

991 11 a.m. Clinical Yield of Routine Use of Molecular Testing for Adult Outpatients with Diarrhea
STEPHEN CLARK, MD, University of
Virginia, Charlottesville, VA

992 11:15 a.m. Enteropathogen Detection in Children with Diarrhea and/or Vomiting: A Cohort Study Comparing Rectal Flocked Swabs and Stool Specimens
STEPHEN FREEDMAN, MDCM, MSC,
University of Calgary, Calgary, AB, Canada

993 11:30 a.m. Rapid phenotypic antibiotic susceptibility testing through RNA detection
ROBY BHATTACHARYA, MD, PHD,
Massachusetts General Hospital, Boston, MA

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Investigative
ID/Pediatric ID/Trainee

134. Oral Abstract Session

Where Did That Come From? Transmission Risks in Healthcare

Friday, 10:30 a.m. – noon 01AB

Moderators:

JUDITH GUZMAN-COTTRILL, DO; Oregon Health and Science
University, Portland, OR
CURTIS J. DONSKEY, MD; Case Western Reserve University,
Cleveland, OH

Speakers:

995 10:30 a.m. Tracking an unusual carbapenemase-producing organism from drains to patient using whole genome sequencing
AMANDA M. RAMSBURG, B.S.N., NIH
Clinical Center, NIH, Bethesda, MD

996 10:45 a.m. Bare Below the Elbows: A Randomized Trial to Determine if Wearing Short-Sleeved Coats Reduces the Risk for Pathogen Transmission
AMRITA JOHN, MBBS, University Hospitals
Case Medical Center, Cleveland, OH

997 11 a.m. Defining Aerosol Generating Procedures and Pathogen Transmission Risks in Healthcare Settings
HILARY M BABCOCK, MD, MPH,
Washington University, St Louis, MO

998 11:15 a.m. Utility of Routine Genomic Sequencing for Infection Control Surveillance
RICHARD T ELLISON III, MD, FIDSA,
FSHEA, University of Massachusetts Medical
School, Worcester, MA

999 11:30 a.m. Invasive *Mycobacterium abscessus* Infection after Cardiac Surgery: Epidemiology and Clinical Outcomes
ARTHUR W. BAKER, MD, MPH, Duke
Infection Control Outreach Network, Duke
University Medical Center, Durham, NC

1000 11:45 a.m. Daily Chlorhexidine Bathing in General Hospital Units – Results of the ABATE Infection Trial (Active BATHing to Eliminate Infection)

SUSAN S. HUANG, MD, MPH, FIDSA,
FSHEA, University of California Irvine School
of Medicine, Irvine, CA

No CME credit is offered for this session.

No CPE credit is offered for this session.

Pediatric ID

135. Oral Abstract Session

PIDS Featured Abstracts

Friday, 10:30 – 11 a.m. 15AB

Moderator:

Paul Spearman, MD, FIDSA, FPIDS, Emory University School of
Medicine, Atlanta, GA

Speakers:

1001 10:30 a.m. A Single Dose Monoclonal Antibody (mAb) Immunoprophylaxis Strategy to Prevent RSV Disease in All Infants: Results of the First in Infant Study with MEDI8897
JOSEPH B. DOMACHOWSKIE, MD, SUNY
Upstate Medical University, Syracuse, NY

1002 10:45 a.m. Respiratory Syncytial Virus bronchiolitis: impact of second hand smoke exposure on immune profiles
ALEJANDRO DIAZ, MD, The Research
Institute at Nationwide Children's Hospital,
Columbus, OH

No CME credit is offered for this session.

No CPE credit is offered for this session.

Pediatric ID/Trainee

136. Named Lecture

Caroline B. Hall Lectureship

Friday, 11 a.m. – noon 15AB

Objectives: At the conclusion of the session, participants will be able to:

- identify the type of patients at risk for severe outcomes of common respiratory viral infections
- describe clinical presentation of respiratory viruses in immunocompromised hosts.
- explain laboratory methods of sensitive diagnosis and clinical evaluation of respiratory viral infections in the immunocompromised patient
- discuss current and potential future therapy to prevent or treat respiratory viral infections in the high-risk patient

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners.

Moderator:

OCTAVIO RAMILO, MD, FPIDS; Nationwide Children's Hospital, Columbus, OH

Speakers:

- 1003** 11 a.m. **Respiratory Viral Infections in the High Risk Patient**
JANET A. ENGLUND, MD, FIDSA, FPIDS;
Seattle Children's Hospital, Seattle, WA



Maximum of 1.00 hours of *AMA PRA Category 1 Credit™*



ACPE 1 knowledge-based contact hours of pharmacy CE;
0221-9999-17-274-L01-P

Poster Sessions**Poster Hall CD**

Friday	10:00 a.m. – 6:00 p.m.	On display
	12:30 – 2 p.m.	Lunch in the Exhibit Hall
	12:30 – 2:00 p.m.	Presenters at posters

#	Session Title
137.	Adult CNS Infection (1004–1019)
138.	Adult Immunization – Miscellaneous (1020–1025)
139.	Adult Viral Infection (1026–1054)
140.	Assorted Pediatric Vaccines (1055–1070)
141.	Clinical Practice Issues (1071–1119)
142.	Clinical: Soup to Nuts (1120–1125)
143.	Clinical: UTI (1126–1146)
144.	Diagnostics: Biomarkers (1147–1153)
145.	Diagnostics: Viral (1155–1179)
146.	Enteric Infections and Diagnostics (1180–1197)
147.	Expanded Spectrum – New Antimicrobial Susceptibility Testing (1198–1244)
148.	<i>C. difficile</i>: From the Bench to Bedside (1245–1273)
149.	HAI: <i>C. difficile</i> Epidemiology, Impact, and Testing (1274–1299)
150.	HAI: <i>C. difficile</i> Risk Assessment and Prevention (1300–1321)
151.	HAI: Hand Hygiene (1322–1336)
152.	Herpes Zoster Vaccine (1337–1351)
153.	HIV Care Continuum (1352–1367)
154.	HIV Drug Resistance (1368–1375)
155.	HIV Testing (1376–1379)
156.	HIV: Antiretroviral Therapy (1380–1401)
157.	HIV: Health Care Utilization and Costs (1402–1409)
158.	HIV: Pre-Exposure Prophylaxis (1410–1420)
159.	HIV: Rapid ART Initiation (1421–1424)
160.	ID Medical Education (1425–1453)
161.	Influenza and Influenza Vaccines (1454–1466)
162.	Maternal/Infant Immunization (1467–1471)
163.	Pediatric Viral Infections (1472–1480)
164.	Pneumococcal Immunization and Epidemiology-Global (1481–1486)
165.	Pneumococcal Immunization and Epidemiology-North America (1487–1498)
166.	Pneumococcal Immunization in Adults (1499–1505)
167.	Preclinical Study with New Antibiotics and Antifungals (1506–1540)
168.	Stewardship: Improving Outcomes (1541–1591)
169.	Stewardship: Pediatric Antimicrobial Stewardship (1592–1615)
170.	Stewardship: Targets for Intervention (1616–1638)

- 171. Vaccine Hesitancy** (1639–1642)
172. Vaccine Strategy and Policy (1643–1651)
173. Viral Treatment and Prevention (1652–1662)

Adult ID/HIV-STD-TB/Pediatric ID/Trainee**174a. Poster Discussion Round****Antiretroviral Therapy**

Friday, 12:30 – 2 p.m.

Speakers:

- 1663a** **Group Leader**
MICHAEL SAAG, MD, FIDSA; University of Alabama at Birmingham, Birmingham, AL

No CME credit is offered for this session.

No CPE credit is offered for this session.

HIV-STD-TB/Trainee**174b. Poster Discussion Round****PrEP**

Friday, 12:30 – 2 p.m.

Poster Hall CD

Speakers:

- 1663b** **Group Leader**
JOHN T. BROOKS, MD; Centers for Disease Control and Prevention, Atlanta, GA

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Trainee**175. Poster Discussion Round****Big Beasts - Clinical**

Friday, 12:30 – 2 p.m.

Poster Hall CD

Speakers:

- 1664** **Group Leader**
DANIEL MCQUILLEN, MD, FIDSA; Lahey Hospital & Medical Center, Burlington, MA

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Trainee**176. Poster Discussion Round*****Clostridium difficile***

Friday, 12:30 – 2 p.m.

Poster Hall CD

Speakers:

- 1665** 12:30 p.m. **Group Leader**
L. CLIFFORD MCDONALD, MD, FSHEA;
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA

No CME credit is offered for this session.

No CPE credit is offered for this session.

177. Poster Discussion Round**Education**

Friday, 12:30 – 2 p.m.

Poster Hall CD

Speakers:

1666

Group Leader

JOSHUA NOSANCHUK, MD, FIDSA; Albert Einstein College of Medicine, Bronx, NY

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Pediatric ID/Trainee**178. Poster Discussion Round****Stewardship II**

Friday, 12:30 – 2 p.m.

Poster Hall CD

Speakers:

1667

Group Leader

LAURI HICKS, DO; Centers for Disease Control and Prevention, Atlanta, GA

1668

Group Leader

JASON NEWLAND, MD, MED, FPIDS; Washington University at St. Louis, St. Louis, MO

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/HIV-STD-TB/Pediatric ID/Trainee**179. Interactive Session****Case-Based Problems in Vaccines: Beyond the Guidelines**

Friday, 2 – 3:30 p.m.

11AB

Objectives: At the conclusion of this presentation, participants will be able to:

- discuss the use of the conjugate pneumococcal vaccine in adults
- evaluate rotavirus vaccine use in NICU
- discuss if LAIV should be reintroduced in the US vaccination program

Intended Audience: academicians, clinicians, fellows, healthcare workers, infectious diseases pediatricians, nurses, pharmacists, public health practitioners, vaccinologists.**Moderators:**ANDREW PAVIA, MD, FIDSA, FSHEA, FPIDS; University of Utah School of Medicine, Salt Lake City, UT
H. KEIPP TALBOT, MD MPH FIDSA; Vanderbilt University Medical Center, Nashville, TN**Panelists:**

JANET ENGLUND, MD, FIDSA, FPIDS; Seattle Children's Hospital, Seattle, WA

KATHRYN EDWARDS, MD, FIDSA; Vanderbilt University School of Medicine, Nashville, TN
GEETA SWAMY, MD; Duke University Medical Center, Durham, NCMaximum of 1.50 hours of *AMA PRA Category 1 Credit™*

ACPE 1.5 application-based contact hours of pharmacy CE; 0221-9999-17-281-L01-P

Adult ID/Epidemiology and Infection Control/Investigative ID/Pediatric ID/Trainee**180. Interactive Session****Nightmare Bugs: A Case-Based Symposium**

Friday, 2 – 3:30 p.m.

20ABCD

**Objectives:** At the conclusion of this session, participants will be able to:

- discuss the clinical and therapeutic approach of infections caused by multidrug-resistant organisms
- review the clinical relevant data supporting the use of new antimicrobials against infections caused by multi-drug resistant organisms
- assess and appraise the pre-clinical evidence available for the selection of particular antimicrobials when a clinician is faced with a challenging infection to treat.
- list relevant mechanisms of antimicrobial resistance and put them in a clinical context

Intended Audience: academicians, clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, researchers, scientists.**Moderators:**CESAR ARIAS, MD, PHD, FIDSA; University of Texas McGovern School of Medicine, Houston, TX
ROBERT A. BONOMO, MD, FIDSA; Case Western Reserve University, Cleveland, OH
DAVID ANDES, MD, FIDSA; University of Wisconsin School of Medicine and Public Health, Madison, WI**Panelists:**CATHERINE LIU, MD, FIDSA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
LILIAN M. ABBO, MD, FIDSA; University of Miami-Jackson Memorial Hospital, Miami, FL
DIMITRIOS FARMAKIOTIS, MD; Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, RI
ROY CHEMALY, MD, MPH, FIDSA; MD Anderson Cancer Center, Houston, TXMaximum of 1.50 hours of *AMA PRA Category 1 Credit™*

ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-284-L01-P

181. Interactive Session
Sexually Transmitted Infections in the HIV Care Setting: An Interactive Case-Based Approach

Friday, 2 – 3:30 p.m.

06AB

Objectives: At the conclusion of this session, participants will be able to:

- outline strategies for preventing, diagnosing, and managing common sexually transmitted infections in HIV care settings
- develop therapeutic approaches to managing these infections in an era of increasing drug resistance and in the setting of drug allergies
- review evidence-based treatment guidelines for managing STIs in HIV-infected persons

Intended Audience: fellows, HIV clinicians, HIV specialists, members-in-training, nurses, pharmacists, public health practitioners.

Moderators:

BRADLEY P. STONER, MD, PHD, FIDSA; Washington University, St Louis, MO
CHRISTINE JOHNSTON, MD, MPH, FIDSA; University of Washington, Seattle, WA

Panelists:

STEPHANIE E. COHEN, MD, MPH; San Francisco Department of Public Health, San Francisco, CA
KATHERINE HSU, MD, MPH; Massachusetts Department of Public Health, Jamaica Plain, MA
SUSAN TUDDENHAM, MD, MPH; Johns Hopkins University, Baltimore, MD
NICHOLAS VAN WAGONER, MD, PHD; University of Alabama at Birmingham, Birmingham, AL



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-286-L02-P

Adult ID/Epidemiology and Infection Control/Pediatric ID/Trainee

182. Symposium
Diagnostic Updates: Syndrome-Based Diagnostics

Friday, 2 – 3:30 p.m.

16AB

Objectives: At the conclusion of this session, participants will be able to:

- list new syndrome-based diagnostics
- describe the clinical benefits of syndrome-based diagnostics
- discuss the risks of using syndrome-based diagnostics and strategies for minimizing these risks

Intended Audience: academicians, clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, lab

personnel, medical students and residents, members-in-training, microbiologists.

Moderators:

RANDALL HAYDEN, MD; St. Jude Children's Research Hospital, Memphis, TN
JEAN PATEL, PHD, D(ABMM); Centers for Disease Control and Prevention, Atlanta, GA
RICHARD HODINKA, PHD; University of South Carolina School of Medicine Greenville, Greenville, SC

Speakers:

1669 2 p.m.

Respiratory Infections

RICHARD HODINKA, PHD; University of South Carolina School of Medicine Greenville, Greenville, SC

1670 2:25 p.m.

Gastrointestinal Infections

ALEXANDER MCADAM, MD, PHD; Boston Children's Hospital, Boston, MA

1671 2:50 p.m.

What's New in Syndrome-Based Diagnostics

AMY LEBER, PHD; Nationwide Children's Hospital, Columbus, OH

3:15 p.m. **Q&A**

Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Global ID/Investigative ID/Pediatric ID/Trainee

183. Symposium
Evolution Informing Infectious Diseases, Infectious Diseases Informing Evolution

Friday, 2 – 3:30 p.m.

14AB

Objectives: At the conclusion of this session, participants will be able to:

- describe how the evolutionary processes can drive the development, spread and epidemiology of infectious diseases
- identify the mechanisms that shape evolution that have been identified through the study of infectious microbes
- relate how an understanding of microbial evolution can drive the development of novel methods for the treatment and prevention of infectious diseases

Intended Audience: academicians, clinicians, epidemiologists, fellows, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, pharmacists, researchers, scientists.

Moderators:

VINCENT B. YOUNG, MD, PHD, FIDSA; University of Michigan, Ann Arbor, MI
ADAM LAURING, MD, PHD; University of Michigan, Ann Arbor, MI

Speakers:

1672 2 p.m.

Influenza Evolution on Local Scales

ADAM LAURING, MD, PHD; University of Michigan, Ann Arbor, MI

1673 2:25 p.m. **Drivers of the Evolution of Bacterial Pathogens**
SHANNON D. MANNING, PHD; Michigan State University, East Lansing, MI

1674 2:50 p.m. **The Evolution of Adaptive Immunity, the Evolution of Influenza, and the Consequences for Vaccination**

SARAH COBEY, PHD; The University of Chicago, Chicago, IL

3:15 p.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-282-L01-P

Adult ID/Pediatric ID/Trainee

184. Symposium

Expect the Unexpected: Evolving Infection Risks in Transplantation

Friday, 2 – 3:30 p.m.

06DE

Objectives: At the conclusion of this session, participants will be able to:

- formulate a management approach to organ donor and recipient infections in the pre and peri transplant setting.
- outline strategies to enhance safe living after transplantation
- discuss emerging tropical and travel related infections in transplantation

Intended Audience: clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists.

Moderators:

RAYMUND R. RAZONABLE, MD, FIDSA; Mayo Clinic, Rochester, MN

RACHEL MILLER, MD, FIDSA; Duke University, Durham, NC

Speakers:

1675 2 p.m. **The Evaluation of the Infected Organ Donor and Recipient**

CAMERON WOLFE, MBBS(HONS), MPH, FIDSA; Duke University, Durham, NC

1676 2:25 p.m. **Safe Living After Transplantation**

DEEPA KUMAR, MD; University Health Network, Toronto, ON, Canada

1677 2:50 p.m. **Emerging Infections in Transplantation**

MICHELE I MORRIS, MD, FIDSA; University of Miami Miller School of Medicine, Miami, FL

3:15 p.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-283-L01-P

Adult ID/Epidemiology and Infection Control/Pediatric ID

185. Symposium

Infection Prevention Down the Drain: Water Fixtures in Healthcare Settings

Friday, 2 – 3:30 p.m.

17AB

Objectives: At the conclusion of this session, participants will be able to:

- identify potential risk of acquiring waterborne pathogens from plumbing fixtures and equipment in healthcare facilities
- explain modes of transmission of waterborne pathogens in healthcare facilities
- examine possible measures to prevent transmission of waterborne pathogens in healthcare facilities

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, public health practitioner.

Moderators:

TARA PALMORE, MD; National Institutes of Health Clinical Center, Bethesda, MD

REKHA MURTHY, MD, FIDSA; Cedars-Sinai Medical Center, Los Angeles, CA

Speakers:

1678 2 p.m. **Mycobacterial Infections: From Dentists to Cardiothoracic Surgeons**

MATTHEW ZAHN, MD, FIDSA; Orange County Health Care Agency, Santa Ana, CA

1679 2:25 p.m. **Waterborne Gram Negatives: Eradication and Control Challenges**

AMY MATHERS, MD; University of Virginia Health System, Charlottesville, VA

1680 2:50 p.m. **Healthcare-Associated Legionella: A Growing Problem**

LOREEN A. HERWALDT, MD, FIDSA, FSHEA; University of Iowa Carver College of Medicine, Iowa City, IA

3:15 p.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/HIV-STD-TB/
Pediatric ID/Trainee

186. Symposium

Nontuberculous Mycobacterial Infections in Children

Friday, 2 – 3:30 p.m.

06CF

Objectives: At the conclusion of this session, participants will be able to:

- recognize difficulties in diagnoses, management and infection control in the setting of infections with Mycobacterium abscessus - the new “toughest one in the room”

- understand the diagnosis, medical and surgical management of nontuberculous mycobacterial cervical adenitis.
- discuss the clinical and infection control issues related to contamination of cardiopulmonary heater/cooler units due to *Mycobacterium chimaera*.

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, pharmacists.

Moderator:

SARAH PARKER, MD; Children's Hospital Colorado, Aurora, CO

Speakers:

- 1681** 2 p.m. **Mycobacterium Abscessus the New "Toughest One in the Room": Difficult Infections, Management, Infection Control**
GWEN HUITT, MD, MS; National Jewish Health, Denver, CO
- 1682** 2:25 p.m. **Nontuberculous Mycobacterial Cervical Adenitis: Diagnosis, Medical, and Surgical Management**
MARC TEBRUEGGE, MD; University of Southampton, Southampton, United Kingdom
- 1683** 2:50 p.m. **Mycobacterium Chimaera Outbreak and Implications to Children Who Have Undergone Bypass Surgery**
KIRAN MAYI PERKINS, MD, MPH; Centers for Disease Control and Prevention, Atlanta, GA

3:15 p.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-285-L01-P

Adult ID/Epidemiology and Infection Control/Pediatric ID

187. Symposium

Stewardship Accreditation Standards in Action

Co-organized with Society of Infectious Diseases Pharmacists

Friday, 2 – 3:30 p.m. 15AB

Objectives: At the conclusion of this session, participants will be able to:

- describe the new Joint Commission accreditation standard for antibiotic stewardship
- explain important factors in meeting new accreditation/regulatory standards for antibiotic stewardship in hospitals
- identify important factors in meeting new accreditation/regulatory standards for antibiotic stewardship in nursing homes

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners.

Moderators:

ARJUN SRINIVASAN, MD, FSHEA; Centers for Disease Control and Prevention, Atlanta, GA

PAYAL PATEL, MD, MPH; University of Michigan, Ann Arbor, MI

Speakers:

- 1683a** 2 p.m. **Stewardship Accreditation Standards in Long Term Care**
CHRISTOPHER CRNICH, MD, PHD; University of Wisconsin School of Medicine and Public Health, Madison, WI
- 1683b** 2:25 p.m. **Steward Accreditation Standards in Acute Care**
LISA E. DAVIDSON, MD; Carolinas HealthCare System, Charlotte, NC
- 1683c** 2:50 p.m. **The Joint Commission Accreditation Standard for Antibiotic Stewardship**
DAVID BAKER, MD, MPH; The Joint Commission, Oakbrook Terrace, IL
- 3:15 p.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-287-L01-P

Adult ID/HIV-STD-TB/Trainee

188. Oral Abstract Session

HIV: Modern ART

Friday, 2 – 3:30 p.m.

07AB

Moderators:

RAJESH GANDHI, MD, FIDSA; Massachusetts General Hospital, Boston, MA

AADIA RANA, MD; University of Alabama, Birmingham, Birmingham, AL

Speakers:

- 1684** 2 p.m. **Obesity Following Antiretroviral Therapy (ART) Initiation is Common and Influenced by Both Traditional and HIV-/ART-Specific Risk Factors**
DAVID BAKAL, BS, University of California, Los Angeles, Los Angeles, CA
- 1685** 2:13 p.m. **Predictors of Linkage to and Retention in HIV Care Following Release from Connecticut Jails and Prisons**
KELSEY B. LOELIGER, MPHIL, BS, Yale University, New Haven, CT
- 1686** 2:26 p.m. **48-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1**
BRINDA EMU, MD, Yale School of Medicine, New Haven, CT
- 1687** 2:39 p.m. **Selected CNS outcomes among INSTI antiretrovirals**
DAVID WOHL, MD, University of North Carolina, Chapel Hill, NC
- 1688** 2:52 p.m. **Viral Failure Among Persons Living with HIV Initiating Dolutegravir-Based vs. Other**

Recommended Regimens in Real-World Clinical Care Settings

HEIDI M. CRANE, MD, MPH, University of Washington, Seattle, WA

- 1689a** 3:05 p.m. **Association Between Patient Portal Access and Viral Suppression Among People Living with HIV in a Large Southeastern Clinical Cohort**

SARAH SCOTT, MD, Vanderbilt University Medical Center, Nashville, TN

- 1689b** 3:18 p.m. **Week 48 results of EMERALD: A Phase 3, randomized, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors (bPI) plus emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) regimens to the once daily (QD), single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically-suppressed, HIV-1-infected adults**

CHLOE ORKIN, MD, Barts Health NHS Trust, London, United Kingdom

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Global ID/
Pediatric ID

189. Oral Abstract Session

Hepatitis B and C Across the Lifespan

Friday, 2 – 3.30 p.m.

5AB

Moderators:

SUSANNA NAGGIE, MD, FIDSA; Duke University Medical Center, Duke Clinical Research Institute, Durham, NC
MICHAEL SAAG, MD, FIDSA; University of Alabama at Birmingham, Birmingham, AL

Speakers:

- 1690** 2 p.m. **Performance of NS3, NS5a AND NS5b Hepatitis C Virus (HCV) Antiviral Resistance Sequencing Assays**
JAMIE NUTT, BS, Viracor Eurofins Clinical Diagnostics, Lees Summit, MO

- 1691** 2:15 p.m. **Is there Failure to Screen for Hepatitis C in Newborns Suffering from Neonatal Abstinence Syndrome?**
JOHN MYERS, PHD MSPH, University of Louisville, Louisville, KY

- 1692** 2:30 p.m. **The incidence of hepatocellular carcinoma is not increased in individuals with chronic hepatitis C after treatment with interferon-free regimens: an ERCHIVES study**
DARRICK K. LI, MD, PHD, Massachusetts General Hospital, Boston, MA

- 1693** 2:45 p.m. **Antiviral Treatment among Hepatitis B Virus-Infected Pregnant Women — New York City and Michigan, 2013–2015**
RUTH LINK-GELLES, PHD, MPH, Centers for Disease Control and Prevention, Atlanta, GA

- 1694** 3 p.m. **Treatment as prevention for hepatitis C (TraP HepC). A real-world experience from**

the first 12 months of a nationwide elimination program in Iceland

MAGNUS GOTTFREDSSON, MD, PHD, Landspítali University Hospital, Reykjavik, Iceland

- 1695** 3:15 p.m. **Maternal Risk Factors Associated with Inadequate Testing and Loss to Follow-up in Infants with Perinatal Hepatitis C Virus Exposure**

AMRITA BHARDWAJ, MD, MetroHealth Medical Center, Cleveland, OH

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Pediatric ID 190. Oral Abstract Session

Resist! MDROs in Healthcare

Friday, 2 – 3:30 p.m.

01AB

Moderators:

MICHAEL DAVID, MD; University of Pennsylvania, Philadelphia, PA
KYLE J POPOVICH, MD, MS, FIDSA; Rush University Medical Center, Chicago, IL

Speakers:

- 1696** 2 p.m. **When a Home is Not a Home: MultiDrug-Resistant Organism (MDRO) Colonization and Environmental Contamination in 28 Nursing Homes (NHs)**
JAMES A. MCKINNELL, MD, Infectious Disease Clinical Outcomes Research (ID-CORE), LA Biomed at Harbor-UCLA Medical Center, Torrance, CA

- 1697** 2:15 p.m. **Prospective surveillance and rapid whole-genome sequencing detects two unsuspected outbreaks of carbapenemase-producing *Klebsiella pneumoniae* in a UK teaching hospital**
ESTEE TOROK, MBBS, PHD, FRCP, FRCPATH, University of Cambridge, Cambridge, United Kingdom

- 1698** 2:30 p.m. **Comparison of 30- and 90-Day Mortality Rates in Patients with Cultures Positive for Carbapenem-resistant Enterobacteriaceae and Acinetobacter in Atlanta, 2011–2015**
MARY ELIZABETH SEXTON, MD, Georgia Emerging Infections Program, Decatur, GA

- 1699** 2:45 p.m. **Prevalence and acquisition of MRSA during incarceration at a large inner-city jail**
KYLE J POPOVICH, MD, MS, FIDSA, Rush University Medical Center, Chicago, IL

- 1700** 3 p.m. **Differences in pre- and post-discharge methicillin-resistant Staphylococcus aureus (MRSA) infection rates by colonization status in US Department of Veterans Affairs (VA) hospitals**
RICHARD E. NELSON, PHD, VA Salt Lake City Health Care System, Salt Lake City, UT

- 1701** 3:15 p.m. **The impact of active surveillance culture and decolonization programs on NICU MRSA**

transmission: A multicenter, mechanistic modeling approach.

REBECCA PIERCE, MS, BSN, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Trainee

191. Interactive Session

Debate: Clinical Controversies

Friday, 3:45 – 5:45 p.m.

06AB

Objectives: At the conclusion of this session, participants will be able to:

- describe the advantages and disadvantages of mandating an annual influenza vaccine for healthcare workers in an acute care setting
- identify the components of value of regular anal PAP screening for persons with HIV disease including time, resource utilization, and likelihood of identifying unsuspected HPV
- define the risks and benefits of active surveillance compared with immediate surgery for persons with a spinal epidural abscess

Intended Audience: academicians, clinicians, fellows, healthcare workers, HIV clinicians, HIV specialists, infectious diseases physicians, medical students and residents, members-in-training, pharmacists.

Moderators:

ANN MACINTYRE, DO, MHS; Palmetto Hospital, Miami, FL
PATRICK JOSEPH, MD, FIDSA, FSHEA; University of California, San Francisco, San Ramon, CA

Speakers:

3:45p.m. **Mandatory Flu Vaccine for HCWs: Worthwhile or Not**

1703

Pro

TRISH PERL, MD, MSC, FIDSA, FSHEA; University of Texas, Southwestern, Dallas, TX

1704

Con

MICHAEL EDMOND, MD, MPH, MPA, FIDSA, FSHEA; University of Iowa Hospitals and Clinics, Iowa City, IA

4:25p.m. **Anal Cancer Screening for HIV+ Persons: Yes or No?**

1706

Pro

TIMOTHY WILKIN, MD, MPH, FIDSA; Weill Cornell Medicine, New York, NY

1707

Con

LUIS F. BARROSO, MD; Wake Forest University Health Sciences, Winston-Salem, NC

5:05p.m. **Spinal Epidural Abscess: Surgery for Everyone?**

1709

Pro

ALLAN R. TUNKEL, MD, PHD, FIDSA; Monmouth Medical Center, Long Branch, NJ

1710

Con

STAN DERESINSKI, MD, FIDSA; Stanford University, Palo Alto, CA



Maximum of 2.00 hours of *AMA PRA Category 1 Credit™*



ACPE 2 knowledge-based contact hours of pharmacy CE; 0221-9999-17-288-L01-P

Adult ID/Global ID/HIV-STD-TB/Pediatric ID/Trainee 192. Interactive Session

Tropical Medicine Cases: Conundrums and Case Management

Friday, 3:45 – 5:45 p.m.

06CF

Objectives: At the conclusion of this session, participants will be able to:

- determine the approach to differential diagnosis of tropical medicine cases
- describe the work-up and management of tropical medicine cases presented

Intended Audience: clinicians, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training.

Moderator:

CHRISTINA COYLE, MD; Albert Einstein College of Medicine, Bronx, NY

Panelists:

CHRISTINA COYLE, MD; Albert Einstein College of Medicine, Bronx, NY

MICHAEL LIBMAN, MD; McGill University, Montreal, QC, Canada

PRISCILLA RUPALI, MD; Christian Medical College, Vellore, India



Maximum of 2.00 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Global ID/ HIV-STD-TB/Investigative ID/Pediatric ID/Trainee

193. Named Lecture

SHEA Lectureship

Friday, 3:45 – 4:15 p.m.

20ABCD

Objectives: At the conclusion of this session, participants will be able to:

- describe the principles of high reliability organizations
- discuss how infectious diseases physicians, healthcare epidemiologists, and antimicrobial stewardship leaders can promote interventions to achieve high reliability in healthcare
- frame their work and influence behavior change in the context of a high reliability model

Intended Audience: epidemiologists, hospital epidemiologists, infection preventionists.

Moderator:

SARA E. COSGROVE, MD, MS, FIDSA, FSHEA; Johns Hopkins Medical Institutions, Baltimore, MD

Speakers:

- 1711 3:45 p.m. My Worlds Collide: Infectious Diseases and High Reliability in Healthcare**
NEIL O. FISHMAN, MD, FIDSA, FSHEA;
University of Pennsylvania Perelman School of
Medicine, Philadelphia, PA



Maximum of 1.00 hours of *AMA PRA Category 1 Credit™*



ACPE 2 knowledge-based contact hours of pharmacy CE;
0221-9999-17-383-L04-P

Adult ID/Epidemiology and Infection Control/Investigative ID/Pediatric ID/Trainee

194. Oral Abstract Session

SHEA Featured Oral Abstract

Friday, 4:15 – 4:30 p.m.

20ABCD

Moderator:

SARA E. COSGROVE, MD, MS, FIDSA, FSHEA; Johns Hopkins Medical Institutions, Baltimore, MD

Speakers:

- 1712 4:15 p.m. The CDC SHIELD Orange County Project – Baseline Multi Drug-Resistant Organism (MDRO) Prevalence in a Southern California Region**
SUSAN S. HUANG, MD, MPH, FIDSA, FSHEA, University of California Irvine School of Medicine, Irvine, CA

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Global ID/HIV-STD-TB/Investigative ID/Pediatric ID/Trainee

195. Awards Session

Awards Session

Friday, 4:30 – 4:45 p.m.

20ABCD

Moderator:

SARA E. COSGROVE, MD, MS, FIDSA, FSHEA; Johns Hopkins Medical Institutions, Baltimore, MD

Awardees:

SHEA Antibiotic Stewardship Scholarship Award

SARA E. COSGROVE, MD, MS, FIDSA, FSHEA; Johns Hopkins Medical Institutions, Baltimore, MD

SHEA Mentor Scholar Award

KENT SEPKOWITZ, MD, FIDSA, FSHEA; Memorial Sloan Kettering Cancer Center, New York, NY

SHEA Mid-Career Scholarship Award

NASIA SAFDAR, MD, PHD, FSHEA; University of Wisconsin School of Medicine and Public Health, Madison, WI

SHEA Pediatric Scholarship Award

PRANITA TAMMA, MD, MHS; Johns Hopkins University School of Medicine, Baltimore, MD

SHEA William Jarvis Award

JACQUI S. REILLY, PHD, Glasgow Caledonian University, Glasgow, United Kingdom

SHEA Barry Farr Award

DAVID K. WARREN, MD, MPH, FIDSA; Washington University in St. Louis, St. Louis, MO

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Investigative ID/Trainee

196. Symposium

Influential Publications in Healthcare

Epidemiology and Infection Control in the Past Year

Friday, 4:45 – 5:45 p.m.

20ABCD

Objectives: At the conclusion of this session, participants will be able to:

- list at least three important publications in healthcare epidemiology and infection prevention
- describe the potential implications of these publications on policy and/or practice

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, members-in-training, microbiologists, researchers.

Moderator:

SARA E. COSGROVE, MD, MS, FIDSA, FSHEA; Johns Hopkins Medical Institutions, Baltimore, MD

Speakers:

- 1713 4:45 p.m. Influential Publications in Healthcare Epidemiology and Infection Control from the Past Year**

YEHUDA CARMELI, MD, MPH; Tel Aviv Medical Center, National Center Antibiotic Resistance, Tel Aviv, Israel

- 1714 5:05 p.m. Influential Publications in Healthcare Epidemiology and Infection Control from the Past Year**

L. SILVIA MUNOZ-PRICE, MD, PHD; Medical College of Wisconsin, Milwaukee, WI



Maximum of 1.00 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Global ID/HIV-STD-TB/Investigative ID/Pediatric ID/Trainee

IDWeek Town Hall 2.0 - Join the Conversation

Friday, 6 – 7:30 p.m.

06DE

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection

preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiology.

Moderators:

NESLI BASGOZ, MD, FIDSA; Massachusetts General Hospital, Boston, MA

RAVI JHAVERI, MD, FIDSA, FPIDS; University of North Carolina, Chapel Hill, NC

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Pediatric ID/Trainee

197. Meet-the-Professor Session

Active Surveillance Testing for MDROs: Where and When?

Saturday, 7 – 8:15 a.m. 01AB

Objectives: At the conclusion of this session, participants will be able to:

- describe when active surveillance culture is most important
- identify tests that are most effective for detecting MDRO colonization
- describe measures other than active surveillance culture for preventing infections

Intended Audience: epidemiologists, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, lab personnel, microbiologists, pharmacists.

Speakers:

1715 7 a.m. Prevention of MRSA Infections
MARY K. HAYDEN, MD, FIDSA, FSHEA; Rush University Medical Center, Chicago, IL

1716 7:30 a.m. Detecting CRE Colonization
PATRICIA SIMNER, PHD, D,(ABMM); Johns Hopkins Medical Institutions, Baltimore, MD

8 a.m. Q&A



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-17-289-L01-P

Adult ID/Global ID/Pediatric ID/Trainee

198. Meet-the-Professor Session

Combination Antifungal Treatment for Mold Infections: Pros and Cons

Saturday, 7 – 8:15 a.m. 11AB

Objectives: At the conclusion of this session, participants will be able to:

- describe the antifungal drug options for combination treatment against molds
- review the evidence in favor or against the use of combination antifungal therapy against mold infections

Intended Audience: academicians, clinicians, epidemiologists, fellows, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, pharmacists, researchers, scientists.

Moderators:

MICHAEL LIONAKIS, MD, SCD, FIDSA; National Institutes of Health, Bethesda, MD

DIMITRIOS P. KONTOYIANNIS, MD, SCD, PHD (HON), FIDSA; The University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:

1717 7 a.m. Combination Antifungal Treatment for Mold Infections: Pros

KIEREN MARR, MD, FIDSA; The Johns Hopkins Hospital, Baltimore, MD

1718 7:30 a.m. Combination Antifungal Treatment for Mold Infections: Cons

LINDSEY BADEN, MD, FIDSA; Brigham & Women's Hospital, Boston, MA

8 a.m. Q&A



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-17-290-L01-P

Adult ID/Epidemiology and Infection Control/Global ID/Pediatric ID/Trainee

199. Meet-the-Professor Session

Don't Make These Mistakes: Frequent Barriers in Antimicrobial Stewardship Programs

Co-organized with Society of Infectious Diseases Pharmacists

Saturday, 7 – 8:15 a.m. 07AB

Objectives: At the conclusion of this session, participants will be able to:

- apply lessons learned from “real-world” stewardship programs
- explain how to avoid pitfalls that set back a stewardship program
- plan how to turn a stewardship failure into a stewardship success

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, members-in-training, microbiologists, nurses, pharmacists.

Moderator:

DEBORAH GOFF, PHARM D; Ohio State University, Columbus, OH

Speakers:

1719 7 a.m. EDWARD SEPTIMUS, MD, FIDSA, FSHEA; HCA Inc., Nashville, TN

1720 7:30 a.m. ELIZABETH DODDS ASHLEY, PHARM D, MHS; University of Rochester Medical Center, Rochester, NY

8 a.m. Q&A



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-291-L01-P

Adult ID/Epidemiology and Infection Control/Pediatric ID 200. Meet-the-Professor Session

National Healthcare Safety Network Updates

Saturday, 7 – 8:15 a.m. 17AB

Objectives: At the conclusion of this session, participants will be able to:

- list important updates in NHSN definitions
- describe changes in NHSN surveillance and/or reporting methodologies

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists.

Moderator:

ARJUN SRINIVASAN, MD, FSHEA; Centers for Disease Control and Prevention, Atlanta, GA

Speakers:

- 1721 7 a.m. MARGARET DUDECK, MPH; Centers for Disease Control and Prevention, Atlanta, GA
8 a.m. Q&A



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 application-based contact hours of pharmacy
CE; 0221-9999-17-292-L05-P

Adult ID/HIV-STD-TB 201. Meet-the-Professor Session

Our Toughest Coinfection Cases

Saturday, 7 – 8:15 a.m. 16AB

Objectives: At the conclusion of this session, participants will be able to:

- identify key aspects of the medical evaluation, diagnosis and treatment of HIV-infected patients with complicated conditions
- evaluate different strategies and options in managing complicated HIV-infected patients.

Intended Audience: clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases physicians, members-in-training, nurses, pharmacists, public health practitioners.

Moderator:

ERIC DAAR, MD; Harbor-UCLA Medical Center, Torrance, CA

Speakers:

- 1722 7 a.m. GAIL BOLAN, MD; Centers for Disease Control and Prevention, Atlanta, GA
1723 7:30 a.m. JEFFREY LENNOX, MD, FIDSA; Emory University School of Medicine, Atlanta, GA
8 a.m. Q&A



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-293-L01-P

Adult ID/Pediatric ID 202. Meet-the-Professor Session

Outpatient Parenteral Antimicrobial Therapy

Co-organized with the IDSA Clinical Affairs Committee

Saturday, 7 – 8:15 a.m. 05AB

Objectives: At the conclusion of this session, the participants will be able to:

- explain the role of OPAT in infectious disease practice
- describe how OPAT can be used in different patient populations
- discuss new opportunities for patient care using OPAT

Intended Audience: academicians, clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, pharmacists.

Moderators:

ANNE H. NORRIS, MD; University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
AKSHAY SHAH, MD, FIDSA; Metro Infectious Disease Consultants, Northville, MI

Speakers:

- 1724 7 a.m. **What's Next in OPAT?/Leveraging Prevention in Readmissions/Measuring Outcomes in OPAT**
SHIREESHA DHANIREDDY, MD, FIDSA; University of Washington, Seattle, WA
1725 7:20 a.m. **Cutting Edge OPAT**
LISA GORSKI, MS, RN, HHCNS-BC, CRNI; Wheaton Franciscan Healthcare, Mequon, WI



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-294-L01-P

Adult ID/Epidemiology and Infection Control/Global ID/ HIV-STD-TB/Investigative ID/Pediatric ID/Trainee 203. Meet-the-Professor Session

Tuberculosis Management

Saturday, 7 – 8:15 a.m. 14AB

Objectives: At the conclusion of this session, participants will be able to:

- explain why TB is widespread in HIV and persons in resource poor environments
- describe methods to prevent TB in those with HIV
- identify TB therapy for those with HIV
- review how TB management guidelines were developed
- explain what is new and controversial in the 2016 TB guidelines

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists,

hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists.

Moderator:

WESLEY VAN VOORHIS, MD, PHD, FIDSA; University of Washington, Seattle, WA

Speakers:

- 1726** 7 a.m. **Prevention and Treatment of Tuberculosis in HIV Infected Individuals**
 CONSTANCE BENSON, MD, FIDSA; University of California, San Diego, San Diego, CA
- 1727** 7:30 a.m. **Tuberculosis and 2016 Guidelines**
 DAVID LEWINSOHN, MD, PHD; Oregon Health & Science University, Portland, OR
- 8 a.m. **Q&A**



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy
 CE; 0221-9999-17-295-L01-P

Adult ID/Pediatric ID/Trainee

204. Meet-the-Professor Session

Women in Infectious Diseases

Marriott Marquis
 Saturday, 7 – 8:15 a.m. Grand Ballroom 1 + 2

Objectives: At the conclusion of this session, participants will be able to:

- discuss compensation disparities across gender in ID
- describe barriers to career enhancement across gender in ID
- identify strategies to enhance career success and satisfaction

Intended Audience: academicians, clinicians, epidemiologists, fellows, infectious diseases pediatricians, infectious diseases physicians, members-in-training, pharmacists.

Moderators:

HILARY M. BABCOCK, MD, MPH; Washington University School of Medicine, St. Louis, MO
 KRISTINA BRYANT, MD, FIDS; University of Louisville School of Medicine, Louisville, KY

Speakers:

- 1728** 7 a.m. **Gender Disparities in ID Task Force Report**
 WENDY ARMSTRONG, MD, FIDSA; Emory University, Atlanta, GA
- 1729** 7:15 a.m. **Academia**
 VICTORIA J. FRASER, MD, FIDSA, FSHEA; Washington University School of Medicine, St. Louis, MO
- 1730** 7:30 a.m. **Community/Private Practice**
 ALLISON LIDDELL, MD; Texas Health Presbyterian Dallas, Dallas, TX
- 1731** 7:45 a.m. **Clinical Practice**
 ANN T. MACINTYRE, DO, MHS; Mercy Hospital, Miami, FL



Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*



ACPE 1.25 knowledge-based contact hours of pharmacy
 CE; 0221-9999-17-296-L04-P

Adult ID/Pediatric ID/Trainee

205. Interactive Session

Challenging Transplant Cases: When Transplant ID Specialists say, What?!

Co-organized with the American Society of Transplantation

Saturday, 8:30 – 10 a.m.

06CF

Objectives: At the conclusion of this session, participants will be able to:

- explain the challenges in the diagnosis and management of infectious syndromes after organ and stem cell transplantation

Intended Audience: academicians, clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, researchers, scientists.

Panelists:

MICHAEL G. ISON, MD, FIDSA; Northwestern University, Chicago, IL
 MARIAN MICHAELS, MD, MPH; Children's Hospital of Pittsburgh, Pittsburgh, PA
 ATUL HUMAR, MD; University of Toronto, Toronto, ON, Canada
 STEVEN PERGAM, MD, MPH, FIDSA; Fred Hutchinson Cancer Research Center, Seattle



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.50 application-based contact hours of pharmacy
 CE; 0221-9999-17-299-L01-P

Epidemiology and Infection Control/Pediatric ID

206. Symposium

Advancing Pediatric Infection Prevention: Moving the Needle

Saturday, 8:30 – 10 a.m.

15AB

Objectives: At the conclusion of this session, participants will be able to:

- list the best practices for surgical site infection prevention in children
- describe controversies surrounding the diagnosis, treatment and prevention of *C. difficile* in children
- outline the healthcare burden of hospital-onset sepsis in children and prevention initiatives

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, members-in-training, nurses, pharmacists, public health practitioners.

Moderators:

GALIT HOLZMANN-PAZGAL, MD, FSHEA; University of Texas Health Sciences Center at Houston, Houston, TX
LYNN RAMIREZ, MD; University of California San Francisco, San Francisco, CA

Speakers:

1732 8:30 a.m. **Advancing Surgical Site Infection Prevention**
ANN-CHRISTINE NYQUIST, MD, MSPH, FPIDS; University of Colorado School of Medicine, Aurora, CO

1733 8:55 a.m. ***Clostridium difficile*: Persistent Challenges**
LARRY KOCIOLEK, MD, MSCI; Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

1734 9:20 a.m. **Preventing Hospital-Onset Sepsis**
W. CHARLES HUSKINS, MD, MSC, FIDSA, FSHEA, FPIDS; Mayo Clinic, Rochester, MN

9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-297-L01-P

Adult ID/Global ID/HIV-STD-TB/Investigative ID/Pediatric ID/Trainee

207. Symposium

Bad Bugs: Emerging High Consequence Viruses

Saturday, 8:30 – 10 a.m.

14AB

Objectives: At the conclusion of this session, participants will be able to:

- describe the clinical manifestations of Ebola and Lassa virus and New World Arenavirus infections and disease epidemiology
- describe the sequelae of Ebola and Lassa disease
- list the latest updates in emerging poxviruses, and disease epidemiology

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, microbiologists, pharmacists, researchers, scientists, vaccinologists.

Moderators:

INGER DAMON, MD, PHD, FIDSA; Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA
DANIEL BAUSCH, MD, MPH & TM; World Health Organization, Geneva, Switzerland

Speakers:

1735 8:30 a.m. **Lassa and South America Arenaviruses: New Looks at the Forgotten Viral Hemorrhagic Fevers**
DANIEL BAUSCH, MD, MPH&TM; World Health Organization, Geneva, Switzerland

1736 8:55 a.m. **Ebola Virus Disease and Its Consequence(s): Update from a Steep Learning Curve™**

IAN CROZIER, MD; Infectious Diseases Institute, Kampala, Uganda

1737 9:20 a.m. **Beyond Smallpox Eradication: the Continuing Threat of Poxviruses**

BRETT PETERSEN, MD, MPH; Centers for Disease Control and Prevention, Atlanta, GA

9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-298-L01-P

Adult ID/Epidemiology and Infection Control/Pediatric ID/Trainee

208. Symposium

Clostridium difficile Diagnostics

Saturday, 8:30 – 10 a.m.

11AB

Objectives: At the conclusion of this session, participants will be able to:

- list the strengths and weakness of PCR diagnostics for *Clostridium difficile* infection
- identify alternative tests for diagnosis of *Clostridium difficile* infection
- describe future directions for diagnosing and managing *Clostridium difficile* infections

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners.

Moderators:

JEAN PATEL, PHD, D(ABMM); Centers of Disease Control and Prevention, Atlanta, GA
RANDALL HAYDEN, MD; St. Jude Children's Research Hospital, Memphis, TN

Speakers:

1738 8:30 a.m. **The Benefits of PCR Diagnostics**
FERRIC C. FANG, MD; University of Washington, Seattle, WA

1739 8:55 a.m. **The Pitfalls of PCR Diagnostics and Alternatives**
CHRISTOPHER POLAGE, MD; University of California, Sacramento, CA

1740 9:20 a.m. **The Future of *Clostridium difficile* Diagnostics**
LAWRENCE MCDONALD, MD; Centers for Disease Control and Prevention, Atlanta, GA

9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-300-L01-P

209. Symposium

Combination Therapies for Super-Bugs

Saturday, 8:30 – 10 a.m.

06AB

Objectives: At the conclusion of this session, participants will be able to:

- appraise the current approaches for combination therapy in bacterial and fungal pathogens
- review the clinical data related to the use of combination therapies in relevant bacterial and fungal pathogens
- discuss advantages and disadvantages of combination therapy against bacterial and fungal pathogens.

Intended Audience: academicians, clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, pharmacists, researchers, scientists.

Moderators:

CESAR ARIAS, MD, PHD, FIDSA; University of Texas McGovern School of Medicine, Houston, TX
DAVID ANDES, MD, FIDSA; University of Wisconsin School of Medicine and Public Health, Madison, WI
ROBERT A. BONOMO, MD, FIDSA; Case Western Reserve University School of Medicine, Cleveland, OH

Speakers:

- 1741 8:30 a.m. **Combination Therapies for Gram-Positive Super-Bugs**
USHA STIEFEL, MD; Case Western Reserve University School of Medicine, Cleveland, OH
- 1742 8:55 a.m. **Combination Therapies for Gram-Negative Super-Bugs**
DAVID NICOLAU, PHARM.D., FIDSA; Hartford Hospital, Hartford, CT
- 1743 9:20 a.m. **Combination Therapies for Fungal Pathogens**
LUIS OSTROSKY-ZEICHNER, MD, FIDSA, FSHEA; McGovern Medical School, Houston, TX
- 9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-301-L01-P

Adult ID/Pediatric ID/Trainee

210. Symposium

Infectious Disease Telehealth

Co-organized with the IDSA Clinical Affairs Committee

Saturday, 8:30 – 10 a.m.

17AB

Objectives: At the conclusion of this session, participants will be able to:

- describe how to build and introduce a telehealth program
- discuss how billing is done for telehealth services
- recognize how telehealth is applied in everyday ID practice

Intended Audience: academicians, clinicians, epidemiologists, fellows, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, pharmacists.

Moderator:

BRIAN WOOD, MD; Mountain West AIDS Education and Training Center ECHO Telehealth Program, Seattle, WA

Speakers:

- 1744 8:30 a.m. **How to Build a Telehealth Program**
JOHN SCOTT, MD, MSC, FIDSA; University of Washington, Seattle, WA
- 1745 8:50 a.m. **Billing Telehealth**
JAVEED SIDDIQUI, MD, MPH; TeleMed2U, Roseville, CA
- 1746 9:10 a.m. **A Day in the Life: Step by Step Telehealth**
JEREMY YOUNG, MD, MPH; University of Illinois At Chicago, Chicago, IL



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 application-based contact hours of pharmacy
CE; 0221-9999-17-302-L04-P

Adult ID/Epidemiology and Infection Control/Pediatric ID

211. Symposium

Promising Interventions in Antimicrobial Stewardship Programs

Saturday, 8:30 – 10 a.m.

05AB

Objectives: At the conclusion of this session, participants will be able to:

- describe the role of post-prescription review in antimicrobial stewardship programs
- recognize the potential impact of biomarkers on antimicrobial stewardship
- describe the potential role of allergy testing in antimicrobial stewardship

Intended Audience: epidemiologists, fellows, hospital epidemiologists, infection preventionists, members-in-training.

Moderators:

DEBORAH GOFF, PHARM.D.; Ohio State University, Columbus, OH
TARA PALMORE, MD; National Institutes of Health Clinical Center, Bethesda, MD

Speakers:

- 1747 8:30 a.m. **Time Out! Post Prescription Review**
KERRI THOM, MD; University of Maryland, Baltimore, MD
- 1748 8:55 a.m. **Use of Biomarkers to Guide Antibiotic Administration and Duration**
JENNIFER HAN, MD, MSCE; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
- 1749 9:20 a.m. **Improved Allergy Testing to Support Antimicrobial Stewardship Programs**
KEITH HAMILTON, MD; Hospital of the University of Pennsylvania, Philadelphia, PA
- 9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-303-L01-P

Adult ID/Pediatric ID

212. Symposium

Shots Across the Bow: Debates in Vaccinology

Saturday, 8:30 – 10 a.m.

06DE

Objectives: At the conclusion of this session, participants will be able to:

- discuss the complexities of the use of pneumococcal vaccines in adults
- list the benefits and risks of using rotavirus vaccine in an inpatient setting in a very immune naive population
- discuss the future of the use of LAIV in the United States

Intended Audience: academicians, clinicians, epidemiologists, healthcare workers, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, investigators, pharmacists, public health practitioners, vaccinologists.

Moderators:

H. KEIPP TALBOT, MD MPH FIDSA; Vanderbilt University Medical Center, Nashville, TN
ANDREW PAVIA, MD, FIDSA, FSHEA, FPIDS; University of Utah School of Medicine, Salt Lake City, UT

Speakers:

1750 8:30 a.m. **Should the Conjugate Pneumococcal Vaccines Be Used in Adults**

1751 **Pro**
CYNTHIA WHITNEY, MD, MPH, FIDSA; Centers for Disease Control and Prevention, Atlanta, GA

1752 **Con**
RON DAGAN, MD, FIDSA; Ben-Gurion University of the Negev, Beer-Sheva, Israel

1753 9 a.m. **Rotavirus Vaccine Should Be Used in the NICU**

1754 **Pro**
ANDI L. SHANE, MD, MPH, MSC, FIDSA, FPIDS; Emory University School of Medicine, Atlanta, GA

1755 **Con**
EVAN J. ANDERSON, MD; Emory University School of Medicine, Atlanta, GA

1756 9:30 a.m. **LAIV Should Be Reintroduced Into the US Vaccination Program**

1757 **Pro**
MARK LOEB, MD, MSC; McMaster University, Hamilton, ON, Canada

1758 **Con**
EMILY T. MARTIN, MPH, PHD; University of Michigan School of Public Health, Ann Arbor, MI



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-304-L01-P

Adult ID/HIV-STD-TB

213. Symposium

Update on the HIV Prevention and Care Cascade

Saturday, 8:30 – 10 a.m.

16AB

Objectives: At the conclusion of this session, participants will be able to:

- describe improvements in patient outcomes along the care continuum
- evaluate same day initiation of antiretroviral therapy for HIV-infected patients
- describe strategies to support patients with adhering to treatment and staying connected to their medical care

Intended Audience: fellows, HIV clinicians, HIV specialists, infectious diseases physicians, members-in-training, pharmacists, public health practitioners.

Moderators:

JEANNE MARRAZZO, MD, MPH, FIDSA, University of Alabama at Birmingham School of Medicine, Birmingham, AL
SUSAN S. PHILIP, MD, MPH; San Francisco Department of Health, San Francisco, CA

Speakers:

1759 8:30 a.m. **Progress Along the Care Cascade**
PATRICK SULLIVAN, DVM, PHD; Emory University, Atlanta, GA

1760 8:55 a.m. **Novel Approaches to Improving Outcomes: Same Day Initiation of ART**
SERENA KOENIG, MD, MPH; Brigham & Women's Hospital, Boston, MA

1761 9:20 a.m. **Adherence and Care Engagement**
MICHAEL J. MUGAVERO, MD, MHSC; University of Alabama at Birmingham, Birmingham, AL

9:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-305-L02-P

Adult ID/Investigative ID/Trainee

214. Oral Abstract Session

Host-Pathogen Integration

Saturday, 8:30 – 10 a.m.

07AB

Moderators:

VINCENT B. YOUNG, MD, PHD, FIDSA; University of Michigan, Ann Arbor, MI
MARCIA GOLDBERG, MD, FIDSA; Harvard Medical School, Cambridge, MA

Speakers:

1762 8:30 a.m. **Complicated *Staphylococcus aureus* bacteremia (SAB) is associated with genetic variation in *GLS2***

VANCE FOWLER JR., MD, MHS, FIDSA,
Duke University, Durham, NC

- 1763** 8:45 a.m. **Role of M cells in human mucosal immunity to *Mycobacterium tuberculosis***
MICHAEL U. SHILOH, MD, PHD, University of Texas Southwestern Medical Center, Dallas, TX
- 1764** 9 a.m. **Investigating Immune Correlates of Protection to Tuberculosis Using an Ultra-Low Dose Infection in a Mouse Model**
BENJAMIN GERN, MD, Center for Infectious Disease Research, Seattle, WA
- 1765** 9:15 a.m. **Strain-level determination of the contribution of gut microbiota to the development of bacteremia in patients undergoing stem cell transplantation**
TESSA ANDERMANN, MD, MPH, Stanford, Stanford, CA
- 1766** 9:30 a.m. **The Gut Microbiota of Healthy Infants in the Community is a Reservoir for ESBL and Carbapenemase Producing Bacteria.**
MEHREEN ARSHAD, MD, Duke University Medical Center, Durham, NC
- 1767** 9:45 a.m. **Longitudinal comparison of the microbiota during *Klebsiella pneumoniae* carbapenemase-producing *Klebsiella pneumoniae* (KPC-Kp) acquisition in Long-Term Acute Care Hospital (LTACH) patients**
ANNA SEEKATZ, PHD, University of Michigan, Ann Arbor, MI

No CME credit is offered for this session.

No CPE credit is offered for this session.

215. Oral Abstract Session

National Trends in HAIs

Saturday, 8:30 – 10 a.m.

08

Moderators:

MICHAEL BELL, MD; Centers for Disease Control and Prevention, Atlanta, GA
REKHA MURTHY, MD, FIDSA; Cedars-Sinai Health System, Los Angeles, CA

Speakers:

- 1768** 8:30 a.m. **Reduction in the prevalence of healthcare-associated infections in U.S. acute care hospitals, 2015 versus 2011**
SHELLEY S. MAGILL, MD, PHD, Centers for Disease Control and Prevention, Atlanta, GA
- 1769** 8:45 a.m. **Assessing The Impact of The National Healthcare Safety Network's (NHSN's) New Baseline on Acute Care Hospital Standardized Infection Ratios (SIRs)**
MINN SOE, MBBS, MPH, Centers for Disease Control and Prevention, Atlanta, GA
- 1770** 9 a.m. **Wide range of Carbapenem-resistant Enterobacteriaceae incidence and trends in Emerging Infections Program surveillance, 2012–2015**

NADEZHDA DUFFY, MD, MPH, Centers for Disease Control and Prevention, Atlanta, GA

- 1771** 9:15 a.m. **The Effect of National Healthcare Safety Network (NHSN) Rebaselining on Community Hospital SIRs**
CHRISTOPHER HOSTLER, MD, MPH, Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC
- 1772** 9:30 a.m. **Uropathogens and antibiotic resistance among nursing home residents - National Healthcare Safety Network (NHSN)**
TANIECE EURE, MPH, Centers for Disease Control and Prevention, Atlanta, GA
- 1773** 9:45 a.m. **Reductions in MRSA, *Clostridium difficile* and Intensive Care Unit (ICU) Acquired Bloodstream Infections and over 9 years from 276 United Kingdom ICUs**
RAHUL BATRA, MD, Centre for Clinical Infection & Diagnostics Research, Guy's and St Thomas NHS Foundation Trust, London, United Kingdom

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID

216. Oral Abstract Session

The Fungus Among-us: Clinical Advances

Saturday, 8:30 – 10 a.m.

01AB

Moderators:

TOBIAS M. HOHL, MD, PHD, FIDSA; Memorial Sloan Kettering Cancer Center, New York, NY
DIMITRIOS P. KONTOYIANNIS, MD, SCD, PHD (HON), FIDSA; The University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:

- 1774** 8:30 a.m. **Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT1): A Prospective, Multicenter Study of the T2Candida Panel**
CORNELIUS J. CLANCY, MD, University of Pittsburgh, School of Medicine, Pittsburgh, PA
- 1775** 8:43 a.m. **Impact of Infectious Diseases Consultation on Mortality in Patients with Candidemia**
CARLOS MEJIA, MD, Washington University, Saint Louis, MO
- 1776** 8:56 a.m. **Breath-Based Diagnosis of Invasive Mucormycosis (IM)**
SOPHIA KOO, MD, FIDSA, Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
- 1777** 9:09 a.m. **Corticosteroid Use Following the Onset of Invasive Aspergillosis is Associated with Increased Mortality: A Propensity Score-Matched Study**
MICHAEL ABERS, MD, Massachusetts General Hospital, Harvard Medical School, Boston, MA

- 1778 9:22 a.m. **Catheter-free period over 2 days is associated with better outcome in catheter-related bloodstream infection due to candida**
TAKAHIRO MATSUO, MD, St. Luke's International Hospital, Tokyo, Japan
- 1779 9:35 a.m. **Prevalence of and Factors Associated with *Clostridium difficile* Co-infection Among Patients with Candidemia, United States, 2014–2016.**
SHARON TSAY, MD, Centers for Disease Control and Prevention, Atlanta, GA
- 1780 9:48 a.m. **Routine Cryptococcal Antigen Screening in Solid Organ Transplant Recipients: Is it Time to Save Lives and Money?**
IGE GEORGE, MD, Washington University School of Medicine, Saint Louis, MO

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Global ID

217. Oral Abstract Session

Zika: A to Z

Saturday, 8:30 – 10 a.m.

02

Moderators:

WESLEY VAN VOORHIS, MD, PHD, FIDSA; University of Washington, Seattle, WA
ROBERTA DEBIASI, MD, MS, FIDSA; Childrens National Health System/GWU School of Medicine, Washington, DC

Speakers:

- 1781 8:30 a.m. **Galidesivir, a direct-acting antiviral drug, abrogates viremia in Rhesus macaques challenged with Zika virus**
JAMES WHITNEY, PHD, Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA
- 1782 8:45 a.m. **Outcomes of women with laboratory evidence of Zika infection in pregnancy**
NAIOMI GUNARATNE, BS, University of Miami Miller School of Medicine, Miami, FL
- 1783 9 a.m. **Environmental and Climatic Risk Factors for Zika and Chikungunya Virus Infections in Rio de Janeiro, Brazil, 2015–16**
TREVON FULLER, PHD, MA, UCLA, Los Angeles, CA
- 1784 9:15 a.m. **Differential Neuronal Susceptibility and Apoptosis in Congenital Zika Virus Infection**
ROBERTA DEBIASI, MD; MS, Childrens National Health System/GWU School of Medicine, Washington, DC
- 1785 9:30 a.m. **Risk Factors Associated with Persistence of Zika Virus Nucleic Acid in Serum and Semen**
MATTHEW LOZIER, PHD, Centers for Disease Control and Prevention, San Juan, PR, Puerto Rico

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/HIV-STD-TB/Pediatric ID/Trainee

218. Interactive Session

State of the Art: Clinical Management of Hepatitis C

Saturday, 10:30 a.m. – noon

06CF



Objectives: At the conclusion of this session, participants will be able to:

- compare treatment of HCV infection in adolescents with adults
- review the principles of treating HCV infection in persons with renal insufficiency
- recognize causes of liver disease after SVR

Intended Audience: academicians, clinicians, fellows, HIV clinicians, infectious diseases pediatricians, infectious diseases physicians, pharmacists.

Moderators:

DAVID THOMAS, MD, MPH, FIDSA; Johns Hopkins University School of Medicine, Baltimore, MD
SUSANNA NAGGIE, MD, MHS, FIDSA; Duke University Medical Center, Durham, NC

Panelists:

DAVID WYLES, MD; Denver Health, Denver, CO
RAVI JHAVERI, MD, FIDSA, FPIDS; University of North Carolina, Chapel Hill, NC
KENNETH SHERMAN, MD; University Cincinnati Medical Center, Cincinnati, OH



Maximum of 1.50 hours of AMA PRA Category 1 Credit™



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-311-L01-P

Adult ID/HIV-STD-TB/Investigative ID/Pediatric ID/Trainee

219. Symposium

B Cell Biology: What the ID Physician Needs to Know

Saturday, 10:30 a.m. – noon

17AB

Objectives: At the conclusion of this session, participants will be able to:

- identify the biology of B cells, natural antibodies, and autoantibodies, and their role in immune responses.

Intended Audience: academicians, clinicians, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, microbiologists, researchers, scientists, vaccinologists.

Moderator:

MARCIA GOLDBERG, MD, FIDSA; Massachusetts General Hospital and Harvard Medical School, Cambridge, MA

Speakers:

- 1787 10:30 a.m. **Overview of B Cell Biology**
SHIV PILLAI, MD, PHD; Harvard Medical School, Cambridge, MA

1788 10:55 a.m. **B Cells and Autoantibodies**
PAUL UTZ, MD; Stanford University, Stanford, CA

1789 11:20 a.m. **Role of Natural Antibodies and IgM in Infection**
NICOLE BAUMGARTH, DVM, PHD; University of California at Davis, Davis, CA

11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Adult ID/Pediatric ID/Trainee

220. Symposium

Beating and Breathing: Updates in the Management of Transplant Candidates and Recipients

Saturday, 10:30 a.m. – noon

16AB

Objectives: At the conclusion of this session, participants will be able to:

- discuss the management of infections associated with mechanical circulatory devices, both as destination therapy and in the pre/peri transplant period
- list the updated guidelines related to managing fungal infections in thoracic transplant recipients
- outline the management of respiratory viral infections in hematopoietic stem cell transplant recipients

Intended Audience: clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, pharmacists.

Moderators:

RAYMUND R. RAZONABLE, MD, FIDSA; Mayo Clinic, Rochester, MN

RACHEL MILLER, MD, FIDSA; Duke University, Durham, NC

Speakers:

1790 10:30 a.m. **Infections Associated with Mechanical Circulatory Devices**

M. RIZWAN SOHAIL, MD, FIDSA; Mayo School of Graduate Medical Education, Rochester, MN

1791 10:55 a.m. **Management of Fungal Infections in Thoracic Transplant Recipients**

ORLA MORRISSEY, MD, PHD; Monash University, Melbourne, Australia

1792 11:20 a.m. **Management of Respiratory Virus Infections in Hematopoietic Stem Cell Transplantation**
ROY CHEMALY, MD, MPH, FIDSA; UT MD Anderson Cancer Center, Houston, TX

11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-306-L01-P

Adult ID/Epidemiology and Infection Control/Global ID/
Pediatric ID/Trainee

221. Symposium

Big Beasts in ID II

Saturday, 10:30 a.m. – noon

06AB

Objectives: At the conclusion of this session, participants will be able to:

- describe the current epidemiology of influenza virus infection
- define the factors leading to the increase in *Bordetella pertussis* infections in the last 20 years
- identify persons at risk for contracting coccidioidomycosis

Intended Audience: academicians, clinicians, epidemiologists, fellows, medical students and residents, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists.

Moderator:

SAMUEL SHELBURNE, MD, PHD, FIDSA; MD Anderson Cancer Center, Houston, TX

KATHLEEN WINTER, MPH, PHD, FIDSA; University of Kentucky College of Public Health, Lexington, KY

Speakers:

1793 10:30 a.m. **Influenza: What the Infectious Diseases Practitioner Needs to Know in 2017**

FREDERICK HAYDEN, MD, FIDSA; University of Virginia, Charlottesville, VA

1794 10:55 a.m. **Pertussis: What Happened in California and Where Do We Go From Here?**

KATHLEEN WINTER, MPH, PHD, FIDSA; University of Kentucky College of Public Health, Lexington, KY

1795 11:20 a.m. **Coccidioidomycosis: Taming the Biggest Beast of the Desert Southwest**

JOHN GALGANI, MD, FIDSA; University of Arizona, Tucson, AZ

11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-307-L01-P

Adult ID/Global ID/HIV-STD-TB/Investigative ID/Pediatric ID/Trainee

222. Symposium

Cryptococcus in 2017: Bench to Bedside

Saturday, 10:30 a.m. – noon

15AB

Objectives: At the conclusion of this session, participants will be able to:

- describe the therapeutic challenges of managing patients with cryptococcosis
- develop strategies to improve the outcomes of patients with cryptococcosis
- identify virulence determinants of *Cryptococcus neoformans*
- describe how the host responds to *Cryptococcus neoformans*
- explain the dynamic between cryptococcal virulence factors and host responses

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, pharmacists, researchers, scientists.

Moderators:

TIHANA BICANIC, MD; St George's University of London, London, United Kingdom
JOSHUA NOSANCHUK, MD, FIDSA; Albert Einstein College of Medicine, Bronx, NY

Speakers:

1796 10:30 a.m. An Overview of Host Defense Against Cryptococcus

LIISE-ANNE PIROFSKI, MD, FIDSA; Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY

1797 10:55 a.m. Novel Insights into Cryptococcal Virulence
ANDREW ALSPAUGH, MD; Duke University, Durham, NC

1798 11:20 a.m. Translating Insights from Research on Cryptococcus into Clinical Practice

TIHANA BICANIC, MD; St George's University of London, London, United Kingdom

11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-308-L01-P

Adult ID/HIV-STD-TB/Pediatric ID/Trainee

223. Symposium

HIV Prevention 2017

Saturday, 10:30 a.m. – noon

14AB

Objectives: At the conclusion of this session, participants will be able to:

- describe the latest approaches to vaccine development for HIV
- review best practices for increasing the uptake of PrEP in the US.
- discuss prevention strategies effective in Uganda and their applications in the U.S.

Intended Audience: fellows, HIV clinicians, HIV specialists, infectious diseases physicians, members-in-training, pharmacists, public health practitioners.

Moderators:

JEANNE MARRAZZO, MD, MPH, FIDSA, University of Alabama at Birmingham School of Medicine, Birmingham, AL
MICHELLE CESPEDES, MD, MS; Icahn School of Medicine at Mount Sinai, New York, NY

Speakers:

1799 10:30 a.m. HIV Vaccine Update

PAUL GOEPFERT, MD; University of Alabama at Birmingham School of Medicine, Birmingham, AL

1800 10:55 a.m. Optimizing PrEP in the US: Where We Are, and Where We're Going

RAPHAEL J. LANDOVITZ, MD, MSC; University of California Los Angeles, Los Angeles, CA

1801 11:20 a.m. Scaling Up Combination Prevention Globally: Lessons from the Rakai Community Cohort

KATE GRABOWSKI, PHD, SCM; Johns Hopkins School of Medicine, Baltimore, MD

11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-309-L01-P

Pediatric ID/Trainee

224. Symposium

Kawasaki Disease: What's New?

Saturday, 10:30 a.m. – noon

11AB

Objectives: At the conclusion of this session, participants will be able to:

- discuss the current status of establishing an etiology and diagnostic testing for Kawasaki Disease.
- describe adjunctive and second/third line therapies that can be considered for Kawasaki Disease patients.
- review recommendations for follow up of Kawasaki Disease patients based on degree of coronary artery involvement.

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, pharmacists, researchers.

Moderators:

SAMUEL DOMINGUEZ, MD, PHD; University of Colorado School of Medicine, Aurora, CO
PREETI JAGGI, MD; The Ohio State University, Columbus, OH

Speakers:

1802 10:30 a.m. Where are We on Kawasaki Disease Etiology and Diagnostics?

ANNE ROWLEY, MD, FPIDS; Northwestern University Feinberg School of Medicine, Chicago, IL

1803 10:55 a.m. Treatment of Kawasaki Disease- Beyond IVIG

JANE C. BURNS, MD, FIDSA; University of California, San Diego, La Jolla, CA

1804 11:20 a.m. Follow-up of Kawasaki Disease Patients

JANE NEWBURGER, MD; Boston Children's Hospital, Boston, MA

11:45 a.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-310-L01-P

225. Symposium

Using Whole Genome Sequencing to Advance Infection Prevention

Saturday, 10:30 a.m. – noon

05AB

Objectives: At the conclusion of this session, participants will be able to:

- review the opportunities and challenges in current whole genome sequencing techniques
- identify the role of whole genome sequencing in the evaluation of outbreaks
- determine the opportunities afforded by whole genome sequencing in assessing endemic infections in healthcare settings

Intended Audience: academicians, clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, microbiologists, pharmacists, public health practitioners, researchers.

Moderators:

MARY K. HAYDEN, MD, FIDSA, FSHEA; Rush University Medical Center, Chicago, IL
AMY MATHERS, MD; University of Virginia Health System, Charlottesville, VA

Speakers:

- 1805 10:30 a.m. Whole Genome Sequencing to Evaluate Endemic Infections in Healthcare**
BRENDAN KELLY, MD, MSCE; University of Pennsylvania School of Medicine, Philadelphia, PA
- 1806 10:55 a.m. Whole Genome Sequencing for Outbreak Investigation and Response**
DERRICK CROOK, PROFESSOR; University of Oxford, Oxford, United Kingdom
- 1807 11:20 a.m. Genomics: The Ultimate Molecular Epidemiology?**
WILLIAM HANAGE, PHD; Harvard University, Boston, MA

11:45 a.m. Q&A



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-312-L01-P

Adult ID/Epidemiology and Infection Control/Global ID/Investigative ID/Pediatric ID/Trainee

226. Symposium

Zika Without Borders

Co-organized with the Brazilian Society of Infectious Diseases and the Pan-American Society of Infectious Diseases

Saturday, 10:30 a.m. – noon

06DE

Objectives: At the conclusion of this session, participants will be able to:

- review the epidemiology of Zika in Brazil and important clinical manifestations in relation with microcephaly

- discuss unusual presentations of Zika Virus disease in endemic countries in Latin America
- identify the impact of Zika in the United States

Intended Audience: academicians, clinicians, epidemiologists, fellows, HIV clinicians, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, pharmacists, researchers, scientists, vaccinologists.

Moderators:

CESAR ARIAS, MD, PHD, FIDSA; University of Texas McGovern School of Medicine, Houston, TX
WESLEY VAN VOORHIS, MD, PHD, FIDSA; University of Washington, Seattle, WA
CHRISTINA COYLE, MD; Albert Einstein College of Medicine, Bronx, NY

Speakers:

- 1808 10:30 a.m. Brazilian Contributions to the Knowledge of Zika Virus Infection**
PATRICIA BRASIL, MD, PHD; Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
- 1809 10:55 a.m. Unusual Presentations of Zika**
ALFONSO J RODRIGUEZ-MORALES, MD, MSC; Universidad Tecnológica de Pereira, Pereira, Colombia
- 1810 11:20 a.m. Zika in the United States**
J. ERIN STAPLES, MD, PHD; Centers for Disease Control and Prevention, Fort Collins, CO
- 11:45 a.m. Q&A



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-313-L01-P

227. Oral Abstract Session

HIV: Co-Morbidities and Co-Infections

Saturday, 10:30 a.m. – noon

08

Moderators:

TURNER OVERTON, MD; University of Alabama at Birmingham, Birmingham, AL
COLLEEN KELLEY, MD, MPH; Emory University, Infectious Diseases, Decatur, GA

Speakers:

- 1811 10:30 a.m. Changes in invasive pneumococcal disease among adults living with HIV following introduction of 13-valent pneumococcal conjugate vaccine, 2008–2014**
MIWAKO KOBAYASHI, MD, MPH, Centers for Disease Control and Prevention, Atlanta, GA
- 1812 10:45 a.m. Cancer Mortality among Persons with Human Immunodeficiency Virus Infection in New York City, 2001–2015**
CHITRA RAMASWAMY, MBBS, DCGO, MPH, New York City Department of Health and Mental Hygiene, Long Island City, NY
- 1813 11 a.m. Fatty Liver Disease in HIV: Predictors and Response to Statin Therapy**

VANESSA EL KAMARI, MD, Case Western Reserve University, Cleveland, OH

- 1814 11:15 a.m. Leveraging the ART Advantage: diabetes and hypertension along the HIV care cascade in rural South Africa**
JENNIFER MANNE-GOEHLER, MD, DSC, MSC, Beth Israel Deaconess Medical Center, Boston, MA
- 1815 11:30 a.m. Prevalence of Systemic Hypertension Among HIV-Infected and HIV-Uninfected Young Adults**
PATRICK RYSCAVAGE, MD, Institute of Human Virology of the University of Maryland School of Medicine, Baltimore, MD
- 1816 11:45 a.m. Effect of Macrolide Prophylactic Therapy on AIDS-Defining Conditions and HIV-Related Mortality**
MARK KRISTOFFER PASAYAN, MD, Research Institute for Tropical Medicine, Muntinlupa, Philippines

No CME credit is offered for this session.

No CPE credit is offered for this session.

228. Oral Abstract Session

Late Breaker Oral Abstracts

Saturday, 10:30 a.m. – noon

02

Moderators:

ERIC DAAR, MD; Harbor-UCLA Medical Center, Torrance, CA
NATASHA CHIDA, MD; Johns Hopkins University School of Medicine, Elkridge, MD

Speakers:

- LB-1 10:30 a.m. A Randomized Trial of High Dose Influenza Vaccine in Adult Solid Organ Transplant Recipients**
YOICHIRO NATORI, MD, University Health Network, Toronto, ON, Canada
- LB-2 10:40 a.m. Cap-Dependent Endonuclease Inhibitor S-033188 for the Treatment of Influenza: Results from a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study in Otherwise Healthy Adolescents and Adults with Seasonal Influenza**
SIMON PORTSMOUTH, MD, SHIONOGI INC., Florham Park, NJ
- LB-3 10:50 a.m. Possible impact of wide-scale vaccination against serogroup B *Neisseria meningitidis* on gonorrhoea incidence rates in one region of Quebec, Canada**
PHILIPPE DE WALS, MD, PHD, INSPQ, Montreal, QC, Canada
- LB-4 11 a.m. Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results**
ERIC S DAAR, MD, Harbor-UCLA Medical Center, Torrance, CA

LB-5 11:10 a.m. The SEP-SEQ Trial - Clinical Validation of the Karius Plasma Next-Generation Sequencing Test for Pathogen Detection in Sepsis

SIMONE THAIR, PHD, Stanford University Medical Center, Stanford, CA

LB-6 11:20 a.m. Ethanol Lock Treatment and Secondary Prophylaxis for Central Line-Associated Bloodstream Infection in Pediatric Hematology and Oncology: A Randomized, Double-Blind, Placebo-Controlled, Intervention Trial

JOSHUA WOLF, MBBS FRACP, St. Jude Children's Research Hospital, Memphis, TN

LB-7 11:30 a.m. Prevention of Recurrent Acute Uncomplicated Cystitis by Increasing Daily Water in Premenopausal Women: A Prospective Randomized Controlled Study

MARIACRISTINA VECCHIO, PHARM, Danone Nutricia Research, Palaiseau, France

LB-8 11:40 a.m. Sorting the Wheat from the Chaff: Vaccine-Associated Rash Illness Occurring amidst a Large Measles Outbreak — Minnesota, 2017

RAJAL MODY, MD, MPH, Office of Public Health Preparedness and Response, Centers for Disease Control and Prevention, Atlanta, GA

LB-9 11:50 a.m. Broad Spectrum Investigational Agent GS-5734 for the Treatment of Ebola, MERS Coronavirus and Other Pathogenic Viral Infections with High Outbreak Potential

ROBERT JORDAN, PHD, Gilead Sciences, Inc, Foster City, CA

No CME credit is offered for this session.

No CPE credit is offered for this session.

— Epidemiology and Infection Control/Pediatric ID — 229. Oral Abstract Session

Miscellaneous Advances in Vaccinology

Saturday, 10:30 a.m. – noon

07AB

Moderators:

RUTH LYNFIELD, MD, FIDSA; Minnesota Department of Health, St. Paul, MN
OCTAVIO RAMILO, MD, FPIDS; Nationwide Children's Hospital, Columbus, OH

Speakers:

- 1817 10:30 a.m. Analysis of a Phase 2b Study of GEN-003, a Genital Herpes Immunotherapy, Showed Significant Reductions in Viral Shedding and Lesion Rate Versus Placebo**
THOMAS C. HEINEMAN, MD, PHD, Genocoe Biosciences, Cambridge, MA
- 1818 10:45 a.m. Immunogenicity of Inactivated Varicella Zoster Vaccine (ZV_{IN}) in Autologous Hematopoietic Stem Cell Transplant (auto-HSCT) Recipients**
MICHAEL BOECKH, MD, FIDSA, Fred Hutchinson Cancer Research Center, Seattle, WA

- 1819** 11 a.m. **Vaccine effectiveness against influenza-associated hospitalization among children aged <13 years using a hospital-based surveillance system in Minnesota, 2013 – 2016**
ASHLEY FOWLKES, MPH, Centers for Disease Control and Prevention, Atlanta, GA
- 1820** 11:15 a.m. **Impact of Prior Vaccination History on Risk of Vaccine Failure with Live Attenuated and Inactivated Influenza Vaccines in Children, 2013–14 through 2015–16**
HUONG Q. MCLEAN, PHD, MPH, Marshfield Clinic Research Institute, Marshfield, WI
- 1821** 11:30 a.m. **Impact of a Provider Communication Training Intervention on Adolescent Human Papillomavirus Vaccination: A Cluster Randomized, Clinical Trial**
SEAN O'LEARY, MD, MPH, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO
- 1822** 11:45 a.m. **Interferon gene expression as marker of immune maturation and response to vaccination**
RAQUEL GIACOMELLI CAO, MD, PHD, Nationwide Children's Hospital, Columbus, OH

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Investigative ID/Pediatric ID

230. Oral Abstract Session

Thinking Beyond Your Hospital: Stewardship on a Broader Scale

Saturday, 10:30 a.m. – noon

01AB

Moderators:

WHITNEY BUCKEL, PHARMD; Intermountain Healthcare, Murray, UT
HEIDI WALD, MD, MSPH; University of Colorado School of Medicine, Aurora, CO

Speakers:

- 1823** 10:30 a.m. **Decrease in Antibiotic Sales in Brazil After New Control Legislation**
DOUGLAS SLAIN, PHARMD, BCPS, FCCP, FASHP, West Virginia University, Morgantown, WV
- 1824** 10:45 a.m. **Colorado's Statewide Antimicrobial Stewardship (AMS) Collaborative Final Results: Facilitating Syndrome-Specific Interventions for Skin and Soft Tissue Infection (SSTI) and Urinary Tract Infection (UTI)**
HEIDI WALD, MD, MSPH, University of Colorado School of Medicine, Aurora, CO
- 1825** 11 a.m. **Improving Antimicrobial Use by Implementing the CDC Antimicrobial Stewardship Core Elements Across a Diverse Healthcare System**
MICHAEL A. LANE, MD, MPH, MSC, Washington University School of Medicine, St. Louis, MO

- 1826** 11:15 a.m. **Outcomes of a Provincial Pilot Program to Reduce Unnecessary Urine Culturing and Antibiotic Overuse in Long-term Care**
KEVIN BROWN, PHD, University of Toronto, Toronto, ON, Canada
- 1827** 11:30 a.m. **Impact of an antibiotic stewardship program in long-term care facilities: A nursing home network experience**
FABIAN ANDRES ROMERO, MD, Infectious Disease, NMS Healthcare, Hyattsville, MD
- 1828** 11:45 a.m. **A Multicenter Stewardship Initiative to Decrease Excessive Duration of Antibiotic Therapy for the Treatment of Community-Acquired Pneumonia (CAP)**
FARNAZ FOOLAD, PHARMD, The University of Texas MD Anderson Cancer Center, Houston, TX

No CME credit is offered for this session.

No CPE credit is offered for this session.

Poster Sessions

Poster Hall CD

Saturday	10:00 a.m. – 6:00 p.m.	On display
	12:30 – 2 p.m.	Lunch in the Exhibit Hall
	12:30 – 2:00 p.m.	Presenters at posters

#	Session Title
231.	Clinical Study with New Antibiotics and Antifungals (1829–1888)
232.	Clinical: Bacteremia and Endocarditis (1889–1949)
233.	Clinical: Respiratory Track (1950–2011)
234.	Diagnostics: Bacterial Identification & Resistance (2012–2051)
235.	Diagnostics: Diarrheal Disease (2052–2065)
236.	Diagnostics: Mycology (2066–2081)
237.	Diagnostics: Novel Diagnostics (2082–2096)
238.	Diagnostics: Pharyngitis (2097–2101)
239.	Diagnostics Mycobacteriology (2102–2116)
240.	Stewardship: Impact of Diagnostics (2117–2139)
241.	HAI: Device Related Infections (2140–2164)
242.	HAI: MRSA, MSSA, and Other Gram Positives (2165–2192)
243.	HAI: Surgical Site Infections (2193–2219)
244.	HIV and HBV (2220–2223)
245.	HIV and HCV (2224–2237)
246.	HIV and Women (2238–2242)
247.	HIV: Pediatrics (2243–2251)
248.	HIV: Sexually Transmitted Infections (2252–2261)
249.	Non-Tuberculous Mycobacteria: Epidemiology and Management (2262–2281)
250.	Pediatric Bacterial Infections: From A to Z (2281–2302)
251.	Pediatric Potpourri (2303–2319)
252.	Pediatric Virology (2320–2346)
253.	Transplant Infections: Epidemiology (2347–2364)
254.	Transplantation: Bacterial Infections (2365–2380)
255.	Transplantation: Pretransplantation Screening + Evaluation (2381–2384)
256.	Transplantation: Prophylaxis and Prediction (2385–2404)
257.	Transplantation Fungal Infections (2405–2409)
258.	Tuberculosis: Epidemiology and Management (2410–2427)
259.	Viral Infections in Transplantation (2428–2451)

260. Advances in Diagnostics and Impact on Stewardship

Saturday, 12:30 – 2 p.m.

Poster Hall CD

Speakers:

2452 **Group Leader**
Speaker TBD

No CME credit is offered for this session.

No CPE credit is offered for this session.

261. Poster Discussion Round

Gram Positives in Healthcare Epidemiology

Saturday, 12:30 – 2 p.m.

Poster Hall CD

Speakers:

2453 **Group Leader**
DAVID P. CALFEE, MD, MS, FIDSA, FSHEA;
Weill Cornell Medicine, New York, NY

No CME credit is offered for this session.

No CPE credit is offered for this session.

262. Poster Discussion Round

New Antibiotics

Saturday, 12:30 – 2 p.m.

Poster Hall CD

Speakers:

2454 **Group Leader**
HELEN W. BOUCHER, MD, FIDSA; Tufts
Medical Center, Boston, MA

No CME credit is offered for this session.

No CPE credit is offered for this session.

263. Poster Discussion Round

Pediatric Bacterial Infections

Saturday, 12:30 – 2 p.m.

Poster Hall CD

Speakers:

2455 **Group Leader**
JOHN S. BRADLEY, MD, FIDSA, FPIDS;
University of California at San Diego School of
Medicine, San Diego, CA

No CME credit is offered for this session.

No CPE credit is offered for this session.

264. Poster Discussion Round

Pediatric Viral Infections

Saturday, 12:30 – 2 p.m.

Poster Hall CD

Speakers:

2456 **Group Leader**
JANET ENGLUND, MD, FIDSA, FPIDS;
University of Washington/Seattle Children's
Hospital, Seattle, WA

No CME credit is offered for this session.

No CPE credit is offered for this session.

265. Poster Discussion Round

HIV and Hepatitis

Saturday, 12:30 – 2 p.m.

Poster Hall CD

Speakers:

2457 **Group Leader**
Speaker TBD

No CME credit is offered for this session.

No CPE credit is offered for this session.

266. Poster Discussion Round

Transplants

Saturday, 12:30 – 2 p.m.

Poster Hall CD

Speakers:

2458 **Group Leader**
EMILY BLUMBERG, MD, FIDSA; University
of Pennsylvania Health System, Philadelphia, PA

No CME credit is offered for this session.

No CPE credit is offered for this session.

267. Interactive Session

ID BugBowl

Saturday, 2 – 3:30 p.m.

06AB

Intended Audience: academicians, clinicians, epidemiologists, fellows, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public.

Moderator:

ADARSH BHIMRAJ, MD; Cleveland Clinic, Cleveland, OH

Come match your ID Trivia knowledge, with contestants from three Southern California programs! From Anaplasmosis to Zika,

any topic is fair game. Watch the battle and see who comes out on top, in the 2017 IDBugBowl.



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

Epidemiology and Infection Control/Pediatric ID/Trainee

268. Symposium

Antimicrobial Stewardship Programs in Pediatrics

Saturday, 2 – 3:30 p.m.

17AB

Objectives: At the conclusion of this session, participants will be able to:

- implement antibiotic stewardship programs in diverse pediatric populations
- formulate effective communication strategies for talking with parents about antibiotics

Intended Audience: epidemiologists, hospital epidemiologists, infection preventionists, infectious diseases physicians, members-in-training, nurses, pharmacists, public health practitioners.

Moderators:

MICHAEL SMITH, MD; University of Louisville, Louisville, KY
ANGELA MYERS, MD, MPH, FPIDS; Children's Mercy Hospital, Kansas City and University of Missouri-Kansas City School of Medicine, Kansas City, MO

Speakers:

2459 2 p.m. **Challenges with NICU Stewardship**
DMITRY DUKHOVNY, MD, MPH; Oregon Health and Science, Portland, OR

2460 2:25 p.m. **Outpatient Antibiotic Control**
JASON NEWLAND, MD, MED, FPIDS; Washington University, St. Louis, St. Louis, MO

2461 2:50 p.m. **Talking to Parents about Antibiotic Use**
RITA MANGIONE-SMITH, MD, MPH; University of Washington, Seattle, WA

3:15 p.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-314-L01-P

Adult ID/Epidemiology and Infection Control/Pediatric ID/Trainee

269. Symposium

Challenges in the Management of Complicated Urinary Tract Infections

Saturday, 2 – 3:30 p.m.

06DE

Objectives: At the conclusion of this session, participants will be able to:

- describe how antimicrobial resistance contributes to difficulty in treating complicated urinary tract infections

- define approaches to the treatment and prevention of pediatric urinary tract infections
- explain how presence of surgical devices, such as nephrostomy tubes, impacts the occurrence and treatment of urinary tract infections

Intended Audience: academicians, clinicians, epidemiologists, fellows, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, researchers, scientists.

Moderators:

SAMUEL SHELburne, MD, PHD, FIDSA; MD Anderson Cancer Center, Houston, TX

BARBARA W. TRAUTNER, MD, PHD, FIDSA; Baylor College of Medicine, Houston, TX

Speakers:

2462 2 p.m. **Antimicrobial Resistance in Complicated Urinary Tract Infections**
KALPANA GUPTA, MD, MPH; Yale University, West Haven, CT

2463 2:25 p.m. **New Approaches to Recurrent/Complicated Urinary Tract Infections in the Pediatric Setting**
DAVID HAINS, MD; Riley Hospital for Children at Indiana University Health, Indianapolis, IN

2464 2:50 p.m. **From Neo-Bladders to Nephrostomy Tubes: The Surgical Anatomy of Complicated Urinary Tract Infections**
CHRISTOPHER SAIGAL, MD, MPH; Geffen School of Medicine at UCLA, Los Angeles, CA

3:15 p.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-315-L01-P

Adult ID/Epidemiology and Infection Control/Trainee

270. Symposium

Critical Medical Devices: Friend and Foe

Saturday, 2 – 3:30 p.m.

14AB

Objectives: At the conclusion of this session, participants will be able to:

- describe recent outbreaks associated with hemodialysis machines
- explain the current epidemiology and recommendations to address mycobacterial infections associated with heater/cooler devices
- identify key steps in assessing the infection control risks posed by new medical devices

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners.

Moderators:

ARJUN SRINIVASAN, MD, FSHEA; Centers for Disease Control and Prevention, Atlanta, GA
EBBING LAUTENBACH, MD, MPH, MSCE, FIDSA, FSHEA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
THOMAS TALBOT, MD, MPH, FIDSA, FSHEA; Vanderbilt University, Nashville, TN

Speakers:

- 2465** 2 p.m. **ERCP/Scope Cleaning Update**
PRITI PATEL, MD, MPH; Centers for Disease Control and Prevention, Atlanta, GA
- 2466** 2:25 p.m. **Mycobacterium chimaera and Heater-Cooler Units: Update on a Global Outbreak**
DANIEL J. DIEKEMA, MD, FIDSA, FSHEA; University of Iowa Hospitals and Clinics, Iowa City, IA
- 2467** 2:50 p.m. **Developing a Device Risk Assessment (ICRA)**
THOMAS TALBOT, MD, MPH, FIDSA, FSHEA; Vanderbilt University, Nashville, TN
- 3:15 p.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-316-L01-P

— Adult ID/Global ID/Investigative ID/Pediatric ID — 271. Symposium

Donations with Unintended Consequences: A Multidisciplinary Approach to Reduce Blood, Cell, Tissue, and Organ Donor-Transmitted Infections

Co-organized with the American Association of Blood Banks

Saturday, 2 – 3:30 p.m. 20D

Objectives: At the conclusion of this session, participants will be able to:

- review the mechanism of infection transmission through tissue transplantation and blood transfusion
- evaluate the role of diagnostic Microbiology in the prevention and diagnosis of donor transmitted infections
- recognize the importance of biovigilance in the prevention of donor derived infections

Intended Audience: academicians, clinicians, fellows, healthcare workers, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, members-in-training, microbiologists, nurses, researchers, scientists.

Moderators:

RAYMUND R. RAZONABLE, MD, FIDSA; Mayo Clinic, Rochester, MN
RACHEL MILLER, MD; Duke University, Durham, NC

Speakers:

- 2468** 2 p.m. **Epidemiology and Clinical Impact of Blood, Cell, Tissue, and Organ Donor Transmitted Infections**
ATUL HUMAR, MD; University of Toronto, Toronto, ON, Canada
- 2469** 2:25 p.m. **Laboratory Response to Emerging Threats of Blood, Cell, and Tissue Donor Transmitted Infections**
STEVE KLEINMAN, MD; University of British Columbia, Victoria, BC, Canada
- 2470** 2:50 p.m. **Role of Biovigilance in Preventing Infectious Disease Transmission**
DOUGLAS STRONG, PHD; WHO Notify Project, Seattle, WA
- 3:15 p.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

— Adult ID/HIV-STD-TB/Pediatric ID/Trainee — 272. Symposium

Holistic Management of Patients with HIV

Saturday, 2 – 3:30 p.m. 16AB

Objectives: At the conclusion of this session, participants will be able to:

- identify key issues to effectively manage patients with HIV during pregnancy
- identify risk of heart disease in patients with HIV
- describe the effects of smoking in patients with HIV and strategies for assisting patients with smoking cessation

Intended Audience: fellows, HIV clinicians, HIV specialists, infectious diseases physicians, medical students and residents, members-in-training, pharmacists, public health practitioners.

Moderators:

JEANNE MARRAZZO, MD, MPH, FIDSA; University of Alabama at Birmingham School of Medicine, Birmingham, AL
AADIA RANA, MD; The Warren Alpert Medical School of Brown University, Providence, RI

Speakers:

- 2471** 2 p.m. **HIV and Pregnancy**
ANDREA CIARANELLO, MD, MPH; Massachusetts General Hospital, Boston, MA
- 2472** 2:20 p.m. **HIV and the Heart**
VIRGINIA TRIANT, MD, MPH; Massachusetts General Hospital, Boston, MA
- 2473** 2:40 p.m. **HIV and Smoking Cessation**
JOHN T. BROOKS, MD; Centers for Disease Control and Prevention, Atlanta, GA



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-317-L02-P

273. Symposium

Hot, Hot, Hot, Topics in Public Health

Saturday, 2 – 3:30 p.m.

05AB

Objectives: At the conclusion of this session, participants will be able to:

- describe the role of transmission in global epidemics of multi-drug resistant tuberculosis
- describe one aspect of the public health response to the emergence of pathogens with novel resistance mechanisms
- describe two of the epidemiologic features of patients with acute flaccid myelitis of unknown cause in the United States

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists.

Moderators:

PATRICIA M. GRIFFIN, MD, FIDSA; Centers for Disease Control and Prevention, Atlanta, GA
CINDY FRIEDMAN, MD; Centers for Disease Control and Prevention, Atlanta, GA

Speakers:

- 2474 2 p.m. **The Role of Transmission in Global Epidemics of Multidrug Resistant Tuberculosis**
SARITA SHAH, MD, MPH; Centers for Disease Control and Prevention, Atlanta, GA
- 2475 2:25 p.m. **Public Health Response to Emergence of Pathogens with Novel Resistance Mechanisms**
ALEXANDER KALLEN, MD, MPH; Centers for Disease Control and Prevention, Atlanta, GA
- 2476 2:50 p.m. **Investigations of Acute Flaccid Myelitis of Unknown Cause in the United States**
MANISHA PATEL, MD, MS; Centers for Disease Control and Prevention, Atlanta, GA
- 3:15 p.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-318-L01-P

— Adult ID/Investigative ID/Pediatric ID/Trainee —

274. Symposium

New Anti-Infective Clinical Trials that Will Change Your Practice

Saturday, 2 – 3:30 p.m.

11AB

Objectives: At the conclusion of this session, participants will be able to:

- discuss the results and methods of recent trials in antivirals
- describe the results and methods of recent trials in antibacterials
- identify the results and methods of recent trials in antifungals

Intended Audience: academicians, clinicians, epidemiologists, fellows, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists.

Moderators:

DAVID VAN DUIN, MD, PHD; University of North Carolina, Chapel Hill, NC
FRANCISCO M. MARTY, MD, FIDSA; Brigham and Women's Hospital, Boston, MA

Speakers:

- 2477 2 p.m. **Recent Trials in Non-HIV Antivirals**
FRANCISCO M. MARTY, MD, FIDSA; Brigham and Women's Hospital, Boston, MA
- 2478 2:25 p.m. **Recent Trials in Antibacterials**
SUSAN J. REHM, MD, FIDSA; Cleveland Clinic, Cleveland, OH
- 2479 2:50 p.m. **Recent Trials in Antifungals**
GEORGE R. THOMPSON, MD, FIDSA; University of California, Davis, Davis, CA
- 3:15 p.m. **Panel Discussion**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy
CE; 0221-9999-17-319-L01-P

Adult ID/Epidemiology and Infection Control/Investigative
ID/Pediatric ID/Trainee

275. Symposium

The Cutting Edge of Science in Pediatric Transplantation

Saturday, 2 – 3:30 p.m.

15AB

Objectives: At the conclusion of this session, participants will be able to:

- review the challenges and infectious issues associated with xenotransplantation
- explain the biomarkers for Post-Transplant Lymphoproliferative Disorders in pediatric transplant patients
- describe the role of metagenomics for detection of colonization, invasion, and patient-to-patient transmission of multidrug resistant bacteria among transplant patients

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, pharmacists, researchers, scientists, other: transplantation phys.

Moderators:

BETSY C. HEROLD, MD, FIDSA, FPIDS; Albert Einstein College of Medicine, Bronx, NY
HAYLEY A. GANS, MD, FIDSA; Stanford University Medical Center, Stanford, CA

Speakers:

2480 2 p.m. **Challenges and Infectious Issues Associated with Xenotransplantation**
MARIAN MICHAELS, MD, MPH; Children's Hospital of Pittsburgh, Pittsburgh, PA

2481 2:25 p.m. **Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children**
OLIVIA MARTINEZ, PHD; Stanford University, Stanford, CA

2482 2:50 p.m. **Precision Metagenomics Reveals Colonization, Invasion, and Patient-To-Patient Transmission of Multidrug Resistant Bacteria among Transplant Patients**
DAVID HASLAM, MD; Cincinnati Children's Hospital, Cincinnati, OH

3:15 p.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-320-L01-P

Adult ID/Epidemiology and Infection Control/Investigative ID/Pediatric ID/Trainee

276. Symposium

The Microbiome and Antibiotic Resistance

Saturday, 2 – 3:30 p.m. 06CF

Objectives: At the conclusion of this session, participants will be able to:

- describe the data that indicates that the microbiome can serve to harbor and disseminate antibiotic resistance determinants
- list the methods that can be used to identify and follow antibiotic resistance determinants in the human microbiome
- describe how the external environment can serve to harbor and spread antibiotic resistance determinants

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, publ.

Moderators:

VINCENT B. YOUNG, MD, PHD, FIDSA; University of Michigan, Ann Arbor, MI
LAWRENCE MCDONALD, MD; Centers for Disease Control and Prevention, Atlanta, GA

Speakers:

2483 2 p.m. **Antibiotic Resistance in Humans and the Natural and Built Environments**
ERICA HARTMANN, PHD; Northwestern University, Evanston, IL

2484 2:25 p.m. **Resistance Genes in the Microbiome of Critically Ill Patients**
WILLEM VAN SCHAIK, PHD; University of Birmingham, Birmingham, United Kingdom

2485 2:50 p.m. **Microbiome Indices for Drug Development, Diagnostics, Infection Control, and Public Health**

LAWRENCE MCDONALD, MD; Centers for Disease Control and Prevention, Atlanta, GA

3:15 p.m. **Q&A**



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-321-L01-P

Global ID

277. Oral Abstract Session

Global Infections

Saturday, 2 – 3:30 p.m.

01AB

Moderators:

WESLEY VAN VOORHIS, MD, PHD, FIDSA; University of Washington, Seattle, WA
CHRISTINA COYLE, MD; Albert Einstein College of Medicine, Bronx, NY

Speakers:

2486 2 p.m. **Arboviral Infections Following the 2016 Olympic and Paralympic Games in a Cohort of US Athletes and Support Staff**
KROW AMPOFO, MD, FIDSA, FPIDS., University of Utah School of Medicine, Salt Lake City, UT

2487 2:15 p.m. **Measles CEA**
EMILY HYLE, MD, MSC, Massachusetts General Hospital, Boston, MA

2488 2:30 p.m. **Clinical Implications of Asymptomatic *Plasmodium falciparum* Infections in Malawi**
ANDREA BUCHWALD, BA, Division of Malaria Research, Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD

2489 2:45 p.m. **Silent Polio Transmission: A Spatial Analysis**
CHRISTOPHER JARVIS, MSC, London School of Hygiene and Tropical Medicine, London, United Kingdom

2490 3 p.m. **Phylogenetic Analysis of an Unusual Increase in *Salmonella enterica* serovar Paratyphi A Infection among Travelers Returning from Myanmar**
TAKASHI MATONO, MD, National Institute of Infectious Diseases, Tokyo, Japan

2491 3:15 p.m. **Murine typhus: a common cause of acute febrile illness with potential for serious complications**
ZEESHAN AFZAL, MD, McAllen Family Medicine Residency Program, The University of Texas Rio Grande Valley, McAllen, TX

No CME credit is offered for this session.

No CPE credit is offered for this session.

278. Oral Abstract Session**Pneumococcal and Pertussis Vaccines**

Saturday, 2 – 3:30 p.m.

08

Moderator:

KATHRYN EDWARDS, MD, FIDSA; Vanderbilt University School of Medicine, Nashville, TN

Speakers:

- 2492** 2 p.m. **Direct and Indirect Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) Among Children and Adults in the U.S.**
TAMARA PILISHVILI, MPH, Centers for Disease Control and Prevention, Atlanta, GA
- 2493** 2:15 p.m. **Invasive pneumococcal disease in Massachusetts children six years following introduction of PCV13**
INCI YILDIRIM, MD MSC, Emory University, Atlanta, GA
- 2494** 2:30 p.m. **Analysis of Invasive Pneumococcal Infections Due to 13-Pneumococcal Conjugate Vaccine Serotypes at 8 US Children's Hospitals During 2014 to 2016**
SHELDON L. KAPLAN, MD, FIDSA, Baylor College of Medicine and Texas Children's Hospital, Houston, TX
- 2495** 2:45 p.m. **Changes in Pneumonia Incidence and Infant Mortality 5 Years Following Introduction of the 13-valent Pneumococcal Conjugate Vaccine in a "3 + 0" Schedule in Nicaragua**
SYLVIA BECKER-DREPS, MD, MPH, University of North Carolina At Chapel Hill, Chapel Hill, NC
- 2496** 3 p.m. **A population-based study of recurrent symptomatic *Bordetella pertussis* infections in children in California, 2010–2015**
LAUREN PLATT, BA, David Geffen School of Medicine at UCLA, Los Angeles, CA
- 2497** 3:15 p.m. **Effectiveness of prenatal Tdap immunization in the prevention of infant pertussis in the US**
SYLVIA BECKER-DREPS, MD, MPH, University of North Carolina At Chapel Hill, Chapel Hill, NC

No CME credit is offered for this session.

No CPE credit is offered for this session.

279. Oral Abstract Session**STIs: Diagnostics and Therapy**

Saturday, 2 – 3:30 p.m.

07AB

Moderators:

STEPHANIE E. COHEN, MD, MPH; San Francisco Department of Public Health, San Francisco, CA
KIMBERLY WORKOWSKI, MD, FIDSA; Emory University School of Medicine, Atlanta, GA

Speakers:

- 2498** 2 p.m. **Cervical Adenocarcinoma in Situ in the United States: Results from Population-based Laboratory Surveillance, 2008–2014.**
ANGELA AHLQUIST CLEVELAND, MPH, Centers for Disease Control and Prevention, Atlanta, GA
- 2499** 2:15 p.m. **Trends in *Neisseria gonorrhoeae* Antimicrobial Susceptibility in California, 2005–2016**
JULIET STOLTEY, MD, MPH, California Department of Public Health-STD Control Branch, Richmond, CA
- 2500** 2:30 p.m. **Asymptomatic Lymphogranuloma Venereum among Nigerian Men who have Sex with Men**
TREVOR CROWELL, MD, PHD, Walter Reed Army Institute of Research, Silver Spring, MD
- 2501** 2:45 p.m. **Real-Time PCR Targeting Mosaic *penA* XXXIV for Prediction of Extended-Spectrum Cephalosporins Susceptibility in Clinical *Neisseria gonorrhoeae* Isolates**
PEERA HEMARAJATA, MD, PHD, David Geffen School of Medicine at UCLA, Los Angeles, CA
- 2502** 3 p.m. **Electronic Reminder Notifications Improve Uptake of Targeted Ciprofloxacin Therapy for *Neisseria gonorrhoeae* Infections at the University of California, Los Angeles Health System**
LAO-TZU ALLAN-BLITZ, BA, University of California Los Angeles, Los Angeles, CA
- 2503** 3:15 p.m. **Gonorrhea (GC) and Chlamydia (CT) Infection in a Large, Well-Characterized Military Cohort: Prevalence, Incidence, Site of Infection, and Patient Characteristics.**
CHRISTA EICKHOFF, MD, Walter Reed National Military Medical Center, Bethesda, MD

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Global ID/
HIV-STD-TB/Investigative ID/Pediatric ID/Trainee

280. Named Lecture**Joseph E. Smadel Lecture**

Saturday, 3:45 – 4:30 p.m.

06AB

Objectives: At the conclusion of this session, participants will be able to:

- describe ecological factors that impact the emergence of infectious diseases
- discuss social factors that impact the transmission of infectious diseases
- describe approaches to detect, prevent and control emerging infectious diseases

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiology.

Moderator:

ANDREW PAVIA, MD, FIDSA, FSHEA, FPIDS; University of Utah School of Medicine, Salt Lake City, UT

Speakers:

- 2504 3:45 p.m. Human Activity and Infectious Disease Outbreaks: Can Insight Impact the Trajectory?**
RUTH LYNFIELD, MD, FIDSA; Minnesota Department of Health, St. Paul, MN



Maximum of 0.75 hours of *AMA PRA Category 1 Credit*TM



ACPE 0.75 knowledge-based contact hours of pharmacy CE; 0221-9999-17-322-L01-P

Adult ID/Epidemiology and Infection Control/Global ID/HIV-STD-TB/Investigative ID/Pediatric ID/Trainee

281. Awards Session

Awards Session

Saturday, 4:30 – 4:45 p.m. 06AB

Moderator:

WILLIAM POWDERLY, MD, FIDSA; Washington University School of Medicine, Saint Louis, MO

Awardees:

IDSA Clinical Teacher Award

MICHAEL BARZA, MD, FIDSA; Tufts University School of Medicine, Boston, MA

IDSA Oswald Avery Award for Early Achievement

WILLIAM J. STEINBACH, MD, FIDSA, FPIDS; Duke University Medical Center, Durham, NC

IDSA Walter E. Stamm Mentor Award

STEPHEN B. CALDERWOOD, MD, FIDSA; Massachusetts General Hospital, Wellesley, MA

IDSA Clinical Practice Innovation Award

KAVITA P. BHAVAN, MD, FIDSA; UT Southwestern Medical Center, Dallas, TX

IDSA D.A. Henderson Award for Outstanding Contributions to Public Health

F. MARC LaFORCE, MD, FIDSA; Serum Institute of India, Ltd., Pune, India, Haymarket, VA

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID

282. Session

Featured Oral Abstract

Saturday, 4:45 – 5 p.m. 06AB

Moderator:

ANDREW PAVIA, MD, FIDSA, FSHEA, FPIDS; University of Utah School of Medicine, Salt Lake City, UT

Speakers:

- 2505 4:30 p.m. Integration of Next-Generation Sequencing, Viral Sequencing, and Host-Response Profiling for the Diagnosis of Acute Infections**
HENRY CHENG, MS, Stanford University School of Medicine, Stanford, CA

No CME credit is offered for this session.

No CPE credit is offered for this session.

Adult ID/Epidemiology and Infection Control/Global ID/HIV-STD-TB/Investigative ID/Pediatric ID/Trainee

283. Named Lecture

Maxwell Finland Lecture

Saturday, 5 – 5:45 p.m. 06AB

Objectives: At the conclusion of this session, participants will be able to:

- discuss the critical differences between pulmonary and disseminated nontuberculous mycobacterial disease
- describe the different genetic lesions leading to either pulmonary or disseminated nontuberculous mycobacterial disease
- recognize the most common immune defects associated with disseminated nontuberculous mycobacterial disease

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiology.

Moderator:

PAUL AUWAERTER, MD, MBA, FIDSA; Johns Hopkins University, Baltimore, MD

Speakers:

- 2506 5 p.m. Understanding Nontuberculous Mycobacteria in the Human Context**
STEVEN HOLLAND, MD; National Institutes of Health, Bethesda, MD



Maximum of 0.75 hours of *AMA PRA Category 1 Credit*TM



ACPE 0.75 knowledge-based contact hours of pharmacy CE; 0221-9999-17-323-L01-P

Special Event

PIDS Business Meeting

Marriott Marquis Marina Ballroom

Saturday, 6 – 8 p.m.

PAUL SPEARMAN, MD, FIDSA, FPIDS; Emory University School of Medicine, Atlanta, GA

284. Mini-Symposium**Controversies in Prosthetic Joint Infections**

Sunday, 8 – 9 a.m.

11AB

Objectives: At the conclusion of this session, participants will be able to:

- describe methods for diagnosing prosthetic joint infection
- discuss the relationship between biofilm production and need for surgery to treat prosthetic joint infection

Intended Audience: academicians, clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, microbiologists, pharmacists, researchers, scientists.

Moderator:

SAMUEL SHELBURNE, MD, PHD, FIDSA; MD Anderson Cancer Center, Houston, TX

Speakers:

2507 8 a.m. In the Beginning Was the Biofilm... Surgical Controversies and New Perspectives in a Changing Panorama
CARLO LUCA ROMANO, MD; Galeazzi Orthopaedic Institute, Milan, Italy

2508 8:25 a.m. Diagnostic Challenges in Prosthetic Joint Infection
ROBIN PATEL, MD, FIDSA, D(ABMM); Mayo Clinic, Rochester, MN

8:50 a.m. **Q&A**

Maximum of 1.00 hours of *AMA PRA Category 1 Credit™*



ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-17-324-L01-P

Adult ID/Global ID/HIV-STD-TB/Pediatric ID

285. Mini-Symposium**Global Eradication of Hepatitis C**

Sunday, 8 – 9 a.m.

01AB

Objectives: At the conclusion of this session, participants will be able to:

- compare methods of eradicating HCV infection
- identify the key impediments for eradication
- discuss the roles of prevention and treatment in eradication

Intended Audience: clinicians, fellows, HIV clinicians, infectious diseases pediatricians, infectious diseases physicians, pharmacists.

Moderators:

DAVID THOMAS, MD, MPH, FIDSA; Johns Hopkins University School of Medicine, Baltimore, MD

JOHN WARD, MD; Centers for Disease Control and Prevention, Atlanta, GA

Speakers:

2509 8 a.m. Report of the NAM on HCV Elimination in North America
SHRUTI MEHTA, PHD, MPH; Johns Hopkins University, Baltimore, MD

2510 8:20 a.m. Plan for Implementation of Hepatitis C Elimination
JOHN WARD, MD; Centers for Disease Control and Prevention/NCHHSTP, Atlanta, GA



Maximum of 1.00 hours of *AMA PRA Category 1 Credit™*



ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-17-325-L01-P

Adult ID/Global ID/Pediatric ID/Trainee

286. Mini-Symposium**Maternal-Child Infections: Antimicrobial Pharmacokinetics and Pharmacodynamics**

Co-organized with Society of Infectious Diseases Pharmacists

Sunday, 8 – 9 a.m.

05AB

Objectives: At the conclusion of this session, participants will be able to:

- review antibiotic use during pregnancy
- discuss antimicrobial use in infants

Intended Audience: academicians, clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, pharmacists, researchers.

Moderators:

JOSEPH CANTEY, MD; University of Texas Health Science Center, San Antonio, TX

MILENA MCLAUGHLIN, PHARM.D, MSC, BCPS-AQ ID, AAHIVP; Midwestern University - Chicago College of Pharmacy, Chicago, IL

Speakers:

2511 8 a.m. Antibiotic Use During Pregnancy
BROOKE GRIFFIN, PHARM.D, BCACP; Midwestern University Chicago College of Pharmacy, Downers Grove, IL

2512 8:25 a.m. Antimicrobial Use in Infants
JACOB JOHNSON, MD; University of North Carolina at Chapel Hill, Chapel Hill, NC

8:50 a.m. **Q&A**

Maximum of 1.00 hours of *AMA PRA Category 7 Credit™*



ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-17-326-L01-P

287. Plenary Session

Closing Plenary: 21st Century Cures in Infectious Disease

Sunday, 9:15 – 10:45 a.m.

06AB

Objectives: At the conclusion of this session, participants will be able to:

- describe the role of treatment in elimination of HCV infection
- compare the roles of antiviral medication in prevention and treatment to eliminate HCV infection
- summarize the obstacles to elimination of HCV infection in the USA

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiology.

Moderators:

ANDREW PAVIA, MD, FIDSA, FSHEA, FPIDS; University of Utah School of Medicine, Salt Lake City, UT

RAJESH GANDHI, MD, FIDSA; Massachusetts General Hospital, Boston, MA

Speakers:

2513 9:15 a.m. Monoclonal Antibodies for Infectious Diseases: Why We are on the Threshold of a Major Therapeutic Revolution

JAMES E. CROWE JR., MD, FIDSA; Vanderbilt University Medical Center, Nashville, TN

2514 9:45 a.m. Pathogen Eradication: The View Ahead

CHRISTOPHER KARP, MD, FIDSA; Bill & Melinda Gates Foundation, Seattle, WA

2515 10:15 a.m. The Pivotal Role of Treatment in the Elimination of HCV

DAVID THOMAS, MD, MPH, FIDSA; Johns Hopkins University School of Medicine, Baltimore, MD



Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*



ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-17-384-L01-P

**Pediatric ID/Investigative ID/Epidemiology and Infection
Control/Adult ID**

28. Oral Abstract Session

CDI Prevention

Thursday, 8:30 a.m. – 10:00 a.m.

07AB

- 76 Association of Hospital-Onset *Clostridium difficile* Infection Rates and Antibiotic Use in U.S. Acute Care Hospitals, 2006–2012: an Ecologic Analysis
- 77 *Clostridium difficile*: investigating transmission patterns between symptomatic and asymptomatic patients using whole genome sequencing
- 78 Antibiotic Prescribing for Dental Procedures in Community-Associated *Clostridium difficile* cases, Minnesota, 2009–2015
- 79 Testing Stewardship: A ‘Hard Stop’ to Reduce Inappropriate *C. diff* Testing
- 80 Impact of an automatic hospital probiotic protocol on *Clostridium difficile* infection rates and antibiotic usage patterns
- 81 Etiology of Infectious Diarrhea in Patients Tested for *Clostridium difficile*: If It Isn't *Clostridium difficile*, What Is It?

Pediatric ID/Investigative ID/Adult ID

29. Oral Abstract Session

**Identification, Treatment, and Prevention of
Pediatric Bacterial Pathogens**

Thursday, 8:30 a.m. – 10:00 a.m.

05AB

- 82 The association of molecular characteristics, vancomycin MIC and clinical outcomes in methicillin-susceptible *Staphylococcus aureus* osteoarticular infections in children.
- 83 Impact of Vancomycin Serum Trough Concentrations and Vancomycin AUC/MIC on Vancomycin Response, In-Hospital Outcomes and Acute Kidney Injury in Pediatric *Staphylococcus aureus* Pneumonia
- 84 Comparative Effectiveness of Beta-lactams Versus Azithromycin for Treatment of Outpatient Pediatric Community-Acquired Pneumonia
- 85 Comprehensive detection of pathogens in immunocompromised children with bloodstream infections by next-generation sequencing
- 86 Passive Immunization with Anti-Pertussis Toxin Humanized Monoclonal Antibody Mitigates Clinical Signs of Pertussis Infection in Newborn Baboons

Pediatric ID/Adult ID

30. Oral Abstract Session

It's not just Bones: Skin and Bones

Thursday, 8:30 a.m. – 10:00 a.m.

01AB

- 88 Risk factors for early hip or knee prosthetic joint infection (PJI): Analysis of a nationwide American insurance claims dataset
- 89 U.S. Combat-related Invasive Fungal Wound Infection (IFI) Epidemiology and Wound Microbiology: Afghanistan Theater 2009–2014

- 90 Increasing *Kingella* Identification in Bone and Joint Infections in Young Children
- 91 Microbiology of Vertebral Osteomyelitis and Implications on Empiric Therapy
- 92 Concordance of Results of Blood and Tissue Cultures from Patients with Pyogenic Spondylitis
- 93 Home environmental contamination is associated with community-associated methicillin-resistant *Staphylococcus aureus* re-colonization in treated patients

Adult ID

40. Oral Abstract Session

Adult Central Nervous System Infection

Thursday, 10:30 a.m. – 12:00 p.m.

07AB

- 124 Current Epidemiology of Serogroup W Meningococcal Disease—United States, 2010–2015
- 125 Increased risk of invasive meningococcal disease associated with primary and secondary immunodeficiency
- 126 Use of Adjunctive Steroids and Incidence of Delayed Cerebral Venous Thrombosis in Adults with Bacterial Meningitis
- 127 Retrospective Evaluation of Infants 1–60 Days Evaluated for Meningitis Using the FilmArray® Meningitis/Encephalitis (ME) Panel
- 128 A Single-center, Quasi-experimental Study to Evaluate the Impact of a Multiplex Polymerase Chain Reaction System Combined with Antimicrobial Stewardship Intervention on Time to Targeted Therapy in Patients with Suspected Central Nervous System Infection
- 129 How do advanced molecular tests compare to routine clinical laboratory evaluation of CSF in meningoencephalitis? A Study in 10 Urban Emergency Departments across the United States.

Adult ID/Investigative ID/Pediatric ID/Trainee

41. Oral Abstract Session

Infections in Transplantation

Thursday, 10:30 a.m. – 12:00 p.m.

05AB

- 130 Does Detection of Respiratory Viral Infection in Upper Respiratory Tract (URT) Predict Lower Respiratory Tract (LRT) Disease in Hematopoietic Cell Transplant (HCT) Patients?
- 131 A Multicenter Study on Clinical Outcomes of Infections within 200 days of Liver Transplantation among Recipients age 65 years and older
- 132 Solid Organ Transplantation (SOT) & Data Mining: Bloodstream Infections (BSI) Have a Significant Impact on One-Year Survival, and qSOFA ≥ 2 Predicts 30-Day Mortality.
- 133 *Strongyloides stercoralis* Infection Incidence, Risk Factors and Outcomes Among Solid Organ Transplant Candidates and Recipients; a Florida Center Experience
- 134 Investigation of a Contaminated, Nationally-Distributed, Organ Transplant Preservation Solution – United States, 2016–2017
- 135 Outcomes of Kidney Transplantation with a CMV Matching Allocation Schema

**Pediatric ID/Investigative ID/Epidemiology and Infection
Control/Adult ID/Trainee**

42. Oral Abstract Session

**The Cutting Edge in Antimicrobial Resistance
Emergence Therapy**

Thursday, 10:30 a.m. – 12:00 p.m.

01AB

- 136** SYN-004 (ribaxamase) prevents New Onset *Clostridium difficile* Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study
- 137** Collaborative Use Repurposing Engine (CURE): FDA-NCATS/NIH Effort to Capture the Global Clinical Experience of Drug Repurposing to Facilitate Development of New Treatments for Neglected and Emerging Infectious Diseases
- 138** Cefazolin plus Clavulanic Acid Overcomes the Inoculum Effect in a Methicillin-Susceptible *Staphylococcus aureus* (MSSA) Rat Endocarditis Model
- 139** Epidemiology of Inappropriate Empiric Antibiotic Therapy for Bacteremia Based on Discordant *In vitro* Susceptibilities: Risk factors and Taxon-level Variation in Burden and Outcome in 156 US hospitals, 2000–2014
- 140** Evolution of antibiotic tolerance during oxacillin, daptomycin and dalbavancin therapy results in breakthrough *Staphylococcus aureus* bacteremias
- 141** Carbapenem-resistant Enterobacteriaceae (CRE) or Delayed Appropriate Therapy (DAT)—Does One Affect Outcomes More Than the Other Among Patients With Serious Infections Due to Enterobacteriaceae?

Pediatric ID/HIV-STD-TB/Global ID/Adult ID

93. Oral Abstract Session

**Preventing and Identifying New HIV
Infections**

Thursday, 2:00 p.m. – 3:30 p.m.

07AB

- 879** Medical Students Have Limited Awareness, Knowledge, Beliefs, and Experiences of Pre-exposure Prophylaxis (PrEP) for HIV Prevention
- 880** Characterization of New HIV Infections among Adults ≥45 Years – New York City, North Carolina, San Francisco, 2011–2013.
- 881** HIV Transmission Rates and Factors Associated with Recent HIV Infection: Results from the Ndhwa HIV Impact Assessment, South Nyanza, Kenya, 2012
- 882** Recent HIV Risk Behavior and Partnership Type Predict PrEP Adherence in Men who have Sex with Men
- 883** HIV antiretroviral resistance and transmission in mother-infant pairs enrolled in a large perinatal study
- 884** Missed Opportunities to Initiate Pre-exposure Prophylaxis in South Carolina – 2013–2016

Adult ID/Pediatric ID

94. Oral Abstract Session

Respiratory Infection Diagnosis

Thursday, 2:00 p.m. – 3:30 p.m.

01AB

- 885** Comparison of respiratory pathogen detections from routine hospital testing and expanded systematic testing from the Minnesota Severe Acute Respiratory Illness surveillance program, 2015–2016

- 886** Pneumococcal urinary antigen testing in US hospitals: underutilized and rarely acted upon.
- 887** Impact of Procalcitonin Guidance on the Management of Adults Hospitalized with Pneumonia
- 888** Detection of Respiratory Pathogens in Parapneumonic Effusions by Hypothesis-free, Next-Generation Sequencing (NGS)
- 889** Utility and challenges of a multi-pathogen diagnostic platform for characterizing public health threats of severe acute respiratory infections in six countries
- 890** Impact of Antivirals in the Prevention of Serious Outcomes Associated with Influenza in Hospitalized Canadian Adults: A Pooled Analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN)

Pediatric ID/Investigative ID/Adult ID

95. Oral Abstract Session

**Use ‘em and Lose ‘em: Preventing Antibiotic
Overuse**

Thursday, 2:00 p.m. – 3:30 p.m.

05AB

- 891** Antibiotic Consumption and Antibiotic Resistance across Organisms, Drugs, and Consumer Groups
- 892** Improvement of Gram Negative Susceptibility to Fluoroquinolones After Implementation of a Pre-Authorization Policy for Fluoroquinolone Use: A Decade-Long Experience
- 893** Inpatient plus post-discharge durations of therapy to identify antimicrobial stewardship opportunities at transitions of care
- 894** Prevent Antibiotic overUSE (PAUSE): Impact of a provider driven antibiotic-time out on antibiotic use and prescribing
- 895** Implementing Antimicrobial Stewardship in Two Community Nepali Hospitals
- 896** The Ontario Program To Improve AntiMicrobial USE (OPTIMISE): A Descriptive Analysis of Dispensed Antibiotics

HIV-STD-TB/Adult ID

99. Oral Abstract Session

Featured Oral Abstract

Thursday, 4:45 p.m. – 5:00 p.m.

20ABCD

- 898** Trends and Associations with PrEP Prescription among 602 New York City (NYC) Ambulatory Care Practices, 2014–16

Pediatric ID/Investigative ID/Global ID/Adult ID

121. Oral Abstract Session

**Emerging Paradigms: Pediatric Viral
Infections**

Friday, 8:30 a.m. – 10:00 a.m.

01AB

- 944** Perinatal Case Fatality Rate Related to Congenital Zika Syndrome in Brazil: a Cross-Sectional Study
- 945** Fetal and Postnatal Brain Imaging for the Detection of ZIKV Encephalopathy in the Fetus/Newborn
- 946** Maternal Immunization with a Single-Cycle Herpes Simplex Virus (HSV) Candidate Vaccine, ΔgD-2, Protects Neonatal Mice from Lethal Viral Challenge

- 947 Blood Viral Load (VL) Not Clinically Meaningful in Symptomatic Congenital Cytomegalovirus (cCMV) Infection
- 948 Incidence of *UL97* Resistance Mutations in Infants with Congenital Cytomegalovirus Disease Receiving Six Months of Oral Valganciclovir Therapy
- 949 Programmatic Congenital CMV Universal Screening Program

**Pediatric ID/Global ID/Epidemiology and Infection Control/
Adult ID**

**122. Oral Abstract Session
Public Health Potpourri
Friday, 8:00 a.m. – 10:30 a.m.
07AB**

- 950 Evidence for Cross-species Influenza A Virus Transmission within Swine Farms, China
- 951 Causes of in-hospital and post discharge mortality among patients hospitalized with laboratory-confirmed influenza, Influenza Hospitalization Surveillance Network, 2014–15.
- 952 Estimating Risk to Humans Exposed to Highly Pathogenic Avian Influenza Outbreaks in the United States, 2014–2017
- 953 Vaccine waning and mumps re-emergence in the United States
- 954 Interdisciplinary Public Health Intervention in a Multigenerational Tuberculosis (TB) Outbreak in Harris County, Texas: A Case Study with Implications for Disease Control Process Improvement and Transmission Cycle Interruption
- 955 Retail meat as a potential transmission source of community-acquired urinary tract infection

**123. Oral Abstract Session
Stewardship Tools
Friday, 8:30 a.m. – 10:00 a.m.
05AB**

- 956 Getting it Right the First Time: Relating Pharmacokinetic-Pharmacodynamic Target Attainment and Patient Outcomes
- 957 Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients
- 958 A Novel Antimicrobial Stewardship Program-Guided Procalcitonin Initiative for Emergency Department Diagnosis of Bacterial Pneumonia in New York City
- 959 Communicating Microbiology Results: It's Not Just What You Say, But How You Say It.
- 960 Can antibiotic de-escalation be measured without chart review? A proposed electronic definition
- 961 The Role of Negative Methicillin-Resistant *Staphylococcus aureus* Nasal Surveillance Swabs in Predicting the Need for Empiric Vancomycin Therapy

Pediatric ID/Investigative ID/Adult ID

**132. Oral Abstract Session
Advances in Management of Bacteremia and
Sepsis
Friday, 10:30 a.m. – 12:00 p.m.
07AB**

- 983 Doing the Same with Less: A Randomized, Multinational, Open-Label, Adjudicator-Blinded Trial of an Algorithm vs. Standard

of Care to Determine Treatment Duration for Staphylococcal Bacteremia

- 984 Induced Hypothermia in Patients with Septic Shock and Ventilator-demanding Respiratory Failure
- 985 The Emperor's New Clothes: Prospective Observational Evaluation of the Association between the Day 2 Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE)
- 986 Comparing the Outcomes of Adults with *Enterobacteriaceae* Bacteremia Receiving Short-Course versus Prolonged-Course Antibiotic Therapy
- 987 Infectious Disease Consultation Is Associated with Decreased Mortality with *Enterococcal* Bloodstream Infections
- 988 “Big data” and gram-negative resistance: a multiple logistic regression model using EMR data to predict carbapenem resistance in patients with *Klebsiella pneumoniae* bloodstream infection

**Trainee/Investigative ID/Epidemiology and Infection Control/
Adult ID**

**133. Oral Abstract Session
Diagnostics and Why They Matter
Friday, 10:30 a.m. – 12:00 p.m.
05AB**

- 989 Direct Detection and Identification of Prosthetic Joint Pathogens in Synovial Fluid (SF) by Metagenomic Shotgun Sequencing
- 990 Clinical Impact of Two Different Multiplex Respiratory Panel Assays on Management of Hospitalized Children aged ≤ 24 months
- 991 Clinical Yield of Routine Use of Molecular Testing for Adult Outpatients with Diarrhea
- 992 Enteropathogen Detection in Children with Diarrhea and/or Vomiting: A Cohort Study Comparing Rectal Flocked Swabs and Stool Specimens
- 993 Rapid phenotypic antibiotic susceptibility testing through RNA detection

**Trainee/Pediatric ID/Investigative ID/Epidemiology and
Infection Control/Adult ID**

**134. Oral Abstract Session
Where Did That Come From? Transmission
Risks in Healthcare
Friday, 10:30 a.m. – 12:00 p.m.
01AB**

- 995 Tracking an unusual carbapenemase-producing organism from drains to patient using whole genome sequencing
- 996 Bare Below the Elbows: A Randomized Trial to Determine if Wearing Short-Sleeved Coats Reduces the Risk for Pathogen Transmission
- 997 Defining Aerosol Generating Procedures and Pathogen Transmission Risks in Healthcare Settings
- 998 Utility of Routine Genomic Sequencing for Infection Control Surveillance
- 999 Invasive *Mycobacterium abscessus* Infection after Cardiac Surgery: Epidemiology and Clinical Outcomes
- 1000 Daily Chlorhexidine Bathing in General Hospital Units – Results of the ABATE Infection Trial (Active BATHing to Eliminate Infection)

Pediatric ID

135. Oral Abstract Session
PIDS Featured Abstracts
Friday, 10:30 a.m. – 11:00 a.m.
15AB

- 1001** A Single Dose Monoclonal Antibody (mAb) Immunoprophylaxis Strategy to Prevent RSV Disease in All Infants: Results of the First in Infant Study with MEDI8897
- 1002** Respiratory Syncytial Virus bronchiolitis: impact of second hand smoke exposure on immune profiles

Adult ID/HIV-STD-TB/Trainee

188. Oral Abstract Session
HIV: Modern ART
Friday, 2:00 p.m. – 3:30 p.m.
07AB

- 1684** Obesity Following Antiretroviral Therapy (ART) Initiation is Common and Influenced by Both Traditional and HIV-/ART-Specific Risk Factors
- 1685** Predictors of Linkage to and Retention in HIV Care Following Release from Connecticut Jails and Prisons
- 1686** 48-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1
- 1687** Selected CNS outcomes among INSTI antiretrovirals
- 1688** Viral Failure Among Persons Living with HIV Initiating Dolutegravir-Based vs. Other Recommended Regimens in Real-World Clinical Care Settings
- 1689a** Association Between Patient Portal Access and Viral Suppression Among People Living with HIV in a Large Southeastern Clinical Cohort
- 1689b** Week 48 results of EMERALD: A Phase 3, randomized, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors (bPI) plus emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) regimens to the once daily (QD), single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically-suppressed, HIV-1-infected adults

**Pediatric ID/Global ID/Epidemiology and Infection Control/
 Adult ID**

189. Oral Abstract Session
Hepatitis B and C Across the Lifespan
Friday, 2:00 p.m. – 3:30 p.m.
05AB

- 1690** Performance of NS3, NS5a AND NS5b Hepatitis C Virus (HCV) Antiviral Resistance Sequencing Assays
- 1691** Is there Failure to Screen for Hepatitis C in Newborns Suffering from Neonatal Abstinence Syndrome?
- 1692** The incidence of hepatocellular carcinoma is not increased in individuals with chronic hepatitis C after treatment with interferon-free regimens: an ERCHIVES study
- 1693** Antiviral Treatment among Hepatitis B Virus-Infected Pregnant Women — New York City and Michigan, 2013–2015
- 1694** Treatment as prevention for hepatitis C (TraP HepC). A real-world experience from the first 12 months of a nationwide elimination program in Iceland

- 1695** Maternal Risk Factors Associated with Inadequate Testing and Loss to Follow-up in Infants with Perinatal *Hepatitis C* Virus Exposure

Pediatric ID/Epidemiology and Infection Control/Adult ID

190. Oral Abstract Session
Resist! MDROs in Healthcare
Friday, 2:00 p.m. – 3:30 p.m.
01AB

- 1696** When a Home is Not a Home: MultiDrug-Resistant Organism (MDRO) Colonization and Environmental Contamination in 28 Nursing Homes (NHs)
- 1697** Prospective surveillance and rapid whole-genome sequencing detects two unsuspected outbreaks of carbapenemase-producing *Klebsiella pneumoniae* in a UK teaching hospital
- 1698** Comparison of 30- and 90-Day Mortality Rates in Patients with Cultures Positive for Carbapenem-resistant Enterobacteriaceae and Acinetobacter in Atlanta, 2011–2015
- 1699** Prevalence and acquisition of MRSA during incarceration at a large inner-city jail
- 1700** Differences in pre- and post-discharge methicillin-resistant *Staphylococcus aureus* (MRSA) infection rates by colonization status in US Department of Veterans Affairs (VA) hospitals
- 1701** The impact of active surveillance culture and decolonization programs on NICU MRSA transmission: A multicenter, mechanistic modeling approach.

**Adult ID/Epidemiology and Infection Control/Investigative
 ID/Pediatric ID/Trainee**

194. Oral Abstract Session
SHEA Featured Oral Abstract
Friday, 4:15 p.m. – 4:30 p.m.
20ABCD

- 1712** The CDC SHIELD Orange County Project – Baseline Multi Drug-Resistant Organism (MDRO) Prevalence in a Southern California Region

Trainee/Investigative ID/Adult ID

214. Oral Abstract Session
Host-Pathogen Integration
Saturday, 8:30 a.m. – 10:00 a.m.
07AB

- 1762** Complicated *Staphylococcus aureus* bacteremia (SAB) is associated with genetic variation in *GLS2*
- 1763** Role of M cells in human mucosal immunity to *Mycobacterium tuberculosis*
- 1764** Investigating Immune Correlates of Protection to Tuberculosis Using an Ultra-Low Dose Infection in a Mouse Model
- 1765** Strain-level determination of the contribution of gut microbiota to the development of bacteremia in patients undergoing stem cell transplantation
- 1766** The Gut Microbiota of Healthy Infants in the Community is a Reservoir for ESBL and Carbapenemase Producing Bacteria.
- 1767** Longitudinal comparison of the microbiota during *Klebsiella pneumoniae* carbapenemase-producing *Klebsiella pneumoniae* (KPC-Kp) acquisition in Long-Term Acute Care Hospital (LTACH) patients

215. Oral Abstract Session
National Trends in HAIs
Saturday, 8:30 a.m. – 10:00 a.m.
08

- 1768** Reduction in the prevalence of healthcare-associated infections in U.S. acute care hospitals, 2015 versus 2011
- 1769** Assessing The Impact of The National Healthcare Safety Network's (NHSN's) New Baseline on Acute Care Hospital Standardized Infection Ratios (SIRs)
- 1770** Wide range of Carbapenem-resistant Enterobacteriaceae incidence and trends in Emerging Infections Program surveillance, 2012–2015
- 1771** The Effect of National Healthcare Safety Network (NHSN) Rebaselining on Community Hospital SIRs
- 1772** Uropathogens and antibiotic resistance among nursing home residents – National Healthcare Safety Network (NHSN)
- 1773** Reductions in *MRSA*, *Clostridium difficile* and Intensive Care Unit (ICU) Acquired Bloodstream Infections and over 9 years from 276 United Kingdom ICUs

Adult ID

216. Oral Abstract Session
The Fungus Among-us – Clinical Advances
Saturday, 8:30 a.m. – 10:00 a.m.
01AB

- 1774** Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT1): A Prospective, Multicenter Study of the T2Candida Panel
- 1775** Impact of Infectious Diseases Consultation on Mortality in Patients with Candidemia
- 1776** Breath-Based Diagnosis of Invasive Mucormycosis (IM)
- 1777** Corticosteroid Use Following the Onset of Invasive Aspergillosis is Associated with Increased Mortality: A Propensity Score-Matched Study
- 1778** Catheter-free period over 2 days is associated with better outcome in catheter-related bloodstream infection due to candida
- 1779** Prevalence of and Factors Associated with *Clostridium difficile* Co-infection Among Patients with Candidemia, United States, 2014–2016.
- 1780** Routine Cryptococcal Antigen Screening in Solid Organ Transplant Recipients: Is it Time to Save Lives and Money?

Global ID/Adult ID

217. Oral Abstract Session
Zika – A to Z
Saturday, 8:30 a.m. – 10:00 a.m.
02

- 1781** Galidesivir, a direct-acting antiviral drug, abrogates viremia in Rhesus macaques challenged with Zika virus
- 1782** Outcomes of women with laboratory evidence of Zika infection in pregnancy
- 1783** Environmental and Climatic Risk Factors for Zika and Chikungunya Virus Infections in Rio de Janeiro, Brazil, 2015–16

- 1784** Differential Neuronal Susceptibility and Apoptosis in Congenital Zika Virus Infection
- 1785** Risk Factors Associated with Persistence of Zika Virus Nucleic Acid in Serum and Semen

227. Oral Abstract Session
HIV: Co-Morbidities and Co-Infections
Saturday, 10:30 a.m. – 12:00 p.m.
08

- 1811** Changes in invasive pneumococcal disease among adults living with HIV following introduction of 13-valent pneumococcal conjugate vaccine, 2008–2014
- 1812** Cancer Mortality among Persons with Human Immunodeficiency Virus Infection in New York City, 2001–2015
- 1813** Fatty Liver Disease in HIV: Predictors and Response to Statin Therapy
- 1814** Leveraging the ART Advantage: diabetes and hypertension along the HIV care cascade in rural South Africa
- 1815** Prevalence of Systemic Hypertension Among HIV-Infected and HIV-Uninfected Young Adults
- 1816** Effect of Macrolide Prophylactic Therapy on AIDS-Defining Conditions and HIV-Related Mortality

228. Oral Abstract Session
Late Breaker Oral Abstracts
Saturday, 10:30 a.m. – 12:00 p.m.
02

- LB1** A Randomized Trial of High Dose Influenza Vaccine in Adult Solid Organ Transplant Recipients
- LB2** Cap-Dependent Endonuclease Inhibitor S-033188 for the Treatment of Influenza: Results from a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study in Otherwise Healthy Adolescents and Adults with Seasonal Influenza
- LB3** Possible impact of wide-scale vaccination against serogroup B *Neisseria meningitidis* on gonorrhoea incidence rates in one region of Quebec, Canada
- LB4** Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results
- LB5** The SEP-SEQ Trial - Clinical Validation of the Karius Plasma Next-Generation Sequencing Test for Pathogen Detection in Sepsis
- LB6** Ethanol Lock Treatment and Secondary Prophylaxis for Central Line-Associated Bloodstream Infection in Pediatric Hematology and Oncology: A Randomized, Double-Blind, Placebo-Controlled, Intervention Trial
- LB7** Prevention of Recurrent Acute Uncomplicated Cystitis by Increasing Daily Water in Premenopausal Women : A Prospective Randomized Controlled Study
- LB8** Sorting the Wheat from the Chaff: Vaccine-Associated Rash Illness Occurring amidst a Large Measles Outbreak — Minnesota, 2017
- LB9** Broad Spectrum Investigational Agent GS-5734 for the Treatment of Ebola, MERS Coronavirus and Other Pathogenic Viral Infections with High Outbreak Potential

Pediatric ID/Epidemiology and Infection Control

229. Oral Abstract Session**Miscellaneous Advances in Vaccinology****Saturday, 10:30 a.m. – 12:00 p.m.****07AB**

-
- 1817** Analysis of a Phase 2b Study of GEN-003, a Genital Herpes Immunotherapy, Showed Significant Reductions in Viral Shedding and Lesion Rate Versus Placebo
- 1818** Immunogenicity of Inactivated Varicella Zoster Vaccine (ZV_{IN}) in Autologous Hematopoietic Stem Cell Transplant (auto-HSCT) Recipients
- 1819** Vaccine effectiveness against influenza-associated hospitalization among children aged <13 years using a hospital-based surveillance system in Minnesota, 2013–2016
- 1820** Impact of Prior Vaccination History on Risk of Vaccine Failure with Live Attenuated and Inactivated Influenza Vaccines in Children, 2013–14 through 2015–16
- 1821** Impact of a Provider Communication Training Intervention on Adolescent Human Papillomavirus Vaccination: A Cluster Randomized, Clinical Trial
- 1822** Interferon gene expression as marker of immune maturation and response to vaccination

Pediatric ID/Investigative ID/Epidemiology and Infection Control/Adult ID

230. Oral Abstract Session**Thinking Beyond Your Hospital: Stewardship on a Broader Scale****Saturday, 10:30 a.m. – 12:00 p.m.****01AB**

-
- 1823** Decrease in Antibiotic Sales in Brazil After New Control Legislation
- 1824** Colorado's Statewide Antimicrobial Stewardship (AMS) Collaborative Final Results: Facilitating Syndrome-Specific Interventions for Skin and Soft Tissue Infection (SSTI) and Urinary Tract Infection (UTI)
- 1825** Improving Antimicrobial Use by Implementing the CDC Antimicrobial Stewardship Core Elements Across a Diverse Healthcare System
- 1826** Outcomes of a Provincial Pilot Program to Reduce Unnecessary Urine Culturing and Antibiotic Overuse in Long-term Care
- 1827** Impact of an antibiotic stewardship program in long-term care facilities: A nursing home network experience
- 1828** A Multicenter Stewardship Initiative to Decrease Excessive Duration of Antibiotic Therapy for the Treatment of Community-Acquired Pneumonia (CAP)

Global ID

277. Oral Abstract Session**Global Infections****Saturday, 2:00 p.m. – 3:30 p.m.****01AB**

-
- 2486** Arboviral Infections Following the 2016 Olympic and Paralympic Games in a Cohort of US Athletes and Support Staff
- 2487** Measles CEA
- 2488** Clinical Implications of Asymptomatic *Plasmodium falciparum* Infections in Malawi

- 2489** Silent Polio Transmission: A Spatial Analysis
- 2490** Phylogenetic Analysis of an Unusual Increase in *Salmonella enterica* serovar Paratyphi A Infection among Travelers Returning from Myanmar
- 2491** Murine typhus: a common cause of acute febrile illness with potential for serious complications

Pediatric ID

278. Oral Abstract Session**Pneumococcal and Pertussis Vaccines****Saturday, 2:00 p.m. – 3:30 p.m.****08**

-
- 2492** Direct and Indirect Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) Among Children and Adults in the U.S.
- 2493** Invasive pneumococcal disease in Massachusetts children six years following introduction of PCV13
- 2494** Analysis of Invasive Pneumococcal Infections Due to 13-Pneumococcal Conjugate Vaccine Serotypes at 8 US Children's Hospitals During 2014 to 2016
- 2495** Changes in Pneumonia Incidence and Infant Mortality 5 Years Following Introduction of the 13-valent Pneumococcal Conjugate Vaccine in a "3 + 0" Schedule in Nicaragua
- 2496** A population-based study of recurrent symptomatic *Bordetella pertussis* infections in children in California, 2010–2015
- 2497** Effectiveness of prenatal Tdap immunization in the prevention of infant pertussis in the US

279. Oral Abstract Session

STIs – Diagnostics and Therapy**Saturday, 2:00 p.m. – 3:30 p.m.****07AB**

-
- 2498** Cervical Adenocarcinoma in Situ in the United States: Results from Population-based Laboratory Surveillance, 2008–2014.
- 2499** Trends in *Neisseria gonorrhoeae* Antimicrobial Susceptibility in California, 2005–2016
- 2500** Asymptomatic Lymphogranuloma Venereum among Nigerian Men who have Sex with Men
- 2501** Real-Time PCR Targeting Mosaic *penA* XXXIV for Prediction of Extended-Spectrum Cephalosporins Susceptibility in Clinical *Neisseria gonorrhoeae* Isolates
- 2502** Electronic Reminder Notifications Improve Uptake of Targeted Ciprofloxacin Therapy for *Neisseria gonorrhoeae* Infections at the University of California, Los Angeles Health System
- 2503** Gonorrhea (GC) and Chlamydia (CT) Infection in a Large, Well-Characterized Military Cohort: Prevalence, Incidence, Site of Infection, and Patient Characteristics.

Adult ID

281. Oral Abstract Session**Featured Oral Abstract****Saturday, 4:30 p.m. – 4:45 p.m.****06AB**

-
- 2505** Integration of Next-Generation Sequencing, Viral Sequencing, and Host-Response Profiling for the Diagnosis of Acute Infections

43. Poster Abstract Session
***Candida Auris*: Coming Soon to a**
Patient Near You
Thursday, 12:30 p.m. – 2:00 p.m.

- 142 Emergence and Spread of *Candida auris* in New York State
 - 143 Mitigating *Candida auris* at a Busy Community Hospital: A Quasi-Experimental Near Real-time Approach
 - 144 Public Health Response to U.S. Cases of *Candida auris*, a Globally-Emerging, Multidrug-Resistant Yeast, 2013–2017
 - 145 Assessment of *Candida auris* response to antifungal drugs using time-kill assays and an animal model
 - 146 Pharmacodynamic Optimization for the Treatment of Invasive *Candida auris* Infection
-

44. Poster Abstract Session
Clinical Mycology
Thursday, 12:30 p.m. – 2:00 p.m.

- 147 Risk Predictive Model for 90-Day Mortality in *Candida* Bloodstream Infections
- 148 Time Trends in the Burden of Hospitalizations with Invasive Aspergillosis in the US, 2004–2013
- 149 β -d-glucan Testing is Overused in Patients Without Solid Organ/Stem Cell Transplant or Hematologic Malignancies.
- 150 Risk Factors and Mortality Associated with *Candida krusei* Bloodstream Infections
- 151 Risk Factors Predicting *Candida glabrata* Bloodstream Infection
- 152 Primary or Secondary Prophylaxis with Voriconazole Compared to Posaconazole for Prevention of Invasive Fungal Infections after Hematopoietic Stem Cell Transplantation
- 153 Coccidioidomycosis after Solid Organ Transplantation – a Population Based Study.
- 154 Posaconazole Induced Hypertension and Hypokalemia: Mechanistic Evaluation
- 155 Detection of (1,3)- β -D-Glucan in Cerebrospinal Fluid in *Histoplasma* Meningitis
- 156 Real-world experience of Voriconazole Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients – A Single Center Study
- 157 Natural History of Non-CNS Disseminated Coccidioidomycosis
- 158 Presentation and outcome of Cryptococcal infection varies by pre-disposing illness
- 159 Invasive Mold Infections (IMI) among Liver Transplant Recipients (LTR): Is it Time to Reconsider the Risk Factors that Determine Antifungal Prophylaxis?
- 160 Antifungal Resistance Patterns in Molds Isolated from Wounds of Combat-Related Trauma Patients
- 161 Safety and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children
- 162 Invasive Mold Infections (IMIs) of the Central Nervous System (CNS) in patients (pts) with hematologic cancer (HC) (2000–2016): Uncommon but deadly
- 163 Risk factors for candidemia as compared to patients with negative blood cultures placed on empiric micafungin
- 164 Erythema Sweetobullosum a Rare Presentation of Coccidioidomycosis
- 165 Outcomes Comparing Initial Short versus Long Course Echinocandin Therapy in Patients with Candidemia Caused by Fluconazole Susceptible Strains
- 166 Breakthrough Invasive Candidiasis in Children
- 167 Comparing Diagnostic Driven Approaches to Empiric Therapy in the Treatment of Invasive Aspergillosis in Patients with Hematologic Malignancy
- 168 *In Vitro* Interactions of Echinocandins With Triazoles Against Multidrug-Resistant *Candida auris*
- 169 Disseminated Coccidioidomycosis Among Children in Central California: A Retrospective Review
- 170 Real-World Use – Isavuconazole at a Large Academic Medical Center

- 171 Epidemiology and Clinical Features of Invasive Fungal Disease in a U.S. Healthcare Network
 - 172 *Blastomyces helicus*, an Emerging Dimorphic Fungal Pathogen Causing Fatal Pulmonary and Disseminated Disease in Humans and Animals in Western Canada and United States
 - 173 QTc Prolongation in Patients Receiving Triazoles and Amiodarone
 - 174 Increasing Incidence of Blastomycosis Infection in Vermont
 - 175 Epidemiology and Prognostic Factors of Non-*albicans* *Candida* species Candidemia: A Multicenter Study
 - 176 Ocular Candidiasis in Patients with Candidemia at a Large Tertiary Care Center
 - 177 The Risk Factors and the Characteristics of Fungal Endophthalmitis Following *Candida* Blood Stream Infection, a Case-control Study
 - 178 Antifungal Resistance and Predictors of Response in Patients with Hematologic Malignancy
 - 179 *Candida parapsilosis* Candidemia Resistance Patterns and Treatment Outcomes: an Opportunity for Antifungal Stewardship
 - 180 Phaeohyphomycosis: A Ten-Year Review (2006–2016)
 - 181 Clinical Outcomes of the Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
 - 182 Clinical Characteristics and Outcomes in Hospitalized Patients with Proven and Probable Coccidioidomycosis at the National Institute of Respiratory Diseases in Mexico City.
 - 183 Do Liver Transplant Recipients Have a Higher Risk for Cryptococcosis Than Non-liver Transplant Recipients?
 - 184 Review of Treatment Regimens for Mucormycosis in a Las Vegas County Hospital Between 2013–2017
 - 185 The trends in the distribution of *Candida* species causing candidemia at a community hospital in 2005 and 2014.
 - 186 Epidemiology of Invasive Fungal Disease by *Aspergillus* in a University Hospital in Santiago – Chile, During the Period 2005–2015
 - 187 Candidemia with ocular manifestations: a review of 26 cases in a university hospital in Japan
 - 188 Epidemiology, Risk factors and Outcomes of *Candida* Empyema: A 5-year Single Centered Experience
 - 189 Epidemiology and Outcomes of Hospitalizations with Invasive Aspergillosis in the US, 2010–2013
 - 190 Epidemiology and Risk Factors for Antifungal Resistance in Patients with Candidemia
 - 191 Improved Survival of *Candida* CLABSI by Adherence to Standard of Care and Involvement of Infectious Diseases Consultant: A 5-year Experience in a Single Academic Center
 - 192 Treatment Bundle Improves Outcomes in the Management of Candidemia at Large Urban Academic Medical Center
 - 193 Validation of an Empiric Candidemia Treatment Algorithm
-

45. Poster Abstract Session
Clinical: Bone and Joint Infection
Thursday, 12:30 p.m. – 2:00 p.m.

- 194 Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
- 195 Low Rate of Microbiologic Relapse in Two Stage Exchange for Hip Prosthetic Joint Infections
- 196 Clinical Characteristics and Outcomes of Healthcare-Associated Hematogenous Vertebral Osteomyelitis
- 197 The Spectrum of Pediatric Osteoarticular Infections: A Comparative Study
- 198 Utility of Diagnostic Bone Biopsies in the Management of Osteomyelitis through Retrospective Analysis: How Golden is this Gold Standard?
- 199 Comparative Analysis of Initial Antibiotic Dosing Among Healthy Weight, Overweight, and Obese Children with Osteomyelitis
- 200 Septic Arthritis of Native Joints: Are Outcomes Better with Medical or Surgical Management?
- 201 Assessment of Musculoskeletal Infection Society (MSIS) Diagnostic Criteria as Predictors of Treatment Success in Hip Arthroplasty Infections Treated with Two-Stage Exchange
- 202 Factors Associated with Success in Revision Surgery for Infected Hip and Knee Arthroplasties

- 203 Assessment of a Modified Antibiotic Prophylaxis Open Fracture Protocol
- 204 Pubic Osteomyelitis: Epidemiology and Factors Associated with Management Failure in Two French Reference Centers
- 205 Reexamining BSA as a Preoperative Predictor of Risk of Prosthetic Joint Infection
- 206 Variability in Management of Acute Osteoarticular Infections at a Children's Hospital and Favorable Outcomes with Increasing Early Transition to Oral Therapy
- 207 Septic Arthritis due to Oral Streptococcal Species Following Intra-articular Injection: A Case Series and Retrospective Chart Review
- 208 Clinical Comparison between Native Vertebral Osteomyelitis with Abscess versus without Abscess in Clinical Features and Outcomes
- 209 Time-to-report of the Bone Culture and Microbiologic Adequacy of Empiric Antibiotics in Patient's with Diabetic Foot Osteomyelitis
- 210 Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Patients with Diabetes Mellitus
- 211 *Corynebacterium* Bone and Joint Infection (BJI): A Retrospective Cohort Study in a Reference Center for BJI Management
- 212 Microbiological Epidemiology Depending on Time to Occurrence of Prosthetic Joint Infection (PJI): Impact on the Empirical Antimicrobial Strategies.
- 213 Clinical Characteristics and Treatment Outcomes of Patients with Sternoclavicular Septic Arthritis Caused by *Staphylococcus aureus*
- 214 Oral Versus Intravenous Antibiotics for the Treatment of Acute Bacterial Osteomyelitis in the Veteran Population
- 215 Multidrug-Resistant Gram-negative bacilli prosthetic joint infection: a worrisome scenario.
- 216 Clinical Outcomes of Antipseudomonal vs Non-Antipseudomonal Therapy in Patients with Osteomyelitis
- 217 Predictive Factors for Successful Treatment in Candidial Bone & Joint Infection
- 218 The Influence of Obesity on the Infection Risk of Prosthetic Joint Infection in the Geriatric Orthopedic Population
- 219 Searching for Bacterial Pathogens in Pediatric Patients with Chronic Recurrent Multifocal Osteomyelitis Using 16S rRNA Quantitative Real-Time PCR
- 220 Clinical Experience with Tigecycline in the Treatment of Prosthetic Joint Infections
- 221 Subcutaneous Suppressive Antibiotic Therapy for Bone and Joints Infections : Safety and Outcome in a Cohort of 10 Patients
- 222 Clinical Outcomes of Prosthetic Knee Joint Infection in a United States Tertiary Health Care Center
- 223 Microbiological Epidemiology in Patients Experiencing Microbiological or Clinical Failure Following Reimplantation After a 2-stage Exchange Strategy for Hip or Knee Prosthetic Joint Infection (PJI)
- 224 Pressure Ulcer-Related Pelvic Osteomyelitis: Evaluation of a Two-Stage Surgical Strategy (Debridement, Negative Pressure Therapy and Flap Coverage) with Prolonged Antimicrobial Therapy
- 225 Microbiologic Predictors of Pelvic Osteomyelitis Related to Decubitus Ulcers
- 226 Clinical and Epidemiological Aspects Related to Infection of Orthopedic Prostheses in Argentinean Children. A Ten-years Period Study.
- 227 Epidemiology and Clinical Features of Septic Arthritis in Children
- 228 The Use of Rifampin Therapy to Treat Diabetic Patients with Osteomyelitis of the Foot in the Veterans Health Administration: Patient Characteristics and Clinical Outcomes
- 229 Recent Respiratory Tract Infection and Additional surgeries Increase Risk for Surgical Site Infection in Total Joint Arthroplasty: A Retrospective Analysis of 2255 patients
- 230 Clinical features and treatment outcomes of bone-joint infection between bacteria and mycobacterium tuberculosis

46. Poster Abstract Session

Clinical: Sexually Transmitted Infections

Thursday, 12:30 p.m. – 2:00 p.m.

- 231 Factors Associated with Not Using a Condom at Last Sex among Sexually Active U.S. Navy and Marine Corps Personnel across a Shipboard Deployment

- 232 The Detection Rates of Urogenital *Chlamydia Trachomatis* and *Neisseria Gonorrhoeae* in Chinese Population Applying for U. S. Immigration
- 233 High-level *Neisseria gonorrhoea* Resistance Detected in a Newly Implemented Surveillance Program in Kampala, Uganda
- 234 Effect of Rectal Hygiene on Sexually Transmitted Infections Among HIV-Negative Men Who Have Sex with Men (MSM)
- 235 Macrolide Resistance in *Mycoplasma genitalium* in Singapore
- 236 Optimizing Screening for Sexually Transmitted Infections in Men Using Self-Collected Swabs — A Systematic Review
- 237 Comparative *In Vitro* Activity of Ciprofloxacin and Sitafloxacin against *Neisseria gonorrhoeae*
- 238 Alcohol Misuse and Associated Risk Factors across a Shipboard Deployment among Active Duty U.S. Navy and Marine Corps Personnel
- 239 Extragenital Gonorrhea and Chlamydia Testing among Women Reporting Extragenital Exposure at an Urban STD Clinic: Is it Worth the Cost?
- 240 Assessment of the sexual violence situation in a Regional Hospital in Guatemala: The need for a multidisciplinary clinic.
- 241 The Impact of Recent Antibiotic Usage on Oropharyngeal *Neisseria* spp. in MSM of Hanoi, Vietnam
- 242 Ocular syphilis: case series (2000–2015) from two tertiary care centers in Montreal
- 243 Watch Out! Syphilis Is Back – Case Series of Four Cases of Ocular Syphilis
- 244 Similar Sexually Transmitted Infections Prevalence Despite Lower HIV Prevalence Among Transgender Women Compared to Men Who Have Sex With Men in Thai Community-based Test and Treat Cohort
- 245 How many patients who present to North Central Bronx Hospital with a sexually transmitted disease (chlamydia, gonorrhea) are tested for HIV?
- 246 Lymphogranuloma Venereum: a Croatian Case Report of a Patient with Proctitis and Concurrent Cervical Lymphadenitis
- 247 Agar Gradient Diffusion Susceptibility Testing for *Neisseria gonorrhoeae*: A Reliable Alternative to Agar Dilution?
- 248 High Correlation of Visual Inspection and a Smartphone-Based Electronic Reader of Two Dual Rapid Diagnostic HIV/Syphilis Assays
- 249 Use of Oral Fluid in a Rapid Syphilis Test Assay

47. Poster Abstract Session

Clinical: Skin and Soft Tissue

Thursday, 12:30 p.m. – 2:00 p.m.

- 250 Tigecycline Susceptibility Trends among Pathogens Isolated from Complicated Skin and Soft Tissue Infections in North and Latin America: 2012–2016
- 251 Risk Factors for *Pseudomonas aeruginosa* in Diabetic Foot Infections
- 252 Less Is More: Surgical Procedure Time and Risk of Infections, Length-of-Stay, and Readmission across Three Distinct Surgeries
- 253 Microbiology and Clinical Characteristics of Industrial Oil Burns
- 254 Hospital Costs for Patients with Lower Extremity Cellulitis: A Retrospective Population-Based Study
- 255 Sex Work, Injection Drug Use, and Abscesses: Associations in Women, But Not Men
- 256 Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Obese Population
- 257 More than just an Anti-Infective Agent: A Prospective Pilot Clinical Trial to Determine the Effectiveness of IV Ertapenem in Severe Hidradenitis Suppurativa
- 258 High Rates of Multidrug Resistance in Diabetic Foot Infection in Detroit Area: Does It Matter?
- 259 Risk Factors and Outcomes for Bloodstream Infections (BSI) Among Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- 260 Post-discharge antibiotic therapy in patients with acute bacterial skin and skin structure infections

- 261 Evaluation of Dalbavancin and Oritavancin as Cost-Effective Treatments of Acute Bacterial Skin and Skin Structure Infections in Hospitalized Patients
- 262 Emergence of Multi-Drug Resistant Organisms (MDROs) Causing Fournier's Gangrene
- 263 Orthopedic-implant associated infection due to Gram-negative bacilli: the worrisome impact of *Acinetobacter baumannii* multi-drug resistance in a Brazilian center
- 264 Polymicrobial Soft Tissue Infection (P-STI) in the Lower Extremities, Perineal, Sacral or Gluteal Locations: Is Empirical Coverage for *Staphylococcus Aureus* (SA) Necessary.
- 265 Dynamics of *S. aureus* acquisition and colonization in a military training environment
- 266 The Efficacy of Intramuscular Benzathine Penicillin for Preventing Recurrent Cellulitis: A Nationwide Population-Based Study
- 267 Identification of Pathogens Directly From Diabetic Foot Infections by Shotgun Metagenomic Sequencing
- 268 Seasonal and environmental variation of lower extremity cellulitis incidence among emergency department patients in three geographic locations
- 269 Diabetic Foot Wounds: Which Patients are More Prone to Tetanus?

48. Poster Abstract Session

Fungus Among Us: Basic Science

Thursday, 12:30 p.m. – 2:00 p.m.

- 270 *Aspergillus fumigatus* (Af) Hydroxamate Siderophores Protect Formation of Af Biofilms from the *Pseudomonas aeruginosa* (Pa) Product Pyoverdine
- 271 Development of a clinically relevant murine model of fungal (*Aspergillus*) endophthalmitis
- 272 De novo *STAT3* Mutation in a Patient with Fatal, Treatment-Refractory Sino-orbital Aspergillosis
- 273 C5ar1-dependent phagocyte effector functions protect against systemic candidiasis
- 274 VT-1598 Inhibits the *in vitro* Growth of Mucosal *Candida* Isolates and Protects Against Oropharyngeal Candidiasis in IL-17 Deficient Mice
- 275 Replicative Aging in *Candida auris* has an Effect on Antifungal Resistance
- 276 Mechanisms of flucytosine resistance in *Cryptococcus gattii* may be independent of the FCY2-FCY1-FUR1 pathway.
- 277 Fungal Mechanobiology: High Shear Forces Increase *Rhizopus* Virulence
- 278 Optimization of the CRISPR/Cas9 System to Manipulate Gene Function in *Rhizopus delemar*
- 279 Studies of *Pseudomonas aeruginosa* Mutants Indicate Pyoverdine as the Central Factor in Inhibition of *Aspergillus fumigatus* Biofilm

49. Poster Abstract Session

Global Health Potpourri

Thursday, 12:30 p.m. – 2:00 p.m.

- 280 *Aedes aegypti* and *Aedes albopictus* Occurrences in Guatemala.
- 281 Efficacy of a Novel Nutritional Product in Acute Childhood Diarrhea in Guatemala: Secondary and Exploratory Analyses of a Randomized, Double Blind, Placebo Controlled Trial.
- 282 Endoscopic characteristics comparison of *Helicobacter pylori* and *Orientia tsutsugamushi* infection
- 283 Soil-Transmitted Helminths Prevalence in Refugees Arriving to Colorado in 2009–2012
- 284 High Prevalence of Parasitic Infections Among Recent Immigrants in Chicago
- 285 Disease And Injury Epidemiology Among Military Personnel Deployed to West Africa During the 2014–2015 Ebola Outbreak
- 286 Predictors of Measles and Rubella Serostatus in Mother-Infant Pairs in Rural Nepal
- 287 Source of piped drinking water supply and soil transmitted helminth infections (STHI) in school children in El Salvador

- 288 Community Health Workers can Strengthen Isoniazid Preventive Therapy Implementation in Rural KwaZulu-Natal, South Africa
- 289 Frequency of Combination Medications Associated with QTc Prolongation in a Travel Clinic
- 290 Clinical and Epidemiological Characteristics of Japanese Spotted Fever and Scrub Typhus in Central Japan, 2004–2015
- 291 Clinico-Epidemiological Profile of Adolescent and Adult Patients with Tegumentary Leishmaniasis from the Colombian Southwest 2004–2014: Considerations for Local Therapies.
- 292 Systemic Cat Scratch Disease in Immunocompetent Adults – a Retrospective Case Series

50. Poster Abstract Session

Global Infections

Thursday, 12:30 p.m. – 2:00 p.m.

- 293 What is Different When Dealing With Bacteremic Brucellosis?
- 294 Follow-up Evaluation of Air Force Blood Donors Screening Positive for Chagas Disease
- 295 Primary care-based screening for *Trypanosoma cruzi* in high-risk populations: results of the Strong Hearts Pilot in East Boston, Massachusetts
- 296 Discovery of new class of trypanocidal compounds targeting the energy metabolism of African trypanosomes
- 297 Serial Multiplex PCR May Help Differentiate Causal Pathogens from Colonizing Organisms in Children with Acute Diarrhea in Guatemala
- 298 Clinical Features of PCR Confirmed Human Ehrlichiosis and Anaplasmosis in an Endemic Area of the Northeast U.S.
- 299 Microbiome Manipulation: Antibiotic Effects on Cutaneous Leishmaniasis Presentation and Healing
- 300 Clinical Evaluation of Latent Visceral Leishmaniasis in US Service Members Deployed to Operation Iraqi Freedom
- 301 A Stealth Parasite: Prevalence and Characteristics of Risks for Latent Visceral Leishmaniasis in a Cohort of US Soldiers deployed to Operation Iraqi Freedom
- 302 Imported Malaria in Travelers Presenting to a Tertiary Urban Hospital, 2000–2016
- 303 Cotrimoxazole Prophylaxis Associated With Reduced Anemia Hazard in HIV-Exposed Infants in a Malaria-Endemic Setting
- 304 Preventing Polio Post-eradication: Revertant Proportion Patterns of OPV Serotypes
- 305 Acute Q Fever in Israel: Clinical and Demographic Data 2006–2016
- 306 Immediate Hypersensitivity Reaction Related to *Rabies* Post-Exposure-Prophylaxis in Thailand with Subsequent Rabies Vaccine Change to Avoid Polygeline Vaccine Excipient with Successful Challenge and Treatment Tolerance in the United States
- 307 Could We Predict Severe Rickettsiosis?
- 308 Endothelial Injury and Oxidative Stress in Patients with Schistosomal Hepatic Fibrosis: Relation to Renal Dysfunction and Hemodynamics.
- 309 Assessing Clinical Diagnosis of Sexually Transmitted Infections among Women Initiating Contraceptive Implants in Kingston, Jamaica
- 310 Where's the Eschar?: Non-eschar cases and Eschar Distribution between the serotypes of Karp, Irie/Kawasaki and Hirano/Kuroki Causing Scrub Typhus in Fukushima, Japan
- 311 Scrub Typhus and Abnormal Electrocardiography
- 312 CADM1 Overexpression and CD7 Down regulation in *Strongyloides stercoralis* and HTLV-1 Coinfection as Possible Markers for Adult T-cell Leukemia/Lymphoma progression.
- 313 Comparison of clinical and demographic characteristics and disability at 6-months post neurologic onset among Puerto Rico Guillain-Barré syndrome patients with and without evidence of Zika virus infection
- 314 Six Months Follow up of Patients with Guillain-Barré Associated to Zika Virus Infection
- 315 Clinical manifestations, hematology, and chemistry profiles of the six most common etiologies from an observational study of acute febrile illness in Indonesia

51. Poster Abstract Session Emerging Resistance – Epidemiology and Mechanisms

Thursday, 12:30 p.m. – 2:00 p.m.

- 316 Characteristics of *Streptococcus pneumoniae* Serotype 19A Isolates from Children in the pre and post Conjugate Vaccine Era
- 317 Ceftolozane-Tazobactam Resistance in Multidrug-Resistant *Pseudomonas aeruginosa* Isolates Not Associated with AmpC Activity
- 318 Reduced Ertapenem Susceptibility Due to OXA-2 Production in *Klebsiella pneumoniae* ST258
- 319 Co-occurrence of NDM-5, OXA-181 and CMY-2 in a Clinical *E. coli* Isolate From a Patient in the United States
- 320 Characterization of *Enterobacter* and *Citrobacter* spp. Isolates from United States (US) Hospitals by Whole Genome Sequencing (WGS) Analysis and Activity of Ceftazidime-Avibactam and Comparator Agents
- 321 Frequency and Mechanisms of Spontaneous Fosfomycin Non-susceptibility Observed upon Disk Diffusion Testing of *Escherichia coli*
- 322 The Gastrointestinal Tract is a Major Source of Echinocandin Drug Resistance in a *Candida glabrata* Colonization Mouse Model
- 323 Genomic Pathways Associated With Daptomycin (DAP) Resistance in DAP-Susceptible *Enterococcus faecium* Harboring Substitutions in LiaFSR
- 324 Emergence of *mcr-1* among Nontyphoidal *Salmonella* Isolates in the United States
- 325 Lack of Fosfomycin Resistance in Commensal *E. coli* after Fosfomycin Treatment
- 326 β -lactamase Characterization of Baseline *Pseudomonas aeruginosa* (PSA) from Five Ceftazidime-avibactam (CAZ-AVI) Phase 3 Clinical Trials
- 327 The association of mRNA expression of cell wall biosynthesis related genes and the reversion to daptomycin (DAP) susceptibility in DAP non-susceptible methicillin-resistant *Staphylococcus aureus*
- 328 Dominance of a macrolide resistant lineage resulting from capsular switching among group B *Streptococcus* invasive disease in non-pregnant adults in Portugal (2009–2015)
- 329 Sustained *In Vitro* Activity of Linezolid and Evolving Resistance Mechanisms: Summary of the Zyvox® Annual Appraisal of Potency and Spectrum Program for 2016
- 330 Emerging Carbapenem Resistant *Aeromonas* Infections in Cali, Colombia.
- 331 Molecular Characterization of Fluoroquinolone Resistance Mechanisms in Isolates from the Delafloxacin Acute Bacterial Skin and Skin Structure Infections Clinical Trials
- 332 *Streptococcus pneumoniae* with High-Level Resistance Worldwide: Results from the ATLAS (Antimicrobial Testing Leadership and Surveillance) Database (2004–2015)
- 333 Regional Analysis of Resistance Phenotypes among *Staphylococcus aureus* Causing Infections in US Census Divisions: Telavancin Activity against Resistant Pathogens (2014–2016)
- 334 Antimicrobial Susceptibility Assessment of Clinical *Clostridium difficile* Isolates in Relation to CRISPR-Cas
- 335 Low Prevalence of Azole Resistance in *Aspergillus fumigatus* in Australia, and Molecular Characterisation of Resistant Isolates
- 336 A Novel Mechanism of Resistance Against Antimicrobial Peptides Involves Extracellular Sensing Coupled with Membrane Remodeling Mediated by a Single Protein
- 337 Unidirectional recombination of antibiotic resistance genes within nasopharyngeal pneumococcal biofilm consortia
- 338 The LiaR-Regulon of Daptomycin-Resistant *Enterococcus faecium*
- 339 Ceftazidime/avibactam Susceptibility Patterns in Carbapenem-Resistant Enterobacteriaceae in the US: Results from the Consortium on Resistance against Carbapenems in Klebsiella and Other Enterobacteriaceae (CRACKLE-2)
- 340 Minocycline enhances the antimicrobial capacity of unpolarized macrophages against *Acinetobacter baumannii* while inducing an anti-inflammatory profile
- 342 Proportion of *Staphylococcus aureus* With a Vancomycin Minimum Inhibitory Concentration (MIC) of 1 mg/L Increases Between 2012 and 2017 in Singapore

- 343 Emergence of Daptomycin (DAP) Resistance in Community-Associated MRSA USA300 Latin American Variant (USA300-LV)
- 344 Correcting for Antimicrobial Testing Methodology Reveals Temporary Decline in Daptomycin MIC Following Intervention

52. Poster Abstract Session HAI: MDRO-GNR/Emerging Resistant Bacterial Pathogens

Thursday, 12:30 p.m. – 2:00 p.m.

- 345 Prevalence of Carbapenemase-producing *Enterobacteriaceae* (CPE) in Hospital Drains and Relationship to Patient Isolates in Toronto, Canada
- 346 Genomic Epidemiology of bla-KPC *Klebsiella pneumoniae* (KPC-Kp) in a High-Transmission Long-Term Acute Care Hospital (LTACH)
- 347 The importance of ventilator skilled nursing facilities (vSNFs) in the regional epidemiology of carbapenemase-producing organisms (CPOs)
- 348 The MDR Upon Admission Score: Shortening Time to Initiation of Appropriate Antimicrobial Therapy in the Era of Resistance in the Community
- 349 Carbapenemase Gene Transfer among Canadian Patients Colonized or Infected with Carbapenemase-Producing *Enterobacteriaceae*
- 350 Outbreak Investigation of GES-5 Containing Carbapenem Resistant Enterobacteriaceae in a Tertiary Care Hospital
- 351 Cost Utility of Carbapenemase Producing *Enterobacteriaceae* (CPE) Screening Strategies in a Low Prevalence Setting
- 352 Investigation of Epidemiology and Pathogenesis of Co-infection with Multiple Carbapenem-Resistant *Enterobacteriaceae* in Hospitalized Patients
- 353 Carbapenem-Resistance in Gram-Negative Organisms using a Large US Clinical Database
- 354 Molecular and Microbiological Evaluation of Carbapenem-resistant *Enterobacteriaceae* (CRE) at Two Centers in Texas
- 355 Sensitivity of Different Anatomic Sites for Detection and Duration of Colonization with Carbapenemase-producing *Enterobacteriaceae* (CPE)
- 356 Changing Epidemiology of Carbapenem-Resistant *Enterobacteriaceae* Bloodstream Infections in United States Veterans Affairs Hospitals, 2004–2014
- 357 Optimized Beta-Lactam Therapy Improves Survival in Carbapenem Non-Susceptible Gram-Negative Infections
- 358 Explosive Emergence of Colistin-resistant and Carbapenem-resistant Enterobacteriaceae (CRE) Among Community Food-handlers in Kuwait.
- 359 Clinical outcomes of patients with IMP-type carbapenemase-producing *Enterobacteriaceae*
- 360 Carbapenem-resistant Enterobacteriaceae Associated with High Rates of Clinical Failure Despite Best Available Therapy
- 361 Prevalence and Predictors of Infections Due to Carbapenem-Only Susceptible Organisms After Escalation of Antibiotic Therapy in Hospitalized Patients
- 362 Early implementation of active surveillance on detection of carbapenemase-producing *Enterobacteriaceae*
- 363 Carbapenem-Resistant *Enterobacteriaceae* (CRE) Bacteremia: Risk Factors for Death at 17 US Centers, 2010–14
- 364 Minocycline in the Treatment of Carbapenem-Resistant *Klebsiella pneumoniae*
- 365 Risk Factors Associated with Community-Onset CRE Colonization
- 366 An Evaluation of Meropenem Use and Resistance in a Mixed Medical/Surgical Intensive Care Unit
- 367 Clinical Characteristics, Risk Factors, and Outcomes of Carbapenem-resistant *Enterobacteriaceae* Infection among Patients Hospitalized in the US Military Health System
- 368 Carbapenem Resistant Enterobacteriaceae Implications Amongst Patients with Hematological Malignancies and Hematopoietic Stem Cell Transplant Recipients
- 369 Clinico-Epidemiologic Profile and Outcomes of Pediatric Patients with Multi-Drug Resistant Gram Negative Healthcare-Associated Infections in Philippine General Hospital

- 370 The Epidemiology and Microbiology of Outpatient Carbapenem-Resistant *Enterobacteriaceae*
- 371 National Prevalence and Regional Variation of Carbapenem-resistant Gram-negative Bacteria in the Ambulatory and Acute Care Settings in the United States in 2016
- 372 Carbapenemase-producing *Enterobacteriaceae* in Transplanted Patients
- 373 Modeling Carbapenem Resistance Among Gram Negative Pathogens Using Commonly Available Clinical Data
- 374 Burden of Carbapenem-resistant Gram-negative Infections in US Hospitals
- 375 Global Prevalence of Colistin- and Carbapenem-Resistant Gram-Negative Organisms: SMART 2015–2016
- 376 Attributable Clinical and Economic Burden of Carbapenem Non-susceptible Gram-negative Infections among Patients Hospitalized with Respiratory Infections
- 377 Evaluation of Risk Factors for Catheter Related Urinary Tract Infections caused by Carbapenem Resistant *Klebsiella pneumoniae*
- 378 Surveillance Screening for Extended-Spectrum Beta-Lactamases in Skilled Nursing Facility Admissions
- 379 Risk Factors Associated with Isolation of Carbapenem Resistant *Enterobacter* sp. or *Klebsiella* sp. in Stool or Rectal Swab Surveillance Cultures Using a Matched Case-Control Sample of Patients Hospitalized between 2013–2015 Across a Large Integrated Healthcare System
- 380 Risk Factors for Colonization or Infection with Cefepime Resistant, Piperacillin-Tazobactam Susceptible Gram-Negative Bacilli
- 381 Risk Factors Associated with Carbapenem Resistant *Enterobacter* sp. or *Klebsiella* sp. Infection Using a Matched Case-Control Sample of Patients Hospitalized between 2010–2016 Across a Large Integrated Healthcare System
- 382 Comparison of epidemiology of IMP-type metallo-beta-lactamase producing carbapenem-resistant *Klebsiella pneumoniae* vs *Enterobacter cloacae* in a tertiary care hospital in Japan over 5 years
- 383 *Mcr-1* in Connecticut: Investigations of an Emerging Resistance Gene in Two Patients, 2016–2017
- 384 Identification of Three Patients with Colistin Resistant *Escherichia coli* Isolates Containing the *mcr-1* (Mobile Colistin Resistance) Gene from a Single Health System in Michigan, USA
- 385 Clinical and Microbiological Characteristics of Colistin-Resistant *Enterobacteriaceae* at a Large Tertiary Care Center in Michigan
- 386 Risk Factors for Colistin Resistance; A 10 Year Experience at a Tertiary Medical Center
- 387 Intestinal Colonization with *Escherichia coli* Sequence Type 131 (ST131) and Other Fluoroquinolone (FQ)-Resistant *E. coli* (FQREC) within Households (HHs) of Veterans
- 388 Longitudinal Analysis of ICU Surface Multidrug Resistant Organism Contamination in the US and Pakistan
- 389 EVALUATION OF THE MANAGEMENT OF ESBL PRODUCING ENTEROBACTERIACEAE INFECTIONS: CHI HEALTH OMAHA
- 390 Enhanced Gram Negative Resistance Gene Surveillance in Clinical Samples using a Rapid Microarray System
- 391 Discordant Ertapenem/Imipenem Susceptibilities in *Enterobacter* bacteremia: Frequency and Outcomes
- 392 Trends in the incidence of bacteremia with carbapenem non-susceptible *Acinetobacter* spp. in patients from the US Veterans Health Administration, 2000–2015.
- 393 Prevalence and Geographic Distribution of Select Antibiotic Resistant Bacteria Reported among Healthcare-Associated Infections, California, 2014–2015
- 394 Gram-negative bacilli in critically ill burn patients
- 395 Risk Factors for Death from Carbapenem-Resistant *Acinetobacter baumannii* (CRAB) Bacteremia at 12 US Medical Centers, 2010–14
- 396 Trends in Resistant *Enterobacteriaceae* (ENT), *Acinetobacter baumannii* (ACB) and Extended Spectrum Beta-Lactamase (ESBL) Organisms in Hospitalized Patients in the US: 2011–2016
- 397 Validating the Nosocomial XDR Score: Novel Intervention of Improving Prescription Practices in the Era of Extensively Drug Resistant Pathogens in Hospitals
- 398 *Pseudomonas* Infections in Healthcare: Increasing Resistance in Children
- 399 Evaluation of Treatment Outcomes for *Chryseobacterium indologenes* Bacteremia developed during Broad Spectrum Antimicrobial Therapy
- 400 Prevalence of Extended Spectrum Beta-Lactamase (ESBL) and Quinolone Non-susceptible (QNS) *Enterobacteriaceae* in Inpatient and Outpatient Settings in the USA from 2011–2016
- 401 Characteristics and Predictive Factors for Multidrug-Resistant Gram-Negative Infection Following Deployment-Related Trauma
- 402 Antimicrobial Resistance Profile in Key Gram Negative Bacilli found in Urocultures at a Teaching Hospital in Guatemala.
- 403 Clinical Characteristics and Resistance Patterns of *Pseudomonas aeruginosa* isolated from Operations Enduring Freedom and Iraqi Freedom Trauma Patients
- 404 Current Antimicrobial Resistant Prevalence by Hospital Characteristics: Analysis of Microbiological Data from October 2016 to March 2017 in 339 US Hospitals
- 405 Changing Trends in Antimicrobial Resistance Pattern in *Klebsiella species* Bacteremia in an Out-patient Hemodialysis Unit over 6 Years (2010–2015) in a Tertiary Care Hospital in Pakistan
- 406 High Asymptomatic Carriage of Carbapenem Resistant *Enterobacteriaceae* and Vancomycin Resistant *Enterococcus* by Active Screening for Intubated Patients in Intensive Care Units and Respiratory Care Units
- 407 Impact of Screening/Decolonization Program on Carbapenem-Resistant *Enterobacteriaceae* (CRE) and Methicillin-Resistant *Staphylococcus aureus* (MRSA) Colonized Patients and their Subsequent Risk for Infections
- 408 Sustainability of Vancomycin Resistant *Enterococci* (VRE) Control: Collateral Effects of Hospital-wide Carbapenem Resistant *Enterobacteriaceae* (CRE) Control Program
- 409 Multi-drug Resistant Organisms (MDROs) Have Escaped the Hospital: Evidence of Community Acquisition at a Regional Hospital
- 410 Active Surveillance for Carbapenem-resistant *Enterobacteriaceae*, Vancomycin-resistant *Enterococci* and toxigenic *Clostridium difficile* among Patients transferred from Long-term Care Facilities at a Tertiary Hospital in Korea

53. Poster Abstract Session HAI Non-Acute Care Thursday, 12:30 p.m. – 2:00 p.m.

- 411 Change in human body temperature over time: defining a new “normal”
- 412 The Role of Whole Genome Sequencing in Defining Institutional Influenza Outbreaks
- 413 Infection Control in Long-Term Care Facilities: Frequently Identified Gaps in Infrastructure, Surveillance and Safety
- 414 The Burden of Invasive *Staphylococcus aureus*, Carbapenem-Resistant Gram-Negative Bacilli and *Clostridium difficile* Infections in Nursing Homes in Monroe County, NY
- 415 The Investigation of Multi-Drug Resistant Bacteria Colonization in Geriatric Population in A Turkish Nursing Home
- 416 High Prevalence of Multidrug Resistant Organisms: MRSA, VRE, CRE, ESBLs and *C. difficile* at a Chicago LTACH
- 417 Estimating the Impact of Post-Prescribing Review on the Quality of Antibiotic Prescribing in Skilled Nursing Facilities
- 418 Antibiotic Stewardship and Urinary Tract Infections in U.S. Nursing Homes Reporting to the National Healthcare Safety Network 2015–2016
- 419 Trends in Outpatient Bacteremia in British Columbia, Canada between 2010–2015
- 420 Scratching the Surface: Detecting the Presence of Viral Pathogens in Pediatric Primary Care Clinics
- 421 Challenges During Contact Investigation of a Patient with Pulmonary tuberculosis in a Day Care Center

54. Poster Abstract Session HAI: Epidemiologic Methods Thursday, 12:30 p.m. – 2:00 p.m.

- 422 Red Box: Creating a Safe Zone to Improve Communication with Isolated Patients

- 423 Decreasing Blood Culture Contamination Rates in a Children's Hospital
- 424 Superiority of Remnant *Clostridium difficile* Diarrhea Specimens in Detecting Carbapenem-Resistant *Enterobacteriaceae* (CRE) Colonization in a Tertiary Care Hospital with Low Endemicity
- 425 Performance of a Smartphone Application-Based Participatory Syndromic Surveillance System for Acute Febrile Illness and Acute Gastroenteritis in Rural Guatemala
- 426 Quasi-Experimental Studies in the Fields of Infection Control and Antibiotic Resistance, 10 Years Later: A Systematic Review for the CDC Prevention Epicenter Program
- 427 Retrospective Optimization of Statistical Process Control (SPC) Charts to Detect Clinically-Relevant Increases in Surgical Site Infection (SSI) Rates
- 428 Estimating Time Between Central Line-associated Bloodstream Infection Events
- 429 Bias in Studies of Antimicrobial Resistant Healthcare-Associated Infection (HAI) Interventions Due to Trends in Length of Stay and Patient Census
- 430 Assessment of Healthcare Facility Network Analysis to Inform Facility Enrollment into Regional Antimicrobial Resistance Prevention Collaboratives
- 431 An Estimate of Inappropriate Antibiotic Prescribing Rates for Outpatient Uncomplicated Urinary Tract Infections.
- 432 Measuring Multiple Dimensions Of Cumulative Antibiotic Exposure- The Antibiotic Exposure Index
- 433 Evaluating Models Used in Clinical Decision Support for Empiric Antibiotic Therapy

55. Poster Abstract Session

HAI: Occupational Health

Thursday, 12:30 p.m. – 2:00 p.m.

- 434 Feasibility of Active Surveillance for Acute Respiratory Illnesses among Staff in Pediatric Long-term Care Facilities
- 435 Small Changes Make a Big Difference in the Fit of N95 Respirators
- 436 Agreement with employer influenza vaccination requirements among U.S. health care personnel during the 2015–16 season
- 437 Characteristics of Health Care Workers That Decline Influenza Vaccination for Varying Reasons
- 438 Managing a Large-scale Occupational Exposure to *Brucella abortus* in a High Throughput Clinical Laboratory
- 439 Aggressive contact investigation of in-hospital exposure to active pulmonary tuberculosis including patients, visitors and healthcare workers
- 440 Impact of Insulin Delivery Devices on the Incidence of Needlestick Injuries Among Nurses in a Community Hospital, 2007–2016
- 441 Evaluation of a Novel Powered Air Purifying Respirator (PAPR) vs. a N95 Respirator Mask for the Protection against Influenza in a Human Exposure Model
- 442 Adherence to contact precautions among different categories of healthcare workers through video monitoring in a tertiary hospital facility
- 443 Tracking Healthcare Worker Competencies and Automated Active Symptom Surveillance for Ebola Virus Disease
- 444 Experiences of Hospitals in the Chicago Area with PPE Acquisition and Use During the 2014 Ebola Virus Disease Outbreak
- 445 What Are the Appropriate Personal Protective Equipment (PPE) for Frontline Workers (FLW) Caring for Filovirus/Ebola Virus Disease (EVD) Patients?
- 446 Importance of the Medical Attire: Perception of Patients, Families and Staff in Mexico City.
- 447 Effective Healthcare Personnel (HCP) Influenza Vaccination Policies In Acute Care Hospitals Across Tennessee
- 448 Multi-Facility Assessment of Variation in Transmission-Based Precautions (TBP) Policies and Healthcare Personnel (HCP) Personal Protective Equipment (PPE) Use Behavior

56. Poster Abstract Session

HAI: Outbreaks

Thursday, 12:30 p.m. – 2:00 p.m.

- 449 Epidemiologic Characteristics of Healthcare-Associated Outbreaks and Lessons Learned from Multiple Outbreak Investigations
- 450 State and Local Public Health Department Healthcare Outbreak Response Capacity Self-Assessment – United States 2016
- 451 Calling Out Gastrointestinal (GI) Illness: Surveillance and Response to GI Clusters in Healthcare Workers and Patients
- 452 Control of a Hospital Norovirus Outbreak Using Hydrogen Peroxide and Peroxyacetic Acid (H2O2-PAA) Disinfectant Cleaner
- 453 The comparison of risk factors of CRE colonization between hospitals
- 454 Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Among Patients Without Usual Risk Factors — Kentucky, 2016
- 455 Detection of NDM-7-Producing *Escherichia coli* by Surveillance Culture of Healthcare Workers in an Outbreak Setting
- 456 Endoscopic Retrograde Cholangiopancreatography Associated with Ceftriaxone-Resistant *Escherichia coli* Bloodstream Infections: Looking for Hay in a Haystack
- 457 Electronic and Microbiological Detection, Investigation, and Surveillance for Potential Hospital- Acquired Device Associated Infections at ERCP.
- 458 Rapid Detection of Invasive *Mycobacterium chimaera* Infection by Using a Novel Plasma-Based Next-Generation Sequencing Assay
- 459 An Outbreak of *Pseudomonas aeruginosa* Infection in Coronary Artery Bypass Graft Patients Related to Endoscopic Vein Harvesting Equipment.
- 460 The Burden of *Acinetobacter baumannii* in the Intensive Care Unit of a Teaching Hospital in Kuwait Over a 3-year Period.
- 461 *In Vitro* Susceptibility Profiles of *Klebsiella* spp. Isolated from ICU and non-ICU Wards in North and Latin America (TEST Program 2012–2016)
- 462 An Increase in Invasive Infections due to *Corynebacterium striatum* at an Academic Medical Center
- 463 Control of Cat Flea Infestation in Neonatal and Pediatric Intensive Care Units
- 464 A Cluster of Fluconazole-Resistant *Malassezia pachydermatis* in a Neonatal Intensive Care Unit — California, 2015–2016

57. Poster Abstract Session

HAI: Surveillance + Reporting

Thursday, 12:30 p.m. – 2:00 p.m.

- 465 Return on Investment: How Infection Preventionists (IPs) Spend Their Time at an Academic Medical Center
- 466 The cost and mortality burden of hospital-onset antimicrobial resistant healthcare-associated infections in the United States
- 467 Molecular epidemiology of carbapenem-resistant *Enterobacter cloacae* in a University Hospital in Japan.
- 468 Antimicrobial Resistance and Attributable Burden of *Pseudomonas aeruginosa* in Hospitalized Patients
- 469 Use of the Extensively Drug Resistant Organism (XDRO) Registry for Carbapenem-Resistant Enterobacteriaceae (CRE) Reporting and Initiation of Transmission Precautions — Chicago, Illinois, 2016
- 470 Antibiotic Resistance Increases with Local Temperature
- 471 Molecular Characterization of Carbapenem-Resistant Enterobacteriaceae in the United States, 2011–2015
- 472 Instituting Public Health Laboratory Surveillance for Methicillin-resistant *Staphylococcus aureus* (MRSA), Extended-Spectrum Beta Lactamase producing Enterobacteriaceae (ESBL), and Carbapenem-resistant Enterobacteriaceae (CRE) in a Large Metropolitan County
- 473 Map The Gap: Using Regional Mapping To Determine The State Of The Infectious Diseases Workforce With Regards To Health Care Associated Infections And Sepsis Mortality.

- 474 2015 NHSN CAUTI Definition Change and its Impact on CLABSI Rates at an Academic Medical Center
- 475 Surveillance of hemodialysis events: A prospective multicenter study, first report from Turkey
- 476 Introducing Hospital Onset Bloodstream Infection (HOBSSI) as a Tool to Evaluate Infection Prevention: Assessment of 51 US Hospitals
- 477 Comparison of clinical characteristics and outcomes between community-acquired and healthcare-associated bacteremia cases due to *Bacteroides* species
- 478 Hospital Onset *Staphylococcus aureus* Bacteremia is a Better Measure than MRSA Bacteremia in Assessing Infection Prevention: Evaluation of 51 US Hospitals
- 479 Preventability of Hospital Onset Bacteremia and Fungemia: A Pilot Study of a Potential New Indicator of Healthcare-Associated Infections

- 507 Sinks in Healthcare Facilities are a Potential Source for Dissemination of *Candida* Species
- 508 The Efficacy of Targeted Ultraviolet-C in Reducing Environmental Aerobic Colony Counts with and without Disinfection
- 509 Impact of Multidisciplinary Team on Duodenoscope Reprocessing to Minimize Infections with High-Risk Organisms
- 510 Detecting Colonized Patients, Training Healthcare Workers and Adequate Disinfection as Effective Strategies for Infections Control by Multidrug-Resistant Microorganisms During the Transfer to a New Hospital Area at a General Hospital in Mexico City
- 511 Next-Generation UV: Evaluation of a Robotic Ultraviolet-C Room Disinfection Device
- 512 Light Emitting Diode Disinfection as Continuous Room Surface Decontamination against Healthcare-Associated Pathogens

58. Poster Abstract Session

HAI: The Environment

Thursday, 12:30 p.m. – 2:00 p.m.

- 480 Lack of Association Between Surface Disinfection and Fluorescent Marker Score
- 481 How Clean Are the Clinics? Assessment of Environmental Cleanliness in Ambulatory Care
- 482 Portable Medical Equipment: A network analysis showing the potential missing link in infection prevention practices.
- 483 A Preliminary Study of Germicidal Efficacy against *Candida auris*
- 484 An Equally Effective but Better Tolerated Formulation of Bleach
- 485 Environmental Cleaning and Disinfection in Long-Term Care Facilities: Opportunities for Improvement
- 486 Application of Dilute Hydrogen Peroxide Gas Technology for Continuous Room Decontamination of Multidrug-Resistant Organisms: Negative Results from A Preliminary Experimental Study
- 487 Germicidal Activity against Carbapenem/Colistin Resistant *Enterobacteriaceae* Using A Quantitative Carrier Test Method
- 488 Does cleaning time matter? A study to determine the effect of unlimited vs limited time for terminal disinfection
- 489 Contaminated re-usable thermometers are a potential vector for dissemination of pathogens
- 490 Frequent Contamination of Healthcare Worker Scrubs
- 491 Likelihood of Environmental Contamination of Patient Rooms in Six Acute Care Facilities based on Facility, Unit-Type, and Precautions Status
- 492 The Utility of Preliminary Patient Evaluation in a Febrile Respiratory Infectious Disease Unit Outside the Emergency Department
- 493 Quantitative Assessment of the Bioburden of High-Touch Environmental Surfaces in Pediatric Operating Rooms
- 494 Shedding of Methicillin-Resistant *Staphylococcus aureus* (MRSA) by Hospitalized Patients during Procedures
- 495 Successful Environmental Disinfection to Prevention Transmission of *Candida Auris*
- 496 Impact of a Copper-Infused Countertop Material on the Bacterial Surface Burden: Results of a Field and Laboratory Study
- 497 Mold Contamination Due to Construction Dust in Ventilation System Detected During Routine Pre-commissioning Air Sampling
- 498 Does pulsed-xenon ultraviolet disinfection add additional value to manual cleaning?
- 499 National Survey of Environmental Cleaning Among Thai Hospitals
- 500 Investigation of *Mycobacterium Pseudo*-outbreak
- 501 Infection Prevention and Control Education for Environmental Services Workers (ESW): “Cleaner is Safer – ESW on the Frontline of Infection Prevention”
- 502 *Sphingomonas* Infections Arising from Hospital Plumbing Fixtures
- 503 Implementation of Cleaning Process for Mobile Patient Equipment
- 504 Developing an Outpatient High Level Disinfection Competency Program
- 505 Quantitative Analysis of Microbial Burden on Hospital Room Environmental Surfaces Contributing to Healthcare-Associated Infections
- 506 Eyewash Stations in Teaching and Research Laboratories Host Potential Pathogenic Microbiota

59. Poster Abstract Session

Hepatitis B and C in Varied Settings

Thursday, 12:30 p.m. – 2:00 p.m.

- 513 Hepatitis C Testing Strategies in a Correctional Setting
- 514 High Incidence of Hepatitis C Virus (HCV) Infection among an Urban Emergency Department (ED) Patients, 2003 – 2016.
- 515 Where is the US Hepatitis C Epidemic *Now*? Putting the “Pen” on the Map as Elimination Efforts Hunt for Remaining Cases.
- 516 African-Born Status and Risk of Hepatocellular Carcinoma among Patients with Chronic Hepatitis B Infection
- 517 Characterization of Novel Hepatitis B Virus B/C Intergenotypic Recombinants in 3'-terminal Reverse Transcriptase Sequences among Chronic Hepatitis B Patients
- 518 APRI Score as A predictor of Significant Liver Fibrosis In Chronic Hepatitis B
- 519 Effectiveness and Safety of Sofosbuvir/Ledipasvir and Paritaprevir/ritonavir/Ombitasvir + Dasabuvir in Patients with Chronic Kidney Diseases: Results from ERCHIVES
- 520 Factors associated with appropriate hepatocellular carcinoma (HCC) screening among chronic hepatitis C (HCV) patients with cirrhosis at an urban safety-net hospital system
- 521 Patterns of Testing in Children Exposed Perinatally Exposed to Hepatitis C
- 522 Fibrosis Progression and Incidence of Cirrhosis and Hepatic Decompensation in Persons Treated with Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir: Results from ERCHIVES
- 524 Racial/Ethnic and Socioeconomic Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus in an Insured Population
- 525 Making the Case for Universal Screening of Pregnant Women for Hepatitis C Virus: One State at a Time
- 526 Is DAA Treatment Associated with HBV Reactivation? Results from ERCHIVES
- 527 Mental Health, Heart Disease, and Lack of Insurance Associated with Not Receiving Hepatitis C Treatment in Safety-Net Hospitals
- 528 HCV Treatment Initiation in Patients with Chronic Kidney Disease: Results from ERCHIVES
- 529 Evaluation of the Hepatitis C Cascade of Care in a Multidisciplinary Infectious Diseases Clinic
- 530 Infectious Disease-Led Hepatitis C Care in a Primary Care Clinic Setting: Cascade of Care Modeling and Experiences From an Integrated Clinic
- 531 Results of a Hepatitis C Virus Screening Program of the 1945–1965 Birth Cohort in a Large Emergency Department in New Jersey
- 532 Using a Mobile-Health System to Monitor and Provide Support along the Hepatitis C Virus Continuum of Care for People with Opioid Use Disorders: Experience from a Randomized Trial
- 533 The Impact of Hepatitis C Virus (HCV) Treatment with Direct-Acting (DAA) on the Incidence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Liver Disease.
- 534 Use of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma
- 535 Effectiveness of 8 or 12 Week Treatment Duration of Ledipasvir/Sofosbuvir for Hepatitis C: Evidence from a Large Academic Medical Center

- 536** Patients Followed in an Addiction Medicine Clinic Are Less Likely to Be Eligible to Hepatitis C Drug Studies Regardless of Drug Use
- 537** Telehealth for Hepatitis C care in the DAA era; ensuring everyone can access a cure
- 538** Cascade of Care for Hepatitis C Virus (HCV) infected patients in an Urban Community Health Center in Massachusetts in the era of Direct Acting Antivirals (DAAs)
- 539** Barriers to Successful Linkage to Care Among HCV Positive Individuals Presenting to a Major Tertiary Medical Center on Long Island, New York.
- 540** Implementation of a Comprehensive Hepatitis C Virus (HCV) Treatment Program in Metro-Detroit
- 541** Improving Hepatitis C Screening Rates in Primary Care
- 542** Impact of Insurance and Treatment Regimens on HCV Outcome: Longterm follow up study
- 543** Salvage Therapy in Cancer Patients With Hepatitis C Infection Failing Direct-Acting Antivirals – A Prospective Study
- 544** Retreatment of chronic HCV infection after second generation DAA failure in patients in the NJ VA Healthcare System
- 545** Assessing gaps in Hepatitis C Care in Primary Care.
- 546** Direct-acting antivirals induce lymphoproliferative disease response in HCV-infected patients: A prospective case series

60. Poster Abstract Session HIV and Central Nervous System Thursday, 12:30 p.m. – 2:00 p.m.

- 547** Incidence of symptomatic CSF viral escape in HIV infected adults receiving atazanavir/ritonavir (ATV/r)-containing ART: A tertiary care cohort in western India
- 548** Stroke outcomes among HIV-infected patients in a large, urban, tertiary hospital in the United States, 1999–2016
- 549** MoCA Utility as a Quick Testing Tool for Neurocognitive Disorders in HIV Patients: Analysis of a Prospective Cohort
- 550** Neurocognitive Decline in People Living with HIV in India and Correlation with 3T Magnetic Resonance Spectroscopy
- 551** Aberrant Autophagy in Macrophages and Astrocytes after HIV Nef or Antiretroviral Treatment: Contribution to the Pathogenesis of HIV-associated Neurocognitive Disorders

61. Poster Abstract Session HIV and Fungal Infection Thursday, 12:30 p.m. – 2:00 p.m.

- 552** Appropriate time to start antiretroviral therapy in HIV-infected patients with Penicilliosis marneffeii
- 553** Survival in HIV-infected Asymptomatic Cryptococcal Antigenemia without CSF Positivity Treated with Fluconazole Did Not Differ from Cryptococcal Antigen (CrAg) Negative with CD4 <150.
- 554** High Prevalence of *Cryptococcal* Antigenaemia and Disseminated *Cryptococcal* disease amongst patients with Advanced HIV disease in Pune, India.
- 555** HIV/AIDS and cryptococcosis in Costa Rica
- 556** Characteristics and Outcomes of Patients with *Pneumocystis jirovecii* Pneumonia Who were Initiated on Antiretroviral Therapy While Hospitalized: A Preliminary Study.

62. Poster Abstract Session HIV and Mycobacterial Infections Thursday, 12:30 p.m. – 2:00 p.m.

- 557** Using a Validated Calculator to Assess the Risk of Disease Progression and Treatment Completion in Patients with Human Immunodeficiency Virus Infection and Latent TB
- 558** Integration of Tuberculosis (TB) Screening in The Ryan White Program in Arkansas

63. Poster Abstract Session HIV Clinical Care and Outcomes Thursday, 12:30 p.m. – 2:00 p.m.

- 559** White Blood Count, Albumin, and BMI Enhance VACS Index Prognostic Model, but Nadir CD4 and CD8 Metrics Do Not
- 560** The Impact of Continuous Virologic Suppression on the Development of Non-AIDS Diagnoses
- 561** Screening for comorbid conditions among people with HIV in medical care
- 562** The Prevalence of *Legionella* Species as a Co-pathogen in HIV-Associated Community-Acquired Pneumonia
- 563** Performance of Early Warning Scores in Predicting Mortality in an HIV-Infected Population with Sepsis in Uganda
- 564** Hearing Loss and Quality of Life Among Human Immunodeficiency Virus (HIV)-Infected and Uninfected Adults
- 565** Cutaneous Diseases among an Aging HIV Cohort, Receiving Care at an Infectious Diseases/Primary Clinic
- 566** When Viral Suppression Is Not Enough: Clinical Characteristics of HIV Infected Patients with Poor Immune Recovery
- 567** Assessing residents' perception of their ability to manage chronic musculoskeletal pain in HIV infected patients.
- 568** Systematic Review of Interventions for Depression for People Living with HIV in Africa

64. Poster Abstract Session HIV: Cancer and Dysplasia Thursday, 12:30 p.m. – 2:00 p.m.

- 569** Immune Microenvironments of Anal Cancer Precursors Differ by HIV-Serostatus and are Associated with Ablation Outcomes
- 570** Alarmingly High Rate of Prostate Cancer Detected by Routine Prostate-Specific Antigen Screening in a County HIV Clinic.
- 571** Clinical Characteristics and Outcomes of HIV-Infected Patients with Non-AIDS Defining Cancers in a National Institute Cancer in Mexico

65. Poster Abstract Session HIV: Cardiovascular Disease, Lipids, Diabetes Thursday, 12:30 p.m. – 2:00 p.m.

- 572** Missed Opportunities for Primary Prevention of Cardiovascular Disease in an HIV Clinic
- 573** A comparative analysis of cardiovascular risk in HIV sero-positive and sero-negative pre-menopausal women
- 574** Statin Utilization among human-immunodeficiency virus (HIV)-infected individuals based on the 2013 American College of Cardiology and American Heart Association (ACC/AHA) Blood Cholesterol Guideline
- 575** Abacavir Use and Risk for Myocardial Infarction and Coronary Artery Disease: Updated Meta-analysis of Data from Clinical Trials
- 576** Comparison of Risk Category Predictions of Framingham Risk Score (FRS), Atherosclerotic Cardiovascular Disease Risk Score (ASCVD), Systematic Coronary Risk Evaluation (SCORE) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) in HIV Infected Patients
- 577** Dyslipidaemia among Children living with HIV after 48 weeks of First-line Antiretroviral therapy
- 578** Echocardiographic Assessment of US Air Force Members with Early HIV Infection
- 579** Associations between Apolipoprotein-A5 Genotype, High-Fat Diet and Plasma Lipid Levels among HIV-infected Children initiating Antiretroviral Therapy in India
- 580** The prevalence and outcome of pre-DM/DM in an urban HIV primary care clinic
- 581** Venous Thromboembolism in Patients Infected with Human Immunodeficiency Virus

66. Poster Abstract Session
HIV: General Opportunistic Infections
Thursday, 12:30 p.m. – 2:00 p.m.

- 582** Opportunistic infections in patients with HIV/AIDS at the Hospital Universitario de Santander: an anatomopathological study in the period 2004–2016
- 583** Strongyloidiasis Epidemiology and Treatment Response in Patients with HIV Infection
- 584** *Varicella zoster* Virus IgG Antibody Levels in HIV Infected Patients Managed at Ryan White Clinics in Three South Carolina Counties
- 585** Incidence of Herpes Zoster in a Large Cohort of Persons Living with HIV
- 586** Epidemiology of Most Common HIV Indicator Diseases in Hungary Between 2005 and 2015

67. Poster Abstract Session
HIV: Kidney, Bone + Liver Effects
Thursday, 12:30 p.m. – 2:00 p.m.

- 587** Incidence of Nephrotoxicity Among Antiretroviral Therapy-naïve Patients with Human Immunodeficiency Virus Infection Taking Tenofovir at the Philippine General Hospital
- 588** ART – induced nephrotoxicity and Chronic Kidney Diseases among ambulatory HIV – infected patients with low Body Mass Index in Brazzaville, Congo: incidence and associated risk factors.
- 589** Recovery of Renal Function after Switching from Tenofovir Disoproxil Fumarate to Other Antiretroviral Agents in HIV-infected Patients with Renal Insufficiency
- 590** Calcium Intake and Bone Mineral Density in HIV, Hepatitis C, Co-infected HIV/Hepatitis C, and Uninfected Patients
- 591** Medium Grade Proteinuria Is Not a Relevant Predictor of Chronic Kidney Disease in People Living with HIV/AIDS
- 592** Low rate of routine proteinuria screening among male HIV patients in an urban clinic
- 593** Real-World Experience with Higher-Than-Recommended Doses of Lamivudine in Patients with Varying Degrees of Renal Impairment
- 594** The clinical value of cystatin C as a marker of renal function in HIV patients receiving dolutegravir
- 595** Exposure to Antiretrovirals and Risk of Chronic Kidney Disease in HIV-positive Patients with Normal Renal Function: A Single Center Cohort Study
- 596** Exploring Strategies for Attenuating Changes in Bone Mineral Density in MSM on TDF/FTC HIV Pre-exposure Prophylaxis
- 597** The Incidence and Risk Factors Associated with Chronic Liver Enzyme Elevation (cLEE) in HIV-Monoinfected Persons

68. Poster Abstract Session
HIV: Pathogenesis and Inflammation
Thursday, 12:30 p.m. – 2:00 p.m.

- 598** Fungal Gastrointestinal Translocation is Associated with Immune Activation and Systemic Inflammation in Treated HIV
- 599** Respiratory Mucosal Immune Suppression in HIV-infected Individuals
- 600** Immunological Changes In HIV Infected Patients After Supervised Exercise Thet, A; Figueroa, N; Rodrigues, J; Singleton, R; Sivapalan, V; Mannheimer, S
- 601** HIV-specific CD8 T cell cross-reactivity following Ad5-based vaccination is shaped by vaccine regimen and prior Ad5 exposure

69. Poster Abstract Session
Immunology – Host Response
Thursday, 12:30 p.m. – 2:00 p.m.

- 602** Absence of IL-22 Binding Protein Favors Host During Pneumococcal Pneumonia.
- 603** The Immunology of Recurrent Group A Streptococcus Tonsillitis
- 604** Dysfunctional Platelet Aggregation in Patients with Acute Lassa Fever
- 605** Primed Innate Immune Responses in Monocytes from Kenyan Children with Uncomplicated Falciparum Malaria
- 606** Lipidomics Analysis of *Rhinovirus* Infection in Human Airway Epithelial Cells
- 607** Increased Level and Interferon- γ Production of Circulating Natural Killer Cells in Patients with Scrub Typhus
- 608** Hemozoin directly induces inflammation and upregulation of CD36 in lung epithelium and endothelium
- 609** Solithromycin Inhibits MUC5AC Production Induced by *Streptococcus pneumoniae* and *Haemophilus influenzae* in Human Airway Epithelial Cells
- 610** Mucosal Shedding and Cellular Immune Response After First Episode Genital Herpes Simplex Virus Type 1 Infection
- 611** Immunomodulatory Effects of Lactoferrin during *Burkholderia thailandensis* Infection
- 612** Assessing Phagolysosomal Escape of *Staphylococcus epidermidis* RP62A in Intracellularly Infected Human Fibroblasts
- 613** Pro-Inflammatory and Dysfunctional Immunologic Changes and Risk for Infection in the Older Kidney Transplant Recipient
- 614** Human antibodies induced by an immunotherapeutic vaccine (NDV-3A) containing Als3p, abrogate virulence traits of *Candida albicans*.
- 615** Seroepidemiology of Opsonophagocytic Antibodies to Serotype Ia, Ib, II, III, and V Group B Streptococcus among Infant, Young Adult, and Elderly Koreans
- 616** Retinal Innate Response to *Candida albicans* in Exogenous Fungal Endophthalmitis
- 617** Comparison Between Palivizumab Competitive Antibody (PCA) Assay Containing Pre-Fusion, Intermediate, and Post-Fusion Conformation of the Fusion (F) Protein of Respiratory Syncytial Virus (RSV)
- 618** Investigating Systemic Immunity to Typhoid and Paratyphoid Fever: Characterising the response to re-challenge in a controlled human infection model

70. Poster Abstract Session
Legionella
Thursday, 12:30 p.m. – 2:00 p.m.

- 619** National Patterns in the Use of Legionella Urine Antigen Testing, United States, 2013–2016
- 620** Legionella Colonization Prevention in Ice Machines
- 621** Lessons Learned from Pseudo-Outbreak of Legionella pneumophila Serogroup 1 Infections
- 622** Health Care-Associated Legionnaires' Disease: Surveillance Data from 20 States and a Large Metropolitan Area – United States, 2015

71. Poster Abstract Session
Microbial Pathogenesis
Thursday, 12:30 p.m. – 2:00 p.m.

- 623** Genome-Wide Analysis of *S. aureus* Strains to Identify Variants Associated with Infection versus Colonization
- 624** Prevalence of ST171 in *Enterobacter* Isolates from 2001 to 2013 in 15 Hospitals in NYC

- 625 CRISPR-Cas May Prevent Acquisition of Drug Resistance in *Klebsiella pneumoniae*
- 626 Differences in Gene Expression Levels of Methicillin-Resistant *Staphylococcus aureus* Genes between Persistent and Resolving Bacteremia
- 627 Virulence factors of healthcare associated infection by uropathogenic *E. coli* strains isolated in Korea

72. Poster Abstract Session Microbiome

Thursday, 12:30 p.m. – 2:00 p.m.

- 628 The Gut Microbiome: An Advanced Understanding of Microbial Health Across Countries and Cultures
- 629 The Gut Microbiome in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients
- 630 SYN-006, a Novel Carbapenemase, Intended to Protect the Gut Microbiome from Antibiotic-Mediated Damage May Also Reduce Propagation of Carbapenem-Resistant Pathogens
- 631 The Impact of Antibiotic Use in Breastfeeding Women on the Infant's Gut Microbiome – A Prospective Cohort Study.
- 632 HIV-Associated Changes in the Gut Microbiome in Untreated, Treated, and Immunologically Controlled Disease
- 633 Gut Antibiotic Inactivation by Beta-Lactamases Is Intended to Prevent Microbiome Damage and Attenuate Antibiotic Resistance in Large Animal Models
- 634 Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana
- 635 Impact of Proton Pump Inhibitor Use on Gut Microbiota Composition and Other Markers of Health in Older Adults
- 636 The Lung Tissue Microbiota of Mild and Moderate Chronic Obstructive Pulmonary Disease
- 637 Oropharyngeal Bacterial Community Composition Correlates with Baseline and Post-Vaccination Pneumococcal Polysaccharide Antibody Levels in HIV-Infected Subjects
- 638 Evaluation of bloodstream infections, *Clostridium difficile* infections, and altered gut microbiota in pediatric oncology patients
- 639 Microbial Disruption Indices in the Fecal Microbiome Predicting Acquisition of Multidrug-Resistant Organisms in Nursing Homes
- 640 Changes in the Oropharyngeal Microbiome Preceding Ventilator-Associated Pneumonia
- 641 High Dietary Fiber is Associated with Reduced Prevalence of Gut Colonization by Multi-Drug Resistant Organisms

73. Poster Abstract Session

Outbreaks and Public Health Across the Globe

Thursday, 12:30 p.m. – 2:00 p.m.

- 642 Improving Patient and Employee Safety through Implementation of an Infection Risk Screening Process for International Patients at Boston Children's Hospital – The "AIRSHIP" Protocol
- 643 Infectious Complications of Intravenous Drug Use: A Single-Center Review of Hospitalized Patients in Massachusetts, 2012–2015
- 644 A Cloud Based Epidemiology Network to Investigate Geographical Dynamics of Respiratory Disease
- 645 Mumps Outbreak — Colorado, 2017
- 646 Use of Unannounced "Mystery Patient Drills" to Assess Hospital Emergency Department Preparedness for Communicable Diseases of Public Health Concern in New York City, 2016
- 647 Transmission dynamics of respiratory viruses in a congregated military population: prospective cohort study
- 648 Identical Strain of *Mycobacterium conceptionense* Isolated from Patients at 2 Veterans Affairs Medical Centers within the Same Metropolitan Area over a 4 Year Period
- 649 Transmission of *N. meningitidis* Serogroup W, ST-11 During an International Flight

- 650 *Mycoplasma genitalium* Prevalence and Variability Based on Gender, Race and Sexual Preference in Patients Attending the Oakland County Health Department Disease Clinic
- 651 Brucellosis in Dallas, Texas: a Case Series
- 652 Underreporting of Necrotizing Fasciitis and Streptococcal Toxic Shock Syndrome in Invasive Group A *Streptococcus* Cases in New York State, 2007–2016
- 653 Use of single-dose azithromycin to control a community outbreak of *emm26.3* group A *Streptococcus* invasive disease— Alaska, 2017
- 654 Mumps, 2016: A National Overview
- 655 An Outbreak of Invasive Group A Streptococcal Infections in Injection Drug Users
- 656 Isolates from Patients with Noninvasive *Listeria monocytogenes*: Are They Important?
- 657 Changes in incidence of pediatric Hemolytic Uremic Syndrome and associated Shiga toxin-producing *E.coli* infections, FoodNet, 2006–2014
- 658 Brucellosis Outbreaks Associated with Domestic Consumption of Legally Imported Unpasteurized Goat Cheese — Dallas County, Texas, 2016
- 660 International Importations of Measles Virus into the United States during the Post-Elimination Era, 2001–2015
- 661 Burden of Influenza-like Illness among military personnel receiving advanced training at Ft. Sam Houston, TX
- 662 First mumps outbreak in a decade: measuring impact of mumps among naïve population - Tokunoshima Island, Japan
- 663 Epidemiological Characteristics of Congenital Rubella Syndrome Cases during Rubella Epidemic in Japan, 2012–2014
- 664 Establishing outbreak thresholds for Army Active Duty Soldiers, 2013–2016.
- 665 Introduction of Preventive Vaccination of Meningococcal Meningitis using MenAfriVac in Northern Uganda 2017
- 666 Ebola and Beyond-Developing an Infectious Diseases Treatment Infrastructure in the United States
- 667 SIX-YEAR SURVEILLANCE OF DIPHTHERIA OUTBREAK IN INDONESIA
- 669 Physician and Infection Preventionists Perceptions on Communicable Disease Reporting—Indiana, 201
- 670 A Collaborative Response by Public Health and Local Hospitals to a NICU Tuberculosis Exposure
- 671 Hepatitis A Outbreak Among Persons Experiencing Homelessness — Maricopa County, Arizona, 2017
- 672 Comparative Analysis of Incidence and Outcomes of Acute Hepatitis A (HAV) and B Virus Infections (HBV) in Children Aged ≤ 20 years in the United States (US)
- 673 Emerging Azithromycin Resistance among Nontyphoidal *Salmonella* Isolates in the United States

74. Poster Abstract Session

Stewardship: Data and Program Planning

Thursday, 12:30 p.m. – 2:00 p.m.

- 674 Antibiotic Consumption Point Prevalence Survey in a Teaching Hospital in Guatemala.
- 675 Appropriateness of antibiotic prescriptions for acute sinusitis and pharyngitis in ambulatory care settings of an integrated health care system
- 676 Protecting Our Most Vulnerable: Why Antimicrobial Stewardship for Senior Living is a Must – Results from Four Large Senior Living Centers
- 677 Antibiotic Use in an Accident and Emergency Department in a Teaching Hospital in Ghana
- 678 Point Prevalence Survey on Antimicrobial Use in Pediatric Post-acute Care Facilities
- 679 Geographical analysis of Antimicrobial Consumption Surveillance using the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB JAPAN) 2011–2013
- 680 Antibiotic Use Data From 30 Community Long-Term Care Facilities Suggests Initial Targets for Antibiotic Stewardship Programs

- 681 Use of the web by public health jurisdictions to disseminate practical information to strengthen antimicrobial stewardship programs and enhance surveillance —United States, 2017
- 682 Benchmarking Antimicrobial Use in Emergency Departments among Community Hospitals in the Duke Antimicrobial Stewardship Outreach Network
- 683 ASP Strategies and Appropriate Antibiotic Use
- 684 How to use antimicrobial use data? A model to support decision-making and facilitate understanding
- 685 Working Together to Define Antibiotic Appropriateness: Point Prevalence Survey in 47 Intensive Care Units from 12 US Hospitals, Partnership for Quality Care, March 2017
- 686 Broad Spectrum Antibiotic Use at Choice, Change, and Completion throughout VA: Patterns of Initiation and De-escalation
- 687 Predictors of Total Antibiotic Use among a National Network of Academic Hospitals
- 688 Antibiotic Utilization in the Dental Clinic over 7 Years; Room for Improvement.
- 689 Antibiotic Prescribing and Stewardship Opportunities within a Veterans Affairs Dental Care Practice
- 690 Antibiotic Prescribing by Dentists and Geographic Variability in the Veterans Affairs (VA) Health System
- 691 Antibiotic Use Metrics to Guide Antibiotic Stewardship Priorities: Dental Antibiotic Prescribing in the U.S. Veterans Affairs (VA) System
- 692 *Use of Antibiotic Prophylaxis for Tooth Extractions, Dental Implants and Periodontal Surgical Procedures*
- 693 Preparing for The Joint Commission Standard on Antimicrobial Stewardship: Practical Tips for Survey Success
- 694 What Do They Want? A Survey of Residents' Attitudes of Procalcitonin Use and Appropriate Utilization
- 695 Physician Perceptions and Attitudes Towards an Antimicrobial Stewardship Program and Computerized Decision-making Systems: A Focus Group Study
- 696 Variability in Emergency Medicine (EM) Provider Decisions on Hospital Admission and Antibiotic (ABX) Treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSI)
- 697 Effects of Policy and Resources on Antimicrobial Stewardship Interventions in the VA: Applying a Transaction Cost Economics Framework
- 698 Antimicrobial Stewardship Curriculum and Training among Health Professional Schools and Residency Training Programs in California
- 699 Knowledge and Perspectives of Antimicrobial Stewardship: A Comparison of Inpatient versus Outpatient Providers
- 700 Patient Preferences in the Emergency Department (ED) Before Treatment for Acute Bacterial Skin and Skin Structure Infection (ABSSI)
- 701 Frequently Identified Gaps in Antimicrobial Stewardship Programs in Critical Access Hospitals
- 702 Frequently Identified Gaps in Antimicrobial Stewardship Programs in Long-Term Care Facilities
- 703 Structure of Antimicrobial Stewardship Programs in Leading U.S. Hospitals
- 704 Antimicrobial Stewardship Practices Reported by California Hospitals Following New Legislative Requirements: Analysis of National Healthcare Safety Network Annual Survey Data, 2014–2015
- 705 Antibiotic use among future health professionals: A multicentre cross sectional study of Chinese medical student
- 706 Physician Perspectives on the Optimization of Carbapenem Use in a Four Hospital, Large Urban Healthcare System
- 707 Comparison of an Emergency Department-Specific Antibigram to Hospital Antibigram: Influence of Patient Risk Factors on Susceptibility
- 710 Validation and Evaluation of Antimicrobial Orders Indication for Use
- 711 Antimicrobial stewardship among hospitalized patients with Influenza Respiratory Tract Infections
- 712 Successful Establishment of an Antimicrobial Stewardship Program (ASP) for Outpatient Parenteral Antimicrobial Therapy (OPAT)
- 713 Impact of an antimicrobial stewardship program (ASP) on the optimal selection of antibiotic prophylaxis in cesarean delivery in a hospital without restrictions on the use of antibiotics: First ASP in Costa Rica.
- 714 Development of an Evidence-Based Antimicrobial Stewardship Smartphone App in a Tertiary Academic Pediatric and Women's Health Centre in Canada
- 715 Implementation of a Vancomycin AUC Monitoring Program: Peaks and Pitfalls
- 716 A Longitudinal Four-year Pre-Post Intervention Study Evaluating the Use of an Antimicrobial Stewardship Application
- 717 An Antimicrobial Stewardship Initiative to Evaluate Penicillin Allergy Labels in Spinal Cord Injury and Long-Term Care Patients
- 718 Pre-implementation Assessment of An Antimicrobial Stewardship Program for Acute Respiratory Infections within Emergency and Urgent Care Settings
- 719 Comparing a Clinical Decision Tree vs. Standard of Care for Predicting ESBL+ Bacteremia in a VA Population
- 720 Implementation of an Antimicrobial Restriction Policy: Is the "Paper" More Persuasive?
- 721 Remote Antimicrobial Stewardship: a Solution for Meeting the New Joint Commission Standard?
- 722 Results of a Pilot 4th year Medical Student Elective in Antimicrobial Stewardship
- 723 Effect of Leadership Commitment and Education on Antimicrobial Use and Hospital-Acquired *Clostridium difficile* infection rates at a Community Hospital
- 724 Formulary Management and Antimicrobial Stewardship: a 7-year Evaluation at an Integrated Health-System
- 725 YouTube video educational package increased acceptance of antibiotic clinical decision support system recommendations
- 726 Using the Epic® Antimicrobial Stewardship (ASP) Module to Optimize Antimicrobial Stewardship Interventions
- 727 Impact of a Targeted Fluoroquinolone Restriction on Antimicrobial Usage at Two Community Hospitals
- 728 IMPACT OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM AT A LARGE ACADEMIC MEDICAL CENTER, A DECADE OF EXPERIENCE
- 729 Impact of An Electronic "Antibiotic Time Out" on Provider Prescribing Patterns
- 730 Implementation and Outcomes of an Advanced Antimicrobial Stewardship Program at a Quaternary Care Hospital in the United Arab Emirates
- 731 A Cluster Randomized Controlled Trial Comparing Early and Late Carbapenems De-escalation in the Medicine Units, Maharaj Nakorn Chiang Mai Hospital
- 732 Antimicrobial Stewardship Program Intervention Package for Increasing Appropriate Outpatient Antibiotic Usage: A Clinic-Feedback Based Approach
- 733 A novel educational paradigm to address gaps in antimicrobial prescribing knowledge, attitudes, and practices
- 734 Penicillin Allergy Skin Testing as an Antibiotic Stewardship Intervention in Hematopoietic Cell Transplant Recipients
- 735 Impact of an Antimicrobial Stewardship and Emergency Department Initiated Dalbavancin Guideline for Patients with Acute Bacterial Skin and Soft Tissue Infections
- 736 Antimicrobial Stewardship in the Neonatal Unit: A Quality Improvement Initiative
- 737 Implementation of Antibiotic stewardship : A South Indian experience
- 738 Grading the Impact of a Standardized Beta Lactam Antibiotic Allergy Assessment Protocol for Treatment Decisions: An Antimicrobial Stewardship Target
- 739 Use of a *Clostridium difficile* Risk Calculator to Optimize Antimicrobial Stewardship
- 740 Antimicrobial Stewardship Program in a Tertiary Neonatal Intensive Care Unit
- 741 Patterns of Use of an Institution-Specific Antimicrobial Stewardship Smartphone Application

75. Poster Abstract Session

Stewardship: Program Implementation

Thursday, 12:30 p.m. – 2:00 p.m.

- 708 Evaluating Patient-Specific Antibigrams
- 709 The Regional Antibigram Is an Important Public Health Tool to Improve Empiric Antibiotic Selection, *Stenotrophomonas maltophilia* As A Case Example

- 742 Impact of an antimicrobial stewardship intervention on antibiotic prescribing practices for community-acquired acute uncomplicated cystitis in the emergency department
- 743 Quality Assessment of Process Measures in Antimicrobial Stewardship: Concordance of Cefepime Indication Without Automatic Prospective Approval in Computerized Provider Order Entry
- 744 Antimicrobial Stewardship with a Unique Pharmacist-Managed Penicillin Skin Testing (PST) Service
- 745 Implementation of a Carbapenem Prescribing Algorithm at a Community Hospital
- 746 University of Washington Tele-Antimicrobial Stewardship Program (UW-TASP/ECHO): Collaboration Across Washington State to Improve Antimicrobial Use
- 747 Concordance of Outpatient Antibiotic Prescribing with Infectious Diseases Society of America (IDSA) Guidelines for the Treatment of Acute Uncomplicated Cystitis in Southern Maine
- 748 Challenges of Antibiotic Stewardship on the Internal Medicine Ward
- 749 Embracing Handshake Stewardship: Utility of Collaborative, Prospective Audit and Feedback Rounds in an Intensive Care Unit at Royal University Hospital, Saskatoon, Saskatchewan
- 750 A Review of Antibiotic Prophylaxis for Interventional Radiology Procedures and Identification of Antimicrobial Stewardship Opportunities
- 751 The Impact of a Pharmacist Driven 48-hr Antibiotic Time Out during Multi-disciplinary Rounds on Antibiotic Utilization in a Community Non-teaching Hospital
- 752 What's Next?: Sustaining Hospital-Initiated Nursing Home Antimicrobial Stewardship Programs
- 753 Antimicrobial stewardship program for broad-spectrum oral antibiotic use in a pediatric emergency department: an interrupted time-series analysis
- 754 Don't Ask, Don't Tell: Quality of β -lactam Allergy Assessment in Patients with Methicillin-Susceptible *Staphylococcus aureus* (MSSA) Infections at a Tertiary-Care VA Medical Center
- 755 Promoting judicious antibiotic use: Results of an outpatient-based randomized EMR-generated intervention study
- 756 Emergency Department Specific Antimicrobial Stewardship Intervention Reduces Antibiotic Duration and Selection for Discharged Adult and Pediatric Patients with Skin and Soft Tissue Infections
- 757 Antibiotic Stewardship in the Medical Intensive Care Unit of an Academic Medical Center: Impact of a Pneumonia Diagnostic Bundle with Pharmacist Intervention
- 758 Antimicrobial Stewardship Facetime: Comparison of Two Rounding Models at a Tertiary Medical Center
- 759 At a Rural Veterans Affairs Medical Center, Telehealth Decreased Antibiotic Use in Long-Term, but not Acute Care
- 760 Reduction of Overall and Inappropriate Antibiotic Prescribing within a Veterans Affairs Primary Care System through Peer Comparison of Overall Antibiotic Prescribing Rates
- 761 Quality Assessment of Process Measures in Antimicrobial Stewardship: Concordance of Valacyclovir Indication and Automatic Prospective Approval in Computerized Provider Order Entry
- 762 A Hospitalist-Led Initiative to Promote Antibiotic Citizenship on Internal Medicine Teaching Services
- 763 Peripherally Inserted Central Venous Catheters (PICCs): An Opportunity for Antimicrobial Stewardship
- 764 Developing Surgical Antimicrobial Prophylaxis Interventions Using Theoretical Domains Framework
- 765 Partners in Stewardship: Collaboration Between a Tertiary Hospital and Local Skilled Nursing Facilities to Improve Management of Suspected Urinary Tract Infections
- 766 Posters that Contain Information About Antibiotic Related Harm Reduce Expectations for Antibiotic Treatment of Viral Upper Respiratory Tract Infections
- 767 The development and assessment of a physician-specific antibiotic usage and spectrum feedback tool
- 768 An Opt-out Approach to Antimicrobial Stewardship Utilizing Electronic Alert Recommendations at a Community Hospital
- 769 Center-level variability in broad-spectrum antibiotic prescribing for children undergoing hematopoietic cell transplantation for acute leukemia.

- 770 Nurse Prompting for Prescriber-Led Review of Antimicrobial Use in the Critical Care Unit: A Quality Improvement Intervention with Controlled Interrupted Time Series Analysis.
- 771 Implementation of a Centralized Telehealth-based Antimicrobial Stewardship Program (ASP) for 16 Small Community Hospitals (SCHs)
- 772 Volume-adjusted antimicrobial prescribing rate: An automated method for identifying antimicrobial over-prescribers in ambulatory care
- 773 Hiding in Plain Sight: Observations from a Review of Positive Urine Cultures Prior to an Antimicrobial Stewardship Program Campaign Targeting Asymptomatic Bacteriuria
- 774 The Experience of Stewards in Using a Visual Analytic Tool to Benchmark and Track Therapy Duration for Pneumonia, Urinary Tract Infections, and Skin and Soft Tissue Infections
- 775 Development of a Collaborative Practice Agreement Template to Promote the Role of the Pharmacist in Managing Urinary Tract Infections in Long Term Care Residents

76. Poster Abstract Session

Treatment of Resistant Infections – Clinical Analyses

Thursday, 12:30 p.m. – 2:00 p.m.

- 776 Comparative effectiveness of Trimethoprim-Sulfamethoxazole vs. Levofloxacin for *Stenotrophomonas maltophilia* Bacteremia: Analysis of targeted therapy at 90 US Hospitals, 2000–2014
- 777 Combination Vancomycin/Cefazolin (VAN/CFZ) for Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bloodstream Infections (BSI)
- 778 Modeling Likelihood of Coverage for Narrow Spectrum Antibiotics in Patients Hospitalized with Urinary Tract Infections
- 779 Therapeutic efficacy of isavuconazole in experimental *Aspergillus fumigatus* endophthalmitis
- 780 Piperacillin-tazobactam versus carbapenem for treating blood stream infections due to extended spectrum beta-lactamase producing bacteria: Systematic review and meta-analysis
- 781 Pharmacokinetic Assessment of Continuous Infusion Ceftolozane/Tazobactam for Drug-Resistant *Pseudomonas aeruginosa* Left Ventricular Assist Device Driveline Infection
- 782 Antimicrobial resistance patterns of colonizing *Streptococcus pneumoniae* among young child-mother pairs in the rural highlands of the Peruvian Andes
- 783 Associations Between Timeliness of Therapy and Clinical and Economic Outcomes Among Patients With Serious Infections Due to Gram-negative Bacteria (GNB): How Much Does Delayed Appropriate Therapy (DAT) Matter?
- 784 Effectiveness of Daptomycin in Patients with Persistent Methicillin-Resistant *Staphylococcus aureus* Bacteremia Despite Vancomycin
- 785 Assessment of risk factors for inappropriate empiric antibiotic therapy in patients with Gram-negative sterile site infection complicated by sepsis or septic shock
- 786 Effect of Generic vs. Brand-Name Meropenem on Mortality in a Colombian Hospital's Intensive Care Unit
- 787 Echinocandin Resistant *Candida tropicalis* Bloodstream Infections
- 788 Factors Associated with Mortality in Carbapenem-Resistant *Enterobacteriaceae* Bacteremia: Focus on Antibiotic Therapy
- 789 Ceftolozane-tazobactam for the Treatment of Multi Drug Resistant *Pseudomonas aeruginosa* (MDRPA) Infections
- 790 Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam
- 791 Health Outcomes from Multi-Drug Resistant *Salmonella* Infections in High-Income Countries: A Systematic Review and Meta-Analysis
- 792 Comparison of Rates of Acute Kidney Injury with Vancomycin/Piperacillin-Tazobactam vs. Vancomycin/Meropenem Combination Therapy
- 793 Risk Factors and Outcomes of Vancomycin-Resistant vs. Vancomycin-Sensitive *Enterococcal* Blood Stream Infections in Patients with Acute Myeloid Leukemia
- 794 Retrospective Study of Linezolid versus Daptomycin for the Treatment of Vancomycin-Resistant Enterococcal Bloodstream Infection

- 795 Mortality Impact of CLSI Carbapenem Breakpoint Changes in *Enterobacteriaceae* Bloodstream Infections: a Patient-level Analysis of Published Data
- 796 Carbapenem versus Piperacillin-tazobactam for the treatment of ceftriaxone resistant gram negative bacteremia: matched cohorts by propensity score
- 797 Real World Analysis of Prescribing Patterns and Susceptibility of Ceftolozane/Tazobactam (C/T) Treatment using an Electronic Medical Record (EMR) Database in the United States
- 798 The Successful Recovery of Bacteriophages with Activity against Vancomycin-Resistant Enterococci (VRE) from Stool Samples of Hematopoietic Cell Transplant (HCT) Recipients
- 799 Epidemiologic Patterns and Clinical Implications of Genotypic Resistance Mechanism for Carbapenem-Resistant Enterobacteriaceae (CRE) Surveillance Isolates from Los Angeles County
- 800 Improving definitive therapy among patients with Methicillin-resistant *Staphylococcus aureus* bloodstream infections: Predictors of early therapeutic switch to linezolid or daptomycin
- 801 The Clinical Impact of Daptomycin Non-susceptible *Enterococcus* Bacteremia in Hematologic Malignancy
- 802 Evaluation of telavancin dose capping in a large community hospital

77. Poster Abstract Session

Use of PK/PD to optimize existing antibiotics and antifungals

Thursday, 12:30 p.m. – 2:00 p.m.

- 803 Impact of minocycline, polymyxin B, meropenem, and amikacin on growth-prevention of *Acinetobacter baumannii* with various biofilm-forming capabilities
- 804 Pharmacokinetics and Tissue Distribution of Minocycline following Intravenous Administration in Rabbits
- 805 Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Dalbavancin Alone and in Combination with Ceftaroline against Methicillin-Resistant Strains (MRSA) of *Staphylococcus aureus*
- 806 Pharmacokinetics of Ceftazidime/Avibactam following Intravenous Administration in Rabbits: Developing the Preclinical Foundation for Treatment of KPC-*Kp* Pneumonia in Immunocompromised Patients
- 807 Using a Mathematical Model to Demonstrate the Effect of Variations in Immune Response Efficacy on Optimal Antibiotic Treatment Strategies for an Acute Bacterial Infection
- 808 Multiple Ascending Dose Safety, Tolerability, and Pharmacokinetics of KBP-7072, a Novel Third Generation Tetracycline
- 809 Evaluation of Vancomycin Dosing in Intravenous Drug Users Admitted to an Internal Medicine Service
- 810 Pharmacokinetics of Daptomycin in Pediatric Intensive Care Patients
- 811 Implementation of a Beta-Lactam Therapeutic Drug Monitoring Program
- 812 Standard Levofloxacin Dosing May Be Insufficient in Critically Ill Trauma Patients
- 813 Use of translational PKPD infection models to understand impact of neutropenia on efficacy of tedizolid phosphate
- 814 Dosing Voriconazole in Obese Patients
- 815 Correlating isavuconazole serum levels with efficacy and adverse effects (AE) among immunocompromised patients
- 816 Pharmacokinetics of Tedizolid in Adults with Cystic Fibrosis
- 817 A Novel Vancomycin Standardized Calculations Method Achieved Therapeutic Trough Goals in Obese and Non-obese Patients in a Veterans Affairs Health Care System
- 818 Evaluation of early achievement of an AUC/MIC of >400 for Vancomycin in children with methicillin-resistant *Staphylococcus aureus* bacteremia
- 819 Spatio-temporal Activity of Human-Simulated Exposures of Meropenem (MEM) and Ceftolozane (TOL) on *Pseudomonas aeruginosa* Biofilms
- 820 Vancomycin Prescribing Habits – Are We Still Afraid of Mississippi Mud?

- 821 Clearance of ceftazidime-avibactam in an *in vitro* continuous venovenous hemodialysis model
- 822 Relationship between Vancomycin Area Under the Concentration-Time Curve (AUC) and Nephrotoxicity in Adults
- 823 Genetic Polymorphisms influencing Low Posaconazole Plasma Concentration in Patients with Hematologic malignancies
- 824 Vancomycin (VAN) administered as continuous infusion (CIV) versus intermittent infusion (IIV) in children with Methicillin-Resistant *Staphylococcus aureus* (MRSA) infections
- 825 Plasma Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Subjects with Cystic Fibrosis
- 826 Incidence of Nephrotoxicity Among Patients Initiated on Vancomycin and Beta-lactam Combination Therapies
- 827 Safety, Tolerability, and Pharmacokinetics (PK) of Posaconazole (POS) Intravenous (IV) Solution and Oral Powder for Suspension in Children With Neutropenia
- 828 Real World Evaluation of Ceftolozane/Tazobactam (C/T) Use and Clinical Outcomes at an Academic Medical Center in Las Vegas
- 829 Therapeutic Drug Monitoring (TDM) of Suspension (SUS), Extended-Release (ER), and Intravenous (IV) Posaconazole (POS) at a Large Transplant Center
- 830 Clinical Manifestations and Outcome of Fluoroquinolone Associated Acute Interstitial Nephritis
- 831 Traditional PK-PD Indices for Efficacy – Can We Do Better?
- 832 At the Crossroads of Stewardship and Technology: Impact of Pharmacokinetic-Pharmacodynamic (PK-PD) Integrated Electronic Decision Support Software (EDSS) on the Treatment of Patients Infected with Pneumonia
- 833 Breaking New Ground: An Evaluation of Susceptibility Breakpoints for Echinocandins against *Candida* Species
- 834 *In Vitro* Antibacterial Activity of Ceftolozane/Tazobactam (C/T) Alone and in Combination with other Antimicrobial Agents against Multidrug-Resistant (MDR) *Pseudomonas aeruginosa* (PSA)
- 835 Impact of an Extended Infusion Beta-lactam Strategy on Outcomes in Critically Ill Patients with Pseudomonas Infections
- 836 Influence of Polymyxin B Dose on Development and Recovery of Acute Kidney Injury
- 837 Assessing the Risk of Nephrotoxicity Associated With Non-renally Adjusted Intravenous Polymyxin B Compared to Traditional Dosing
- 838 Creation and Validation of a Pediatric Vancomycin Nomogram for a Goal Trough of 10-15 mg/L at a Quaternary Care Children's Hospital

78. Poster Abstract Session

Zika Virus

Thursday, 12:30 p.m. – 2:00 p.m.

- 839 ZIKA-001: Safety and Immunogenicity of an Engineered DNA Vaccine Against ZIKA virus infection
- 840 Zika Virus Epidemic in the Dominican Republic, 2016
- 841 Dengue IgG Seropositivity and Zika Viral Load
- 842 Challenges of Zika Virus Testing in Pregnancy in the Setting of Local Mosquito-Borne Transmission
- 843 Efficacy of Galidesivir against Ebola Virus Disease in Rhesus Monkeys
- 844 Zika Virus Serologic Diagnosis by NS1 ELISA in Curacao
- 845 Utilizing an Equitable and Multifaceted Zika Screening Tool to Identify At-Risk Individuals For Testing and Education: Successes, Challenges, and Lessons Learned in Harris County, Texas.

137. Poster Abstract Session

Adult CNS Infection

Friday, 12:30 p.m. – 2:00 p.m.

- 1004 Are New Biomarkers Useful in the Diagnosis of Meningitis in Adults?
- 1005 Epidemiology, Outcomes and Prognosis of Central Nervous System Infections in Singapore. Preliminary results from The Singapore Neurologic Infections Programme (SNIP)

- 1006** Diagnostic accuracy of CSF cell index and corrected CSF white blood cell count in healthcare-associated ventriculitis and meningitis after intracranial hemorrhage
- 1007** Achieving optimal specialty cerebrospinal fluid (CSF) testing: Are electronic medical record order sets helpful?
- 1008** Brain abscess risk associated with genotypic polymorphism of the matrix metalloproteinase-1, 2, 3 and 9 in North Indian population
- 1009** The etiologies and clinical characteristics of patients hospitalized with an acute febrile illness and central nervous system syndromes in Indonesia
- 1010** Viral Infections of the Central Nervous System in Qatar: epidemiology, pathogenesis and clinical outcomes
- 1011** Acute Flaccid Myelitis Cases Presenting During a Spike in Respiratory Enterovirus D68 Circulation: Case Series From a Single Pediatric Referral Center.
- 1012** Hearing Loss in Cryptococcal Meningitis Survivors
- 1013** Infectious Causes and Infectious Mimics of Acute Encephalitis: a Prospective Study from Thailand
- 1014** Long Term Outcomes of Acute Aseptic Encephalitis In Adults - a Single Center Study
- 1015** Meningitis in the Kaiser Permanente Northern California (KPNC) Pediatric Population 2012 through 2016 and Its Association with Prior Traumatic Brain Injury (TBI)
- 1016** Implementation of In-house PCR Testing for Herpes Simplex Virus Encephalitis: Impact on Patient Acyclovir Exposure
- 1017** A Primary Amebic Meningoencephalitis Case Associated with Rafting on an Artificial Whitewater River
- 1018** Lyme Disease in Hispanics in Long Island, New York: A New Health Disparity in the U.S.
- 1019** Varicella Zoster Virus Neurovasculitis (VZV-NV) in the Setting of Autoantibodies to Interferon alpha (anti-IFN α)

138. Poster Abstract Session Adult Immunization – Miscellaneous Friday, 12:30 p.m. – 2:00 p.m.

- 1020** Development of a Novel Anthrax Vaccine Comprising LF-PA Chimera
- 1021** Phase 1 Clinical Trial of a Replication-Defective Human Cytomegalovirus (CMV) Vaccine
- 1022** Establishing Models of Herpes Simplex Virus Type 2 Superinfection of Herpes Simplex Virus Type 1 Seropositive Mice to Test The Efficacy of a Novel Vaccine
- 1023** Sustained Lesion and Shedding Rate Reductions in Genital Herpes Patients 24 Months after Immunization with GEN-003, a Genital Herpes Immunotherapy
- 1024** Estimating the health and economic impact of universal varicella vaccination in Jordan
- 1025** Serum and lung pharmacokinetics of ASN100, a monoclonal antibody combination for the prevention and treatment of *Staphylococcus aureus* pneumonia

139. Poster Abstract Session Adult Viral Infection Friday, 12:30 p.m. – 2:00 p.m.

- 1026** Comparison of Viral Loads in Patients with Co-infections vs. Single-virus Infections
- 1027** Study to Address Threats of Acute Respiratory Infections among Congregate Military Populations (ATARI)
- 1028** Pharmacokinetics (PK) and Safety of Intravenous (IV) Brincidofovir (BCV) in Healthy Adult Subjects
- 1029** A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
- 1030** Human Coronavirus Circulation in the United States, 2014–2017

- 1031** PCR array profiling of antiviral genes in human embryonic kidney cells expressing human coronavirus OC43 structural and accessory proteins
- 1032** Human Coronavirus (HCoV) Infection Among Adults in Cleveland, Ohio: An Increasingly Recognized Respiratory Pathogen
- 1033** Evaluation of serum TNF-alpha, IL-6, IL-10, and IFN-gamma levels in patients with Crimean-Congo hemorrhagic fever
- 1034** Etiologic Involvement of Enterovirus and Human Bocavirus in Acute Flaccid Paralysis Cases in India
- 1035** Frequency of Epstein-Barr Virus Genotypes in Pakistani Transgender Sex Workers
- 1036** Risk factors for herpes zoster: a systematic review and meta-analysis
- 1037** Herpes-zoster infection in a tertiary hospital in Brazil
- 1038** Epidemiology of Influenza Viruses in Canada over the 2011/2012 to 2013/2014 Seasons: A Study from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN)
- 1039** Co-circulation of Influenza A and B during the 2016–2017 Influenza Season at Rush University Medical Center.
- 1040** Burden of Hospitalization Associated with Seasonal Influenza in Toronto, Canada, 2011–2016
- 1041** Estimated Hospitalization Rates for Seasonal Influenza in Adults and Children in Middle Tennessee using a Capture-Recapture Method
- 1042** Evaluating the Risk of Viral Myocarditis following Influenza Infection among Hospitalized Patients during 2014–2015 and 2015–2016 Influenza Seasons.
- 1043** Influenza Vaccination and Treatment with Antiviral Agents Among Hospitalized Adults in the 2014–15 and 2015–16 Influenza Seasons
- 1044** Active surveillance to quantify the burden of norovirus in a U.S. Veterans Affairs (VA) patient population, Houston, 2015–2016
- 1045** Norovirus, Astrovirus, and Sapovirus in a Tertiary Care Research Hospital
- 1046** Incidence of Norovirus-Associated Acute Gastroenteritis in Four Veteran's Affairs Medical Center Populations in the United States, 2011–2015
- 1047** WU Polyomavirus Associated with Severe Respiratory Failure in Children
- 1048** Clinical Characteristics of Parainfluenza Virus Infection among Healthy Subjects with Influenza-like Illness
- 1049** Epidemiology and Clinical Outcomes of Respiratory Viral Infections at a Single Tertiary Centre in Alberta, Canada
- 1050** Morbidity, and short- and intermediate-term mortality, in adults ≥ 60 years hospitalized with respiratory syncytial virus infection versus seasonal influenza virus infection
- 1051** Clinical and Economic Burden of Respiratory Viral Infections in Hematopoietic Stem Cell Transplant Recipients: The MD Anderson Experience
- 1052** Severe Fever with Thrombocytopenia Syndrome Virus Infection Associated with Hemophagocytic Lymphohistiocytosis as Poor Prognostic Factor
- 1053** Factors for Hospitalizations and Neurologic Complications in Zika Virus Infection in the Department of Veterans Affairs (VA)
- 1054** Clinical and Laboratory Characteristics of Parvovirus B19 Infection During 2013/2014 Outbreak in Zagreb, Croatia

140. Poster Abstract Session Assorted Pediatric Vaccines Friday, 12:30 p.m. – 2:00 p.m.

- 1055** HAEMOPHILUS INFLUENZAE TYPE B INVASIVE DISEASE IN A PEDIATRIC HOSPITAL OF ARGENTINA.
- 1056** Single-Dose Universal Hepatitis A Immunization in one year old infants in Argentina: High prevalence of protective antibodies up to 11 years following vaccination
- 1057** No viral spreading after rotavirus vaccination in NICU
- 1058** M Protein-Deficient Respiratory Syncytial Virus (RSV) Vaccine Protects Infant Baboons Against RSV Challenge.

- 1059** Measles, Mumps, and Rubella Antibody: Patterns of Persistence and Rate of Decline Following the Second Dose of the MMR Vaccine
- 1060** Persistence of Bactericidal Activity at 4 Years After 2 Primary Doses of a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults
- 1061** Vaccinating High-Risk Pediatric Patients and Their Families in the Hospital Setting: Give it a Shot!
- 1062** Pertussis-Associated Persistent Cough in Previously Vaccinated Children
- 1063** Mapping Pediatric Tetanus Cases in Central Pennsylvania and Analyzing Hospital Costs Associated with Treatment
- 1064** Reported history of measles and long-term impact on antibody to tetanus in children 6–59 months of age receiving DTP in the Democratic Republic of Congo
- 1065** Cord blood Antibody Seroprevalence against Diphtheria, Pertussis, Measles, Mumps and Rubella among Term Healthy Indian Newborns
- 1066** Title: Trends in the burden and seasonality of rotavirus in the United States, 2000–2016
- 1067** Differential Gene Expression Elicited by Children in Response to the 2015–16 Live Attenuated versus Inactivated Influenza Vaccine
- 1068** Varicella Vaccination Coverage among Adolescents Ages 13–17 Years, United States, National Immunization Survey, 2007–2014
- 1069** Human Papillomavirus (HPV) Knowledge, Vaccine Acceptability and Acceptability of Text Message Reminders for Vaccine Doses in Adolescents Presenting to an Urban Emergency Department (ED)
- 1070** Perception of Japanese Physicians about Human Papillomavirus Vaccine
- 1087** Outpatient Parenteral Antimicrobial Therapy (OPAT) Practices at a Veterans Affairs Hospital: Potential for Pharmacist Impact
- 1088** Safety and Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) in the Aged Population
- 1089** Emergency Department Utilization during Self-Administered Outpatient Parenteral Antimicrobial Therapy
- 1090** Early ID Outpatient Follow-up of OPAT Patients Reduces 30-day Readmission
- 1091** Follow-up Appointment Adherence of Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients
- 1092** Pilot of a Home Telehealth Platform in a Pediatric OPAT Program
- 1093** Utilizing a Post-discharge Telephone Call in Outpatient Parenteral Antimicrobial Therapy (OPAT): Findings from a Quality Improvement Project
- 1094** Emergency Department Visits during Outpatient Parenteral Antimicrobial Therapy: A Cohort Study
- 1095** Outpatient Parenteral Antibiotic Therapy (OPAT) Serial Readmissions and High Utilizers: Drilling Down on Readmission Following Discharge on Intravenous Antibiotics
- 1096** Risk Factors for Readmission in Patients with Outpatient Parenteral Antimicrobial Therapy
- 1097** Impact of an Antimicrobial Stewardship Program Led OPAT Program on Clinical Complications and Frequency of Hospital Readmissions
- 1098** Characterization of Readmissions Among Patients Enrolled in an Outpatient Parenteral Antimicrobial Therapy (OPAT) Program Over a Two-Year Period at UNC Medical Center
- 1099** Predictive clinical rule for readmissions in OPAT. Improving in security
- 1100** Stability of Anidulafungin in Concentrated Pharmaceutical Solution
- 1101** Impact of obesity on acute kidney injury incidence among patients treated with piperacillin-tazobactam and vancomycin
- 1102** Incidence of acute kidney injury among intensive care unit patients receiving vancomycin in combination with cefepime or piperacillin-tazobactam
- 1103** A Little Bit of Dalba Goes a Long Way: Dalbavancin Use in a Vulnerable Patient Population
- 1104** Safety and Efficacy of Telavancin at an Outpatient Parenteral Antibiotic Therapy (OPAT) Unit in New York City
- 1105** To Add or Not to Add: Would the Addition of Dalbavancin to Formulary Decrease Admissions for Acute Bacterial Skin and Skin Structure Infections (ABSSI)?
- 1106** Is there a significant difference in acute kidney injury incidence among patients treated with vancomycin combined with cefepime or meropenem?
- 1107** Pharmacist-Directed Use of Dalbavancin in Acute Bacterial Skin and Skin Structure Infections to Reduce Hospital Length of Stay
- 1108** Experience with High Dose Once-daily Vancomycin for Patients with Skin and Soft Tissue Infections in an Ambulatory Setting
- 1109** Using Group-Based Trajectory Temperature Modeling to Predict Postoperative Infections after Total Knee Arthroplasty
- 1110** Weighing in: Effect of BMI on postoperative fever and complications in patients undergoing three distinct surgeries
- 1111** Current Use of Intravenous (IV) Long Acting Antibiotic (LAA) Therapy in the Aetna Health Plan among Patients with Acute Bacterial Skin and Skin Structure Infection (ABSSI)
- 1112** Peripherally Inserted Central Catheter Complications in Rural vs. Urban Children Receiving Long-Term Parenteral Antimicrobial Therapy
- 1113** Injection Drug Use and Infectious Disease Practice: A National Provider Survey
- 1114** Implementation of a Standardized Protocol for Hospitalized Patients Who Inject Drugs and Require Long-Term Antibiotics Reduces Length of Stay Without Increasing 30-Day Readmissions
- 1115** Systematic Review of Professional Liability when Prescribing Beta-Lactams for Patients with a Known Penicillin Allergy
- 1116** Adverse Drug Reactions Among Patients Enrolled in an Outpatient Parenteral Antimicrobial Therapy (OPAT) Program 2015–2016 at UNC Medical Center
- 1117** Variation in Reporting of Penicillin Allergy and its Consequences: an Evaluation of 13 Hospitals
- 1118** Adverse Events Related to Antibiotic Use in Patients with Myasthenia Gravis
- 1119** Antibiotic Allergies—Is de-labeling based on clinical history feasible?

141. Poster Abstract Session

Clinical Practice Issues

Friday, 12:30 p.m. – 2:00 p.m.

- 1071** Indications for Antibiotic Orders: How Accurate Are They?
- 1072** Fixed Versus Free-Text Documentation Of Indication For Antibiotic Orders
- 1073** Antibiotic prescription patterns for acute diarrhea in a hospital in Shanghai in 2016: a cross-sectional study
- 1074** Causal Conditions Supporting Antibiotic Stewardship Information Dashboards
- 1075** Changing Pattern of Antibiotics Usage Among Hospitalized Patients of a Tertiary Hospital in South Korea: 2004–2013
- 1076** Effectiveness of Antimicrobial Use and Diagnostic Testing in the Postoperative Setting for Colectomy, Craniectomy and Knee Arthroplasty
- 1077** Using Preventive Health Alerts in the Electronic Health Record Improves Testing Rates for Infants Perinatally-Exposed to Hepatitis C
- 1078** Use of a Precision Antibiotic Therapy (PAT) Prediction Model to Identify Multidrug-Resistant (MDR) *Enterobacteriaceae*
- 1079** Joint consultation clinic by Infectious Diseases Specialists and Podiatry team (ID-POD) compliments the care of diabetic patients with foot infections by reducing cost and decreasing outpatient clinic visits
- 1080** Opportunities in the Acute Care Setting for Infectious Diseases/Hospitalist Patient Co-Management
- 1081** Implementation of a Centralized Infectious Diseases Telehealth (IDt) Service for 16 Small Community Hospitals
- 1082** Population-Level Hepatitis C Testing Using A Personal Electronic Health Portal System Significantly Improves Screening Rates in Baby Boomers
- 1083** 2015–2016, Georgia Department of Public Health Districts, Evaluating Oral Health Services in Ryan White Part B Clinics
- 1084** Comparison of Outcomes in Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients Receiving Vancomycin versus Non-Vancomycin Anti-MRSA Therapy
- 1085** Potentially Inappropriate Durations of Anti-Infective Therapy at Hospital Discharge Despite Inpatient Antimicrobial Stewardship
- 1086** Patient Self-Referral to Infectious Diseases Clinic: You Don't Always Get What You Want, But Hopefully What You Need
- 1107** Pharmacist-Directed Use of Dalbavancin in Acute Bacterial Skin and Skin Structure Infections to Reduce Hospital Length of Stay
- 1108** Experience with High Dose Once-daily Vancomycin for Patients with Skin and Soft Tissue Infections in an Ambulatory Setting
- 1109** Using Group-Based Trajectory Temperature Modeling to Predict Postoperative Infections after Total Knee Arthroplasty
- 1110** Weighing in: Effect of BMI on postoperative fever and complications in patients undergoing three distinct surgeries
- 1111** Current Use of Intravenous (IV) Long Acting Antibiotic (LAA) Therapy in the Aetna Health Plan among Patients with Acute Bacterial Skin and Skin Structure Infection (ABSSI)
- 1112** Peripherally Inserted Central Catheter Complications in Rural vs. Urban Children Receiving Long-Term Parenteral Antimicrobial Therapy
- 1113** Injection Drug Use and Infectious Disease Practice: A National Provider Survey
- 1114** Implementation of a Standardized Protocol for Hospitalized Patients Who Inject Drugs and Require Long-Term Antibiotics Reduces Length of Stay Without Increasing 30-Day Readmissions
- 1115** Systematic Review of Professional Liability when Prescribing Beta-Lactams for Patients with a Known Penicillin Allergy
- 1116** Adverse Drug Reactions Among Patients Enrolled in an Outpatient Parenteral Antimicrobial Therapy (OPAT) Program 2015–2016 at UNC Medical Center
- 1117** Variation in Reporting of Penicillin Allergy and its Consequences: an Evaluation of 13 Hospitals
- 1118** Adverse Events Related to Antibiotic Use in Patients with Myasthenia Gravis
- 1119** Antibiotic Allergies—Is de-labeling based on clinical history feasible?

142. Poster Abstract Session

Clinical: Soup to Nuts

Friday, 12:30 p.m. – 2:00 p.m.

- 1120 Correlations between environmental factors and increasing Lyme disease incidence in Canada
- 1121 Classical fever of unknown origin: retrospective study in Infectious Clinical Hospital №2
- 1122 Responses to Fever Overnight: Do Residents Choose Wisely?
- 1123 Patient safety and efficacy of Metronidazole 1 gram intravenous every 24 hours
- 1124 Acute kidney injury associated with combination antimicrobial therapy in the Medical Information Mart for Intensive Care (MIMIC) III database
- 1125 Impact of Vancomycin-Associated Acute Kidney Injury on Patient Outcomes in MRSA Bacteremia

143. Poster Abstract Session

Clinical: UTI

Friday, 12:30 p.m. – 2:00 p.m.

- 1126 National cohort study of preoperative bacteriuria, surgical prophylaxis, and postoperative outcomes
- 1127 The Utility of Repeat Blood Cultures for Bacteremic Urinary Tract Infections and Associated Durations of Therapy
- 1128 Urinary tract infections after combat-related genitourinary trauma
- 1129 Case-Control Study Evaluating Risk Factors and Treatment Outcomes for Community-Acquired Urinary Tract Infections (UTI) Caused by Extended-Spectrum Beta-Lactamase (ESBL)-Producing Pathogens
- 1130 Risk Factors For Community Acquired Extended-Spectrum Beta-lactamase (ESBL) Producing *Enterobacteriaceae* Urinary Tract Infections (UTIs)
- 1131 Why and Where We Choose to Treat Children with Intravenous Antibiotic for Febrile Urinary Tract Infection/Pyelonephritis.
- 1132 Assessment of Reflex Urine Culture Criteria Changes and its Impact on Treatment of Asymptomatic Bacteriuria
- 1133 Susceptibility Trends of Urinary Tract Infections Over a Fifteen Year Period on a University Campus
- 1134 Assessment of Antimicrobial Susceptibility Testing Profiles of Urine Isolates from Veterans to Guide Empiric Therapy for Suspected Urinary Tract Infection
- 1135 Poor Clinical Outcomes Associated with Community-Onset Extended-Spectrum Cephalosporin-Resistant Enterobacteriaceae Urinary Tract Infections
- 1136 Antibiotic bladder irrigation in preventing and reducing chronic urinary catheter related urinary tract infections (UTI)
- 1137 Antibiotic Susceptibilities and Appropriateness of Initial Drug Selection for Community-Acquired Urinary Tract Infections (UTI) Caused by Extended-Spectrum Beta-Lactamase (ESBL)-Producing Pathogens
- 1138 Prevalence and accuracy of screening test of asymptomatic bacteriuria during pregnancy in Siriraj Hospital
- 1139 Epidemiology, Microbiology and Outcomes of Catheter-Associated Urinary Tract Infection and Complicated Urinary Tract Infection in the US
- 1140 Significance of Prior Culture History for Predicting Urinary Tract Infection Caused by Multi-drug Resistant Enterobacteriaceae
- 1141 Contemporary Epidemiology of Catheter-Associated Urinary Tract Infections (CAUTIs) in a Tertiary Care Center: Is Foley Re-Insertion a Novel Risk Factor?
- 1142 Impact of culturing all uncomplicated urinary tract infections on the estimated prevalence of resistance in the primary care setting
- 1143 Percutaneous Nephrostomy Tube Related-Infections
- 1144 Characterizing Clinical Demographics, Susceptibility Patterns, and Development of Resistance in *Raoultella ornitholytica* Infections in Southern Virginia
- 1145 Are Urinalyses Used Inappropriately in the Diagnosis of Urinary Tract Infections?
- 1146 Antibiotic Prescription Practice for Pediatric Urinary Tract Infection in a Tertiary Center

144. Poster Abstract Session

Diagnostics: Biomarkers

Friday, 12:30 p.m. – 2:00 p.m.

- 1147 Comparison of Inflammatory Markers between Adult and Pediatric Brucellosis Patients
- 1148 Impact of Procalcitonin (PCT)-Guided Antibiotic Therapy on Mortality in Critically Ill Patients: A Systematic Review and Meta-Analysis of 18 Randomized Controlled Trials
- 1149 Serial Procalcitonin Levels Correlate with Microbial Etiology in Hospitalized Patients with Pneumonia
- 1150 A Novel Host-protein Assay Accurately Distinguishes Bacterial From Viral Upper Respiratory Tract Infections
- 1151 Biomarker-based Assessment of Urinary Tract Infection in Persons with Spinal Cord Injury
- 1152 Serum Procalcitonin as a Marker for Infection in Patients with Acute Myocardial Infarction
- 1153 The prognostic importance of platelet indices in patients with Crimean-Congo Hemorrhagic Fever

145. Poster Abstract Session

Diagnostics: Viral

Friday, 12:30 p.m. – 2:00 p.m.

- 1155 Impact of a Pharmacist-Driven Respiratory Viral Panel Stewardship Program on Antibiotic Exposure Within a Multicenter Community Health System
- 1156 BioFire FilmArray Decreases Infection Control Isolation Times by 4 days in ICU, BMT and Respiratory Wards
- 1157 Multidisciplinary approach to improve utilization and cost savings of Multiplex Polymerase chain reaction (PCR) respiratory pathogen testing in a large community hospital
- 1158 The Impact of Biofire Filmarray Respiratory Panel on Antibiotic Usage in the Emergency Department at an Academic Medical Center
- 1159 When to Order a Respiratory Viral Panel (RVP): Physician Use in Clinical Practice
- 1160 A Multidisciplinary Study of the Use and Outcomes Associated with Expanded Respiratory Viral Studies at a Mid-Sized Children's Hospital
- 1161 A Mid-Turbinate Swab Appears Comparable to Nasopharyngeal Swabs for Quantitative Detection of RSV in Infants
- 1162 MEASLES ORAL SWAB AS FIELD BASED SCREENING TEST IN CHILDREN
- 1163 Sensitivity and Specificity of the Quidel Sofia Influenza A + B FIA Rapid Influenza Detection Test in Long-Term Care Facilities
- 1164 Influenza Clinical Diagnostic Testing and Antiviral Treatment among Children Hospitalized with Acute Respiratory Illness during the 2015–16 Influenza Season
- 1165 Analytical and Clinical Performance of a real-time screening PCR assay identifying congenital CMV infection
- 1166 Detection of cytomegalovirus (CMV) in saliva of congenitally infected neonates
- 1167 Cytomegalovirus Management in Adult Hematopoietic Stem Cell Transplant Patients with Pre-Engraftment Viremia: A Single-Center, Retrospective, Descriptive Study
- 1168 Quality Assessment of Cytomegalovirus PCR Testing at an Academic Tertiary Referral Hospital
- 1169 Comparison of Roche and Abbott Cytomegalovirus Quantitative PCR Assays in Allogeneic Hematopoietic Cell Transplant Recipients
- 1170 CSF HSV PCR testing in adults and children with meningitis and encephalitis
- 1171 The Expression of hsp-miRNA-200b-3p and -200c-3p in Human Cytomegalovirus-infected Formalin-Fixed, Paraffin-Embedded Tissues
- 1172 Human Adenovirus (HAdV) viremia in immunocompetent children with HAdV infection in respiratory specimens: Does viremia predict severity of illness?
- 1173 Molecular Epidemiological Investigation of Human Parainfluenza 3 Virus Outbreak in a Pediatric Bone Marrow Transplantation Unit
- 1174 Molecular Investigation of an Ontario Mumps Outbreak using Whole Genome Sequencing

- 1175 Optimization of a Polymerase Chain Reaction System for Whole Genome Amplification of Human Immunodeficiency Virus Type 2 (HIV-2)
- 1176 Comparison of Roche TaqMan v.2.0, Abbott RealTime and Modified Abbott Residual Viremia Assays in Testing of Routine Samples for Viremia Monitoring in HIV Care
- 1177 Meteorology-driven prediction of RSV/RHV incidence in rural Nepal
- 1178 Feasibility and validation of viral respiratory disease surveillance in a combat theater using the FilmArray respiratory panel
- 1179 Experience of Sublingual Microcirculation Evaluation in Adults Patients with Severe Dengue

146. Poster Abstract Session
Enteric Infections and Diagnostics
Friday, 12:30 p.m. – 2:00 p.m.

- 1180 Identifying Enteropathogens in Children with Acute Gastroenteritis Presenting With Isolated Vomiting – APPETITE Study
- 1181 Enteropathogen Identification by Multiplex PCR in Guatemalan Children with Acute, Non-bloody Diarrhea
- 1182 Appropriateness of a Rapid Multiplex Gastrointestinal Panel in the Investigation of Suspected Infectious Diarrhea After Implementation at an Academic Medical Center
- 1183 Clinical Predictors of *Shigella* and *Campylobacter* Infection in Children in the United States
- 1184 High Genetic Variability of Norovirus Leads to Diagnostic Test Challenges
- 1185 Risk Factors and Clinical Outcomes of Cancer Patients with *Clostridium difficile* Associated Diarrhea Co-infected with a Second Enteropathogen.
- 1186 Clinical Characteristics of Diarrheal Illness with Enteropathogenic *E. coli* (EPEC) Diagnosed with FilmArray (BioFire Diagnostics, Salt Lake City, UT) Multiplex PCR (MPCR) Testing. Maria Georgen BS, Paul Schreckenberger, PhD, Paul O'Keefe MD. Loyola University Medical Center, Maywood IL, USA
- 1187 Gastroenteritis Severity - A Prospective Cohort Comparison of Children in Emergency Department and Home Settings
- 1188 Genetic Variation in Shiga toxin-producing *Escherichia coli* Recovered from Patients in Michigan and Connecticut
- 1189 The Global Burden of Rotavirus Diarrheal Diseases: results from the Global Burden of Diseases Study 2016
- 1190 Relationship between Enteropathogen and Acute Gastroenteritis Disease Severity: A Prospective Cohort Study
- 1191 Comparison of Antibiotic Regimens In Intra-abdominal Infections
- 1192 Microbiology of Infected Walled-off Necrosis Following Severe Acute Pancreatitis
- 1193 Risk factors for the development of bacteremia in previously healthy children with non-typhoidal *Salmonella* gastroenteritis
- 1194 Clinically Important Resistance among *Salmonella enterica* Serotype Typhi Isolates—United States, 2003–2015
- 1195 Impact of fecal microbiota transplantation on digestive tract colonization due to carbapenem-resistant enterobacteriaceae and vancomycin-resistant enterococci
- 1196 The global burden of *Shigella* and Enterotoxigenic *E. coli*: results from the Global Burden of Disease study 2016
- 1197 Frequency of Antimicrobial Resistance in Shiga Toxin-Producing *Escherichia coli* (STEC) and Non-Typhoidal *Salmonella* (NTS) Clinical Infections and Association with Epidemiological Factors

147. Poster Abstract Session
Expanded Spectrum – New Antimicrobial
Susceptibility Testing
Friday, 12:30 p.m. – 2:00 p.m.

- 1198 Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2012–2016) *Enterobacteriaceae* and *Pseudomonas aeruginosa* from ICU vs non-ICU Isolates Collected in US Medical Centers

- 1199 *In vitro* Activity of Cefiderocol against Globally Collected Carbapenem-Resistant Gram-Negative Bacteria Isolated from Urinary Tract Source: SIDERO-CR-2014/2016
- 1200 Activity of the novel extended-spectrum β -lactamase inhibitor AAI101 in combination with cefepime towards a challenge panel of *Acinetobacter baumannii*
- 1201 Comparative *in vitro* Activities of Ceftazidime-avibactam and Ceftolozane-tazobactam against Characterized β -Lactamase-producing *Pseudomonas aeruginosa*
- 1202 Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Surveillance Isolates Collected from Pediatric Patients in the US during 2012–2016 as Part of a Global Surveillance Program
- 1203 *In Vitro* Activity of Newer Antimicrobials and Relevant Comparators Versus 349 *Stenotrophomonas maltophilia* Clinical Isolates Obtained from Patients in Canadian Hospitals (CANWARD, 2011–2016)
- 1204 The Novel β -Lactamase Inhibitor, ETX-2514, in Combination with Sulbactam Effectively Inhibits *Acinetobacter baumannii*
- 1205 Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016)
- 1206 Assessment of the *In Vitro* Antifungal Activity of SCY-078 Against a Collection of *C. parapsilosis* Clinical Isolates
- 1207 Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008–2016)
- 1208 *In vitro* Evaluation of Delafloxacin Activity When Tested against Contemporary Community-Acquired Bacterial Respiratory Tract Infection Isolates (2014–2016): Results from the SENTRY Antimicrobial Surveillance Program
- 1209 *In Vitro* Activity of Eravacycline and Comparator Antimicrobials Against 143 Strains of *Bacteroides* Species.
- 1210 Broad *In Vitro* Activity Analysis of Tedizolid Compared with Other Agents against a Global Collection of Gram-Positive Isolates Causing Bloodstream Infections (2014–2016)
- 1211 *In vitro* Susceptibility Testing of Essential Oils against Gram-positive and Gram-negative Clinical Isolates, including Carbapenem-resistant *Enterobacteriaceae* (CRE).
- 1212 Lysin CF-301 Demonstrates *In Vitro* Synergy with Conventional Antibiotics against *Staphylococcus aureus*
- 1213 Activity of Antistaphylococcal Lysin CF-301 against Contemporary *Staphylococcus aureus* Clinical Isolates from the USA and Europe
- 1214 Synergistic antiviral activity of S-033188/S-033447, a novel inhibitor of influenza virus cap-dependent endonuclease, in combination with neuraminidase inhibitors *in vitro*.
- 1215 Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Nosocomial- and Community-Acquired Infections in United States Hospitals (2014–2016)
- 1216 Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2012–2016) *Enterobacteriaceae* and *Pseudomonas aeruginosa* Isolates by US Census Division
- 1217 *In Vitro* Activity of Ceftolozane-Tazobactam Versus Antimicrobial Non-Susceptible *Pseudomonas aeruginosa* Clinical Isolates Obtained from Across Canada as Part of the CANWARD study, 2008–2016
- 1218 *In Vitro* Activity of Lefamulin against *S. aureus* Collected Worldwide from Hospitalized Patients with Bacterial Pneumonia
- 1219 Effects of Iclaprim and Trimethoprim on Exotoxin Production by Methicillin-resistant *Staphylococcus aureus*
- 1220 *In Vitro* Activity of Lefamulin Against a Global Collection of Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP, SENTRY 2015)
- 1221 Antimicrobial Activity of Dalbavancin and Comparator Agents Tested against Gram-Positive Clinical Isolates Causing Bone and Joint Infections in United States (US) Medical Centers (2011–2016)
- 1222 Activity of Delafloxacin When Tested against Bacterial Surveillance Isolates Collected in the US and Europe During 2014–2016 as Part of a Global Surveillance Program.
- 1223 *In Vitro* Activity of Omadacycline and Comparator Compounds against Gram-positive Isolates Collected in the USA During 2016 as Part of a Global Surveillance Program
- 1224 *In vitro* Activity of Fosfomycin, Alone and Combined with Cefepime and Meropenem, Against Carbapenemase-Producing Gram-Negative Bacteria
- 1225 Activity of Ceftolozane-Tazobactam (C/T) against *Escherichia coli* Isolates from U.S. Veterans in Relation to Co-resistance and Sequence Type 131 (ST131) *H30/H30Rx* Status

- 1226 Cefepime-Zidebactam (WCK 5222) Activity Tested against Gram-negative Organisms Causing Bloodstream Infections Worldwide
- 1227 Ceftazidime-avibactam and Meropenem Double Disk Diffusion Test for Identifying Carbapenem-Resistant Enterobacteriaceae and Distinguishing Between Serine and Metallo- β -Lactamase Producing Organisms
- 1228 AAI101, a Novel β -Lactamase Inhibitor: Microbiological and Enzymatic Profiling
- 1229 *In vitro* Activity of Cefiderocol Against Gram-Negative Clinical Isolates Collected from Urinary Tract Source: SIDERO-WT-2014/SIDERO-WT-2015
- 1230 *In Vitro* Activity of Cefiderocol against Multi-Drug Resistant Carbapenemase-Producing Gram-Negative Pathogens
- 1231 Activity of Ceftolozane/tazobactam (C/T) and Ceftazidime/avibactam (CZA) against Extended-spectrum Beta-lactamase (ESBL)-producing *Enterobacteriaceae* and Multidrug-resistant (MDR) *Pseudomonas aeruginosa* Isolates
- 1232 Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant *Enterobacteriaceae* and *Pseudomonas aeruginosa* Isolates from United States (US) Medical Centers (2013–2016)
- 1233 Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Tested against Contemporary (2016) Clinical *Enterobacteriaceae* Isolates
- 1234 Activity of Meropenem-Vaborbactam Against *Enterobacteriaceae* Isolates Carrying *bla*_{KPC} Collected Worldwide
- 1235 Activity of Plazomicin against *Enterobacteriaceae* Isolates Collected in the United States Including Isolates Carrying Aminoglycoside-Modifying Enzymes Detected by Whole Genome Sequencing
- 1236 *In-vivo* efficacy of tigecycline-based therapy against *Vibrio vulnificus* sepsis: comparison with pre-existing regimens
- 1237 Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against *Enterobacteriaceae* and *Pseudomonas aeruginosa* from United States (US) Medical Centers Stratified by Infection Type (2015–2016)
- 1238 Antimicrobial Activity of Dalbavancin Tested against *Staphylococcus aureus* with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from United States (US) Medical Centers
- 1239 Evaluation of *In Vitro* Activity of Ceftaroline Tested against *Streptococcus pneumoniae* Isolates from United States Hospitals: Results from 7 Years of the AWARE Surveillance Program (2010–2016)
- 1240 *In Vitro* and *In Vivo* Activity of Single and Dual Antimicrobial Agents Against KPC-producing *Klebsiella pneumoniae*
- 1241 *In vitro* Activity of Ceftaroline Against Pathogens Collected Globally from the AWARE Surveillance Program, 2016
- 1242 Activity of ceftazidime-avibactam against respiratory isolates of *Enterobacteriaceae* and *Pseudomonas aeruginosa* collected in Latin America as part of the INFORM global surveillance program, 2014–2016
- 1243 Activity of ceftazidime-avibactam against respiratory isolates of *Enterobacteriaceae* and *Pseudomonas aeruginosa* collected in Asia/Pacific as part of the INFORM global surveillance program, 2014–2016
- 1244 Activity of Ceftolozane-Tazobactam Against Global *Pseudomonas Aeruginosa* and Non-Susceptible Phenotypes: SMART 2016
- 1249 Prevalence of *Clostridium difficile* and Multidrug Resistant Gram-negative rods in the Soil from Southeastern Wisconsin
- 1250 Induced Human Intestinal Organoids (iHIOs) as Model Systems for Chemotherapy-associated *Clostridium difficile* (CD) Infections
- 1251 Change in bacterial diversity of fecal microbiota drives mortality in a hamster model of antibiotic-induced *Clostridium difficile* colitis
- 1252 CD4+ T Cells Specific for *C. difficile* Toxins are a Marker of Patients with Active Relapsing Disease
- 1253 Discordance of SHEA/IDSA *Clostridium difficile* Disease Severity Scale in Solid Organ Transplant Patients
- 1254 Prospective, open-label trial to evaluate efficacy of lyophilized fecal microbiota transplantation for treatment of recurrent *C. difficile* infection
- 1255 Probiotics to Reduce *Clostridium difficile* Infection: Clinical Experience in a Tertiary Care Center
- 1256 Efficacy of oral vancomycin, oral metronidazole, or IV metronidazole prophylaxis at reducing the risk of *Clostridium difficile* recurrence.
- 1257 Tetracyclines are Associated with a Reduced Risk of *Clostridium difficile* Infection: A Systematic Review and Meta-analysis
- 1258 Durability and Long-Term Clinical Outcomes of Fecal Microbiota Transplant (FMT) Treatment in Patients with Recurrent *C. difficile* Infection
- 1259 Clinical and Economic Evaluation of commercialized Fecal Microbiota Transplant (cFMT) for patients with recurrent *Clostridium Difficile* infection (CDI) in a large Community Hospital
- 1260 Fecal microbiota transplantation (FMT) for recurrent/refractory *Clostridium difficile* infection (CDI) in pediatric immunocompromised patients: a single center experience
- 1261 Weight Changes in Fecal Microbiota Transplant for *Clostridium difficile*
- 1262 Comparison of Fidaxomicin and Vancomycin for Recurrent *Clostridium difficile* Colitis
- 1263 Factors Affecting Effectiveness of Fecal Microbiota Transplant
- 1264 Cost Effectiveness Analysis of Fecal Transplant Delivery Methods for Recurrent *Clostridium difficile* Infections in Outpatients
- 1265 Ribotypes matter, significance of *Clostridium difficile* ribotypes in cancer patients with diarrhea.
- 1266 Bezlotoxumab (BEZ) for Prevention of *Clostridium Difficile* Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)
- 1267 Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent *Clostridium Difficile* Infection is Associated with More Pronounced Alterations in Microbiome Profile
- 1268 Changes to the Composition of the Gastrointestinal Microbiome after Probiotics for *Clostridium difficile* Infection in Adults
- 1269 Endogenous Serum IgG Antibodies to *Clostridium difficile* Toxin B Are Associated with Protection against *C. difficile* Infection Recurrence
- 1270 Comparative Effectiveness of Vancomycin Versus Metronidazole in Mild *Clostridium difficile* Infections, and Potential Impact on Subsequent Vancomycin-Resistant *Enterococcus* (VRE) Isolation.
- 1271 Bezlotoxumab (BEZ) for Prevention of *Clostridium difficile* Infection (CDI) Recurrence (rCDI): Distinguishing Relapse from Reinfection with Whole Genome Sequencing (WGS)
- 1272 Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of *Clostridium Difficile* Infection (CDI)
- 1273 Initial Oral Vancomycin Versus Oral Vancomycin After Metronidazole for Severe *Clostridium difficile* Infection

148. Poster Abstract Session

C. difficile: From the Bench to Bedside

Friday, 12:30 p.m. – 2:00 p.m.

- 1245 Genome Wide Analysis Reveals Host Genetic Variants that Associate with Reduction in *Clostridium difficile* Infection Recurrence (rCDI) in Patients Treated with Bezlotoxumab
- 1246 Engraftment and Augmentation of Microbiome Following Fecal Microbiota Transplantation for Recurrent *Clostridium difficile* infection
- 1247 Lyophilized fecal microbiota transplantation capsules for recurrent *Clostridium difficile* infection
- 1248 Socioeconomic Status Factors Associated with Increased Incidence of Community-Associated *Clostridium difficile* Infection

149. Poster Abstract Session

HAI: *C. difficile* Epidemiology, Impact, and Testing

Friday, 12:30 p.m. – 2:00 p.m.

- 1274 Epidemiology and Outcomes of *Clostridium difficile* Infection in Hospitalized Patients within the US Military Health Care System
- 1275 *Clostridium Difficile* Infection in Hematopoietic Stem Cell Transplant Patients: A Single-Center experience.

- 1276 Longitudinal Trends of *Clostridium difficile* infection (CDI) within Department of Veterans Affairs (VA) Medical Centers—Acute Care and Long Term Care
- 1277 Epidemiologic Trends in *Clostridium difficile* Isolate Ribotypes in United States from 2010–2014
- 1278 Epidemiology of *Clostridium difficile* infection Among Patients with Newly Diagnosed or Relapsed Acute Leukemia: A Single Center Experience.
- 1279 Incidence of Pediatric Community Associated *Clostridium difficile* Infection Following Common Antibiotics
- 1280 Increasing Economic Burden of Inpatient *Clostridium difficile* Infection in the United States: National Trends in Epidemiology, Outcomes, and Cost of Care from 2000–2014
- 1281 Declining rates of *Clostridium difficile* infections (CDI) in Veterans Affairs (VA) long-term care facilities (LTCF)
- 1282 A 10-year Review of *Clostridium difficile* Infection in Acute Care Hospitals in the United States
- 1283 Impact of *Clostridium difficile* infection on patients' quality of life: a French Hospital prospective study
- 1284 The *Clostridium difficile* Infection – Daily Symptoms (CDI-DaySyms™) Patient-Reported Outcome (PRO) Questionnaire: Final Validation and Responder Thresholds
- 1285 *Clostridium difficile* Testing Algorithm: Is There a Difference in Patients Who Test Positive by Enzyme Immunoassay vs. Those Who Only Test Positive by Nucleic Acid Amplification Methodology?
- 1286 Line of Service-Specific Performance and Antibiotic Prescribing Habits Following Introduction of a Two-Step Diagnostic Approach Using NAAT Followed by Enzyme Immunoassay in Cancer Patients with Suspected *Clostridium difficile* Infection.
- 1287 Differences in Clinical Characteristics and Outcomes of Patients with Community-Onset *Clostridium difficile* Infection who Tested Positive by EIA Compared with NAAT through a Two-Step Algorithm
- 1288 Toxin detection by cell culture neutralization assay [CYT] and Toxin based EIA [Tox EIA] among recurrent episodes of CDI diagnosed by PCR
- 1289 PCR Cycle-Threshold-Derived Toxin Identifies Patients at Low-Risk for Complications of *C. difficile* Infection Who Do Not Require Treatment
- 1290 Clinical Correlation of a *Clostridium difficile* Testing Algorithm Reflexing PCR Positive Specimens to Toxin Enzyme Immunoassay (EIA)
- 1291 Clinical characteristics and outcomes of hematologic malignancy patients with *Clostridium difficile* toxin EIA versus PCR positive test results
- 1292 Using Clinical Decision Support to Improve Evidence Based Testing and Diagnosis of *Clostridium difficile* infection
- 1293 Impact of a Multi-disciplinary *C. difficile* Action team
- 1294 *Clostridium difficile* (CD) Action Team (CDAT): An Intervention to Improve Care for Patients with a Positive CD PCR
- 1295 Know When to Test: Optimizing Diagnostic Practices for *Clostridium difficile* Infection (CDI) Among Patients at a Tertiary-Care Cancer Center
- 1296 The Impact of Diagnostic Stewardship on *Clostridium difficile* Infections
- 1297 Enzyme Immunoassay for *C. difficile* toxin reduces Lab ID events but fails to detect clinically significant *C. difficile* infection
- 1298 *Clostridium difficile* Laboratory Identification Event Reporting – A Need for Diagnostic Stewardship.
- 1299 An Assessment of 2016 National Healthcare Safety Network (NHSN) and National Electronic Disease Surveillance System (NEDSS) *Clostridium difficile* Infections (CDI) in Nebraska
- 1302 Genotypic Correlation between Cases of *Clostridium difficile* (CDI) with Community-Onset Diagnosis after Recent Hospital Discharge and Their Prior Unit-Based Contacts
- 1303 Association of Acid Suppression and Antimicrobial Use with *Clostridium difficile* Infection in Children
- 1304 Association Between Hospital-Onset *Clostridium difficile* infection and Admission to a Multi-Bed Room: A Case-Control Study
- 1305 External validation of predictive scores for mortality following *Clostridium difficile* infection
- 1306 Risk factors for healthcare-associated *Clostridium difficile* infection in pediatric hematopoietic stem cell transplant recipients
- 1307 Derivation and Validation of a Clinical Prediction Rule for Complications of *Clostridium difficile* Infection Using a Multicenter Prospective Cohort
- 1308 Are Patients with Prior *Clostridium difficile* Infection (CDI) a Potential Source of Transmission during Hospital Admissions?
- 1309 External validation of clinical scores to predict complications of *Clostridium difficile* infection
- 1310 Hospital-Nursing Home Transfer Patterns and Influence on Nursing Home *Clostridium difficile* Infection Rates
- 1311 Risk factors for *Clostridium difficile* infection in *C. difficile* colonized ICU patients
- 1312 Use of Electronic Data to Identify Risk Factors Associated with *Clostridium difficile* Infection (CDI) and to Develop CDI Risk Scores
- 1313 A data-driven approach to predict daily risk of *Clostridium difficile* infection at two large academic health centers
- 1314 *C. difficile* Screening for Colonization among Surgical Ward Admissions Is Feasible and Useful
- 1315 Optimizing Environmental Hygiene to Successfully Decrease *Clostridium difficile* Transmission
- 1316 A Nurse-Driven Protocol to Reduce Hospital-Acquired *Clostridium difficile* Infections
- 1317 A Multi-Pronged Approach to Control Healthcare Facility-Onset *Clostridium difficile* Infection in a Tertiary Care Community Hospital
- 1318 Decrease of Hospital-Onset *Clostridium difficile* through Enhanced Electronic Decision Support
- 1319 First Environmental Investigation of Toxigenic *Clostridium difficile* at a Large Hospital in Bangladesh
- 1320 Enhanced Cleaning and Education to Prevent Transmission of *Clostridium difficile* in Pediatrics
- 1321 A Successful Strategy to Reduce Hospital-Onset *Clostridium difficile*

150. Poster Abstract Session

HAI: *C. difficile* Risk Assessment and Prevention

Friday, 12:30 p.m. – 2:00 p.m.

- 1300 Antibiotic Exposure and Risk of Community-associated *Clostridium difficile* infection (CA-CDI): A Self-Controlled Case Series Analysis
- 1301 Predictors of 30-day All-cause Mortality in Veterans with First Recurrence of *Clostridium difficile* Infection (CDI)

151. Poster Abstract Session

HAI: Hand Hygiene

Friday, 12:30 p.m. – 2:00 p.m.

- 1322 Frequently Identified Infection Control Gaps Related to Hand Hygiene in Long-Term Care Facilities
- 1323 Impact of Electronic Hand Hygiene Monitoring on Hospital-Acquired *Clostridium difficile* Infection Rates
- 1324 Sustained Improvement in Hand Hygiene Compliance Using a Centralized, Technology-Based Approach
- 1325 Electronic Hand Hygiene Monitoring: A Tool to Drive Improvement and Measure Impact
- 1326 Improving Hand Hygiene: Anonymously Validated Data Driven Approach Producing Sustainable Culture Change Utilizing “One and Up” Accountability Agents across a Healthcare System- A Cost-effective National Best Practice.
- 1327 Monitoring Hand hygiene Compliance among Healthcare Workers at a Tertiary Care Center: Use of secret observers is the way forward
- 1328 What psychological theories of behaviour change can teach us about improving hand hygiene adherence: Do we mean what we say?
- 1329 Alcohol-based Hand Rubs Are Effective for Reduction of Multi-Drug Resistant Candida
- 1330 Reducing Dissemination of Viruses from Computer Touchscreens through Patient Hand Hygiene and an Automated Ultraviolet-C Touchscreen Disinfection Device
- 1331 Comparison of Two Glove-Sampling Methods to Discriminate Between Study Arms of a Hand Hygiene and Glove-Use Study.

- 1332 An Appeal to Incorporate Hand Hygiene Education into Standard Elementary School Curriculum
- 1333 The Use of Instructional Technology to Increase Independent Patient Hand Hygiene Practice of Hospitalized Adults in an Acute Care Setting
- 1334 Hand hygiene: Knowledge and Practices of Clinical Teachers in Selected Teaching Hospitals in Kenya
- 1335 Painting the Gown Red: Using a Colored Paint Quality Improvement Process to Evaluate Healthcare Worker Personal Protective Equipment for Highly Pathogenic Infections
- 1336 Patients' Family Empowering to Increase Hand Hygiene (HH) Compliance in Health-Care Workers (HCW) from a Hematology-Oncology Ward in Mexico City

152. Poster Abstract Session Herpes Zoster Vaccine Friday, 12:30 p.m. – 2:00 p.m.

- 1337 Performance of Zoster Vaccine Live (Zostavax): A Systematic Review of 12 years of Experimental and Observational Evidence
- 1338 Assessment of the Potential Herpes Zoster and Post Herpetic Neuralgia Case Avoidance with Vaccination in the United States
- 1339 Effectiveness of Live Zoster Vaccine in Preventing Herpes Zoster Ophthalmicus (HZO)
- 1340 Immune Senescence Factors Associated with the Immunogenicity of a Live Attenuated Zoster Vaccine (ZV) in Older Adults
- 1341 Humoral and Cellular Immunogenicity of Zoster Vaccine within One Year after Herpes Zoster
- 1342 Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: A Phase III, Group-Matched, Clinical Trial
- 1343 Persistence of Immune Response to an Adjuvanted Varicella-Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults
- 1344 Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial
- 1345 A Replication-Defective Herpes Simplex Virus (HSV)-2 Vaccine, HSV529, is Safe and Well-Tolerated in Adults with or without HSV Infection and Induces Significant HSV-2-Specific Antibody Responses in HSV Seronegative Individuals
- 1346 Results of a Safety Pooled Analysis of an Adjuvanted Herpes Zoster Subunit Vaccine in More than 14,500 Participants Aged 50 Years or Older
- 1347 A Cost-Effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-Herpetic Neuralgia
- 1348 Immunogenicity and Safety of a Candidate Subunit Adjuvanted Herpes Zoster Vaccine (HZ/su) in Adults Post Renal Transplant: a Phase III Randomized Clinical Trial
- 1349 Immunogenicity and Safety of a Candidate Subunit Adjuvanted Herpes Zoster Vaccine in Adults with Solid Tumors Vaccinated Before or During Immunosuppressive Chemotherapy Treatment: A Phase II/III, Randomized Clinical Trial
- 1350 Vaccination Response to an Ongoing Meningitis Outbreak: Uptake and Attitudes among Men Who Have Sex with Men in Los Angeles, CA
- 1351 Bivalent Norovirus VLP Vaccine Candidate in Older Adults: Impact of MPL and a Second Dose in a Randomized, Controlled, Double-Blind Clinical Trial

153. Poster Abstract Session HIV Care Continuum Friday, 12:30 p.m. – 2:00 p.m.

- 1352 Improved HIV markers and decreased emergency room usage and hospital admission with initiation of a pilot specialty pharmacy at a southeastern Ryan-White-funded clinic over a three year period
- 1353 HIV Risk Assessment using Longitudinal Electronic Health Records
- 1354 Linkage to HIV Outpatient Care Following an Inpatient Stay

- 1355 Healthcare Engagement among Persons with HIV: More Than Just Viral Load and Clinic Attendance
- 1356 Social Determinants of Health and Disparities in Linkage to Care Among Newly Diagnosed HIV Cases – South Carolina, 2009–2011
- 1357 Mortality and Retention in Care of HIV-Infected Patients According to Year of Admission and Availability of Antiretroviral Drugs in the Chilean National AIDS Program: Fundacion Arriaran 1990–2015
- 1358 Impact of Patient Navigators in Linkage to Care for HIV-Positive Patients in an Urban Emergency Department in Newark, NJ
- 1359 Assessment of personal experiences navigating medical systems and society for patients of a midwestern Ryan White funded HIV Clinic
- 1360 Predictors of Viral Load Suppression in HIV-infected Patient in Rural Eastern North Carolina.
- 1361 Factors Associated with Elevated HIV RNA Levels in HIV-Infected Individuals
- 1362 Travel time to Clinic but not Neighborhood Crime Rate is associated with Retention in Care among HIV-positive Patients
- 1363 Electronic data sharing between public health department and clinical providers improves accuracy of HIV retention data
- 1364 How Acceptable Is A Wireless Pill Bottle That Monitors and Texts In Response To Missed Doses: Focus Groups With Young African American MSM Living With HIV
- 1365 Improving Appointment Adherence among Young Adults with HIV in Peru with an mHealth Intervention: a Feasibility Study
- 1366 Patient-level Factors Associated with HIV Suppression at Admission Across a Large Integrated Healthcare System
- 1367 Late Presentation among Patients Diagnosed with HIV in an Inpatient Setting

154. Poster Abstract Session HIV Drug Resistance Friday, 12:30 p.m. – 2:00 p.m.

- 1368 HIV Transmitted Drug Resistance in the Philippines: The Case for Baseline Genotyping and Drug Resistance Testing
- 1369 Transmitted Drug Resistance in Treatment-naïve HIV-Infected VCT clients in Taiwan, 2007–2016
- 1370 Monitoring of HIV Drug Resistance Mutations in Newly Diagnosed Patients in Cyprus (2010–2012)
- 1371 DRUG RESISTANCE AFTER FAILURE OF WHO RECOMMENDED FIRST-LINE ANTIRETROVIRAL REGIMEN FOR ADULT HIV-1 INFECTION IN SOUTH AFRICA: A MODELING ANALYSIS
- 1372 Antiretroviral Therapy Prescribing Practices and Virologic Response in HIV-Infected Individuals with the M184V Mutation: Results from the 550 Clinic Cohort Study
- 1373 Moderate Levels of Pre-Treatment HIV Drug Resistance — Zimbabwe, April–July 2015
- 1374 Reviewing Clinical Outcomes of Patients with the E157Q Mutation in Detroit
- 1375 Clinical Outcomes Following the Use of Archived HIV-1 DNA Sequencing to Guide Antiretroviral Therapy Regimen Adjustment and Simplification

155. Poster Abstract Session HIV Testing Friday, 12:30 p.m. – 2:00 p.m.

- 1376 Routinization of HIV & HCV Testing in the Inpatient Setting: Involvement of Residents and Nurses
- 1377 Identifying African American Women with HIV Infection in an Expanded HIV testing and Linkage to Care (X-TLC) Program in Healthcare Settings on the South and West Sides of Chicago.
- 1378 Making a Big Impact on Expanding HIV Inpatient Testing with a Small EHR Modification
- 1379 Can an HIVSmart! App-optimized Self-Testing Strategy be Operationalized in Canada?

156. Poster Abstract Session
HIV: Antiretroviral Therapy
Friday, 12:30 p.m. – 2:00 p.m.

- 1380** A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination
- 1381** No Emergent Resistance in HIV-1 Infected Virologically-Suppressed Subjects Who Switched to R/F/TAF
- 1382** Sword 1 & 2: Subgroup Analysis of 48 Week Results by Age, Race and Gender
- 1383** Efficacy and Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate in HIV-infected, Virologically Suppressed Black and Non-Blacks Adults Through Week 96: Subgroup Analysis of a Randomized Switch Study
- 1384** Viral Blips Were Infrequent in HIV-1-Infected Virologically-Suppressed Adults Treated with Tenofovir Alafenamide or Tenofovir DF Rilpivirine-Containing Regimens
- 1385** High Tenofovir Failure Rates in an Emerging, Non-B Subtype HIV Epidemic
- 1386** Lack of Clinically Relevant Effect of Bictegravir (BIC, B) on Metformin (MET) Pharmacokinetics (PK) and Pharmacodynamics (PD)
- 1387** Impact of Tablet Burden and Antiretroviral Therapy (ART) Choice on Virologic Outcomes in Treatment Naïve HIV+ Individuals Attending an Inner City Clinic
- 1388** Pharmacokinetics of Cabotegravir in Subjects with Moderate Hepatic Impairment
- 1389** Pharmacokinetics of Cabotegravir in Subjects with Severe Renal Impairment
- 1390** Pharmacokinetics of Tenofovir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment
- 1391** Efavirenz-metabolizing polymorphisms, viral suppression, and depression in HIV-infected individuals initiating antiretroviral therapy in southwestern Uganda
- 1392** Darunavir and Dolutegravir Combination Therapy in ART experienced HIV-infected Patients: A Preliminary Report. Alexandra Stang, Tracy Perry, Nada Fadul
- 1393** Patient Experience & Views on Antiretroviral Treatment - Findings from the Positive Perspectives Survey
- 1394** Comparison of Time to Viral Suppression Among Treatment-Naïve HIV-Infected Adults Initiating Combination Antiretroviral Therapy by Antiretroviral Regimen Class
- 1395** The Safety of Substitution of Antiretroviral Regimen in Non-Clinical Trial Settings in Asian Countries
- 1396** Clinical outcomes associated with once daily ritonavir-boosted darunavir in HIV infected patients harboring single or multi-class resistant virus
- 1397** Gender Differences in Virologic Response after Antiretroviral Therapy in Treatment-naïve HIV-infected Individuals: Results from the 550 Clinic HIV Cohort Study.
- 1398** WEIGHT GAIN AFTER SWITCH FROM EFVIRENZ-BASED TO INTEGRASE INHIBITOR-BASED REGIMENS
- 1399** Application of The Change Point Analysis to The Long-Term Restoration of CD4 Count Among Well-Controlled HIV-1 Infected Patients Who Started Antiretroviral Therapy
- 1400** Treatment of HIV and Use of HAART in HIV Infected Patients with Acute Septic Shock
- 1401** A Prediction Model of Pre-treatment HIV RNA Levels in Naïve Thai HIV-infected Patients: An Application for Resource-limited Settings

157. Poster Abstract Session
HIV: Health Care Utilization and Costs
Friday, 12:30 p.m. – 2:00 p.m.

- 1402** Principal Components and Costs of HIV-Associated Hospitalizations in the United States: A National Study in the Current Era
- 1403** What Determines Do-Not-Resuscitate Status in Critically Ill HIV Patients?

- 1404** Hospitalization and Emergency Room Visits: The Opportunity for Re-Engagement for People Living with HIV/AIDS (PLWHA)
- 1405** Healthcare Resource Utilization and Costs Associated with Switching First-line Antiretroviral Therapy among HIV-infected Patients in the United States
- 1406** Avoiding Inpatient Delays in Antiretroviral Therapy via Low Cost Formulary Management
- 1407** Management of End Stage Renal Disease in Persons Living with HIV: A Cost-Effectiveness Analysis
- 1408** The Costs of Home-Based ART Initiation and Mobile Refill in Uganda
- 1409** HIV in Ecuador: A Current Perspective of the Epidemics from a Major HIV Care Center.

158. Poster Abstract Session
HIV: Pre-Exposure Prophylaxis
Friday, 12:30 p.m. – 2:00 p.m.

- 1410** Knowledge, Attitude and Practice of Pre-exposure prophylaxis (PrEP) against HIV infection of medical providers at an academic center
- 1411** HIV Pre-Exposure Prophylaxis (PrEP) Uptake, Initiation, and Persistence in the Detroit Public Health STD Clinic
- 1412** Predictors of First-Year Medication Adherence in a National Cohort of Veterans Initiating Pre-Exposure Prophylaxis (PrEP) to Prevent HIV Infection
- 1413** Perceptions of HIV Pre-exposure prophylaxis (PrEP) among young pregnant women from KwaZulu-Natal, South Africa
- 1414** Partnerships between a University-Affiliated Clinic and Community Based Organizations to Reach Black Men who have Sex with Men for PrEP Care
- 1415** PrEP Uptake and Emergent HIV infections in Southern Arizona: Is There A Disconnect?
- 1416** Comfort Discussing HIV Pre-Exposure Prophylaxis with Patients Among Physicians in an Urban Emergency Department
- 1417** Frame me if you must: PrEP framing and the impact on adherence to HIV Pre-exposure Prophylaxis
- 1418** Baseline Characteristics from PrEP Chicago: A Randomized Controlled Diffusion-Based Network Intervention for HIV Prevention Among Young Black Men Who Have Sex With Men
- 1419** Perspectives of women prescribed HIV pre-exposure prophylaxis (PrEP)
- 1420** Client-Centered Counseling-Based Resource Center Increased Uptake of HIV Pre-Exposure Prophylaxis (PrEP) in a Randomized Controlled Trial of Young Black Men who have Sex with Men

159. Poster Abstract Session
HIV: Rapid ART Initiation
Friday, 12:30 p.m. – 2:00 p.m.

- 1421** Linkage and Anti-Retroviral Therapy Within 72-hours at a Ryan White-Funded FQHC in the Deep South
- 1422** Acute HIV infection (AHI): Trained Service Linkage Workers and 4th Generation Assay Significantly Shorten Time to Antiretroviral Therapy Initiation.
- 1423** Effect of a Multidisciplinary Intervention for Early ART Initiation for Inpatients with Newly Diagnosed HIV
- 1424** Implementing an HIV Test and Treat Rapid Response Anti Retroviral Initiation Program in a Southern City with High HIV Incidence

160. Poster Abstract Session
ID Medical Education
Friday, 12:30 p.m. – 2:00 p.m.

- 1425** Needs Assessment for Resident Education Within the Collaboration for Vaccine Education and Research (CoVER)

- 1426 Assessment of Knowledge, Attitudes, and Practices (KAP) of Providers Towards Internal Reporting of Antimicrobial Use
- 1427 Identifying Educational Opportunities from Phone calls to the Microbiology Laboratory
- 1428 HIV PrEP and PEP in Graduate Medical Education: A Novel Curriculum
- 1429 Flipping Expectations: Are Active Learning Strategies Sufficient or Necessary To Teach Principles of Antimicrobial Stewardship in Medical School?
- 1430 Problem Based Learning (PBL) in an Infectious Diseases Fellowship
- 1431 A study assessing the educational value of serious games in infectious diseases – Going beyond memorization
- 1432 Medical Education in Infectious Diseases. Using Smartphone Apps for Active Learning
- 1433 Use of simulation for antimicrobial stewardship Infectious Disease fellowship curriculum
- 1434 Virtual Patient Simulation in HIV: An Online Educational Tool to Improve Evidence-Based Clinical Decision-Making
- 1435 Use of an Email Question and Answer Service to Characterize Vaccine Education Needs in the U.S.
- 1436 Virology Online: a free, web-based, adaptive-learning course
- 1437 Let's talk about sex: Improving the adoption of pre-exposure prophylaxis by internal medicine resident physicians in New Orleans
- 1438 Spotting Sepsis: Blended Learning to Assess Student Recognition and Management
- 1439 Factors Impacting Selection of Infectious Disease Training for Military Internal Medicine Residents
- 1440 Effect of Experience of Internal Medicine Residents during Infectious Disease Elective on Future Infectious Disease Fellowship Application
- 1441 How Did the Zika Virus Outbreak Impact Residency and Fellowship Recruitment in Miami, FL?
- 1442 The Impact of an Online, Episodic CME Strategy on Improving Physicians' Knowledge and Competence in the Care of Persons Living With HIV
- 1443 Strengthening the HIV Provider Workforce Through a Residency Pathway: Outcomes and Challenges
- 1444 HIV/AIDS Training and Skills of Infectious Disease Fellows Among 33 US Academic Institutions
- 1445 Bridging the Gap: An Assessment and Intervention for Pediatric Providers on the Prevention of Perinatal Transmission of HIV
- 1446 Development and Assessment of an HIV-focused E-learning Flipped Classroom Curriculum in an Infectious Diseases Fellowship Program
- 1447 Reluctance to Prescribe Pre-Exposure Prophylaxis (PrEP) Among Internal Medicine Residents (IMRs) Training at a U.S. Hospital with a Large HIV-infected Population
- 1448 How to Save a Failing Fellowship: Drexel Infectious Disease Improvement in ACGME Fellow Survey Results
- 1449 What are they here to learn? Meeting the needs of medical students and residents on an Infectious Disease service
- 1450 Foundational Science Instruction for Clerkship-Phase Medical Students through Integrated Clinical Experience in Transplantation, Transplant Infectious Diseases, and Immunodeficiency
- 1451 Interpersonal and Communication Skills Competency Assessment in ID programs
- 1452 Improving Fellows' Presentations at Case-Conference: A Quality Improvement Initiative
- 1453 Perception, attitude and knowledge of antimicrobial resistance, appropriate antimicrobial use, and infection control among the first year residents and fellows across medical specialties

161. Poster Abstract Session Influenza and Influenza Vaccines Friday, 12:30 p.m. – 2:00 p.m.

- 1454 Safety of Influenza Vaccination among Hospitalized Patients
- 1455 Influenza Vaccine Effectiveness in the United States during the 2016–17 Season
- 1456 Impact of Prior Season Influenza Vaccination on Seasonal Influenza Vaccine Effectiveness: An Analysis over Four Consecutive Seasons from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN)

- 1457 Influenza Vaccine Effectiveness Against Influenza-Associated Pneumonia and Pneumococcal Pneumonia in Older Adults: A Prospective Test-Negative Design Study
- 1458 Effectiveness of Influenza Vaccine in Preventing Death among Ontario Residents Aged ≥ 65 Years during 20 Seasons
- 1459 The Pregnancy Vaccine Effectiveness Network (PREVENT): Establishing a Multi-Country Cohort to Estimate Vaccine Effectiveness (VE) against Hospitalized Influenza during Pregnancy
- 1460 Are Higher Vitamin D Levels Associated with Improved Influenza Vaccine Immunogenicity and Fewer Healthcare Encounters for Respiratory Infections among Young Adults?
- 1461 The Influence of Mandatory Versus Non-Mandatory Influenza Vaccination Policies on Workplace Absenteeism During Respiratory Virus Season
- 1462 Transcriptome Analysis in Human Breast Milk and Blood after Inactivated or Attenuated Influenza Immunization
- 1463 Enhanced Potency and Durability of Antibody Response to Seasonal Trivalent Inactivated Influenza Vaccine (TIV) Combined with a Novel Water-in-Oil Adjuvant System at Reduced Hemagglutinin (HA) Doses
- 1464 Influenza Vaccine Effectiveness among Elderly and Non-Elderly Adults Aged ≥ 45 Years in the United States, 2011–12 to 2015–16
- 1465 Efficacy and Effectiveness of High-Dose Influenza Vaccine for Older Adults: A Systematic Review and Meta-analysis
- 1466 Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines among Veterans: 2015–2016 and 2016–2017 Seasons

162. Poster Abstract Session Maternal/Infant Immunization Friday, 12:30 p.m. – 2:00 p.m.

- 1467 Effectiveness of a Web-Based Intervention to Increase Uptake of Maternal Vaccines
- 1468 Provider Attitudes and Practices Regarding Maternal Vaccination Among Obstetrician-Gynecologists: A National Survey
- 1469 Durability and Kinetics of Maternal Pertussis Antibodies in Infants of Mothers Immunized with Tdap during Pregnancy
- 1470 Tdap and influenza vaccination among women with a live birth, Internet panel survey, United States, 2015–16
- 1471 Pregnant Women's Acceptance of Hypothetical Zika Vaccine

163. Poster Abstract Session Pediatric Viral Infections Friday, 12:30 p.m. – 2:00 p.m.

- 1472 Clinical Presentation, Risk Factors, and Cross-Protection from Repeated Respiratory Viral Infections in Infants in Nepal
- 1473 Enterovirus (EV)-D68 in Pediatric Patients with Respiratory Tract Infection: the Circulation of new B3 Clade in Italy
- 1474 Asymptomatic Adults and Children Can Transmit Human Parechoviruses and Enteroviruses to Neonates and Young Infants
- 1475 Characterization of Circulating RSV Strains Among Patients In The Outsmart RSV Program During the 2015–16 Winter Viral Season in the United States
- 1476 Respiratory Syncytial Virus-Associated Hospitalizations in Young Children in the United States, 2015–2016
- 1477 Molecular epidemiology of respiratory syncytial virus A G-protein for 9 years and emergence of ON1 genotype having 72 nucleotide duplication in Korea
- 1478 Hospitalizations in the First Year of Life for Infants with Respiratory Syncytial Virus and Unspecified Bronchiolitis in a Population-Based Cohort
- 1479 WHO Severe Acute Respiratory Infections (SARI) Definition often Underdiagnoses Serious Respiratory Viral Infections in Hospitalized Jordanian Children
- 1480 Varicella Outbreak Surveillance in the United States, 2015–2016

164. Poster Abstract Session Pneumococcal Immunization and Epidemiology-Global Friday, 12:30 p.m. – 2:00 p.m.

- 1481 Non-invasive pneumococcal pneumonia in adults in Portugal (2012–2015): resilience of vaccine serotypes and emergence of non-vaccine serotypes.
- 1482 Pediatric Community- Acquired Bacteremia Before and After the Introduction of the Pneumococcal Conjugate Vaccine into the National Immunization Program in Israel
- 1483 Changes in the Serotype Distribution among Antibiotic Resistant Carriage *Streptococcus pneumoniae* Isolates in Children after the Introduction of the Extended-Valency Pneumococcal Conjugate Vaccine
- 1484 *Streptococcus pneumoniae*(Spn) Nasopharyngeal Carriage in Children Under 3 Years Old, Attending Day Care Centers in Argentina.
- 1485 Community Acquired Pneumonia Incidence Among Children Under 5 Years of Age in Concordia Argentina. Universal Vaccination Impact
- 1486 IMPACT OF TEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINE INTRODUCTION ON SEROTYPE DISTRIBUTION TRENDS IN COLOMBIA: AN INTERRUPTED TIME-SERIES ANALYSIS

165. Poster Abstract Session Pneumococcal Immunization and Epidemiology-North America Friday, 12:30 p.m. – 2:00 p.m.

- 1487 Estimating the Clinical and Economic Impact of Maintaining use of 13-valent Pneumococcal Conjugate Vaccine (PCV13) in Mexico
- 1488 Post-licensure Surveillance of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Children 6 weeks–59 months old, Vaccine Adverse Event Reporting System (VAERS), United States, 2010–2017
- 1489 Invasive pneumococcal disease in a population with underlying comorbidities
- 1490 Pneumococcal vaccination provides substantial value for money for Canadians
- 1491 The Risk of Febrile Seizures Following Influenza and 13-Valent Pneumococcal Conjugate Vaccines
- 1492 Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
- 1493 Enhanced detection of vaccine type colonization and dual serotype carriage with molecular strategies for identification of *Streptococcus pneumoniae* colonization.
- 1494 Antibiotic Prescription Rates In Children <24 Months Old Following PCV7/PCV13 Sequential Implementation
- 1495 The changing epidemiology of invasive pneumococcal disease among the indigenous and non-indigenous population of north-western Ontario, Canada, from 2006 through 2015 and emergence of non-vaccine serotypes.
- 1496 Yearly Trends of Antimicrobial Non-susceptibility among *Streptococcus pneumoniae* Serotypes Causing Infections in Adult Patients in the United States (2009–2015)
- 1497 Changing Epidemiology of Invasive Pneumococcal Disease due to Conjugate Vaccine Serotypes in Toronto, Canada After Introduction of a Routine Pediatric PCV13 Program.
- 1498 Impact of PCV13 on Serotype 3 invasive pneumococcal disease and nasopharyngeal carriage in Massachusetts' children

166. Poster Abstract Session Pneumococcal Immunization in Adults Friday, 12:30 p.m. – 2:00 p.m.

- 1499 Excess Risk of Invasive Pneumococcal Disease (IPD) Persists in Adults with Comorbid Conditions in the Era of PCV13 Childhood and Adult Immunization
- 1500 Distributions and Annual Changes of *Streptococcus pneumoniae* Serotypes Causing Infections in Adult Patients: Eight Years of US Surveillance (2009–2016)
- 1501 Disparities in Uptake of 13-valent Pneumococcal Conjugate Vaccine among Older Adults Following Routine Recommendation in the United States
- 1502 The Impact of Patients' Demographics, Insurance Payor and Comorbidities on Pneumococcal Vaccine Uptake in a Resident Community Internal Medicine Clinic.
- 1503 Implementing Pneumococcal Vaccination in Hospitalized Adults With COPD, Asthma, Current Smokers, And/Or Over Age 65 years. A Performance Improvement Project.
- 1504 Sequential administration of PCV13 followed by PPSV23 results in a more robust immune response in PPSV23-naïve adults age 60–64 years
- 1505 Efficacy of Influenza and Pneumococcal Vaccination In Preventing COPD Exacerbation

167. Poster Abstract Session Preclinical Study with New Antibiotics and Antifungals Friday, 12:30 p.m. – 2:00 p.m.

- 1506 Assessment of the *In Vivo* Efficacy of Plazomicin (PLZ) Alone or in Combination with Meropenem (MEM) or Tigecycline (TGC) against Enterobacteriaceae (EB) Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent (I+) Murine Septicemia Model
- 1507 Vancomycin (VAN) Combinations with Beta-Lactams (BLs) against Methicillin-Resistant *Staphylococcus aureus* (MRSA), Heterogeneous Intermediate-Level Resistance to Vancomycin (hVISA) and Vancomycin-Intermediate *Staphylococcus aureus* (VISA)
- 1508 SCY-078 Demonstrates Significant Tissue Penetration in Rats and Mice Following Oral or IV Administration
- 1509 Efficacy of Lefamulin Against *Staphylococcus aureus* - Induced Bacteremia in a Neutropenic and Immunocompetent Murine Model
- 1510 Evaluation of the *In Vitro* and *In Vivo* Antifungal Activity of APX001A/APX001 Against *Candida auris*
- 1511 SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis
- 1512 *In Vivo* Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models
- 1513 Absorption, Distribution, and Excretion of ¹⁴C-APX001 after Single-Dose Administration to Rats and Monkeys
- 1514 Delayed Dosing of S-033188, a Novel Inhibitor of Influenza Virus Cap-dependent Endonuclease, Exhibited Significant Reduction of Viral Titer and Mortality in Mice Infected with Influenza A Virus.
- 1515 Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with Invasive Aspergillosis
- 1516 DS11960558, A Water Soluble Prodrug of DS-2969b, for Intravenous Treatment of *Clostridium difficile* Infection
- 1517 ZTI-01 Treatment Improves Survival of Animals Infected with Multidrug Resistant *Pseudomonas aeruginosa*
- 1518 Evaluation of the Efficacy of CD101, a Novel Echinocandin, in the Treatment of *Candida auris* Infection Using a Murine Model of Disseminated Candidiasis

- 1519 Delayed therapy with plasma gelsolin improves survival in murine pneumococcal pneumonia
- 1520 *In Vivo* Efficacy of Humanized Exposures of Cefiderocol Compared with Cefepime (FEP) and Meropenem (MEM) against Gram-negative Bacteria in a Murine Thigh Model
- 1521 APX001A Protects Immunosuppressed Mice from *Rhizopus dele-mar* Infection
- 1522 Fungal Cytological Profiling of *Candida albicans* Exposed to Diverse Antifungal Agents Including the Novel Gwt1 inhibitor APX001A
- 1523 Fosfomycin (FOS) Plus Meropenem (MER) Suppresses Resistance Emergence Against *P. aeruginosa* (PA) PAOI in the Hollow Fiber Infection Model (HFIM)
- 1524 Good Correlation of Cefiderocol Between *In Vivo* Efficacy Murine Thigh/Lung Infection Models and MIC Determined in Iron-Depleted Conditions
- 1525 Efficacy Evaluation of Iclaprim in a Neutropenic Rat Lung Infection Model with Methicillin-Resistant *Staphylococcus aureus* Entrapped in Alginate Microspheres
- 1526 Discovery of a Series of Potent and Selective Nucleotide Prodrug Inhibitors of Respiratory Syncytial Virus (RSV) Replication
- 1527 Novel immunization strategies against multi-drug resistant Gram negative bacteria
- 1528 *In vivo* Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CDI01 against *C. albicans* and *C. glabrata* in the Neutropenic Murine Disseminated Candidiasis Model
- 1529 Efficacy of Oral APX001 in a Murine Model of Cryptococcal Meningitis
- 1530 Diol-Based Polymer Microparticles for Treatment of Cutaneous Aspergillosis in an Immunocompromised Murine Model
- 1531 *In vivo* Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against *Staphylococcus aureus* (SA) in the Murine Thigh Infection Model
- 1532 Human Target Attainment Probabilities for Delafloxacin against *Escherichia coli* and *Pseudomonas aeruginosa*
- 1533 Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model
- 1534 *In vitro* synergistic activity of biapenem combination with sulbactam, colistin, and fosfomycin sodium against multidrug-resistant *Acinetobacter baumannii* isolates from tertiarycare hospitals in Thailand
- 1535 Nitric Oxide-Releasing Chitosan for the Treatment of Multi-Drug Resistant Superbugs
- 1536 Discovery of Antifungal Compounds from Kampo Medicine against Dermatophytes
- 1537 Feasibility of Neuphapheresis™ as a Therapy for Multidrug Resistant Gram-negative Bacterial Meningitis
- 1538 Evaluation of a 15-valent pneumococcal conjugate vaccine in an adult Rhesus macaque immunogenicity model
- 1539 Foley Catheter with Peri-Urethral Antimicrobial Irrigation for the Prevention of Catheter Associated Urinary Tract Infections – Assessment in an *in vitro* model
- 1540 *In Vitro* Characterization of the Neurapheresis™ System for the Treatment of Cryptococcal Meningitis
- 1545 Reduction of *Clostridium difficile* Infection in a Community Teaching Hospital Associated with Antimicrobial Stewardship Team Interventions on Fluoroquinolone Utilization
- 1546 Reduction in antibiotic consumption upon implementation of antibiotic indication requirement
- 1547 Impact of a Stewardship Initiative to Decrease Treatment of Asymptomatic Bacteriuria and Pyuria in the Emergency Department
- 1548 Early antimicrobial de-escalation is associated with decreased acute kidney injury in patients receiving empiric combination therapy
- 1549 Impact of Procalcitonin (PCT)-Guided Antibiotic Management on Antibiotic Exposure and Outcomes: Real World Evidence
- 1550 Economic and Clinical Outcomes of Antimicrobial Stewardship Program Implementation at a Community Hospital Affiliated with a Regional Health System
- 1551 Clinical Outcome Evaluation of an Antimicrobial Stewardship Program in an Accountable Care Organization
- 1552 The effect of the preauthorization system on oral antimicrobials at a maternal and children's hospital in Japan
- 1553 Eight Years of Antimicrobial Stewardship Program (ASP) at a Large Academic Medical Center: Antibiotic Utilization, Hospital-onset *Clostridium difficile* infection (HO-CDI) and Resistance Trends.
- 1554 Clinical Impact of an Antibiotic Stewardship Program at Two Non-Teaching Community Hospitals
- 1555 Clinical Impact of Antimicrobial Stewardship Programs in Colombian Acute Care Hospitals
- 1556 Outcomes of Bedside Nurse-Driven Interdisciplinary Antibiotic Stewardship and Infection Prevention Rounds
- 1557 Vancomycin Safety Monitoring Using an Electronic Health Record Database
- 1558 Efficacy and Safety of a Vancomycin (VAN) Dosing Protocol Developed for Morbidly Obese (MO) Patients
- 1559 Balancing the Efficacy and Safety of Implementing a Piperacillin/tazobactam (PTZ) Antibiotic Time-out
- 1560 Safety of a Carbapenem Restriction Policy in Patients with Gram-Negative Bacteremia
- 1561 Impact of an Antimicrobial Stewardship Bloodstream Surveillance Program (BSP) in Hospitalized Patients
- 1562 Impact of Education on Fluoroquinolone Use in Uncomplicated Cystitis
- 1563 Effect of a Multifaceted Stewardship Intervention on Antibiotic Prescribing and Outcomes for Acute Bacterial Skin and Skin Structure Infections
- 1564 High- versus Low-Intensity Prospective Audit and Feedback on Internal Medicine Wards and Impact on Antimicrobial Use at a Community Hospital
- 1565 Implementation of an Automated Electronic Medical Record “Antibiotic Timeout” Alert at a Tertiary, Academic Medical Center
- 1566 Cost-Savings Associated With Delayed Switch To Outpatient Antibiotic Regimen For Patients Requiring Daptomycin Therapy
- 1567 Antimicrobial Stewardship Challenges: Could Generic Antibiotic Use Policies Improve Economic Outcomes in Acute Care Hospitals?
- 1568 Economic Outcomes of Isavuconazole to Prevent Invasive Fungal Infection in Immunocompromised Adults: Initial Experience at an Academic Medical Center
- 1569 Transition of Care with Dalbavancin: a Successful Cost-Saving Stewardship Program through Decreased Length of Stay
- 1570 Impact of a Standardized Penicillin Allergy Assessment Program to Optimize Penicillin Allergy Documentation and Beta-lactam Antibiotic Use at an Academic Medical Center
- 1571 Use of Penicillin Skin Testing as an Antimicrobial Stewardship Initiative: Clinical and Economic Evaluation at a Community Health System
- 1572 Elimination of Aerosol Ribavirin Use In Immunocompromised Patients With Metapneumovirus and Parainfluenza Virus Infections.
- 1573 Antipseudomonal Drug Exposure Associated with MDR Organisms in the Liver and Lung Transplant Population
- 1574 An Antimicrobial Stewardship Initiative within a for-profit hospital: Impact of Criteria for Appropriate Use on Utilization
- 1575 Enhancing Antibiotic Stewardship Team (AST) Efforts in Decreasing Inappropriate Vancomycin Usage in Neutropenic Fever (NF) Patients through Unit Based Pharmacist Intervention

168. Poster Abstract Session

Stewardship: Improving Outcomes

Friday, 12:30 p.m. – 2:00 p.m.

- 1541 An Offer You Can't Refuse: Clinical Impact of Accepting or Rejecting a Recommendation from an Antibiotic Stewardship Program
- 1542 Safety of Stopping Antibiotics Prescribed “Just in Case”—Comparison of Mortality, Readmissions and *Clostridium difficile* in Patients with Accepted Stewardship Interventions Compared to Declined
- 1543 A Multi-Faceted Antimicrobial Stewardship Program (ASP) Intervention Using Clinical Pharmacists Reduces Antibiotic Use and Hospital-Acquired *Clostridium difficile* Infection (HA-CDI)
- 1544 Impact of System-wide Adoption of CDC Core Elements on Antimicrobial Use and *Clostridium difficile* Infection in a Large Health System

- 1576 Unintended Consequences of Pre-transplant VRE Screening on Antimicrobial Stewardship Among Allogeneic Hematopoietic Cell Transplant Recipients
- 1577 Evaluation of a Risk Stratification Guideline for the Treatment of Neutropenic Fever in Oncology Patients
- 1578 Outpatient Antimicrobial Stewardship Intervention Targeting Cytomegalovirus (CMV) Viremia in Solid Organ Transplant (SOT) Recipients
- 1579 Reduction of Antimicrobial Resistance among Gram-Negative Pathogens after Antimicrobial Stewardship in Three Tertiary Egyptian Hospitals
- 1580 Impact of an Antimicrobial Stewardship Initiative Focused on *Staphylococcus aureus* Bacteremia
- 1581 The Value of Antimicrobial Stewardship Team (AST) in Conjunction with Infectious Diseases Consult in Reducing the 30-day Mortality of Patients with *Staphylococcus aureus* Bacteremia in a Single Academic Medical Center.
- 1582 Impact of an Unsolicited, Simple Standardized Form Based Antimicrobial Stewardship Intervention to Improve Guideline Adherence in the Management of *Staphylococcus aureus* Bacteremia
- 1583 Impact of an antimicrobial stewardship bundle of rapid identification of methicillin susceptibility and active intervention on treatment of *Staphylococcus aureus* bacteremia
- 1584 Use of Diagnosis Related Group-Based Days of Therapy to Evaluate Fluoroquinolone Use Optimization Across a Large Healthcare System
- 1585 Impact of an Emergency Medicine Pharmacist on Appropriate Empiric Antibiotic Prescribing for Community-Acquired Pneumonia and Intra-Abdominal Infections
- 1586 Is More *Always* Better? Effect of a Combination *Pseudomonas* Antibigram on Levofloxacin Use and Patient Outcomes for Pneumonia in a Large Community Hospital
- 1587 Adherence to institutional guidelines for community and nosocomial pneumonia and its impact on in-hospital mortality and 30-day readmission in a community health system
- 1588 De-escalation of Broad Spectrum Antibiotics Following Negative Cultures in Pneumonia: Rates and Outcomes
- 1589 Evaluation of the Empiric use of Levofloxacin in Combination with Antipseudomonal Beta-Lactams for the Treatment of Pneumonia
- 1590 Potential Impact of the DRIP Score on Antibiotic Use: a Retrospective Single-Center Study
- 1591 Impact of Antimicrobial Stewardship Program Guidance on the Management of Community-Acquired Pneumonia in Hospitalized Adults

169. Poster Abstract Session

Stewardship: Pediatric Antimicrobial Stewardship

Friday, 12:30 p.m. – 2:00 p.m.

- 1592 Appropriateness of Antibiotic Prescribing in U.S. Children's Hospitals: A National Point Prevalence Survey
- 1593 Recurrent Antibiotic Prescriptions in the Kentucky Medicaid Population
- 1594 Impact of Patient Diagnoses and Provider Years of Practice on Antimicrobial Stewardship Program (ASP) Activities at a Non-freestanding Children's Hospital
- 1595 Route of Administration for Highly Orally Bioavailable Antibiotics Utilizing the Electronic Health Record to Construct Syndrome-Specific Antibigrams for Previously Healthy Children
- 1597 Automated Metrics for Potential Adverse Outcomes in Pediatric Antimicrobial Stewardship
- 1598 Perceptions among Pediatric Staff Nurses on Their Role and Confidence in Performing Antimicrobial Stewardship Activities
- 1599 Cefoxitin vs piperacillin/tazobactam for acute appendicitis in pediatric patients
- 1600 *Mycoplasma pneumoniae* Macrolide Resistance in Children in Central Ohio Detected by Sequencing
- 1601 Impact of Personalized Audit and Feedback on Management of Pediatric Outpatient Community-Acquired Pneumonia

- 1602 Antibiotic Prescribing for Pediatric Community-Acquired Pneumonia at Children's Hospitals and General Hospitals Following National Guideline Release
- 1603 Diagnosis and Management of Pediatric Community Acquired Pneumonia Requiring Hospitalization: How Well Are We Following National Guidelines?
- 1604 Use of MRSA Nasal Swab to guide empiric antibiotic treatment of hospital acquired or community acquired pneumonia in a pediatric population.
- 1605 Consistent Differences between Wound Culture and Osteoarticular Infection *Staphylococcus aureus* Susceptibilities and Institutional Antibigrams at a Children's Hospital
- 1606 Adverse effects from antibiotics for acute respiratory tract infections in children: comparison of two data sources
- 1607 Impact of Multiplex Polymerase Chain Reaction Testing for Respiratory Pathogen Detection in Pediatric Patients
- 1608 Cost Analysis of an Antimicrobial Stewardship Program (ASP) Protocol for Adherence to the 2014 American Academy of Pediatrics (AAP) Palivizumab Prophylaxis Recommendations in a Freestanding Children's Hospital
- 1609 Implementation of a Pragmatic Biomarker-Driven Algorithm to Guide Antibiotic Use in the Pediatric Intensive Care Unit: the Optimizing Antibiotic Strategies in Sepsis (OASIS) II Study
- 1610 Decreasing Vancomycin Utilization in the NICU by Optimizing Treatment Decisions in Suspected Late Onset Sepsis
- 1611 Assessment of Surgical Antibiotic Prophylaxis in Pediatrics (ASAP-P)
- 1612 Short versus (vs) Prolonged Course of Therapy for Ventilator-associated Tracheitis (VAT) Caused by Non-lactose-fermenting Gram-negative Rods (NLFGNR) in the Pediatric Intensive Care Unit (PICU)
- 1613 Uncomplicated Urinary Tract Infection (UTI) in Ambulatory Primary Care Pediatrics. Are We Using Antibiotics Appropriately?
- 1614 Characteristics of Prospective Audit and Feedback in a Pediatric Cardiovascular Intensive Care Unit
- 1615 Improving Institutional Management of MSSA Infections in Children: A Quality Improvement Initiative

170. Poster Abstract Session

Stewardship: Targets for Intervention

Friday, 12:30 p.m. – 2:00 p.m.

- 1616 Antimicrobial Prescribing Rates Comparing On-Site Visits with Two Types of Virtual Care Visits Across a Large Integrated Healthcare System
- 1617 Age-specific Distribution of Antimicrobial Use Surveillance using National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB Japan) 2011–2013
- 1618 Variation in Antibiotic Prescribing among Emergency Departments, Urgent Care Centers, and Retail Health Clinics in the United States, 2014
- 1619 Pharmacoepidemiology of Antibiotic Prescribing Among 135,000 Adult Outpatient Encounters in Northeast Ohio
- 1620 Outpatient Antibiotic Prescribing Among Older Adults in the United States, 2011 to 2014
- 1621 Evaluating the Impact of Long-Term Outpatient Ertapenem (ETP) versus Ceftriaxone (CTX) on Clinical Success and Development of Resistance for Documented *Enterobacteriaceae* Infections
- 1622 Evaluation of discharge antibiotic prescribing at a freestanding children's hospital: Opportunities for Stewardship
- 1623 Antibiotic Utilization and Antimicrobial Stewardship in Community Hospitals
- 1624 Assessing Appropriateness of Antimicrobial Treatment in Hospitalized Patients; A Point Prevalence Study
- 1625 A Multicenter Study to Optimize Carbapenem Use
- 1626 The Management of Outpatient Cellulitis at The Moncton Hospital before and after the Initiation of a Clinical Treatment Pathway
- 1627 The Impact of Respiratory Viral Testing in Hospitalized Adult Patients at a Tertiary Care Facility
- 1628 Epidemiology of Polymyxin use in a tertiary care setting of South India
- 1629 Impact of Asymptomatic Bacteriuria (ASBU) Overtreatment During a Controlled Trial of Antimicrobial Stewardship (AS).

- 1630** Correlation between Tennessee Antibiotic Use Point Prevalence Survey and NHSN AUR Module in four acute care hospitals
- 1631** Validation of NHSN Annual Hospital Survey questions: Do responses differ depending on the professional completing the survey?
- 1632** Map The Gap: Mapping The Spread Of Antimicrobial Stewardship Programs With The Infectious Diseases Workforce.
- 1633** Visual Analytic Tools for Automated Measurement and Tracking of Durations of Therapy for Pneumonia, Urinary Tract Infections, and Skin and Soft Tissue Infections
- 1634** Exploring Visual Analytic Tools for Antimicrobial Stewardship Intervention across 8 Veterans Affairs Hospitals
- 1635** Changes in Broad-Spectrum Antibiotic Use Following Implementation of the CMS Sepsis (SEP-1) Measure in Select Locations Reporting to NHSN's Antibiotic Use Option
- 1636** Meropenem Extended Infusion (EI) versus (vs) Standard Infusion (SI) in Critically ill Patients: Evaluation of Outcomes
- 1637** St John Sepsis Alert Correlation with Management of Infections and Antimicrobial Selection: A Pilot Study
- 1638** Encephalopathy in the Setting of Cefepime Use – Incidence and the Complexities in Assessing Etiology

171. Poster Abstract Session Vaccine Hesitancy Friday, 12:30 p.m. – 2:00 p.m.

- 1639** Personal Values as Mediators of Receipt of Non-influenza Childhood Vaccines
- 1640** Childcare Situations and Parental Immunization Decisions for Young Children
- 1641** Public health and economic consequences of vaccine hesitancy for measles in the United States
- 1642** Vaccine Refusal Among Pregnant Women: A National Survey of Obstetrician-Gynecologists

172. Poster Abstract Session Vaccine Strategy and Policy Friday, 12:30 p.m. – 2:00 p.m.

- 1643** Immunizing Patients with Adverse Events Following Immunization in the Canadian Special Immunization Clinic Network (2015–2017)
- 1644** Household Contact Immunizations: A Feasible Method to Increase 'Cocoon' Protection in the Pediatric Population
- 1645** Adherence to Vaccination Guidelines in Patients Awaiting Kidney or Kidney-Pancreas Transplant
- 1646** A Collaborative Program Using Student Pharmacists to Increase Adult Vaccination Rates for the At Risk Patient Population Attending Urgent Care Clinics
- 1647** Implementation of Multi-Modal Intervention to Increase Adult Vaccination Rates in a Large Integrated Healthcare System
- 1648** Impact of Palivizumab Guideline Revision on the Incidence of RSV in Children residing in Pediatric Long-term Care Facilities
- 1649** Knowledge, Attitude And Practice Survey Regarding Pertussis Vaccination Among Transplant Health Care Workers.
- 1650** Development of a Vaccine Confidence Index for Monitoring and Assessing Parental Confidence in Childhood Vaccination
- 1651** Adherence to Multi-Dose Hepatitis A and Hepatitis B Vaccine Schedules in the United States

173. Poster Abstract Session Viral Treatment and Prevention Friday, 12:30 p.m. – 2:00 p.m.

- 1652** CHIKUNGUNYA: A Mortality Report
- 1653** Cost Analysis of Ganciclovir (GCV) and Foscarnet (FOS) in Recipients of Allogeneic Hematopoietic Cell Transplant (aHCT) with Cytomegalovirus (CMV) Viremia

- 1654** Correlation between Cytomegalovirus (CMV) Breakthrough in High Risk Solid Organ Transplant Recipient and Valganciclovir Dose Modification
- 1655** Significant Neutralizing Antibody and Cytolytic T Cell Responses to GEN-003, a Herpes Simplex Virus Immunotherapy, in a Phase 2b Study
- 1656** A Phase 2a Study to Evaluate the Safety of MEDI8852 in Outpatient Adults with Acute, Uncomplicated Influenza A
- 1657** Single Dose IV Peramivir Treatment in Pediatric Influenza: Lack of Development of Influenza Virus Variants with Reduced Susceptibility to Peramivir
- 1658** 2016–2017 Seasonal Influenza Vaccine Availability at Urgent Care Centers in the state of Arizona, USA
- 1659** Intranasal administration of Integrase Defective lentiviral vectors expressing mAbs protects from H5 influenza virus challenge *in vivo*.
- 1660** Antiviral Activity of Peptide Nucleic Acid against Human Parechovirus Type 3
- 1661** Preventing Respiratory Viruses in the Neonatal ICU
- 1662** Use of Oral Ribavirin for the Treatment of RSV Infections in Hematopoietic Cell Transplant (HCT) Recipients

231. Poster Abstract Session Clinical Study with New Antibiotics and Antifungals Saturday, 12:30 p.m. – 2:00 p.m.

- 1829** Pharmacokinetics (PK) of Eravacycline in Subjects with Renal or Hepatic Impairment Compared to Healthy Subjects
- 1830** Phenotypic Antibiotic Resistance in ZEUS: A Multi-center, Randomized, Double-Blind Phase 2/3 Study of ZTI-01 versus Piperacillin-Tazobactam (P-T) in the Treatment of Patients with Complicated Urinary Tract Infections (cUTI) including Acute Pyelonephritis (AP)
- 1831** Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol in Subjects Without Infection and Patients With Complicated Urinary Tract Infection and Acute Uncomplicated Pyelonephritis
- 1832** Impact of Meal Timing on Eravacycline Exposure During the Oral Portion of an IV to Oral Transition Dosing Regimen
- 1833** Per Pathogen Outcomes from the ZEUS study, a Multi-center, Randomized, Double-Blind Phase 2/3 Study of ZTI-01 (fosfomycin for injection) versus Piperacillin-Tazobactam (P-T) in the Treatment of Patients with Complicated Urinary Tract Infections (cUTI) including Acute Pyelonephritis (AP)
- 1834** Efficacy and Safety of Omadacycline in Chronic Kidney Disease (CKD) Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI): A Subgroup Analysis from the OASIS Trial
- 1835** Meropenem-Vaborbactam Pharmacokinetics in Subjects with Chronic Renal Impairment, Including Hemodialysis
- 1836** Safety and Pharmacokinetics (PK) in Humans of Intravenous ETX2514, a β -lactamase Inhibitor (BLI) which Broadly Inhibits Ambler Class A, C, and D β -lactamases.
- 1837** Safety Results from the ZEUS Study: Multi-center, Randomized, Double-Blind Phase 2/3 Study in Hospitalized Adults with Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP) who Received Intravenous Fosfomycin (ZTI-01)
- 1838** Efficacy and Safety of Omadacycline in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and High Body Mass Index or Type 2 Diabetes: A Subgroup Analysis from the OASIS Trial
- 1839** A Phase 1 Study to Assess the Pharmacokinetics of Sulopenem Etzadroxil (PF-03709270)
- 1840** First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
- 1841** A Phase 1 Study in Healthy Subjects to Investigate Safety, Pharmacokinetics, and Effect on Intestinal Flora of Multiple Ascending Doses of DS-2969b, A Novel Oral DNA Gyrase B Inhibitor for The Treatment of *Clostridium difficile* Infection
- 1842** Preservation of gut microbiome following ridinilazole versus fidaxomicin treatment of *Clostridium difficile* infection

- 1843** SYN-004 (ribaxamase) Protects the Diversity of the Gut Microbiome in Patients Receiving Intravenous Ceftriaxone Treatment
- 1844** Prevention of Lung Pathology and Mortality in Rabbit *Staphylococcus aureus* Pneumonia with Cytotoxin-Neutralizing Monoclonal IgGs that Penetrate Epithelial Lining Fluid
- 1845** Intravenous Fosfomycin (ZTI-01) for the Treatment of Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP): Results from a Multi-center, Randomized, Double-Blind Phase 2/3 Study in Hospitalized Adults (ZEUS)
- 1846** Ceftolozane/Tazobactam Dose Evaluation for Pediatric Subjects with Complicated Intra-Abdominal Infection and Complicated Urinary Tract Infection
- 1847** Phase I Study To Evaluate The Pharmacokinetics Of Two Dosing Regimens Of Oral Fosfomycin Tromethamine In Healthy Adult Participants
- 1848** Population Pharmacokinetic (PPK) Analysis of ZTI-01 (Fosfomycin for Injection) Using Data from Healthy Subjects and Patients with Complicated Urinary Tract Infections (cUTI)
- 1849** Population Pharmacokinetic Model for Intravenous ASN100 in Healthy Subjects
- 1850** A Pharmacometric Comparison of Omadacycline and Tigecycline Epithelial Lining Fluid (ELF) Penetration
- 1851** Population Pharmacokinetic (PPK) and Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Support Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- 1852** Meropenem-Vaborbactam Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses as Support for Dose Selection in Patients with Normal Renal Function and Varying Degrees of Renal Impairment
- 1853** Improved Outcomes with Plazomicin (PLZ) Compared with Colistin (CST) in Patients with Bloodstream Infections (BSI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE): Results from the CARE Study
- 1854** Impact of Delafloxacin (DLX) and Vancomycin/Aztreonam (VAN/AZ) on Resolution of Signs and Symptoms of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- 1855** Plazomicin Versus Meropenem for Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP): Diagnosis-specific Results From the Phase 3 EPIC Study
- 1856** Outcomes with IV/oral Delafloxacin (DLX) Compared to Vancomycin/Aztreonam (VAN/AZ) in Treatment of Patients (pts) with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Gram-negative (GN) Pathogens
- 1857** Outcomes with IV/oral Delafloxacin (DLX) Compared to Vancomycin/Aztreonam (VAN/AZ) in Treatment of Patients (pts) with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Gram-positive (GP) Pathogens
- 1858** Comparison of Safety Profile of Delafloxacin (DLX) versus Vancomycin/Aztreonam (VAN/AZ) in the Treatment of Patients (Pts) with Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Integrated Safety Findings from Two Phase III Studies
- 1859** Improved Outcomes at Late Follow-up (LFU) with Plazomicin Compared with Meropenem in Patients with Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) in the EPIC Study
- 1860** Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability
- 1861** Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Preliminary results from the Telavancin Observational Use Registry (TOUR™)
- 1862** Clinical Outcomes of Serious Infections due to Carbapenem-Resistant Enterobacteriaceae (CRE) in TANGO II, a Phase 3, Randomized, Multi-National, Open-Label Trial of Meropenem-Vaborbactam (M-V) Versus Best Available Therapy (BAT)
- 1863** RBX2660 is Safe, Superior to Antibiotic-Treated Controls for Preventing Recurrent *Clostridium difficile*, and May Rehabilitate Patient Microbiomes: Open Label Trial Results
- 1864** Phase 3, randomized, double-blind noninferiority (NI) study of ceftazidime-avibactam (CAZ-AVI) versus meropenem (MER) in the treatment of patients with Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP): Analyses of the REPROVE study per US FDA Endpoints
- 1865** A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens (REVIVE-1)
- 1866** Meropenem-Vaborbactam vs. Piperacillin-Tazobactam in TANGO I (a Phase 3 Randomized, Double-blind Trial): Outcomes by Baseline MIC in Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis
- 1867** Meropenem-Vaborbactam vs. Best Available Therapy for Carbapenem-Resistant Enterobacteriaceae Infections in TANGO II: Primary Outcomes by Site of Infection
- 1868** Meropenem-Vaborbactam vs. Best Available Therapy for Carbapenem-Resistant Enterobacteriaceae Infections in TANGO II: Outcomes in Immunocompromised Patients
- 1869** Clinical Response of Cefiderocol Compared with Imipenem/Cilastatin in the Treatment of Adults with Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis: Results from a Multicenter, Double-blind, Randomized Study (APEKS-cUTI)
- 1870** Microbiome Profile is Distinct in Patients with Successful Response to Microbiota-Based Drug RBX2660 Relative to Placebo Responders
- 1871** Micafungin versus Posaconazole Prophylaxis in Patients with Acute Leukemia or Myelodysplastic Syndrome: A Randomized, Open-label Study
- 1872** Immunogenicity of a 2+1 Infant Vaccination Series with 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by Pneumococcal Non-Typeable *Haemophilus influenzae* Protein D Conjugate Vaccine (PHiD-CV): a Randomized Trial Exploring Interchangeability of PCVs
- 1873** Sub-group Analyses from the EXTEND Study: a Randomised, Controlled, Open-Label, Phase III/IV Study Comparing the Efficacy of Extended-Pulsed Fidaxomicin with Standard Vancomycin Therapy for Sustained Clinical Cure of *Clostridium difficile* Infection in an Older Population
- 1874** Assessment of MIC Increases with Meropenem-Vaborbactam and Ceftazidime-Avibactam in TANGO II (a Phase 3 Study of the Treatment of CRE Infections)
- 1875** Analysis of the Microbiological data from the Omadacycline (OMC) Phase 3 Community-Acquired Bacterial Pneumoniae (CABP) trial: The OPTIC study
- 1876** Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) with Dalbavancin in Patients with Systemic Inflammatory Response Syndrome (SIRS)
- 1877** Analysis of CAMERA-1 *S. aureus* Bacteremia Trial Results using the DOOR
- 1878** The Impact of Tigecycline on Fibrinogen Level post Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Patients. A Randomized Controlled Study
- 1879** Meropenem-Vaborbactam: Outcomes in Subjects with Renal Impairment in Phase 3 Studies TANGO I and II
- 1880** Phase I Study To Evaluate The Safety And Tolerability Of Two Dosing Regimens Of Oral Fosfomycin Tromethamine In Healthy Adult Participants
- 1881** Fosfomycin trometamol is noninferior to trimethoprim-sulfamethoxazole for acute uncomplicated cystitis in women
- 1882** Pharmacokinetics (PK)/Pharmacodynamics (PD) and Safety of 3 g Ceftolozane/Tazobactam (TOL/TAZ) in Ventilated, Critically-Ill Patients
- 1883** A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Subjects with CABP (The OPTIC Study).
- 1884** Ceftaroline Fosamil (CPT) versus Vancomycin (VAN) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- 1885** Efficacy and Safety of Omadacycline in Intravenous Drug Using (IVDU) and Hepatitis C-Positive (HCV+) Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI): A Subgroup Analysis from the OASIS Trial
- 1886** Cardiac Safety of Omadacycline in the IV/oral Phase 3 Acute Bacterial Skin and Skin Structure Infection (ABSSSI) and in the IV/oral Phase 3 Community-acquired Bacterial Pneumonia (CABP) Studies

- 1887** Evaluation of Efficacy, Safety, and Sustained Clinical Response of Oritavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in a Hospital-Owned Infusion Clinic
- 1888** Outcomes of Ceftaroline Fosamil q8h vs q12h Dosing Frequency for High-Burden, Gram-positive Infections

232. Poster Abstract Session

Clinical: Bacteremia and Endocarditis

Saturday, 12:30 p.m. – 2:00 p.m.

- 1889** Twenty-One Years of *Staphylococcus aureus* Bacteremia (SAB): Variations in Bacterial Genotype and Clinical Phenotype in the *S. aureus* Bacteremia Group Prospective Cohort Study (SABG-PCS) from 1995 to 2015
- 1890** A Prospective Study of Enterococcal Bacteremia in Cancer vs. Non-Cancer Populations: One Disease, Two Tales
- 1891** Blood Stream Infection in LVAD Recipients: More than Meets the Eye
- 1892** Utility of ¹⁸F-FDG PET/CT in Evaluation of *Staphylococcus aureus* Bacteremia
- 1893** Utility of Prior Cultures in Predicting Antibiotic Resistance of Bloodstream Infections Due to Gram-negative Pathogens
- 1894** Clinical and Economic Comparison of Ceftaroline Fosamil (CPT) and Daptomycin (DAP) for Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bloodstream Infections (BSI)
- 1895** Clinical characteristics of *Bacillus cereus* bloodstream infection in a tertiary care hospital in Japan: the rate of true bloodstream infections and mortality are much higher than previously reported
- 1896** *Escherichia coli* Bacteremia Trends over Five Years: Progressively Rising Incidence and Decreasing Antibiotic Resistance
- 1897** Predictors and Clinical Implications of Bloodstream Infections in Continuous Flow Left Ventricular Assist Device Recipients: A Single Institutional Experience of 212 Patients
- 1899** Decreasing Numbers of Blood Cultures: Does it Matter?
- 1898** Development and Validation of a Risk Prediction Score For Enterococcal Endocarditis
- 1900** Sequence type 393 associated with increased mortality in *Escherichia coli* bloodstream infections
- 1901** Sensitivity and Specificity of Duke Criteria for Diagnosis of Definite Infective Endocarditis: A Cohort Study
- 1902** Colonic Lesions in Patients with Enterococcal Endocarditis
- 1903** Infective Endocarditis in a Tertiary-Center in Jerusalem, an 8-Year Prospective Survey: Effects of Surgery on Mortality
- 1904** Trends in rates of Gram-negative Bloodstream Infections (BSI) and Fluoroquinolone (FQ) resistance in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients at Memorial Sloan Kettering Cancer Center (MSK) during 2012–2016
- 1905** *Escherichia coli* ST131 is Associated With Increased Mortality In Bloodstream Infections From Urinary Tract Source
- 1906** Recurrent Enterococcal Bloodstream Infection in Patients with Acute Leukemia
- 1907** Clinical characteristics of invasive disease caused by a rare Group A *Streptococcus* subtype (*emm*26.3) — Alaska, 2016–2017
- 1908** Clinical Practice Variation in the Management of *Staphylococcus aureus* Bacteremia: Results from an Emerging Infections Network Survey
- 1909** Sero-Epidemiology of Nursing Home Associated Invasive Pneumococcal Disease After Implementation of a Routine Pediatric PCV13 Program in Ontario, Canada.
- 1910** Clinical Outcomes of Patients with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bacteremia Treated with Vancomycin at an Institution with Suppressed Minimum Inhibitory Concentration (MIC) Reporting: Impact of Vancomycin MIC
- 1911** Actinomyces in Blood: Is it Clinically Significant or Insignificant?
- 1912** Long-term Impacts of Infectious Diseases Consultation on Post-Discharge Outcomes for Patients with *Staphylococcus aureus* Bacteremia: a Cohort Analysis in Veterans Health Administration
- 1913** Epidemiologic Evaluation of Rothia Bacteremia-A Single Cancer Center Three Year Experience
- 1914** Reduced Mortality with Early Infectious Disease Consultation in Patients with AmpC Gram Negative Bacteremia
- 1915** A Simplified Pitt Bacteremia Score (qPitt) to Predict Mortality in Patients with Gram-Negative Bloodstream Infection
- 1916** *Clostridium ramosum* (*C. ramosum*) Bacteremia: Single Center Study
- 1917** Clinical Outcomes of Patients Receiving Fluoroquinolones to Treat Bacteremia Caused by Enterobacteriaceae Isolates Considered Intermediate or Resistant to These Agents According to the Recently Revised Susceptibility Testing Standards by the Clinical and Laboratory Standards Institute (CLSI).
- 1918** Comparative Efficacy of Oral Fluoroquinolones and Beta-lactams as Stepdown Therapy for Enterobacteriaceae Bloodstream Infection
- 1919** Evaluating Adherence to National Guidelines and Clinical Outcomes in *Staphylococcus aureus* Bacteremia
- 1920** Prosthetic Valve Endocarditis
- 1921** Outcome Based Study of Carbapenem Use Relative to ESBLs (OBSCURE)
- 1922** *Staphylococcus aureus* Bacteremia (SAB) Management in a Large Metropolitan Integrated Health Region: Quality of Care Determinants (QoCD)
- 1923** Clinical Outcomes with Penicillin Versus Alternative Beta-Lactams in the Treatment of Penicillin-Susceptible *Staphylococcus aureus* Bacteremia
- 1924** A Multicenter Evaluation of Cardiovascular Implantable Electronic Device (CIED) Infection Management
- 1925** *Staphylococcus aureus* Bacteremia in a Secondary Level Spanish Hospital: Clinical implications of Vancomycin MIC ≥ 2 Isolates.
- 1926** Clinical Presentation of Infective Endocarditis in the Early 21st Century: A Descriptive Study
- 1927** Clinical characteristics of *Streptococcus pyogenes*, *Streptococcus agalactiae* and *Streptococcus dysgalactiae* subsp. *equisimilis* bacteremia in adults: A 15-year retrospective study at a major teaching hospital in Okinawa, Japan
- 1928** Penicillin Resistant Erysipelothrix Septicemia Case Report with Review of the Literature
- 1929** Changes of clinical manifestations of *Sphingomonas paucimobilis* bacteremia
- 1930** Prevalence and Factors associated with Mortality Rate in Infective Endocarditis: a 10 Year Experience at a University Hospital, Thailand
- 1931** Management and Outcomes of Cardiovascular Implantable Electronic Device Infections due to Gram-Negative Bacteria
- 1932** Risk Factors for Mortality in Patients with *Aeromonas* Bacteremia
- 1933** Extra-intestinal Pathogenic *Escherichia coli* Bloodstream Infections (BSIs) in 2016: Antibiotic Susceptibility Patterns in Calgary, Alberta, Canada
- 1934** Evaluation of a Prolonged β -Lactam Antibiotic Infusion Policy on Clinical Outcomes in Patients with *Pseudomonas aeruginosa* Bacteremia
- 1935** Is the prognosis of septic shock different in case of malignancies?
- 1936** Sources and Microbiology of Bloodstream Infections Among Left Ventricular Assist Device Recipients
- 1937** The Importance of an Infectious Disease Consult in Management of *Staphylococcus aureus* Bacteremia
- 1938** Adherence to Quality of Care Indicators in the Management of *Staphylococcus aureus* Bacteremia
- 1939** Resurgence of Methicillin Susceptible (MSSA) *Staphylococcus aureus* (SA) in Bacteremia.
- 1940** Infective Endocarditis: What Does the Surgical Specimen Teach us? A Real Life Experience
- 1941** Outcomes after exclusive medical treatment for prosthetic valve endocarditis
- 1942** Polymicrobial Bloodstream Infections due to Intra-Abdominal Infections: A Retrospective Analysis of 158 Cases at a Tertiary Care Hospital in Japan
- 1943** *Staphylococcus aureus* Bacteremia due to Central Venous Catheter Infection: A Clinical Comparison of Infections Caused by Methicillin-Resistant and Methicillin-Susceptible Strains.
- 1944** The Prevalence of Extended-Spectrum β -lactamase (ESBL) – And Carbapenem-Resistant Enterobacteriaceae (CRE) Isolates in Positive Blood Cultures of Patients in A Teaching Hospital in Kuwait Over A 2-year Period
- 1945** Invasive *Staphylococcus Epidermidis* Isolates are Highly Clonal and Distinct from Commensal Strains: Time for a New Paradigm in Infection Control?

- 1946 Infective Endocarditis due to Nutritionally Variant Streptococci (*Granulicatella* and *Abiotrophia*): The Cleveland Clinic Experience
- 1947 Long-Term Prognosis of Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bacteremia at a Tertiary Care Hospital in the United States (US)
- 1948 Role of Adjunctive Clindamycin in β Beta-lactam-treated Cases of Invasive Group A Streptococcal Bacteremia: A Propensity score-matched analysis from 134 US hospitals
- 1949 Polymyxin Monotherapy versus Combination Therapy for the Treatment of Carbapenem-Resistant *Enterobacteriaceae* Bloodstream Infection: A National Cohort Study

233. Poster Abstract Session

Clinical: Respiratory Track

Saturday, 12:30 p.m. – 2:00 p.m.

- 1950 Health Outcomes Associated with Mild versus Moderate-to-Severe Laboratory-Confirmed Influenza in 6- to 35-month-old Children
- 1951 Pediatric *Bordetella parapertussis* Emergence in the Era of Acellular Pertussis Vaccine
- 1952 RSV disease burden among children under two years of age in the United States
- 1953 Respiratory Syncytial Virus (RSV) Hospitalizations of US Preterm Infants Born at 29-35 Weeks Gestational Age: Proportions by Chronologic Age and Birth Month
- 1954 High Mortality Associated with Parainfluenza Virus Infection in Hospitalized Adults
- 1955 Decrease in PCV13 Serotypes in Adults Hospitalized with Pneumococcal Pneumonia Over Time: Evidence of Herd Immunity Effects from Childhood Vaccination
- 1956 Antimicrobial De-escalation Rates following Positive Cultures in Pneumonia
- 1957 Neighborhood-Level Poverty, Poverty-Associated Factors, and Severe Outcomes among Adults Hospitalized with Influenza—United States, 2012–2015
- 1958 Provider Compliance with Rapid Influenza Detection Testing Guidelines During the 2016–17 Influenza A Season
- 1959 Rhinovirus Detection in Children Hospitalized with Acute Respiratory Illness and Asymptomatic Outpatients
- 1960 RSV Epidemiology and Clinical Outcomes in Adults ≥ 60 Years of Age Seeking Outpatient Care for Respiratory Illness
- 1961 Epidemiological Monitoring and Antibiotic Therapies of Macrolide-Resistant *Mycoplasma pneumoniae* in Chinese Patients With Community-Acquired Pneumonia: A Prospective Multicenter Surveillance Study
- 1962 Treatment and Outcomes of Extensively Drug-resistant *Pseudomonas aeruginosa* Nosocomial Pneumonia
- 1963 Adults Hospitalized with Pneumonia in the United States: Incidence, Epidemiology & Mortality
- 1964 Predicting Risk of Drug-Resistant Pathogens in Patients with Pneumonia
- 1965 *Streptococcus pneumoniae* as a Cause of Community-Acquired Pneumonia: Changes Over the Past 100 Years
- 1966 Evaluating Symptom Severity of Influenza Viral Infection Using the Influenza Patient-reported Outcomes Instrument (FLU-PRO) in a Healthy Human Challenge Model
- 1967 Predictors of Clinical Respiratory Virus Testing Among Adults Hospitalized with Acute Respiratory Illness (ARI) (2015–16)
- 1968 A Cross-Sectional Surveillance Study of Acute Respiratory Illness (ARI) in Pregnant Women
- 1969 Burden of Community-Acquired Pneumonia due to PCV-13 *Streptococcus pneumoniae* Serotypes Among Hospitalized Adults in the United States
- 1970 Frailty Hinders Recovery From Acute Respiratory Illness in Older Adults
- 1971 Impact of Procalcitonin Guidance on Management of Adults Hospitalized with COPD Exacerbations
- 1972 Measles Morbidity and Mortality in the Developed World are Greater than the Public Perceives
- 1973 Estimating influenza vaccination status among Medicare beneficiaries: Comparison of billing claims and vaccination data obtained from medical records and self-report
- 1974 Molecular Analysis of Respiratory Syncytial Virus (RSV) F and G Proteins In the OUTSMART Surveillance Program during the 2015–16 Winter Season in the United States
- 1975 Clinical characteristics and outcomes of severe *Klebsiella pneumoniae* pneumonia patients admitted to intensive care unit compared with those of severe *Streptococcus pneumoniae* pneumonia patients: A prospective cohort study
- 1976 Acute Hospitalizations for Pneumonia in Adults in the United States in 2014
- 1977 Assessment of a Healthcare-Associated Pneumonia (HCAP) Risk Stratification and Empiric Treatment Guideline: A New Antimicrobial Stewardship Initiative
- 1978 Long-term respiratory complication in patients with Middle East Respiratory Syndrome: One year follow-up after the 2015 outbreak in South Korea
- 1979 Impact of timing of diagnosis of respiratory syncytial virus (RSV) disease on hospital length of stay (LOS) in adults: final analysis from a retrospective chart review study
- 1980 Evaluation of Antibiotic Prescribing for Acute Respiratory Tract Infections in the Ambulatory Care Setting
- 1981 Microbiological and clinical significance of prior hospitalization in patients admitted with community-onset pneumonia: a propensity score matching study
- 1982 Parainfluenza Virus in Hospitalized Adults: A Seven-Year Retrospective Study
- 1983 Retrospective Cohort Study of the Efficacy of Azithromycin Versus Doxycycline as Part of Combination Therapy in Non-Intensive Care Unit Veterans Hospitalized with Community-Acquired Pneumonia
- 1984 Co-circulation of Rhinovirus A and C during the EV-D68 Epidemic Period
- 1985 Epidemiology and Outcomes of Mild-Moderate Immunosuppressed (MMI) Patients with Pneumonia
- 1986 Incidence and Organism Specific Mortality Associated with Healthcare Associated Pneumonia Over a Six Year Period
- 1987 Evaluation of the Duration of Antimicrobial Therapy for Community-Acquired Pneumonia at a Large Academic Medical Center
- 1988 Impact of Appropriate Empiric Antibiotic Therapy on Outcomes in Patients with Pneumonia and Positive Blood versus Respiratory Cultures
- 1989 Characteristics of Patients Clinically Diagnosed with Respiratory Syncytial Virus Infection in the United States: a Retrospective Database Analysis.
- 1990 A Novel Ordinal Endpoint is Proposed to Evaluate Clinical Status Over Time in Hospitalized Patients with Influenza
- 1991 Etiology of Community-Acquired Pneumonia and Antibiotic Susceptibility in Hospitalized Patients 50 Years Old and above in a Tertiary Care Hospital in Mexico City: 2010–2016.
- 1992 Clinical Outcomes of Hospital-Acquired and Healthcare-Associated Pneumonia with and without Empiric Vancomycin in a Non-critically Ill Population
- 1993 Ceftaroline Fosamil for the Treatment of Intensive Care Unit Patients With Pneumonia: CAPTURE Study Experience
- 1994 Assessment of Patient Specific Characteristics Influencing Antibiotic Prescribing in the Emergency Department among Patients with Positive Respiratory Viruses Multiplex Polymerase Chain Reaction (PCR) Results
- 1995 Severe Influenza; Greece 2016–2017: Vaccine Failures in Type A Influenza and Risk Factors for Poor Outcome
- 1996 Epidemiologic Risk, Influenza Subtype, Clinical Severity and Viral Shedding as a Function of Baseline Influenza A Viral Load
- 1997 Evaluation of the Use of a Respiratory PCR Panel for De-Escalating Atypical Antibiotic Coverage
- 1998 Incidence and Predictors of Fluoroquinolone-Associated Adverse Tendon Events among Veterans Affairs Patients with Community Acquired Bacterial Pneumonia
- 1999 *Mycoplasma pneumoniae* spread, persistence and resistance. Lessons from a single urban area
- 2000 Clinical and laboratory findings between Legionella and Non-Legionella pneumonia in a Veteran population
- 2001 Etiology and clinical characteristics of influenza-like illness in healthy adults by hospitalization status
- 2002 High prevalence of macrolide resistant *Mycoplasma pneumoniae* among middle age pneumonia in Japan.
- 2003 Non-ventilator hospital-acquired versus pneumonia on admission in patients who develop sepsis: Incidence and cost

- 2004** Antibiotic Treatment of Community-Acquired Pneumonia in Hospitalized Patients in Argentina (2010–2015)
- 2005** Effect of *Stenotrophomonas maltophilia* Treatment on Pulmonary Function in Pediatric Patients
- 2006** Prevalence of *Streptococcus dysgalactiae* and Microbial Codetection in Patients Presenting with Pharyngitis
- 2007** Risk Predictive Markers for Severe Community-Acquired Pneumonia in Hospitalized Elderly Patients
- 2008** Characteristics of Pleural Effusion and Role of Computed Tomography (CT) Attenuation values (Hounsfield units) in Differentiating Pleural Fluid transudate, exudate and empyema.
- 2009** Impact of a Negative Procalcitonin Level on Antibiotic Usage and 30 Day Readmission Rates in a Community-Based Teaching Hospital.
- 2010** Poor Quality Non-Bronchoscopic Bronchoalveolar Lavage Specimens Lead to Inappropriate Diagnosis and Treatment of Ventilator-Associated Pneumonia
- 2011** Smoking and Opportunistic Infections Contribute to High Rates of Respiratory Symptoms Among HIV-Infected Smokers

- 2031** Prospective Evaluation of Accelerate Pheno™ System (AXDX) Version 1.1 for Reducing Turn-Around-Time (TAT) in Identification/Antimicrobial Susceptibility Testing (ID/AST) of Gram-Negative Bacilli (GNB) from Positive Blood Cultures (+BC) using AXDX PhenoTest™ BC Kits
- 2032** Clinical Impact of Rapid Identification (ID) and Phenotypic Antimicrobial Susceptibility Testing (AST) by Accelerate Pheno™ System (AXDX) for Gram-negative (GNB) Bloodstream Infections
- 2033** Evaluation of the FilmArray Meningitis/Encephalitis Molecular Panel in a Tertiary Care Public County Hospital
- 2034** Colistin Susceptibility Testing of *Enterobacteriaceae* by Agar Dilution (AD), Broth Microdilution (BMD) and Polymyxin NP
- 2035** Significant Reduction of Blood Culture Contamination in the Emergency Department (ED) Using the Steripath® Blood Diversion Device
- 2036** Combined Bacterial Identification and Antimicrobial Susceptibility Testing Directly from Whole Blood
- 2037** Polymyxin B Etest Fails to Distinguish Carbapenem-resistant *Enterobacteriaceae* with Elevated Polymyxin B MICs
- 2038** Retrospective Evaluation of Accelerate Pheno™ System (AXDX, Version 1.1) for Identification/Antimicrobial Susceptibility Testing (ID/AST) of Gram-Negative Bacilli (GNB) including Carbapenemase-Producing Organisms (CPO) from Seeded Blood Culture Bottles (SBCB) Tested using AXDX PhenoTest™ BC Kits
- 2039** Direct-On-Target Microdroplet Growth Assay for Rapid Detection of Carbapenem Resistance in *Pseudomonas aeruginosa* using MALDI-TOF Mass Spectrometry
- 2040** Analytical Performance Characteristics of the Accelerate Pheno™ System for Pathogen Identification and Susceptibility Testing for Gram-negative Bacteremia and Candidemia
- 2041** The Effect of Clinical Concentrations of Meropenem (MEM), Ceftolozane/tazobactam (C/T), and Ceftazidime/avibactam (CZA) on Time to Detection (TTD) and Growth of *Pseudomonas aeruginosa* (PSA) in bioMerieux BacT/ALERT®FA Plus Blood Culture (BC) Bottles
- 2042** Molecular Epidemiology of β -lactamase Production in Penicillin-susceptible *Staphylococcus aureus* under High-susceptibility Conditions
- 2043** Rapid and Specific Detection of *Escherichia coli* Sequence Type 131 (ST131) and its Key Subclones Using a Novel Single-tube Multiplex PCR Assay
- 2044** Epidemiological and Molecular Characteristics of Carbapenemase-Producing *Enterobacteriaceae* in a Tertiary Hospital in Korea: Possible Emergence of KPC-Producing *Escherichia coli* ST471 strain
- 2045** Molecular serotype specific identification of *Haemophilus influenzae* using the loop-mediated isothermal amplification method.
- 2046** Bacterial Identification using 16S rRNA Gene Sequencing in a University Teaching Hospital
- 2047** Descriptive Analysis of Cases with Suspected Infections that Used 16S ribosomal RNA PCR Testing
- 2048** Comparative Phylogenomic Analysis of *Escherichia coli* ST131 Isolates and IncF-type Plasmids from North Carolina Community Hospitals and Other Regions of the United States
- 2049** Comparison of the Sepsis-2 and Sepsis-3 Definitions of Sepsis and Their Ability to Predict Mortality in a Prospective Intensive Care Unit Cohort
- 2050** A Whole Genome Sequencing (WGS) Approach to Predict Daptomycin (DAP) Susceptibility of *Enterococcus faecium*
- 2051** Plasmid Promiscuity Explains High Endemicity of KPC-2 Among Colombian Enterobacteriaceae

234. Poster Abstract Session Diagnostics – Bacterial Identification & Resistance Saturday, 12:30 p.m. – 2:00 p.m.

- 2012** Lysis Centrifugation Method for the Direct Identification of Positive Blood Cultures Using MALDI-TOF MS
- 2013** Not So Common? Late Neuroborreliosis in a Referred Population
- 2014** Screening for Lyme Disease with C6 Peptide at a Veterans Hospital in Long Island, NY
- 2015** Hypervirulent *Klebsiella pneumoniae* liver abscess: A case series of invasive disease and complications at an academic community healthcare system in Cambridge, Massachusetts
- 2016** Lactose vs Non-Lactose Fermenting *E. coli*: Epidemiology, Clinical Outcomes, and Resistance
- 2017** Colistin Susceptibility Testing Using the MicroScan® Colistin Well
- 2018** Performance of TEM-PCR versus Culture for Bacterial Identification in Pediatric Musculoskeletal Infections
- 2019** Molecular characterization and antimicrobial susceptibility of extended-spectrum β -lactamases (ESBL) producing enterobacteriaceae (ESBLPE) causing urinary tract infections (UTI): Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010–2015, South Africa
- 2020** Multifaceted Approach to Optimize Blood Volume Inoculated into Culture Bottles in the Pediatric Intensive Care Unit
- 2021** The Development of an IMP Metallo- β -lactamase Detection Assay Using a Bioinformatic Approach
- 2022** Quantiferon conversions and reversions among HIV patients on antiretroviral therapy
- 2023** Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy for Rapid Identification of Non-Fermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis
- 2024** Aminoglycoside Susceptibility Agreement between an Automated System and Broth Microdilution for Carbapenem-resistant *Enterobacteriaceae*
- 2025** Impact of Automation Process on Microbiological Laboratory Efficiency
- 2026** Performance Verification of the Accelerate Pheno™ System for Rapid Identification and Antimicrobial Susceptibility Testing from Positive Blood Culture in a Pediatric Population
- 2027** Reproducibility of Ceftolozane/Tazobactam MIC Results for Enterobacteriaceae and *Pseudomonas aeruginosa* Using MicroScan Dried Gram Negative MIC Panels
- 2028** Reproducibility of Ceftazidime/Avibactam MIC Results for Enterobacteriaceae and *Pseudomonas aeruginosa* Using MicroScan Dried Gram Negative MIC Panels
- 2029** Evaluation of the Accelerate Pheno™ system for the identification and antimicrobial susceptibility testing of Gram-negative bacteria, compared with conventional laboratory testing.
- 2030** An Evaluation of Vitek2™ Direct Susceptibility Testing (DST) of Gram-Negative Bacteria (GNB) from Positive Blood Cultures (+BC).

235. Poster Abstract Session Diagnostics – Diarrheal Disease Saturday, 12:30 p.m. – 2:00 p.m.

- 2052** Rate of Detection of Multiple Organisms and *Clostridium difficile* with Stool Multiplex PCR Detection Test in Pediatrics
- 2053** FilmArray® Gastrointestinal (GI) Panel for viral acute gastroenteritis detection in pediatric patients
- 2054** Prevalence of Hypervirulent BI/NAP1/027 *Clostridium difficile* Strains in Cali-Colombia

- 2055** Utilization of FilmArray Gastrointestinal Panel (GIP) Results on Altering Empiric Antibiotic (ABX) Use in Patients with Acute Diarrhea
- 2056** A New Enzyme-Linked Immunosorbent Assay (ELISA) for Vi Antigen as a Potential Diagnostic for Infections by *Salmonella* Typhi
- 2057** Evolution of Testing Algorithms at a tertiary Care Hospital for the Detection of *Clostridium difficile* Infections
- 2058** *Vibrio cholerae* Detection by the FilmArray® Gastrointestinal (GI) Panel
- 2059** Comparison of Perianal Swab and Stool Samples for Detection of Gastrointestinal Colonization with Ceftriaxone-Resistant and Fluoroquinolone-Resistant Enterobacteriaceae
- 2060** Evaluation of the FilmArray Gastrointestinal Panel on Health Care Utilization in Immunocompetent Adults Presenting to the Emergency Department with Non-*Clostridium difficile* Acute Gastrointestinal Infection
- 2061** Diagnostic Utility of Interferon-gamma Release Assay in Tuberculous Lymphadenitis
- 2062** Metabolic profiling of human in-patient stools: The influence of *C. difficile* infection and recurrence.
- 2063** Fecal Host Transcriptomics for Non-invasive Mucosal Immune Profiling in Human *Clostridium difficile* Infection
- 2064** Molecular Detection of Enteropathogens from Diarrheic Stool of HIV positive Patients in Gondar, Ethiopia
- 2065** Implementation of Electronic Medical Record Hard Stop Alerts for Inappropriate *Clostridium difficile* Tests in Academic and Community Hospital Setting; Impact on Testing Rates and Clinical Outcomes

236. Poster Abstract Session

Diagnostics – Mycology

Saturday, 12:30 p.m. – 2:00 p.m.

- 2066** Utilization of the T2 Candida Panel for rapid Candida species detection in a large community hospital
- 2067** Relationship of T2Candida Panel to Disease Severity, Mortality and Time to Therapy in Patients with Candidemia
- 2068** High-volume sputum culture for the diagnosis of pulmonary aspergillosis
- 2069** Automated Detection of *Candida auris* Direct from Whole Blood by T2MR
- 2070** Contribution of the qPCR for the diagnosis of pneumocystosis
- 2071** Endocarditis Is Not Rare and Is An Independent Predictor of Mortality in Candidaemia
- 2072** Comparison of one versus two BACTEC Myco/F Lytic bottles for recovery of fungi and mycobacteria.
- 2073** Utility of Serial β -D-Glucan Levels in Patients with High Risk for Invasive Candidiasis – A Potential Tool for Antifungal Stewardship
- 2074** Frequent False Positive Bronchoalveolar Lavage Galactomannan Values in a Real World Setting
- 2075** First nine cases of *Candida auris* infection Reported in Central America: Importance of accurate diagnosis and susceptibility testing
- 2076** Low Yield of Routine Fungal Culture from Periprosthetic Joint Specimens
- 2077** Experience with β -D-Glucan Assay for Diagnosis of Invasive Candidiasis in ICU Patients: Pilot Study from India
- 2078** Clinical Utility of Broad-Range Fungal PCR
- 2079** PCR-based Diagnosis of Mucormycosis Targeting Mucorales specific Genes
- 2080** Invasive *Candidiasis* in Pediatric Patients at King Fahad Medical City in Riyadh, Saudi Arabia: A 5-year Retrospective Study
- 2081** Does a Negative Rapid Diagnostic Test for Detection of *Candida* Bloodstream Infection Lead to Less Antifungal Use?

237. Poster Abstract Session

Diagnostics – Novel Diagnostics

Saturday, 12:30 p.m. – 2:00 p.m.

- 2082** Rapid Detection of Pediatric Bacteriuria Using Narrow Angle Forward Laser Scattering Technology (NAFLST) with Bacterioscan

- 2083** Direct Detection and Quantification of Bacterial Cell-free DNA in Patients with Bloodstream Infection (BSI) Using the Karius Plasma Next Generation Sequencing (NGS) Test
- 2084** Performance of the Karius Plasma Next Generation Sequencing Test in Determining the Etiologic Diagnosis of Febrile Neutropenia: Results from a Pilot Study
- 2085** Metagenomic Analysis reveals Importance of Anaerobes in Development and Clinical Outcome of Necrotizing Soft Tissue Infections
- 2086** Evaluation of a Multiplex PCR Assay with Molecular Beacon Probes to Rapidly Detect Bacterial Pathogens Directly in Bronchial Alveolar Lavage (BAL) Samples from Patients with Hospital-Acquired Pneumonia (HAP)
- 2087** A Novel Real Time PCR Assay for the Detection of *Babesia microti* in a Highly Endemic Area Using Luminex Aries System
- 2088** A novel diagnostic method for Malaria using loop mediated isothermal amplification (LAMP) and MinION nanopore sequencer
- 2089** Accelerating Time to Pathogen-adapted Antibiotic Treatment through Culture-independent Antimicrobial Susceptibility Testing in Patients suffering from Sepsis
- 2090** T Cell Immunity Panel Measures CMV Specific CD4 and CD8 T Cell Responses
- 2091** Application of Laser Light Scattering Technology in Rapid Diagnosis of Urinary Tract Infections and Antimicrobial Susceptibility Testing in a Tertiary Children's Hospital
- 2092** Development and Characterization of a Synthetic DNA, NUversa, to Be Used as a Standard in All Quantitative PCR Reactions for Molecular Pneumococcal Serotyping
- 2093** The DISCOVER Trial: Application of the Karius Plasma Next-Generation Sequencing Test for Pathogen Detection in Stem-Cell Transplant Patients
- 2094** Futility of Centor Score (CS) for Predicting Group A Streptococcal (GAS) Pharyngitis in an Adult Hyper-endemic Native American (NA) Population
- 2095** How can we do better? Experience of Hepatitis C Testing for Baby Boomers (1945–1965) in six primary care clinics
- 2096** Impact of Clinical Pathway and Rapid Direct Influenza Polymerase Chain Reaction Test Introduction on Readmissions Among Non-hospitalized Children with Influenza-Like Illness

238. Poster Abstract Session

Diagnostics – Pharyngitis

Saturday, 12:30 p.m. – 2:00 p.m.

- 2097** Performance of routine rapid antigen diagnostic testing and bacterial culture compared to PCR testing for the detection of Group A Strep
- 2098** Optimizing Test Ordering Language to Minimize Group A *Streptococcus* Reflex Culture for Adults
- 2099** Inducible Clindamycin Resistance is More Common in Lancefield groups C and G streptococci Compared to group A in Clinical Specimens: a Single Center Experience, 2013 to 2016
- 2100** Use of PCR for Diagnosis of Group A Streptococcal Pharyngitis in the United States, 2011–2015
- 2101** Co-detection of Group A Streptococcus and Viruses in Children with Pharyngitis

239. Poster Abstract Session

Diagnostics Mycobacteriology

Saturday, 12:30 p.m. – 2:00 p.m.

- 2102** Elevated Neutrophil-to-Lymphocyte Ratio is an Effective Prognosis Indicator In Extra-Pulmonary Tuberculosis
- 2103** Detection of KatG/INH_A mutation to guide isoniazid and ethionamide use for drug-resistant tuberculosis
- 2104** Does Disseminated Nontuberculous Mycobacterial Disease cause False-positive Determine TB-LAM Lateral Flow Assay Results?
- 2105** Evaluation of the High Indeterminate Rate of the QuantiFERON®-TB Gold In-Tube Assay in a Children's Hospital

- 2106 Utilization and Performance of a Laboratory Developed Nucleic Acid Amplification Test for the Diagnosis of Pulmonary and Extrapulmonary Tuberculosis in a Low Prevalence Area: A 14 Year Study.
- 2107 Correlation of Specific Mutations in Line Probe Assay (LPA) and Drug Susceptibility Test (DST) with respect to Fluoroquinolone Resistance in Drug Resistant *Mycobacterium tuberculosis*
- 2108 Lateral Flow Urine Lipoarabinomannan Assay (LF-LAM) for Diagnosis of Active Tuberculosis in HIV-Infected Adults: a Prospective Cohort Study
- 2109 Improved Detection and Accuracy of *Mycobacterium* Species Identification from Paraffin Embedded Tissues of Patients by Using Multigene Targeted PCR and Sequencing
- 2110 Interferon gamma release assay performance in pediatric tuberculosis disease in California
- 2111 Diagnostic Usefulness of Bronchoalveolar Lavage Fluid Xpert MTB/RIF in Patients with Suspected Pauci-bacillary Pulmonary Tuberculosis
- 2112 Season Is Associated with Interferon Gamma Measured in QuantiFERON Gold In-Tube Test
- 2113 Safety & Benefits of Directly Observed Therapy with Rifapentine and Isoniazid for Latent Tuberculosis Infection – Less is More?
- 2114 Prevalence of Tuberculous Spondylodiscitis and Diagnostic Utility of Xpert MTB RIF
- 2115 Prevalence of Gene Mutations profiles by GenoType MTBDR^{plus}/sl to First Line Antituberculosis Drugs and Clinical Characteristics in Drug Resistant Tuberculosis Patients Referred to the National Institute of Respiratory Diseases in Mexico City.
- 2116 Resistance of *Mycobacterium* and outcomes of pulmonary tuberculosis depending on VNTR-profile among different age groups of patients in Ukraine

240. Poster Abstract Session

Stewardship: Impact of Diagnostics

Saturday, 12:30 p.m. – 2:00 p.m.

- 2117 Gram-Negative Polymicrobial Bloodstream Infections and Clinical Decision Making with a Microarray Testing System
- 2118 Rapid Direct Disc Diffusion Tests (RDDDT) Direct From Blood Cultures (BSI) with Gram Negative Bacilli (GNB) Coupled with Prompt Intervention is an Effective and Safe Antibiotics Stewardship Strategy
- 2119 Clinical Impact of Expedited Pathogen Identification and Susceptibility Testing for Gram-negative Bacteremia and Candidemia Using the Accelerate PhenoTM System
- 2120 Validation of an Antimicrobial Stewardship Driven Verigene® Blood-Culture Gram-Negative Treatment Algorithm to Improve Appropriateness of Antibiotics
- 2121 Rapid Identification of Gram-Negative Bacteremia and Impact on Anti-Pseudomonal Antibiotic Consumption in Combination with Antibiotic Stewardship at a Community-Based Hospital System
- 2122 Rapid Multiplex Gastrointestinal Pathogen Panel Testing Improves Antibiotic Stewardship in Patients with Suspected Infectious Diarrhea Compared to Conventional Methods
- 2123 Implementation of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) and Antimicrobial Stewardship Intervention at an Academic Medical Center
- 2124 Impact of Verigene Multiplex PCR for Positive Blood Cultures and Gram Negative Bacteremia
- 2125 Costs of Blood Culture Contamination: Justification for Rapid Diagnostics in a Community Hospital
- 2126 Impact of a Rapid Diagnostic for Bloodstream Infections with Antimicrobial Stewardship Intervention at a Comprehensive Cancer Center
- 2127 Impact of Multiplex Polymerase Chain Reaction Technology with Antimicrobial Stewardship Interventions in the Management of Patients with Positive Blood Cultures
- 2128 Direct Disk Diffusion Susceptibility Testing for *Staphylococcus aureus* from Blood Cultures: Diagnostic Accuracy and Impact on Antimicrobial Stewardship
- 2129 MALDI-TOF MS in adult inpatients with bloodstream infections: pre-and post-intervention study

- 2130 Outcomes of Rapid Identification of Multi-Drug Resistant Gram-Negative Organisms Causing Bacteremia in Combination with Antimicrobial Stewardship in a Community Health System.
- 2131 Successful Implementation of BCID across large healthcare system using a central testing laboratory and multidisciplinary pharmacy team.
- 2132 Evaluation of the Clinical Impact of the Biofire Filmarray® Rapid Multiplex PCR Assay in Blood Culture Identification Combined with Antimicrobial Stewardship Intervention
- 2133 Clinical Utility of Universal PCR and its Real-world Impact on Patient Management
- 2134 Impact of Accelerate Pheno System on Time to Antimicrobial Stewardship Intervention in Patients with Gram-Negative Blood Stream Infections
- 2135 Direct Disk Diffusion Susceptibility Testing for Gram Negative Bacteria from Blood Cultures: Diagnostic Accuracy and Impact on Antimicrobial Stewardship
- 2136 Effect of the Methicillin-Resistant *Staphylococcus aureus* Nasal Polymerase Chain Reaction on Vancomycin Days and Clinical Outcomes in Pneumonia
- 2137 Influence of T2Candida testing for rapid diagnosis of *Candida* infections on antifungal stewardship efforts at a large academic medical center: a retrospective, single-center study
- 2138 Effect of Rapid Molecular Diagnostic Testing and Antimicrobial Stewardship on Antimicrobial Therapy of Respiratory Infections
- 2139 Impact of PBP2a Assay on Antibiotic Therapy of Patients with Non-Blood, Non-Urine *Staphylococcus aureus* Infections

241. Poster Abstract Session

HAI: Device Related Infections

Saturday, 12:30 p.m. – 2:00 p.m.

- 2140 Trends of device utilization ratios in intensive care units during 10 years in South Korea : Results from the Korean National Healthcare-associated Infections Surveillance System
- 2141 Impact of a Hospital-wide Daily Interdisciplinary Safety Huddle on Device Utilization and Device-related Hospital Acquired Infections.
- 2142 Characterization and Biofilm Formation of Pediatric *Staphylococcus aureus* Device Related Infection Isolates Compared to Skin and Soft Tissue Infection Isolates from 2008–2016
- 2143 Catheter-associated Urinary Tract Infections Prevention: Physician Be Aware.
- 2144 The Intern Intervention: The Effect of Daily Rounding on Reducing Indwelling Urinary Catheter Device Utilization
- 2145 Impact of Implementing a Multi-Model Set of Interventions on the Surveillance Rates of Catheter-Associated Urinary Tract Infection
- 2146 Clinical Relevance of the 2014 and 2015 National Healthcare Safety Network's Catheter-Associated Urinary Tract Infection Definitions
- 2147 The NHSN 2015 Rebaseline-How Updating CAUTI Risk adjustment affects the SIRs
- 2148 Insights on the Extremely High Mortality of Ventilator Associated Pneumonia in Cancer Patients
- 2149 Current epidemiology of ventilator-associated pneumonia in an intensive care unit in Vietnam
- 2150 Quality of Non-Bronchoscopic Bronchoalveolar Lavage Specimens and the Diagnosis of Ventilator-Associated Pneumonia
- 2151 Real-Time Automated Surveillance for Ventilator Associated Events Using Streaming Electronic Health Data
- 2153 Catheter Lock with Minocycline, EDTA and Ethanol for Salvaging of Central Venous Catheters in the Setting of Catheter Related Bloodstream Infections
- 2154 Catheter related complications and potential risk factors among catheterized cancer patients receiving parenteral nutrition at The University of Texas MD Anderson Cancer Center: a 26,000 parenteral nutrition-day experience
- 2155 Microbial Colonization of Intravenous Luer Lock Connector During Active Infusions Among Hospitalized Patients
- 2156 Unnecessary Removal of Central Venous Catheters in Cancer Patients with Bloodstream Infections: Impact on Symptom Burden
- 2157 Identifying Structural Factors Associated with Central Line-Associated Bloodstream Infections (CLABSI) Risk in a Single-Center Pediatric Academic Hospital

- 2158** Comparative efficacies of Antimicrobial Catheter Lock Solutions for Fungal Biofilm Eradication in an *in vitro* model of Catheter-Related Fungemia
- 2159** The Impact of a national intervention on hospital-acquired blood-stream infection rates in Israeli intensive care units
- 2160** Peripheral Intravenous Catheters – “They Don’t Get No Respect”
- 2161** Prolonged and Inappropriate Central Line Utilization in Nursing Homes (NH) Related to Broad Spectrum Antibiotics
- 2162** Comparison of Midline *versus* Central venous catheter-related blood-stream infections: Are midlines safer than central venous lines?
- 2163** Predictors of Infections and Mortality in Adult Patients Undergoing Extracorporeal Membrane Oxygenation
- 2164** To Be a CLABSI or Not to Be a CLABSI – That is the Question: The Epidemiology of Bloodstream Infections in a Large ECMO Population

242. Poster Abstract Session
HAI: MRSA, MSSA, and Other Gram
Positives
Saturday, 12:30 p.m. – 2:00 p.m.

- 2165** Variation in Community-Onset Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infection Rates — United States Hospitals, 2015
- 2166** Patients Colonized with Methicillin-Susceptible *Staphylococcus aureus* Rarely Get Methicillin-Resistant *Staphylococcus aureus* Infections
- 2167** Relatedness of MRSA and VRE strains isolated from post-acute care patients and their environment: a longitudinal assessment
- 2168** The population dynamics of antibiotic resistance in *Staphylococcus aureus* in Boston: A return to antibiotic susceptibility
- 2169** Predictive Characteristics of Methicillin-Resistant *Staphylococcus aureus* (MRSA) Nasal Swab for MRSA Positive Culture in Hospitalized Veterans
- 2170** Association of Active Surveillance and Decolonization Program on Incidence of Clinical Cultures Growing *Staphylococcus aureus* in the Neonatal Intensive Care Unit
- 2171** Treatment of *Staphylococcus aureus* bacteremia in children: is intravenous therapy always needed?
- 2172** Prevalence and characteristics of *qacA/B*-positive methicillin-resistant *Staphylococcus aureus* (MRSA) bloodstream infection isolates in a tertiary hospital.
- 2173** Suspending use of Contact Precautions in Patients Colonized with Methicillin-Resistant *Staphylococcus aureus* in a Level III Neonatal ICU and its Effects on Rates of Transmission
- 2174** Risk of Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infection during a Hospitalization among MRSA Carriers and Non-Carriers in the Absence of Contact Isolation
- 2175** Intra-Facility Acquisition of Methicillin-Resistant *Staphylococcus aureus* (MRSA) in Southern Wisconsin Skilled Nursing Facilities
- 2176** A Multidisciplinary Evaluation of *Staphylococcus aureus* Screening, Decolonization and Patient Adherence to Pre-Operative Decolonization Procedures
- 2177** Electronic Detection of MRSA Infections in a National VA Population Augments Current Manual Process
- 2178** Developing a Checklist to Identify and Manage MRSA Outbreaks in the Neonatal ICU using a Multi-Disciplinary Approach
- 2179** Trends in the Incidence of *Staphylococcus aureus* Bacteraemia at a Teaching Hospital in Nassau, Bahamas 2012 to 2015
- 2180** Dissemination of the Methicillin Resistant *Staphylococcus aureus* (MRSA) Pediatric Clone (ST5-T002-IV-Pv1+) as a Major Cause of Community Associated (CA) Staphylococcal Infections in Bedouin Children, Southern Israel
- 2181** Impact of Methicillin-Resistant *Staphylococcus aureus* Colonization on Transfer to a Nursing Home
- 2182** Molecular epidemiology of community-associated and hospital-associated methicillin-resistant *Staphylococcus aureus* in a Japanese university hospital
- 2183** Post-intervention Survey on Scaling Back Contact Precautions for MRSA and VRE
- 2184** Systemic Analysis of the *mecA* Gene Using a Bioinformatics Tool

- 2185** Impact of Antibiotic Treatment on the Burden of Nasal *Staphylococcus aureus* (SA) Among Hospitalized Veterans
- 2186** Times Up! Manually Working to Remove Patients from Methicillin resistant *Staph. aureus* (MRSA) and Vancomycin Resistant *Enterococcus faecium* (VRE) Isolation Precautions
- 2187** Epidemiology, Associated Conditions, and Outcomes of Hospital Associated Vancomycin-Resistant *Enterococcus* Infections in the US Military Health Care System
- 2188** Predictors of Vancomycin-Resistant *Enterococcus* (VRE) Bacteremia in Ontario, Canada
- 2189** Case-Control Study of VRE Acquisition in a Tertiary Care Hospital: Testing the Roles of Antibiotic use, Proton Pump Inhibitor Use and Colonization Pressure
- 2190** Single Nucleotide Polymorphisms (SNPs) Analyses Reveal Potential Vancomycin-Resistant Enterococci (VRE) Transmission Networks Between Rooms and Patients in a Hospital Setting
- 2191** Characteristics of Tedizolid Non-susceptible Enterococcal Clinical Isolates
- 2192** Emergence of Alarming Clindamycin and Erythromycin Resistant *Streptococcus* group B over 2004-to-2016 in Kuwait

243. Poster Abstract Session
HAI: Surgical Site Infections
Saturday, 12:30 p.m. – 2:00 p.m.

- 2193** Optimal Timing of Surgical Antimicrobial Prophylaxis with Cefuroxime: Challenging the WHO Guidelines with 121’000 prospectively followed Patients
- 2194** The Impact of a Reported Penicillin Allergy on Surgical Site Infection Risk
- 2195** Impact of a Guideline-Driven Quality Improvement Intervention on Intraoperative Antibiotic Redosing Compliance and Surgical Site Infections
- 2196** Pre-Operative Staphylococcal Screening for Patients Undergoing Ventral Hernia Repair: A Strategy to Reduce Post-Operative Infections
- 2197** Challenges in implementing pre-surgical chlorhexidine shower or bath for prevention of surgical site infection
- 2198** Assessment of the Persistent Antimicrobial Efficacy of a CHG/IPA Preoperative Skin Preparation against Resident Human Skin Flora on the Abdominal and Inguinal Regions
- 2199** Broad-Spectrum Microbicidal Activity of Tinted and Colorless 2% chlorhexidine gluconate (CHG)/70% isopropyl alcohol (IPA) –2% CHG/70% IPA (polymer) using a Modified Time-Kill Procedure
- 2200** In-vitro evaluation of Povidone-Iodine and Chlorhexidine against Outbreak and Non-outbreak strains of *Mycobacterium abscessus* using Standard Quantitative Suspension and Carrier Testing
- 2201** Surgical Antibiotic Prophylaxis is not Associated with Risk for Post-Operative Antibiotic-Resistant Infections
- 2202** Incidence and Risk Factors for colonization of Multidrug-Resistance Organisms (MDROs) among Patients Undergoing Elective Orthopedic Surgery at Thammasat University Hospital
- 2203** *Serratia* and Surgical Site Infections: Risk factors and Epidemiology
- 2204** The Relationship between Payer and Risk of Surgical Site Infection following Cesarean Delivery
- 2205** Should cefazolin be the first line antimicrobial prophylaxis choice in patients undergoing hysterectomy? A systematic review and meta-analysis
- 2206** Surgical site Infections after Colon Surgery: What the SIR doesn’t tell you
- 2207** Risk Factors of Surgical Site Infections after Colon Surgery in Community Hospitals: a Multicenter Retrospective Cohort Study
- 2208** Enhanced colorectal surgery bundle to reduce surgical site infections
- 2209** Increased Mortality Attributable to Mediastinitis Following Coronary Artery Bypass Graft Surgery
- 2210** Impact of Narrow vs. Broad-Spectrum Surgical Antibiotic Prophylaxis in Pediatric Patients with Enteral Tubes Undergoing Cardiac Surgery
- 2211** Epidemiology and Microbiology of first Ventricular Assist Device infection and their effect on outcomes.

- 2212 Analysis of Cardiac Implantable Electronic Device Infection Costs at One Year in a Large United States Healthcare Organization
- 2213 Risk Factors for Incident Vascular Graft Infections
- 2214 Epidemiology and Risk Factors Associated with Surgical Site Infection Following Thoracic Aortic Surgery
- 2215 Vancomycin prophylaxis (VAN PPx) for Intra-aortic balloon pump (IABP)
- 2216 Cost and Hospital Resource Utilization of *Staphylococcus aureus* Infection Post Elective Posterior Instrumental Spinal Fusion Surgeries in the United States: a Retrospective Cohort Study
- 2217 Projected Burden of Complex Surgical Site Infections following Total Hip and Knee Arthroplasty among Adults in the United States, 2020 through 2030
- 2218 Risk Factors of Surgical Site Infections after Simultaneous Kidney Pancreas (SKP) Transplantation.
- 2219 Effectiveness of Fosfomycin Tromethamine Prophylaxis in Preventing Infection Following Ultrasound-guided Prostate Needle Biopsies: Results from a Large Canadian Cohort

244. Poster Abstract Session HIV and HBV Saturday, 12:30 p.m. – 2:00 p.m.

- 2220 HIV/Hepatitis B Coinfection is usually treated together. Is Hepatitis B forgotten?
- 2221 Markers of Cirrhosis and Inflammation in HIV/HBV Co-infection in a Ugandan Cohort
- 2222 Calculated Globulin Adds Predictive Value to Hepatitis B Vaccine Response in HIV-infected Persons Independently of HIV Viral load and CD4 Cell Count
- 2223 HBV infection in untreated HIV-infected adults in Maputo, Mozambique

245. Poster Abstract Session HIV and HCV Saturday, 12:30 p.m. – 2:00 p.m.

- 2224 Longterm Evaluation of Hemoglobin A1c Following Hepatitis C Therapy in Patients with and without HIV Co-infection
- 2225 Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Patients Coinfected with HCV and HIV-1
- 2226 The Natural History and Predictors of Liver Fibrosis Progression Using the FIB-4 Score Among HIV/HCV Co-infected Adults in an Outpatient Clinic in the U.S.
- 2227 Hepatitis C Virus Treatment Response to Ledipasvir/Sofosbuvir among patients co-infected with HIV and HCV: Real World Data in a Black Population
- 2228 Treatment of HCV NS3/4a protease inhibitor experienced patients with sofosbuvir containing regimens in an Outpatient Clinic
- 2229 Difference in SVR12 outcomes in the HIV/HCV co-infected population in New Orleans, Louisiana
- 2230 Sustained Virologic Response with Direct Acting Antivirals in HIV Coinfected Hepatitis C Patients and Its Effect on Liver Fibrosis
- 2231 Hepatitis C Viremia Post Direct Acting Therapy Did Not Correlate with Treatment Failure in HCV/HIV Co-Infected Patients
- 2232 Eliminating HCV co-infection in HIV: A Positive Health Clinic (PHC) Venture
- 2233 Barriers to Hepatitis C Treatment in HIV co-infected Patients in the Era of new Direct-Acting Antiviral Therapy
- 2234 Real World Experience of Sofosbuvir/Ledipasvir Therapy in HIV Patients Co-infected with HCV: A Retrospective Study
- 2235 Hepatitis C and HIV Primary Care Screening Intervention Increases Identification and Linkage to Care within a Large Healthcare system
- 2236 Viral Hepatitis among HIV+ Patients in Northern Vietnam
- 2237 Relationship of Risk Screening to HIV and Viral Hepatitis Detection for Participants in a Colorado Narcotic Replacement Therapy Program.

246. Poster Abstract Session HIV and Women Saturday, 12:30 p.m. – 2:00 p.m.

- 2238 Prevalence of Drug-drug Interactions with Hormonal Contraceptives and Antiretrovirals in Women Living with HIV
- 2239 Safety and Tolerability of High Dose Atazanavir/ritonavir and Lopinavir/ritonavir in Pregnant Women Living with Human Immunodeficiency Virus
- 2240 Comparison of two Antiretroviral Therapy Regimens in Human Immunodeficiency Virus (HIV-) Infected Pregnant Women
- 2241 Prevalence and Risk Factors for Intimate Partner Violence in Women Living with HIV in Uganda
- 2242 Effective Contraceptive Use Following Unplanned Pregnancy Among Ugandan Women Living with HIV

247. Poster Abstract Session HIV: Pediatrics Saturday, 12:30 p.m. – 2:00 p.m.

- 2243 Association of Self-Reported Adherence and Antiretroviral Drug Concentrations in Hair Among Youth with Virologic Failure in Tanzania
- 2244 Reducing Delays to Antiretroviral (ARV) Receipt in Children Prescribed Post-Exposure Prophylaxis (PEP) for HIV: Meds-in-Hand and a Multidisciplinary Team Approach
- 2245 Persistence of Depressed but Stable Levels of Pediatric Vaccine Induced Antibodies over 16 years in Perinatally HIV Infected Individuals on Combined Anti-Retroviral Therapy
- 2246 Trajectories of Condom Non-Use and Predictors of Trajectory Group Membership Among African-American Adolescents
- 2247 No Difference in Antibody Responses to Tetanus Vaccine Among HIV-Exposed and -Unexposed infants in Botswana
- 2248 *Evaluating Outcomes of Mother-Infant Pairs Using Dolutegravir for Treatment of HIV During Pregnancy*
- 2249 Long Term Virological Outcome in Children on First-line Antiretroviral Therapy in India
- 2250 Assessing the Acceptability of a Community-Based Intervention to Improve the Continuum of Care of Postpartum Women Living with HIV
- 2251 Identifying Demographic, Social and Environmental Determinants of Treatment Failure among HIV-Infected Children in Uganda

248. Poster Abstract Session HIV: Sexually Transmitted Infections Saturday, 12:30 p.m. – 2:00 p.m.

- 2252 Primary Care Providers Have Limited Knowledge About STI Screening And HIV PrEP in Men Who have Sex with Men
- 2253 Incident Syphilis Infections in an HIV Population: Presentation and Care
- 2254 Housing Insecure HIV Patients Have Higher Positive Gonorrhea and Chlamydia Test Results but Lower Testing Rates in a Patients with a Primary Care Setting
- 2255 Earlier detection of latent syphilis: Every 3 month screening with MSM and HIV
- 2256 Self-Testing is a Feasible and Acceptable Option for Identifying Extra-genital Gonorrhea (GC) and Chlamydia (CT) infections in HIV Infected Persons
- 2257 Clinical Characteristics and Outcomes of Patients with Orosyphilis and HIV Infection
- 2258 Risk Factors Associated with Sexually Transmitted Infections among Pre-Exposure Prophylaxis Users in an Urban Multi-Clinic Healthcare System
- 2259 High Rate of Asymptomatic Bacterial Sexually Transmitted Infections (STIs) in Men who Have Sex with Men on Pre Exposure Prophylaxis (PrEP)

- 2260 Improving extra-genital GC/CT screening among HIV-positive patients at the University of North Carolina Infectious Diseases clinic
- 2261 High-risk behavior among U.S. Military HIV-Infected Active-Duty and Retired Personnel

249. Poster Abstract Session

Non-Tuberculous Mycobacteria – Epidemiology and Management

Saturday, 12:30 p.m. – 2:00 p.m.

- 2262 Extrapulmonary nontuberculous mycobacterial infections in Southern Arizona
- 2263 Disseminated Mycobacterium Hemophilum presenting as leprosy like cutaneous lesions in an immunocompromised host
- 2264 Tuberculosis and Leprosy Co-Infection: A Perspective on Diagnosis and Treatment
- 2265 The epidemiology of non-tuberculous mycobacteria (NTM) from non-pulmonary sites over 4 years in Nebraska
- 2266 Septic Olecranon Bursitis caused by Non-tuberculous Mycobacteria, the Mayo Clinic Experience
- 2267 Rare Atypical Presentations in Type 2 Leprosy Reaction: A Case Series
- 2268 Patterns of Fluoroquinolone Prescribing at a Tuberculosis Hospital
- 2269 Disseminated Mycobacterium genavense in the immunocompromised: a case series at Mayo Clinic Rochester
- 2270 Mycobacterium gordonae isolation in Oregon, 2005–2012
- 2271 Clofazimine for Rapidly Growing Mycobacterial Infections
- 2272 Healthcare resource utilization and costs following diagnosis of nontuberculous mycobacterial lung disease in the US
- 2273 Major risk factors for leprosy in a non-endemic area of the United States
- 2274 Rate of all-cause hospitalization at year 2 between treatment groups following diagnosis of nontuberculous mycobacterial lung disease in the US
- 2275 Reduction in Nontuberculous Mycobacteria at a Tuberculosis Hospital Following a Quality Assurance Intervention.
- 2276 Evaluation of Ceftaroline-Avibactam Activity *in vitro* and *ex vivo* Against Mycobacterium abscessus Complex
- 2277 Clofazimine for Treatment of Mycobacterium abscessus Infections in Children
- 2278 A Randomized Controlled Trial of Anti-TNF α Bio-similar Adalimumab versus Prednisolone in the Management of Leprosy Patients with New Type 1 Leprosy Reaction
- 2279 Nontuberculous Mycobacteria Isolates at a Cancer Center: A 5-year Experience at H. Lee Moffitt Cancer Center in Tampa, Florida
- 2280 Pott's Disease Caused by Mycobacterium bovis Following Intravesical BCG Therapy for Bladder Cancer
- 2281 Treatment Regimens Prescribed for Mycobacterium avium complex Infections Diagnosed in Hospitalized Patients throughout the United States, 2008–2013

250. Poster Abstract Session

Pediatric Bacterial Infections: From A to Z

Saturday, 12:30 p.m. – 2:00 p.m.

- 2282 Clinical and Radiologic Manifestations of Cat-Scratch Osteomyelitis in Children
- 2283 Epidemiological Profile of Children Infected with Bordetella pertussis at Varela Santiago Children's Hospital: a Retrospective Study
- 2284 Epidemiology and Trends of Pertussis among Infants — United States, 2000–2015
- 2285 The Impact of Routine Chlamydia trachomatis (CT) Screening during Pregnancy on the Seroepidemiology of Chlamydial Infection in Children, 1991–2015
- 2286 Risk Factors for Community-Associated Clostridium difficile Infection in Children

- 2287 Risk Factors for Recurrent Pediatric Community Associated Clostridium Difficile Infection
- 2288 Clostridium difficile Molecular Epidemiology in a Prospective Cohort of Canadian Children Compared to Cases of C. difficile Infection.
- 2289 A Multicenter Study of the Clinical and Molecular Epidemiology of TEM- and SHV-type Extended- Spectrum Beta-Lactamase producing (ESBL) Enterobacteriaceae (Ent) Infections in Children
- 2290 Impact of Multidrug Resistant Enterobacteriaceae Bloodstream Infections in Children
- 2291 Mother to Child Transmission of Extended Spectrum Beta-Lactamase Producing Enterobacteriaceae
- 2292 A Multicenter Case-Case-Control Study of Factors Associated with Klebsiella pneumoniae Carbapenemase (KPC)-Producing Enterobacteriaceae (KPC-CRE) Infections in Children
- 2293 Epidemiology of Nontuberculous Mycobacterial Lung Disease among Cystic Fibrosis Patients Residing in Hawaii, USA
- 2294 Continuous Pneumococcal Invasive Disease reduction, high impact on pneumococcal empyemas and meningitis, and serotype 19A disappearance following PCV-13 vaccination in children: eleven and a half years of Active Surveillance in a Mexican hospital on the U.S. border
- 2295 Shigellosis in Children: Antimicrobial Susceptibility Testing by Automated Instrument versus Etest Reveals Disagreements
- 2296 Genetic structures of Streptococcus pneumoniae invasive isolates from Korean children obtained between 1995 and 2013
- 2297 Predictors of Persistence Community Acquired Staphylococcus aureus Bacteremia in Children. Cohort Study.
- 2298 Association of Staphylococcus aureus Colonization with the Evolving Neonatal Nasal Microbiome and the Impact of Intranasal Mupirocin
- 2299 An Outbreak of Group A Streptococcus Invasive Infections among Pediatric Patients in Columbus, Ohio
- 2300 Staphylococcus aureus bacteremia in children: The effect of methicillin resistance
- 2301 Osteoarticular Infections Following Open or Penetrating Trauma in Children in the Era of Community-Acquired MRSA
- 2302 Increase in Systemic and Locally Invasive Group A Streptococcal Disease in a Pediatric Population: Feb-March 2017

251. Poster Abstract Session

Pediatric Potpourri

Saturday, 12:30 p.m. – 2:00 p.m.

- 2303 Post-Exposure Prophylaxis for Animal Bites : A low cost model for enhancing reach and affordability of biologicals in high burden countries
- 2304 Validation of a definition for K-12 student absenteeism due to influenza-like illness (ILI) for school-based influenza activity monitoring in Oregon School District, Wisconsin — ORCHARDS (Oregon Child Absenteeism and Respiratory Disease Study)
- 2305 Unbiased Screening of Kawasaki Disease Sera for Viral Antigen Exposure
- 2306 Familial and Environmental Impact on Colonization with Antibiotic Resistant Organisms in the Neonatal Intensive Care Unit
- 2307 Surveillance for Antimicrobial Resistant Organisms in Infants Transferred to the Neonatal Intensive Care Unit: Trends in Colonization and Practices
- 2308 Clinic characteristics are not associated with the risk of health-care-associated influenza-like illness (HA-ILI) among young children in pediatric primary care settings
- 2309 Epidemiology of Meningitis and Encephalitis in Infants and Children in the United States from 2011 – 2014.
- 2310 Quality of Life Following Childhood Bacterial Meningitis in Luanda, Angola
- 2311 Visitor Restriction Policies and Practices in Children's Hospitals: Results of an Emerging Infections Network Survey
- 2312 Epidemiology of Serious Bacterial Infections in a Cohort of Infants in the Military Health System from 2005–2015.
- 2313 An All-Harm Index Quantifying Central Line Associated Infectious and Non-Infectious Complications Among Pediatric Oncology Patients

- 2314 Risk Factors for Bloodstream Infection in Children with Intestinal Insufficiency on Parenteral Nutrition
- 2315 Incidence and Outcomes of Endophthalmitis Associated Hospitalizations in Children Aged ≤ 20 years: A Population-Based Cohort Study
- 2316 Fever in Infants: Assessing Variability in Sepsis Evaluation
- 2317 Outcomes of children treated with short versus long course parenteral antibiotic for acute hematogenous osteoarticular infections
- 2318 Nutritional Status is Not Associated with Diarrhea Duration or Weight Recovery in Young Children in a Resource-Poor Setting
- 2319 Bacteremia in Children Without a Bacterial Infection

252. Poster Abstract Session Pediatric Virology Saturday, 12:30 p.m. – 2:00 p.m.

- 2320 2016 Acute Flaccid Myelitis Outbreak in Texas: Promising Outcomes
- 2321 Rapid virologic response to Brincidofovir in pediatric, CD34⁺ selected allogeneic hematopoietic stem cell transplant (HCT) recipients with disseminated adenovirus infection.
- 2322 Human Bocavirus Transmission and Illness Among Pregnant Mothers and Infants in Ugandan Households
- 2323 Congenital Cytomegalovirus Infection Incidence is Higher in the African Americans, the Medicaid insured, and those born in the South and West; an Analysis of 1,773 Cases Using a Nationally Representative Database in the United States, 2000–2012
- 2324 The incidence of symptomatic congenital cytomegalovirus (CMV) infection in Korea; A 15-year Multi-center study
- 2325 Head Ultrasound or MRI? The Role of Neuroimaging in the Assessment of Symptomatic and Asymptomatic Infants with Congenital CMV infection
- 2326 “Targeted” Screening for Cytomegalovirus (CMV)-Related Hearing Loss: It's Time for Universal CMV Screening in the NICU!
- 2327 Monitoring Of Cytomegalovirus Infection In Non-Transplant Pediatric Leukemia During Chemotherapy
- 2328 First Cluster of Acute Flaccid Myelitis Related to Enterovirus D-68 in Argentinean children
- 2329 Enterovirus Infection in Young Infants: Prevalence, Clinical and Laboratory Characteristics in Columbus, Ohio
- 2330 Comparison of Prevalence, Clinical and Laboratory Characteristics of Enterovirus (EV) and Human Parechovirus (HPeV) Infections in Infants Less Than Two Months of Age in Columbus, Ohio
- 2331 Prevalence, Genotypes, Clinical Manifestations and Outcomes Associated with Human Parechovirus (HPeV) Infections in Infants up to 2 Months old in Central Ohio.
- 2332 Can We Distinguish between Human Parechovirus Type 3 and Enteroviruses Infection in Neonates and Young Infants Based on their Clinical and Laboratory Findings?
- 2333 An Assessment of the Validity of the Comprehensive Severity Index (CSI) as a Measure of Severity of Influenza Infection in Children
- 2334 Neurological Manifestations of Hospitalized Children with Influenza During the 2016–2017 Season
- 2335 Single Dose IV Peramivir is Safe and Effective in the Treatment of Pediatric Influenza
- 2336 A Systems Analysis Approach to Define the Protective Host Immune Responses of Children with Mild Respiratory Syncytial Virus Infection
- 2337 National Bronchiolitis Hospitalization Rates Among Preterm and Full Term Infants: 2010–2015
- 2338 Asthma Exacerbations and Risk of Emergency Department Management Failure: Burden and Impact of Various Respiratory Pathogens in a Pediatric Population.
- 2339 Human Rhinovirus Detection by PCR in Febrile Infants and Risk of Concomitant Bacterial Infection
- 2340 A varicella outbreak among preschool children despite one-dose vaccination
- 2341 Congenital Zika Syndrome (CZS) Phenotype Seen in Older Children
- 2342 Evaluation of Pregnant Women, Fetuses and Infants with Zika Virus Exposure and Infection: Lessons Learned from the Congenital Zika Program at Children's National

- 2343 Congenital Neurological Disorders in Children with Microcephaly Related to Exanthematous Diseases During Pregnancy: A Cohort Study
- 2344 Clinical and Epidemiological Profile of the Chikungunya and Zika Outbreak in Neonates 2014–2016, Cartagena-Colombia
- 2345 Infants Born in New York City to Women with Zika Virus Exposure During Pregnancy, January 2016–May 2017
- 2346 Evaluation of Mothers and Infants with Presumed Exposure to Zika Virus: A Look into the Lehigh Valley Experience.

253. Poster Abstract Session Transplant Infections – Epidemiology Saturday, 12:30 p.m. – 2:00 p.m.

- 2347 Predictive Models of Fever and Adverse Outcomes in Hospitalized Patients with Neutropenia
- 2348 Infectious Complications of Bronchial Stenosis in Lung Transplant Recipients
- 2349 Infectious Complications of CD19-Targeted Chimeric Antigen Receptor-Modified T Cell Immunotherapy
- 2350 Opportunistic Infections (OIs) in Patients with Hematologic Malignancies (HM) Treated with Bruton's tyrosine kinase (BTK) and Phosphoinositide 3 kinase (PI3K) Inhibitors: An 8-Year Retrospective Cohort Study.
- 2351 Change in clinical management associated with flexible bronchoscopy and bronchoalveolar lavage in hematopoietic stem cell transplant recipients with new pulmonary infiltrates
- 2352 Prediction of Febrile Neutropenia after Chemotherapy Based on Pre-treatment Risk Factors among Cancer Patients
- 2353 Infections in Patients Receiving Ibrutinib for Treatment of Lymphoma – A Single Center Experience
- 2354 *Torque Teno Virus* (TTV) and *Epstein-Barr Virus* (EBV) Viral Load in Peripheral Blood as a Biomarker of “Net Immunosuppression”: Factors Influencing Viral Load in Adult Patients Awaiting Solid Organ Transplantation
- 2355 A Contemporary Analysis of Neutropenic Fever in Leukemia Patients Presenting to the Emergency Center – Importance of Pneumonia
- 2356 Lymphopenia after Radiotherapy and Risk of Infection
- 2357 *Trypanozoma cruzi* infection in patients undergoing solid organ transplantation
- 2358 Infection Risk Associated with Daratumumab
- 2359 Infectious Risks and Complications in Adult Acute Lymphoblastic Leukemia (ALL) Patients Receiving Blinatumomab
- 2360 Classification of Death Causes after Transplantation (CLASS): Evaluation of Methodology and Initial Results.
- 2361 Incidence and risk factors for infections after liver transplant in children: single-center experience for 15 years
- 2362 Febrile neutropenia as a marker of an infectious phenotype and poor long-term outcomes among patients treated with chemotherapy for malignant diseases
- 2363 Characteristics and Early Outcomes of Older Adults Undergoing Kidney Transplantation
- 2364 Perceptions Among Canadian Physicians and Patients Regarding the Risk of Human T-Lymphotropic Virus in Solid Organ Transplantation

254. Poster Abstract Session Transplantation – Bacterial Infections Saturday, 12:30 p.m. – 2:00 p.m.

- 2365 The impact of infections caused by carbapenem-resistant Gram-negative bacillus in the risk of recurrent urinary tract infection after kidney transplant
- 2366 *In vitro* Activity of Esomeprazole against *Ureaplasma* species
- 2367 Does the Gram-negative bacteria colonization impact on the risk of develop infection by those organisms during neutropenia?
- 2368 Breakthrough bacteremia with meropenem-resistant *Pseudomonas aeruginosa* in hematologic malignancy patients receiving levofloxacin prophylaxis

- 2369** Risk factors for Drug Resistant of Gram-negative Bloodstream Infection in Patients with Hematological Malignancies
- 2370** Risk factors and prognosis for multidrug resistant *Acinetobacter baumannii* infection in Lung transplantation recipients.
- 2371** Vancomycin Resistant Enterococci: Differing Rates and Patterns of Colonization in Liver versus Non-Liver Solid Organ Transplant
- 2372** Colonization with Ceftriaxone-Resistant Enterobacteriaceae and Risk of Bacteremia in Patients Receiving Induction Chemotherapy for Acute Leukemia
- 2373** A 20-Year Experience with Nocardiosis in Solid Organ Transplant (SOT) Recipients in the Southwestern United States: A Single-Center Study
- 2374** Association of Bacteriuria by Time and Organism Following Kidney Transplantation with Allograft Survival and Rejection
- 2375** Epidemiology of Bloodstream Infections in Kidney Transplant Recipients: A Systematic Review and Meta-analysis
- 2376** *Nocardia* Infections: Comparison of Manifestations and Outcomes in Immunocompromised (IC) and Non-Immunocompromised (Non-IC) Patients
- 2377** Prophylactic Antibiotic Therapy and Blood Stream Infections in Leukemia Patients Presenting to the Emergency Center
- 2378** Multi-Drug Resistant Organism (MDRO) Infections in Liver Transplant Recipients 30 Days Post-Transplant
- 2379** *Clostridium difficile* Infection in Solid Organ and Haematopoietic Stem Cell Transplant Recipients
- 2380** MULTIDRUG-RESISTANT GRAM-NEGATIVE BACTEREMIA IN CANCER PATIENTS: DEVELOPMENT OF A CLINICAL SCORE FOR RISK ASSESSMENT

255. Poster Abstract Session
Transplantation – Pretransplantation
Screening + Evaluation
Saturday, 12:30 p.m. – 2:00 p.m.

- 2381** Screening for multidrug-resistant (MDR) gram-negative organisms and progression to bloodstream infections in hematopoietic cell transplant (HCT) patients: a single-center pilot study
- 2382** Organs from a highly virulent zoonotic outbreak strain of *Streptococcus agalactiae* Serotype III, multilocus sequence type 283 infective endocarditis did not result in transmission with adequate prophylactic antibiotic cover
- 2383** Ten Year Trends in Incidence of Vancomycin-resistant Enterococcus Among Allogeneic Hematopoietic Cell Transplant Recipients
- 2384** Prevalence of Bloodstream Infections in Neutropenic Patients with Bacteriuria

256. Poster Abstract Session
Transplantation – Prophylaxis and Prediction
Saturday, 12:30 p.m. – 2:00 p.m.

- 2385** Comparison of Posaconazole and Voriconazole Prophylaxis Following Induction Chemotherapy for Acute Myeloid Leukemia
- 2386** Use of Trimethoprim-Sulfamethoxazole and Alternative Agents for Prevention of Opportunistic Infections in Heart and Lung Transplant Recipients at a Large-Volume Academic Transplant Center: Current Practices and Post-Transplant Opportunistic Infections
- 2387** Low-dose valganciclovir for CMV prophylaxis in intermediate-risk liver transplant recipients: a single center retrospective study
- 2388** Role of secondary prophylaxis with valganciclovir in the prevention of recurrent cytomegalovirus disease in solid organ transplant recipients
- 2389** Use of a Sulfa Desensitization Protocol in Solid Organ Transplant Recipients
- 2390** Incidence of Febrile Neutropenia in Autologous Hematopoietic Stem Cell Transplant (HSCT) Recipients on Levofloxacin Prophylaxis at a Single Center Midwest Cancer Center

- 2391** Establishing the Optimal Viral Load Threshold for Initiation of Therapy for Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients: A Prospective Derivation Cohort Study Using the International Standardized CMV Quantitative Nucleic Acid Testing
- 2392** Impact of Choice of Surgical Infection Prophylaxis in Left ventricular Assist Device Infections
- 2393** Revisiting Infectious Complications in Hematopoietic Stem Cell Transplantation Recipients who Receive Total Parenteral Nutrition
- 2394** Secondary Prophylaxis with Oral Vancomycin to Prevent Recurrence of *Clostridium difficile* Infections among Hematopoietic Stem Cell Transplant Patients Receiving Systemic Antimicrobial Agents
- 2395** Comparative Effectiveness of Cidofovir Pre-emptive Therapy for Human Adenovirus Infection in Pediatric Hematopoietic Cell Transplant Recipients
- 2396** Multi-Center Observational Characterization of Cytomegalovirus Antiviral use in Allogeneic Hematopoietic Stem-Cell Transplantation (HCT) Recipients
- 2397** Febrile Neutropenia Syndromes in Children: Should Management Differ for Primary, Persistent, Recurrent or Engraftment Fever?
- 2398** Impact of a shorter duration of antimicrobial prophylaxis in orthotopic liver transplantation (OLT) patients
- 2399** Influence of *Pneumocystis jirovecii* Pneumonia Prophylactic Agents on the Occurrence of Urinary Tract Infections after Renal Transplantation
- 2400** Burden of Cytomegalovirus DNAemia among Pediatric Renal Transplant Patients on Antiviral Prophylaxis: A Hospital-Based Analysis
- 2401** Patterns of Linezolid and Daptomycin Use in Leukemia Patients with Neutropenic Fever Presenting to the Emergency Center
- 2402** The Characteristics of Febrile Neutropenia among Allogeneic Hematopoietic Stem Cell Transplant Recipients on Levofloxacin Prophylaxis.
- 2403** Effectiveness of Fluoroquinolone Prophylaxis for High Risk Patients with Neutropenia in Hematopoietic Stem Cell Transplant Recipients in the Era of Rising Gram Negative Bacterial Resistance
- 2404** “Immune response to *Bordetella pertussis* vaccine in candidates and receptors of solid organ transplant”

257. Poster Abstract Session
Transplantation Fungal Infections
Saturday, 12:30 p.m. – 2:00 p.m.

- 2405** Breakthrough Invasive Fungal Infections (bIFI) in Adult Patients with Leukemia Receiving Isavuconazole (ISA)
- 2406** Invasive Fungal Infections (IFI) After Heart Transplantation (HT): An 11-Year, Single-Center Experience
- 2407** Clinical Manifestations and Outcomes in Immunocompetent and Immunocompromised Patients with Blastomycosis
- 2408** Micafungin breakthrough fungemia in patients with hematological disorders: a retrospective study to determine therapeutic strategy
- 2409** Increased Prevalence of Potentially Resistant Non-*Aspergillus* Molds Isolated in Lung Transplant Recipients after Voriconazole and Posaconazole Prophylaxis

258. Poster Abstract Session
Tuberculosis: Epidemiology and Management
Saturday, 12:30 p.m. – 2:00 p.m.

- 2410** A Survey of the Tuberculosis Workforce in the Country of Georgia
- 2411** Abdominal tuberculosis in children: experience in a tertiary hospital in Mexico City.
- 2412** Latent Tuberculosis Infection in a Cohort of Refugee Patients Resettling in New England
- 2413** Risk factors of ethambutol optic neuropathy among patients with tuberculosis and NTM infection
- 2415** Chest computed tomography characteristics and time to culture conversion among patients with pulmonary tuberculosis.

- 2416 Clinical Signs and Parameters for Distinguishing Tuberculous Meningitis from Viral Meningitis
- 2417 Detecting TB Cases among Household Contacts of Patients with Pulmonary TB through Active Contact Tracing in the Arsi Zone, Ethiopia.
- 2418 New Insights into an Old Problem: Increasing Medical Complexity of Patients with Active Tuberculosis in California
- 2419 Use of a Validated Online Calculator to Determine TB Progression Risk in Patients with Latent Tuberculosis Infection on TNF α Therapy
- 2420 A Cross-Sectional Survey to Measure the Prevalence of Chronic Pulmonary Aspergillosis (CPA) Complicating Pulmonary Tuberculosis in Northern Uganda
- 2421 Prognostic Factors Associated with Mortality during Tuberculosis Treatment - A Large Population-Based Analysis
- 2422 Comparison of Pulmonary Tuberculosis Treatment Efficacy With Moxifloxacin for 4 Months Vs. Standard Treatment of Pulmonary Tuberculosis. Intention-to-Treat Analysis (ITT)
- 2423 Identification and Characterization of *Mycobacterium tuberculosis* (Mtb) Effector Proteins
- 2424 Risk factors associated with in-hospital mortality among patients with active TB disease: 25-year experience in the US
- 2425 Frequency of symptoms and treatment discontinuation during programmatic use of the 12-dose Isoniazid-Rifapentine Regimen for Treatment of Latent Tuberculosis Infection
- 2426 A Novel Tool to Detect Treatment Failures Early in the course of Antituberculosis treatment: Old Wine in New Bottle?
- 2427 Prevalence and Reactivation of Latent Tuberculosis Infection among Foreign-born Subpopulations, United States, 2011–2012
- 2432 Five-Year Experience with Ganciclovir Resistant Cytomegalovirus in Renal Transplant Recipients at a Single Academic Center
- 2433 Immunologic monitoring with cytomegalovirus (CMV) ELISPOT for prediction of recurrent CMV infection and late-onset CMV disease in pediatric allogeneic hematopoietic stem cell transplant (HSCT) recipients
- 2434 Duration of Antiviral Prophylaxis and Risk of Herpes Zoster (HZ) among Patients with Solid Tumor Malignancy on Chemotherapy (STMc)
- 2435 Epidemiology and Outcomes of Fever During the First Two Months after Simultaneous Pancreas-Kidney (SPK) Transplant
- 2436 Cost of Hematopoietic Stem Cell Transplant and Cytomegalovirus Related Complications in a Large Inpatient Claims Database
- 2437 Cytomegalovirus (CMV) associated health care utilization in unmodified and *ex-vivo* T-cell depleted hematopoietic stem cell transplantation (HCT).
- 2438 Respiratory syncytial virus in Hematopoietic Stem Cell Transplantation- Risk Stratification and Outcomes
- 2439 Prevalence of Hepatitis E Virus Infection Among Kidney Transplant Recipients in King Chulalongkorn Memorial Hospital, Thailand
- 2440 Clinical outcomes in HIV⁺/HCV⁺ co-infected kidney transplant recipients in the pre- and post-direct acting antiviral (DAA) therapy eras: 10 year single center experience.
- 2441 Impact of CMV Blips in Transplant Recipients
- 2442 Ganciclovir-resistant CMV (GCV-R CMV) Infection Leads to Poor Clinical Outcomes and Economic Burden of Ganciclovir-resistant *Cytomegalovirus* Infection in Lung Transplant Recipients
- 2443 BK polyoma virus nephropathy in hematopoietic cell transplant recipients with renal dysfunction
- 2444 Coronavirus Infection in Hematopoietic Stem Cell Transplant Recipients
- 2445 Respiratory Viral Infections in Multiple Myeloma Patients
- 2446 Clinical features and outcomes of immunocompromised adults hospitalized with laboratory-confirmed influenza in the United States, 2011–2015
- 2447 Incidence and Outcomes of Cytomegalovirus (CMV) Infection among Hematopoietic Stem Cell Transplant (HSCT) Recipients
- 2448 Risk factors for development of cytomegalovirus resistance in solid organ transplantation: a retrospective nested case control study
- 2449 Changes in the CD4⁺ T cell phenotypes may contribute to CD8⁺ T cell exhaustion in chronic EBV high viral load pediatric solid organ transplant patients.
- 2450 Lymphopenia: a novel predictor for recurrent cytomegalovirus disease in solid organ transplant recipients
- 2451 Genetic Diversity of Epstein - Barr Virus Lytic Gene BZLF-1 among Patients with and without Post-transplant Lymphoproliferative Disorder

259. Poster Abstract Session

Viral Infections in Transplantation

Saturday, 12:30 p.m. – 2:00 p.m.

- 2428 Multiplex Detection of DNA Viruses in Transplant Recipients
- 2429 Danger of Biologic Therapy with Unrecognized Human T-cell Lymphotropic Virus 1 (HTLV-1)
- 2430 Epstein-Barr viral load monitoring for diagnosing posttransplant lymphoproliferative disorder in pediatric liver and heart transplant recipients
- 2431 Renal Dysfunction in a Cohort of Renal Transplant Recipients: Impact of BK Polyomavirus
- 2432 Five-Year Experience with Ganciclovir Resistant Cytomegalovirus in Renal Transplant Recipients at a Single Academic Center
- 2433 Immunologic monitoring with cytomegalovirus (CMV) ELISPOT for prediction of recurrent CMV infection and late-onset CMV disease in pediatric allogeneic hematopoietic stem cell transplant (HSCT) recipients
- 2434 Duration of Antiviral Prophylaxis and Risk of Herpes Zoster (HZ) among Patients with Solid Tumor Malignancy on Chemotherapy (STMc)
- 2435 Epidemiology and Outcomes of Fever During the First Two Months after Simultaneous Pancreas-Kidney (SPK) Transplant
- 2436 Cost of Hematopoietic Stem Cell Transplant and Cytomegalovirus Related Complications in a Large Inpatient Claims Database
- 2437 Cytomegalovirus (CMV) associated health care utilization in unmodified and *ex-vivo* T-cell depleted hematopoietic stem cell transplantation (HCT).
- 2438 Respiratory syncytial virus in Hematopoietic Stem Cell Transplantation- Risk Stratification and Outcomes
- 2439 Prevalence of Hepatitis E Virus Infection Among Kidney Transplant Recipients in King Chulalongkorn Memorial Hospital, Thailand
- 2440 Clinical outcomes in HIV⁺/HCV⁺ co-infected kidney transplant recipients in the pre- and post-direct acting antiviral (DAA) therapy eras: 10 year single center experience.
- 2441 Impact of CMV Blips in Transplant Recipients
- 2442 Ganciclovir-resistant CMV (GCV-R CMV) Infection Leads to Poor Clinical Outcomes and Economic Burden of Ganciclovir-resistant *Cytomegalovirus* Infection in Lung Transplant Recipients
- 2443 BK polyoma virus nephropathy in hematopoietic cell transplant recipients with renal dysfunction
- 2444 Coronavirus Infection in Hematopoietic Stem Cell Transplant Recipients
- 2445 Respiratory Viral Infections in Multiple Myeloma Patients
- 2446 Clinical features and outcomes of immunocompromised adults hospitalized with laboratory-confirmed influenza in the United States, 2011–2015
- 2447 Incidence and Outcomes of Cytomegalovirus (CMV) Infection among Hematopoietic Stem Cell Transplant (HSCT) Recipients
- 2448 Risk factors for development of cytomegalovirus resistance in solid organ transplantation: a retrospective nested case control study
- 2449 Changes in the CD4⁺ T cell phenotypes may contribute to CD8⁺ T cell exhaustion in chronic EBV high viral load pediatric solid organ transplant patients.
- 2450 Lymphopenia: a novel predictor for recurrent cytomegalovirus disease in solid organ transplant recipients
- 2451 Genetic Diversity of Epstein - Barr Virus Lytic Gene BZLF-1 among Patients with and without Post-transplant Lymphoproliferative Disorder

Financial Disclosures

Financial Disclosures 1. 119

Financial Disclosures 2. 134

Financial Disclosures 3. 142

Financial Disclosures 1

The following participants have provided financial disclosures for the below listed sessions:

Name	Session(s)	Company	Disclosure(s)*	What was received†
*Role of Faculty Member			†What was received	
A. Board Member	F. Investigator	J. Shareholder (excluding diversified mutual funds)	1. Salary	6. Research grant
B. Collaborator	G. Member		2. Educational grant	7. Research support
C. Consultant	H. Research contractor	K. Speaker	3. Educational support	8. Speaker honorarium
D. Employee	I. Scientific advisor (Review panel or Advisory committee)	L. Independent contractor	4. Grant recipient	9. Consulting fee
E. Grant investigator		O. Other	5. Licensing agreement or royalty	10. Other financial benefit
Alexander, Barbara D.	PW3	Astellas	E, I	6, 9
		Gilead	F	7
		Scynexis	E, I	6, 9
		Shire	F, I	6, 9
Ali, Omar	173	MedImmune	D	1
Anderson, Evan J.	212, 233	AbbVie	C	9
		MedImmune	H	6, 7
		NovaVax	H	7
		Regeneron	H	6
Andes, David	007, 088, 107, 109, 116, 126, 128, 209	Actelion	E	4
		Amplix	E	4
		Astellas	E	4
	180	Cidara	E	7
	007, 088, 107, 109, 116, 126, 128, 209	Cidara	E	4
		Geom	E	4
		Medicines	C	9
		Meiji	E	4
	007, 088, 107, 109, 116, 126, 128, 180, 209	Paratek	E, H	6, 7
	007, 088, 107, 109, 116, 126, 128, 209	Theravance	C, E	4, 9
		Zavante	C, E	4, 9
Andrew, Melissa K.	233	GSK	E	6
		Pfizer	E	6
		Sanofi-Pasteur	E	6
Apewokin, Senu	148	Astellas	I	9
		T2 biosystems	F	7
Arias, Cesar	088, 107, 109, 116, 126, 180, 209, 226	Allergan	E	6
		Merck	E	4
		The Medecins Company	E	6
Asturias, Edwin J.	PW3	Takeda Pharmaceuticals	C, E	4
Atmar, Robert	127	Takeda Vaccines, Inc.	E	6
Auwaerter, Paul	018, 283	Collidion	C	10
		JNJ	J	10
Barat, Stephen	147, 167	Scynexis, Inc.	D	1
Becker-Dreps, Sylvia	278	Pfizer	C, E	6, 9
Benson, Constance	203	Gilead	F	7
		GSK/ViiV	O	10
Berbari, Elie F.	096	Pfizer	H	4
Bhatt, Ami	036	Janssen Human Microbiome Institute / Johnson and Johnson	C	9
Bhavnani, Sujata M.	231	Melinta Therapeutics	H	7
		The Medicines Company	H	7
Bicanic, Tihana	222	Gilead Sciences	O	8
Bischoff, Werner	055	Celios	H	6, 8
Blaschke, Anne J.	252	BioFire Diagnostics LLC	B, F, O	5, 7
	040, 145	BioFire Diagnostics, LLC	B, E, F, O	5, 7
	145	Gilead Sciences, Inc.	F	7

Name	Session(s)	Company	Disclosure(s)*	What was received†
Blumberg, Emily.....	092, 266	Bristol Myers Squibb	O	9
.....	Glaxo Smith Kline	O	10
.....	Merck	C	9
.....	Shire	F	7
.....	The Medicine Shop/Rempex	F	7
Boeckh, Michael.....	114, 229	GlaxoSmithKline	H	7
.....	Merck	F, H, I	7, 9
Bonine, Nicole G.....	076	Allergan plc.....	D	1
Bonomo, Robert A.....	088, 107, 109, 116, 126, 180, 209	Allegra	E	6
.....	Allergan	E	6
.....	Entasis.....	E	6
.....	GSK.....	E	6
.....	Merck.....	E	6
.....	Roche	E	6
.....	Shionogi	E	6
.....	Wockhardt	E	6
Borges, Álvaro H	259	Lundbeckfonden	O	4, 6
Borrito-Esoda, Katyna	167	Scynexis Inc	C	9
Bradley, John S.	029	Merck & Co., Inc.	F	7
Britt, Nicholas S.....	052, 232	Gilead Sciences, Inc.	E	9
.....	Merck & Co., Inc.	E	9
Broyles, Michael.....	168	bioMerieux	I	8
.....	Roche Diagnostics	I	2, 9
.....	Thermo Fisher Scientific	I	2, 9
Bryant, Amy	147	Motif Biosciences	E	6
Bryant, Kristina	113, 204, 206, 268	Pfizer	E	7
Burdet, Charles	148	Da Volterra	C, H	9
Busch, Michael	027	Blood Systems, Inc.	D	1
.....	Grifols, Inc.	B, E	6, 8
.....	Roche Molecular Systems	B, F	7, 8
Butler, Lesley	233	Genentech, Inc.	D	1
Butt, Adeel	059	Merck	F	4
Cai, Bin	052	Shionogi Inc	D	1
Calfee, David P.....	261	Hardy Diagnostics	O	10
Cammarata, Sue	088, 107, 231	Melinta Therapeutics	D	1
Carling, Philip.....	150	Ecolab	C	10
Caro, Luzelena	231	Merck	D	1
Cassone, Marco	242	Centers for Disease Control and Prevention	F	7
.....	National Institute on Aging	E	6
Castanheira, Mariana	147	Achaogen	H	6
.....	051	Allergan	H	6
.....	147	Rempex, a wholly owned subsidiary of The Medicines Company	H	6
Celum, Connie	100	Gilead Sciences	E	10
Center, Kimberly J.....	PW4	Pfizer Inc.....	D, J	1, 10
Chemaly, Roy	220	Ansun	F	6
.....	180	Astellas	C	9
.....	Chimerix	C, F	6, 9
.....	220	Gilead	C, F	6, 9
.....	GSK	F	6
.....	180	Merck	C, E, F	4, 6, 9
.....	Novartis	F	6
.....	Oxford Immunotec	C	9
.....	Shire	F	6
Chilson, Erica	166	Pfizer Inc	D, J	1
Choi, Sae Rom	252	Korean Society of Pediatric Infectious Disease	G	6
Clarke, Kimon	235	BioFire Diagnostics, LLC	D	1
Cline, Adriana	237	Bacterioscan	O	10
Colwell, Rita	072	CosmosID	A	1
Connelly, Sheila	072	Synthetic Biologics, Inc.	D	1
Connolly, Lynn	088, 107	Achaogen, Inc.	D, J	1
Conway, James	087	gsk	C	9
.....	sanofi pasteur	E	4
Cook, Camille	073	BioFire Diagnostics	D	1
Cornely, Oliver A.....	231	Astellas Pharma, Inc.	C, H, K	6, 8, 9
Cornett, Julia Kang	059	Gilead Sciences	O	4
Crane, Heidi M.....	188	VIIV	I	10
Creech, C. Buddy	PW4	GSK Vaccines	C, E	6, 9
.....	Horizon Pharmaceuticals	I	9

*Role of Faculty Member			†What was received	
A. Board Member	F. Investigator	J. Shareholder (excluding diversified mutual funds)	1. Salary	6. Research grant
B. Collaborator	G. Member		2. Educational grant	7. Research support
C. Consultant	H. Research contractor	K. Speaker	3. Educational support	8. Speaker honorarium
D. Employee	I. Scientific advisor (Review panel or Advisory committee)	L. Independent contractor	4. Grant recipient	9. Consulting fee
E. Grant investigator		O. Other	5. Licensing agreement or royalty	10. Other financial benefit

Name	Session(s)	Company	Disclosure(s)*	What was received†
		Pfizer	E	6
		Premier, Inc.	C	9
Crowe, James E.	287	Atreca	B	4
		Inovio	B	6
		Mapp Biopharmaceutical	F	5
		Moderna	F	4
		Novavax	C	9
		PaxVax	I	9
		Regeneron	C	9
		Sanofi	C	5, 6, 9
		Sanofi Pasteur	F	5
		Takeda	I	6, 9
Curcio, Daniel	051, 233	Pfizer	D	1
Currier, Judith	082	Theratechnologies	E	6
Custodio, Joseph	156	Gilead Sciences	D, J	1
D'Amico, Ronald	156	ViiV Healthcare	D, J	1, 10
Daar, Eric	007, 021, 120, 201	Bristol Myers Squibb	C	9
	228	Bristol-Myers Squibb	C	9
	007, 021, 120, 201	Gilead	C, E	6, 9
	228	Gilead Sciences, Inc.	C, E, I	7, 9
	007, 021, 120, 201, 228	Janssen	C, E, I	7, 9
		Merck	C, E, I	6, 7, 9
	007, 021, 120, 201	Teva	C	9
	228	Teva Pharmaceuticals	C, I	9
	007, 021, 120, 201	Theratechnologies	C	9
	007, 021, 120, 201, 228	ViiV	C, E, I	4, 7, 9
Dagan, Ron	165, 212	Memed	C	9
		MSD	C, E, F, H, I	4, 6, 7, 9
		Pfizer	C, E, F, H, I, K	4, 6, 7, 8, 9
	212	VaxYnethic	C	9
Dawson, Paul	233	Diatherix Laboratories, LLC	D	1
De Wals, Philippe	228	GlaxoSmithKline	E, I	4, 10
	165	GSK	F, I	6, 10
	228	Novartis	E, I	4, 10
	165, 228	Pfizer	E, I	4, 6, 10
	228	Sanofi-Pasteur	E, I	4, 10
	165	Sanofi Pasteur	E	6, 10
Denning, David	086	Basilea	K	9
		F2G	J	10
		Gilead	C, K	8, 9
		MSD	K	8
		Pfizer	K	8
Desjardins, Michaël	046	Alere	H	7
		BD	H	7
		bioMerieux	H	7
		Oxoid	H	7
Dhand, Abhay	242	Astellas	C	9
		Merck, Pfizer, Allergan	K	8
Doi, Yohei	109	Allergan	I	9
		Roche	I	9
		The Medicines Company	I	9
Domachowske, Joseph B.	135	Glaxo Smith Kline	F	6
		Janssen	F	6
		Medimmune	F	6
		Novavax	F	6
		Pfizer	F	6
		Regeneron	F	6
Dorr, Mary Beth	148	Merck & Co., Inc.	D, J	10
Downes, Kevin	169	Merck, Inc.	E	6
		Pfizer, Inc.	E	6
Doyle, Michael	127	Conagra Brands	C, I	9

Name	Session(s)	Company	Disclosure(s)*	What was received†
		Foster Poultry Farms	C, I	9
		McDonald's	C, I	9
		Roka Bioscience	A	1
		Taco Bell	C, I	9
Dropulic, Lesia	152	Sanofi Pasteur	B	7
Dubberke, Erik R.	113	Alere	O	8
		Biofire	O	8
		Merck	C	9
		Pfizer	C	9
		Rebiotix	C, F	7, 9
	231	Rebiotix, Inc.	I	9
	113	Sanofi Pasteur	E	4
		valneva	C	9
Dudley, Michael	088, 107	The Medicines Company	D, J	1
Dukhovny, Dmitry	268	Vermont Oxford Network	B, C, O	1, 8, 9
Duncan, Leonard R.	051	Theravance Biopharma US, Inc.	H	6
Dunne, Michael	231	Iterum Therapeutics	D, J	1
Eby, Elizabeth L.	243	Medtronic, plc	D	1
Echols, Roger	088, 107	Shionogi, Inc.	C	9
Eckburg, Paul B.	231	Zavante Therapeutics, Inc.	C, J	9
Edmonds-Wilson, Sarah	151	GOJO Industries	D	1
Edwards, Kathryn	179	Novartis	E	6
Edwards, Morven	001	Pfizer, Inc.	E	6
Ellis-Grosse, Evelyn J.	088, 107	zavante	J	1
	167, 231	Zavante Therapeutics, Inc.	D, J	1
Ellison, Richard T.	134	Philips Healthcare	C, E	6, 9
Elsherif, May	139	Canadian Institutes of Health Research	F	6
		GSK	F	6
		Public Health Agency of Canada	F	6
Emu, Brinda	188	TaiMed Biologics	D, J	1
Englund, Janet	136, 179, 264	Alios	F	7
		Chimerix	F	7
		Gilead	C, F	7
		GlaxoSmithKline	F	7
		MedImmune	F	7
		Novavax	F	7
Eron, Joseph	021	Bristol-Myers Squibb	C	9
		Gilead Sciences	B, E	4, 9
		Janssen	C, E	6, 9
		Merck	C	9
		ViiV Healthcare	C, E	6, 9
Espinosa, Claudia	059	Astrazeneca	F	6
		Cempra	F	6
		Multiple Industry Sponsors (Merck, Sanofi Pasteur, Novartis, GlaxoSmithKline, Pfizer, Gilead)	O	7, 10
		Regeneron Pharmaceuticals, Inc	F	6
		The Medicines company	F	6
Fang, Ferric C.	084, 208	BioFire	B, C, I	7, 8, 9
		Cepheid	B, C, I	2, 7, 8, 9
Farmakiotis, Dimitrios	180	Astellas Pharma	O	7
Ferry, Tristan	045	HERAEUS	C	8
File, Thomas M.	240	BioMerieux	I	9
Flamm, Jason A.	156	Gilead	F	7
Flamm, Robert K.	147	Basilea Pharmaceutica International Ltd.	H	6
		Melinta Therapeutics	H	6
		Paratek Pharma, LLC	H	6
Flash, Charlene	112	Gilead Sciences	I	9
Flattery, Amy	077	Merck	D	1
Fowler, Vance	016, 214	Green Cross, Cubist, Cerexa, Durata, Theravance; Debiopharm	C, O	8, 9
	214	NIH, Basilea, MedImmune, Cerexa/Forest/Actavis/Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Cubist/Merck; Medical Biosurfaces; Locus; Affinergy; Contrafect; Karius	E	6
	016	NIH, MedImmune, Cerexa/Forest/Actavis/Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Cubist/Merck; Medical Biosurfaces; Locus; Affinergy; Contrafect; Karius; Genentech	E	4
		Patent Pending	O	10
	016, 214	Pfizer, Novartis, Galderma, Novadigm, Durata, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., Cerexa, Tetrphase, Trius, MedImmune, Bayer, Theravance, Cubist, Basilea, Affinergy, Janssen, xBiotech, Contrafect	C	9

*Role of Faculty Member			†What was received	
A. Board Member	F. Investigator	J. Shareholder (excluding diversified mutual funds)	1. Salary	6. Research grant
B. Collaborator	G. Member		2. Educational grant	7. Research support
C. Consultant	H. Research contractor	K. Speaker	3. Educational support	8. Speaker honorarium
D. Employee	I. Scientific advisor (Review panel or Advisory committee)	L. Independent contractor	4. Grant recipient	9. Consulting fee
E. Grant investigator		O. Other	5. Licensing agreement or royalty	10. Other financial benefit
Name	Session(s)	Company	Disclosure(s)*	What was received†
Fraser, Victoria	106	UpToDate	O	5, 10
		CDC	E	6
		Express Scripts	O	10
		Foundation for Barnes-Jewish Hospital	E	6
		NIH	E	6
Fraser, Victoria J	204	CDC	E	6
		Express Scripts	O	10
		Foundation for Barnes-Jewish Hospital	E	6
		NIH	E	6
Frenette, Catherine	PW6	Abbvie	K	8
		Bristol Meyers Squibb	K	8
		Gilead	K	8
		Merck	K	8
		Salix	K	8
Furuno, Jon P	090, 259	Merck & Co	C, E	6, 8, 9
Gaensbauer, James	049	PanTheryx, Inc	E, F	6
Galgiani, John	221	Pfizer	J	10
		Valley Fever Solutions	A, J	7
Gallant, Joel	PW3	AbbVie	E	7
		Bristol-Myers Squibb	E, I	7, 9
		Gilead Sciences	D, I	1, 7, 9
		Janssen Therapeutics	E	7
		Merck & Co	H, I	7, 9
		Sangamo Biosciences	E	7
		Theratechnologies	I	9
		ViiV Healthcare/GlaxoSmithKline	E, I	7, 9
Gandhi, Rajesh	PW3, 005, 012, 037, 129, 287	EMD Serono	C	9
		Gilead	O	2
		Merck	O	2
		Theratechnologies	I	9
		ViiV	O	2
Gelone, Steven P	088, 107	Nabriva Therapeutics	D, J	1
Georgiades, Benjamin	047	Allergan plc	D	1
Gilbert, David	PW1	Biofire	E	6
		Biomerieux	C	9
		Medicine company	O	9
Girgis, Samia A	168	MSD	F	7
Giuliano, Karen	233	Sage Products	D	1
Gohil, Shruti K	241	Clorox	O	10
		Sage Products	O	10
		Xttrium Laboratories	O	10
Golan, Yoav	231	Achaogen, Inc	C, J	9
	148	Allergan	E, I	6, 8
		Merck & Co., Inc	E, I, K	7, 8
		Pfizer	I	8
		Seres Pharmaceuticals	I	8
		The Medicines Company	I	8
Good, Steven	167	Atea Pharmaceuticals, Inc	D, J	1
Gorse, Geoffrey J	161	Nova Immunotherapeutics Limited	O	10
Gottfredsson, Magnus	189	Astellas	C	8
		Gilead	E, I	7, 9
Greenberg, David	017, 036, 103	Accelerate Diagnostics	C, I	9
		Boston Pharmaceuticals	C, I	9
		Sarepta	O	5
Griffiths, Paul	114	Shire	O	10
Groll, Andreas H	077	Merck Sharp & Dohme	C, F, I, K	8, 9
Gupta, Kalpana	269	Iterum Therapeutics	C	9
		Melinta Therapeutics	C	9
		Paratek Pharmaceuticals	C	9
		Tetraphase Pharmaceuticals	C	9
Gupta, Vivek	239	International Society of Infectious Diseases, USA	E	6
Haessler, Sarah	094, 111	AHRQ	F	6

Name	Session(s)	Company	Disclosure(s)*	What was received†
Halasa, Natasha B.	163	Astra Zeneca	H	4
		Sanofi Pasteur	H	7
Hamelin, Marie-Ève	173	BioCryst Pharmaceuticals	B	7
Hammond, Sarah	124	Merck	F	7
Hasbun, Rodrigo	137, 251	Biofire	K	8
		Biomerieux	C	9
		Medicine's Co	K	8
		Merck	K	8
		Pfizer	K	8
Hayajneh, Wail	138	Merck & Co., Inc.	C	9
Hayden, Frederick	221	Celltrion	O	10
		GSK	O	10
		Seqirus	C	10
		Shionogi	C, I	10
		U of Alabama Antiviral Drug Discovery and Development Consortium	I	9
		WHO	C	9, 10
Hayden, Mary K.	197, 225	CDC	E	6
	079	Clorox	O	10
	197, 225	Clorox, Inc.	E, O	7, 10
	079, 197, 225	Molnlycke	O	10
	197	OpGen	O	7
	079, 225	OpGen, Inc.	O	7
	079	Sage Products	O	10
	197, 225	Sage, Inc.	O	10
Heineman, Thomas	138	Genocea Biosciences	D	1
Heineman, Thomas C.	229	GSK group of companies	C, J	9
Heinrich, Kirstin	243	Pfizer Inc.	D	1
Hemmersbach Miller, Marion	253	T32 Research Grant (NIH)	O	4, 10
Henn, Matthew	148	Seres Therapeutics	D, J	1, 10
Hernández-Gómez, Cristhian	168	Merck Sharp & Dohme	C	9
		Pfizer	C	9
Hicks, Charles	112, 160	Gilead Sciences, Inc.	C, I	9
		Janssen	C, I	9
		Merck	C, I	9
		ViiV	C, I	9
Hirsch, Elizabeth B.	147	Merck	E	6
		The Medicines Company	K	8
Hodges, Michael R.	231	Amplix Pharmaceuticals	D	1
Horn, Patrick	088, 107, 231	Tetraphase Pharmaceuticals	D	1
Houngsaitong, Jantana	167	Thai Meiji Co., Ltd	O	6
Hsu, Katherine	181	Gilead	I	10
		GlaxoSmithKline	I	10
Huang, David	088, 107, 167, 231	Motif Bio	D	1
Huang, Susan S.	134, 194	3M	O	10
		Clorox	O	10
		Molnlycke	O	10
		Sage Products	O	10
		Xttrium Laboratories	O	10
Hughes, James M.	097	Member, PREDICT 2 External Advisory Cmte, University of California, Davis; Project funded by USAID	C	9
Humar, Atul	205, 271	Astellas	E, I	6, 8
		Chimerix	I	8
		Qiagen	E	6
Hurst, Simi	160	Medscape Education	D	1
Idelevich, Evgeny A.	234	Bruker	O	5
Inoue, Satoshi	231	Daiichi Sankyo Co., Ltd.	D	1
Isaacs, R.	231	Entasis Therapeutics	D	1
Ison, Michael G.	205	Beckman Coulter	E	6
		Chimerix	E	6
		Gilead	E	6
Jain, Mamta K.	059	Gilead	E	6, 7
		Merck	E	6
Jhaveri, Ravi	PW4, 218	Abbvie	E, F	4, 7
		Gilead	E, F	4, 7
		Merck	E	4, 6
Jinadatha, Chetan	058	NIH	E	4
		Xenex Healthcare Services	O	7

*Role of Faculty Member			†What was received	
A. Board Member	F. Investigator	J. Shareholder (excluding diversified mutual funds)	1. Salary	6. Research grant
B. Collaborator	G. Member		2. Educational grant	7. Research support
C. Consultant	H. Research contractor	K. Speaker	3. Educational support	8. Speaker honorarium
D. Employee	I. Scientific advisor (Review panel or Advisory committee)	L. Independent contractor	4. Grant recipient	9. Consulting fee
E. Grant investigator		O. Other	5. Licensing agreement or royalty	10. Other financial benefit

Name	Session(s)	Company	Disclosure(s)*	What was received†
Johnson, Kelly	172	Merck & Co., Inc.	D	1
Johnston, Brian D.	147	Actavis	B	7
		Merck Sharpe & Dohme, Corp.	B	7
Jones, Bruce	168	ALK	C, E, I	4, 8, 9
	141	Allergan	K	8
Jordan, Robert	228	Gilead	D	1
Kaleko, Michael	072	Synthetic Biologics, Inc.	D, J	1, 10
Kaplan, Sheldon L.	278	Pfizer	E, O	6, 8
Karam, George H.	PW1	Ilum	I	9
		Merck	O	8
		Philips Health Care	I	9
		Shionogi	C	9
Katsube, Takayuki	231	Shionogi & Co., Ltd.	D	1
Kaye, Keith S.	126, 231	Merck	C, E	7, 9
		The Medicines Company	C, E	7, 9
		Xellia	C	9
Kelly, Ciaran P.	148	TBD	F	8
Keyloun, Katelyn R.	141	Allergan	D	1
Khanna, Sahil	148	Rebiotix, Inc.	I	9
Kim, Eun Jin	241	Korean Nosocomial Infections Surveillance System (KONIS)	F	7
King, Jennifer	233	Novavax	F	7
Kinoshita, Noriko	168	Standardization and dissemination of a community based network of infection control targeting children MHLW H29-SHINKOGYOSEI-IPAN-002	A	1
Kirn, Thomas	084	T2 Biosystems	L	8
Kleiboeker, Steve	145	Viracor Eurofins Laboratories	D	1
Klein, Nicola P.	150, 152, 233	GSK	F	4
		MedImmune	F	4
	150	Merck & Co.	F	4
	152, 233	Merck & Co.	F	4
	150, 152, 233	Pfizer	F	4
	152, 233	Protein Science	F	4
	150	Protein Sciences	F	4
	150, 152, 233	Sanofi Pasteur	F	4
Kleinman, Steve	271	Cerus Corporation	C, J	9
Klinker, Kenneth	077	The Medicines Company	I	9
Knight, Rob.	119	American Academy of Anti-Aging Medicine	O	8
		Biota, Inc.	A, J	1
		CommenSe Inc.	A	9
		J&J/Janssen Human Microbiome Innovation Center	A, C	9
		Prometheus Therapeutics & Diagnostics	A, C	9
Kobzik, Lester	167	BioAegis	B, O	10
Kociolek, Larry	206	Actelion	I	9
		Alere/Techlab	F	7
		Merck	E	4
Kokai-Kun, John	042, 231	Synthetic Biologics, Inc.	D	1
Kontoyiannis, Dimitrios P.	044, 198	Amplix	O	8
		Astellas	H	7, 8
		Cidara	O	8
		F2G	O	8
		Merck	O	8
		Pfizer	H	7, 8
Krilow, Leonard R.	252	AstraZeneca/MedImmune	C	6, 7
Kubiak, David W.	232	Astellas Pharma	C	9
		Shionogi	C	9
Kuehnert, Matthew	271	MTF	D	1
Kuhn, Susan	015	Sanofi Pasteur Canada	F	10
Kumar, Ashok	076	Astellas Pharma Global Development, Inc	E	6
Kumar, Deepali	184	GSK	E	4
		Pfizer	K	8
		Sanofi	K	8
Lacy, D. Borden	089	MedImmune	B	7
		Merck	B	7

Name	Session(s)	Company	Disclosure(s)*	What was received†
Lakota, Elizabeth	231	Paratek Pharmaceuticals	H	7
Landon, Emily	151	GOJO	O	10
Landovitz, Raphael J.	223	Gilead Sciences	E, I	6, 9
LaPlante, Kerry	150	Achaogen	I	9
.....	Allergan	I	9
.....	Bard/ Davol	I	9
.....	Cempra	I	9
.....	Merck	E	4
.....	Ocean Spray	E, I	4, 9
.....	Pfizer	E	4
.....	The Medicines Company	E	4
.....	Zavante	I	9
Larson, Kajal	077, 231	Merck	D	1
Lautenbach, Ebbing	206	3M	E	6
.....	AstraZeneca	E	6
Lawrence, Laura	231	Melinta	D	1
Leber, Amy	182	BioFire Diagnostics	E, I, K	6, 8, 10
.....	Cepheid	E	6
.....	Diasorin	E	6
.....	Hologic	E, K	6, 8, 10
Lee, Brian R.	074	Merck	E	4
.....	PCORI	E	4
Lee, Henry	163	AstraZeneca	E	6
Lee, Jason	161	Sanofi Pasteur	D	1
Lennox, Jeffrey	201	ViiV	E	6
Lewnard, Joseph	073, 122	Pfizer	E	6
Lin, Lynn-Yao	147	Allergan plc	D	1
Lin, Michael Y.	052	OpGen, Inc.	O	7
.....	Sage, Inc.	O	10
Lines, Tara	160	National Institutes of Health	F	10
Lionakis, Michail	086, 198	Matinas BioPharma	O	6
.....	Viamet Inc.	O	4
.....	048	Viamet Pharmaceuticals	O	7
Liu, Catherine	180	Theravance	C	9
Ljungman, Per.	139	Merck & Co., Inc.	C, F	6, 8, 9
Lodise, Thomas	042	Allergan plc	C, I, K	8, 9
Lodise, Thomas P.	132	allergan.	C, E, I, K	8, 9
.....	medicines company	C, E, I, K	7, 8, 9
.....	melinta	C	9
.....	motif	C, I	9
.....	nabriva	C	9
.....	paratek	C, I	9
Loeb, Mark	212	Astra Zeneca	O	8
.....	Canadian Institute for Health Research	O	6
.....	Sanofi pasteur	I, O	7, 8
.....	Seqirus	O	6
.....	World Health Organization	I	7
Lomovskaya, Olga	231	The Medicine's Company	D, J	1
López-Fauqued, Marta. ...	152	GSK Biologicals'	D	1
Lu, Bin	233	Medimmune	D	1
Luteran, Briann	067	Viiv	E	6
Lutgen, Cory B.	237	Viracor Eurofins Clinical Diagnostics	D	1
M. Rubino, Christopher ..	231	The Medicines Company	H	7
Maglione, Paul	017	Shire	I	9
Magyarics, Zoltan	138	Arsanis Biosciences GmbH	D	1
.....	Arsanis, Inc.	J	10
Malani, Anurag	PW2	Vizient, Inc.	C	9
Manning, Brendan	236	T2 Biosystems	D, J	1
Mansbach, Robert	167	Amplix Pharmaceuticals Inc.	C	9
Marr, Kieren	198	Amplix	C	9
.....	Chimerix	C	9
.....	Cidara	C	9
.....	F2G	C	9
.....	Merck	C	9
.....	MycMed Technologies	A	5
.....	Scynexis	C	9
.....	Vical	C	9
Marra, Andrea	167	Melinta Therapeutics	D	1
Martel-Laferrrière, Valérie .	059	Abbvie	E	6

*Role of Faculty Member			†What was received	
A. Board Member	F. Investigator	J. Shareholder (excluding diversified mutual funds)	1. Salary	6. Research grant
B. Collaborator	G. Member		2. Educational grant	7. Research support
C. Consultant	H. Research contractor	K. Speaker	3. Educational support	8. Speaker honorarium
D. Employee	I. Scientific advisor (Review panel or Advisory committee)	L. Independent contractor	4. Grant recipient	9. Consulting fee
E. Grant investigator		O. Other	5. Licensing agreement or royalty	10. Other financial benefit
Name	Session(s)	Company	Disclosure(s)*	What was received†
		Gilead Inc.	C, E	6, 9
		Merck	C	9
Martin, Emily T.	233, 252	Merck	I	6
		Multiparty Group For Advice on Science	I	6
		Pfizer	I	6
Marty, Francisco M.	092, 274	Astellas Pharma US	C, E	4, 9
		Chimerix	C, E	4, 9
		Fate Therapeutics	I	9
		Gilead Sciences	C, E	4, 9
		LFB	C	9
		Merck	C, E, I	4, 9
		Roche Molecular Systems	C	9
		Shire	C, E	4, 9
Masuda, Nobuhisa	167	Daiichi Sankyo Co., Ltd.	D	1
Mayer, Kenneth	006	Gilead Sciences	E	6
		VIIV Healthcare	E	6
Maynard, Jennifer	029	Synthetic Biologics, Inc.	B	7
McCann, Eilish	052	Merck	D	1
McGovern, Paul	231	Paratek Pharmaceuticals	D, J	1
	088, 107	Paul McGovern	D	1
McKinnell, James A.	190	3M	O	10
	075, 190	Achaogen	H, I, J	7
	231	Achaogen, Inc.	C, J	9
	075, 190	Allergan	H, I, K	7, 8, 9
		Cempra	H, I	7
	190	Clorox	O	10
	075, 190	Expert Stewardship, LLC	A, D	1
	190	Sage Products	O	10
	075, 190	Science 37	H	1
		Theravance	H	7
		Thermo Fisher	I	1
	190	Xttrium Laboratories	O	10
McKinnon, John	145	Abbott Molecular	K	4, 6, 8
McLaughlin, John	166	Pfizer Inc	D, J	1
McLean, Huong Q.	229	MedImmune	E	7
McNeil, Jonathon	029	NIAID, NIH	E	4
McNeil, Lisa K.	173	Genocoe Biosciences	D	1
Mejias, Asuncion	038	Abbvie	C, I	8
		Janssen	F, I	7, 9
		NIH	F	6
		Novartis	O	8
Melia, Michael T.	PW3	Merck, Sharpe & Dohme; Janssen; Gilead; Bristol-Myers Squibb; and AbbVie	F	7, 10
Melo-Cristino, Jose	051, 164	Bial	K	8
		GSK	E, K	4, 8
		Novartis	K	8
		Pfizer	E, K, L	4, 6, 8
Mendes, Rodrigo E.	051	AstraZeneca	H	6
		Melinta Therapeutics	H	6
	147	Merck	H	6
	051, 165, 166	Pfizer, Inc.	H	6
Merchant, Sanjay	057, 143	Merck & Co., Inc.	D, J	1
Micek, Scott	076	Merck	E	6
Michaels, Marian	108, 205	pzifer	E	4
Mody, Lona	090	Centers for Disease Control and Prevention	F	7
		National Institute on Aging	E	6
Molnar, Esther	076	Merck	E	6
Morris, Michele I	184	Chimerix	F, I	7, 9
		Merck	F	7
		Novartis	C	9
		Optimer	F	7
Morrissey, Orla	220	Gilead Sciences	E	6
		Merck, Sharp and Dohme Australia	E	6

Name	Session(s)	Company	Disclosure(s)*	What was received†
Mugavero, Michael J.	213	Gilead Sciences	I	9
Musey, Luwy	138	Meck	D	1
Naderer, Odin	139	Chimerix	D, J	1
Nagel, Jerod	233	Merck	E	6
Naggie, Susanna	120, 218	Abbvie	E, F	6, 7
.	BMS	E, F	6, 7
.	218	Clinical Care Options	K	10
.	120	Gilead	F	6
.	218	Gilead Sciences	C, E	6, 10
.	IAS-USA	K	10
.	120	Janssen	F	6
.	218	Janssen Pharmaceutical	E	7
.	Mentor Meetings	K	10
.	120, 218	Merck	E, F	6, 7
.	218	Platform Q Health Inc	K	10
.	Practice Point Communications	K	10
.	120, 218	Tacere	E, F	6, 7
.	218	Vindico	K	10
Nakamura, Rio	167	SHIONOGI & CO., LTD.	D	1
Nathan, Ramesh V.	075	Allergan	K	8
.	Merck	K	8
Newland, Jason	178	Allergan	E	6
.	Merck	E	6
Ngyen, Tri	155	Gilead FOCUS	D	4
Nicolau, David	209	Bayer	C, E, K	4, 8, 9
.	Cepheid	K	8
.	Merck	E, K	4, 8
.	Pfizer	K	8
.	Shionogi	E	4
Nir-Paz, Ran	233	SpeedX	E	6
Nolan, Terry	140	GSK group of companies	H, I	6
.	Pfizer	H	6
Nordby, Tera	243	3M	D	1
Nosanchuk, Joshua	PW8	National Board of Medical Examiners	G	10
Novak, Susan M.	009	Copan Diagnostics	C	9
.	Qvella	C	9
Nowak, Michael	045, 231, 233	Allergan plc	D	1
Nutt, Jamie	189	Viracor Eurofins Laboratories	D	1
Nyquist, Ann-Christine	087, 206	DebMed	I	9
.	PRA Health Sciences (AstraZeneca/Pfizer)	O	9
Olesky, Melanie	052	Tetraphase	D	1
Olsen, Margaret	130	Pfizer	C, E, I	6, 9
.	Sanofi Pasteur	E	6
Olson, Adriana	047	Mirodermis	E	6
Olson, Daniel	054	Takeda Pharmaceuticals	C	4
Olson, Linda	243	3M Health Care	D	1
Oostvogels, Lidia	152	GSK	D, J	1, 10
.	GSK group of companies	D, J	1, 10
Orenstein, Robert	231	Rebiotix, Inc	I	9
Orkin, Chloe	188	Gilead Sciences	E, I, K	6, 8, 9, 10
.	Janssen Pharmaceuticals	E, I, K	6, 8, 9, 10
.	MSD	E, I, K	6, 8, 9, 10
.	Viiv Healthcare	E, I, K	6, 8, 9, 10
Ostrosky-Zeichner, Luis	209	Astellas	C, E	6, 9
.	Cidara	E, I	6, 9
.	Merck	I, K	8, 9
.	Pfizer	E, K	4, 8
.	Scynexis	E, I	4, 9
Oved, Kfir	144	MeMed Diagnostics	A, D, J	1
Overly, Shannon	054, 075	Teqqa, LLC	D	1
Page, Iain	258	Astellas	E	6
.	Dynamiker	B, O	7
.	Genesis	B, O	7
.	Serion	B, O	7
.	Siemens	B, O	7
Paniagua, Miguel	PW8	NBME	D	1
Papanicolaou, Genovefa	231, 259	Astellas Pharma	C, E	6, 7, 9
.	Merck & Co	F, O	6, 7, 9

*Role of Faculty Member			†What was received	
A. Board Member	F. Investigator	J. Shareholder (excluding diversified mutual funds)	1. Salary	6. Research grant
B. Collaborator	G. Member		2. Educational grant	7. Research support
C. Consultant	H. Research contractor	K. Speaker	3. Educational support	8. Speaker honorarium
D. Employee	I. Scientific advisor (Review panel or Advisory committee)	L. Independent contractor	4. Grant recipient	9. Consulting fee
E. Grant investigator		O. Other	5. Licensing agreement or royalty	10. Other financial benefit

Name	Session(s)	Company	Disclosure(s)*	What was received†
Papp-Wallace, Krisztina M.	147.	Allegra	E	6
		Allergan	E	6
		Entasis	E	6
		Merck	E	6
		Roche	E	6
Parasrampur, Ridhi	156	GlaxoSmithKline	D, J	1
Paschke, Amanda	088, 107	Merck	D	1
Pastula, Susan	163	AstraZeneca	H	7
Patel, Nimish	233	Gilead Sciences, Inc.	E	6
		Merck & Co., Inc.	E	6
		Theravance Biopharma US, Inc.	C, K	8
Patel, Robin	284	A patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued	O	10
		Actelion	O	10
		ASM	A	10
		ASM and IDSA	O	10
		CD Diagnostics, BioFire, Curetis, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, and The Medicines Company	E	4
		Curetis	C	10
		NBME, Up-to-Date and the Infectious Diseases Board Review Course	O	10
Patel, Sameer	169	Merck Pharmaceuticals	F	6
Patel, Twisha	259	Merck	E	6
Paterson, David L.	231	Achaogen	C	9
		GlaxoSmithKline	C	9
		Merck	C, F	6, 9
		Shionogi	C	9
Patterson, Brandon J.	152	GSK	D, J	1, 10
		Pennsylvania Pharmacists Association	I	10
Patterson, Jan E.	147.	Young Living Essential Oils	L	1
Paukner, Susanne	147.	Nabriva Therapeutics	D, J	1
Pelton, Stephen I.	166	GSK	A	8, 9
		Merck vaccines	A	8, 9
		Pfizer	A, E	6, 8, 9
		Sequiris	A	8, 9
Pergam, Steven	117, 205.	Merck	C, F	9
Perl, Trish	191.	Medimmune	E	4
Perlin, David	167.	Amplix	H, I	6
		Astellas	H	6
		Cidara	H, I	6
		Matinas	I	7
		Merck	H	6
		Scynexis	H, I	6
Petrak, Russell	202	HHI Infusion	A, J	10
Phillip, Susan	129	GlaxoSmithKline	F	7
Plotkin, Stanley A.	131.	All vaccine manufacturers	C	9
		Vaxconsult	C	9
Pogue, Jason M.	076	Achaogen, Inc.	C	9
Polage, Christopher	208	Alere	F	7
		Beckman Coulter	C	9
		BioFire Diagnostics	I	6, 7, 9
		Cepheid	F	7
		GenePOC	I	9
		Meridian Bioscience	C	9
		Seres Therapeutics	I	9
		Singulex	C, I	9
		SlipChip	C	9
		TechLab	F	7
Polk, Christopher	156	Gilead Sciences	F	7
		Viiv Healthcare	F	7

Name	Session(s)	Company	Disclosure(s)*	What was received†
Porter, Danielle	156	Gilead Sciences, Inc.	D, J	1
Portsmouth, Simon	228, 231	SHIONOGI INC.	D	1
Poutsiaika, Debra D.	234	Mochida Pharmaceuticals	F	7
Powderly, William	086	Astellas	E	4
.....	Gilead	C	9
.....	Merck	C, E	4, 9
.....	MiraVista	E	4
Puenpatom, Amy	059	Merck	D	1
Puttagunta, Sailaja	052	Iterum Therapeu	D, J	1
Rada, Ana Mercedes	234	COLCIENCIAS	O	6, 7
Ramilo, Octavio	136	Abbvie	A	9
.....	Janssen	A, F	6, 9
.....	NIH	E	6
.....	Regeneron	A	9
Rana, Aadia	272	ViiV	I	9
Rao, Sonia	231	Allergan plc	D	1
Rao, Suchitra	252	GSK	F	7
Ray, Amy	109	Cubist	I, K	3, 8
.....	Merck	F, K	8
Rehm, Susan J.	274	Amgen	J	10
.....	Merck	J	10
.....	Pfizer	C, J	9, 10
Reilly, Joseph	231	Theravance Biopharma US, Inc.	I, K	8
Ridgway, Jessica P.	153	Gilead FOCUS	E	4
Robinson, Philip	022	Expert Stewardship, Inc.	A, D, J	1, 10
.....	Providence St. Joseph Health	C, O	9
Rodriguez-Morales, Alfonso J	226	Sanofi	I	9
Roilides, Emmanuel	044	Pfizer	E, F, H, K	4, 6, 8
Rosenblatt, Joel	167, 241	Infective Technologies, LLC.	J, O	5
.....	UT MD Anderson Cancer Center	I, O	5
Rowley, Anne	224	NIAMS-NIH	E	4
.....	UpToDate	O	9
Ruane, Peter	245	Abbott	F, I, K	7, 8
.....	BMS	C, F, K	7, 8, 9
.....	Boehringer	F, I, K	7, 8, 9
.....	Gilead	F, I, J	7, 9
.....	Idenix	F	7
.....	Janssen	F, I, K	7, 8, 9
.....	Merck	K	8
.....	ViiV	I, K	8, 9
Rupp, Mark E.	002	3M	C, E, I	6, 9
Rybak, Michael J.	126	Allergen	I	9
S. Konstantynovska, Olha	239	Kharkiv Medical Academy of Postgraduate Education.	D	1
Saag, Michael	174	BMS	C, E	6, 9
.....	Gilead	C, E	6, 9
.....	Merck	C, E	6, 9
.....	Proteus	C, E	6, 9
.....	ViiV	C, E	4, 9
Sader, Helio S.	147	Allergan	H	6
.....	The Medicines Company	H	6
.....	Wockhardt Bio Ag	H	6
Salim, Abdulbaset	172	Merck, Inc.	F	6
Salvana, Edsel Maurice	154, 156	Merck	I, K	8, 9
Sandkovsky, Uriel	259	Merck	E	6
Satlin, Michael	254	Allergan	E	6
.....	235, 254	Hardy Diagnostics	F	7
.....	254	Merck	E	4
Satta, Giovanni	234	Accelerate Diagnostics	F	7
Sax, Paul	112, 156	AbbVie	C	9
.....	BMS	C, F	6, 7, 9
.....	Gilead	C, F	6, 7, 9
.....	GlaxoSmithKline/ViiV	C, F	6, 7, 9
.....	Janssen	C	9
.....	Merck	C	9
Schelfhout, Jonathan	259	Merck	D	1
Schmader, Kenneth	131	GlaxoSmithKline	F	6
.....	Merck	F	6
Schooley, Robert T.	PW3	Antiva Biosciences	J	10

*Role of Faculty Member			†What was received	
A. Board Member	F. Investigator	J. Shareholder (excluding diversified mutual funds)	1. Salary	6. Research grant
B. Collaborator	G. Member		2. Educational grant	7. Research support
C. Consultant	H. Research contractor	K. Speaker	3. Educational support	8. Speaker honorarium
D. Employee	I. Scientific advisor (Review panel or Advisory committee)	L. Independent contractor	4. Grant recipient	9. Consulting fee
E. Grant investigator		O. Other	5. Licensing agreement or royalty	10. Other financial benefit

Name	Session(s)	Company	Disclosure(s)*	What was received†
		CytoDyn	C	9
		Gilead Sciences	I	4
Schuch, Raymond	147	ContraFect Corp	D	1
Schweizer, Marin	076, 130	B Braun	O	10
Scott, John	210	Merck	F	1
		Novartis	A	1
Selvarangan, Rangaraj	133	BioFire Diagnostics	A, F	6, 9
		Luminex Diagnostics	F	6
Sevinsky, Heather	156	ViiV Healthcare	D	1
Shaefer, Mark S.	065	ViiV Healthcare	D, J	1
Shaik, Jafar Sadik	156	GlaxoSmithKline	D, J	1
Shane, Andi L.	212	The Gerber Foundation	E	6, 10
Sharp, Marc	167	Linnaeus	D	1
Shaw, Peter	148	Merck & Co., Inc.	D	10
Sherman, Kenneth	218	AbbVie	F	6
		BMS	E	4
		Gilead	F, I	6, 9
		Intercept	F	6
		MedImmune	E, I	6, 9
		MedPace	I	9
		Merck	E, F, I	6, 9
		Watermark	I	9
Sherwood, Jim	152	Takeda Pharmaceuticals International AG	D	1
Shortridge, Dee	147	Melinta Therapeutics	H	6
		Merck	H	6
Simner, Patricia	197	bioMerieux	H	7
		Check-Points Health BV	H	7
Sims, Charles	045	Theravance Biopharma US, Inc.	F, K	6, 7, 8
Skarinsky, David	231	Zavante Therapeutics, Inc.	D, J	1
Slutsker, Laurence	033	Gates Foundation	E	7
		Innovative Vector Control Consortium	B	7
		Malaria No More - UK	B	7
		Tableau Foundation	B	7
		UNITAID	F	4
		USAID	B	4
Smulders, Maartje	233	Janssen Pharmaceutica Beerse	C	6
Snydman, David R	149	Actelion	E	6
		BioK +	C	9
		Merck	C, E	6, 9
		Shire	C	9
		Summit PLC	C, E	6, 9
Spellberg, Brad	118	Cempra, The Medicines Company, Medimmune, Tetraphase, AstraZeneca, Merck, Genentech, Forge, Pfizer	C	9
		Motif, BioAIM, Synthetic Biologics, Mycomed	J	10
Steenbergen, Judith N.	231	Paratek Pharmaceuticals	D, J	1
Strasfeld, Lynne	041, 256	Merck	L	1
Stulik, Lukas	231	Arsanis	D, J	1
Suaya, Jose	233	Pfizer Inc	D, J	1
Sulkowski, Mark	120	AbbVie	E, I	7, 9
		Gilead	E, I	7, 9
		Janssen	F, I	7, 9
		Merck	F, I	9
		Trek	I	9
Sullivan, Patrick	213	Centers for Disease Control and Prevention	C, E	6, 8
		Gilead Sciences	E	4
		MAC AIDS Fund	A	10
Sullivan, Sean M.	167	Vical Incorporated	D	1, 10
Syriopoulou, Vassiliki	051	Hellenic Center for Disease Control and Prevention	E	6
		Pfizer Inc. Pharmaceutical Company	E	6
Szajewska, Hania	036	Arla	E	4
		Biocodex	F, I	8, 9
		BioGaia	F, I	7, 8
		Danone/Nutricia	I	8, 9

Name	Session(s)	Company	Disclosure(s)*	What was received†
.....	Dicofarm	I.....	10
.....	Hipp	I.....	8
.....	NNI	I.....	8, 9
Tabak, Ying	052	Becton Dickinson and Company	A.....	1
Takata, Tohru	044	Taisho Toyama Pharma	K.....	8
Talbot, George H.	149	Actelion	A, C, I.....	9
Talbot, H. Keipp	PW1	Gilead	H.....	7
.....	Sanofi Pasteur	H.....	7
.....	VaxInnate	I.....	9
.....	Watermark/Sequirus	I.....	9
Talbot, Keipp	039, 131, 179, 212. .	Gilead	H.....	7
.....	MedImmune	H.....	7
.....	Sanofi Pasteur	H.....	7
.....	Sequirus	I.....	9
.....	VaxInnate	I.....	9
Talley, Angela K.	231	Allergan plc.....	D.....	1
Tan, Tina	087	Merck	E, I	4, 6
.....	Pfizer	E, I	4, 6
.....	Sanofi Pasteur	E, I	2, 6
Tebuegge, Marc	186	Cellectis/Qiagen	O.....	10
Temte, Jonathan	145	Quidel	F	7
Thomas, David	PW6, 218, 285, 287 .	Merck	I.....	9
.....	Oxford University Press.....	O.....	1
.....	UpToDate.....	O.....	1
Thompson, George R. . .	274	Associates of Cape Cod	C.....	9
.....	Astellas	C.....	7, 9
.....	Cidara	C.....	7
.....	Merck	C.....	6
.....	Scynexis	C.....	7, 9
.....	Vical	C.....	9
.....	Wako	C.....	6
Thompson, Matthew	238	Alere, Inc.	E.....	6
.....	Phoresa, Inc.	A, J.....	10
.....	Roche	C.....	9
Top, Karina A	172	GSK	F	6
.....	Pfizer	F	7
Torres, Victor	116	Janssen Biotech Inc.	B, E.....	4, 5, 6
Trang, Michael	231	Zavante Therapeutics, Inc.	H.....	7
Trautner, Barbara W.	269	Zambon Pharmaceuticals	E	6
Trotman, Robin	PW3	Merck	K.....	8
Truitt, Christopher	058	GermBlast	F	7
Tseng, Hung Fu	139	Novavax	E	6
Tsuji, Masakatsu	147	Shionogi & Co.	D.....	1
Van Anglen, Lucinda J. . .	141	Theravance	I.....	9
Van Duin, David	034, 051, 118, 274 .	Achaogen	I.....	9
.....	Allergan	I.....	9
.....	Astellas	I.....	9
.....	MedImmune	I.....	9
.....	Shionogi	I.....	9
Van Schooneveld, Trevor .	PW2	Rebiotrix	F	7
Van Wagoner, Nicholas . .	181	Genocea Biosciences	C	10
Van Wart, Scott A.	231	Arsanis	H.....	7
Vanchiere, John	252	BioCryst Pharmaceuticals	C, F.....	7, 9
Vecchio, Mariacristina. . .	228	Danone Research	D.....	1
Villegas, Maria Virginia .	168	Merck Sharp & Dohme	C.....	7, 9
.....	Pfizer	C.....	7, 9
Vink, Peter	152	GSK group of companies.	D.....	1, 10
Wagenlehner, Florian M.E.	231	Achaoge, Inc.....	C, F.....	9
Wald, Heidi	230	Colorado Hospital Association	C	9
Walmsley, Sharon	156	BMS	E, F, I, K.....	4, 6, 8, 9
.....	Gilead Sciences	A, C, E, F, I, K.....	4, 6, 8, 9
.....	GSK	A, C, E, F, I, K.....	4, 6, 8, 9
.....	Janssen	A, C, E, F, I, K.....	4, 6, 8
.....	Merck	A, C, E, F, I, K.....	4, 6, 8, 9
.....	ViiV Healthcare	A, C, E, F, I, K.....	4, 6, 8, 9
Walsh, Thomas J.	231	Allergan	C, F.....	6, 9
.....	Astellas	C, F.....	6, 9
.....	Merck	C, F.....	6, 9
.....	The Medicines Company.....	C, F.....	6, 9

*Role of Faculty Member			†What was received	
A. Board Member	F. Investigator	J. Shareholder (excluding diversified mutual funds)	1. Salary	6. Research grant
B. Collaborator	G. Member		2. Educational grant	7. Research support
C. Consultant	H. Research contractor	K. Speaker	3. Educational support	8. Speaker honorarium
D. Employee	I. Scientific advisor (Review panel or Advisory committee)	L. Independent contractor	4. Grant recipient	9. Consulting fee
E. Grant investigator		O. Other	5. Licensing agreement or royalty	10. Other financial benefit
Name	Session(s)	Company	Disclosure(s)*	What was received†
Wanda, Lisa	237	Karius, Inc.	B, D	1
Wang, Gui-Qiang	PW6	BMS	C, K	8, 9
		GSK	C, K	8, 9
		Roche	C, K	8, 9
Warren, David	113	Carefusion, Inc.	C	9
Wasserman, Matt	165	Pfizer	D	1
Webb, Brandon	044	Astellas Pharma Global Development, Inc.	E	6
Weinberg, Adriana	152	merck	E	6
Wicha, Wolfgang W.	167	Nabriva Therapeutics AG	D, J	1
Wilcox, Mark	231	Alere, Actelion Pharma, Astellas, Optimer, Sanofi Pasteur, Summit Pharma, bioMerieux, Da Volterra, Qiagen, Cerexa, Abbott, AstraZeneca, Pfizer, Durata Therapeutics, Seres Therapeutics, Valneva, Nabriva Therapeutics, Roche, The Medicines Company, Basilea P	C	9
		Alere, Actelion Pharmaceuticals, Pharmaceuticals, Astellas, Optimer Pharmaceuticals, Sanofi Pasteur, Summit Pharmaceuticals, bioMerieux, Da Volterra, Qiagen, Cerexa, and Abbott	E	4
		Cubist	C, E, K	4, 8, 9
		Merck & Co., Inc.	C	9
Wilkin, Timothy	129, 191	Bristol Myers Squibb	E	7
		Glaxo Smith Kline/ViiV Healthcare	C, E	6, 9
		Johnson&Johnson	J	10
Wiley, Barbara M.	234	Mount Sinai Hospital	F	3
Williams, Montgomery F.	169	BioFire Diagnostics	C	8
		Joint Commission Resources	C	8
Williams, S Elizabeth	160	pfizer fund	E	10
Wilmont, Sibyl	055	Columbia University Medical Center Pediatric Infectious Diseases	D	1
Wohl, David	188	Bristol-Myers Squibb	C	9
		Gilead Sciences	C, F	6, 9
		Janssen	C	9
		ViiV	C, F	6, 9
Wohl, David A.	156	Bristol Myers Squibb	C	9
		Gilead Sciences Inc.	C, F	6, 9
		Janssen	C	9
		ViiV	C, F	6, 9
Wong, Titus	145	bioMerieux	F	6
Wood, James	234	Diatherix	F	7
Wunderink, Richard	231	The Medicines Company	C, F	6, 9
Wyles, David L.	PW6, 120, 218	AbbVie	C, H, I	7, 9
		Gilead	C, E, H	6, 7, 9
		Merck	C, H	7, 9
Xie, Jinfu	167	Merck & Co. Inc.	D	1
Yacyszyn, Mary Beth	235	Merck	E	6
Yamano, Yoshinori	167	SHIONOGI & CO., LTD.	D	1
Yang, Fred	077	KBP Biosciences Co., Ltd.	D	1
Yang, Katherine	077	Merck	E	4
Young, Benjamin	156	Gilead	C, I	7, 9
		Merck	C, I, K	7, 9
		ViiV Healthcare	C, I	7, 9
Yun, Heather	PW8	American Board of Internal Medicine, Infectious Disease Board	A	10
Zaoutis, Theoklis	038	Astellas	C	9
		Merck	E	6
		nabrivav	C	9
Zerr, Danielle	092	Chimerix	E	4
Zhang, Dongmu	259	Merck	D	1
Zhang, Quanwu	249	Insmid Incorporated	D	1
Zhu, Chelsea	145	IDSA Foundations Medical Scholars Program 2015-2016	G	10
Zilberberg, Marya D.	044	Astellas	E	7
		Astellas Pharma Global Development, Inc.	E	7
Zimmer, Andrea	PW1	Astellas	F	7
		Merck	F	7
Zimmerman, Richard	140	Merck & Co, Inc.	E	6
		Pfizer, Inc.	E	6
		Sanofi Pasteur	E	6

Financial Disclosures 2

The following participants indicated that there were no financial disclosures for the below listed sessions:

A

Aagaard, Theis; 253
 Aaron, Justin G.; 254
 Abbas, Hashim; 259
 Abbas, Omar; 058
 Abbo, Lilian M.; PW3, 013, 125, 180
 Abdel-Messih Khalil, Ibrahim; 146
 Abdelaziz, Mohammed M.; 241
 Abdelraouf, Kamilia; 167
 Abdulhaleem, Mohammed; 236
 Abelenda, Gabriela; 232
 Abers, Michael; 216, 233
 Abou Chakra, Claire Nour; 150
 Abrams-Downey, Alexandra; 248
 Abrantes-Figueiredo, Jessica I.; 137
 Aburjania, Nana; 256
 Ackerman, Kathleen; 058
 Acosta, Kaitlyn; 074
 Adams, Daniel; 052
 Adams, Eleanor H.; 043
 Adams, Matthew; 240
 Adamson, Paul; 059
 Adani, Shaili; 232
 Addisu, Anteneh; 076, 232, 249
 Adjemian, Jennifer; 250
 Adler-Shohet, Felice C.; 249
 Advani, Sonali; 057
 Afzal, Zeeshan; 277
 Agarwal, Saroochi; 239
 Aggarwal, Somya; 138
 Agrawal, Umang; 239
 Aguilar-Rodea, Bianca; 058
 Agyemang, Elfriede; 093
 Ahmed, Bilaal; 140
 Ahmed, Nabeela; 170
 Aitken, Samuel L.; 256
 Aizawa, Yuta; 250
 Ajdukovic, Mia; 139
 Ajmal, Saira; 059
 Akinde, Yetunde; 247
 Akpoji, Ukwen; 075
 Akselrod, Hana; 050
 Aksoy, Firdevs; 144
 Al Duhailib, Zainab; 231
 Al Obaidi, Mohanad; 245
 Al Sidairi, Hilal; 234
 Al-Rufaye, Zaid; 232
 Al-Sayyed, Ban; 169
 Al-Sweih, **Noura; 052, 242
 Alali, Muayad; 256
 Alam, M. Jahangir; 150
 Alawdah, Laila; 073
 Albalawi, Fadyah; 054
 Alghounaim, Mohammad; 143
 Alhinai, Zaid; 045
 Alhmidi, Heba; 151
 Alholm, Zachary; 162
 Aliabadi, Negar; 140
 Allan-Blitz, Lao-Tzu; 046, 279
 Allen, David; 077
 Allen, Upton; 259
 Allison, Waridibo E.; 140
 Almarzoky Abuhussain, Safa; 074
 Almirol, Ellen; 157
 Almoosa, Zainab; 236
 Alramadhan, Morouge; 247
 Alsaggaf, Rotana; 054
 Alsaghayer, Alhusain; 070
 AlSalman, Ahmad; 166
 Alsbaugh, Andrew; 222
 Altamirano, Jonathan; 050
 Alvarado, Gadriel; 065
 Alyanak, Elif; 233

Aman, Abu Tholib; 137
 Amlani, Mohan; 053
 Ampofo, Krow; 094, 277
 Anagnostopoulos, Alexia; 243
 Ananthanarayanan, Rajalakshmi; 239
 Andermann, Tessa; 214
 Anderson, Marsha; 087, 106, 224
 Andini, Nadya; 234
 Ando, Naokatsu; 057
 Andrews, Shannon; 045
 Andujar-Vazquez, Gabriela M.; 240
 Anesi, Judith; 143
 Anjan, Shweta; 259
 Ankamah, Pierre; 077, 144
 Anma, Akihiro; 232
 Ansari, Rahila; 137
 Ansari, Uzma; 057
 Antonara, Stella; 250
 Antonioli, Luciana; 139
 Apidechkul, Tawatchai; 062
 Apisarnthanarak, Anucha; 058
 Arana, Jorge; 165
 Araos, Rafael; 072
 Arauz Rodriguez, Ana Belen; 236
 Armitige, Lisa; PW1
 Armstrong, Wendy; 007, 100, 204
 Aronson, Naomi; 003
 Arrieta, Antonio; 038
 Arriola, Carmen; 233
 Arroyo, Julio; 066
 Arshad, Mehreen; 214
 Arteta-Acosta, Cindy; 252
 Asadi, Leyla; 258
 Asadi, Tannaz; 232
 Ashbaugh, Hayley; 140
 Aslam, Anoshé; 149, 150
 Assoumou, Sabrina A.; 059
 Ataman Hatipoglu, Cigdem; 052
 Athans, Vasilios; 170
 Avkan-Oguz, Vildan; 053
 Awadh, Hesham; 046
 Awali, Reda; 059
 Ayaz, Celal; 144
 Aye, Chaw; 236
 Ayoade, Folusakin; 045

B

Babbel, Danielle; 168
 Babcock, Hilary; 013, 113
 Babcock, Hilary M.; 134
 Babcock, Hilary M.; 204
 Babic, Maja; 096
 Babik, Jennifer; 104
 Baca, Amy; 064
 Bachna, Jon; 168
 Badalii, Hamid; 044
 Baden, Lindsey; 198
 Bader, Justin C.; 077
 Bae, Ji Yun; 030
 Baggs, James; 243
 Baghban, Adam; 259
 Bagwell, Autumn; 059
 Bajrovic, Valida; 073
 Bakal, David; 188
 Baker, Arthur W.; 134
 Baker, Carol J.; 001
 Baker, David; 187
 Baker, Meghan; 165
 Baldin, Clara; 048, 236
 Ball, Sarah; 161
 Ballard, Christi; 167
 Balogun, Emmanuel Oluwadare; 050
 Baluni, Manjari; 139

Banach, David; 052
 Bandali, Aiman; 256
 Banga, Jaspreet; 245
 Bannietts, Natalie; 250
 Bansal, Nitin; 236
 Barakat, Rayad; 050
 Barber, Gerard; 143
 Barbut, Frederic; 149
 Bares, Sara; 160
 Barie, Philip; 031
 Barkham, Timothy; 046
 Barlam, Tamar; PW2
 Barnett, Elizabeth; 087
 Barrett, Kelly A.; 073
 Barroso, Luis; PW7, 191
 Barsoumian, Alice; 160
 Bartlett, Allison H.; 058
 Bartram, Logan; 160
 Barza, Ruby; 053
 Basein, Tinzar; 240
 Basgoz, Nesli; 124
 Batra, Rahul; 052, 215
 Battle, Sarah E.; 232
 Bays, Derek; 044
 Beachum, Natasha; 141
 Bean, Holly; 168
 Bearman, Gonzalo; 031
 Beatty, Norman; 146, 173, 240
 Beaulieu, Ronald; 137
 Beauregard-Paultre, Catherine; 150
 Beckham, J. Michael; 050
 Bedimo, Roger; 067
 Beganovic, Maya; 047, 077
 Beidas, Meshal; 139
 Bell, Michael; 002
 Bemke, Ryan; 236
 Ben Abid, Fatma; 137
 Ben Jemaa, Mounir; 050, 059, 239
 Ben-Ami, Ronen; 043, 254
 Ben-David, Debby; 241
 Benamu, Esther; 237
 Bengoetxea, Itsaso; 141
 Benjamin, Carla; 071
 Benneyan, James; 054
 Benowitz, Isaac; 091
 Bernardo-Buensalido, Marja; 067
 Bernhardt, Thomas; 116
 Berti, Andrew; 042
 Beveridge, Stockton; 139
 Bhaimia, Eric; 141
 Bhardwaj, Amrita; 189
 Bhatnagar, Julu; 239
 Bhattacharyya, Roby; 133
 Bhatti, Alexandra; 039
 Bhauria, Sandeep; 076
 Bhavan, Kavita; 141
 Bhimraj, Adarsh; 034, 085, 096, 267
 Bhowmick, Tanaya; 236
 Biary, Nora; 045
 Biehle, Lauren; 160
 Biggs, Holly M.; 139
 Bini Viotti, Julia; 241
 Bininashvili, Tamara; 052
 Bio, Laura; 169
 Bischoff, Werner; 149
 Black, Carla; 162
 Blanco Guzman, Merilda; 243
 Blanco, Natalia; 151
 Blankson, Joel; 007
 Bleasdale, Susan C.; 231
 Bloch, Karen; 024
 Bluen, Benjamin; 145, 237
 Blum, Laura; 054

Blumenthal, Jill; 093
 Blyth, Dana M.; 160
 Boero, Joe; 032, 110
 Boge, Craig L.K.; 256
 Bohan, Jefferson; 143
 Bolan, Gail; 006, 201
 Bonimy, Charlyon C.; 242
 Bonnar, Paul E.; 075
 Boonyaratanakornkit, Jim; 163
 Boppana, Suresh; 001
 Boppana, Sushma; 068
 Boreyko, John; 233
 Borgundvaag, Emily; 052
 Borkowski, Jaime; 075
 Boucher, Helen W.; 262
 Boulware, David; 086
 Bourassa, Lori; 236
 Bowden, Jarred; 077
 Box, Maggie; 148, 240
 Boyd, Sandra; 147
 Bozio, Catherine; 029
 Braden, Amy; 058
 Bradley, John S.; 263
 Brasil, Patricia; 226
 Brault, Aaron; 027
 Bremmer, Derek; 094, 233, 256
 Brito, Maximo; 078
 Brock, Jeff; 143
 Brooks, John T.; 272
 Brown, Alfonza; 073
 Brown, Kevin; 230
 Brumwell, Amanda; 232
 Brundige, Mary Lourdes; 075
 Bruno-Murtha, Lou Ann; 150
 Bryant, Penelope; 143
 Bryson-Cahn, Chloe; 141
 Buchwald, Andrea; 277
 Budak, Jehan; 160
 Budge, Philip J.; PW1
 Bueno Rios, Maria; 149
 Bui, Jennifer; 168
 Bukhari, Abdullah; 052
 Bulik, Catharine C.; 077, 123
 Buluku, Gabriel; 155
 Bunnell, Kristen L.; 077
 Burdick, Bethany; 146
 Burgess, Donna R.; 075
 Burgess, Mary J.; 259
 Burke, Deirdre; 047
 Burnham, Jason; 234, 240
 Burns, Jane C.; 224
 Buss, Brian; 240
 Bye, Maria; 028

C

Cabrera, Nicolo; 059
 Cadena Zuluaga, Jose; 234
 Cadnum, Jennifer; 058
 Cain, Stacy; 045
 Camins, Bernard; 113
 Camou, Fabrice; 232
 Campbell, Angela P.; 145
 Campbell, Lauren; 150
 Campbell, Wesley; 052
 Canet, Miriam; 046, 049, 052
 Cano Cevallos, Leonardo; 157
 Cantey, Joseph; 286
 Caragol, Laura; 046
 Carballo, Carolina; 252
 Carey, George B.; 249
 Carignan, Alex; 168
 Carmeli, Yehuda; 196
 Carpenter, Christopher; 152
 Carr, Amy; 044
 Carr, J. Andrew; 141
 Carr, Kristin; 248
 Carrillo-Marquez, Maria; 121
 Carter, Rebecca; 074
 Castro, Robert; 041
 Cavanaugh, Shaelyn; 141
 Cavildo-Jerónimo, Denisse; 064
 Cazali, Iris; 074
 Cespedes, Michelle; 223
 Chacon-Cruz, Enrique; 250
 Chaftari, Anne-Marie; 241

Chaisavaneeyakorn, Sujittra; 258
 Chaiwarith, Romanee; 075
 Challener, Douglas; 047
 Chambal, Lucia; 244
 Chambers, Henry; 016, 124
 Chan, Fu Zi Yvonne; 137
 Chan, Shuk-Ying; 044, 232, 252
 Chanderraj, Rishi; 242
 Chandrasekaran, Alamelu; 237
 Chandrasekaran, Padmapriyadarsini; 247, 258
 Chang, Jonathan; 156
 Chang, Yeh-Chung; 237
 Chao, Andrew; 149
 Chao, Yusuf; 169
 Chapin, Ryan; 233
 Charalambous, Lefko; 167
 Chatterjee, Archana; 001, 011, 038, 119, 136, 286, 287
 Chatterjee, Jahnavi; 054
 Chatterjee, Soumya; PW5
 Chau, Jennifer; 234
 Chaudhury, Chloe; 245
 Chauhan, Lakshmi; 074
 Chavda, Kalyan D.; 237
 Chen, Derrick; 238
 Chen, Jason; 173
 Chen, Jiandong; 046
 Chen, Joy; PW3
 Chen, Wei-Ju; 073
 Cheney, Laura; 060
 Cheng, Aristine; 243
 Cheng, Henry; 282
 Cheong, Haesuk; 232
 Cherabuddi, Kartikeya; 232
 Cherian, Sree; 053
 Cherry, James D.; 233
 Chia, Laura; 047
 Chidiac, Christian; 248
 Chihara, Shingo; 146
 Chiller, Tom; 004, 020
 Chin, Jacinta; 168
 Chinn, Raymond; 056, 150
 Cho, Oh-Hyun; 242
 Choi, Heun; 232
 Choi, Min Joo; 051
 Chopra, Teena; 090
 Chotiprasitsakul, Darunee; 123, 132
 Chou, Andrew; 052, 075
 Chou, Ann; 074
 Chu, Helen; 035
 Chu, Victoria; 137, 252
 Chua, Alvin Qijia; 074, 236
 Chung, Philip; 074
 Chung, Wendy; 073
 Church, Deirdre; 009
 Ciaranello, Andrea; 272
 Ciccone, Emily; 170
 Citron, Diane; 147
 Claeys, Kimberly; 240
 Clancy, Cornelius J.; 216
 Clark, Abbye; 030
 Clark, Stephen; 133
 Clement, Meredith; 158
 Clemenzi-Allen, A Asa; 248
 Clemmons, Nakia; 073
 Cleveland, Angela Ahlquist; 279
 Close, Ryan; 237
 Co, Edgie-Mark; 050
 Cobey, Sarah; 183
 Coffey, Kc; 056
 Cohen, Margot; 243
 Cohen, Stephanie E.; 181
 Cole, Kelli; 075, 240
 Coles, Christian; 139
 Collier, Jenny; 101
 Collins, Jennifer; 259
 Collison, Maggie; 074
 Comeau, Jeannette L.; 075
 Contreras, German; 234
 Cook, Gregory; 044
 Cooley, Laura; 117
 Cope, Jennifer; 137
 Copeland, Matthew J.; 248
 Copeland, Nathaniel K.; 050, 244
 Coppin, John; 058
 Corace, Kimberly; 151

Cortes, Jorge; 050
 Cortes-Penfield, Nicolas; 066
 Cosgrove, Sara E.; 193, 196
 Costa Salles, Mauro; 047
 Costantini, Patricia; 254
 Cowley, Maren; 233
 Coyle, Christina; 003, 015, 026, 192, 226
 Crist, Matthew; 056
 Crnich, Christopher; 187, 242
 Croft, Lindsay D.; 055
 Crook, Derrick; 225
 Crotty, Matthew; 052
 Crowell, Trevor; 279
 Crozier, Ian; 207
 Cruz, Chancellor; 153
 Cubillos, Ashley; 145, 235

D

D'Agostino, Lydia; 077
 Da Silva, Juliana; 154
 Da, Xia; 167
 Dalcin, Daniel; 165
 Daly, Judy; 234
 Dalziel, Andrew; 170
 Damon, Inger; 035, 207
 Dan, Jennifer; 069
 Daniel-Wayman, Shelby; 139
 Danino, Dana; 242, 250
 Dantes, Raymond; 057
 Daragjati, Florian; 141
 Darlow, Christopher A.; 235
 Das, Sanchita; 239
 Datta, Siddhant; 074, 232
 Davido, Benjamin; 146
 Davidson, Lisa E.; 170, 187
 Davis, Denise; 115
 Davis, John; 115
 Davis, Meghan; 030
 De Comarmond, Charles; 059
 De Perio, Marie; 055
 DeBiasi, Roberta; 024, 186, 217, 252, 275
 Deering, Caytlin; 245
 DeFelic, Nathaniel; 233
 Degener, Tyler; 153
 Dekitani, Ken; 258
 Dela Cruz, Lesley Anne; 052
 Demetriades, Ioannis; 154
 Deresinski, Stan; 007, 191
 Desai, Alpa; 142
 Deshpande, Abhishek; 168, 233
 Destache, Christopher; 052
 Dhand, Abhay; 172, 232
 Dhanireddy, Shireesha; 012, 112, 202
 Diaz Madriz, Jose Pablo; 075
 Diaz, Alejandro; PW4, 135
 Dickey, Linda; 117
 DiDiodato, Giulio; 150
 Diekema, Daniel J.; 270
 Din, Sadia Salahud; 139
 Ding, Yajun; 154
 Dirlikov, Emilio; 050
 Doan, Thien-Ly; 077
 Dobbs, Katherine; 069
 Dodani, Sunil; 052
 Dodds Ashley, Elizabeth; 019, 199
 Doernberg, Sarah B.; PW2, 032
 Dogan, Tiffany; 242
 Doi, Yohei; 051
 Dominguez, Samuel; 224
 Dona, Daniele; 242
 Donatoni, Gina; 150
 Dong, Huan; 046
 Dong, Sara; 044
 Dooling, Kathleen; 152
 Doron, Shira; 110
 Donskey, Curtis; 002, 034
 Dow, Gordon; 168
 Drees, Marci; 002, 028, 130
 Drew, Richard H.; 150
 Dubrovskaya, Yanina; 168
 Duchin, Jeff; 091, 117
 Duchon, Jennifer; 251
 Dudeck, Margaret; 200
 Duffalo, Chad; 148
 Duffy, Nadezhda; 215

Duggan, Joan; 156
 Dulek, Daniel; 160
 Duong, Nikki; 063
 Dupont, Hebert; 148
 Durkin, Michael J.; 054
 Dworkin, Mark; 153
 Dyer, April; 095

E

Eberly, Matthew; 149
 Eby, Joshua; 055
 Echeandia, Sebastian; 050
 Edmond, Michael; 191
 Edwards, Brett; 073, 251
 Edwards, Jonathan; 054
 Eggers, Shoshannah; 148
 Eichenberger, Emily; 259
 Eickhoff, Christa; 279
 Eiras, Daniel; 151
 Ekat, Martin Herbas; 067
 El Aggan, Hayam; 050
 El Aggan, Hoda; 059
 El Haddad, Hanine; 143
 El Haddad, Lynn; 076, 242
 El Kamari, Vanessa; 227
 El Sahly, Hana M.; PW5, 006, 124
 El-Lababidi, Rania; 075
 Elgarten, Caitlin; 075
 Elliott, Gerald; 240
 Ellis, Kristen; 154
 Ellorin, Eric; 158
 Elsheikh, Malak; 058
 Elshimy, Ghada; 143
 Epstein, David J.; 256
 Epstein, Lauren; 023
 Epstein, Rachel; 247
 Erdem, Guliz; 250
 Ereshefsky, Benjamin; 148
 Erme, Marguerite; 073
 Ernst, Joel; 033
 Escobar, Daniel; 058
 Esposito, Susanna; 140, 163
 Esquer Garrigos, Zerelda; 232
 Eure, Taniece; 215
 Evans, Christopher; 170
 Evans, Martin; 149
 Evans, Mary; 093
 Evans, Scott; 016
 Ewing, Alexander; 050

F

Fabre, Valeria; 044, 149
 Facchini, Victoria; 170
 Fadul, Nada; 153, 156
 Fairchok, Mary; 139
 Fakihi, Mohamad; 057
 Fallis, Rebecca; 253
 Farel, Claire; 141
 Farid, Saira; 077
 Fauci, Anthony; 008
 Feemster, Kristen; 031, 251
 Feeney, Margaret; 105
 Fehrenbacher, Lynne; 075
 Feinberg, Judith; 005, 128
 Feinstein, Max; 076
 Felder, Kimberly; 141
 Feller, Daniel; 153
 Felsen, Christina B.; 075
 Ferguson, Jessica; 074
 Ferreira, Kristine; 077
 Ferreira, Matthew; 158
 Ferren, Ryan; 168
 FigueroaSierra, Marileys; 153
 File, Thomas M.; 231
 Fisher, Brian T.; PW4
 Fishman, Neil O.; 019, 193
 Fitzgerald, Teresa; 053
 Flannery, Brendan; 161
 Flannigan, Lillian; 171
 Fleischner, Zachary; 050
 Fleming-Dutra, Katherine; 170
 Flett, Kelly B.; 243
 Florita, Catalin; 249
 Flynt, Lauren K.; 052
 Fong, Gary; 044
 Fong, Karen; 169

Foolad, Farnaz; 173, 230
 Foote, Mary; 073
 Foral, Pamela; 077, 232
 Ford, Mary; 052
 Fortin, Claude; 046
 Foster, Catherine; 241
 Foster, Charles B.; 251
 Foster, Rachel; 076
 Fowlkes, Ashley; 229
 Fox, Neal; 141
 Fox, Teresa; 242
 Franco Garcia, Alexandra; 149
 Francois Watkins, Louise; 051, 073
 Freedman, Stephen; 133, 146
 Freeman, Alexandra F.; 017
 Freire, Maristela; 254
 Freshwater, Dustin; 141
 Frew, Paula; 074, 171, 172
 Friedman, Cindy; 025, 273
 Fries, Bettina C.; 048
 Fritz, Stephanie; 031
 Fuh, Jennifer; 143
 Fukao, Keita; 167
 Fukukawa, Naokatsu; 242
 Fukuoka, Kahoru; 075
 Fuller, Trevon; 217
 Fung, Monica; 237, 257

G

Gaisa, Michael; 064
 Galindo-Fraga, Arturo; 055
 Gallagher, Megan; 141
 Gallagher, Thomas; 091
 Gallegos, Cinthia; 040
 GallegosSalazar, Jaime; 143
 Gandhi, Monica; 021
 Gandhi, Neel; 026
 Ganesan, Anuradha; 030, 248
 Gans, Hayley A.; 275
 Garber, Gary; 242
 Gardiner, Bradley; 256, 259
 Gavigan, Patrick; PW4
 Ge, Maojun; 243
 Geissler, Aimee L.; 127
 Gentile, Angela; 164
 George, Ige; 044, 216
 Georgen, Maria; 146
 Georgescu, Anca; 158
 Gerber, Jeffrey S.; PW2, 169
 Gerber, Susan; 035
 Gern, Benjamin; 214
 Ghanem, Angie; 243
 Ghanem, Khalil G.; PW1, 006
 Ghantaji, Shashank S.; 139
 Giacomelli Cao, Raquel; 229
 Gibani, Malick M.; 069
 Giddens, Julie; 168
 Gilbert, Jack; 119
 Gilbert, Laura; 066
 Gill, Harmeet; 153
 Gilroy, Shelley; 245
 Gittzus, Jennifer; 073
 Giwa, Bashirat; 244
 Gjurasin, Branimir; 046, 049
 Glaser, Carol; 024
 Goepfert, Paul; 223
 Goetz, Matthew; 074
 Goff, Debra; 125, 199, 211, 268
 Gogia, Atul; 173
 Goldberg, Marcia; 089, 219
 Goldeh, Peyman; 148
 Gomez, Beatriz L.; 086
 Gonzalez S, Napoleon; 258
 Gonzalez-Orta, Melany; 150
 Gordon, Lori; 129
 Gordon, Rachel; 160
 Goto, Michihiko; 232
 Goyal, Dheeraj; 143
 Grabowski, Kate; 223
 Grady, Kimberly Y.; 074
 Graham-Glover, Bri; 241
 Grant, Jennifer; 141
 Gray, Gregory; 122
 Green Hines, Andrea; 169
 Green, Shikerria; 232
 Gregory, Eric; 168

Gregson, Daniel; 234
 Griffin, Brooke; 286
 Griffin, Patricia M.; 027, 273
 Grisaru-Soen, Galia; 164
 Grupper, Mordechai; 234
 Grytdal, Scott; 139
 Gu, Mofan; 062
 Guerra, Alberto; 051
 Guerrero, M. Lourdes; 233
 Guharoy, Roy; 074, 168
 Gulick, Roy M.; PW1, 012
 Gulleen, Elizabeth; 253
 Gunaratne, Naomi; 217
 Guner, Rahmet; 057, 146
 Gupta, Amita; 026
 Gupta, Kalpana; PW2, 150
 Gupta, Kartik; 060
 Gupta, Neha; 048
 Gupta, Siddhi; 141

H

Ha, David; 168
 Ha, Lawrence; 239
 Hachem, Ray Y.; 241
 Hachisu, Yushi; 073
 Hackel, Meredith; 147
 Hacker, Elizabeth; 158
 Hager, Christopher; 167
 Haidar, Ghady; 077
 Hains, David; 269
 Hakkio, Morgan; 254
 Hale, Andrew; 160
 Hall, Toni; 075
 Halperin, Jason; 159
 Halperin, John; 085
 Hamburg, Margaret; 008
 Hamdy, Rana F.; 250
 Hamill, Richard; 006, 112
 Hamilton, Keith; 125, 211
 Han, Alison; 233
 Han, Jennifer; 032, 211
 Hanage, William; 225
 Handy, Lori; 029, 169
 Hanisch, Benjamin; 052
 Hankins, Richard; 241
 Hanna, Zachary; 256
 Hanson, Kim; 084, 260
 Harbertson, Judith; 046
 Hart-Cooper, Geoff; 010
 Hartmann, Erica; 276
 Hasan, Irtiza; 051
 Hasan, Mustafa; 232
 Haslam, David; 275
 Hassan, Adiba; 046
 Hassoun, Ali; 076, 143, 145, 148, 231
 Hassouna, Habiba; 044
 Hatwar, Trupti; 053
 Hatzileris, Alexandria; 233
 Hause, Anne; 233
 Havers, Fiona P.; 161
 Hawken, Shawn E.; 052
 Hayakawa, Kayoko; 052, 241
 Hayden, Randall; 009, 084, 182, 208
 Hayes, Justin F.; 240
 Haynie, Aisha; 078, 122
 Hazard, Riley; 063
 Head, Breanne; 063
 Healey, Kelley; 051
 Healy, C. Mary; 162
 Hebert, Courtney; 076
 Heidari, Arash; 044
 Heil, Emily; 123, 141, 149
 Heinonen, Santtu; 252
 Helou, Elie; 139
 Hemarajata, Peera; 279
 Hendon, Natalie; 240
 Heng, Shi Thong; 075
 Henig, Oryan; 047
 Henry, Michael; 045
 Herc, Erica; 255
 Hernandez Munoz, Francisco; 234
 Hernandez, Alfonso; 258
 Herold, Betsy C.; 275
 Herrick, Jessica; 049
 Herwaldt, Loreen a.; 185
 Hibberd, Patricia; 036

Hicks, Lauri; 178
 Hill, Brandon; 045
 Hill, Joshua; 253
 Hiramatsu, Hiroyuki; 140
 Hiransuthikul, Akarin; 046
 Hirschfeld, Cole; 045
 Hitchcock, Matthew; 149
 Hlatshwayo, Matifadza; 233
 Hoban, Daryl; 047, 056
 Hobbs, Athena L. V.; 168
 Hochstatter, Karli; 059
 Hodinka, Richard; 182
 Hoff, Brian; 168, 243
 Hoffmann, Wesley; 143
 Hojat, Leila; 141
 Holland, M. Siobhan; 232
 Holland, Steven; 283
 Holland, Thomas L.; 132, 231
 Holloway, Ian; 152
 Holman, Katherine; 141
 Holmer, Haley K.; 074
 Holowka, Thomas; 052
 Holzmann-Pazgal, Galit; 206
 Honein, Margaret (Peggy); 027
 Hong, Jeongmin; 233
 Hong, Jin; 168
 Horiba, Kazuhiro; 029
 Horton, Lucy E.; 069
 Hosry, Jeff; 059
 Hossin, Tamanna; 053
 Hostler, Christopher; 215
 Hou, I-Lun; 052
 Housman, Erica; 075
 Howard, Leigh; 076
 Howard-Anderson, Jessica; 142
 Howell, Crystal; 075
 Howell, Martha; 160
 Howell, Seth; 259
 Hu, Yanhong; 141
 Huang, Angela; 168
 Huang, Victoria; 141
 Huddleston, Paul; 096
 Huitt, Gwen; 186
 Hurley, Hermione; 245
 Husada, Dominicus; 073, 145
 Huskins, W. Charles; 206
 Hussam, Dina; 148
 Huynh, Hoang A.; 150
 Hwang, Joo-Hee; 052
 Hyle, Emily; 277
 Hymes, Saul; 011, 087

I

Ibrahim, Ashraf; 167
 Ibrahim, Ashraf S.; 167
 Ilett, Emma Elizabeth; 254
 Imai, Kazuo; 237
 Imp, Brandon; 093
 Inagaki, Kengo; 252
 Iovleva, Alina; 051
 Isada, Carlos; 160
 Ishiekwe, Celestine; 044
 Ishikane, Masahiro; 052
 Ishikawa, Kazuhiro; 232
 Islam, Shamim; 169
 Issa, Nahema; 236
 Issa, Nicolas; 253
 Ivaska, Lauri; 238
 Iverson, Sally Ann; 073
 Ivey, Kelsey S.; 139
 Ivy, Morgan; 133
 Iwata, Yasunori; 051
 Izumita, Ryohei; 163, 252

J

Jackson, Brendan; 143
 Jacobson, Karen; 156
 Jaggi, Preeti; 224
 Jagtiani, Anil; 249
 Jamal, Alainna; 052
 Jamal, Wafaa; 056
 James, Charles; 168
 James, Scott H.; 121
 Jamil, Saad Bin; 166
 Jandhyala, Deeksha; 253, 254
 Jansen, Jeffrey W.; 044, 045

Jarolimova, Jana; 246
 Jarovsky, Daniel; 165
 Jarvis, Christopher; 277
 Jeffres, Meghan; 141
 Jencson, Annette; 058
 Jensen, Jens Ulrik Stæhr; 132
 Jeong, Su Jin; 254
 Jeong, Wooyong; 045
 Jeong, Young-Gwang; 065
 Jerahian, Aram; 168
 Jerez Torra, Kihara Alejandra; 066
 Jhaveri, Ravi; 038
 Jilg, Nikolaus; PW3
 Joe, Winston B.; 157
 John, Amrita; 058, 134
 John, Blessy; 044
 Johnson, Candace; 074
 Johnson, Jacob; 286
 Johnson, Leonard; 067
 Johnson, Linda; 240
 Johnson, Melissa; 044
 Johnsrud, Joyce J; 253
 Johnston, Brian D.; 234
 Johnston, Christine; 069, 181
 Jones, Makoto; 074
 Jones, Milissa; 160
 Jones, Travis; 074
 Jones, Zachary; 249
 Joo, Su Jin; 258
 Joseph, Olajumoke; 145
 Joseph, Patrick; 191
 Joya, Christie; 063
 Jump, Robin; 075
 Jun, Kang Il; 233
 Jung, In Young; 156
 Juthani-Mehta, Manisha; 090

K

Kabbani, Sarah; 053, 170
 Kacka, Michael; 065
 Kadri, Sameer S.; 042, 232
 Kain, Taylor; 139
 Kainer, Marion; 025
 Kajon, Adriana; 035
 Kale-Pradhan, Pramodini; 076
 Kallen, Alexander; 273
 Kambhampati, Anita; 139
 Kamboj, Mini; 149
 Kamidani, Satoshi; 050
 Kamiyama, Davin; 075
 Kanai, Mizue; 073
 Kanamori, Hajime; 056, 058, 234
 Kandel, Christopher; 045
 Kang, Jun Sik; 058
 Kang, Seung Ji; 069
 Kanjilal, Sanjat; 242
 Kanwar, Anubhav; 139, 160, 242
 Kanwar, Neena; 235
 Kao, Carol; 121
 Kapadia, Shashi; 158
 Karp, Christopher; 287
 Karppinen, Mariia; 251
 Karrasch, Matthias; 237
 Kassamali, Zahra; 075, 240
 Katanami, Yuichi; 055
 Kato, Hideaki; 044
 Katsuta, Tomohiro; 140
 Kaur, Ishminder; 250
 Kawai, Kosuke; 139
 Kay, Alexander; 239
 Kazakova, Sophia; 028
 Kazmierczak, Krystyna; 147
 Kean, Jacob; 141
 Keaton, Nicholas; 044
 Kebriaei, Razieh; 077
 Kelly, Brendan; 072, 225
 Kelly, Devin; 047
 Kelly, Matthew; 072
 Kerins, Janna L.; 057
 Khader, Karim; 242
 Khalil, Ibrahim; 146
 Khan, Ayesha; 051
 Khan, Salman; 240, 256
 Khare, Reeti; 055
 Khatib, Riad; 232
 Khatri, Akshay; 052

Khawcharoenporn, Thana; 056, 233
 Khoo, Teresa; 137, 148, 234
 Kiatsimkul, Pornpip; 044
 Kiartiburanakul, Sasisopin; 156
 Kilpatrick, Dustin; 249
 Kim, Arthur; 120
 Kim, Bongyoung; 141
 Kim, Dong-Min; 049, 050
 Kim, H. Nina; 059
 Kim, Hyun Kyung; 045
 Kim, Jae Choon; 253
 Kim, Kye-Hyung; 056
 Kim, Pauline; 077
 Kim, Peter; 148
 Kim, Seong Eun; 147
 Kim, So Lim; 141
 Kim, Tae Hun; 234
 Kimura, Muneyoshi; 257
 Kinnear, Clare; 051
 Kirkpatrick, Lauren; 154
 Kizilbash, Quratulain; 249
 Klatte, J. Michael; 169
 Kline, Susan; 075
 Klugman, Keith; 033, 081
 Knepper, Bryan; 151
 Knighton, Shanina; 151
 Kobayashi, Miwako; 227
 Kobayashi, Takaaki; 234
 Kochman, Michael; 091
 Koenig, Serena; 213
 Koffi, Jues; 142
 Koganti, Sreelatha; 058
 Koksai, Iftihar; 137
 Kollef, Marin; 002
 Kong, Ling Yuan; 028
 Koo, Sophia; 216
 Kopelman, David; 052
 Korgenski, E. Kent; 233
 Korten, Volkan; 065
 Kortenaar, Jean-Luc; 067
 Kosasih, Herman; 050
 Kougoulos, Terry; 167
 Koutsari, Christina; 047
 Kovacs, Christopher; 075
 Kowalewska, Christina A.; 168
 Kralovic, Stephen; 149
 Kreiswirth, Barry N.; 249
 Krishna, Amar; 045, 151
 Krishnasamy, Vikram; 073
 Kroger, Andrew; 160
 Kronen, Ryan; 044
 Kulengowski, Brandon; 234
 Kulwicki, Benjamin; 168
 Kuper, Kristi; 170
 Kuriakose, Kevin; PW3
 Kurugol, Zafer; 252
 Kwal, Jaclyn; 078
 Kwendakwema, Natasha; 148
 Kwon, Jennie H.; 028, 052
 Kyvernitakis, Andreas; 232

L

La Hoz, Ricardo; PW3
 Lai, Yi Ling; 076
 Lakatos, Botond; 066
 Lakota, Elizabeth; 077
 Lall, Ambika; 141
 Lam, John; 232
 Lamb, Molly; 251
 Lanata Piazzon, Mariana; 169
 Lane, Michael A.; 230
 Lang, Raynell; 248
 Langford, Bradley; 168
 Lanza, David; 168
 Lapidot, Rotem; 165
 Larkin, Emily; 167
 Larson, Derek; 145, 248
 Lastering, Allison; 045
 Laurant, Adam; 183
 Lazar, Rachael; 063
 Le, Audrey; 236
 Leal, Aura Lucia; 164
 Leblanc, Jason; 233
 Lebron, Dora; 245
 Lee, Adria; 073
 Lee, Bonita; 146

Lee, Bonny; 044
 Lee, Ellen H.; 252
 Lee, Eunyoung; 152
 Lee, Francesca; 111
 Lee, Grace C.; 071
 Lee, Ji Hyen; 069
 Lee, Jonghoo; 233
 Lee, Joon Kee; 164
 Lee, Kyoung Hwa; 145
 Lee, Nelson; 233
 Lee, Philip; 077
 Lee, Rachael A.; 076
 Lee, Rachel; 161
 Lee, Ru Min; 149
 Lee, Seung Hyun; 239
 Lee, Yeon Joo; 259
 Lee, Yu-Lin; 044
 Lemeneh, Tefera; 023
 Lemos-Ramirez, Juan; 173
 Leonard, Michael; 153, 245
 Leonczyk, Ken; 022
 Lepak, Alexander; 043, 167, 232
 Lesho, Emil; 043
 Letourneau, Alyssa R.; 019
 Leung, Daniel; 235
 Leung, Jessica; 140
 Leung, Vivian; 052
 Leuthner, Kimberly D.; 077
 Lewinsohn, David; 203
 Li, Darrick K.; 189
 Li, Justin; 233
 Li, Sui Kwong; 075
 Liang, Emily; 069
 Libman, Michael; 192
 Liddell, Allison; 204
 Lieberman, Rachel; 233
 Lier, Audun; 059
 Limaye, Ajit; 108, 114
 Lin, Charlotte; 044
 Lin, Michael; 257
 Lin, Szu-Han; 047
 Lindsay, Patrick; 075
 Linfesty, Daniel; 169
 Lingegowda, Pushpalatha
 Bangalore; 141
 Link-Gelles, Ruth; 189
 Linn, Alexandra; 145
 Lionakis, Michail; 048
 Lipsett, Pamela; 125
 LiPuma, John; 119
 Little, Brent A.; 165
 Liu, Baoming; 059
 Liu, Catherine; 125
 Liu, Terrence; 041
 Liu, Wenxi; 233
 Liu, Xiaqing; 235
 Livorsi, Daniel; 075
 Lloyd, Colin; 250
 Lloyd, Elizabeth; PW4
 Lo, Nathan C.; 171
 Lob, Sibylle; 052, 147
 Lodding, Isabelle Paula; 259
 Loeliger, Kelsey B.; 188
 Lofgren, Sarah; 063, 137
 Logan, Latania K.; 103
 Lombardi, Juliana; 169
 Lopez, Adriana S; 163
 Lor, Angela; 148
 Loudermilk, Elaine; 055
 Louie, Arnold; 167
 Lozier, Matthew; 217
 Lucas, Aaron; 051
 Lucas, Gregory; 021
 Lucero-Obusan, Cynthia; 161
 Luevano, Jesus; 072
 Lunchenkov, Nikolay; 142
 Lundbo, Lene Fogt; 040
 Luo, Ruihong; 149
 Luque, Amneris; 124
 Lutgring, Joseph; 234
 Luther, Megan; 142
 Luther, Vera; 104
 Lyke, Kirsten; 105
 Lynch, John B.; 014, 018, 019, 210
 Lynfield, Ruth; 280

M

M'Ikanatha, Nkuchia; 074
 MacAllister, Trenton; 255
 Macfadden, Derek; 053, 057, 232
 Machaidze, Mamuka; 258
 MacIntyre, Ann; 191
 Macintyre, Ann T.; 022, 204
 Mackow, Natalie; 071
 Magazi, Beki Temba; 234
 Magill, Shelley S.; 215
 Maharom, Pasri; 052
 Mahmood, Maryam; 232, 249
 Mahoney, Monica V.; 075, 148
 Majeed, Aneela; 149, 254
 Maki, Gina; 233
 Malavade, Sharad; 049
 Maldonado, Samuel; 153
 Malinis, Maricar; 041
 Mamo, Yafet; 148
 Mana, Thriveen; 058
 Mañez, Noelia; 253
 Mangione-Smith, Rita; 268
 Mangla, Saisho; 235
 Mani, Nandita S.; 168
 Mankame, Siddhi; 063
 Manne-Goehler, Jennifer; 050, 227
 Manning, Shannon D.; 183
 Mansouri, M. David; 144
 Mao, Jianbin; 157
 Maragakis, Lisa L.; 002
 Marbin, Jyothi; 010
 Marchaim, Dror; 052, 144
 Marculescu, Camelia; 096
 Marcus, Joseph; 050
 Marcus, Julia; 059
 Markelz, Ana; 049
 Marra, Christina; 085
 Marras, Theodore; 249
 Marrazzo, Jeanne; 112, 213, 223, 272
 Marrs, Rachel; 057, 058
 Marsh, Ketzela J.; 143
 Marshall, Mary Beth; 168
 Marsico, Concetta; 121
 Martin, Elena; 058
 Martin, Elise; 052
 Martin, Emily T.; 212
 Martin, Isabella; 145
 Martin, Jonathan; 160
 Martinez, Olivia; 275
 Martinez-Orozco, Jose Arturo; 044, 239
 Marx, Ashley; 141
 Marx, Grace; 073
 Mathers, Amy; 185, 225, 231
 Mathews, Samantha; 233
 Matic, Nancy; 052, 234
 Matono, Takashi; 234, 277
 Matsubayashi, Sachii; 258
 Matsui, Yusuke; 073
 Matsuo, Takahiro; 045, 216
 Mattar, Caline; 232
 Maude, Rapeephan; 158
 Maves, Ryan; 233
 May, Larissa; 075
 Mcadam, Alexander; 182
 McBride, Darrell; 060
 McBride, Joseph; 257
 Mccarthy, Karen; 075
 McConnell, Ian; 045
 McCoy, Christopher; 075
 McDonald, L. Clifford; 176, 208, 276
 Mcfarlane, Alexandra; 254
 Mcgeer, Allison; 165, 232
 McGowan, Craig; 122
 Mcintyre, Mark T.; 075
 McLaughlin, Milena; 286
 McLaughlin, Milena M.; 246
 Mclean, Huong Q.; 140
 Mcmanus, Dayna; 168
 Mcneil, Jonathon; 250
 McNulty, Moira C.; 155
 McQuillen, Daniel; 022, 175
 Medalla, Felicita; 146
 Meddings, Jennifer; 113
 Medford, Richard; 075
 Medisetty, Mahender Kumar; 061

Medoro, Alexandra; 252
 Mehta, Kayur; 256
 Mehta, Meera; 145
 Mehta, Shruti; 285
 Mejia, Carlos; 216
 Melgar, Mario; 146
 Mena Lora, Alfredo; 241
 Mendis, Shehara M.; 051
 Menon, Vidya; 170
 Menza, Timothy; 248
 Merckx, Joanna; 252
 Mercuro, Nicholas; 232
 Merlin, Toby L.; 040
 Mertz, Dominik; 075
 Messacar, Kevin; 024
 Messina, Julia; 232
 Messina, Maria; 173
 Michaels, Marian; 275
 Miller, Andy; 045
 Miller, Bahnsen; 149
 Miller, Jessica; 074
 Miller, Loren; 005
 Miller, Rachel; 092, 108, 184, 205, 220
 Miller, William; 042, 051
 Mills, John P.; 052
 Milstone, Aaron M.; 013, 130, 250
 Milucky, Jennifer; 094
 Miraldi, Emily; 102
 Miranda Katz, Margot; 149
 Mishra, Priyanka; 137
 Mitha, Ismail; 231
 Mitra, Debdeep; 249
 Modi, Mayank; 073
 Mody, Rajal; 228
 Moehring, Rebekah W.; PW2, 123
 Moenster, Ryan P.; 141
 Mohamed, Muhanad; 052
 Mohan, Charan; 245
 Mohareb, Amir; 258
 Mohd Noh, Rosnida; 056
 Mohr, John; 088, 107
 Molina-Jaimes, Aaron; 151
 Molino, Suzanne T.; 233
 Monogue, Marguerite; 077, 167
 Monsees, Elizabeth; PW2, 169, 241
 Montgomery, Susan; 003
 Montpetit, Louis-Philippe; 243
 Moon, Chisook; 052
 Moon, Song Mi; 046
 Morikane, Keita; 243
 Morimoto, Konosuke; 233
 Morris, Andrew M; 074
 Morrissey, Ian; 147
 Morse, Annie; 059
 Mosier, Evan; 058
 Mosites, Emily; 073, 232
 Most, Zachary; 172
 Mourad, Ahmad; 077
 Muchimba, Maureen; 247
 Mui, Emily; 168
 Mukerji, Shibani; 129
 Mukherjee, Sanjana; 146
 Mukka, Mallikarjuna; 059
 Mulkey, Sarah; 121
 Munita, Jose M.; 232
 Munoz-Price, L. Silvia; 196
 Murai, Takemi; 077
 Murray, Alastair; 049
 Murray, Meghan; 172
 Murthy, Rekha; 185
 Musgrove, Mary; 123
 Mushtaq, Ammara; 241
 Musick, William; 256
 Myers, Angela; 268
 Myers, John; 189
 Myint, Thein; 044

N

N. Mendes Neto, Nilson; 121, 250, 252
 Na Songkhla, Munjit; 239
 Naccache, Samia; 137
 Naeem, Fouzia; 044, 075
 Nagel, Jerod; 047
 Naglik, Julian; 089
 Nakaranurack, Chotirat; 232

Namburete, Evangelina; 239
 Nanayakkara, Deepa; 150
 Narita, Masashi; 050
 Natarajan, Mukil; 048
 Nath, Sarath; 147
 Natori, Yoichiro; 228, 243
 Ndegwa, Linus; 151
 Negishi, Kay; 242
 Nel, Jeremy; 239
 Nelson, Richard E.; 057, 190
 Nelson, Sandra; 022, 080, 096
 Nematollahi, Saman; 160
 Nepal, Shaili; 233
 Nett, Jeniel; 020
 Newburger, Jane; 224
 Newland, Jason; 001, 268
 Neyra, Karyna; 044
 Nguyen, David C.; 250
 Nguyen, Duc T.; 258
 Nguyen, Hien Huy; 019
 Nguyen, Minh Ly; 153
 Nichols, Michaela; 161
 Nigo, Masayuki; 243
 Nkwata, Allan; 241
 Nocon, Allina; 045
 Nolt, Dawn; 056
 Nomura, Jim; 056
 Non, Lemuel; 065
 Nordvig, Josefine; 253
 Norris, Anne H.; 202
 Norton, Sarah; 049
 Norwood, Jamison; 156
 Nosanchuk, Joshua; 010, 020, 115, 177, 222
 Nowbakht, Cima; 143
 Noyola, Estela; 251
 Nurutdinova, Diana; 153
 Nwanyanwu, Rita; 159
 Nycz, Bryan; 072

O

O'Bryan, Thomas; 244
 O'Donnell, J Nicholas; 076
 O'Donnell, Max; PW5
 O'grady, Naomi; 034
 O'hagan, Justin; 054
 O'Halloran, Jane; 044
 O'horu, John; 232, 243
 O'Leary, Erin; 170
 O'Leary, Sean; 162, 171, 229
 O'Malley, Christopher; 046
 O'Malley, Sean; 074
 O'Neal, Catherine; PW1
 Oda, Gina; 073
 Odeniyi, Folasade; 053
 Ogura, Sho; 256
 Ohl, Christopher; PW1, PW7, 231
 Ohl, Michael; 158
 Okeke, Nwora Lance; 153
 Okoye, Stella; 093
 Olesen, Scott; 095
 Olsen, Sonja; 122
 Olson, Jared A; 170
 Onuorah, Luke; 055
 Ortiz-Brizuela, Edgar; 233
 Ostrowsky, Belinda; 118
 Ota, Kenji; 069
 Otsuka, Taketo; 173
 Otto, William; 251
 Ovalle, Anais; 059
 Overton, Turner; 037, 112
 Owaisi, Anjum; 018
 Owusu-Ofori, Alex; 074
 Oyamada, Jun; 144

P

Pacholec, Marie; 067
 Padhye, Amruta; 072
 Padmanabhan, Arjun; 166
 Paek, Hana; 169
 Pallotta, Andrea; 172
 Palmer, Samuel; 242
 Palmore, Tara; 002, 090, 185, 196, 211, 225
 Palmore, Tara N.; 058
 Panda, Ashutosh; 073
 Papic, Neven; 137

Pappoe-Ashong, Prince Jonathan; 145
 Parikh, Ronak; 047
 Parisi, Andrea; 076
 Park, Connie; 158, 160
 Park, Ki-Ho; 045
 Park, Se Yoon; 055
 Park, Sunmin; 139
 Parker, Sarah; 186
 Parmar, Deepika; 250
 Parpia, Tarina; 254
 Parra, Liliana; 145
 Pasayan, Mark Kristoffer; 227
 Patel, Anuj; 059
 Patel, Atul; 060
 Patel, Jean; 009, 025, 084, 182, 208
 Patel, Manisha; 273
 Patel, Payal; 187
 Patel, Priti; 270
 Patel, Roma; 160
 Patel, Sachin; 052
 Patel, Saloni; 256
 Patel, Twisha S.; 168
 Patriquin, Glenn; 253
 Pavia, Andrew; 039, 131, 179, 212, 280, 287
 Pavkovich, David; 154
 Pawelec, Graham; 114
 Payette, Alyssa M.; 055
 Payne, Michael; 240
 Payoong, Paruspak; 259
 Pedati, Caitlin; 149
 Peermohamed, Shaqil; 075
 Peixoto, Driele; 241
 Pepper, Dominique; 144
 Peraza, Jellyana; 249
 Pereira Rodrigues, Otavio; 232
 Perez Cortes Villalobos, Armelle
 Marveya; 256
 Perez, Federico; 118
 Perez, Kimberly; 069
 Perez, M. Guadalupe; 250
 Perkins, Kiran Mayi; 186
 Perl, Trish; PW3
 Pernia, Sonia; 076
 Perreault, Sarah; 168
 Perumal Kannabiran, Bhavani; 065
 Perz, Joseph; 091
 Petersen, Brett; 207
 Petersen, Lyle; 027
 Petraitis, Vidmantas; 077
 Pettit, Natasha N; 075, 170
 Phan, Tuong; 049
 Phasuk, Nonthapan; 252
 Philip, Simi; 232
 Phipps, Erin C.; 149
 Pierce, Rebecca; 190
 Pierce, Virginia; 084
 Pilishvili, Tamara; 278
 Pillai, Shiv; 219
 Pillinger, Kelly E.; 076
 Pirofski, Liise-Anne; 007, 222
 Platt, Lauren; 278
 Pleasants, Katherine; 075
 Polak, Jonathan; 149
 Politis, Paula; 168
 Pollock, Daniel; 025
 Pong, Alice; 001, 031, 251
 Poonawala, Husain; 160, 234
 Pop-Vicas, Aurora; 243
 Popovich, Kyle J; 190
 Porreca, Ann Marie; 232
 Pottinger, Paul; 014
 Pottinger, Paul S.; 075
 Powderly, William G.; 097
 Powell, Kelsey; 040
 Pragman, Alexa A.; 072
 Preiksaitis, Jutta; 253
 Pritchard, Haley; 059
 Privette, Grayson; 056
 Prochazka, Mateo; 153
 Procop, Gary; 084
 Prokesch, Bonnie; 036, 168, 233
 Protsiv, Myroslava; 053
 Pruskowski, Kaitlin A.; 077
 Purandare, Amol; 169
 Puri, Shruti; 233

Q

Quadri, Syeda; 073
 Query, Ashley; 070, 242
 Quiat, Daniel; 251
 Quick, Rachel; 030, 252
 Qutub, Mohammed; 044, 235

R

Rabalais, Gerard; 106
 Rabold, Elizabeth; 141
 Rahmati, Elham; 076
 Rai, Rena; 076
 Raj, Deepa; 055
 Rajagopal, Sumanth; 076
 Ralston, Shawn; 038
 Ramanan, Poornima; 234, 236
 Ramaswamy, Chitra; 227
 Ramchandrar, Nanda; 251
 Ramesh, Mayur; 047
 Ramirez Amado, Maria Fernanda; 258
 Ramirez, Julio; 233
 Ramsburg, Amanda M.; 134
 Ramsey, Natalie; 138
 Rand, Kenneth; 232
 Rao, Arundhati; 238
 Rapoport, Alison B.; 073, 141
 Rattanaumpawan, Pinyo; 139, 160
 Rausch, Caitlin R.; 257
 Raux, Brian R.; 235
 Raval, Krupal; 044
 Raybardhan, Sumit; 075
 Raza, Ambreen; 065
 Razonable, Raymund R.; 092, 108, 184, 205, 220, 271
 Read, Jennifer; 078
 Reddy, Archana; 065
 Reese, Sara; 058
 Reich, Patrick; 251
 Reisfeld, Sharon; 050, 170
 Reitzel, Ruth; 241
 Reller, L. Barth; 084
 Reveles, Kelly R.; 072
 Reyes Vega, Andrea; 156
 Reyes, Jinnethe; 051
 Rha, Brian; 163
 Rhee, Chanu; 023
 Riccobono, Denise; 169
 Richards, Shawn; 073
 Richardson, Katherine; PW4
 Richter, Stefan; 052
 Ricotta, Emily; 249
 Ridgway, Jessica P.; 149
 Rispens, Jared R.; 250
 Ritchie, Stephen; 075
 Rizzo, Kyle; 052, 074
 Roberts, D. Allen; 157
 Roach, Ryan; PW4
 Rock, Clare; 149, 235
 Rodriguez, George D.; 123, 141
 Rodriguez-Weber, Miguel Angel; 231
 Roghmann, Mary-Claire; 090
 Rohde, Benjamin; 145
 Roilides, Emmanuel; 077
 Rolfe, Robert J.; 141
 Romano, Carlo Luca; 284
 Romero, Fabian Andres; 230
 Romi, Renata P.; 254
 Root, Heather; 159
 Roshdy, Danya; 168
 Ross, Jack; 056, 151
 Ross, Sarah; 240
 Rosso, Fernando; 051, 145, 235
 Rotimi, Vincent; 232
 Rottmann, Bruce G.; 069
 Rowlands, Gemma V.; 073
 Rupali, Priscilla; 192
 Rupp, Mark E.; 058, 241
 Russell, Celeste; 045
 Russell, Elliott; 233
 Rutala, William A.; 058
 Rutter, W. Cliff; 141, 142, 168
 Rybak, Michael J.; 047
 Rysavage, Patrick; 227
 Ryu, Byunghan; 045, 071
 Ryu, Seong Yeol; 071

S

Sabin, Arick; 238
 Saeed, Huma; 141
 Saffar, Nasia; PW2, 072, 243
 Saigal, Christopher; 269
 Saini, Ena; 141
 Sakai, Fuminori; 237
 Sakurai, Aki; 232, 258
 Salcuni, Paul; 099
 Salee, Parichat; 045, 061
 Salim, Tanzila; 054
 Salles, Mauro; 045
 Salsgiver, Elizabeth; 075
 Salvatore, Mirella; 173
 Sandkovsky, Uriel; 055, 254
 Sando, Eiichiro; 049
 Sandora, Thomas J.; 038
 Santos, Carlos; 157
 Sarubbi, Christina; 168
 Sass, Gabriele; 048
 Sayood, Sena; 143
 Schell, Wiley A.; 167
 Schicker, Rebekah Stewart; 233
 Schirmer, Patricia; 139
 Schlaffer, Kathryn; 240
 Schlaudecker, Elizabeth P.; 161
 Schlett, Carey; 047
 Schmidt, Monica; 052, 240
 Schmit, Kathryn; 251
 Schofield, Christina; 233
 Schultz, Sara; 160
 Schulz, Thomas Ray; 059
 Schuster, Jennifer; 233
 Schwartz, Brian; PW8, PW3, 010, 104, 115
 Schwartz, Ilan S.; 044
 Schwartz, Kevin; 095
 Schwartzstein, Richard; 115
 Scolarici, Michael; 062
 Scott, Anna; 145
 Scott, Sarah; 188
 Scully, Morgan; 095
 Searns, Justin; 045
 Seddik, Talal; 251
 See, Isaac; 242
 Seekatz, Anna; 214
 Segaloff, Hannah E.; 139
 Seidelman, Jessica; 241
 Seki, Mitsuko; 234
 Selheimer, Heather; 146
 Sellers, Subhashini; 068
 Semel, Jeffery; 170
 Sengodan, Prasanna; 232
 Seo, Euri; 259
 Seo, Susan; 125, 255
 Septimus, Edward; 199
 Serrano, Ruth; 052
 Seshadri, Pratibha; 059
 Sewnarine, Michelle; 239
 Sexton, Mary Elizabeth; 190
 Seybold, Ulrich; 067
 Sfeir, Maroun; 076
 Shaffelburg, Zach; 094
 Shah, Aditya; 057, 170
 Shah, Akshay; 202
 Shah, Arpan; 245
 Shah, Megan; 232
 Shah, Megha; 077
 Shah, Pooja; 061
 Shah, Sarita; 273
 Shah, Shivang; 069
 Shah, Tulsi; 245
 Shakya, Sampurna; 232
 Shane, Andi L.; 038
 Shannon, Chelsea; 046
 Sharma, Neha; 045
 Sharma, Tanvi; PW4
 Shaw, Albert; 131
 Shay, David; 161
 Shelburne, Samuel; 221, 269, 284
 Shelly, Mark; 148
 Shenoy, Erica S.; 150, 241, 243
 Sherbuk, Jacqueline; 168
 Sherman, Amy; 170
 Shieh, Andrew; 169
 Shihadeh, Kati; 075
 Shiloh, Michael U.; 214

Shimata, Stacy; 075
 Shively, Nathan R.; 075
 Shoji, Kensuke; 234
 Shrestha, Nabin; 232, 242
 Shroba, Jenny; 256
 Shulder, Stephanie; 240
 Shurko, James; 047
 Sibliss, Kedesha; 247
 Siddiqui, Javeed; 014, 210
 Siegel, Marc; 158
 Signorelli, Jessie; 256
 Sikka, Monica K.; 055
 Sim, Jean; 249, 255
 Simanek, Amanda; 114
 Simberkoff, Michael S.; 161
 Simms, Andrew; 139
 Simon, Tracey; 059
 Simpfendorfer, Claus; 096
 Singh, Jasjit; 140
 Singh, Kamaljit; 234
 Singh, Sanjeev; 075
 Singh, Supriya; 241
 Sirajuddin, Sara; 240
 Skinner, Andrew; 052
 Skrobarcek, Kimberly; 148
 Skulsjirapa, Benjawan; 137
 Slagle, Dustin; 259
 Slain, Douglas; 028, 230
 Slayton, Rachel; 130
 Small-Saunders, Jennifer L.; 044
 Smallwood, Megan; 155
 Smiljkovic, Mina; 252
 Smith, Becky; PW1, 056
 Smith, Christiana; 247
 Smith, Daniel; 159
 Smith, Hayden; 234
 Smith, Jessica; 168
 Smith, Michael; 169, 268
 Smith, Timothy; 146
 Smoke, Steven; 075
 Snowden, Jessica; 001
 Snyder, Graham M.; 044
 So, Wonhee; 253
 Soda, Elizabeth; 070
 Soe, Minn; 215
 Soeters, Heidi; 040
 Sohail, M. Rizwan; 220
 Soldatos, Ariane; 024
 Sommerstein, Rami; 072
 Song, Eunkyung; 145
 Song, Matthew; 075
 Souli, Maria; 232
 Southwick, Karen; 242
 Spivak, Emily; PW3, PW2, 020, 032, 039
 Spivey, Justin; 233
 Srinivasan, Arjun; PW2, 002, 014, 023, 083, 130, 187, 196, 200, 270
 Srinivasan, Ramalingam; 065
 Srisompong, Jintana; 143
 Ssewankambo, Fred; 073
 Stachel, Anna; 075
 Stagliano, David; 242
 Stahl, Jean-Paul; 085
 Staicu, Mary; 168
 Stanek, Vanina; 060
 Stankiewicz Karita, Helen; PW3
 Staples, J. Erin; 226
 Stapleton, Ann; 231
 Stapleton, Patrick; 145
 Stawarz, Kimberly; 059
 Stead, Wendy; PW3
 Steffens, Andrea; 094
 Steinbrink, Julie; 254
 Steiner, Theodore; 148
 Steingrover, Radjin; 078
 Steinkuller, Fozia; 058
 Sterling, Timothy R.; PW5
 Stevenson, Kurt; 074
 Stiefel, Usha; 209
 Stohs, Erica; 168
 Stokes, William; 235
 Stoltey, Juliet; 279
 Stone, Heather; 042
 Stoner, Bradley P.; 181
 Strahilevitz, Jacob; 232
 Streit, Judy a; 049

Strickland, Courtney; 233
 Strnad, Luke; 232
 Strong, Douglas; 271
 Strymish, Judith; 242
 Stuckey, Matthew; 041
 Suady Barake, Suhairereine; 234
 Subedi, Shradha; 051
 Suda, KJ; 074
 Suh, Hyeon Jeong; 077
 Sukiennik, Teresa; 052
 Sullivan, Timothy; 132
 Sun, Hsin-Yun; 044
 Sundaramoorthy, Varun; 044
 Sundquist, Hannah; 157
 Sungkanuparph, Somnuek; 067
 Sutton, Jesse; PW2, 170
 Suwantararat, Nuntara; 243
 Suzuki, Motoi; 161
 Swanson, Douglas; 087
 Szymczak, Julia E.; PW2, 019

T

Tabb, Zachary; 247
 Taborda Vidarte, Cesar A.; 059
 Takakura, Shunichi; 232
 Talbot, Thomas; 039, 270
 Taldone, Sabrina; 160
 Tallman, Gregory B.; 044, 143
 Tambyah, Paul Ananth; 003
 Tamma, Pranita D.; PW2, 103, 126
 Tan, Susanna K.; 259
 Tanabe, Masaki; 074
 Tande, Aaron; 030, 047
 Tang, Stephanie; 075
 Tanner, Windy; 058
 Tanveer, Farah; 047
 Tariq, Raseen; 148
 Tartof, Sara; 161
 Tasova, Yesim; 047
 Tatara, Alexander; 048, 167
 Tate, Danielle; 246
 Tate, Janet P.; 063
 Taur, Ying; 116
 Tauxe, Robert V.; 127
 Taveras, Jeanette; 252
 Taylor, Barbara S.; PW1
 Taylor, Paige A.; 168
 Teale, Alastair; 139
 Tebas, Pablo; 078
 Temte, Jonathan; 251
 Terriff, Colleen; 168
 Terrones, Cynthia; 253
 Tetsuka, Nobuyuki; 057
 Thabit, Abrar; 170
 Thaden, Joshua T.; 232
 Thair, Simone; 228
 Thamlikitkul, Visanu; 046
 Thet, Andrea; 068
 Thom, Kerri; 095, 211
 Thompson, George R.; 044
 Thompson, Melanie; 101
 Tien, Vivian; 241
 Tierney, Maureen; 249
 Tiwari, Yagya; 243
 To, Kelvin; 069
 Tomatis Souverbielle, Cristina; 252
 Torda, Adrienne; 141
 Torok, Estee; 190
 Tortelli, Brett; 158
 Toy, Carolyn; 075
 Tracy, Alexis; 063
 Tran, Dat; 252
 Tran, Josephine; 052
 Tran, Kieu-Nhi; 167
 Tran, M. Tuan; 077
 Tran, Truc T.; 051
 Trevejo-Nunez, Giralina; 069
 Triant, Virginia; 272
 Tribble, Alison; 169
 Trifilio, Steven; 256
 Trinh, Trang D.; 076, 231
 Trivedi, Kavita K.; 074
 Tsai, Hung-Chin; 154
 Tsai, Shin-Yi; 242
 Tsay, Sharon; 043, 216
 Tsiodras, Sotirios; 233

Tuddenham, Susan; 181
 Tufa, Tafese Beyene; 061, 258
 Tulloch, Luis; 232
 Tunkel, Allan; 191
 Turbett, Sarah; PW3
 Turnbull, Caitlin; 045
 Turner, Nicholas; 052
 Turner, Orlando D.; 236
 Turvey, Shannon L.; 157
 Twardy, Brandon; 063
 Tyner, Kate; 058, 151

U

Uda, Kazuhiro; 139
 Ue, Frances; 234
 Uppuluri, Priya; 069
 Uribe, Andrés; 049
 Urueña, Analía; 140
 Uyeki, Timothy; 004

V

Vaisman, Alon; 150, 258
 Valdez, Luis; 160
 Valenzuela, Pablo; 044
 Vallieres, Emilie; 234
 Van De Beek, Diederik; 085
 Van Schaik, Willem; 276
 Van Voorhis, Wesley; 026, 033, 105, 203, 226, 277
 Van, Tam; 237
 Vanairsdale, Sharon; 073
 Vanderkooi, Otto G.; 146
 Varga, Alexandra; 141
 Varghese, George; 003
 Varley, Cara; 249
 Varughese, Tilly A.; 253
 Vasina, Logan; 075
 Vaz, Louise; 141
 Vazquez Guillaumet, Laia Jimena; 158
 Veach, Lisa; 172
 Vega, Ana; 059
 Veillette, John J.; 075
 Velez, Juan Diego; 052
 Vento, Todd J.; 141
 Vergara Lobo, Carlos Mauricio; 045
 Vergidis, Pascal; 236
 Verma, Sanjay; 140
 Veve, Michael P.; 075, 095, 168
 Vidal, Jorge; 051
 Villalobos, Juan; 061
 Villamagna, Angela; 044
 Visser, Jennifer; 015
 Vissicelli, Nicole; 253
 Vivek, Meghana; 041
 Vizzotti, Carla; 164
 Vo, Daniel; 132

Voskertchian, Annie; 242
 Vu, Betty; 052
 Vu, Kiem; 048

W

Waddell, Joel; 045
 Walensky, Rochelle; 021
 Walker, Durane; 248
 Walker, Jeremy; 148
 Walker, Lorne; 250
 Walkty, Andrew; 147
 Wallace, Andrew; 070
 Walsh Lang, Colleen; 247
 Wang, Joshua; 077
 Wang, Nan; 075, 168
 Wang, Shu-Hua; 258
 Ward, John; 285
 Wareham, Neval Ete; 253
 Warren, Travis; 078
 Washer, Laraine L.; 052
 Watanabe, Mika; 170
 Watson, Jasmine; 151
 Watson, John; 035
 Weiner, Lukasz; 068
 Weir, Charlene; 075
 Welliver, Robert C.; 140
 Weng, Mark; 250
 Wenzler, Eric; 231
 Wey, Shiuian (Shannon); 044
 Whitney, Cynthia; 117, 212
 Whitney, James; 217
 Wi, Yu Mi; 254
 Widmer, Andreas F.; 243
 Wiederhold, Nathan P.; 147
 Wiens, Jenna; 102
 Wilcox, Mark; 231
 Wiley, Zanthia; PW3
 Wilkinson, Robert; PW5, 026
 Williams, Ian; 127
 Williams, Jonathan; 044
 Williams, Shannon; 052
 Williamson, Julie E.; 075
 Wilson Dib, Rita; 044, 232
 Wilson, Brigid; 045
 Winston, Lisa G.; 124
 Winter, Kathleen; 221
 Wolf, Joshua; 228
 Wolfe, Cameron; 184
 Wolff, Marcelo; 153
 Wolford, Hannah; 243
 Wong, Maggie; 141
 Wood, Shannon; 067
 Wooten, Darey; 232
 Workneh, Meklit; 046
 Wrenn, Rebekah; 075
 Wright, Patty; PW1

Wright, Shelton; 069
 Wu, Janet; 052
 Wunderink, Richard G.; 019
 Wungwattana, Minkey; 075

Y

Yaffee, Anna; 056
 Yagi, Tetsuya; 052
 Yajaman Belludi, Yajaman Belludi; 251
 Yalamanchili, Harika; 146
 Yamada, Masaki; 259
 Yamaji, Reina; 122
 Yamamoto, Atsuko; 147
 Yamamoto, Norihisa; 056
 Yamasaki, Daisuke; 170
 Yang, Catherine; 141
 Yang, Haoshu; 075
 Yaratha, Gokul; 234
 Yared, Nicholas; 046
 Ye, Xunyan; 069
 Yeganeh, Nava; 093
 Yelk Woodruff, Rachel; 258
 Yeoh, Siang Fei; 141
 Yepez Guevara, Eduardo; 148
 Yfran. E.W, Eduardo Walter; 140
 Yi, Jongyou; 234
 Yi, Sarah H.; 243
 Yildirim, Inci; 278
 Yilmaz, Gurdal; 139
 Yin, Yudong; 233
 Yoshikazu, Mutoh; 156
 Yoshino, Yusuke; 067
 Young, Cynthia R.; 246
 Young, Heather; 075, 151, 241
 Jeremy Young; 210
 Young, Vincent B.; 102, 119, 183, 276
 Youngster, Ilan; 072, 148
 Yuh, Bianca; 245
 Yun, Ki Wook; 163, 250
 Yung, Lok; 046, 232

Z

Zachariah, Philip; 054
 Zahn, Matthew; 011, 057, 101, 185
 Zasowski, Evan J.; 232
 Zeitler, Kristen; 141
 Zhao-Fleming, Hannah; 237
 Zhou, Xudong; 074
 Zhou, Yuan; 150
 Zhu, Shichao; 241
 Zia, Yasaman; 050
 Ziegler, Matthew; 149
 Zon, Rebecca (Becky); 075
 Zurek, Karen; 168

Financial Disclosures 3

The following participants did not indicate whether or not there were financial disclosures for the below listed sessions prior to the publication of this program (please see the *Final Program Addendum* for their disclosures):

B

Bar, Katharine; 037
Bausch, Daniel; 207

C

Chiu, Charles Y.; 024

G

Galan, Jorge; 089
Gnann, John W.; PW1
Godofsky, Eliot; PW6, 018

K

Kroshinsky, Daniela; 034
Kuritzkes, Daniel; 037

L

Linder, Jeffrey; PW2, 032
Litwin, Alain; 005
Loomba, Rohit; PW6

P

Philip, Susan S.; 213

R

Ramirez, Lynn; 206
Rodríguez-Baño, Jesús; 118
Rodwell, Timothy C.; PW5

S

Scully, Eileen; 037
Swamy, Geeta; 179

T

Trivedi, Kavita; PW2, 019, 032, 090, 110, 111

U

Utz, Paul; 219

IDWeek 2017 Program Committee Financial Disclosures

Chairs:

David R. Andes, MD, FIDSA, IDWeek Chair, IDSA, University of Wisconsin Hospital, Madison, WI: Advisory/Consultant Role: Astellas, Cubist, Merck, Pfizer, Seachaid, Viamet; Research Grants: Actellion, Astellas, Kalidex, Merck, Novozymes, Seachaid; Editorial Board Member: Antimicrobial Agents and Chemotherapy, Journal of Infectious Diseases, Diagnostic Microbiology and Infectious Diseases, Current Fungal Infection Reports, Mayo Clinic Proceedings, Virulence, Medical Mycology, Pharmaceuticals, Frontiers in Mycology

Hilary M. Babcock, MD, IDWeek Chair, SHEA, Washington University School of Medicine, St. Louis, MO: Nothing to disclose

Rajesh T. Gandhi, MD, FIDSA, IDWeek Chair, HIVMA, Massachusetts General Hospital, Boston, MA: Educational Grant: Mass Gen – Gilead, Mass Gen – Merck, Mass Gen – ViiV

Archana Chatterjee, MD, PhD, FIDSA, IDWeek Chair, PIDS, University of South Dakota Sanford School of Medicine, Sioux Falls, SD: Honoraria: Merck; Advisory/Consultant Role: Astra Zeneca, Pfizer; Research Grant/Sanford University/Vaccine Studies: GSK, Merck, MedImmune

Vice-Chairs:

Andrew T. Pavia, MD, FIDSA, IDWeek Vice-Chair, IDSA, University of Utah, Salt Lake City, UT: Other Remuneration: Alios, Pharmaceutical, Antimicrobial Therapy Inc., Janssen

Ebbing Lautenbach, MD, FIDSA, FSHEA, Vice-Chair, SHEA, University of Pennsylvania School of Medicine, Philadelphia, PA; Research Grants: 3M, AstraZeneca

Jeanne M. Marrazzo, MD, MPH, FIDSA, Vice-Chair, HIVMA, University of Alabama at Birmingham School of Medicine, Birmingham, AL: Nothing to disclose

Marsha S. Anderson, MD, FIDSA IDWeek Vice-Chair, PIDS, University of Colorado School of Medicine, Aurora, CO: Nothing to disclose

Members:

Cesar Arias, MD, PhD, FIDSA, University of Texas Medical School at Houston, Houston, TX: Honoraria: Allergan; Honoraria/Advisory/Consultant: Pfizer, Theravance, Bayer, The Medicine Company; Royalties: UptoDate

Adarsh Bhimraj, MD, Cleveland Clinic Foundation, Cleveland, OH: Nothing to disclose

Robert A. Bonomo, MD, Case Western Reserve University, Cleveland, OH: Research Grants: Allegra, Entasis, GlaxoSmithKline

Kristina Bryant, MD, University of Louisville, Louisville, KY: Honoraria: MedStudy, Pediatric News; Other Remuneration & Research Grants: Pfizer

Christina M. Coyle, MD, Albert Einstein College of Medicine, Larchmont, NY: Nothing to disclose

Inger K. Damon, MD, PhD, FIDSA, Centers for Diseases Control and Prevention, Atlanta, GA: Nothing to disclose

Eric S. Daar, MD, Harbor-UCLA Medical Center, Torrance, CA: Advisory/Consultant Role: Bristol Myers Squibb, Gilead, Janssen, Merck, OptimRx, Teva, ViiV; Other Remuneration: UptoDate; Research Grants: Gilead, Merck, ViiV

Roberta DeBiasi, MD, MS, Children's National Health System, Washington, DC: Research Grant: GSK

Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects with Confirmed Influenza"

Jeffrey S. Duchin, MD, FIDSA, Public Health - Seattle and King County, Seattle, WA: Nothing to disclose

Hana El Sahly, MD, FIDSA, Baylor College of Medicine, Houston, TX: Honoraria: Medical Speaker Network; Research Grant: Novavax; Stocks/Bonds (spouse owned): Met-Test

Debra Goff, PharmD, The Ohio State University Medical Center, Westerville, OH: Advisory/Consultant Role: Activas, Cepheid; Honoraria: Astellas, Merck; Board Member: MAD-ID

David E. Greenberg, MD, UT Southwestern, Dallas, TX: Advisory/Consultant Role: Accelerate Diagnostics, Boston Pharmaceuticals; Other Remunerations: Sarepta Therapeutics

Marcia Goldberg, MD, Massachusetts General Hospital, Boston, MA: Other Remuneration: UptoDate

Patricia Griffin, MD, FIDSA, Center for Disease Control and Prevention, Atlanta, GA: Nothing to disclose

Paul D. Griffiths, MD, University College London, London, United Kingdom: Honoraria Donated: Chimerix, Shire; Research Grant: Roche; Support for clinical trial: Sanofi

Randall T. Hayden, MD, St. Jude Children's Research Hospital, Memphis, TN: Advisory/Consultant Role: Roche Molecular, Quidel Corporation

Michail Lionakis, MD, National Institutes of Health, Washington, DC: Research Grant: Matinas

John B. Lynch, III, MD, University of Washington, Seattle, WA: Advisory/Consultant Role: Astella Pharmaceuticals, Juno Therapeutics

Rachel A. Miller, MD, FIDSA, Duke University, Durham, NC: Nothing to disclose

continues

Joshua D. Nosanchuk, MD, FIDSA, Albert Einstein College of Medicine, Bronx, NY: Advisory/Consultant Role: MicroCures, Inc., Nano Biomed, Inc., RadImmune, Inc.; Stocks/Bonds: ColonyConcepts, LLC

Tara N. Palmore, MD, National Institutes of Health, Bethesda, MD: Nothing to disclose

Jean A. Patel, PhD, Centers for Disease Control and Prevention, Atlanta, GA: Nothing to disclose

Raymund R. Razonable, MD, FIDSA, Mayo Clinic, Rochester, MN: Other Renumeration: Astellas; Research Grants: Beckman Coulter, Roche/Genentech, Shire

Samuel A. Shelburne, MD, PhD, FIDSA, MD Anderson Cancer Center, Houston, TX: Nothing to disclose

Arjun Srinivasan, MD, FSHEA, Centers for Disease Control and Prevention, Atlanta, GA: Nothing to disclose

H. Keipp Talbot, MD, MPH, FIDSA, Vanderbilt University Medical Center, Nashville, TN: Advisory/Consultant Role: MedImmune, Sequiris, VaxInnate; Research Grants: Sanofi Pasteur, Gilead, MedImmune

Kavita Trivedi, MD, Trivedi Consultants, Albany, CA: Advisory/Consultant Role: Diatherix, Vizient Inc, Premier, Inc.

David Van Duin, MD, University of North Carolina Chapel Hill, Chapel Hill, NC: Advisory/Consultant Role: Achaogen, Allergan, Astellas, MedImmune, Sanofi, Tetrphase; Research Grants: Steris Inc., SCYNEXIS

Wesley Van Voorhis, MD, PhD, FIDSA, University of Washington, Seattle, WA: Other **Remuneration**: Novartis Tropical Disease Institute; Patent: ParaTheraTech

Vincent B. Young, MD, PhD, FIDSA, University of Michigan, Ann Arbor, MI Honoraria: MedImmune; Advisory/Consultant Role: MedImmune, Merck, Vedanta

Ex-officio:

William G. Powderly, MD, FIDSA, *IDSA President*, Washington University School of Medicine, St. Louis, MO: Advisory/Consultant Role: CallImmune, Clinical Care Options, Merck, Prism Communications (London), AbbVie, Gilead; Research Grants: Astellas, MiraVista, SCYNEXIS

Paul G. Auwaerter, MD, FIDSA, *IDSA President-Elect*, Johns Hopkins University School of Medicine, Baltimore, MD: Honoraria: Johns Hopkins CME; Advisory/Consultant Role: Biomerieux Cemptra, Medscape Infectious Diseases Advisor; Expert Testimony: Medical Legal Testimony; Stocks/Bonds: Johnson & Johnson, Nestle; Research Grants: Private Funds (Endowment); Website Advisor/Editorial Board: Medscape Infectious Diseases, POC-IT (Point of Care-Information Technology) Center, Johns Hopkins ABX Guide; Johns Hopkins Health Solutions Chief Medical Officer, Managing Editor; Family Trusts: Capricor, private equity investments in health care companies

Chris Busky, CAE, *Chief Executive Officer IDSA*, Arlington, VA: Nothing to disclose

Sandra Vura Harwood, CMP, *Meeting Secretariat, IDWeek*, Arlington, VA: Nothing to disclose

Eve Humphreys, MBA, CAE, *Executive Director, SHEA*, Arlington, VA: Nothing to disclose

Andrea Weddle, MSW, *Executive Director, HIVMA*, Arlington, VA: Nothing to disclose

Terri Christene Phillips, MSA, *Executive Director, PIDS*, Arlington, VA: Nothing to disclose

IDSA Board of Directors

William G. Powderly, MD, FIDSA, Washington University School of Medicine, St. Louis, MO
Paul G. Auwaerter, MD, FIDSA, Johns Hopkins University School of Medicine, Baltimore, MD
Cynthia L. Sears, MD, FIDSA, Johns Hopkins University School of Medicine, Baltimore, MD
Larry K. Pickering, MD, FIDSA, FPIDS, Emory University School of Medicine, Atlanta, GA
Helen W. Boucher, MD, FIDSA, Tufts University School of Medicine, Boston, MA
Johan S. Bakken, MD, PhD, FIDSA, St. Luke's Hospital, Duluth, MN
Angela M. Caliendo, MD, FIDSA, Brown University/Rhode Island Hospital, Providence, RI
Henry F. Chambers, MD, FIDSA, University of California, San Francisco, San Francisco, CA
Janet A. Englund, MD, FIDSA, Seattle Children's Hospital, Seattle, WA
Thomas Fekete, MD, FIDSA, Temple University Medical School, Philadelphia, PA
Lawrence P. Martinelli, MD, FIDSA, Covenant Health, Lubbock, TX
Daniel P. McQuillen, MD, FIDSA, Lahey Hospital & Medical Center, Burlington, MA
Thomas A. Moore, MD, FIDSA, IDC of Kansas, Wichita, KS
Trish M. Perl, MD, MSc, FIDSA, UT Southwestern Medical Center, Dallas, TX
Joel E. Gallant, MD, MPH, FIDSA, HIVMA Representative, Southwest CARE Center, Santa Fe, NM
Janet Gilsdorf, MD, PIDS Liaison, University of Michigan Medical Center, Ann Arbor, Michigan
Sara E. Cosgrove, MD, MS, FIDSA, SHEA Liaison, Johns Hopkins University School of Medicine, Baltimore, MD
Chris Busky, CAE, CEO, Infectious Diseases Society of America, Arlington, VA

SHEA Board of Trustees

Sara E. Cosgrove, MD, MS, FIDSA, Johns Hopkins University School of Medicine, Baltimore, MD
Keith Kaye, MD, MPH, FSHEA, University of Michigan Medical School, Ann Arbor, MI
Hillary Babcock, MD, MPH, Washington University School of Medicine, St. Louis, MO
Grace Lee, MD, MPH, Harvard Pilgrim Health Center, Boston, MA
Eli Perencevich, MD, MPH, FSHEA, University of Iowa Carver College of Medicine, Iowa City, IA
Louise Dembry, MD, MS, MBA, FSHEA, Veterans Affairs Connecticut Healthcare System, West Haven, CT
Deverick Anderson, MD, MPH, FSHEA, Duke University School of Medicine, Durham, NC
Dan Morgan, MD, MS, FSHEA, University of Maryland School of Medicine, VA Maryland, Baltimore, MD
Silvia Munoz-Price, MD, PhD, Institute for Health and Society and Froedtert & the Medical College of Wisconsin, Milwaukee, WI
David Weber, MD, MPH, MHA, FSHEA, University of North Carolina at Chapel Hill, Chapel Hill, NC
Hanan Balkhy, MD, FAAP, MMed, King Abdulaziz Medical City, Riyadh, Saudi Arabia
Kristina Bryant, MD, PIDS Liaison, University of Louisville, Louisville, KY
Walter Hellinger, MD, FSHEA, Community-Based Healthcare Epidemiologist Liaison, Mayo Clinic Jacksonville, Jacksonville, FL
Eve Humphreys, MBA, CAE, The Society for Healthcare Epidemiology of America, Arlington, VA

HIVMA Board of Directors


Wendy Armstrong, MD, FIDSA, Emory University, Atlanta, GA
Melanie Thompson, MD, AIDS Research Consortium of Atlanta, Atlanta, GA
W. David Hardy, MD, Whitman Walker - Elizabeth Taylor Medical Center, Washington, DC
Carlos del Rio, MD, FIDSA, Emory University, Atlanta, GA
Joel Gallant, MD, MPH, FIDSA, IDSA Representative, Southwest CARE Center, Santa Fe, NM
Joel Ang, MD, FIDSA, Private Practice, Washington, DC
Michelle S. Cespedes, MD, MS, Mt. Sinai-The Icahn School of Medicine, New York, NY
Judith Feinberg, MD, FIDSA, West Virginia University School of Medicine, Morgantown, WV
Lisa K. Fitzpatrick, MD, MPH, FIDSA, Washington, DC
Donna Futterman, MD, Albert Einstein College of Medicine, Bronx, NY
Rajesh T. Gandhi, MD, FIDSA, Massachusetts General Hospital, Boston, MA
Lori A. Gordon, PharmD, BCPS, Xavier University of Louisiana, New Orleans, LA
Carole A. Hohl, MHS, PA-C, Boston Healthcare for the Homeless Program, Boston, MA
Michelle Collins Ogle, MD, PIDS Liaison, Warren-Vance Community Health Center, Inc., Henderson, NC
James M. Sosman, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI
William Townner, MD, FIDSA, Kaiser Permanente, Los Angeles, CA
Rochelle Walensky, MD, MPH, FIDSA, Massachusetts General Hospital, Boston, MA
Ira Wilson, MD, MSc, Brown University School of Public Health, Providence, RI
Andrea Weddle, MSW, HIV Medicine Association, Arlington, VA

PIDS Board of Directors

Paul Spearman, MD, FPIDS, Cincinnati Children's, Cincinnati, OH
Janet R. Gilsdorf, MD, FPIDS, University of Michigan Medical Center, Ann Arbor, MI
Kristina Bryant, MD, FPIDS, University of Louisville, Louisville, KY
Buddy Creech MD, MS, FPIDS, Vanderbilt University Medical Center, Nashville, TN
Susan E. Coffin, MD, FPIDS, Children's Hospital of Philadelphia, Philadelphia, PA
Ravi Jhaveri, MD, FPIDS, University of North Carolina School of Medicine, Chapel Hill, NC
Grace Lee, MD, MPH, FPIDS, Harvard Medical School, Boston, MA
Yvonne A. Maldonado, MD, FPIDS, Stanford University, Stanford, CA
Jason Newland, MD, MEd, FPIDS, Washington University, St. Louis, MO
Ann-Christine Nyquist, MD, MSPH, FPIDS, Children's Hospital Colorado, Denver, CO
Debra Palazzi, MD, MEd, FPIDS, Baylor College of Medicine, Houston, TX
Jennifer S. Read, MD, MPH, DTMH, FPIDS, Washington, DC
Andi Shane, MD, MPH, MSc, FPIDS, Emory University School of Medicine, Atlanta, GA
William Steinbach, MD, FPIDS, Duke University Medical Center, Durham, NC
Terri Christine Phillips, MSA, Pediatric Infectious Diseases Society, Arlington, VA

See You Next Year!

October 3-7 • San Francisco, CA • www.idweek.org



IDWeek²⁰¹⁸TM

Advancing Science, Improving Care



IDS

The Infectious Diseases Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.



IDS, in conjunction with ProCE, Inc., will provide continuing education (CE) for pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Visit our websites:

www.idsociety.org • www.shea-online.org • www.hivma.org • www.pids.org

[illegible]

[illegible]

ViiV Healthcare welcomes you to
San Diego



COMING SOON

 **Juluca**
dolutegravir 50 mg/
rilpivirine 25 mg tablets

Sign up at www.julucahcp.com to receive important announcements.



©2017 ViiV Healthcare group of companies. All rights reserved. Printed in USA. 822267R0 June 2017

PNEUMOVAX[®]23

(Pneumococcal Vaccine Polyvalent)

Visit Booth #201